

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800543	HIN100493	54%	99.3%	96.9%
SAU800543	HPY101181	53%	97.4%	51.2%
SAU800543	KPN300484	37%	12.2%	90.6%
SAU800543	KPN302484	52%	97.8%	96.1%
SAU800543	LPN100508	64%	44.2%	98.3%
SAU800543	LMO101517	76%	99.6%	99.7%
SAU800543	MCA101004	50%	97.6%	94.9%
SAU800543	MAV102932	52%	7.0%	0.5%
SAU800543	MBV100906	52%	7.0%	0.5%
SAU800543	MLP101144	52%	7.0%	0.5%
SAU800543	MTU200665	52%	7.0%	0.5%
SAU800543	MGE100349	44%	98.8%	98.7%
SAU800543	MPN100327	45%	98.1%	98.2%
SAU800543	NGO101637	54%	78.1%	38.1%
SAU800543	NME200135	51%	99.5%	98.6%
SAU800543	PMU101736	53%	97.3%	95.0%
SAU800543	PRT104687	54%	78.1%	41.2%
SAU800543	PAE204267	49%	99.8%	98.6%
SAU800543	PPU104498	48%	99.5%	97.5%
SAU800543	PSY103340	48%	99.5%	98.2%
SAU800543	SPA101954	44%	65.5%	100%
SAU800543	STY102668	52%	97.8%	96.1%
SAU800543	STM102060	52%	97.8%	96.1%
SAU800543	SAU800543	100%	100%	100%
SAU800543	SEP201887	95%	100%	100%
SAU800543	SHA100756	90%	6.8%	74.5%
SAU800543	SHA101637	95%	100%	100%
SAU800543	SMU100552	68%	98.4%	98.2%
SAU800543	SPN401774	68%	100%	98.8%
SAU800543	SPY200072	67%	99.9%	99.2%
SAU800543	TPA100239	54%	98.4%	97.0%
SAU800543	UUR100188	44%	97.6%	98.5%
SAU800543	VCH100324	51%	97.8%	96.4%
SAU800543	YPS000478	52%	99.5%	97.6%
SAU800545	ABA100053	58%	99.3%	100%
SAU800545	BAN100648	83%	100%	97.9%
SAU800545	BFR10866	77%	54.7%	88.2%
SAU800545	BPT100844	67%	99.3%	98.4%
SAU800545	BBU100386	71%	99.3%	99.2%
SAU800545	BCE108786	66%	99.3%	97.6%
SAU800545	BFU100844	65%	99.3%	97.6%
SAU800545	BMA100034	66%	99.3%	97.6%
SAU800545	CJU100456	65%	99.3%	96.1%
SAU800545	CPN200197	63%	99.3%	100%
SAU800545	CTR200713	66%	99.3%	100%
SAU800545	CAC103453	66%	99.3%	98.4%
SAU800545	CBO102727	67%	99.3%	98.4%
SAU800545	CDF102422	75%	99.3%	95.1%
SAU800545	CDP100904	66%	99.3%	90.4%
SAU800545	EBC102897	65%	99.3%	99.2%
SAU800545	EFA202015	85%	99.3%	99.3%
SAU800545	ECO103265	65%	99.3%	99.2%
SAU800545	HIN100561	66%	99.3%	99.2%
SAU800545	HPY101180	65%	99.3%	91.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800545	KPN200561	66%	99.3%	99.2%
SAU800545	LMO101449	87%	99.3%	99.3%
SAU800545	MCA100230	61%	99.3%	99.2%
SAU800545	MAV102944	64%	100%	100%
SAU800545	MBV103315	64%	99.3%	99.2%
SAU800545	MLP101142	63%	100%	100%
SAU800545	MTU200679	64%	99.3%	99.2%
SAU800545	MGE100089	74%	99.3%	97.8%
SAU800545	MPN100606	72%	99.3%	97.8%
SAU800545	NGO101631	63%	99.3%	100%
SAU800545	NME200131	63%	99.3%	100%
SAU800545	PMU101354	65%	100%	100%
SAU800545	PRT103411	59%	87.6%	100%
SAU800545	PAE204266	67%	99.3%	100%
SAU800545	PPU112031	68%	99.3%	100%
SAU800545	PSY103389	69%	99.3%	100%
SAU800545	SPA102395	65%	99.3%	99.2%
SAU800545	STY101779	65%	99.3%	99.2%
SAU800545	SAU800545	100%	100%	100%
SAU800545	SEP201889	94%	100%	100%
SAU800545	SHA101640	97%	100%	100%
SAU800545	SMU100684	83%	99.3%	99.3%
SAU800545	SPN400248	82%	99.3%	99.3%
SAU800545	SPY200200	82%	99.3%	99.3%
SAU800545	TPA100240	64%	99.3%	99.2%
SAU800545	UUR100531	73%	99.3%	96.5%
SAU800545	VCH100354	64%	100%	100%
SAU800545	YPS001825	66%	99.3%	99.2%
SAU800546	ABA100054	53%	100%	100%
SAU800546	BAN101047	67%	100%	100%
SAU800546	BAN102922	81%	100%	100%
SAU800546	BFR102620	47%	98.7%	89.2%
SAU800546	BPT100845	60%	100%	90.2%
SAU800546	BBU100385	49%	100%	100%
SAU800546	BCE114655	55%	100%	100%
SAU800546	BFU100845	56%	100%	100%
SAU800546	BMA108128	55%	100%	100%
SAU800546	CJU100457	56%	98.7%	99.4%
SAU800546	CPN200198	50%	100%	100%
SAU800546	CTR200712	49%	100%	100%
SAU800546	CAC101300	68%	100%	100%
SAU800546	CBO100058	72%	100%	90.7%
SAU800546	CDF100549	73%	100%	100%
SAU800546	CDP100907	60%	98.7%	99.4%
SAU800546	EBC102895	60%	100%	100%
SAU800546	EFA202013	78%	100%	100%
SAU800546	ECO103264	60%	100%	87.2%
SAU800546	HIN100560	60%	100%	100%
SAU800546	HPY101179	55%	98.7%	99.4%
SAU800546	KPN300871	62%	92.9%	86.8%
SAU800546	LMO101111	78%	100%	100%
SAU800546	MCA100231	50%	100%	100%
SAU800546	MAV102943	59%	100%	100%
SAU800546	MBV103316	60%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800546	MLP101141	60%	100%	100%
SAU800546	MTU200680	60%	100%	100%
SAU800546	MGE100090	62%	98.7%	99.4%
SAU800546	MPN100605	62%	98.7%	99.4%
SAU800546	NGO101627	58%	100%	100%
SAU800546	NME200130	58%	100%	100%
SAU800546	PMU101355	61%	100%	100%
SAU800546	PRT100252	58%	100%	100%
SAU800546	PAE204265	57%	100%	100%
SAU800546	PPU112217	57%	100%	100%
SAU800546	PSY106485	71%	24.4%	92.7%
SAU800546	SPA102393	54%	66.0%	91.2%
SAU800546	STY101780	60%	100%	100%
SAU800546	SAU800546	100%	100%	100%
SAU800546	SEP200070	100%	100%	100%
SAU800546	SHA102003	95%	25.6%	100%
SAU800546	SMU100686	75%	100%	100%
SAU800546	SPN400249	77%	100%	100%
SAU800546	SPY200201	75%	100%	100%
SAU800546	TPA100241	51%	100%	100%
SAU800546	UUR100530	68%	98.7%	99.4%
SAU800546	VCH100355	61%	100%	100%
SAU800546	YPS001851	60%	100%	100%
SAU800547	ABA100059	58%	88.0%	100%
SAU800547	BAN103750	78%	10.1%	95.9%
SAU800547	BAN113143	70%	76.8%	98.5%
SAU800547	BAN108186	79%	100%	99.0%
SAU800547	BFR12249	55%	63.2%	98.9%
SAU800547	BPT100846	60%	99.1%	99.3%
SAU800547	BBU100539	47%	98.3%	98.4%
SAU800547	BCE105443	59%	99.1%	99.3%
SAU800547	BFU100846	59%	99.1%	99.3%
SAU800547	BMA109643	59%	99.1%	99.3%
SAU800547	CJU100458	60%	99.9%	100%
SAU800547	CPN200199	57%	99.1%	99.6%
SAU800547	CTR200711	58%	99.1%	99.6%
SAU800547	CAC102763	63%	99.7%	100%
SAU800547	CBO100608	64%	99.4%	98%
SAU800547	CDF100548	65%	99.0%	99.4%
SAU800547	CDP100910	59%	99.0%	96.1%
SAU800547	EBC102893	59%	99.3%	99.4%
SAU800547	EFA202007	75%	99.9%	99.7%
SAU800547	ECO103263	59%	99.3%	99.4%
SAU800547	HIN100559	59%	99.7%	99.9%
SAU800547	HPY101178	62%	99.9%	100%
SAU800547	KPN303651	59%	99.1%	99.1%
SAU800547	LMO102926	78%	99.9%	99.3%
SAU800547	MCA100232	58%	99.4%	98.9%
SAU800547	MAV102942	60%	99.1%	98.7%
SAU800547	MBV103317	60%	99.1%	98.7%
SAU800547	MLP101140	60%	99.1%	98.7%
SAU800547	MTU200681	61%	99.1%	98.7%
SAU800547	MGE100091	61%	99.7%	100%
SAU800547	MPN100604	62%	99.7%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800547	NGO101623	57%	99.9%	100%
SAU800547	NME200129	57%	99.9%	100%
SAU800547	PMU101356	59%	99.7%	99.9%
SAU800547	PRT100253	58%	99.7%	94.2%
SAU800547	PAE202069	59%	99.4%	99.6%
SAU800547	PPU109182	58%	100%	100%
SAU800547	PSY103391	56%	93.8%	99.7%
SAU800547	SPA102789	57%	99.3%	99.4%
SAU800547	STY101781	59%	99.3%	99.4%
SAU800547	SAU800547	100%	100%	100%
SAU800547	SEP200071	95%	100%	100%
SAU800547	SMU100688	76%	100%	99.9%
SAU800547	SPN400250	76%	100%	99.9%
SAU800547	SPY200202	76%	100%	100%
SAU800547	TPA100759	44%	98.0%	97.4%
SAU800547	UUR100529	63%	99.1%	99.1%
SAU800547	VCH100356	60%	99.6%	99.9%
SAU800547	YPS001853	60%	99.3%	99.4%
SAU800548	ABA100233	74%	33.5%	98.5%
SAU800548	ABA100062	74%	99.5%	99.5%
SAU800548	BAN106076	81%	100%	100%
SAU800548	BFR12122	73%	99.7%	99.7%
SAU800548	BPT100044	75%	100%	100%
SAU800548	BPT100847	75%	100%	100%
SAU800548	BBU100475	62%	100%	98.3%
SAU800548	BCE112288	70%	15.7%	100%
SAU800548	BCE106056	75%	52.0%	99.0%
SAU800548	BCE108906	75%	100%	100%
SAU800548	BFU100267	70%	37.6%	100%
SAU800548	BFU100847	74%	100%	100%
SAU800548	BMA107343	76%	95.9%	100%
SAU800548	BMA106305	76%	100%	100%
SAU800548	CJU100435	73%	100%	100%
SAU800548	CPN200689	68%	99.5%	99.5%
SAU800548	CTR200588	67%	99.7%	98.5%
SAU800548	CAC103049	73%	100%	100%
SAU800548	CBO100671	69%	10.9%	95.6%
SAU800548	CBO101209	76%	59.1%	100%
SAU800548	CBO101304	73%	99.5%	99.5%
SAU800548	CDF100547	72%	100%	96.1%
SAU800548	CDP100912	71%	100%	100%
SAU800548	EBC101615	72%	33.8%	99.3%
SAU800548	EBC100362	79%	47.7%	100%
SAU800548	EBC102891	75%	99.7%	99.7%
SAU800548	EFA202006	89%	100%	100%
SAU800548	EFM100161	76%	71.3%	100%
SAU800548	ECO103262	75%	99.7%	99.7%
SAU800548	ECO103878	75%	99.7%	99.7%
SAU800548	HIN100558	76%	100%	100%
SAU800548	HIN100613	76%	100%	100%
SAU800548	HPY101188	74%	100%	100%
SAU800548	KPN300520	77%	23.6%	100%
SAU800548	KPN300653	75%	79.9%	99.7%
SAU800548	KPN300869	75%	99.7%	99.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800548	LMO102516	84%	100%	100%
SAU800548	MCA100162	75%	99.5%	99.5%
SAU800548	MAV102941	72%	100%	100%
SAU800548	MBV103318	72%	100%	100%
SAU800548	MLP101139	71%	100%	100%
SAU800548	MTU200682	72%	100%	100%
SAU800548	MGE100460	70%	100%	100%
SAU800548	MPN100177	70%	100%	100%
SAU800548	NGO101620	77%	99.7%	99.7%
SAU800548	NGO101673	77%	99.7%	99.7%
SAU800548	NME200143	78%	99.7%	99.7%
SAU800548	NME200128	78%	99.7%	99.7%
SAU800548	PMU101746	74%	100%	100%
SAU800548	PMU101357	75%	100%	100%
SAU800548	PRT100737	76%	24.6%	100%
SAU800548	PRT100321	75%	99.7%	99.7%
SAU800548	PAE204275	73%	100%	100%
SAU800548	PAE204263	73%	100%	100%
SAU800548	PPU104463	71%	76.9%	100%
SAU800548	PPU104501	71%	100%	100%
SAU800548	PSY107231	71%	99.7%	99.7%
SAU800548	SPA104331	69%	39.3%	99.4%
SAU800548	SPA102798	74%	99.7%	99.7%
SAU800548	STY102689	74%	99.7%	99.7%
SAU800548	STY101782	74%	99.7%	99.7%
SAU800548	STM102043	74%	99.7%	99.7%
SAU800548	SAU800548	100%	100%	100%
SAU800548	SEP200072	96%	100%	100%
SAU800548	SHA101389	97%	100%	100%
SAU800548	SMU101538	74%	99.5%	99.5%
SAU800548	SPN401342	74%	99.5%	99.5%
SAU800548	SPY200441	74%	99.5%	99.5%
SAU800548	TPA100185	65%	99.7%	79.6%
SAU800548	UUR100528	71%	98.7%	98.7%
SAU800548	VCH100316	76%	99.7%	99.7%
SAU800548	VCH100357	76%	99.7%	99.7%
SAU800548	YPS001855	75%	99.7%	99.7%
SAU800548	YPS000510	77%	100%	100%
SAU800550	ABA100563	32%	92.4%	92.5%
SAU800550	BAN108626	73%	98.7%	100%
SAU800550	BAN106368	77%	99.2%	96.0%
SAU800550	BFR10641	41%	99.2%	95.9%
SAU800550	BPT103090	35%	91.1%	88.4%
SAU800550	BCE109390	26%	26.4%	82.4%
SAU800550	BCE113483	40%	100%	97.0%
SAU800550	BFU101208	40%	100%	97.0%
SAU800550	BMA100519	39%	100%	97.0%
SAU800550	CJU100275	27%	84.3%	85.5%
SAU800550	CPN200794	29%	90.1%	90.3%
SAU800550	CDP100242	31%	96.9%	93.7%
SAU800550	EBC102199	41%	99.0%	95.7%
SAU800550	EFM202467	69%	100%	96.7%
SAU800550	ECO103539	41%	99.0%	95.7%
SAU800550	HIN101522	32%	89.8%	90.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800550	KPN303387	40%	99.0%	95.7%
SAU800550	LPN100930	26%	90.1%	82.0%
SAU800550	MCA100378	30%	87.2%	85%
SAU800550	MAV103993	32%	84.3%	82.9%
SAU800550	MBV102883	33%	98.4%	48.6%
SAU800550	MLP100753	34%	84.3%	82.1%
SAU800550	MTU200032	33%	98.4%	48.6%
SAU800550	NGO101594	33%	74.7%	96.9%
SAU800550	NME201859	32%	86.9%	87.9%
SAU800550	PMU101901	32%	93.5%	93.0%
SAU800550	PRT102489	42%	99.0%	95.5%
SAU800550	PAE200500	35%	95.0%	90.0%
SAU800550	PPU107457	37%	92.7%	90.3%
SAU800550	PSY103313	36%	87.7%	95.4%
SAU800550	SPA104075	40%	96.3%	94.1%
SAU800550	STY100333	41%	99.0%	95.7%
SAU800550	STM102073	34%	91.9%	90.6%
SAU800550	SAU800550	100%	100%	100%
SAU800550	SHA101391	93%	100%	96.2%
SAU800550	VCH103606	42%	99.2%	96.2%
SAU800550	YPS001508	43%	99.0%	94.5%
SAU800551	ABA101220	58%	96.6%	97.3%
SAU800551	BAN102049	22%	77.1%	98.6%
SAU800551	BAN102184	22%	77.1%	98.6%
SAU800551	BFR104991	23%	75.7%	97.4%
SAU800551	BPT100429	24%	80.8%	99.5%
SAU800551	BCE101252	61%	99.0%	99.3%
SAU800551	BMA103820	26%	71.6%	89.8%
SAU800551	EFA202431	24%	38.7%	48.7%
SAU800551	EFM202602	25%	68.2%	85.3%
SAU800551	ECO101931	56%	96.6%	97.9%
SAU800551	MCA102445	25%	72.3%	92.3%
SAU800551	MAV102283	22%	70.2%	87.7%
SAU800551	PAE201134	60%	96.6%	97.3%
SAU800551	PPU111301	22%	71.6%	90.2%
SAU800551	PSY102809	24%	77.4%	96.4%
SAU800551	SAU800551	100%	100%	100%
SAU800551	SEP202065	26%	68.8%	84.3%
SAU800551	SHA102397	23%	51.4%	60.1%
SAU800555	BAN109841	26%	96.9%	91.5%
SAU800555	CBO100592	24%	91.6%	88.5%
SAU800555	EFA200270	24%	93.0%	87.2%
SAU800555	MLP101061	24%	58.1%	37.0%
SAU800555	MTU202199	23%	48.9%	94.1%
SAU800555	NME200581	32%	44.9%	62.9%
SAU800555	STM103706	29%	58.1%	84.0%
SAU800555	SAU800555	100%	100%	100%
SAU800555	SEP200091	67%	99.6%	97.8%
SAU800555	SHA101303	61%	99.6%	97.0%
SAU800555	YPS002018	30%	58.1%	84.0%
SAU800561	BAN100965	21%	30.7%	16.5%
SAU800561	BAN111001	20%	63.5%	67.3%
SAU800561	BAN109365	19%	19.1%	37.5%
SAU800561	BFR100579	18%	10.0%	13.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800561	BFR102947	19%	10.0%	16.5%
SAU800561	BFR101444	18%	11.3%	19.3%
SAU800561	BBU100325	21%	21.7%	19.2%
SAU800561	BFU103969	74%	2.8%	39.8%
SAU800561	BMA103470	49%	10.6%	32.7%
SAU800561	BMA101165	47%	7.9%	15.2%
SAU800561	BMA104606	30%	16.6%	64.3%
SAU800561	CJU101103	20%	23.8%	25.8%
SAU800561	CPN200033	15%	12.6%	19.6%
SAU800561	CAC102616	26%	18.0%	82.7%
SAU800561	CBO103272	17%	24.9%	65.8%
SAU800561	CBO103679	27%	10.8%	20.8%
SAU800561	CDF101661	25%	20.5%	89.2%
SAU800561	CDP102558	31%	7.7%	6.4%
SAU800561	CDP101308	33%	24.7%	25.7%
SAU800561	CDP101991	34%	24.0%	14.7%
SAU800561	EFA203524	21%	53.9%	78.5%
SAU800561	EFM201664	22%	22.1%	74.6%
SAU800561	EFM201584	17%	12.1%	47.6%
SAU800561	HPY200074	16%	21.7%	26.6%
SAU800561	KPN206267	43%	54.6%	44.6%
SAU800561	LPN101461	33%	52.0%	60.9%
SAU800561	LMO102167	44%	23.0%	44.5%
SAU800561	MCA100440	42%	8.7%	6.0%
SAU800561	MAV104123	28%	5.7%	57.1%
SAU800561	MBV101055	34%	7.3%	7.9%
SAU800561	MLP100905	33%	4.1%	9.0%
SAU800561	MTU202408	34%	7.3%	7.6%
SAU800561	MGE100318	23%	21.9%	20.2%
SAU800561	MPN100275	12%	20.6%	15.5%
SAU800561	NME201599	17%	8.4%	12.6%
SAU800561	PAE203113	23%	17.4%	22.7%
SAU800561	PSY103818	30%	14.0%	57.4%
SAU800561	SPA103181	24%	10.5%	39.9%
SAU800561	STM102835	24%	16.3%	12.0%
SAU800561	SAU800563	49%	97.5%	6.6%
SAU800561	SAU800562	65%	65.5%	34.3%
SAU800561	SAU800561	100%	100%	100%
SAU800561	SEP200110	39%	89.7%	13.9%
SAU800561	SHA100540	33%	16.1%	98.3%
SAU800561	SHA102998	33%	16.1%	80.1%
SAU800561	SHA100562	48%	58.0%	13.4%
SAU800561	SMU100747	21%	65.3%	97.7%
SAU800561	SMU102548	21%	60.7%	29.6%
SAU800561	SPN401402	21%	8.1%	68.6%
SAU800561	SPY201545	20%	25.1%	63.1%
SAU800561	TPA100366	42%	2.7%	36.2%
SAU800562	BAN100965	25%	5.7%	7.2%
SAU800562	BAN110134	23%	34.7%	51.3%
SAU800562	BAN111001	19%	66.6%	69.3%
SAU800562	BAN109365	18%	65.4%	22.0%
SAU800562	BAN104198	20%	40.1%	43.1%
SAU800562	BFR100579	19%	7.1%	14.3%
SAU800562	BFR102947	19%	8.6%	16.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800562	BFR101444	18%	7.8%	19.3%
SAU800562	BBU100545	25%	12.3%	67.8%
SAU800562	BBU100325	19%	16.8%	19.2%
SAU800562	BFU103969	53%	9.5%	39.8%
SAU800562	BMA104606	30%	14.9%	49.4%
SAU800562	BMA103470	49%	16.2%	32.7%
SAU800562	BMA101165	47%	7.3%	15.2%
SAU800562	CJU101103	20%	17.2%	31.5%
SAU800562	CPN200033	14%	59.6%	34.6%
SAU800562	CAC102616	20%	14.4%	99.5%
SAU800562	CBO103272	16%	18.7%	72.8%
SAU800562	CBO103679	24%	6.3%	18.8%
SAU800562	CDF102641	20%	54.5%	78.4%
SAU800562	CDF101661	26%	22.2%	55.7%
SAU800562	CDP101308	26%	32.2%	56.5%
SAU800562	CDP101991	31%	36.5%	30.2%
SAU800562	EFA203524	22%	44.2%	88.2%
SAU800562	EFM201062	38%	5.0%	65.1%
SAU800562	EFM201664	25%	26.3%	78.5%
SAU800562	EFM201584	16%	8.3%	47.6%
SAU800562	EFM201162	27%	36.6%	16.2%
SAU800562	HPY200074	17%	18.2%	30.3%
SAU800562	KPN206267	51%	33.1%	38.8%
SAU800562	LPN101461	36%	64.8%	46.3%
SAU800562	LMO102167	46%	17.3%	47.0%
SAU800562	MCA100440	42%	3.1%	6.0%
SAU800562	MAV104123	29%	1.2%	57.1%
SAU800562	MBV101055	32%	4.1%	10.4%
SAU800562	MLP100905	32%	2.8%	9.0%
SAU800562	MTU202408	32%	4.1%	10.0%
SAU800562	MGE100318	21%	64.0%	40.1%
SAU800562	MPN100275	11%	17.3%	22.6%
SAU800562	NME100865	22%	28.2%	70.4%
SAU800562	PAE203113	22%	11.0%	24.3%
SAU800562	PSY101467	15%	13.9%	47.5%
SAU800562	PSY108790	15%	60.5%	17.8%
SAU800562	PSY103818	29%	7.9%	56.8%
SAU800562	SPA103181	24%	0.5%	32.9%
SAU800562	STM102835	22%	2.5%	30.5%
SAU800562	SAU800562	100%	100%	100%
SAU800562	SEP200110	41%	46.4%	7.5%
SAU800562	SHA100540	33%	18.1%	85.7%
SAU800562	SHA102998	28%	97.1%	62.1%
SAU800562	SHA100562	50%	96.4%	87.2%
SAU800562	SMU102548	23%	18.1%	20.7%
SAU800562	SMU100747	28%	12.1%	27.4%
SAU800562	SPN401402	22%	12.8%	30.5%
SAU800562	SPY201545	20%	19.3%	70.2%
SAU800566	BFR10892	23%	46.2%	11.2%
SAU800566	BPT101393	33%	87.0%	94.7%
SAU800566	BCE106700	35%	89.0%	89.5%
SAU800566	BFU102591	36%	89.0%	96.6%
SAU800566	BMA107940	35%	89.0%	91.1%
SAU800566	KPN108431	19%	88.7%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800566	NGO100865	35%	89.0%	99.2%
SAU800566	NME200935	35%	89.0%	99.2%
SAU800566	PAE205534	18%	84.2%	92.6%
SAU800566	PPU111596	29%	33.9%	29.0%
SAU800566	PSY105601	24%	48.3%	49.5%
SAU800566	SAU800566	100%	100%	100%
SAU800566	SEP200115	88%	100%	100%
SAU800566	SHA101796	89%	100%	100%
SAU800588	ABA104878	45%	94.8%	42.9%
SAU800588	BAN106141	49%	97.0%	100%
SAU800588	BAN102570	62%	99.7%	100%
SAU800588	BFR101415	45%	99.7%	98.2%
SAU800588	BBU100588	34%	90.5%	88.4%
SAU800588	BCE113410	43%	80.5%	94.7%
SAU800588	BFU103363	43%	98.2%	94.5%
SAU800588	CJU100638	47%	96.3%	62.7%
SAU800588	CAC102832	44%	98.8%	98.5%
SAU800588	CBO102063	52%	50%	90.4%
SAU800588	CDF102626	25%	92.1%	87.1%
SAU800588	CDP101294	50%	97.0%	69.2%
SAU800588	EBC104962	42%	94.8%	43.1%
SAU800588	EFA202248	59%	99.1%	98.8%
SAU800588	EFM200028	53%	62.2%	99.5%
SAU800588	ECO102255	42%	94.8%	43.0%
SAU800588	HIN101176	44%	94.8%	43.2%
SAU800588	HPY200837	47%	97.3%	60.9%
SAU800588	KPN305976	42%	94.8%	43.2%
SAU800588	LPN102073	25%	90.5%	57.7%
SAU800588	LMO100950	62%	99.7%	99.4%
SAU800588	MCA101508	44%	98.2%	64.8%
SAU800588	MAV101929	47%	93.9%	43.9%
SAU800588	MBV102834	47%	94.5%	44.5%
SAU800588	MTU200407	47%	94.5%	44.5%
SAU800588	MGE100305	40%	99.1%	99.4%
SAU800588	MPN100413	40%	99.1%	99.4%
SAU800588	NGO100804	45%	94.8%	61.4%
SAU800588	NME200777	45%	94.8%	61.4%
SAU800588	PMU100705	44%	94.8%	43.1%
SAU800588	PRT100628	45%	94.2%	43.1%
SAU800588	PAE200834	43%	94.2%	43.3%
SAU800588	PPU103956	40%	94.8%	44.6%
SAU800588	PSY102379	39%	97.3%	46.1%
SAU800588	SPA101028	57%	37.8%	86.9%
SAU800588	STY100983	42%	94.8%	43.0%
SAU800588	STM100723	42%	94.8%	43.0%
SAU800588	SAU800588	100%	100%	100%
SAU800588	SEP200137	87%	100%	100%
SAU800588	SHA101700	84%	100%	100%
SAU800588	SMU100210	58%	98.8%	97.3%
SAU800588	SPN401007	55%	99.1%	99.1%
SAU800588	SPY200858	56%	99.1%	97.6%
SAU800588	TPA100093	37%	94.2%	94.3%
SAU800588	UUR100064	25%	80.5%	87.7%
SAU800588	VCH101078	44%	95.4%	43.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800588	YPS000496	43%	94.8%	42.8%
SAU800589	BAN101408	59%	43.9%	91.1%
SAU800589	BAN105953	46%	73.7%	97.3%
SAU800589	BAN102397	52%	94.2%	94.3%
SAU800589	EFA201382	39%	80.9%	81.3%
SAU800589	LMO102312	42%	94.2%	95.3%
SAU800589	PAE204284	28%	41.0%	52.9%
SAU800589	PPU107435	21%	53.6%	63.2%
SAU800589	SAU800589	100%	100%	100%
SAU800589	SEP200138	82%	99.6%	99.3%
SAU800589	SHA101701	86%	98.2%	97.5%
SAU800589	SPY200934	37%	87.1%	85.9%
SAU800591	BBU100685	32%	95.7%	96.8%
SAU800591	EFA200383	56%	99.1%	94.7%
SAU800591	EFM202057	56%	98.8%	99.1%
SAU800591	LPN101401	32%	87.2%	91.1%
SAU800591	LMO100508	50%	91.1%	91.6%
SAU800591	SAU800591	100%	100%	100%
SAU800591	SEP200140	72%	100%	100%
SAU800591	SHA101704	73%	100%	100%
SAU800591	SMU100935	37%	91.4%	90.6%
SAU800591	SPN400339	39%	89.6%	82.8%
SAU800591	SPY200652	41%	90.5%	91.7%
SAU800592	BBU100686	22%	49.7%	52.4%
SAU800592	EFA200384	44%	100%	97.0%
SAU800592	EFM200671	45%	100%	98.6%
SAU800592	LMO101877	38%	98.3%	95.8%
SAU800592	SAU800592	100%	100%	100%
SAU800592	SEP200141	79%	100%	100%
SAU800592	SHA101705	79%	59.8%	100%
SAU800592	SMU100938	29%	97.8%	97.6%
SAU800592	SPN400340	27%	97.8%	96.7%
SAU800592	SPY200653	27%	96.1%	94.9%
SAU800593	BAN113008	60%	65.5%	100%
SAU800593	BAN105544	62%	63.7%	100%
SAU800593	BMA108446	27%	41.6%	14.9%
SAU800593	BMA103867	25%	53.1%	14.6%
SAU800593	BMA106771	24%	64.6%	14.9%
SAU800593	SAU800593	100%	100%	100%
SAU800593	SEP200142	84%	100%	100%
SAU800593	SHA100809	88%	98.2%	98.2%
SAU800593	SPN401580	54%	30.1%	33.7%
SAU800600	ABA101949	30%	92.9%	89.5%
SAU800600	BAN104442	45%	96.5%	99.3%
SAU800600	BAN102029	44%	97.8%	98.7%
SAU800600	BFR100585	29%	95.8%	83.5%
SAU800600	BPT100971	31%	95.5%	86.9%
SAU800600	BBU100527	29%	93.3%	89.8%
SAU800600	BCE111954	31%	87.8%	87.5%
SAU800600	BFU109580	33%	97.8%	93.6%
SAU800600	BFU100521	34%	95.5%	91.2%
SAU800600	BFU100523	36%	92.6%	89.4%
SAU800600	BMA108987	27%	96.5%	96.6%
SAU800600	CBO101231	26%	96.2%	73.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800600	CDF101932	26%	98.1%	74.0%
SAU800600	CDP100172	25%	97.1%	88.5%
SAU800600	EBC102052	31%	97.1%	91.6%
SAU800600	EFM202426	53%	97.4%	98.1%
SAU800600	ECO101739	33%	97.1%	97.2%
SAU800600	HPY101176	31%	86.2%	83.3%
SAU800600	KPN304964	31%	98.1%	93.7%
SAU800600	LPN100428	33%	98.1%	93.2%
SAU800600	LMO100594	30%	98.1%	95.8%
SAU800600	MAV104842	33%	97.1%	93.3%
SAU800600	MBV103911	31%	83.0%	70.7%
SAU800600	MLP100283	32%	94.2%	88.0%
SAU800600	MTU202264	31%	83.0%	77.7%
SAU800600	PAE202533	33%	94.2%	90.6%
SAU800600	PPU106661	27%	95.8%	94.9%
SAU800600	PSY100479	33%	93.6%	89.7%
SAU800600	SPA101563	32%	93.6%	93.4%
SAU800600	STY103216	33%	98.4%	93.9%
SAU800600	STM100076	29%	94.9%	94.5%
SAU800600	SAU800600	100%	100%	100%
SAU800600	SEP200145	78%	99.7%	99.7%
SAU800600	SHA100813	79%	99.7%	100%
SAU800600	SMU100710	28%	84.3%	95.4%
SAU800600	VCH100654	31%	97.8%	94.9%
SAU800600	YPS002522	35%	96.2%	91.8%
SAU800601	BAN113282	46%	66.9%	95.9%
SAU800601	BAN101095	43%	96.1%	93.9%
SAU800601	BPT103683	23%	61.2%	51.4%
SAU800601	BFU105807	30%	36.5%	18.0%
SAU800601	BMA104764	23%	50.6%	44.8%
SAU800601	CAC103679	29%	51.1%	47.9%
SAU800601	CAC102966	25%	93.3%	92.4%
SAU800601	CAC100169	29%	51.1%	47.9%
SAU800601	CBO102960	31%	49.4%	50.3%
SAU800601	CDF102353	26%	50.6%	49.5%
SAU800601	ECO100876	27%	51.7%	47.4%
SAU800601	KPN203154	41%	16.3%	11.2%
SAU800601	LMO101606	22%	77.5%	75.4%
SAU800601	SAU800601	100%	100%	100%
SAU800601	SEP201386	39%	84.3%	96.7%
SAU800601	SHA100814	71%	99.4%	99.4%
SAU800601	SPN401766	45%	21.9%	17.9%
SAU800605	ABA103635	31%	93.5%	90.6%
SAU800605	BAN108675	67%	57.7%	100%
SAU800605	BAN104327	67%	100%	97.7%
SAU800605	BPT100337	27%	99.1%	96.2%
SAU800605	BCE114807	41%	99.4%	87.4%
SAU800605	BFU103004	41%	99.4%	99.1%
SAU800605	BMA100537	41%	99.4%	97.9%
SAU800605	CJU101457	30%	98.5%	94.1%
SAU800605	CDP101455	39%	99.4%	96.8%
SAU800605	EBC101366	68%	99.4%	98.8%
SAU800605	EFA200493	68%	99.7%	98.8%
SAU800605	EFM202247	24%	93.2%	91.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800605	ECO101449	69%	100%	96.5%
SAU800605	HN100176	26%	96.7%	94.4%
SAU800605	HPY101087	26%	98.5%	95.7%
SAU800605	KPN305086	68%	99.4%	98.8%
SAU800605	LPN102926	33%	89.9%	87.9%
SAU800605	MCA102268	27%	82.4%	97.9%
SAU800605	MAV103580	26%	92.6%	90.8%
SAU800605	MBV103685	26%	92.6%	90.8%
SAU800605	MLP101064	28%	93.8%	87.8%
SAU800605	MTU203005	26%	92.6%	90.8%
SAU800605	MPN100278	26%	81.5%	79.5%
SAU800605	NGO101474	64%	99.4%	96.0%
SAU800605	NME200668	64%	99.4%	96.5%
SAU800605	PAE205422	42%	99.7%	98.0%
SAU800605	PPU110079	64%	100%	98.5%
SAU800605	PSY104861	32%	93.8%	90.4%
SAU800605	SPA101864	69%	100%	97.1%
SAU800605	STY104200	69%	100%	99.4%
SAU800605	STM100346	69%	100%	99.4%
SAU800605	SAU800605	100%	100%	100%
SAU800605	SEP200161	87%	99.4%	98.2%
SAU800605	SMU101451	27%	96.7%	96.0%
SAU800605	SPN400262	64%	100%	99.4%
SAU800605	SPY200034	60%	100%	99.4%
SAU800607	ABA102360	39%	93.5%	94.1%
SAU800607	BAN111999	37%	99.5%	99.6%
SAU800607	BAN110976	56%	100%	100%
SAU800607	BFR10875	22%	99.1%	99.5%
SAU800607	BPT101508	40%	99.6%	99.8%
SAU800607	BBU100593	25%	97.8%	97.3%
SAU800607	BCE100461	40%	98.7%	99.2%
SAU800607	BFU103077	40%	98.7%	99.2%
SAU800607	BMA100457	39%	98.9%	98.0%
SAU800607	CJU101100	35%	94.8%	96.8%
SAU800607	CPN200176	21%	95.8%	97.9%
SAU800607	CTR200729	20%	94.2%	95.2%
SAU800607	CAC101790	25%	94.2%	95.6%
SAU800607	CBO100741	23%	94.2%	95.6%
SAU800607	CDF104545	27%	95.8%	96.8%
SAU800607	CDP100057	41%	98.9%	98.4%
SAU800607	EBC101120	27%	40.1%	73.6%
SAU800607	EFA200290	24%	98.7%	99.5%
SAU800607	EFM201011	23%	94.2%	95.2%
SAU800607	ECO101844	25%	98.9%	99.7%
SAU800607	HIN101550	26%	98.9%	99.7%
SAU800607	HPY100315	38%	94.9%	97.0%
SAU800607	KPN301304	25%	98.9%	99.7%
SAU800607	LPN101161	41%	94.8%	95.2%
SAU800607	LMO101656	55%	100%	100%
SAU800607	MCA100331	26%	98.9%	99.7%
SAU800607	MAV106525	41%	97.3%	97.5%
SAU800607	MBV105559	40%	97.3%	97.5%
SAU800607	MLP100693	40%	94.6%	94.4%
SAU800607	MTU201275	40%	97.3%	97.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800607	MGE100389	31%	94.8%	96.5%
SAU800607	MPN100286	33%	94.0%	95.7%
SAU800607	NGO100228	24%	98.6%	99.3%
SAU800607	NME201566	23%	98.6%	99.3%
SAU800607	PMU100551	26%	95.7%	99.1%
SAU800607	PRT100545	25%	98.9%	99.7%
SAU800607	PAE205046	23%	98.9%	98.6%
SAU800607	PPU109126	23%	98.9%	98.6%
SAU800607	PSY103569	22%	99.3%	99.7%
SAU800607	SPA103053	24%	98.9%	99.7%
SAU800607	STY102666	25%	98.9%	99.7%
SAU800607	STM102429	25%	98.9%	99.7%
SAU800607	SAU800607	100%	100%	100%
SAU800607	SEP200171	84%	100%	100%
SAU800607	SHA101545	84%	100%	100%
SAU800607	SMU101264	26%	98.2%	98.9%
SAU800607	SPN401887	25%	98.7%	99.5%
SAU800607	SPY201643	25%	94.2%	95.4%
SAU800607	TPA100822	25%	94.2%	94.4%
SAU800607	UUR100280	39%	98.9%	99.6%
SAU800607	VCH102042	24%	98.9%	96.0%
SAU800607	YPS003380	26%	97.5%	99.0%
SAU800637	BAN101684	46%	96.6%	69.9%
SAU800637	BAN104283	51%	96.6%	47.6%
SAU800637	BPT102745	32%	73.9%	77.4%
SAU800637	BCE106238	39%	92.0%	81%
SAU800637	BFU103333	38%	89.8%	50.8%
SAU800637	BMA109972	36%	89.8%	53.9%
SAU800637	CJU101365	31%	87.5%	98.2%
SAU800637	CAC103450	36%	98.1%	63.5%
SAU800637	CDP101641	31%	88.3%	93.8%
SAU800637	EFA200265	52%	94.7%	58.6%
SAU800637	EFM200599	41%	97.7%	63.1%
SAU800637	KPN305026	45%	68.6%	97.8%
SAU800637	LPN103143	41%	75.4%	42.0%
SAU800637	LMO100876	50%	98.1%	79.9%
SAU800637	MAV105759	31%	87.5%	89.9%
SAU800637	MBV104256	31%	87.5%	88.3%
SAU800637	MLP100082	30%	87.5%	88.6%
SAU800637	MTU203726	31%	87.5%	88.3%
SAU800637	NME200186	37%	74.6%	89.8%
SAU800637	PMU100781	34%	75%	90.0%
SAU800637	PAE201385	37%	90.9%	56.9%
SAU800637	PPU108273	31%	93.6%	61.2%
SAU800637	PSY104047	37%	88.6%	52.0%
SAU800637	SPA103757	40%	70.8%	79.7%
SAU800637	STY101910	40%	70.8%	79.7%
SAU800637	STM101649	40%	70.8%	79.7%
SAU800637	SAU800637	100%	100%	100%
SAU800637	SEP200217	83%	100%	100%
SAU800637	SHA100118	81%	100%	100%
SAU800637	SMU100176	36%	94.3%	62.7%
SAU800637	SPY200583	37%	87.9%	59.1%
SAU800637	VCH100245	36%	79.2%	76.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800641	BFR11919	28%	87.9%	29.2%
SAU800641	BFR11393	28%	89.4%	29.6%
SAU800641	BPT100821	47%	27.3%	22.2%
SAU800641	BCE113991	28%	70.5%	59.0%
SAU800641	BFU109291	28%	70.5%	53.4%
SAU800641	BMA106229	29%	70.5%	59.0%
SAU800641	CJU101075	31%	97.0%	28.2%
SAU800641	EBC103920	30%	94.7%	27.5%
SAU800641	EFA201297	60%	96.2%	97.7%
SAU800641	EFM100213	57%	55.3%	91.5%
SAU800641	ECO102986	30%	94.7%	27.5%
SAU800641	HIN101495	29%	94.7%	27.5%
SAU800641	KPN308271	30%	94.7%	27.5%
SAU800641	LMO101198	71%	95.5%	99.2%
SAU800641	MAV104245	32%	90.2%	91.9%
SAU800641	NGO100989	31%	69.7%	56.0%
SAU800641	NME200331	30%	72.0%	57.7%
SAU800641	PMU100884	35%	51.5%	14.7%
SAU800641	SPA102480	30%	94.7%	28.3%
SAU800641	STY100790	30%	99.2%	28.7%
SAU800641	SAU800641	100%	100%	100%
SAU800641	SEP200670	94%	100%	100%
SAU800641	SHA100548	90%	78.0%	100%
SAU800641	YPS001982	33%	94.7%	27.5%
SAU800680	ABA104575	44%	94.1%	85.5%
SAU800680	BAN101585	39%	98.9%	97.4%
SAU800680	BAN112177	45%	98.4%	97.4%
SAU800680	BFR104201	41%	69.7%	89.1%
SAU800680	BPT100746	40%	95.2%	86.1%
SAU800680	BCE110211	45%	96.3%	93.8%
SAU800680	BFU106340	44%	93.6%	93.1%
SAU800680	BMA103155	45%	96.3%	92.8%
SAU800680	CJU100047	25%	65.4%	63.2%
SAU800680	CBO100465	48%	96.3%	94.3%
SAU800680	CDP102654	39%	92.6%	42.8%
SAU800680	EFA201956	41%	99.5%	96.4%
SAU800680	EFM202384	39%	83.5%	82.7%
SAU800680	KPN300536	54%	75.5%	100%
SAU800680	LPN102317	37%	93.6%	92.6%
SAU800680	MCA100065	41%	94.7%	84.4%
SAU800680	MAV103187	35%	80.9%	49.7%
SAU800680	MBV100232	37%	74.5%	91.4%
SAU800680	MLP100652	33%	93.1%	93.0%
SAU800680	MTU201189	36%	81.9%	81.8%
SAU800680	NGO101834	24%	90.4%	80.5%
SAU800680	NME202039	26%	79.3%	70.5%
SAU800680	PRT102028	46%	100%	97.9%
SAU800680	PAE204918	43%	96.3%	92.8%
SAU800680	PPU107578	41%	95.2%	91.8%
SAU800680	PSY104404	25%	94.7%	55.0%
SAU800680	SPA101481	20%	56.9%	24.8%
SAU800680	SAU800680	100%	100%	100%
SAU800680	SEP200723	81%	100%	100%
SAU800680	SHA100242	81%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800699	BAN102886	47%	98.4%	99.3%
SAU800699	BAN102711	48%	98.4%	99.3%
SAU800699	BBU100629	42%	98.0%	98.0%
SAU800699	BCE112651	28%	97.1%	89.6%
SAU800699	BMA107539	27%	95.8%	59.4%
SAU800699	CAC103266	34%	97.4%	98.7%
SAU800699	CBO101253	42%	97.4%	99.7%
SAU800699	CDF104515	43%	98.0%	99.0%
SAU800699	CDP100365	29%	91.5%	92.5%
SAU800699	EBC102987	29%	92.2%	92.3%
SAU800699	EFA201059	44%	98.0%	98.4%
SAU800699	EFM101242	43%	99.3%	100%
SAU800699	ECO101691	30%	95.8%	97.1%
SAU800699	HIN100427	30%	99.3%	99.0%
SAU800699	KPN300446	35%	36.3%	91.1%
SAU800699	KPN301962	28%	98.0%	99.0%
SAU800699	LMO100871	44%	99.7%	99.3%
SAU800699	MBV102255	26%	95.4%	87.9%
SAU800699	MLP100531	19%	88.2%	85.8%
SAU800699	MTU201996	26%	95.4%	87.9%
SAU800699	MGE100065	25%	81.4%	96.1%
SAU800699	MPN100076	26%	86.3%	87.3%
SAU800699	NME200956	20%	79.7%	75.9%
SAU800699	PMU101796	27%	96.1%	97.7%
SAU800699	PRT106003	29%	98.7%	98.1%
SAU800699	SPA103914	30%	99.0%	100%
SAU800699	STY100943	30%	99.0%	100%
SAU800699	STM101389	30%	99.0%	100%
SAU800699	SAU800699	100%	100%	100%
SAU800699	SEP200740	81%	100%	100%
SAU800699	SHA102369	77%	100%	100%
SAU800699	SMU100817	44%	99.0%	100%
SAU800699	SPN400779	46%	98.0%	99.0%
SAU800699	SPY200637	44%	98.0%	99.0%
SAU800699	YPS001092	28%	94.1%	93.3%
SAU800700	ABA102246	39%	76.5%	86.0%
SAU800700	BAN111327	40%	75.6%	100%
SAU800700	BAN110516	53%	98.0%	99.8%
SAU800700	BPT101778	24%	21.5%	90.3%
SAU800700	BBU100628	41%	96.8%	97.8%
SAU800700	BCE105566	24%	22.5%	96.7%
SAU800700	BFU103417	28%	21.8%	92.7%
SAU800700	BMA103307	28%	20.2%	76.2%
SAU800700	CTR200556	35%	22.5%	88.5%
SAU800700	CBO103578	46%	69.9%	97.6%
SAU800700	CDF102133	48%	98.3%	99.7%
SAU800700	CDP100375	34%	94.8%	97.7%
SAU800700	EBC101473	43%	75.5%	85.9%
SAU800700	EFA201062	49%	97.5%	98.9%
SAU800700	EFM202637	37%	95.2%	99.8%
SAU800700	ECO102126	44%	69.9%	79.4%
SAU800700	HIN100426	43%	70.2%	80.4%
SAU800700	KPN302673	43%	75.2%	85.1%
SAU800700	LMO101732	48%	98.2%	99.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800700	MGE100064	34%	94.2%	94.7%
SAU800700	MPN100077	35%	93.6%	93.8%
SAU800700	NGO101941	33%	22.4%	97.3%
SAU800700	NME200870	34%	22.4%	97.3%
SAU800700	PRT101283	28%	22.7%	96.1%
SAU800700	PAE203558	39%	21.9%	3.8%
SAU800700	PPU101409	40%	21.9%	3.8%
SAU800700	PSY105144	41%	19.3%	0.9%
SAU800700	SPA103916	45%	69.6%	99.3%
SAU800700	STY103897	44%	70.1%	97.6%
SAU800700	STM101392	46%	69.6%	93.9%
SAU800700	SAU800700	100%	100%	100%
SAU800700	SEP200741	87%	100%	100%
SAU800700	SHA102370	86%	97.5%	99.8%
SAU800700	SMU100819	45%	97.5%	99.5%
SAU800700	SPN400780	46%	97.5%	99.4%
SAU800700	SPY200638	47%	97.9%	99.8%
SAU800700	TPA100084	34%	22.7%	100%
SAU800700	VCH103241	43%	21.5%	2.1%
SAU800700	YPS001094	41%	73.5%	82.7%
SAU800701	ABA101441	30%	25.2%	16.2%
SAU800701	BAN112706	37%	94.9%	98.1%
SAU800701	BAN109134	42%	98.5%	97.6%
SAU800701	BFR11566	30%	97.7%	97.9%
SAU800701	BFR11862	30%	97.7%	96.9%
SAU800701	BPT100372	30%	19.6%	14.9%
SAU800701	BBU100150	32%	99.0%	98.8%
SAU800701	BCE111462	37%	96.7%	97.5%
SAU800701	BFU102712	37%	96.7%	97.5%
SAU800701	BMA103808	36%	96.7%	97.5%
SAU800701	CAC100532	42%	97.7%	97.6%
SAU800701	CBO103032	42%	86.8%	88.9%
SAU800701	CDF103827	38%	97.7%	97.1%
SAU800701	CDP101711	34%	83.7%	82.7%
SAU800701	EBC101139	32%	96.4%	96.8%
SAU800701	EFA200139	36%	97.2%	97.4%
SAU800701	EFM101955	34%	49.1%	97.8%
SAU800701	ECO100660	28%	96.4%	96.9%
SAU800701	HIN100133	30%	93.4%	95.5%
SAU800701	KPN301179	29%	96.4%	96.9%
SAU800701	LPN100461	48%	8.4%	7.6%
SAU800701	LMO101310	41%	99.5%	100%
SAU800701	MAV101737	32%	93.4%	93.7%
SAU800701	MBV105301	33%	94.1%	95.0%
SAU800701	MTU203289	33%	94.1%	95.0%
SAU800701	PMU100874	32%	90.1%	92.9%
SAU800701	PRT102743	35%	97.7%	95.9%
SAU800701	PAE203755	35%	96.9%	98.9%
SAU800701	PPU106243	32%	17.6%	10.9%
SAU800701	SPA101690	26%	94.7%	97.4%
SAU800701	STY101830	29%	94.7%	96.4%
SAU800701	SAU800701	100%	100%	100%
SAU800701	SEP200742	70%	99.7%	99.7%
SAU800701	SHA102517	66%	98.7%	98.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800701	SMU100804	39%	86.0%	88.0%
SAU800701	SPN401864	35%	93.4%	93.5%
SAU800701	SPY201302	37%	93.6%	93.7%
SAU800701	VCH100977	33%	86.8%	88.9%
SAU800701	YPS000074	32%	91.3%	93.3%
SAU800719	ABA100200	24%	30.0%	40.3%
SAU800719	BAN101020	52%	70.3%	98.7%
SAU800719	BAN106537	45%	94.1%	97.7%
SAU800719	BFR10189	22%	48.3%	47.7%
SAU800719	BPT100647	21%	48.9%	44.4%
SAU800719	BCE100990	25%	22.4%	23.2%
SAU800719	BMA102844	22%	21.7%	28.0%
SAU800719	CJU101363	28%	17.3%	19.2%
SAU800719	CAC103138	31%	88.1%	91.2%
SAU800719	CBO101190	31%	88.9%	89.7%
SAU800719	CBO100209	31%	95.8%	99.2%
SAU800719	EFA200629	45%	96.6%	91.2%
SAU800719	EFM200738	46%	95.5%	93.0%
SAU800719	ECO101469	29%	11.6%	13.1%
SAU800719	HN101218	21%	75.9%	79.4%
SAU800719	HPY100571	20%	85.0%	85.0%
SAU800719	KPN304077	25%	15.9%	17.5%
SAU800719	LPN102221	19%	80.3%	77.1%
SAU800719	LMO102885	52%	98.1%	97.2%
SAU800719	PMU101683	21%	73.8%	73.2%
SAU800719	PRT102753	24%	28.2%	33.6%
SAU800719	PAE201688	24%	54.3%	48%
SAU800719	PPU108921	23%	24.6%	61.9%
SAU800719	PPU112431	25%	48.0%	77.4%
SAU800719	PSY104669	24%	47.5%	42.3%
SAU800719	STY104492	22%	24.5%	22.5%
SAU800719	SAU800719	100%	100%	100%
SAU800719	SEP200765	89%	100%	100%
SAU800719	SHA101679	87%	99.8%	100%
SAU800719	SMU100078	40%	98.0%	90.8%
SAU800719	SPY200599	38%	96.6%	87.4%
SAU800719	VCH103522	25%	51.4%	45.5%
SAU800719	YPS003644	27%	23.2%	26.8%
SAU800720	ABA100489	37%	84.5%	95.8%
SAU800720	BAN110028	38%	37.4%	76.9%
SAU800720	BAN101564	26%	75.0%	95.1%
SAU800720	BAN109552	27%	20.2%	77.1%
SAU800720	BAN111328	24%	13.6%	89.1%
SAU800720	BAN108174	25%	13.6%	88%
SAU800720	BAN110379	32%	17.6%	75.9%
SAU800720	BAN108774	26%	13.8%	85.5%
SAU800720	BAN112693	31%	17.0%	78.3%
SAU800720	BAN101135	32%	17.0%	80.8%
SAU800720	BAN108206	41%	12%	97.9%
SAU800720	BAN100158	42%	24.5%	94.4%
SAU800720	BAN112678	44%	99.7%	99.5%
SAU800720	BFR10185	37%	46.7%	90.7%
SAU800720	BPT103035	35%	40.2%	82.9%
SAU800720	BCE109252	34%	99.0%	99.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800720	BFU108924	35%	99.0%	99.4%
SAU800720	BMA108966	34%	99.0%	97.3%
SAU800720	CJU100819	31%	54.1%	98.6%
SAU800720	CAC101791	42%	99.8%	99.4%
SAU800720	CBO101696	40%	89.3%	41.4%
SAU800720	CDF101289	39%	99.8%	95.8%
SAU800720	CDP101266	37%	39.4%	95.9%
SAU800720	EBC103175	38%	36.6%	92.6%
SAU800720	EFA201844	46%	98.6%	98.6%
SAU800720	EFM100646	48%	91.8%	98.3%
SAU800720	ECO100924	33%	43.7%	86.3%
SAU800720	HIN101309	35%	14.6%	82.8%
SAU800720	HIN101266	35%	43.2%	86.2%
SAU800720	KPN302187	38%	36.6%	92.9%
SAU800720	LPN103510	35%	97.4%	97.9%
SAU800720	LMO101330	45%	99.7%	100%
SAU800720	MCA100198	35%	37.4%	93.7%
SAU800720	MAV100344	36%	39.4%	95.7%
SAU800720	MBV101523	34%	96.5%	55.2%
SAU800720	MLP100773	35%	87.8%	46.8%
SAU800720	MTU202441	34%	96.5%	55.2%
SAU800720	NGO101191	34%	99.0%	97.8%
SAU800720	NME201150	34%	99.0%	98.7%
SAU800720	PMU100877	34%	52.5%	92.8%
SAU800720	PRT101963	34%	40%	82.9%
SAU800720	PAE204593	34%	40.2%	96.4%
SAU800720	PPU109750	36%	37.4%	94.7%
SAU800720	PSY102871	33%	99.2%	100%
SAU800720	SPA100983	35%	37.8%	95.8%
SAU800720	STY104621	37%	36.6%	92.6%
SAU800720	STM102138	33%	44.3%	88.3%
SAU800720	SAU800720	100%	100%	100%
SAU800720	SEP200773	80%	99.8%	100%
SAU800720	SHA100939	77%	29.6%	88.1%
SAU800720	SHA101681	81%	99.8%	100%
SAU800720	SMU100883	42%	99.7%	100%
SAU800720	SPN401411	44%	97.4%	98.4%
SAU800720	SPY200645	44%	96.5%	96.8%
SAU800720	VCH101463	34%	37.9%	81.5%
SAU800720	YPS002105	34%	39.7%	84.1%
SAU800732	ABA103998	25%	81.4%	79.4%
SAU800732	ABA101388	25%	86.7%	90.3%
SAU800732	BAN111908	50%	98.5%	100%
SAU800732	BFR10832	24%	97.8%	92.8%
SAU800732	BPT102919	26%	79.6%	66.8%
SAU800732	BCE105994	26%	85.4%	71.0%
SAU800732	BFU106488	25%	85.4%	69.6%
SAU800732	BMA101937	27%	85.4%	71.0%
SAU800732	CJU100204	22%	89.2%	84.7%
SAU800732	CPN200855	23%	88.5%	85.0%
SAU800732	CTR200210	22%	86.7%	83.2%
SAU800732	CAC103499	27%	94.1%	91.6%
SAU800732	CBO100701	26%	90.4%	86.0%
SAU800732	CDF101630	49%	98.1%	96.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800732	CDP101412	39%	98.5%	95.1%
SAU800732	EBC100530	37%	98.5%	97.8%
SAU800732	EFA201345	43%	98.5%	96.9%
SAU800732	EFM200562	42%	98.1%	96.6%
SAU800732	ECO102621	36%	98.5%	97.8%
SAU800732	HIN101625	22%	81.7%	77.4%
SAU800732	HPY100360	23%	89.2%	84.2%
SAU800732	KPN304452	36%	98.5%	97.5%
SAU800732	LPN102663	24%	85.4%	77.9%
SAU800732	LMO101175	25%	89.2%	83.1%
SAU800732	MCA101601	23%	81.7%	77.4%
SAU800732	MAV103576	38%	98.5%	96.3%
SAU800732	MBV102489	38%	98.5%	96.9%
SAU800732	MLP101065	37%	98.5%	96%
SAU800732	MTU201948	38%	98.5%	96.9%
SAU800732	MGE100234	32%	98.5%	91.8%
SAU800732	MPN100514	32%	98.5%	92.0%
SAU800732	NGO100274	23%	81.7%	76.0%
SAU800732	NME201364	22%	81.7%	77.5%
SAU800732	PMU100719	22%	81.7%	77.4%
SAU800732	PRT102696	38%	98.5%	96.9%
SAU800732	PAE201154	24%	76.5%	61.9%
SAU800732	PPU108078	22%	76.5%	61.8%
SAU800732	PSY104507	23%	76.5%	61.9%
SAU800732	SPA100937	38%	98.5%	97.8%
SAU800732	STY102724	38%	98.5%	97.8%
SAU800732	STM103201	38%	98.5%	97.8%
SAU800732	SAU800732	100%	100%	100%
SAU800732	SEP201119	54%	99.1%	94.1%
SAU800732	SEP200799	91%	99.7%	100%
SAU800732	SHA100853	90%	99.7%	100%
SAU800732	SMU100848	41%	98.1%	97.2%
SAU800732	SPN401066	42%	97.8%	96.6%
SAU800732	SPY201058	41%	97.8%	96.9%
SAU800732	TPA100052	25%	97.8%	92.3%
SAU800732	VCH101236	23%	81.7%	75.1%
SAU800732	YPS001318	37%	98.5%	96.6%
SAU800733	ABA105082	38%	94.7%	97.8%
SAU800733	BAN113556	34%	85.1%	99.6%
SAU800733	BAN109705	34%	96.0%	89.9%
SAU800733	CJU101276	47%	99.1%	99.1%
SAU800733	CBO102064	50%	97.5%	99.4%
SAU800733	CDF100649	49%	98.1%	100%
SAU800733	EFA201992	44%	95.7%	98.1%
SAU800733	EFM202344	40%	95.7%	97.8%
SAU800733	NGO100092	39%	94.4%	94.4%
SAU800733	NME200420	40%	94.4%	94.4%
SAU800733	PRT102497	40%	96.0%	96.2%
SAU800733	PPU100159	38%	94.1%	97.1%
SAU800733	SAU800733	100%	100%	100%
SAU800733	SEP200801	78%	100%	99.7%
SAU800733	SHA100854	78%	99.4%	99.7%
SAU800733	SMU100104	50%	98.5%	99.4%
SAU800733	SPN401682	38%	96.6%	96.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800733	VCH102962	44%	96.0%	98.4%
SAU800733	YPS002721	39%	95.7%	96.6%
SAU800737	SAU800737	100%	100%	100%
SAU800737	SEP200811	70%	100%	100%
SAU800737	SHA102001	72%	100%	100%
SAU800737	SMU100332	46%	98.1%	99.0%
SAU800737	SPN301332	42%	99.0%	100%
SAU800737	SPY200154	38%	98.1%	96.1%
SAU800738	ABA100810	25%	88.6%	90.9%
SAU800738	BAN105237	37%	92.8%	95.5%
SAU800738	BAN104566	60%	97.4%	98.0%
SAU800738	BFR11211	23%	77.9%	95.1%
SAU800738	BPT102727	23%	76.5%	82.1%
SAU800738	BBU100597	31%	90.2%	92.7%
SAU800738	BCE105021	32%	76.5%	84.4%
SAU800738	BFU110503	28%	56.7%	31.0%
SAU800738	BMA103015	21%	75.2%	76.3%
SAU800738	CJU101581	34%	61.6%	68.2%
SAU800738	CPN200851	32%	91.5%	91.4%
SAU800738	CTR200213	35%	91.5%	93.9%
SAU800738	CAC101781	47%	97.4%	98.0%
SAU800738	CBO101419	48%	97.4%	97.7%
SAU800738	CDF101126	42%	98.4%	95.6%
SAU800738	CDP100735	36%	42.3%	40.6%
SAU800738	EBC104194	26%	80.1%	86.3%
SAU800738	EFA200829	52%	96.1%	98.3%
SAU800738	EFM201956	54%	92.5%	91.3%
SAU800738	ECO103874	26%	86.6%	92.1%
SAU800738	HIN100255	29%	86.3%	92.1%
SAU800738	HPY101397	27%	89.3%	96.1%
SAU800738	KPN300758	27%	78.8%	85.1%
SAU800738	LPN101622	36%	91.5%	93.1%
SAU800738	LMO102057	59%	95.4%	98.3%
SAU800738	MCA100620	26%	57.3%	67.1%
SAU800738	MAV103805	26%	90.6%	94.1%
SAU800738	MBV102338	26%	90.6%	94.0%
SAU800738	MLP101458	25%	88.9%	92.6%
SAU800738	MTU200480	26%	90.6%	94.0%
SAU800738	NGO100898	25%	91.2%	96.8%
SAU800738	NME200943	25%	91.2%	96.8%
SAU800738	PMU101589	25%	79.5%	85.9%
SAU800738	PRT102712	26%	92.2%	97.1%
SAU800738	PAE202975	23%	81.1%	89.1%
SAU800738	PPU101791	24%	88.6%	95.9%
SAU800738	PSY101711	23%	84.7%	92.3%
SAU800738	SPA103331	26%	85.7%	91.5%
SAU800738	STY102701	27%	85.7%	91.5%
SAU800738	STM102039	27%	85.3%	91.2%
SAU800738	SAU800738	100%	100%	100%
SAU800738	SEP200812	83%	99.7%	100%
SAU800738	SHA102002	84%	98.7%	98.7%
SAU800738	SMU100056	53%	92.5%	92.8%
SAU800738	SPN401246	52%	96.7%	94.0%
SAU800738	SPY200834	51%	92.8%	96.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800738	TPA100089	28%	90.9%	92.4%
SAU800738	VCH100313	28%	83.4%	84.9%
SAU800738	YPS000538	24%	78.8%	84.3%
SAU800742	SAU800742	100%	100%	100%
SAU800742	SEP200819	77%	99.5%	98.9%
SAU800742	SHA102006	73%	99.2%	99.5%
SAU800743	BAN100661	50%	89.7%	89.4%
SAU800743	BAN105794	55%	99.5%	99.5%
SAU800743	BFR11051	54%	98.3%	99.0%
SAU800743	CPN200966	29%	16.7%	14.8%
SAU800743	CTR200116	27%	17.2%	15.3%
SAU800743	CAC103052	53%	98.8%	99.3%
SAU800743	CBO101160	52%	97.5%	98.0%
SAU800743	CDF102303	50%	99.5%	99.5%
SAU800743	EBC102861	51%	98.0%	98.5%
SAU800743	EFA202002	47%	97.5%	98.3%
SAU800743	EFA202365	54%	98.5%	99.0%
SAU800743	EFM200402	50%	98.5%	98.8%
SAU800743	ECO101100	51%	99.0%	99.3%
SAU800743	HIN101314	43%	98.3%	97.6%
SAU800743	KPN302598	50%	98.0%	97.8%
SAU800743	LMO102174	53%	98.0%	98.0%
SAU800743	PMU100265	44%	97.5%	96.8%
SAU800743	PRT102290	38%	96.3%	98.0%
SAU800743	SPA104230	52%	86.0%	98.0%
SAU800743	STY102563	50%	98.0%	98.0%
SAU800743	STM102752	50%	98.0%	98.0%
SAU800743	SAU800743	100%	100%	100%
SAU800743	SEP200821	80%	100%	99.0%
SAU800743	SHA102007	78%	100%	99.8%
SAU800743	SMU100892	53%	97.8%	98.3%
SAU800743	SPN400913	51%	98.0%	98.8%
SAU800743	SPY200591	50%	97.8%	98.5%
SAU800743	VCH102915	49%	99.3%	98.8%
SAU800743	YPS003245	49%	98.0%	97.6%
SAU800753	ABA101280	46%	90.2%	97.6%
SAU800753	BAN110913	41%	99.5%	99.4%
SAU800753	BAN103692	59%	99.9%	99.5%
SAU800753	BFR11725	38%	3.6%	8.8%
SAU800753	BPT102975	44%	100%	99.7%
SAU800753	BBU100153	40%	98.8%	98.4%
SAU800753	BCE111466	51%	68.0%	94.8%
SAU800753	BFU106498	45%	99.9%	99.5%
SAU800753	BMA103047	45%	99.9%	99.5%
SAU800753	CJU100872	46%	98.8%	97.4%
SAU800753	CPN201009	41%	7.2%	19.1%
SAU800753	CTR200074	41%	4.0%	16.4%
SAU800753	CAC100650	52%	100%	99.8%
SAU800753	CBO100098	53%	100%	99.2%
SAU800753	CDF100803	49%	92.5%	98.6%
SAU800753	CDF101445	48%	100%	100%
SAU800753	CDP100932	46%	94.3%	99.2%
SAU800753	EBC107179	51%	44.2%	96.2%
SAU800753	EFA200590	56%	99.8%	99.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800753	EFM100280	61%	26.8%	98.2%
SAU800753	ECO100098	45%	98.8%	98.3%
SAU800753	HIN100888	42%	99.9%	99.3%
SAU800753	HPY100773	46%	98.8%	97.3%
SAU800753	KPN300997	45%	98.8%	98.2%
SAU800753	LPN103376	46%	98.7%	98.2%
SAU800753	LMO101013	60%	99.9%	99.5%
SAU800753	MCA100812	42%	98.8%	98.4%
SAU800753	MAV101468	46%	91.3%	88.4%
SAU800753	MBV103337	46%	94.0%	90.8%
SAU800753	MLP100475	46%	92.6%	88.8%
SAU800753	MTU203197	46%	95.3%	90.9%
SAU800753	MGE100074	42%	91.1%	94.3%
SAU800753	MPN100621	43%	91.1%	94.1%
SAU800753	NGO100323	45%	98.8%	98.4%
SAU800753	NME201594	45%	98.8%	98.4%
SAU800753	PMU101219	45%	99.5%	98.9%
SAU800753	PRT105129	46%	98.8%	98.3%
SAU800753	PAE204401	45%	98.8%	98.4%
SAU800753	PPU107707	46%	98.8%	95.4%
SAU800753	PSY103871	46%	97.7%	99.6%
SAU800753	SPA100472	42%	64.3%	85.7%
SAU800753	STY103214	45%	98.8%	98.3%
SAU800753	STM102926	45%	98.8%	98.3%
SAU800753	SAU800753	100%	100%	100%
SAU800753	SEP201381	90%	100%	99.9%
SAU800753	SHA101267	89%	100%	99.8%
SAU800753	SMU101178	55%	99.6%	99.2%
SAU800753	SPN401543	54%	99.6%	99.3%
SAU800753	SPY201389	53%	99.6%	99.0%
SAU800753	TPA100375	42%	98.8%	98.5%
SAU800753	URU100118	43%	91.3%	91.4%
SAU800753	VCH102359	46%	99.6%	99.2%
SAU800753	YPS001804	45%	98.8%	98.3%
SAU800759	ABA101958	56%	99.1%	100%
SAU800759	BAN113089	38%	93.8%	57.7%
SAU800759	BAN100680	70%	99.5%	98.1%
SAU800759	BFR11670	54%	12.1%	75.6%
SAU800759	BPT100944	56%	11.9%	75.8%
SAU800759	BBU100836	53%	75.3%	12.1%
SAU800759	BCE103574	58%	11.8%	75.5%
SAU800759	BFU103391	57%	74.9%	11.6%
SAU800759	BMA102344	57%	98.5%	100%
SAU800759	CJU100311	51%	99.2%	99.7%
SAU800759	CPN200666	35%	62.9%	99.8%
SAU800759	CTR200602	34%	60.7%	99.4%
SAU800759	CAC103028	61%	74.9%	11.8%
SAU800759	CBO100949	63%	74.9%	11.8%
SAU800759	CDF101156	61%	98.5%	99.6%
SAU800759	CDP100967	57%	11.6%	75.1%
SAU800759	EBC104211	57%	11.8%	76.1%
SAU800759	EFA200963	68%	99.1%	100%
SAU800759	EFM100494	74%	33.2%	54.9%
SAU800759	ECO103952	57%	11.8%	76.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800759	HIN100236	58%	12.9%	76.9%
SAU800759	HPY100696	51%	75.2%	12.2%
SAU800759	KPN300132	73%	75.4%	91.3%
SAU800759	KPN304697	57%	11.8%	76.0%
SAU800759	LPN101592	58%	99.1%	99.1%
SAU800759	LMO102288	69%	100%	99.3%
SAU800759	MCA100016	61%	33.0%	55.9%
SAU800759	MAV106576	59%	74.9%	11.4%
SAU800759	MBV101262	56%	11.4%	78.7%
SAU800759	MLP100862	58%	76.3%	13.0%
SAU800759	MTU201617	58%	74.9%	11.4%
SAU800759	MGE100431	55%	11.6%	74.6%
SAU800759	MPN100223	55%	11.6%	75.1%
SAU800759	NGO101264	58%	98.6%	95.3%
SAU800759	NME201071	58%	98.5%	98.6%
SAU800759	PMU101951	58%	12.8%	76.8%
SAU800759	PRT100660	58%	75.4%	12.3%
SAU800759	PAE204232	58%	11.8%	75.7%
SAU800759	PPU108153	58%	11.8%	75.6%
SAU800759	PSY105787	57%	5.1%	74.0%
SAU800759	SPA102876	46%	10.4%	74.8%
SAU800759	STY102276	57%	11.8%	76.0%
SAU800759	SAU800759	100%	100%	100%
SAU800759	SEP201393	90%	99.3%	99.7%
SAU800759	SHA101501	91%	99.4%	99.8%
SAU800759	SMU101222	68%	62.6%	99.5%
SAU800759	SPN400171	66%	99.1%	99.9%
SAU800759	SPY201403	67%	74.9%	11.8%
SAU800759	TPA100510	55%	75.4%	12.1%
SAU800759	UUR100101	54%	74.9%	11.8%
SAU800759	VCH100389	58%	11.6%	75.7%
SAU800759	YPS002814	57%	99.1%	99.6%
SAU800760	BAN107071	45%	95.2%	97.7%
SAU800760	BAN109743	63%	96.1%	96.4%
SAU800760	BPT101777	36%	98.4%	99.7%
SAU800760	BCE114457	35%	92.6%	84.7%
SAU800760	BFU103416	35%	92.6%	89.4%
SAU800760	BMA105321	35%	92.3%	89.1%
SAU800760	CAC103664	46%	96.1%	97.7%
SAU800760	CBO103006	44%	98.1%	98.7%
SAU800760	CDF101148	45%	96.8%	97.1%
SAU800760	EFA201005	50%	96.8%	96.8%
SAU800760	EFM101937	53%	49.7%	96.2%
SAU800760	LMO102906	56%	99.4%	98.7%
SAU800760	MGE100087	30%	90.6%	90.4%
SAU800760	MPN100608	32%	99.4%	98.7%
SAU800760	NGO101943	35%	96.5%	93.8%
SAU800760	NME200871	35%	96.5%	93.8%
SAU800760	SAU800760	100%	100%	100%
SAU800760	SEP201395	89%	100%	100%
SAU800760	SHA101502	88%	100%	99.7%
SAU800760	SMU100034	49%	97.7%	97.7%
SAU800760	SPN401269	49%	96.8%	95.3%
SAU800760	SPY200421	46%	97.7%	98.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800760	TPA100584	46%	95.8%	93.4%
SAU800760	UUR100074	29%	96.5%	97.4%
SAU800765	ABA105050	37%	93.1%	97.2%
SAU800765	BAN105743	42%	81.8%	98.0%
SAU800765	BAN103527	53%	97.0%	99.0%
SAU800765	BPT101774	36%	89.1%	93.1%
SAU800765	BCE105719	40%	94.4%	94.7%
SAU800765	BFU103415	40%	95.4%	92.6%
SAU800765	BMA101496	38%	94.1%	96.0%
SAU800765	CAC100640	46%	95.7%	98.6%
SAU800765	CBO103526	47%	95.7%	98.6%
SAU800765	CDF101175	46%	93.7%	98.6%
SAU800765	CDP100284	41%	92.7%	94.2%
SAU800765	EBC104047	40%	92.7%	96.8%
SAU800765	EFA200958	50%	93.4%	94.6%
SAU800765	EFM102057	65%	13.5%	78%
SAU800765	ECO103135	40%	92.7%	96.8%
SAU800765	HIN101120	42%	88.4%	91.0%
SAU800765	KPN301883	41%	92.7%	96.8%
SAU800765	LMO101258	52%	95.4%	97.6%
SAU800765	MCA100868	36%	93.7%	95.9%
SAU800765	MAV100819	40%	93.4%	91.3%
SAU800765	MBV102154	40%	96.0%	95.7%
SAU800765	MLP100349	40%	96.4%	97.7%
SAU800765	MTU201402	40%	96.0%	95.7%
SAU800765	NGO101945	34%	95.4%	99.3%
SAU800765	NME200872	35%	93.7%	97.5%
SAU800765	PMU100169	42%	93.1%	95.8%
SAU800765	PRT101284	40%	92.7%	97.2%
SAU800765	PAE204463	38%	93.1%	98.3%
SAU800765	PPU103901	39%	93.1%	98.9%
SAU800765	PSY104751	39%	93.1%	98.6%
SAU800765	SPA101395	40%	92.7%	97.2%
SAU800765	STY101515	40%	92.7%	96.8%
SAU800765	STM101784	40%	92.7%	96.8%
SAU800765	SAU800765	100%	100%	100%
SAU800765	SEP201405	84%	99.7%	100%
SAU800765	SHA100647	77%	98.7%	100%
SAU800765	SMU100310	48%	94.7%	95.6%
SAU800765	SPN401423	47%	94.7%	95.6%
SAU800765	SPY200470	49%	93.1%	93.9%
SAU800765	VCH102495	43%	89.4%	93.7%
SAU800765	YPS002374	41%	92.7%	96.8%
SAU800766	BAN111073	43%	90.3%	98.4%
SAU800766	BAN103579	50%	94.6%	98.4%
SAU800766	CAC100700	42%	94.6%	69.8%
SAU800766	CBO102977	42%	94.6%	70.8%
SAU800766	CDF101172	43%	95.2%	86.0%
SAU800766	CDP100282	36%	71.9%	77.4%
SAU800766	EBC102211	35%	74.0%	81.5%
SAU800766	EFA200956	39%	76.4%	78.5%
SAU800766	EFM101137	36%	48.6%	71.4%
SAU800766	ECO100756	36%	74.0%	81.5%
SAU800766	KPN303577	36%	74.0%	81.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800766	LMO102839	46%	90.0%	91.3%
SAU800766	MAV100820	37%	71.0%	68.7%
SAU800766	MBV102152	38%	71.0%	71.9%
SAU800766	MLP100350	37%	71.0%	68.5%
SAU800766	MTU201403	38%	71.0%	71.9%
SAU800766	PMU100626	36%	74.9%	80.5%
SAU800766	PRT106022	32%	90.6%	95.2%
SAU800766	SPA102731	34%	74.0%	81.5%
SAU800766	STY102319	34%	74.0%	81.5%
SAU800766	SAU800766	100%	100%	100%
SAU800766	SEP201410	79%	100%	100%
SAU800766	SHA100648	72%	98.5%	99.4%
SAU800766	SMU100308	40%	92.1%	95.4%
SAU800766	SPN401422	41%	76.4%	80%
SAU800766	SPY200471	42%	75.2%	78.5%
SAU800766	VCH101004	34%	74.0%	83.1%
SAU800766	YPS002147	33%	74.6%	80.8%
SAU800767	BAN105219	58%	99.4%	99.1%
SAU800767	BAN112086	62%	99.4%	99.1%
SAU800767	CAC102108	46%	97.8%	98.7%
SAU800767	CBO101086	48%	98.4%	99.7%
SAU800767	CDF101166	46%	97.8%	98.1%
SAU800767	CDP100280	25%	96.8%	92.7%
SAU800767	EFA200954	60%	97.8%	98.7%
SAU800767	EFM101138	59%	97.8%	98.7%
SAU800767	LMO101438	61%	98.7%	96.3%
SAU800767	MAV100821	27%	97.1%	93.3%
SAU800767	MBV102150	26%	95.9%	92.6%
SAU800767	MLP100351	27%	95.5%	92.3%
SAU800767	MTU201404	26%	95.9%	92.6%
SAU800767	MGE100105	28%	74.8%	84.3%
SAU800767	MPN100590	25%	58.0%	66.1%
SAU800767	SAU800767	100%	100%	100%
SAU800767	SEP201411	91%	100%	100%
SAU800767	SHA100649	91%	100%	100%
SAU800767	SMU100307	41%	97.5%	100%
SAU800767	SPN401421	44%	90.1%	93.4%
SAU800767	SPY200472	41%	97.5%	100%
SAU800767	UUR100071	26%	97.5%	92.4%
SAU800771	BAN108269	31%	70.0%	69.6%
SAU800771	BAN110794	45%	98.8%	97.7%
SAU800771	BCE114311	21%	72.7%	74.4%
SAU800771	BFU102348	23%	73.0%	74.9%
SAU800771	BMA106496	30%	70.9%	73.2%
SAU800771	CAC100566	40%	100%	98.3%
SAU800771	CBO100266	41%	99.7%	97.4%
SAU800771	CDF100380	39%	99.7%	99.1%
SAU800771	CDP101585	25%	75.1%	72.9%
SAU800771	EBC103770	26%	65.3%	71.7%
SAU800771	EFA204507	43%	97.6%	96.5%
SAU800771	EFM102024	45%	42.4%	98.6%
SAU800771	ECO101483	28%	70.0%	75.1%
SAU800771	KPN300900	26%	58.2%	96.2%
SAU800771	LPN102590	28%	29.1%	26.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800771	LMO102755	46%	100%	98.0%
SAU800771	PMU101646	24%	81.6%	89.3%
SAU800771	PRT100531	23%	76.3%	83.8%
SAU800771	PSY101669	25%	70.3%	80.8%
SAU800771	SPA102585	24%	70.3%	75.2%
SAU800771	STY103167	25%	69.7%	74.6%
SAU800771	SAU800771	100%	100%	100%
SAU800771	SEP201414	81%	100%	100%
SAU800771	SHA101580	81%	99.7%	99.7%
SAU800771	SPN400228	24%	71.8%	77.0%
SAU800771	SPY201573	23%	84.6%	89.9%
SAU800771	VCH103344	21%	77.2%	81.0%
SAU800771	YPS000053	21%	84.6%	91.5%
SAU800772	CJU101322	45%	98.8%	99.1%
SAU800772	CPN200121	46%	99.4%	100%
SAU800772	CTR200781	48%	99.4%	100%
SAU800772	CAC100263	73%	99.1%	99.4%
SAU800772	CDF102031	71%	99.4%	99.7%
SAU800772	CDP100278	53%	99.1%	99.4%
SAU800772	EBC102594	57%	88.1%	99.3%
SAU800772	EFA202219	72%	99.4%	100%
SAU800772	EFM201407	57%	99.4%	100%
SAU800772	ECO202059	58%	98.5%	99.4%
SAU800772	KPN300047	57%	44.3%	91.3%
SAU800772	KPN300286	56%	67.0%	88.9%
SAU800772	KPN305000	56%	97.9%	99.1%
SAU800772	LMO100694	74%	100%	100%
SAU800772	MAV104847	50%	99.1%	99.4%
SAU800772	MBV102165	50%	96.7%	97.1%
SAU800772	MLP100354	49%	96.7%	97.1%
SAU800772	MTU201417	50%	96.7%	97.1%
SAU800772	MGE100307	54%	98.8%	97.9%
SAU800772	MPN100411	55%	98.8%	97.9%
SAU800772	NGO100027	70%	98.8%	92.7%
SAU800772	NME200230	70%	98.8%	99.1%
SAU800772	PMU100924	45%	98.5%	98.5%
SAU800772	SAU800772	100%	100%	100%
SAU800772	SEP201415	92%	100%	100%
SAU800772	SHA101581	92%	100%	100%
SAU800772	SMU100690	68%	100%	100%
SAU800772	SPN401823	69%	100%	93.3%
SAU800772	SPY200203	67%	100%	100%
SAU800772	VCH101970	47%	99.1%	100%
SAU800772	YPS000708	47%	99.1%	99.1%
SAU800776	ABA104568	60%	99.8%	100%
SAU800776	BAN112137	75%	8.5%	100%
SAU800776	BAN104797	55%	99.3%	100%
SAU800776	BAN107021	75%	100%	100%
SAU800776	BFR12193	72%	96.8%	97.4%
SAU800776	BPT101700	62%	99.5%	99.8%
SAU800776	BBU100336	62%	98.8%	98.4%
SAU800776	BCE108074	64%	99.5%	99.8%
SAU800776	BFU100260	65%	66.1%	96.9%
SAU800776	BFU102355	63%	99.5%	99.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800776	BMA107873	60%	49.3%	100%
SAU800776	CJU101577	53%	98.4%	99.8%
SAU800776	CPN201052	57%	95.6%	94.6%
SAU800776	CTR200865	55%	98.4%	98.3%
SAU800776	CAC102398	64%	99.3%	98.6%
SAU800776	CBO103490	65%	99.3%	98.6%
SAU800776	CDF100088	71%	22.6%	100%
SAU800776	CDF100292	69%	100%	96.0%
SAU800776	CDP100889	58%	98.8%	98.8%
SAU800776	EBC102297	58%	98.4%	98.6%
SAU800776	EFA202223	74%	99.5%	99.3%
SAU800776	EFM100534	72%	88.2%	99.2%
SAU800776	ECO102719	58%	98.4%	98.6%
SAU800776	HIN100911	59%	98.6%	98.9%
SAU800776	HPY100151	53%	96.1%	96.7%
SAU800776	KPN305114	58%	98.4%	98.6%
SAU800776	LPN102643	56%	94.9%	96.2%
SAU800776	LMO102639	73%	100%	100%
SAU800776	MCA101099	58%	98.8%	95.5%
SAU800776	MAV105503	58%	98.8%	98.1%
SAU800776	MBV103580	56%	98.8%	95.9%
SAU800776	MLP100182	55%	98.8%	94.2%
SAU800776	MTU201012	56%	98.8%	98.1%
SAU800776	MGE100419	52%	98.8%	96.1%
SAU800776	MPN100236	52%	98.8%	96.5%
SAU800776	NGO100995	62%	100%	100%
SAU800776	NME201361	61%	100%	100%
SAU800776	PMU101871	59%	98.6%	98.8%
SAU800776	PRT101034	58%	98.4%	98.6%
SAU800776	PAE203633	62%	98.8%	99.5%
SAU800776	PPU109835	61%	94.2%	99.5%
SAU800776	PSY104326	61%	98.8%	91.0%
SAU800776	SPA104184	58%	98.4%	98.6%
SAU800776	STY103508	58%	98.4%	98.6%
SAU800776	SAU800776	100%	100%	100%
SAU800776	SEP201419	94%	100%	100%
SAU800776	SHA101585	97%	40.1%	100%
SAU800776	SMU100190	82%	100%	100%
SAU800776	SPN401036	81%	100%	100%
SAU800776	SPY200535	81%	100%	100%
SAU800776	TPA100808	58%	98.8%	98.8%
SAU800776	UUR100184	45%	98.2%	98.9%
SAU800776	VCH102411	57%	98.4%	98.6%
SAU800776	YPS000129	58%	98.4%	98.8%
SAU800777	ECO200746	26%	55.9%	80%
SAU800777	KPN101512	27%	63.2%	72.8%
SAU800777	SAU800777	100%	100%	100%
SAU800777	SEP203649	65%	100%	100%
SAU800777	SHA100415	59%	97.4%	89.7%
SAU800782	ABA100100	42%	96.1%	94.3%
SAU800782	BAN113552	61%	97.4%	96.8%
SAU800782	BFR10554	49%	90.9%	94%
SAU800782	BPT101160	45%	92.9%	92.9%
SAU800782	BBU100033	47%	92.2%	94.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800782	BCE114906	43%	93.5%	98.0%
SAU800782	BFU105731	42%	93.5%	98.0%
SAU800782	BMA109523	42%	93.5%	98.0%
SAU800782	CJU101031	40%	92.2%	96%
SAU800782	CPN200415	47%	100%	90.9%
SAU800782	CTR200342	47%	94.2%	96.0%
SAU800782	CAC101932	60%	98.1%	98.1%
SAU800782	CBO103142	65%	99.4%	98.1%
SAU800782	CDF101608	54%	100%	92.6%
SAU800782	CDP101712	49%	77.9%	94.5%
SAU800782	EBC102473	47%	98.1%	97.5%
SAU800782	EFA201607	62%	92.2%	92.2%
SAU800782	EFM200170	58%	92.2%	92.2%
SAU800782	ECO102567	46%	98.1%	97.5%
SAU800782	HIN100962	47%	98.1%	96.3%
SAU800782	HPY101423	37%	94.2%	96.7%
SAU800782	KPN301267	47%	98.1%	97.5%
SAU800782	LPN103276	45%	96.8%	96.2%
SAU800782	LMO101222	68%	93.5%	93.5%
SAU800782	MCA102816	46%	98.1%	98.1%
SAU800782	MAV101105	47%	98.1%	89.3%
SAU800782	MBV105886	48%	93.5%	90%
SAU800782	MLP100416	50%	93.5%	90%
SAU800782	MTU203060	48%	93.5%	90%
SAU800782	MGE100061	36%	92.2%	97.9%
SAU800782	MPN100081	37%	89.0%	93.2%
SAU800782	NGO100293	45%	92.2%	95.3%
SAU800782	NME201585	45%	92.2%	95.3%
SAU800782	PMU100217	45%	98.1%	96.9%
SAU800782	PRT103727	48%	98.1%	97.5%
SAU800782	PAE204764	45%	96.8%	94.3%
SAU800782	PPU108560	42%	96.8%	93.8%
SAU800782	PSY104780	42%	98.1%	95%
SAU800782	SPA103688	47%	98.1%	97.5%
SAU800782	STY102601	47%	98.1%	97.5%
SAU800782	STM102501	47%	98.1%	97.5%
SAU800782	SAU800782	100%	100%	100%
SAU800782	SEP201423	89%	100%	100%
SAU800782	SHA100862	86%	100%	100%
SAU800782	SMU101107	57%	96.1%	95.5%
SAU800782	SPN400879	60%	92.9%	92.3%
SAU800782	SPY200359	57%	92.2%	91.6%
SAU800782	TPA100182	42%	86.4%	99.3%
SAU800782	UUR100056	41%	92.2%	97.9%
SAU800782	VCH100832	43%	98.7%	98.1%
SAU800782	YPS002052	46%	98.1%	97.5%
SAU800811	BAN100965	20%	36.0%	19.6%
SAU800811	BAN111001	21%	5.3%	7.2%
SAU800811	BAN109365	18%	37.2%	25.7%
SAU800811	BFR100579	20%	33.7%	12.7%
SAU800811	BFR102947	19%	18.3%	20.9%
SAU800811	BFR101444	18%	12.9%	23.1%
SAU800811	BBU100325	24%	20.3%	15.5%
SAU800811	BFU103969	74%	14.0%	25%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800811	BMA101165	50%	12.9%	15.2%
SAU800811	BMA103470	54%	6.8%	27.2%
SAU800811	BMA104606	29%	25.0%	64.3%
SAU800811	CJU101103	18%	29.5%	62.5%
SAU800811	CPN200033	17%	32.8%	29.9%
SAU800811	CAC102616	22%	19.1%	39.3%
SAU800811	CBO103272	14%	21.1%	59.3%
SAU800811	CBO103679	27%	2.9%	19.6%
SAU800811	CDF101661	24%	37.6%	65.9%
SAU800811	EFA203524	24%	25.1%	30.4%
SAU800811	EFM201584	17%	48.0%	58.5%
SAU800811	ECO103311	23%	25.0%	61.0%
SAU800811	HPY200074	17%	45.8%	33.9%
SAU800811	KPN206267	72%	35.0%	26.5%
SAU800811	LPN101461	35%	37.2%	43.2%
SAU800811	LMO101963	21%	15.3%	35.6%
SAU800811	LMO102167	36%	30.1%	60.9%
SAU800811	MCA100440	24%	6.2%	11.5%
SAU800811	MAV104123	30%	29.4%	12.4%
SAU800811	MBV101055	29%	9.7%	55.6%
SAU800811	MLP100905	30%	10.1%	63.1%
SAU800811	MTU202408	29%	9.7%	53.4%
SAU800811	MGE100318	19%	47.5%	39.7%
SAU800811	MPN100275	10%	32.2%	8.9%
SAU800811	MPN100632	24%	19.9%	24.1%
SAU800811	NME201599	17%	1.1%	11.9%
SAU800811	PAE203113	26%	4.6%	24.3%
SAU800811	PSY101467	16%	17.1%	60.2%
SAU800811	PSY103818	29%	8.9%	60.2%
SAU800811	PSY108790	15%	25.8%	26.2%
SAU800811	SPA103181	23%	38.0%	45.5%
SAU800811	STM102835	21%	34.5%	12.4%
SAU800811	SAU802630	40%	99.6%	98.7%
SAU800811	SAU800811	100%	100%	100%
SAU800811	SEP200110	28%	95.2%	26.3%
SAU800811	SHA100540	29%	96.3%	86.9%
SAU800811	SHA102998	26%	96.9%	59.9%
SAU800811	SHA100562	74%	38.6%	7.1%
SAU800811	SMU100238	24%	13.6%	20.4%
SAU800811	SMU100747	22%	20.5%	31.1%
SAU800811	SMU102548	21%	9.0%	25.0%
SAU800811	SPN401402	21%	95.4%	92.4%
SAU800811	SPY201545	24%	80.9%	60.7%
SAU800811	TPA100177	18%	34.2%	60.4%
SAU800824	ABA100587	27%	92.7%	95.0%
SAU800824	BAN104019	31%	42.5%	39.5%
SAU800824	BAN110518	27%	93.3%	86.8%
SAU800824	BFU103528	27%	98.4%	90.6%
SAU800824	CAC102383	28%	96.9%	93.9%
SAU800824	CDP100459	25%	93.8%	50.7%
SAU800824	EFM200186	26%	93.3%	88.5%
SAU800824	ECO100628	27%	95.3%	89.2%
SAU800824	KPN302086	27%	90.2%	84.2%
SAU800824	LMO101118	50%	98.4%	93.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800824	MCA101119	29%	79.3%	75.1%
SAU800824	PMU100634	32%	78.2%	72.2%
SAU800824	PRT104691	27%	91.2%	85.1%
SAU800824	PAE201279	28%	79.8%	79.4%
SAU800824	PPU104544	24%	88.6%	92.0%
SAU800824	PSY104527	28%	93.8%	96.8%
SAU800824	SPA100941	27%	90.2%	84.2%
SAU800824	STY100639	27%	90.2%	84.2%
SAU800824	STM100395	27%	90.2%	84.2%
SAU800824	SAU800824	100%	100%	100%
SAU800824	SEP201439	54%	99.0%	98.5%
SAU800824	SHA102912	57%	99.0%	95.0%
SAU800824	SMU100876	47%	99.0%	96.0%
SAU800824	SPN400219	26%	95.9%	83.1%
SAU800824	SPY201361	30%	94.8%	89.4%
SAU800829	ABA105130	32%	88.7%	75.5%
SAU800829	CDF103551	32%	92.9%	85.7%
SAU800829	EFA201048	30%	96.2%	88.5%
SAU800829	EFM201252	31%	92.9%	88.1%
SAU800829	ECO101661	30%	97.5%	94.8%
SAU800829	KPN303925	30%	84.5%	78.8%
SAU800829	LMO100162	31%	96.2%	88.5%
SAU800829	NGO100151	29%	96.6%	88.2%
SAU800829	NME201519	29%	84.9%	75.8%
SAU800829	SPA103732	33%	91.6%	86.5%
SAU800829	STY101078	33%	91.6%	86.5%
SAU800829	SAU800829	100%	100%	100%
SAU800829	SEP201442	52%	100%	99.2%
SAU800829	SHA101462	48%	100%	98.8%
SAU800829	SMU100082	31%	96.6%	95.6%
SAU800829	SPN401234	29%	96.2%	96%
SAU800829	SPY200601	28%	96.2%	94.7%
SAU800830	ABA104578	23%	98.9%	94.8%
SAU800830	BAN104689	29%	87.2%	84.0%
SAU800830	BAN103413	31%	87.2%	83.9%
SAU800830	BPT101113	27%	92.2%	88.7%
SAU800830	BCE112795	25%	78.2%	60.7%
SAU800830	BMA100377	25%	79.3%	71.0%
SAU800830	CDF102776	22%	95.5%	95.0%
SAU800830	CDF103563	23%	97.8%	98.0%
SAU800830	EBC102075	20%	88.3%	87.4%
SAU800830	ECO101733	19%	88.3%	87.4%
SAU800830	KPN301345	20%	88.3%	87.4%
SAU800830	LMO102654	30%	96.1%	94.8%
SAU800830	MCA100181	24%	92.2%	90.6%
SAU800830	MAV100507	27%	26.3%	21.5%
SAU800830	MBV103592	27%	81.6%	36.6%
SAU800830	MLP100459	27%	81.6%	35.9%
SAU800830	MTU203219	27%	81.6%	36.6%
SAU800830	NGO101477	22%	97.8%	96.2%
SAU800830	NME201743	23%	97.8%	96.2%
SAU800830	PMU100672	21%	97.8%	96.2%
SAU800830	PRT105285	24%	88.3%	87.4%
SAU800830	PAE203206	26%	69.8%	69.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800830	PPU101058	27%	88.3%	87.0%
SAU800830	PSY103113	25%	88.3%	87.1%
SAU800830	SAU800830	100%	100%	100%
SAU800830	SEP201443	74%	98.9%	98.3%
SAU800830	SHA100075	74%	91.1%	100%
SAU800830	VCH101029	22%	95.5%	95.1%
SAU800830	YPS000723	21%	88.3%	87.4%
SAU800838	BAN100632	51%	18.6%	81.1%
SAU800838	BAN105551	62%	78.8%	89.7%
SAU800838	BAN106583	60%	93.9%	98.2%
SAU800838	EBC102427	64%	93.5%	97.3%
SAU800838	EFA201706	65%	88.3%	89.5%
SAU800838	EFM202624	52%	100%	100%
SAU800838	LMO100272	63%	93.5%	96.4%
SAU800838	PAE205499	50%	92.6%	95.1%
SAU800838	PPU101954	50%	90.0%	93.3%
SAU800838	PSY101361	52%	90.0%	92.9%
SAU800838	SAU800838	100%	100%	100%
SAU800838	SEP201450	89%	100%	100%
SAU800838	SHA100333	90%	100%	97.5%
SAU800838	SMU100477	47%	89.6%	90.0%
SAU800838	SPN400150	45%	89.6%	89.6%
SAU800838	SPY200235	49%	89.2%	93.2%
SAU800839	BAN108234	42%	90.1%	94.7%
SAU800839	BAN111019	47%	99.3%	98.9%
SAU800839	BAN112085	54%	100%	99.6%
SAU800839	BAN109409	54%	99.3%	98.9%
SAU800839	BPT102993	45%	88.6%	90.5%
SAU800839	BCE106577	41%	89.0%	82.0%
SAU800839	BFU102709	38%	97.4%	97.8%
SAU800839	BMA104983	39%	98.9%	98.9%
SAU800839	CJU100710	36%	95.2%	98.4%
SAU800839	CJU100709	39%	88.6%	91.5%
SAU800839	CJU101125	44%	88.6%	89.3%
SAU800839	CJU100711	50%	87.9%	90.7%
SAU800839	CPN200473	32%	98.9%	97.4%
SAU800839	CAC100740	44%	99.6%	99.6%
SAU800839	CBO102481	28%	98.9%	98.2%
SAU800839	CBO101824	45%	99.3%	98.9%
SAU800839	CBO103909	48%	98.9%	98.1%
SAU800839	CDF100529	45%	99.6%	98.9%
SAU800839	EBC102434	50%	95.2%	97.8%
SAU800839	EFA201707	50%	99.3%	98.9%
SAU800839	EFM201963	50%	99.6%	97.9%
SAU800839	ECO100197	36%	98.2%	97.0%
SAU800839	HPY101541	40%	91.2%	90.4%
SAU800839	KPN301905	36%	98.2%	97.0%
SAU800839	LMO102507	50%	99.3%	98.9%
SAU800839	MPN100427	27%	23.8%	25.8%
SAU800839	NGO101326	31%	99.6%	97.2%
SAU800839	NME200471	31%	99.6%	97.2%
SAU800839	PMU101730	35%	98.9%	98.2%
SAU800839	PRT100159	35%	98.2%	97.0%
SAU800839	PAE205500	42%	96.7%	98.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800839	PFU101952	42%	87.9%	91.8%
SAU800839	PSY101363	42%	99.6%	99.6%
SAU800839	SPA101556	31%	94.5%	92.4%
SAU800839	STY103993	38%	98.2%	97.0%
SAU800839	STM100616	31%	94.5%	92.4%
SAU800839	SAU800839	100%	100%	100%
SAU800839	SEP201451	82%	100%	100%
SAU800839	SHA101832	61%	99.3%	98.5%
SAU800839	SHA100334	83%	100%	100%
SAU800839	TPA100812	30%	98.5%	96.3%
SAU800839	YPS002011	36%	98.2%	97.0%
SAU800842	BAN103123	63%	97.2%	94.3%
SAU800842	BAN101569	80%	98.0%	95.0%
SAU800842	BFR11712	54%	97.2%	99.2%
SAU800842	BMA108445	37%	26.9%	1.5%
SAU800842	CPN200053	41%	95.3%	96.9%
SAU800842	CTR200057	41%	94.5%	96.1%
SAU800842	CAC102249	49%	94.1%	95.2%
SAU800842	CDF101006	31%	90.1%	90.9%
SAU800842	CDP100230	59%	82.2%	98.1%
SAU800842	EBC102240	51%	93.7%	99.6%
SAU800842	EFA200429	77%	98.0%	96.9%
SAU800842	EFM200729	74%	98.0%	96.5%
SAU800842	ECO101650	52%	96.4%	99.2%
SAU800842	KFN301757	53%	93.7%	99.6%
SAU800842	LPN102354	51%	96.0%	98%
SAU800842	LMO100672	79%	98.0%	95.0%
SAU800842	MAV103629	54%	94.9%	95.4%
SAU800842	MBV100927	56%	94.1%	91.7%
SAU800842	MLP100376	54%	94.9%	95.4%
SAU800842	MTU201442	56%	94.1%	91.7%
SAU800842	PRT102237	53%	95.3%	98.0%
SAU800842	SPA103735	52%	96.4%	99.2%
SAU800842	STY101052	52%	96.4%	99.2%
SAU800842	STM103512	52%	96.4%	99.2%
SAU800842	SAU800842	100%	100%	100%
SAU800842	SEP201453	96%	100%	100%
SAU800842	SHA102188	96%	100%	100%
SAU800842	SMU101500	75%	98.0%	96.9%
SAU800842	SPN400771	75%	98.0%	94.3%
SAU800842	SPY200210	71%	98.0%	96.9%
SAU800842	TPA100604	47%	95.7%	92.7%
SAU800842	YPS002982	51%	96.4%	99.2%
SAU800845	ABA105638	43%	51.3%	64.8%
SAU800845	BAN104147	70%	82.5%	95.5%
SAU800845	BAN105227	71%	90.3%	96.5%
SAU800845	BFR104306	36%	28.6%	18.9%
SAU800845	BPT100541	34%	93.5%	94.9%
SAU800845	BCE107071	35%	92.9%	94.1%
SAU800845	BFU114961	35%	94.2%	95.6%
SAU800845	BMA104959	37%	90.9%	87.7%
SAU800845	CUJ100212	27%	53.9%	28.8%
SAU800845	CAC102210	36%	87.0%	95.1%
SAU800845	CBO101838	33%	84.4%	78.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800845	CDF100896	32%	85.7%	78.1%
SAU800845	CDP100224	42%	92.2%	98.7%
SAU800845	EBC103106	32%	90.3%	96.9%
SAU800845	EFA200432	53%	96.1%	94.8%
SAU800845	EFM200870	51%	89.6%	88.5%
SAU800845	ECO102480	33%	90.3%	96.9%
SAU800845	HIN100356	45%	51.3%	65.9%
SAU800845	HPY100217	24%	94.2%	43.9%
SAU800845	KPN305521	32%	90.3%	96.9%
SAU800845	LPN102581	40%	85.7%	88.6%
SAU800845	LMO102434	58%	94.2%	98.6%
SAU800845	MCA100833	43%	51.3%	65.4%
SAU800845	MAV103625	35%	93.5%	96.1%
SAU800845	MBV100931	36%	96.1%	93.8%
SAU800845	MLP100378	38%	96.1%	91.5%
SAU800845	MTU201444	36%	96.1%	93.8%
SAU800845	MGE100346	22%	55.8%	63.0%
SAU800845	MPN100354	24%	58.4%	65%
SAU800845	NGO101047	44%	51.9%	65.6%
SAU800845	NME201455	44%	51.9%	65.6%
SAU800845	PMU100319	32%	90.3%	96.9%
SAU800845	PRT102918	31%	90.9%	97.7%
SAU800845	PAE203810	35%	83.1%	88.3%
SAU800845	PPU109766	31%	83.1%	88.3%
SAU800845	PSY103769	31%	83.1%	88.3%
SAU800845	SPA100052	44%	51.3%	68.0%
SAU800845	STY105166	32%	90.3%	96.9%
SAU800845	SAU800845	100%	100%	100%
SAU800845	SEP201458	95%	100%	100%
SAU800845	SHA102191	96%	99.4%	100%
SAU800845	SMU101506	47%	93.5%	99.3%
SAU800845	SPN400774	45%	89.6%	94.5%
SAU800845	SPY200213	44%	99.4%	95.0%
SAU800845	TPA100608	32%	83.8%	89.1%
SAU800845	UUR100458	30%	86.4%	87.1%
SAU800845	VCH100736	43%	51.3%	65.4%
SAU800845	YPS006083	40%	51.3%	64.8%
SAU800920	ABA103984	34%	90.7%	92.5%
SAU800920	BAN109941	42%	97.7%	99.1%
SAU800920	BAN109931	43%	98.3%	95.9%
SAU800920	BFR10878	32%	81.4%	77.7%
SAU800920	BPT102310	24%	55.5%	58.2%
SAU800920	BCE107000	43%	61.7%	85.2%
SAU800920	BFU102931	27%	81.4%	70%
SAU800920	BMA109386	40%	88.2%	95.4%
SAU800920	CJU101195	26%	79.4%	78.0%
SAU800920	CAC101529	33%	91.3%	89.7%
SAU800920	CBO100347	31%	99.2%	99.4%
SAU800920	CDF100344	43%	18.3%	90.3%
SAU800920	CDF101769	34%	98.0%	96.5%
SAU800920	EFA200241	32%	97.5%	96.2%
SAU800920	HPY100760	34%	35.8%	35.0%
SAU800920	KPN303298	38%	91.0%	92.6%
SAU800920	LPN101854	42%	95.8%	97.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800920	LMO102611	32%	97.5%	97.4%
SAU800920	MAV106430	34%	93.8%	97.3%
SAU800920	MBV101237	32%	93.5%	95.9%
SAU800920	MTU202743	32%	93.5%	95.9%
SAU800920	NGO100380	29%	23.9%	22.0%
SAU800920	NME201526	26%	23.9%	22.0%
SAU800920	PAE204199	35%	96.9%	98.9%
SAU800920	PPU110056	33%	96.6%	95.6%
SAU800920	PSY105312	44%	43.1%	84.4%
SAU800920	SAU800920	100%	100%	100%
SAU800920	SEP100265	56%	98.6%	98.6%
SAU800920	SHA100955	68%	99.2%	98.9%
SAU800920	SMU100545	35%	78.9%	72.9%
SAU800920	SPN400379	33%	91.3%	87.3%
SAU800920	SPY201350	36%	81.4%	75.2%
SAU800924	ABA101031	46%	92.5%	86.0%
SAU800924	ABA105312	47%	92.1%	82.2%
SAU800924	BAN108575	69%	89.8%	99.6%
SAU800924	BAN112410	76%	97.7%	99.7%
SAU800924	BFR10610	47%	93.1%	97.6%
SAU800924	BPT101468	48%	93.4%	85.9%
SAU800924	BCE114309	50%	93.4%	86.7%
SAU800924	BFU109309	51%	93.4%	83.1%
SAU800924	BMA108104	51%	93.4%	86.9%
SAU800924	CPN201019	47%	90.5%	89.6%
SAU800924	CTR200836	45%	94.4%	92.9%
SAU800924	CDP100404	40%	63.0%	80.2%
SAU800924	EBC101385	52%	94.1%	89.7%
SAU800924	ECO100618	51%	94.1%	89.7%
SAU800924	HIN100025	52%	93.4%	89.4%
SAU800924	KPN302685	51%	94.1%	89.7%
SAU800924	LPN101740	52%	92.5%	92.8%
SAU800924	MCA103689	45%	92.1%	77.8%
SAU800924	MAV106038	46%	94.4%	92.8%
SAU800924	MBV104457	45%	94.4%	91.6%
SAU800924	MLP100518	46%	93.4%	89.8%
SAU800924	MTU202184	45%	94.4%	91.6%
SAU800924	NGO100285	50%	94.8%	88.1%
SAU800924	NME201265	50%	94.8%	88.1%
SAU800924	PMU101930	51%	92.8%	88.8%
SAU800924	PRT102872	51%	94.1%	89.7%
SAU800924	PAE203993	44%	93.1%	86.9%
SAU800924	PPU107592	46%	93.8%	85.4%
SAU800924	PSY105080	46%	93.4%	85.1%
SAU800924	SPA102529	49%	94.1%	89.7%
SAU800924	STY101450	50%	94.1%	89.7%
SAU800924	SAU800924	100%	100%	100%
SAU800924	SEP201476	95%	99.7%	100%
SAU800924	SHA100744	95%	99.3%	98.4%
SAU800924	VCH100927	51%	94.1%	89.7%
SAU800924	YPS001177	53%	94.1%	89.7%
SAU800925	BAN102521	51%	70.9%	100%
SAU800925	BAN107044	51%	70.9%	89.1%
SAU800925	EFA200745	42%	74.0%	45.0%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800925	EFM200884	47%	72.4%	40.9%
SAU800925	LMO101257	55%	67.7%	94.5%
SAU800925	SAU800925	100%	100%	100%
SAU800925	SEP201478	77%	99.2%	93.8%
SAU800925	SHA100745	70%	100%	97.7%
SAU800925	SMU100024	47%	74.0%	51.6%
SAU800925	SPN400675	48%	63.0%	44.9%
SAU800925	SPY201183	52%	66.9%	39.3%
SAU800931	BAN105857	53%	58%	62.5%
SAU800931	SAU800931	100%	100%	100%
SAU800931	SEP202312	78%	94%	97.9%
SAU800931	SHA103119	90%	80%	81.6%
SAU800931	SPY103176	46%	58%	76.9%
SAU800932	BAN108686	39%	98.1%	98.8%
SAU800932	BAN113463	44%	98.1%	98.4%
SAU800932	BPT102923	35%	96.1%	94.3%
SAU800932	CJU101231	29%	94.2%	93.8%
SAU800932	CDF103976	38%	96.9%	98.0%
SAU800932	EBC102291	36%	95.7%	93.7%
SAU800932	EFA200814	42%	99.8%	99.6%
SAU800932	EFM201145	41%	95.7%	95.6%
SAU800932	LMO100987	40%	99.6%	99.4%
SAU800932	SAU800932	100%	100%	100%
SAU800932	SEP201491	75%	100%	100%
SAU800932	SHA100310	72%	99.8%	99.8%
SAU800932	SMU100418	32%	99.4%	98.4%
SAU800932	SPN401979	35%	94.4%	99.0%
SAU800932	SPY201011	38%	99.4%	99.0%
SAU800932	VCH101555	28%	71.5%	63.5%
SAU800942	ABA101554	36%	72.5%	73.0%
SAU800942	BAN111566	30%	76.4%	80.9%
SAU800942	BAN105261	36%	84.5%	84.4%
SAU800942	BPT101764	38%	66.4%	64.9%
SAU800942	BCE113716	32%	85.3%	83.1%
SAU800942	BFU111857	31%	98.4%	94.9%
SAU800942	BMA108381	31%	98.4%	95.8%
SAU800942	CJU100859	36%	72.3%	75.6%
SAU800942	CPN200364	33%	95.5%	91.0%
SAU800942	CTR200310	31%	90.4%	89.6%
SAU800942	CDF101233	32%	88.2%	89.9%
SAU800942	CDP100388	37%	71.9%	71%
SAU800942	EBC104062	35%	72.9%	71.8%
SAU800942	ECO104150	35%	72.9%	71.8%
SAU800942	HIN101670	32%	100%	99.6%
SAU800942	HPY100563	35%	71.9%	74.4%
SAU800942	KPN303509	35%	72.9%	71.8%
SAU800942	LPN102543	38%	65.0%	65.0%
SAU800942	MCA103090	37%	72.9%	77.3%
SAU800942	MAV101182	36%	71.1%	68.5%
SAU800942	MBV104444	36%	71.1%	68.7%
SAU800942	MLP100524	36%	71.1%	67.7%
SAU800942	MTU202179	36%	71.1%	68.9%
SAU800942	MGE100403	34%	61.3%	67.6%
SAU800942	MPN100270	38%	59.7%	65.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800942	NGO101321	38%	75.6%	78.2%
SAU800942	NME201617	39%	75.6%	78.2%
SAU800942	PMU100195	29%	100%	99.2%
SAU800942	PRT100707	36%	71.9%	84.7%
SAU800942	PAE203828	36%	92.7%	87.5%
SAU800942	PPU104070	34%	85.3%	92.9%
SAU800942	PSY104267	35%	85.3%	89.1%
SAU800942	SPA100451	36%	71.9%	87.9%
SAU800942	STY104012	35%	72.9%	71.8%
SAU800942	SAU800942	100%	100%	100%
SAU800942	SEP201511	59%	100%	99.6%
SAU800942	SHA100914	59%	99.6%	99.8%
SAU800942	UUR100512	34%	77.8%	83.1%
SAU800942	VCH102465	36%	71.9%	70.6%
SAU800942	YPS000931	36%	72.9%	71.8%
SAU800951	PMU101172	29%	69.0%	38.8%
SAU800951	SAU800951	100%	100%	100%
SAU800951	SEP200154	84%	100%	98.6%
SAU800951	SHA101855	71%	100%	99.3%
SAU800952	ABA105732	38%	98.9%	82.8%
SAU800952	BAN107647	33%	46.2%	61.2%
SAU800952	BAN110840	34%	60.0%	73.7%
SAU800952	BFR11026	33%	61.4%	76.5%
SAU800952	BPT102936	35%	98.0%	79.5%
SAU800952	BBU100411	24%	20.5%	56.0%
SAU800952	BCE105760	30%	52.9%	60.2%
SAU800952	BMA103273	30%	52.9%	60.5%
SAU800952	CJU101474	33%	52.8%	66.1%
SAU800952	CBO101784	33%	10.4%	85%
SAU800952	CDP101683	30%	97.5%	83.4%
SAU800952	EBC104021	28%	70.5%	87.6%
SAU800952	ECO102236	29%	70.5%	87.6%
SAU800952	HPY101254	30%	70.3%	86.8%
SAU800952	KPN303099	27%	70.5%	87.6%
SAU800952	LMO101343	51%	99.4%	99.8%
SAU800952	MAV103503	34%	52.8%	64.2%
SAU800952	MBV105172	31%	60.5%	72.4%
SAU800952	MTU203113	31%	60.5%	72.4%
SAU800952	NGO100646	28%	60.8%	74.5%
SAU800952	NME200002	29%	60.8%	74.5%
SAU800952	PMU101184	29%	12.2%	31.8%
SAU800952	PRT104399	31%	61.4%	78.6%
SAU800952	PAE201053	38%	97.6%	81.7%
SAU800952	PPU111359	34%	98.0%	80.1%
SAU800952	PSY104130	35%	91.3%	78.0%
SAU800952	SPA100263	30%	44.4%	84.3%
SAU800952	STY100604	28%	70.5%	87.6%
SAU800952	SAU800952	100%	100%	100%
SAU800952	SEP200156	80%	100%	100%
SAU800952	SHA101854	78%	100%	99.5%
SAU800952	SMU100737	27%	20.0%	74.6%
SAU800952	VCH102892	34%	94.1%	81.9%
SAU800952	YPS000434	29%	70.5%	87.8%
SAU800962	ABA104828	21%	78.1%	66.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800962	BAN107886	49%	98.2%	100%
SAU800962	BAN113216	70%	99.8%	99.3%
SAU800962	BFR10381	50%	99.3%	100%
SAU800962	BPT100657	27%	80.1%	72.2%
SAU800962	BBU100729	24%	81.0%	69.5%
SAU800962	BCE100058	24%	84.0%	68.0%
SAU800962	BFU101343	24%	81.3%	68.5%
SAU800962	BMA107745	24%	83.3%	69.4%
SAU800962	CJU101444	30%	79.2%	84.5%
SAU800962	CPN200812	24%	87.4%	75.1%
SAU800962	CTR200647	25%	84.9%	72.7%
SAU800962	CAC100048	64%	99.1%	98.7%
SAU800962	CBO102016	60%	99.3%	97.8%
SAU800962	CDF103720	63%	100%	99.8%
SAU800962	CDP100102	25%	78.1%	66.9%
SAU800962	EBC103837	24%	78.1%	67.5%
SAU800962	EFA202329	64%	100%	100%
SAU800962	EFM202538	66%	100%	100%
SAU800962	ECO103919	28%	48.3%	38.3%
SAU800962	HIN101544	23%	93.9%	78.5%
SAU800962	HPY101149	24%	81.9%	71.0%
SAU800962	KPN302607	24%	78.1%	66.7%
SAU800962	LPN103064	21%	35.4%	71.7%
SAU800962	LMO101990	67%	100%	99.6%
SAU800962	MCA101062	23%	77.9%	67.5%
SAU800962	MAV105583	23%	79.5%	66.8%
SAU800962	MBV101975	24%	79.5%	66.9%
SAU800962	MLP100108	23%	79.9%	67.1%
SAU800962	MTU200937	24%	79.5%	66.9%
SAU800962	MGE100113	34%	95.7%	97.5%
SAU800962	MPN100582	33%	92.6%	94.9%
SAU800962	NGO101248	24%	84.0%	69.7%
SAU800962	NME201465	24%	84.0%	72.3%
SAU800962	PMU100416	24%	78.1%	66.8%
SAU800962	PRT101480	23%	78.1%	66.8%
SAU800962	PAE204728	20%	91.6%	74.2%
SAU800962	PPU108446	22%	82.6%	69.0%
SAU800962	PPU108272	22%	82.6%	69.0%
SAU800962	PSY100665	23%	49.0%	38.6%
SAU800962	SPA103272	28%	48.3%	38.5%
SAU800962	STY101906	24%	78.1%	66.7%
SAU800962	STM102761	24%	78.1%	66.7%
SAU800962	SAU800962	100%	100%	100%
SAU800962	SEP200169	90%	100%	100%
SAU800962	SHA100475	100%	12.2%	100%
SAU800962	SHA101567	92%	100%	100%
SAU800962	SHA102448	92%	100%	100%
SAU800962	SMU100622	62%	100%	100%
SAU800962	SPN401879	63%	100%	100%
SAU800962	SPY200159	63%	100%	100%
SAU800962	TPA100471	23%	87.8%	77.2%
SAU800962	VCH100369	23%	78.1%	66.5%
SAU800962	YPS003348	24%	78.1%	66.8%
SAU800965	ABA104917	27%	91.6%	80%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800965	BAN110074	48%	78.0%	98.6%
SAU800965	BAN104864	45%	96.9%	96.8%
SAU800965	BFR104933	52%	23.6%	38.8%
SAU800965	BFR102922	35%	56.5%	48.0%
SAU800965	BFR103785	30%	92.7%	93.2%
SAU800965	BPT102614	32%	90.1%	74.1%
SAU800965	BBU100262	24%	86.9%	94.0%
SAU800965	BCE109420	30%	92.1%	73.4%
SAU800965	BFU101296	31%	92.1%	73.4%
SAU800965	BMA103433	33%	92.1%	73.4%
SAU800965	CJU100795	25%	94.2%	87.9%
SAU800965	CPN200652	47%	22.5%	54.6%
SAU800965	CTR200284	45%	22.5%	54.5%
SAU800965	CAC103745	37%	91.6%	90.2%
SAU800965	CBO101026	33%	94.2%	93.8%
SAU800965	CBO103680	34%	91.6%	93.1%
SAU800965	CDF102071	38%	93.7%	94.9%
SAU800965	CDF103915	41%	93.7%	94.9%
SAU800965	CDF100857	42%	92.1%	91.2%
SAU800965	CDP101133	26%	92.7%	84.1%
SAU800965	EBC102413	23%	91.1%	75.9%
SAU800965	EFA201207	39%	92.7%	92.4%
SAU800965	EFA201464	42%	93.2%	92.3%
SAU800965	EFA202010	33%	85.3%	95.2%
SAU800965	EFA200470	36%	88.5%	63.9%
SAU800965	EFM200768	51%	55.5%	82.1%
SAU800965	ECO102519	23%	91.1%	75.9%
SAU800965	HIN100014	24%	88.5%	69.1%
SAU800965	HPY100569	22%	89.5%	81.0%
SAU800965	KPN303155	34%	91.1%	75.9%
SAU800965	LMO101081	45%	85.3%	88.3%
SAU800965	MCA102001	26%	91.6%	66.8%
SAU800965	MAV102887	26%	93.7%	76.9%
SAU800965	MBV102295	27%	93.7%	75.2%
SAU800965	MLP100983	26%	93.7%	78.9%
SAU800965	MTU202865	27%	93.7%	75.2%
SAU800965	NGO100038	27%	85.9%	67.3%
SAU800965	NME200899	28%	85.9%	78.1%
SAU800965	PMU100062	26%	86.9%	67.4%
SAU800965	PRT105741	25%	99.0%	80.2%
SAU800965	PAE200767	29%	89.5%	72.2%
SAU800965	PAE201302	33%	78.0%	76.5%
SAU800965	PPU107909	28%	93.2%	75.7%
SAU800965	PSY102320	27%	93.2%	75.7%
SAU800965	SPA100368	33%	44.0%	40.7%
SAU800965	STY102115	33%	85.9%	72.8%
SAU800965	SAU800965	100%	100%	100%
SAU800965	SEP200178	79%	100%	100%
SAU800965	SHA101671	75%	99.5%	100%
SAU800965	SMU101279	38%	94.8%	97.4%
SAU800965	SPN400364	35%	92.7%	95.6%
SAU800965	SPY201418	36%	93.7%	97.5%
SAU800965	TPA100183	24%	90.1%	89.4%
SAU800965	VCH102426	29%	87.4%	72.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800965	YPS002228	36%	90.1%	74.7%
SAU800966	BAN101759	25%	99.4%	99.8%
SAU800966	BAN107464	32%	98.3%	98.6%
SAU800966	CAC100694	28%	98.3%	97.9%
SAU800966	CBO102997	28%	97.8%	97.7%
SAU800966	CDF103113	27%	98.5%	99.0%
SAU800966	EFA201462	24%	94.7%	94.1%
SAU800966	EFM200885	24%	99.2%	99.4%
SAU800966	LMO100290	30%	97.9%	98.2%
SAU800966	PRT100901	22%	30.9%	31.9%
SAU800966	SAU800966	100%	100%	100%
SAU800966	SEP200180	72%	99.2%	99.1%
SAU800966	SHA101672	70%	99.4%	99.1%
SAU800966	SMU100470	21%	86.7%	86.8%
SAU800966	SPN401039	19%	82.7%	83.9%
SAU800966	SPY200571	20%	93.5%	93.6%
SAU800967	BAN111196	34%	98.5%	99.1%
SAU800967	BAN105909	36%	99.2%	98.8%
SAU800967	BFR102381	20%	70.3%	78.2%
SAU800967	BBU100632	21%	97.0%	94.2%
SAU800967	CTR200007	20%	77.5%	80.6%
SAU800967	CAC103739	32%	98.8%	99.0%
SAU800967	CBO101540	32%	98.8%	99.1%
SAU800967	CDF102097	31%	98.0%	98.4%
SAU800967	EBC102605	21%	97.5%	95.7%
SAU800967	EFA201460	32%	99.8%	98.2%
SAU800967	EFM200194	34%	98.8%	98.4%
SAU800967	LMO102657	35%	99.4%	98.7%
SAU800967	SAU800967	100%	100%	100%
SAU800967	SEP200182	75%	99.8%	99.3%
SAU800967	SHA101673	66%	99.8%	99.2%
SAU800967	SMU100467	30%	98.2%	96.6%
SAU800967	SPN401040	30%	98.2%	96.6%
SAU800967	SPY200572	29%	98.2%	96.5%
SAU800967	TPA100888	20%	98.6%	97.3%
SAU800968	ABA100124	32%	66.3%	92.0%
SAU800968	BAN101423	36%	93.7%	100%
SAU800968	BAN104355	41%	99.3%	99.7%
SAU800968	BFR11202	30%	58.3%	87.7%
SAU800968	BPT105862	36%	69.3%	73.1%
SAU800968	BCE110171	39%	65.7%	70.7%
SAU800968	BFU110006	43%	77.7%	79.6%
SAU800968	BMA105697	38%	65.7%	66.9%
SAU800968	CJU100021	40%	70.7%	75%
SAU800968	CDF103166	34%	99.3%	97.7%
SAU800968	CDF101613	42%	71%	73.3%
SAU800968	CDP100223	32%	73.3%	77.0%
SAU800968	EBC102101	34%	100%	96.5%
SAU800968	ECO101153	31%	69.3%	93.2%
SAU800968	KPN303993	36%	83%	2.4%
SAU800968	LPN100114	24%	40.7%	38.9%
SAU800968	LMO102616	40%	100%	99.6%
SAU800968	MCA102285	29%	59.7%	83.8%
SAU800968	MAV100179	35%	73%	79.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800968	MBV101328	36%	73%	79.6%
SAU800968	MLP101033	35%	73%	88.4%
SAU800968	MTU202955	36%	73%	88.3%
SAU800968	NGO100109	27%	66%	89.4%
SAU800968	NME201411	28%	66%	89.4%
SAU800968	PMU101529	37%	81%	92.5%
SAU800968	PRT105162	32%	59.7%	83.5%
SAU800968	PAE204119	35%	81%	91.1%
SAU800968	PPU102070	31%	59.7%	82.8%
SAU800968	PSY107523	29%	69.3%	92.8%
SAU800968	SPA104517	38%	68%	93.0%
SAU800968	STY103635	35%	88%	8.6%
SAU800968	STM104158	34%	99.3%	94.2%
SAU800968	SAU800968	100%	100%	100%
SAU800968	SEP200184	87%	100%	99.7%
SAU800968	SHA101674	89%	100%	99.7%
SAU800968	VCH103722	25%	65%	90.7%
SAU800968	YPS003019	34%	82%	93.6%
SAU800974	ABA104297	26%	56.3%	94.9%
SAU800974	BAN111897	23%	49.3%	76.8%
SAU800974	BFR101716	26%	57.1%	87.9%
SAU800974	BCE100247	32%	57.3%	50.9%
SAU800974	BCE111953	32%	57.3%	49.5%
SAU800974	CJU101565	25%	43.2%	55.9%
SAU800974	CDP100706	37%	62.4%	98.7%
SAU800974	EFA200943	35%	97.5%	97.8%
SAU800974	EFM101912	38%	28.3%	100%
SAU800974	KPN309179	29%	13.1%	16.1%
SAU800974	NGO101759	32%	63.6%	57.9%
SAU800974	NME202037	32%	65.7%	61.4%
SAU800974	PSY104429	31%	61.6%	54.0%
SAU800974	STM100162	31%	58.3%	53.9%
SAU800974	SAU800974	100%	100%	100%
SAU800974	SEP200198	68%	98.3%	98.0%
SAU800974	SHA100654	67%	99.2%	98.2%
SAU800974	YPS001466	22%	19.5%	20.5%
SAU800975	ABA101867	51%	99.8%	99.9%
SAU800975	BAN105594	32%	21.2%	100%
SAU800975	BAN100493	44%	26.6%	99.1%
SAU800975	BAN103472	53%	43.2%	91.0%
SAU800975	BAN107108	60%	99.5%	100%
SAU800975	BFR10905	38%	81.2%	79.4%
SAU800975	BFR101559	50%	98.6%	99.3%
SAU800975	BPT101928	53%	98.2%	98.5%
SAU800975	BCE108256	52%	99.3%	99.5%
SAU800975	BFU101142	53%	75.1%	98.9%
SAU800975	BMA104295	52%	98.3%	98.6%
SAU800975	CJU100472	48%	98.0%	98.4%
SAU800975	CPN200617	46%	98.0%	97.7%
SAU800975	CTR200383	49%	98.4%	98.6%
SAU800975	CAC100315	55%	99.1%	99.5%
SAU800975	CBO100316	56%	98.7%	99.3%
SAU800975	CDF100817	56%	98.7%	99.3%
SAU800975	CDP101419	52%	98.2%	98.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800975	EBC100668	54%	64.8%	99.3%
SAU800975	EFA200871	61%	100%	99.9%
SAU800975	EFM202090	61%	100%	99.8%
SAU800975	ECO102539	52%	98.6%	99.3%
SAU800975	HIN100839	52%	98.2%	98.8%
SAU800975	HPY100260	46%	97.4%	97.8%
SAU800975	KPN301209	52%	98.6%	99.3%
SAU800975	LPN102913	51%	96.7%	98.8%
SAU800975	LMO101394	63%	99.4%	99.8%
SAU800975	MCA100931	51%	99.3%	96.3%
SAU800975	MAV101212	53%	98.2%	96.5%
SAU800975	MBV100178	53%	94.9%	100%
SAU800975	MLP101480	53%	98.6%	99.2%
SAU800975	MTU200383	52%	98.6%	99.2%
SAU800975	MGE100365	50%	80.9%	97.3%
SAU800975	MPN100311	50%	80.3%	96.5%
SAU800975	NGO100439	50%	98.6%	99.4%
SAU800975	NME201542	50%	98.6%	99.4%
SAU800975	PMU101704	52%	96.7%	97.3%
SAU800975	PRT105204	52%	98.8%	99.2%
SAU800975	PAE204540	51%	98.6%	99.4%
SAU800975	PPU108177	51%	98.6%	99.4%
SAU800975	PSY100953	52%	93.9%	98.5%
SAU800975	STY102189	52%	98.6%	99.3%
SAU800975	STM103776	38%	81.2%	77.9%
SAU800975	SAU800975	100%	100%	100%
SAU800975	SEP200200	87%	99.7%	99.7%
SAU800975	SHA100227	90%	91.6%	97.9%
SAU800975	SMU100300	44%	96.5%	97.0%
SAU800975	TPA100070	51%	98.6%	99.0%
SAU800975	UUR100394	52%	80.3%	97.4%
SAU800975	VCH100698	51%	98.7%	99.4%
SAU800975	YPS002837	51%	98.7%	99.2%
SAU800984	ABA105798	37%	98.8%	99.5%
SAU800984	ABA100324	40%	99.0%	99.8%
SAU800984	BAN112689	60%	98.3%	99.8%
SAU800984	BAN107953	64%	99.3%	99.8%
SAU800984	BFR12010	50%	98.6%	98.8%
SAU800984	BPT102618	49%	98.3%	99.3%
SAU800984	BCE113298	51%	74.2%	99.0%
SAU800984	BFU100675	52%	98.3%	95.3%
SAU800984	BMA102164	52%	98.3%	99.0%
SAU800984	CJU100410	47%	98.8%	99.8%
SAU800984	CPN200933	47%	98.6%	98.8%
SAU800984	CTR200146	46%	98.8%	98.6%
SAU800984	CAC100013	54%	99.0%	99.8%
SAU800984	CBO102384	53%	99.3%	99.0%
SAU800984	CDF101773	58%	98.8%	99.5%
SAU800984	CDP100587	25%	98.3%	27.7%
SAU800984	EBC100090	50%	63.5%	98.9%
SAU800984	EFA201888	53%	98.8%	99.3%
SAU800984	EFM201378	54%	98.6%	99.3%
SAU800984	ECO101068	51%	98.3%	99.0%
SAU800984	HIN101502	39%	98.6%	99.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800984	HPY100551	46%	98.3%	99.5%
SAU800984	KPN301302	51%	98.3%	99.0%
SAU800984	LPN100053	54%	98.6%	99.3%
SAU800984	LMO100394	64%	98.8%	99.0%
SAU800984	MCA101479	46%	98.3%	100%
SAU800984	MAV103067	39%	97.8%	100%
SAU800984	MBV100653	38%	98.1%	96.9%
SAU800984	MLP101008	39%	98.1%	96.9%
SAU800984	MTU202211	38%	98.1%	96.9%
SAU800984	NGO100696	52%	99.8%	92.6%
SAU800984	NME200042	53%	99.8%	99.8%
SAU800984	PMU100339	39%	99.0%	99.8%
SAU800984	PRT104423	49%	98.3%	99.0%
SAU800984	PAE202963	52%	98.6%	98.8%
SAU800984	PPU104840	53%	98.6%	98.8%
SAU800984	PSY101697	51%	98.6%	98.8%
SAU800984	SPA100629	50%	98.3%	99.0%
SAU800984	STY102533	51%	98.3%	99.0%
SAU800984	STM102723	51%	98.3%	99.0%
SAU800984	SAU800984	100%	100%	100%
SAU800984	SEP200206	88%	99.8%	99.8%
SAU800984	SHA101847	89%	99.8%	99.8%
SAU800984	SMU100539	44%	98.8%	99.0%
SAU800984	SPN400382	46%	98.6%	97.8%
SAU800984	SPY201347	47%	98.8%	99.0%
SAU800984	VCH101989	52%	98.3%	99.0%
SAU800984	YPS003134	49%	98.3%	99.0%
SAU800996	ABA105617	30%	97.9%	96.4%
SAU800996	BAN100511	58%	100%	100%
SAU800996	BAN103479	64%	100%	99.7%
SAU800996	BFR11695	32%	97.3%	92.8%
SAU800996	BPT101857	31%	98.2%	72.9%
SAU800996	BBU100005	33%	99.1%	93.8%
SAU800996	BCE111566	43%	50.2%	42%
SAU800996	BFU104126	39%	98.5%	98.5%
SAU800996	BMA102942	43%	98.5%	98.5%
SAU800996	CJU100356	36%	97.9%	99.4%
SAU800996	CPN201050	29%	98.8%	96.5%
SAU800996	CTR200863	29%	98.8%	96.0%
SAU800996	CAC102256	53%	98.2%	94.5%
SAU800996	CBO103516	53%	98.2%	97.3%
SAU800996	CDF103033	51%	99.7%	98.5%
SAU800996	CDP100799	47%	98.2%	93.9%
SAU800996	EBC103867	51%	97.6%	97.0%
SAU800996	EFA200882	60%	99.7%	92.5%
SAU800996	EFM201661	33%	97.9%	97.6%
SAU800996	ECO103307	51%	98.8%	98.2%
SAU800996	HIN100618	50%	97.6%	97.0%
SAU800996	HPY101236	46%	97.9%	94.4%
SAU800996	KPN301318	51%	98.8%	98.2%
SAU800996	LPN101785	40%	48.9%	40.6%
SAU800996	LMO101120	62%	99.7%	98.8%
SAU800996	MCA100953	30%	97.9%	95.8%
SAU800996	MAV101730	43%	99.1%	97.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU800996	MBV102918	45%	97.6%	96.4%
SAU800996	MLP100424	42%	97.6%	95.6%
SAU800996	MTU203293	45%	97.6%	96.4%
SAU800996	MGE100128	36%	97.3%	96.3%
SAU800996	MPN100568	36%	99.1%	98.3%
SAU800996	NGO100436	30%	97.9%	97.3%
SAU800996	NME201541	30%	97.9%	97.3%
SAU800996	PMU101621	50%	97.6%	97.3%
SAU800996	PRT100815	53%	97.6%	94.7%
SAU800996	PAE204437	30%	97.9%	73.4%
SAU800996	PPU111782	33%	97.9%	73.3%
SAU800996	PSY103844	33%	97.9%	73.3%
SAU800996	SPA103184	46%	62.6%	98.1%
SAU800996	STY101408	51%	98.8%	98.2%
SAU800996	SAU800996	100%	100%	100%
SAU800996	SEP200218	88%	100%	100%
SAU800996	SHA100262	87%	100%	100%
SAU800996	SMU101412	34%	97.9%	97.6%
SAU800996	SPN402031	35%	97.9%	97.4%
SAU800996	SPY201690	34%	97.9%	97.6%
SAU800996	TPA100625	29%	99.7%	98.2%
SAU800996	UUR100175	46%	98.8%	99.7%
SAU800996	VCH102586	48%	97.6%	89.9%
SAU800996	YPS001667	51%	97.6%	93.6%
SAU801001	BAN107249	31%	78.8%	54.9%
SAU801001	BAN110882	32%	76.6%	47.5%
SAU801001	CAC101275	39%	20.7%	37.6%
SAU801001	EFM100918	36%	33.2%	25.3%
SAU801001	LMO101980	28%	82.1%	55.9%
SAU801001	PPU103349	28%	40.2%	25.4%
SAU801001	SAU801001	100%	100%	100%
SAU801001	SEP200228	78%	96.2%	68.3%
SAU801001	SHA100236	78%	96.7%	68.7%
SAU801002	EFA200888	25%	70.4%	40.6%
SAU801002	SAU801002	100%	100%	100%
SAU801003	ABA103708	32%	35.5%	10.3%
SAU801003	BAN109236	44%	44.6%	88.5%
SAU801003	BAN104719	43%	91.7%	89.5%
SAU801003	BAN108205	52%	97.5%	90.2%
SAU801003	BAN109057	52%	97.5%	90.2%
SAU801003	BPT101594	35%	96.7%	85.8%
SAU801003	BCE115088	33%	96.7%	89.0%
SAU801003	BFU111683	31%	97.5%	87.8%
SAU801003	BMA100121	32%	96.7%	71.2%
SAU801003	CJU100430	22%	95.0%	92.1%
SAU801003	CDP101259	29%	95.0%	92.3%
SAU801003	LPN103152	37%	57.0%	62.9%
SAU801003	MAV105125	38%	95.9%	85.8%
SAU801003	MBV101537	38%	95.9%	90.3%
SAU801003	MLP100775	39%	95.9%	94.5%
SAU801003	MTU202434	38%	95.9%	94.5%
SAU801003	SAU801003	100%	100%	100%
SAU801003	SEP200229	77%	100%	95.3%
SAU801003	SHA100235	81%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801007	ABA101740	34%	55.4%	48.7%
SAU801007	BAN113253	59%	82.9%	99.6%
SAU801007	BAN112667	66%	98.1%	99.2%
SAU801007	BFR100600	33%	63.6%	58.6%
SAU801007	BPT103790	28%	61.7%	53.2%
SAU801007	BBU100310	28%	59.5%	55.6%
SAU801007	BCE114005	27%	86.2%	70.6%
SAU801007	BFU102654	29%	76.6%	62.3%
SAU801007	BMA109400	26%	85.9%	66.4%
SAU801007	CJU100602	33%	62.5%	56.3%
SAU801007	CAC101559	25%	86.6%	79.9%
SAU801007	CBO102717	26%	84.0%	77.9%
SAU801007	CDF103162	28%	95.9%	95.9%
SAU801007	CDP101033	25%	84.0%	70.0%
SAU801007	EBC102479	27%	59.1%	58.6%
SAU801007	EFA200895	45%	98.9%	100%
SAU801007	ECO102562	27%	59.1%	53.8%
SAU801007	HIN100070	29%	71.4%	71.3%
SAU801007	HPY101374	28%	66.2%	57.4%
SAU801007	KPN301269	25%	60.2%	54.8%
SAU801007	LPN101990	33%	56.1%	50.5%
SAU801007	LMO100773	57%	97.8%	99.2%
SAU801007	MCA101910	30%	64.3%	55.9%
SAU801007	MAV102046	27%	84.0%	68.8%
SAU801007	MBV105349	26%	84.0%	72.0%
SAU801007	MLP100841	31%	64.7%	53.7%
SAU801007	MTU201674	26%	84.0%	72.0%
SAU801007	MGE100130	28%	75.5%	73.4%
SAU801007	MPN100566	28%	75.8%	73.7%
SAU801007	NGO100871	27%	81.8%	72.3%
SAU801007	NME200939	26%	81.8%	72.3%
SAU801007	PMU100333	24%	84.0%	73.1%
SAU801007	PRT101147	30%	51.7%	62.0%
SAU801007	PAE203086	31%	54.3%	48.8%
SAU801007	PPU105852	31%	54.3%	48.6%
SAU801007	PSY100717	31%	54.3%	48.6%
SAU801007	SPA101531	26%	57.2%	52.6%
SAU801007	STY102233	26%	57.2%	52.1%
SAU801007	STM102487	26%	57.2%	52.1%
SAU801007	SAU801007	100%	100%	100%
SAU801007	SEP200233	94%	100%	100%
SAU801007	SHA100764	91%	100%	100%
SAU801007	SMU100219	44%	97.8%	94.9%
SAU801007	SPN401005	41%	99.3%	96.4%
SAU801007	SPY200856	45%	97.4%	94.2%
SAU801007	TPA100437	27%	61.0%	51.5%
SAU801007	UUR100177	30%	71.7%	67.0%
SAU801007	VCH100837	30%	57.2%	51.7%
SAU801007	YPS002057	29%	54.6%	49.5%
SAU801008	BAN108299	36%	81.0%	82.3%
SAU801008	BAN112738	39%	88.4%	86.5%
SAU801008	EFA200896	32%	95.1%	94.9%
SAU801008	SAU801008	100%	100%	100%
SAU801008	SEP200234	59%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801008	SHA100765	57%	100%	100%
SAU801008	SMU100212	38%	94.0%	92.9%
SAU801008	SPN401006	39%	95.1%	93.3%
SAU801008	SPY200857	36%	97.9%	96.7%
SAU801011	ABA105845	47%	98.4%	87.5%
SAU801011	BAN111495	45%	98.8%	97.8%
SAU801011	BAN110931	63%	98.4%	98.4%
SAU801011	BFR102480	28%	98.4%	86.1%
SAU801011	BPT101515	45%	98.4%	96.6%
SAU801011	BFU100534	44%	98.4%	95.4%
SAU801011	BMA108591	43%	98.4%	95.4%
SAU801011	CJU101319	47%	97.7%	90.5%
SAU801011	CPN200344	33%	97.7%	94.0%
SAU801011	CTR200374	33%	97.7%	94.3%
SAU801011	EBC101481	43%	97.7%	95.0%
SAU801011	EFA201890	51%	97.7%	98.4%
SAU801011	ECO101259	44%	97.3%	94.7%
SAU801011	HIN101698	42%	97.3%	84.1%
SAU801011	HPY100192	45%	98.4%	90.9%
SAU801011	KPN301049	41%	97.7%	95.0%
SAU801011	LPN103417	46%	98.4%	94.0%
SAU801011	LMO102350	53%	99.2%	98.5%
SAU801011	MCA100281	44%	98.4%	93.8%
SAU801011	MAV103640	32%	96.9%	96.3%
SAU801011	MBV101416	31%	97.7%	97.0%
SAU801011	MLP101099	33%	96.9%	96.3%
SAU801011	MTU201463	31%	97.7%	97.0%
SAU801011	NGO101585	45%	97.3%	95.4%
SAU801011	NME201989	45%	97.3%	95.4%
SAU801011	PMU100182	44%	98.4%	96.5%
SAU801011	PRT101421	45%	97.3%	94.7%
SAU801011	PAE201805	43%	97.7%	95.1%
SAU801011	PSY103929	44%	97.7%	95.5%
SAU801011	SPA104351	34%	97.3%	94.7%
SAU801011	STY103075	43%	97.3%	94.7%
SAU801011	STM101286	43%	97.3%	94.7%
SAU801011	SAU801011	100%	100%	100%
SAU801011	SEP200257	93%	100%	100%
SAU801011	SHA100265	95%	47.3%	100%
SAU801013	BAN109098	39%	96.4%	95.0%
SAU801013	BAN104092	44%	96.2%	93.2%
SAU801013	BAN113298	47%	99.0%	92.3%
SAU801013	BAN101687	54%	98.2%	94.4%
SAU801013	CDF100154	51%	60.1%	88.7%
SAU801013	CDF102305	42%	97.6%	93.8%
SAU801013	CDP100704	47%	97.6%	95.2%
SAU801013	EBC101736	53%	96.4%	89.6%
SAU801013	MCA103444	48%	96.8%	94.0%
SAU801013	SAU801013	100%	100%	100%
SAU801013	VCH100771	48%	98.4%	92.1%
SAU801018	ABA100927	31%	93.9%	93.4%
SAU801018	BAN102528	33%	80.4%	94.4%
SAU801018	BAN109007	36%	92.1%	95.2%
SAU801018	BAN108968	33%	91.9%	94.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801018	BAN109347	42%	92.1%	92.5%
SAU801018	BFR11372	30%	94.5%	96.1%
SAU801018	BBU100200	29%	90.9%	90.6%
SAU801018	BCE108649	32%	72.7%	91.6%
SAU801018	BFU100823	33%	88.9%	88.4%
SAU801018	BMA100072	33%	88.9%	88.3%
SAU801018	CJU101547	31%	87.7%	92.0%
SAU801018	CPN200331	32%	93.9%	95.4%
SAU801018	CTR200533	31%	91.3%	92.4%
SAU801018	CAC101131	32%	96.4%	98.1%
SAU801018	CAC103376	33%	94.1%	95.6%
SAU801018	CBO100064	35%	94.5%	96.1%
SAU801018	CDF102952	30%	96.4%	97.7%
SAU801018	CDP101281	34%	78.7%	80.9%
SAU801018	EBC102573	29%	92.3%	93.9%
SAU801018	EFA201208	27%	94.5%	92.5%
SAU801018	EFM201835	28%	91.3%	90.2%
SAU801018	ECO100085	30%	91.3%	92.9%
SAU801018	HIN101107	31%	93.1%	95.9%
SAU801018	HPY101473	32%	74.9%	81.7%
SAU801018	KPN301847	29%	92.3%	93.9%
SAU801018	LPN100418	32%	28.5%	87.0%
SAU801018	LMO101113	34%	94.5%	95.3%
SAU801018	MCA100819	32%	72.9%	69.7%
SAU801018	MAV104018	29%	94.5%	90.8%
SAU801018	MBV100072	27%	79.8%	91.1%
SAU801018	MLP100564	30%	89.3%	84.7%
SAU801018	MTU202124	29%	93.9%	87.7%
SAU801018	NGO100606	33%	90.5%	91.5%
SAU801018	NME201913	33%	90.5%	91.5%
SAU801018	PMU100137	32%	92.1%	94.7%
SAU801018	PRT102626	32%	89.7%	91.5%
SAU801018	PAE204415	33%	91.7%	93.2%
SAU801018	PPU105954	33%	91.1%	92.7%
SAU801018	PSY107311	33%	90.1%	91.8%
SAU801018	SPA102754	28%	91.3%	93.3%
SAU801018	STY103171	30%	91.3%	93.1%
SAU801018	STM102863	29%	91.3%	93.1%
SAU801018	SAU801018	100%	100%	100%
SAU801018	SEP200270	87%	99.8%	99.8%
SAU801018	SHA101090	85%	99.4%	99.4%
SAU801018	SMU100386	28%	89.5%	88.6%
SAU801018	SPN401383	29%	89.9%	89.4%
SAU801018	SPY200283	28%	91.5%	90.9%
SAU801018	TPA100923	28%	91.9%	92.0%
SAU801018	VCH102371	31%	89.7%	87.5%
SAU801018	YPS000993	30%	92.3%	94.9%
SAU801019	SAU801019	100%	100%	100%
SAU801019	SEP202484	36%	85.5%	86.4%
SAU801019	SHA101091	48%	75.9%	76.2%
SAU801020	SAU801020	100%	100%	100%
SAU801021	ABA103073	39%	99.5%	76.8%
SAU801021	BFR10621	39%	99.3%	81.9%
SAU801021	BPT101443	43%	99.8%	75.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801021	BFU103306	44%	88.4%	67.4%
SAU801021	CAC101793	44%	96.5%	75.1%
SAU801021	CBO102015	46%	96.5%	75.0%
SAU801021	CDP100203	34%	100%	77.0%
SAU801021	EBC103571	40%	98.8%	76.7%
SAU801021	EFA201098	59%	100%	77.7%
SAU801021	EFM201941	57%	100%	80.8%
SAU801021	ECO104261	41%	99.3%	76.7%
SAU801021	HIN101699	41%	99.3%	77.0%
SAU801021	KPN302173	43%	88.4%	66.4%
SAU801021	LPN103093	43%	98.8%	82.8%
SAU801021	LMO102853	62%	100%	77.6%
SAU801021	MCA101980	42%	88.9%	68.6%
SAU801021	NGO100799	41%	98.5%	75.7%
SAU801021	NME200772	42%	98.5%	75.7%
SAU801021	PMU100816	40%	99.3%	76.7%
SAU801021	PRT100771	41%	99.3%	76.7%
SAU801021	PAE203900	45%	88.6%	68.3%
SAU801021	PPU101429	41%	98.8%	66.8%
SAU801021	PSY106730	40%	98.8%	76.5%
SAU801021	SPA102185	39%	98.8%	77.5%
SAU801021	STY104563	40%	98.8%	76.4%
SAU801021	STM100343	40%	98.8%	76.4%
SAU801021	SAU801021	100%	100%	100%
SAU801021	SEP200272	92%	100%	77.9%
SAU801021	SHA102902	93%	100%	87.9%
SAU801021	SMU100745	56%	99.0%	77.5%
SAU801021	SPN400396	57%	99.0%	76.8%
SAU801021	SPY201085	59%	99.0%	76.8%
SAU801021	VCH100647	42%	98.8%	76.1%
SAU801021	YPS000093	46%	88.4%	68.1%
SAU801025	CDF100072	21%	21.0%	92.2%
SAU801025	CDF102294	22%	49.6%	42.0%
SAU801025	CDF101487	22%	56.5%	64.9%
SAU801025	CDF103240	22%	54.8%	48.4%
SAU801025	SAU801025	100%	100%	100%
SAU801025	SEP200278	69%	99.2%	96.9%
SAU801025	SHA101420	64%	99.2%	99.0%
SAU801038	BAN107236	35%	75.5%	92.4%
SAU801038	BAN102502	36%	90.6%	92.0%
SAU801038	BCE100353	24%	79.0%	75.1%
SAU801038	BFU107408	25%	79.6%	70.2%
SAU801038	BMA101385	24%	77.4%	63.3%
SAU801038	EBC103345	37%	87.8%	89.3%
SAU801038	ECO104179	36%	87.8%	88.7%
SAU801038	KPN304212	25%	44.5%	48.0%
SAU801038	PMU100131	37%	89.0%	91.6%
SAU801038	PSY102144	35%	85.0%	87.5%
SAU801038	STY103490	25%	40.8%	43.9%
SAU801038	STM103176	25%	40.8%	43.9%
SAU801038	SAU802177	48%	96.9%	96.6%
SAU801038	SAU801038	100%	100%	100%
SAU801038	SEP202004	45%	96.9%	95.5%
SAU801038	SHA100119	56%	49.5%	93.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801038	SPN200521	31%	54.5%	91.7%
SAU801038	VCH100200	29%	47.3%	47.6%
SAU801060	ABA101560	50%	96.7%	99.7%
SAU801060	BAN108287	46%	94.9%	97.8%
SAU801060	BAN107549	60%	96.5%	99.1%
SAU801060	BFR102649	21%	21.9%	79.6%
SAU801060	BPT102772	50%	92.9%	96.1%
SAU801060	BCE104897	49%	98.5%	97.2%
SAU801060	BFU101932	49%	95.3%	94.9%
SAU801060	BMA105777	48%	98.8%	100%
SAU801060	BMA107179	48%	98.8%	97.5%
SAU801060	CDP102039	43%	77.6%	89.7%
SAU801060	EBC103074	47%	65.0%	96.4%
SAU801060	ECO100423	50%	93.2%	93.4%
SAU801060	HPY100141	22%	36.0%	51.6%
SAU801060	KPN303419	50%	93.2%	93.4%
SAU801060	LPN100442	46%	32.0%	94.6%
SAU801060	LMO102701	66%	96.7%	96.8%
SAU801060	MCA101093	19%	62.8%	91.3%
SAU801060	MAV101361	45%	75.2%	91.2%
SAU801060	MBV105923	45%	76.3%	87.6%
SAU801060	MLP101062	45%	76.3%	87.5%
SAU801060	MTU203003	45%	76.3%	87.6%
SAU801060	NGO100639	17%	45.3%	60.6%
SAU801060	NME201828	17%	45.3%	60.1%
SAU801060	PRT104154	47%	96.5%	97.7%
SAU801060	PAE201317	48%	95.3%	95.9%
SAU801060	PPU109665	48%	96.5%	95.1%
SAU801060	PSY104253	49%	95.2%	94.0%
SAU801060	SPA102307	48%	95.5%	96.8%
SAU801060	STY100720	50%	95.2%	95.0%
SAU801060	SAU801060	100%	100%	100%
SAU801060	SEP200351	93%	100%	100%
SAU801060	SHA100553	90%	97.3%	99.4%
SAU801060	VCH101421	17%	48.8%	67.1%
SAU801060	YPS001899	50%	95.2%	95.0%
SAU801061	ABA103655	36%	63.4%	71.1%
SAU801061	BAN111570	37%	59.3%	85.5%
SAU801061	BAN110867	40%	73.5%	94.2%
SAU801061	BPT102774	35%	59.8%	73.7%
SAU801061	BCE104834	33%	63.9%	89.7%
SAU801061	BFU101934	37%	64.8%	85.7%
SAU801061	BMA109512	35%	64.5%	83.6%
SAU801061	BMA107732	35%	66.1%	83.4%
SAU801061	CDP100360	21%	53.8%	72.9%
SAU801061	EBC101217	36%	68.0%	81.0%
SAU801061	ECO100424	35%	68.0%	81.0%
SAU801061	KPN303418	38%	25.7%	64.7%
SAU801061	LMO100640	49%	99.2%	99.7%
SAU801061	MAV102952	22%	24.3%	28.3%
SAU801061	MBV100595	20%	61.2%	89.6%
SAU801061	MLP100533	22%	61.7%	84.1%
SAU801061	MTU202166	20%	62.0%	82.1%
SAU801061	PRT103954	37%	68.3%	82.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801061	PAE201316	36%	63.7%	71.6%
SAU801061	PPU101498	38%	66.4%	78.9%
SAU801061	PSY104255	35%	67.8%	80.5%
SAU801061	SPA102308	34%	47.8%	55.8%
SAU801061	STY100721	36%	68.3%	80.2%
SAU801061	SAU801061	100%	100%	100%
SAU801061	SEP200354	81%	100%	100%
SAU801061	SHA100551	77%	80.1%	100%
SAU801061	YPS001897	38%	69.4%	82.1%
SAU801081	BAN101424	35%	96.7%	98.0%
SAU801081	BAN110238	46%	96.7%	95.2%
SAU801081	BFR11654	28%	98.2%	98.5%
SAU801081	BBU100789	26%	42.1%	32.5%
SAU801081	BCE105292	26%	99.5%	94.6%
SAU801081	BFU105347	25%	99.5%	98.0%
SAU801081	BMA105381	28%	58.5%	95.8%
SAU801081	CPN200218	30%	34.6%	49.5%
SAU801081	CTR200674	30%	33.6%	48%
SAU801081	CDF102444	29%	29.0%	39.3%
SAU801081	EBC100814	28%	96.7%	97.2%
SAU801081	EFA200628	42%	98.2%	97.7%
SAU801081	EFM201297	41%	98.7%	98.5%
SAU801081	ECO100942	29%	89.2%	96.2%
SAU801081	KPN301376	27%	96.7%	95.8%
SAU801081	LPN102414	26%	31.3%	83.6%
SAU801081	LPN102136	24%	74.4%	82.4%
SAU801081	LMO102509	43%	96.2%	95.4%
SAU801081	NGO101096	39%	51.8%	65.1%
SAU801081	NME201438	35%	62.8%	80.6%
SAU801081	PAE200353	24%	83.1%	81.4%
SAU801081	PPU102183	26%	82.6%	80.9%
SAU801081	PSY102744	27%	82.6%	80.9%
SAU801081	SPA103978	27%	96.7%	97.5%
SAU801081	STY103612	27%	96.7%	95.0%
SAU801081	SAU801081	100%	100%	100%
SAU801081	SEP200778	77%	100%	100%
SAU801081	SHA101353	77%	100%	100%
SAU801081	SMU100080	41%	96.9%	87.6%
SAU801081	SPN401235	43%	98.2%	97.4%
SAU801081	SPY200600	43%	97.2%	97.2%
SAU801081	VCH101334	28%	96.7%	91.9%
SAU801081	YPS002174	28%	96.7%	96.7%
SAU801083	ABA104415	34%	79.5%	78.7%
SAU801083	BAN108284	60%	92.0%	93.1%
SAU801083	BAN113302	61%	92.0%	93.1%
SAU801083	BPT101967	38%	95.5%	71.2%
SAU801083	BBU100556	29%	92.0%	94.2%
SAU801083	BCE109463	39%	93.2%	92.1%
SAU801083	BFU102715	35%	93.2%	92.1%
SAU801083	BMA101428	36%	93.2%	92.1%
SAU801083	CPN200726	31%	90.9%	74.1%
SAU801083	CTR200606	32%	87.5%	74.0%
SAU801083	CAC100614	51%	87.5%	89.5%
SAU801083	CBO101012	48%	93.2%	93.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801083	CDF100787	40%	84.1%	86.0%
SAU801083	CDP100378	27%	95.5%	95.5%
SAU801083	EFA201087	64%	100%	100%
SAU801083	EFM100206	63%	100%	100%
SAU801083	KPN300336	41%	87.5%	30.7%
SAU801083	LPN103186	41%	85.2%	84.3%
SAU801083	LMO101585	71%	100%	100%
SAU801083	MGE100041	47%	94.3%	95.5%
SAU801083	MPN100101	44%	94.3%	95.5%
SAU801083	NGO102690	41%	93.2%	92.1%
SAU801083	NME200365	40%	93.2%	92.1%
SAU801083	PMU100898	38%	77.3%	80%
SAU801083	PRT102262	34%	94.3%	97.6%
SAU801083	PPU103902	32%	93.2%	92.2%
SAU801083	PSY104754	31%	95.5%	94.4%
SAU801083	SPA100416	41%	87.5%	27.6%
SAU801083	STM101235	32%	94.3%	97.6%
SAU801083	SAU801083	100%	100%	100%
SAU801083	SEP200782	92%	100%	100%
SAU801083	SHA101355	96%	100%	100%
SAU801083	SMU103189	66%	97.7%	98.9%
SAU801083	SPN401063	67%	97.7%	98.9%
SAU801083	SPY201055	66%	97.7%	98.9%
SAU801083	TPA100582	45%	79.5%	79.5%
SAU801083	UUR100594	30%	97.7%	98.9%
SAU801084	ABA102248	39%	97.9%	57.4%
SAU801084	BAN113590	50%	99.5%	100%
SAU801084	BAN102128	65%	99.5%	99.8%
SAU801084	BFR102843	28%	66.3%	49.5%
SAU801084	BPT101969	40%	89.3%	84.4%
SAU801084	BBU100557	38%	99.1%	99.3%
SAU801084	BCE105897	38%	94.2%	91.0%
SAU801084	BFU102716	37%	94.2%	91.2%
SAU801084	BMA107198	38%	94.2%	91.9%
SAU801084	CPN200725	29%	98.6%	96.5%
SAU801084	CTR200605	27%	98.8%	96.5%
SAU801084	CAC102388	55%	93.4%	98.9%
SAU801084	CBO103848	54%	93.4%	98.9%
SAU801084	CDF100789	56%	97.6%	97.7%
SAU801084	CDP100363	31%	96.7%	95.6%
SAU801084	EBC101637	50%	99.5%	100%
SAU801084	EFA201084	63%	100%	100%
SAU801084	EFM201634	70%	44.2%	99.2%
SAU801084	ECO102367	50%	99.5%	99.1%
SAU801084	HIN101677	50%	99.3%	99.0%
SAU801084	HPY100119	27%	69.6%	51.1%
SAU801084	KPN300705	50%	99.5%	99.1%
SAU801084	LPN100853	34%	93.0%	69.5%
SAU801084	LMO101249	69%	99.7%	99.5%
SAU801084	MCA100687	29%	70.1%	52.5%
SAU801084	MAV102627	27%	12.8%	14.1%
SAU801084	MAV101273	33%	12.9%	13.8%
SAU801084	MAV100488	35%	12.9%	13.4%
SAU801084	MBV104403	35%	12.9%	14.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801084	MLP100590	37%	12.9%	12.0%
SAU801084	MTU201112	35%	12.9%	14.7%
SAU801084	MGE100439	45%	99.7%	98.8%
SAU801084	MPN100215	45%	99.7%	98.8%
SAU801084	NGO101819	35%	99.1%	97.0%
SAU801084	NME200366	35%	99.1%	97.0%
SAU801084	PMU100897	49%	99.3%	99.0%
SAU801084	PRT102260	50%	99.5%	99.1%
SAU801084	PAE203560	38%	99.3%	57.9%
SAU801084	PPU109910	38%	99.0%	58%
SAU801084	PSY105138	40%	98.6%	57.6%
SAU801084	SPA101201	42%	99.5%	99.1%
SAU801084	STY104022	31%	97.7%	74.5%
SAU801084	STM101237	50%	99.5%	99.1%
SAU801084	SAU801084	100%	100%	100%
SAU801084	SEP200784	88%	100%	100%
SAU801084	SHA101356	86%	93.5%	100%
SAU801084	SMU100862	63%	99.8%	99.5%
SAU801084	SPN401062	61%	99.8%	99.5%
SAU801084	SPY201054	61%	99.8%	99.5%
SAU801084	TPA100738	24%	62.4%	48.5%
SAU801084	VCH100949	50%	99.3%	99.3%
SAU801084	YPS000626	51%	99.5%	99.1%
SAU801089	BAN110506	68%	97.5%	100%
SAU801089	BAN101466	68%	98.4%	100%
SAU801089	CJU101614	40%	97.5%	84.3%
SAU801089	CAC102576	47%	97.3%	99.1%
SAU801089	CBO101502	46%	97.3%	99.3%
SAU801089	CBO103283	48%	98.4%	97.7%
SAU801089	CDF101226	50%	93.8%	99.4%
SAU801089	CDP100435	37%	97.0%	79.7%
SAU801089	EFA200195	63%	97.0%	97.5%
SAU801089	EFM202397	67%	69.2%	98.5%
SAU801089	HPY101409	41%	95.9%	78.8%
SAU801089	LMO101604	66%	98.4%	100%
SAU801089	MAV101957	35%	96.6%	94.6%
SAU801089	MBV104272	34%	96.6%	97.0%
SAU801089	MLP100931	35%	96.6%	97.0%
SAU801089	MTU202715	34%	96.6%	97.0%
SAU801089	MGE100141	38%	96.1%	96.5%
SAU801089	MPN100555	38%	96.1%	96.5%
SAU801089	SAU801089	100%	100%	100%
SAU801089	SEP200794	95%	99.1%	100%
SAU801089	SHA100488	92%	98.4%	100%
SAU801089	SMU100700	61%	97.5%	98.2%
SAU801089	SPN400125	62%	98.4%	91.0%
SAU801089	SPY201445	61%	97.5%	98.2%
SAU801089	TPA100485	40%	12.0%	20.2%
SAU801089	UUR100577	38%	98.1%	93.8%
SAU801089	VCH100261	25%	18.4%	21.1%
SAU801093	BAN105734	63%	97.0%	97.6%
SAU801093	BAN110170	74%	97.8%	97.6%
SAU801093	BPT101610	30%	78.1%	91.3%
SAU801093	BCE113547	33%	91.1%	85.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801093	BMA102663	34%	91.6%	86.1%
SAU801093	CPN200448	27%	81.6%	90.6%
SAU801093	CBO103958	32%	85.1%	98.8%
SAU801093	CDF100257	31%	83.8%	98.8%
SAU801093	EFA202418	67%	99.2%	98.9%
SAU801093	EFM201282	53%	19.7%	100%
SAU801093	KPN103829	37%	43.8%	83.4%
SAU801093	LPN103433	41%	95.1%	98.9%
SAU801093	LMO101849	75%	98.6%	98.4%
SAU801093	MAV103610	41%	92.2%	97.5%
SAU801093	MBV101185	40%	91.9%	95.2%
SAU801093	MTU202460	40%	91.9%	92.6%
SAU801093	MGE100280	35%	92.7%	95.5%
SAU801093	MPN100445	35%	91.1%	93.9%
SAU801093	PAE203415	37%	92.7%	94.2%
SAU801093	PPU111106	33%	91.6%	86.1%
SAU801093	SAU801093	100%	100%	100%
SAU801093	SEP200800	94%	100%	100%
SAU801093	SHA100009	93%	75.4%	100%
SAU801093	SMU100295	30%	92.7%	98.6%
SAU801093	SPY200775	28%	83.8%	99.1%
SAU801094	BAN108921	64%	98.5%	100%
SAU801094	BAN101772	74%	100%	100%
SAU801094	BPT101608	41%	98.8%	99.1%
SAU801094	BCE101800	45%	98.8%	96.2%
SAU801094	BMA104981	43%	98.8%	96.0%
SAU801094	CAC102552	23%	70.2%	35.4%
SAU801094	EBC103034	28%	86.8%	85.5%
SAU801094	EFA202409	74%	100%	100%
SAU801094	EFM200042	73%	100%	100%
SAU801094	HIN101408	22%	72.3%	35.8%
SAU801094	KPN303566	27%	71.4%	67.9%
SAU801094	LPN101708	45%	95.7%	96.0%
SAU801094	LMO100303	76%	100%	100%
SAU801094	MCA101840	24%	72.6%	32.9%
SAU801094	MAV103599	46%	98.8%	91.5%
SAU801094	MBV101184	45%	98.5%	92.0%
SAU801094	MTU202459	45%	98.5%	92.0%
SAU801094	MGE100279	39%	99.1%	98.8%
SAU801094	MPN100446	39%	99.1%	98.5%
SAU801094	NGO101578	28%	76.3%	36.3%
SAU801094	NME200546	28%	76.3%	36.3%
SAU801094	PMU100532	25%	68.9%	34.0%
SAU801094	PAE203414	40%	99.4%	97.0%
SAU801094	PPU100927	43%	98.8%	94.6%
SAU801094	SAU801094	100%	100%	100%
SAU801094	SEP200802	91%	100%	100%
SAU801094	SHA100436	90%	99.1%	100%
SAU801095	BAN101075	58%	98.4%	100%
SAU801095	BAN101226	68%	99.8%	99.8%
SAU801095	BCE111259	36%	98.6%	98.6%
SAU801095	BMA108930	37%	29.5%	2.9%
SAU801095	CBO101635	33%	98.1%	98.2%
SAU801095	EFA202405	61%	25.8%	1.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801095	EFM201990	61%	26.7%	2.0%
SAU801095	HIN101204	33%	47.2%	20.3%
SAU801095	KPN301446	34%	77.4%	39.2%
SAU801095	LMO102367	65%	26.0%	1.5%
SAU801095	MAV103601	31%	98.8%	97.7%
SAU801095	MLP100521	34%	24.0%	2.8%
SAU801095	MTU403766	44%	20.7%	98.9%
SAU801095	MTU405732	33%	98.4%	96.7%
SAU801095	MPN100447	30%	97.9%	99.0%
SAU801095	PAE202247	36%	98.6%	98.6%
SAU801095	PPU100765	35%	98.6%	98.6%
SAU801095	PSY103646	35%	44.7%	9.5%
SAU801095	SAU801095	100%	100%	100%
SAU801095	SEP200804	86%	100%	100%
SAU801095	SHA100437	87%	77.7%	100%
SAU801095	SMU101479	35%	99.5%	100%
SAU801095	SPN401049	33%	72.6%	93.1%
SAU801095	SPY200777	33%	99.3%	100%
SAU801096	ABA101766	41%	97.9%	97.9%
SAU801096	BAN101609	50%	99.6%	99.4%
SAU801096	BAN103383	70%	99.6%	99.4%
SAU801096	BFR10034	34%	95.1%	98.4%
SAU801096	BFR11786	37%	94.9%	98.7%
SAU801096	BPT100905	42%	98.1%	77.5%
SAU801096	BCE110691	44%	97.2%	78.5%
SAU801096	BFU101154	43%	95.9%	94.9%
SAU801096	BMA108899	44%	95.9%	97.3%
SAU801096	CPN201018	38%	97.9%	98.3%
SAU801096	CTR200835	38%	97.4%	97.6%
SAU801096	CBO103777	42%	95.3%	96.3%
SAU801096	CBO103904	41%	95.1%	96.5%
SAU801096	CDF102926	39%	97.4%	97.6%
SAU801096	CDP100695	38%	97.4%	98.7%
SAU801096	EBC102751	44%	96.4%	95.6%
SAU801096	EFA202404	64%	99.6%	99.8%
SAU801096	EFM201020	62%	99.6%	99.8%
SAU801096	ECO100116	44%	96.4%	95.6%
SAU801096	HIN101203	44%	96.4%	94.8%
SAU801096	KPN301447	43%	96.4%	95.4%
SAU801096	LPN100879	41%	96.4%	95.6%
SAU801096	LMO101821	71%	99.6%	99.8%
SAU801096	MCA101643	41%	97.9%	97.7%
SAU801096	MAV101768	37%	97.4%	98.7%
SAU801096	MBV103409	36%	97.4%	98.9%
SAU801096	MLP101416	36%	97.4%	98.9%
SAU801096	MTU200460	36%	97.4%	98.9%
SAU801096	MGE100277	37%	97.0%	98.9%
SAU801096	MPN100448	39%	96.4%	98.2%
SAU801096	NGO100074	43%	97.0%	78.6%
SAU801096	NME201415	43%	98.1%	79.5%
SAU801096	PMU100893	43%	96.4%	95.6%
SAU801096	PRT102281	43%	96.4%	95.4%
SAU801096	PAE202248	42%	98.1%	98.9%
SAU801096	PPU100764	40%	98.1%	98.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801096	PSY104859	40%	97.4%	97.5%
SAU801096	SPA100336	42%	83.1%	98.7%
SAU801096	STY103295	44%	96.4%	95.4%
SAU801096	STM103004	44%	96.4%	95.6%
SAU801096	SAU801096	100%	100%	100%
SAU801096	SEP200806	95%	100%	100%
SAU801096	SHA100679	93%	99.6%	100%
SAU801096	SMU100298	37%	96.4%	98.9%
SAU801096	SPN401048	37%	97.6%	79.5%
SAU801096	VCH102377	43%	96.4%	95.4%
SAU801096	YPS000861	44%	96.4%	95.4%
SAU801105	BAN103936	31%	94.4%	94.9%
SAU801105	BAN110850	38%	97.1%	99.3%
SAU801105	BFR103178	29%	92.9%	98.1%
SAU801105	BCE109436	41%	94.7%	95.4%
SAU801105	BFU115276	45%	92%	95.5%
SAU801105	BMA104207	41%	94.7%	95.7%
SAU801105	CAC103270	30%	91.8%	95.4%
SAU801105	EBC101317	36%	92.7%	97.3%
SAU801105	EFA201537	49%	94.7%	83.3%
SAU801105	EFA202292	57%	96.9%	96.0%
SAU801105	EFM202118	52%	61.1%	98.6%
SAU801105	ECO102349	35%	93.1%	96.4%
SAU801105	KPN301759	37%	92.7%	95.6%
SAU801105	LPN101696	26%	34.7%	40.5%
SAU801105	LMO100400	53%	96.9%	95.5%
SAU801105	MCA102057	22%	39.6%	42.3%
SAU801105	MCA103694	20%	56%	58.3%
SAU801105	MAV105572	34%	90%	94.9%
SAU801105	MBV103100	33%	39.6%	97.0%
SAU801105	MLP101268	32%	90.7%	91.5%
SAU801105	MTU200915	33%	93.6%	93.9%
SAU801105	NGO101522	20%	71.8%	73.4%
SAU801105	NME201499	21%	71.8%	73.4%
SAU801105	PMU100681	29%	26.7%	26.8%
SAU801105	PAE204332	46%	92.2%	97.4%
SAU801105	PSY105402	44%	94%	94.5%
SAU801105	SPA103529	36%	92.2%	95.4%
SAU801105	STY101143	35%	92.2%	95.4%
SAU801105	SAU801105	100%	100%	100%
SAU801105	SEP200820	84%	99.6%	100%
SAU801105	SHA100053	78%	69.6%	100%
SAU801105	SMU100063	53%	96%	97.8%
SAU801105	SPN400157	20%	84.2%	88.8%
SAU801105	SPY102082	52%	38.7%	100%
SAU801105	YPS000584	36%	90.9%	94.9%
SAU801109	ABA101290	53%	97.1%	98.7%
SAU801109	BAN108593	70%	99.2%	100%
SAU801109	BAN110377	74%	98.7%	99.3%
SAU801109	BFR12436	48%	97.6%	99.7%
SAU801109	BPT100252	55%	97.2%	96.1%
SAU801109	BCE107416	53%	97.2%	98.5%
SAU801109	BFU101165	52%	97.4%	85.6%
SAU801109	BMA100582	54%	97.2%	98.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801109	CJU100039	54%	97.6%	99.3%
SAU801109	CAC100624	55%	97.7%	99.2%
SAU801109	CBO103040	55%	98.2%	99.2%
SAU801109	CDF100332	48%	97.2%	98.2%
SAU801109	CDP100988	46%	98.2%	99.1%
SAU801109	EBC103136	53%	98.2%	99.5%
SAU801109	EFA200305	72%	98.4%	99.2%
SAU801109	EFM200826	74%	86.7%	100%
SAU801109	ECO103777	54%	95.6%	99.5%
SAU801109	HIN100844	53%	96.7%	96.8%
SAU801109	HPY100476	53%	97.6%	99.8%
SAU801109	KPN301352	54%	98.2%	99.5%
SAU801109	LPN100213	53%	97.6%	98.7%
SAU801109	LMO100625	72%	98.5%	99.3%
SAU801109	MCA100597	52%	98.5%	99.7%
SAU801109	MAV106479	44%	97.6%	99.0%
SAU801109	MBV101431	45%	97.6%	99.0%
SAU801109	MLP100924	44%	97.6%	99.0%
SAU801109	MTU201150	45%	97.6%	99.0%
SAU801109	NGO100315	54%	97.9%	99.7%
SAU801109	NME201257	54%	97.9%	99.7%
SAU801109	PMU101173	53%	98.4%	98.7%
SAU801109	PRT102826	54%	97.1%	96.3%
SAU801109	PAE205112	54%	97.1%	98.7%
SAU801109	PPU101976	53%	98.0%	99.5%
SAU801109	PSY103102	52%	97.7%	99.2%
SAU801109	SPA102685	48%	70.7%	98.6%
SAU801109	STY103413	53%	98.2%	99.5%
SAU801109	STM101499	53%	98.2%	99.5%
SAU801109	SAU801109	100%	100%	100%
SAU801109	SEP200827	92%	100%	100%
SAU801109	SHA100537	93%	99.7%	99.8%
SAU801109	SMU100076	74%	98.9%	99.3%
SAU801109	SPN400598	73%	98.9%	98.4%
SAU801109	SPY201176	73%	98.9%	99.5%
SAU801109	VCH102705	54%	98.7%	99.7%
SAU801109	YPS001324	54%	97.6%	98.8%
SAU801113	ABA103723	30%	86.6%	81.2%
SAU801113	BAN104342	37%	97.6%	93.4%
SAU801113	BAN103666	38%	99.5%	91.4%
SAU801113	BFR100762	27%	80.2%	71.9%
SAU801113	BPT103003	31%	95.2%	87.9%
SAU801113	BCE103498	32%	95.2%	92.6%
SAU801113	BFU100816	32%	95.2%	81.9%
SAU801113	BMA109411	32%	95.2%	81.2%
SAU801113	CJU100966	30%	90.3%	91.7%
SAU801113	CTR200136	29%	85.5%	76.2%
SAU801113	CAC100555	33%	94.4%	91.4%
SAU801113	CBO100202	34%	94.4%	91.1%
SAU801113	CDF103581	34%	89.0%	85.9%
SAU801113	EBC102569	31%	85.8%	76.8%
SAU801113	EFA200310	34%	91.7%	86.6%
SAU801113	EFM200911	35%	90.9%	87.6%
SAU801113	ECO100089	31%	89.3%	78.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801113	HIN101111	36%	86.6%	80.2%
SAU801113	HPY101537	28%	88.5%	89.7%
SAU801113	KPN301852	31%	85.8%	75%
SAU801113	LPN100221	36%	76.4%	94.0%
SAU801113	LMO101232	37%	92.8%	86.2%
SAU801113	MCA103455	30%	95.4%	90.8%
SAU801113	MAV103648	30%	91.2%	54.4%
SAU801113	MBV100525	30%	85.8%	63.8%
SAU801113	MLP100568	31%	91.2%	62.2%
SAU801113	MTU202120	30%	85.8%	59.5%
SAU801113	NGO100588	31%	98.4%	91.0%
SAU801113	NME201907	31%	98.4%	88.5%
SAU801113	PMU100141	32%	86.6%	80.3%
SAU801113	PRT102637	34%	79.4%	73.6%
SAU801113	PAE204411	32%	86.6%	79.7%
SAU801113	PPU112591	33%	86.6%	78.7%
SAU801113	PSY103847	33%	76.7%	70.3%
SAU801113	STY103175	31%	89.0%	78.5%
SAU801113	STM102887	31%	89.0%	78.5%
SAU801113	SAU801113	100%	100%	100%
SAU801113	SEP200834	76%	100%	91.4%
SAU801113	SHA101706	67%	99.2%	98.7%
SAU801113	SMU101535	33%	90.6%	83.3%
SAU801113	SPN400973	32%	89.3%	84.6%
SAU801113	SPY200440	32%	89.5%	81.6%
SAU801113	TPA100383	28%	91.2%	86.2%
SAU801113	VCH102367	30%	98.4%	90.7%
SAU801113	YPS001012	32%	86.3%	78.8%
SAU801114	BAN108934	45%	91.4%	93.8%
SAU801114	BAN112613	63%	99.7%	99.7%
SAU801114	CAC103250	54%	99.7%	99.9%
SAU801114	CBO103581	54%	99.7%	100%
SAU801114	CDF100269	54%	99.4%	99.7%
SAU801114	CDP100823	45%	99.4%	98.7%
SAU801114	EFA200317	58%	99.5%	99.9%
SAU801114	EFM202099	59%	99.3%	99.7%
SAU801114	LMO100679	61%	99.7%	99.9%
SAU801114	MAV103158	45%	99.4%	99.9%
SAU801114	MBV103377	45%	99.1%	99.6%
SAU801114	MTU202929	45%	99.1%	99.6%
SAU801114	PSY103300	37%	53.4%	99.2%
SAU801114	SAU801114	100%	100%	100%
SAU801114	SEP200837	89%	53.1%	100%
SAU801114	SHA101707	87%	53.1%	100%
SAU801114	TPA100055	32%	53.3%	99.2%
SAU801131	BAN104171	29%	58.6%	92.8%
SAU801131	BAN109296	27%	75.8%	17.5%
SAU801131	BAN111612	29%	48.0%	34.6%
SAU801131	BAN104612	32%	80.6%	73.4%
SAU801131	LMO101229	33%	89.4%	90.8%
SAU801131	MPN100554	21%	59.9%	34.2%
SAU801131	SPA106331	44%	15.9%	58.5%
SAU801131	SAU801131	100%	100%	100%
SAU801132	BAN101870	26%	67.3%	52.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801132	BCE107002	21%	31.8%	77.4%
SAU801132	BMA100184	22%	30.4%	49.3%
SAU801132	CDF100362	23%	41.3%	40.5%
SAU801132	EBC105295	32%	16.5%	41.3%
SAU801132	SAU801132	100%	100%	100%
SAU801134	BAN105614	34%	96.7%	83.4%
SAU801134	BAN106021	40%	98.9%	84.7%
SAU801134	LMO101340	45%	97.1%	82.4%
SAU801134	MBV103792	35%	36.3%	20.3%
SAU801134	MTU203401	35%	36.3%	20.3%
SAU801134	SAU801134	100%	100%	100%
SAU801134	SPY201382	44%	97.1%	80%
SAU801135	BAN105520	35%	98.0%	98.4%
SAU801135	BAN110918	42%	87.7%	98.2%
SAU801135	BFR104438	27%	35.2%	17.3%
SAU801135	BBU100793	27%	32.8%	5.8%
SAU801135	CDF102404	29%	35.2%	96.6%
SAU801135	CDF100360	31%	97.5%	99.1%
SAU801135	LMO100254	34%	98.8%	99.2%
SAU801135	PRT104101	25%	42.6%	41.5%
SAU801135	SAU801135	100%	100%	100%
SAU801135	SPY200094	33%	74.2%	76.4%
SAU801138	ABA102496	48%	96.0%	99.4%
SAU801138	BAN107250	37%	96.0%	100%
SAU801138	BAN102079	67%	96.0%	98.3%
SAU801138	BFR10569	47%	92.6%	95.0%
SAU801138	BPT100287	42%	95.7%	98.2%
SAU801138	BBU100512	28%	85.5%	62.1%
SAU801138	BCE106124	42%	97.4%	96.0%
SAU801138	BFU115595	45%	92.0%	95.3%
SAU801138	BMA107718	43%	95.7%	99.1%
SAU801138	CJU100828	42%	94.6%	99.7%
SAU801138	CPN200846	40%	97.4%	99.7%
SAU801138	CTR200219	42%	97.4%	99.7%
SAU801138	CAC101335	51%	96.6%	99.7%
SAU801138	CBO103589	50%	96.6%	99.7%
SAU801138	CDF100403	40%	47.2%	99.4%
SAU801138	CDF100483	63%	37.5%	99.2%
SAU801138	CDF100608	51%	96.6%	98.8%
SAU801138	CDP100986	39%	95.5%	89.7%
SAU801138	EBC102986	50%	96.0%	99.1%
SAU801138	EFA201458	62%	98.6%	100%
SAU801138	EFM202235	65%	97.7%	99.4%
SAU801138	ECO101682	50%	96.0%	99.1%
SAU801138	HIN101277	46%	96.6%	99.7%
SAU801138	HPY100399	45%	92.6%	97.9%
SAU801138	KPN301693	50%	96.0%	99.1%
SAU801138	LPN101724	50%	95.7%	98.8%
SAU801138	LMO102680	64%	97.4%	98.3%
SAU801138	MCA100196	45%	96.6%	94.2%
SAU801138	MAV106540	43%	90.6%	90.2%
SAU801138	MBV103898	43%	88.9%	87.2%
SAU801138	MLP100869	43%	89.2%	88%
SAU801138	MTU201628	43%	88.9%	90.0%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801138	MGE100196	37%	85.8%	89.7%
SAU801138	MPN100049	37%	82.4%	85.0%
SAU801138	NGO101895	42%	96.6%	99.7%
SAU801138	NME200858	42%	96.3%	99.1%
SAU801138	PMU100631	48%	96.6%	99.7%
SAU801138	PRT101305	51%	96.0%	99.1%
SAU801138	PAE202738	52%	96.6%	99.7%
SAU801138	PPU103714	51%	96.6%	99.7%
SAU801138	PSY100067	54%	82.7%	99.7%
SAU801138	SPA100213	49%	92.0%	98.7%
SAU801138	STY101116	50%	96.0%	99.1%
SAU801138	STM103449	50%	96.0%	99.1%
SAU801138	SAU801138	100%	100%	100%
SAU801138	SEP200863	90%	99.7%	99.7%
SAU801138	SHA100441	89%	99.7%	99.7%
SAU801138	SMU100485	62%	97.4%	99.7%
SAU801138	SPN400507	60%	96.9%	91.7%
SAU801138	SPY200564	62%	97.4%	92.8%
SAU801138	TPA100963	29%	68.8%	47.9%
SAU801138	UUR100463	40%	92.9%	96.1%
SAU801138	VCH101200	49%	96.6%	99.7%
SAU801138	YPS003058	49%	96.0%	99.1%
SAU801139	ABA102495	35%	90.6%	100%
SAU801139	BAN109820	37%	74.2%	75.8%
SAU801139	BAN101919	47%	100%	99.9%
SAU801139	BFR11118	33%	100%	100%
SAU801139	BPT100285	34%	99.1%	98.9%
SAU801139	BBU100513	23%	36.2%	49.3%
SAU801139	BCE101979	33%	100%	99.9%
SAU801139	BFU107151	31%	40.8%	93.6%
SAU801139	BMA101914	34%	100%	99.9%
SAU801139	CJU100827	26%	100%	100%
SAU801139	CPN200152	29%	98.4%	97.7%
SAU801139	CTR200749	28%	97.9%	97.3%
SAU801139	CAC101148	37%	98.5%	98.4%
SAU801139	CBO103321	38%	100%	99.9%
SAU801139	CDF100484	45%	32.9%	100%
SAU801139	CDF103760	38%	99.4%	99.0%
SAU801139	CDP100987	30%	97.9%	97.7%
SAU801139	EBC102988	37%	72.8%	99.7%
SAU801139	EFA201457	45%	99.8%	99.6%
SAU801139	EFM200867	44%	99.2%	99.1%
SAU801139	ECO101681	37%	99.4%	99.1%
SAU801139	HIN101278	36%	99.2%	98.6%
SAU801139	HPY100398	25%	98.6%	98.4%
SAU801139	KPN301695	37%	99.4%	99.1%
SAU801139	LPN100643	34%	97.8%	97.5%
SAU801139	LMO101759	47%	100%	100%
SAU801139	MCA100197	33%	99.6%	99.4%
SAU801139	MAV106542	30%	100%	99.9%
SAU801139	MBV101271	32%	73%	90.4%
SAU801139	MLP100870	30%	100%	99.8%
SAU801139	MTU201629	30%	100%	99.9%
SAU801139	MGE100197	26%	88.4%	89.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801139	MPN100048	26%	89.6%	89.6%
SAU801139	NGO101903	34%	100%	99.9%
SAU801139	NME200861	34%	100%	99.9%
SAU801139	PMU100629	35%	99%	98.7%
SAU801139	PRT101304	36%	99%	98.7%
SAU801139	PAE202737	35%	99.4%	99.1%
SAU801139	PPU103715	34%	99%	98.7%
SAU801139	PSY100068	35%	99.4%	99.1%
SAU801139	SPA100516	35%	78%	99.4%
SAU801139	STY101114	36%	99.4%	99.1%
SAU801139	STM103450	37%	99.4%	99.1%
SAU801139	SAU801139	100%	100%	100%
SAU801139	SEP200864	78%	100%	100%
SAU801139	SHA100442	80%	62.4%	94.3%
SAU801139	SMU100476	43%	5.4%	95.7%
SAU801139	SMU100483	44%	100%	100%
SAU801139	SPN400509	45%	99.4%	99.2%
SAU801139	SPY200565	44%	100%	100%
SAU801139	TPA100014	25%	35.2%	44.9%
SAU801139	UUR100462	24%	89.6%	90.4%
SAU801139	VCH101201	35%	100%	99.9%
SAU801139	YPS003055	37%	99%	98.7%
SAU801144	BAN110629	43%	83.2%	82.7%
SAU801144	BAN100015	49%	100%	100%
SAU801144	BFR11777	30%	98.6%	98.4%
SAU801144	BBU100098	31%	86.3%	86.4%
SAU801144	CJU100980	23%	82.1%	84.2%
SAU801144	CAC102136	38%	100%	100%
SAU801144	CBO102295	40%	100%	100%
SAU801144	CDF103406	42%	100%	100%
SAU801144	EFA202339	44%	99.5%	99.5%
SAU801144	EFM201371	43%	100%	100%
SAU801144	HPY100613	24%	92.1%	90.9%
SAU801144	LMO101164	47%	100%	100%
SAU801144	SAU801144	100%	100%	100%
SAU801144	SEP200869	84%	100%	100%
SAU801144	SHA101143	83%	77.0%	99.8%
SAU801144	SMU101270	40%	100%	99.0%
SAU801144	SPN400368	38%	100%	99.9%
SAU801144	SPY201414	40%	99.9%	99.9%
SAU801151	ABA103721	33%	81.2%	79.3%
SAU801151	BAN108866	40%	93.6%	100%
SAU801151	BAN105656	42%	98.5%	97.4%
SAU801151	BAN100164	45%	97.7%	93.5%
SAU801151	BAN103658	51%	98.5%	97.4%
SAU801151	BFR102236	34%	98.1%	96.1%
SAU801151	BPT101248	23%	49.6%	54.9%
SAU801151	BBU100100	23%	87.6%	87.4%
SAU801151	BCE107277	33%	73.7%	92.8%
SAU801151	BFU109172	29%	90.6%	93.8%
SAU801151	BMA106607	30%	98.5%	90.3%
SAU801151	CJU101558	34%	94.4%	98%
SAU801151	CAC101362	37%	72.6%	75%
SAU801151	CBO102188	33%	83.5%	84.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801151	CDF101024	39%	98.9%	98.1%
SAU801151	CDP101353	44%	98.5%	98.5%
SAU801151	EBC101695	32%	84.2%	86.5%
SAU801151	EFA201433	50%	94.4%	91.3%
SAU801151	EFM201002	49%	98.9%	95.3%
SAU801151	ECO103873	31%	80.1%	74.0%
SAU801151	HIN101705	29%	82.0%	81.0%
SAU801151	HPY100542	35%	94.4%	99.2%
SAU801151	KPN308897	31%	77.1%	85.1%
SAU801151	LPN100405	42%	85.7%	81.0%
SAU801151	LMO101688	50%	99.2%	99.2%
SAU801151	MCA100045	30%	81.2%	76.8%
SAU801151	MAV103533	40%	95.9%	93.8%
SAU801151	MBV101876	40%	94.0%	91.9%
SAU801151	MLP100726	40%	95.9%	93.4%
SAU801151	MTU201321	40%	94.0%	91.9%
SAU801151	NGO101679	36%	98.5%	97.0%
SAU801151	NME201872	37%	98.5%	97.0%
SAU801151	PMU100917	30%	82.7%	83.3%
SAU801151	PRT105607	32%	82.0%	76.4%
SAU801151	PAE204659	35%	81.2%	81.1%
SAU801151	PPU109719	33%	98.1%	97.7%
SAU801151	PSY106535	35%	96.2%	92.4%
SAU801151	SPA103848	25%	30.5%	66.9%
SAU801151	STY102718	31%	84.2%	86.5%
SAU801151	STM102035	31%	84.2%	79.5%
SAU801151	SAU801151	100%	100%	100%
SAU801151	SEP200875	86%	100%	99.6%
SAU801151	SHA100464	82%	100%	100%
SAU801151	SMU100491	42%	98.9%	99.2%
SAU801151	SPN401694	45%	98.9%	99.2%
SAU801151	SPY200261	43%	98.5%	98.9%
SAU801151	TPA100402	24%	75.2%	75%
SAU801151	VCH100156	30%	88.7%	86.8%
SAU801151	YPS001748	30%	80.5%	74.9%
SAU801152	ABA101490	43%	95.9%	94.2%
SAU801152	BAN102272	53%	53.8%	29.6%
SAU801152	BAN103467	53%	53.8%	29.8%
SAU801152	BFR100882	42%	96.4%	97.4%
SAU801152	BPT102669	41%	93.3%	80.7%
SAU801152	BBU100246	37%	96.9%	96.5%
SAU801152	BCE101174	43%	53.8%	30.6%
SAU801152	BFU112825	42%	98.5%	93.4%
SAU801152	BMA101121	41%	95.4%	91.4%
SAU801152	CJU101298	38%	96.4%	97%
SAU801152	CPN201078	36%	96.4%	94.2%
SAU801152	CTR200884	38%	96.4%	92.8%
SAU801152	CAC102793	46%	94.9%	94.5%
SAU801152	CBO101239	45%	96.9%	97.5%
SAU801152	CDF103949	41%	94.4%	42.1%
SAU801152	CDP101347	33%	96.9%	97.1%
SAU801152	EBC103395	44%	94.9%	96.4%
SAU801152	EFA204162	30%	92.3%	92.4%
SAU801152	EFA201431	48%	94.9%	41.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801152	EFM201013	55%	53.3%	29.4%
SAU801152	ECO102889	43%	94.9%	96.4%
SAU801152	HIN100246	41%	96.4%	99.0%
SAU801152	KPN300507	52%	27.2%	82.8%
SAU801152	KPN302113	46%	94.9%	96.4%
SAU801152	LPN101495	44%	96.9%	99.0%
SAU801152	LMO101778	47%	95.4%	93.6%
SAU801152	MCA101652	45%	93.3%	93.6%
SAU801152	MAV103539	38%	97.4%	96.6%
SAU801152	MBV101882	37%	93.8%	92.6%
SAU801152	MLP100729	35%	95.9%	89.1%
SAU801152	MTU201324	37%	93.8%	92.6%
SAU801152	NGO100831	41%	92.8%	93.0%
SAU801152	NME200785	41%	92.8%	93.0%
SAU801152	PMU101666	42%	96.4%	96.5%
SAU801152	PRT105468	42%	94.9%	96.4%
SAU801152	PAE200386	40%	95.4%	95.9%
SAU801152	PPU102088	41%	94.9%	94.9%
SAU801152	PSY103557	40%	95.4%	95.5%
SAU801152	SPA102538	45%	94.9%	97.4%
SAU801152	STY104601	45%	94.9%	96.4%
SAU801152	STM100605	46%	94.9%	96.4%
SAU801152	SAU801152	100%	100%	100%
SAU801152	SEP200876	72%	100%	100%
SAU801152	SHA100465	70%	99.0%	100%
SAU801152	SMU100489	41%	97.9%	60.3%
SAU801152	SPN401693	42%	94.9%	56.8%
SAU801152	SPY200262	41%	93.3%	57.0%
SAU801152	TPA100434	39%	89.7%	65.8%
SAU801152	VCH100451	44%	99.0%	99%
SAU801152	YPS000246	48%	94.9%	96.4%
SAU801170	BMA101214	41%	98.7%	95.2%
SAU801170	EBC101762	45%	98.4%	97.2%
SAU801170	EFA201006	51%	99.4%	99.4%
SAU801170	EFA201632	52%	99.0%	97.8%
SAU801170	ECO102810	53%	98.7%	98.4%
SAU801170	HIN100574	41%	99.4%	96.8%
SAU801170	MPN100529	45%	100%	100%
SAU801170	PAE205168	41%	98.1%	95.8%
SAU801170	PPU103958	42%	98.1%	95.8%
SAU801170	STY103966	44%	98.7%	95.5%
SAU801170	SAU801170	100%	100%	100%
SAU801170	SEP202230	89%	100%	100%
SAU801170	SHA100424	68%	54.8%	99.4%
SAU801170	SPN401955	49%	99.4%	98.4%
SAU801179	ABA100924	43%	99.0%	98.0%
SAU801179	BAN107720	43%	99.0%	100%
SAU801179	BAN107471	64%	99.0%	99.4%
SAU801179	BFR10235	40%	98.4%	97.0%
SAU801179	BPT103017	39%	92.9%	78.3%
SAU801179	BBU100305	32%	98.7%	98.0%
SAU801179	BCE109760	40%	97.1%	98.7%
SAU801179	BFU100821	39%	98.1%	95.6%
SAU801179	BMA103495	41%	98.7%	97.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801179	CJU100643	38%	97.1%	94.9%
SAU801179	CPN200328	33%	98.1%	97.0%
SAU801179	CTR200537	32%	98.1%	95.4%
SAU801179	CAC101664	53%	98.7%	98.1%
SAU801179	CBO100001	53%	98.1%	95.6%
SAU801179	CDF103476	49%	98.7%	96.5%
SAU801179	CDP101284	38%	93.2%	88.2%
SAU801179	EBC101940	41%	87.1%	83.2%
SAU801179	EFA202184	63%	99.7%	96.9%
SAU801179	EFM200229	64%	99.7%	97.5%
SAU801179	ECO100082	41%	98.7%	97.4%
SAU801179	HIN101104	41%	98.1%	96.0%
SAU801179	HPY100698	38%	97.4%	96.1%
SAU801179	KPN301853	37%	98.7%	88.2%
SAU801179	LPN101684	43%	99.7%	99.7%
SAU801179	LMO102721	67%	99.0%	98.7%
SAU801179	MCA100816	40%	98.4%	92.2%
SAU801179	MAV103917	40%	98.7%	96.0%
SAU801179	MBV101484	43%	92.0%	87.5%
SAU801179	MLP100561	41%	92.6%	77.7%
SAU801179	MTU202131	40%	98.7%	79.8%
SAU801179	MGE100227	34%	98.1%	97.1%
SAU801179	MPN100521	37%	98.1%	97.4%
SAU801179	NGO100619	43%	98.7%	95.6%
SAU801179	NME201916	43%	98.7%	92.7%
SAU801179	PMU100134	43%	98.7%	96.6%
SAU801179	PRT102632	42%	98.7%	97.1%
SAU801179	PAE204418	42%	99.7%	98.7%
SAU801179	PPU105960	40%	99.7%	98.1%
SAU801179	PSY103858	42%	99.7%	98.7%
SAU801179	SPA102751	38%	98.7%	97.4%
SAU801179	STY103148	39%	98.7%	97.4%
SAU801179	STM102860	39%	98.7%	97.4%
SAU801179	SAU801179	100%	100%	100%
SAU801179	SEP200893	89%	100%	100%
SAU801179	SHA101308	91%	100%	100%
SAU801179	SMU101437	56%	99.7%	98.4%
SAU801179	SPN400302	59%	98.1%	96.8%
SAU801179	SPY201283	57%	99.7%	92.3%
SAU801179	TPA100380	30%	68.2%	59.1%
SAU801179	UUR100389	48%	97.1%	96.4%
SAU801179	VCH102374	38%	99.4%	98.7%
SAU801179	YPS000988	41%	98.7%	95.3%
SAU801180	BAN113715	43%	43.6%	81.7%
SAU801180	BAN110605	34%	78.2%	90.8%
SAU801180	EFA202182	24%	80.5%	79.3%
SAU801180	EFM201482	23%	94.7%	100%
SAU801180	LMO102397	32%	75.2%	80.8%
SAU801180	SAU801180	100%	100%	100%
SAU801180	SEP200895	84%	100%	100%
SAU801180	SHA101309	73%	100%	100%
SAU801180	SMU101439	27%	69.2%	86.0%
SAU801180	SPN400303	16%	64.7%	81.9%
SAU801180	SPY201282	25%	69.2%	86.0%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801181	ABA105255	26%	77.3%	93.3%
SAU801181	BAN113613	30%	9.5%	91.8%
SAU801181	BAN105395	35%	43.0%	95.3%
SAU801181	BAN105591	28%	92.1%	95.1%
SAU801181	BAN110033	36%	95.3%	97.9%
SAU801181	BAN112091	35%	94.6%	97.8%
SAU801181	BFR101372	24%	93.7%	99.0%
SAU801181	BPT103014	29%	65.5%	79.4%
SAU801181	BBU100135	25%	83.3%	95.2%
SAU801181	BCE112144	27%	76.7%	87.3%
SAU801181	BFU100822	27%	76.7%	86.6%
SAU801181	BMA103887	27%	78.1%	90.6%
SAU801181	CPN200330	26%	40.6%	51.6%
SAU801181	CTR200535	25%	59.5%	68.9%
SAU801181	CAC102451	27%	80.1%	99.7%
SAU801181	CAC102718	28%	93.3%	96.4%
SAU801181	CBO100210	28%	95.2%	98.3%
SAU801181	CDF104232	29%	86.8%	98.6%
SAU801181	CDP101283	25%	71.0%	91.5%
SAU801181	EBC102574	26%	76.7%	94.7%
SAU801181	EFA202180	33%	93.4%	95.8%
SAU801181	EFM201754	33%	93.8%	96.3%
SAU801181	ECO100084	26%	76.7%	91.5%
SAU801181	HIN101106	26%	76.6%	87.0%
SAU801181	HPY101533	22%	75.8%	92.0%
SAU801181	KPN301849	26%	76.7%	91.5%
SAU801181	LPN102605	27%	65.5%	85.4%
SAU801181	LMO101211	37%	98.0%	97.7%
SAU801181	MCA100818	24%	77.4%	90.6%
SAU801181	MAV104019	25%	72.3%	82.2%
SAU801181	MBV101482	24%	76.5%	89.3%
SAU801181	MLP100563	25%	74.3%	84.7%
SAU801181	MTU202129	24%	76.5%	84.8%
SAU801181	NGO102402	27%	79.8%	97.7%
SAU801181	NME201914	27%	79.8%	96.0%
SAU801181	PMU100136	27%	73.3%	85.2%
SAU801181	PRT102628	26%	81.6%	98.8%
SAU801181	PAE202270	27%	72.0%	88.8%
SAU801181	PPU111736	26%	76.7%	92.8%
SAU801181	PSY103856	25%	76.7%	93.8%
SAU801181	SPA102753	25%	76.7%	92.1%
SAU801181	STY101764	27%	75.3%	90.7%
SAU801181	STM102862	26%	76.7%	91.5%
SAU801181	SAU801181	100%	100%	100%
SAU801181	SEP200896	80%	100%	95.9%
SAU801181	SHA101310	78%	95.0%	100%
SAU801181	SMU101453	32%	94.1%	96.5%
SAU801181	SPN400304	32%	93.8%	96.4%
SAU801181	SPY201281	30%	95.0%	96.8%
SAU801181	TPA100752	23%	84.5%	92.2%
SAU801181	VCH102372	25%	77.0%	94.3%
SAU801181	YPS000992	25%	76.7%	91.7%
SAU801182	ABA100933	39%	96.6%	90.3%
SAU801182	BAN106826	44%	98.8%	98.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801182	BAN112016	54%	99.4%	97.8%
SAU801182	BFR103500	32%	88.5%	81.0%
SAU801182	BPT103007	39%	96.0%	90.2%
SAU801182	BBU100302	37%	96.6%	92.3%
SAU801182	BCE112929	44%	55.1%	93.0%
SAU801182	BFU100825	38%	96.6%	90.7%
SAU801182	BMA100546	41%	96.6%	90.7%
SAU801182	CJU100401	44%	96.3%	91.2%
SAU801182	CPN200949	34%	96.6%	92.3%
SAU801182	CTR200133	36%	96.6%	94.9%
SAU801182	CAC103184	45%	97.5%	97.5%
SAU801182	CBO103583	44%	97.2%	97.5%
SAU801182	CBO100702	50%	96.9%	97.2%
SAU801182	CDF103820	41%	96.9%	93.3%
SAU801182	CDP101276	38%	97.8%	95.4%
SAU801182	EBC102571	41%	97.5%	90.8%
SAU801182	EFA202177	51%	98.8%	97.8%
SAU801182	EFM200138	51%	99.1%	99.4%
SAU801182	ECO100087	41%	97.5%	90.8%
SAU801182	HIN101109	41%	96.6%	90%
SAU801182	HPY100488	38%	96.3%	90.7%
SAU801182	KPN301856	41%	97.5%	90.8%
SAU801182	LPN102792	42%	67.3%	97.5%
SAU801182	LMO102708	53%	96.9%	95.7%
SAU801182	MCA100821	38%	96.9%	93.2%
SAU801182	MAV103996	36%	98.1%	95.5%
SAU801182	MLP100566	37%	98.1%	95.5%
SAU801182	MTU202122	36%	98.1%	95.5%
SAU801182	NGO100597	41%	96.9%	90.6%
SAU801182	NME201910	42%	96.9%	90.6%
SAU801182	PMU100139	41%	96.6%	90%
SAU801182	PRT102641	44%	96.6%	90%
SAU801182	PAE204413	43%	96.6%	90%
SAU801182	PPU105952	43%	96.6%	90%
SAU801182	PSY103851	43%	96.6%	90%
SAU801182	SPA102756	41%	97.5%	92.9%
SAU801182	STY103173	41%	97.5%	90.8%
SAU801182	STM102884	42%	97.5%	90.8%
SAU801182	SAU801182	100%	100%	100%
SAU801182	SEP200897	87%	100%	100%
SAU801182	SHA101311	87%	100%	100%
SAU801182	SMU101454	40%	98.1%	97.3%
SAU801182	SPN400305	44%	97.5%	97.9%
SAU801182	SPY201280	40%	99.1%	98.2%
SAU801182	TPA100341	26%	84.4%	78.0%
SAU801182	VCH102369	42%	97.5%	90.8%
SAU801182	YPS000995	44%	97.5%	90.8%
SAU801183	ABA105049	29%	95.1%	96.4%
SAU801183	BAN101698	42%	96.4%	99.1%
SAU801183	BAN100427	50%	98.0%	98.7%
SAU801183	BFR11370	36%	95.5%	98.2%
SAU801183	BPT103005	27%	96.2%	95.5%
SAU801183	BBU100584	28%	96.2%	97.1%
SAU801183	BFU100814	26%	95.1%	94.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801183	BMA102821	25%	95.1%	96.8%
SAU801183	CJU100400	25%	81.7%	84.6%
SAU801183	CPN200948	26%	95.5%	96.9%
SAU801183	CTR200134	27%	95.5%	92.8%
SAU801183	CAC103488	33%	96.7%	96.3%
SAU801183	CBO101756	33%	96.2%	96.1%
SAU801183	CDF104583	38%	96.2%	97.8%
SAU801183	CDP101273	27%	96.9%	94.8%
SAU801183	EBC102570	30%	97.6%	98.2%
SAU801183	EFA202176	50%	98.0%	97.8%
SAU801183	EFM201395	51%	96.4%	97.1%
SAU801183	ECO100088	31%	97.6%	98.2%
SAU801183	HIN101110	31%	96.0%	97.3%
SAU801183	HPY100489	26%	82.2%	85.8%
SAU801183	KPN300285	27%	19.2%	55.1%
SAU801183	KPN302061	27%	19.2%	26.5%
SAU801183	KPN300322	34%	37.9%	86.7%
SAU801183	KPN301854	31%	97.6%	98.2%
SAU801183	LPN102050	31%	93.3%	100%
SAU801183	LMO100907	48%	96.2%	95.8%
SAU801183	MCA103645	30%	97.8%	99.6%
SAU801183	MAV103995	30%	44.1%	76.8%
SAU801183	MBV100523	25%	96.4%	95.9%
SAU801183	MLP100567	25%	96.4%	97.3%
SAU801183	MTU202121	26%	96.4%	97.3%
SAU801183	NGO100590	30%	97.3%	99.1%
SAU801183	NME201908	30%	97.3%	99.1%
SAU801183	PMU100140	31%	96.7%	97.9%
SAU801183	PRT102639	32%	97.6%	98.2%
SAU801183	PAE204412	28%	94.9%	96.0%
SAU801183	PPU105951	29%	95.3%	96%
SAU801183	PSY103849	30%	80.8%	93.1%
SAU801183	SPA102757	28%	57.0%	71.5%
SAU801183	STY103174	29%	96.0%	97.3%
SAU801183	STM102886	29%	96.0%	97.3%
SAU801183	SAU801183	100%	100%	100%
SAU801183	SEP200898	89%	100%	100%
SAU801183	SHA101312	86%	59.9%	100%
SAU801183	SMU100079	47%	98.9%	99.1%
SAU801183	SPN400603	46%	96.4%	96.9%
SAU801183	SPY201174	47%	97.6%	97.6%
SAU801183	TPA100893	22%	97.3%	97.9%
SAU801183	VCH102368	28%	97.1%	92.5%
SAU801183	YPS001010	30%	97.6%	98.2%
SAU801184	BAN105429	30%	53.3%	89.3%
SAU801184	BAN113055	30%	56.3%	91.7%
SAU801184	BBU100300	25%	31.0%	56.3%
SAU801184	BMA101206	20%	24.4%	14.4%
SAU801184	CAC103429	21%	52.6%	94.8%
SAU801184	CBO101421	23%	55.8%	95.3%
SAU801184	CDF104368	28%	42.6%	81.3%
SAU801184	EFA202172	26%	76.8%	90.6%
SAU801184	EFM200367	26%	83.8%	89.2%
SAU801184	LMO101774	29%	60.8%	95.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801184	NGO100580	21%	56.7%	96.7%
SAU801184	NME201903	21%	54.9%	96.7%
SAU801184	SAU801184	100%	100%	100%
SAU801184	SEP200899	51%	99.8%	96.1%
SAU801184	SHA100844	47%	83.8%	99.5%
SAU801184	SMU100083	21%	68.3%	84.0%
SAU801184	SPN400605	21%	97.7%	99.2%
SAU801184	SPY201172	23%	72.0%	86.1%
SAU801184	TPA100384	27%	23.7%	39.1%
SAU801185	ABA100623	24%	73.0%	82.1%
SAU801185	BAN111291	37%	77.4%	85.1%
SAU801185	BAN101900	37%	77.4%	84.3%
SAU801185	BFR102146	23%	98.9%	97.7%
SAU801185	BPT102984	28%	77.2%	90.4%
SAU801185	BBU100299	26%	77.9%	90.8%
SAU801185	BCE109663	28%	76.6%	89.3%
SAU801185	BFU100407	28%	76.6%	89.3%
SAU801185	BMA104126	28%	76.6%	89.3%
SAU801185	CJU100645	24%	88.1%	92.2%
SAU801185	CAC100288	22%	91.1%	98.1%
SAU801185	CBO102974	24%	85.5%	94.1%
SAU801185	EBC101798	25%	76.6%	89.2%
SAU801185	EFA202170	30%	78.7%	84.3%
SAU801185	EFM201888	29%	95.5%	96.8%
SAU801185	ECO100094	24%	76.6%	88.8%
SAU801185	HIN101116	28%	77.9%	89.4%
SAU801185	HPY100962	23%	76.6%	80.5%
SAU801185	KPN300531	25%	41.3%	84.9%
SAU801185	LPN103001	28%	71.3%	81.6%
SAU801185	LMO101001	34%	79.6%	88.0%
SAU801185	MCA100438	24%	72.3%	79.4%
SAU801185	NGO100578	28%	78.3%	90.6%
SAU801185	NME201902	28%	78.3%	90.6%
SAU801185	PMU100146	26%	77.9%	89.4%
SAU801185	PRT102629	25%	73.0%	84.0%
SAU801185	PAE204406	28%	76.6%	87.8%
SAU801185	PPU111774	26%	76.8%	89.1%
SAU801185	PSY103837	26%	76.6%	89.3%
SAU801185	SPA101844	25%	76.6%	88.7%
SAU801185	STY103209	25%	76.6%	88.8%
SAU801185	STM102892	25%	76.6%	88.8%
SAU801185	SAU801185	100%	100%	100%
SAU801185	SEP200915	86%	100%	100%
SAU801185	SHA100845	78%	100%	100%
SAU801185	SMU100084	30%	93.4%	95.8%
SAU801185	SPN401510	34%	77.0%	79.2%
SAU801185	SPY201171	30%	85.5%	91.2%
SAU801185	TPA100385	24%	76.6%	90.3%
SAU801185	VCH102363	25%	77.9%	90.2%
SAU801185	YPS001022	26%	76.6%	89.2%
SAU801186	ABA100622	48%	96.2%	96.4%
SAU801186	BAN103024	66%	98.2%	100%
SAU801186	BAN112439	68%	98.2%	100%
SAU801186	BFR12421	47%	77.4%	69.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801186	BPT102981	41%	99.7%	94.7%
SAU801186	BBU100298	52%	95.4%	92.8%
SAU801186	BCE103310	54%	70%	94.1%
SAU801186	BFU100408	53%	77.2%	75.1%
SAU801186	BMA104500	44%	94.6%	96.5%
SAU801186	CJU100646	48%	81.0%	85.7%
SAU801186	CAC100838	59%	98.5%	99.7%
SAU801186	CBO103263	59%	97.9%	100%
SAU801186	CDF102447	57%	97.4%	97.5%
SAU801186	CDP101254	53%	97.9%	92.5%
SAU801186	EBC101797	57%	38.2%	91.4%
SAU801186	EFA202168	69%	80.3%	76.3%
SAU801186	EFM200220	68%	80.3%	75.8%
SAU801186	ECO100095	52%	79.0%	81.2%
SAU801186	HIN101117	46%	78.5%	78.1%
SAU801186	HPY100963	39%	95.1%	93.0%
SAU801186	KPN300530	58%	38.5%	93.8%
SAU801186	LPN100473	51%	7.9%	76.9%
SAU801186	LMO101235	68%	98.2%	99.7%
SAU801186	MCA101528	50%	79.7%	87.1%
SAU801186	MAV103265	55%	94.9%	98.2%
SAU801186	MBV100533	54%	94.9%	98.4%
SAU801186	MLP100572	53%	94.9%	98.4%
SAU801186	MTU202116	54%	94.9%	98.4%
SAU801186	MGE100229	28%	73.6%	81.6%
SAU801186	MPN100519	30%	54.4%	54.7%
SAU801186	NGO100577	53%	78.7%	79.1%
SAU801186	NME201901	50%	85.9%	84.2%
SAU801186	PMU100147	46%	81.0%	78.1%
SAU801186	PRT102627	56%	44.1%	92.0%
SAU801186	PAE204405	45%	97.9%	100%
SAU801186	PPU105993	52%	80.5%	79.1%
SAU801186	PSY103835	52%	81.5%	80.8%
SAU801186	SPA100031	45%	49.5%	74.3%
SAU801186	STY103211	52%	79.0%	81.2%
SAU801186	STM102893	52%	79.0%	81.2%
SAU801186	SAU801186	100%	100%	100%
SAU801186	SEP200917	92%	100%	100%
SAU801186	SHA100846	92%	100%	100%
SAU801186	SMU100085	64%	77.7%	69.8%
SAU801186	SPN401509	65%	77.7%	72.3%
SAU801186	SPY201170	65%	77.7%	69.0%
SAU801186	TPA100386	48%	94.6%	95.0%
SAU801186	VCH102362	52%	78.7%	77.4%
SAU801186	YPS001023	45%	95.1%	97.4%
SAU801188	ABA100699	33%	99.1%	96.5%
SAU801188	BAN102298	60%	86.6%	97%
SAU801188	BAN105813	55%	99.1%	99.6%
SAU801188	BFR10478	35%	99.1%	98.6%
SAU801188	BPT100358	38%	86.2%	73.1%
SAU801188	BCE102004	36%	87.5%	85.8%
SAU801188	BFU102631	35%	97.8%	96.1%
SAU801188	CJU100669	30%	85.3%	91.0%
SAU801188	CAC102293	35%	93.8%	95.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801188	CBO100252	32%	99.1%	97.3%
SAU801188	CDF104041	44%	98.2%	94.9%
SAU801188	CDP100613	40%	85.3%	85.1%
SAU801188	EBC103402	31%	99.1%	97.4%
SAU801188	EFA202166	49%	96.9%	97.8%
SAU801188	EFM200029	45%	98.7%	99.6%
SAU801188	ECO102886	31%	99.1%	97.0%
SAU801188	HIN100089	30%	98.7%	95.8%
SAU801188	HPY100391	32%	86.6%	86.9%
SAU801188	KPN302105	33%	99.1%	97.4%
SAU801188	LPN100888	34%	100%	98.3%
SAU801188	LMO101181	49%	99.6%	98.3%
SAU801188	MCA100523	27%	97.3%	91.5%
SAU801188	MAV103261	27%	66.1%	59.0%
SAU801188	MBV100535	26%	86.2%	79.5%
SAU801188	MLP100574	31%	66.1%	59.2%
SAU801188	MTU202114	26%	86.2%	81.4%
SAU801188	NGO101964	33%	87.1%	86.4%
SAU801188	NME200206	34%	87.1%	86.4%
SAU801188	PMU100112	31%	100%	98.7%
SAU801188	PRT105809	30%	99.1%	97.0%
SAU801188	PAE200393	34%	99.1%	96.1%
SAU801188	PPU102082	35%	98.2%	96.1%
SAU801188	PSY103724	36%	87.5%	85.1%
SAU801188	SPA102546	30%	89.7%	91.8%
SAU801188	STY104582	31%	99.1%	94.0%
SAU801188	STM100599	31%	99.1%	94.0%
SAU801188	SAU801188	100%	100%	100%
SAU801188	SEP200921	74%	99.1%	100%
SAU801188	SHA100042	66%	42.9%	100%
SAU801188	SMU100094	47%	96.9%	98.2%
SAU801188	SPN401508	47%	96.9%	98.2%
SAU801188	SPY201169	51%	87.5%	88.3%
SAU801188	VCH100456	33%	99.1%	96.6%
SAU801188	YPS000235	28%	97.8%	95.7%
SAU801189	BAN107825	43%	66.3%	84.2%
SAU801189	BAN111609	43%	66.3%	82.1%
SAU801189	CAC101019	26%	60.4%	72.0%
SAU801189	CBO102919	29%	67.4%	78.7%
SAU801189	CDF103744	31%	62.6%	71.1%
SAU801189	CDP101251	26%	38.0%	47.7%
SAU801189	EFA205207	33%	94.7%	95.8%
SAU801189	EFM202104	31%	87.7%	88.9%
SAU801189	LMO100809	43%	94.7%	96.7%
SAU801189	MAV103259	25%	55.1%	49.5%
SAU801189	MBV100536	24%	58.3%	46.5%
SAU801189	MLP100575	25%	55.1%	50.5%
SAU801189	MTU202113	24%	58.3%	46.5%
SAU801189	SAU801189	100%	100%	100%
SAU801189	SEP200923	71%	98.4%	100%
SAU801189	SHA100165	64%	97.9%	97.5%
SAU801189	SMU100097	29%	89.8%	88.0%
SAU801189	SPN401507	22%	89.8%	85.5%
SAU801189	SPY201168	28%	76.5%	63.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801192	BAN105377	36%	78.5%	95.8%
SAU801192	BAN104329	36%	78.5%	95.8%
SAU801192	CAC103030	27%	98.5%	95.6%
SAU801192	CBO103567	25%	76.1%	70.3%
SAU801192	CDF101598	26%	78.5%	98.9%
SAU801192	EFA202162	27%	100%	93.6%
SAU801192	EFM200763	26%	92.7%	93.6%
SAU801192	LMO101008	42%	78.5%	92%
SAU801192	MAV103271	25%	69.8%	90%
SAU801192	MBV100524	25%	69.8%	90%
SAU801192	MTU202111	25%	69.8%	90%
SAU801192	SAU801192	100%	100%	100%
SAU801192	SEP200927	77%	98.5%	94.0%
SAU801192	SHA101033	70%	99.0%	89.6%
SAU801192	SMU100106	31%	74.1%	60.1%
SAU801192	SPN401504	31%	74.1%	61.3%
SAU801192	SPY201165	27%	95.6%	83.7%
SAU801192	UUR100397	33%	31.2%	77.8%
SAU801193	ABA103852	41%	99.0%	98.5%
SAU801193	BAN106248	53%	97.1%	100%
SAU801193	BAN106209	62%	87.2%	99.4%
SAU801193	BFR10500	26%	84.1%	80.7%
SAU801193	BPT100432	40%	99.1%	98.5%
SAU801193	BBU100832	27%	94.8%	81.7%
SAU801193	BCE111670	40%	93.5%	94.2%
SAU801193	BFU101230	41%	97.9%	96.4%
SAU801193	BMA102496	35%	99.5%	95.1%
SAU801193	BMA109115	40%	97.9%	96.4%
SAU801193	CJU100989	38%	99.9%	99.8%
SAU801193	CPN200653	28%	90.8%	80.3%
SAU801193	CTR200283	30%	85.9%	76.6%
SAU801193	CAC102765	32%	84.3%	75.2%
SAU801193	CBO100873	33%	55.7%	96.6%
SAU801193	CDF104554	32%	85.2%	76.0%
SAU801193	CDP101247	29%	88.0%	77.9%
SAU801193	EBC102151	41%	98.9%	100%
SAU801193	EFA202160	61%	99.7%	98.7%
SAU801193	EFM201425	60%	99.7%	98.5%
SAU801193	ECO100026	42%	99.0%	98.3%
SAU801193	HPY101401	37%	99.6%	99.6%
SAU801193	KPN300290	52%	4.8%	100%
SAU801193	KPN306610	42%	97.5%	98.5%
SAU801193	LPN101832	44%	99.0%	98.3%
SAU801193	LMO101679	61%	99.6%	99.3%
SAU801193	MCA103671	39%	4.4%	19.2%
SAU801193	MAV103388	28%	92.6%	81.0%
SAU801193	MBV102555	28%	83.5%	75.3%
SAU801193	MLP100743	26%	93.3%	83.8%
SAU801193	MTU201515	28%	83.5%	75.3%
SAU801193	MGE100354	37%	99.5%	99.9%
SAU801193	MPN100322	38%	90.6%	96.1%
SAU801193	NGO101799	42%	99.5%	99.0%
SAU801193	NME200578	42%	99.5%	98.7%
SAU801193	PMU101662	43%	99.6%	98.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801193	PRT101657	43%	99.0%	98.3%
SAU801193	PAE204558	41%	99.0%	98.3%
SAU801193	PPU109898	41%	99.0%	98.3%
SAU801193	PSY102684	41%	97.5%	98.5%
SAU801193	SPA100667	41%	82.4%	97.7%
SAU801193	STY101103	42%	99.0%	98.3%
SAU801193	STM100818	42%	99.0%	98.3%
SAU801193	SAU801193	100%	100%	100%
SAU801193	SEP200928	88%	100%	99.7%
SAU801193	SHA101034	88%	99.5%	100%
SAU801193	SMU100109	55%	99.8%	98.6%
SAU801193	SPN401501	54%	99.7%	98.5%
SAU801193	SPY201164	56%	96.8%	95.5%
SAU801193	TPA100448	25%	95.0%	83.2%
SAU801193	UUR100414	41%	99.6%	99.8%
SAU801193	VCH100669	43%	99.0%	98.3%
SAU801193	YPS000810	43%	99.0%	98.3%
SAU801201	ABA104096	29%	96.5%	98.1%
SAU801201	BAN105008	50%	98.8%	100%
SAU801201	BAN109895	63%	98.8%	97.9%
SAU801201	BFR103702	27%	98.1%	91.5%
SAU801201	BPT102422	26%	89.6%	98.2%
SAU801201	BCE103736	32%	98.6%	98.6%
SAU801201	BFU104929	32%	96.5%	96.0%
SAU801201	BMA105735	32%	98.6%	98.6%
SAU801201	CJU101120	26%	89.9%	91.8%
SAU801201	CAC103721	40%	99.3%	99.5%
SAU801201	CBO101305	31%	97.6%	97.2%
SAU801201	CDF100578	42%	99.1%	99.5%
SAU801201	CDP100341	37%	98.1%	92.9%
SAU801201	EBC104972	38%	11.1%	9.6%
SAU801201	EFA201088	56%	97.6%	97.2%
SAU801201	EFM200431	59%	98.8%	98.6%
SAU801201	ECO100503	29%	98.8%	94.7%
SAU801201	HPY100262	23%	98.6%	97.4%
SAU801201	KPN307585	38%	13.7%	12.3%
SAU801201	LPN103194	34%	13.9%	15.3%
SAU801201	LMO102149	64%	99.8%	99.5%
SAU801201	MCA100879	28%	90.1%	94.2%
SAU801201	MAV103353	37%	95.8%	95.3%
SAU801201	MBV100044	34%	71.5%	96.8%
SAU801201	MLP100325	37%	97.2%	96.7%
SAU801201	MTU201364	38%	95.8%	95.3%
SAU801201	NGO100980	31%	26.4%	32.3%
SAU801201	NME200819	27%	67.5%	79.4%
SAU801201	PAE200400	32%	96.0%	95.7%
SAU801201	PPU109222	33%	95.8%	95.5%
SAU801201	PSY103720	32%	95.5%	95.3%
SAU801201	SPA103882	30%	98.8%	94.7%
SAU801201	STY100935	30%	98.8%	94.7%
SAU801201	STM100648	30%	98.8%	94.7%
SAU801201	SAU801201	100%	100%	100%
SAU801201	SEP201466	78%	100%	100%
SAU801201	SHA102128	83%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801201	SMU101043	41%	99.3%	99.8%
SAU801201	SPN401053	42%	99.3%	99.8%
SAU801201	SPY200678	42%	99.1%	99.5%
SAU801201	VCH103644	24%	65.6%	74.6%
SAU801205	ABA100625	27%	80.8%	80.6%
SAU801205	BAN108573	50%	98.0%	99.0%
SAU801205	BAN110842	60%	100%	96.7%
SAU801205	BFR12198	48%	97.5%	93.4%
SAU801205	BCE100693	33%	92.1%	72.5%
SAU801205	BFU101074	32%	87.2%	78.9%
SAU801205	BMA106142	38%	57.6%	91.5%
SAU801205	BMA105198	32%	92.1%	83.3%
SAU801205	CJU100206	24%	73.4%	76.7%
SAU801205	CPN200137	24%	82.3%	79.0%
SAU801205	CAC100649	31%	41.4%	41.1%
SAU801205	CDP101383	34%	66.5%	76.3%
SAU801205	EBC103731	26%	41.4%	41.8%
SAU801205	EFA201101	60%	98.0%	94.8%
SAU801205	EFM202393	57%	97.0%	94.3%
SAU801205	ECO103564	28%	41.4%	41.8%
SAU801205	HPY101240	24%	73.4%	77.1%
SAU801205	KPN204506	28%	41.4%	41.8%
SAU801205	LPN102097	26%	66.5%	67.6%
SAU801205	LMO102924	59%	98.0%	95.2%
SAU801205	MCA101253	26%	77.3%	87.1%
SAU801205	MAV102308	36%	62.1%	69.2%
SAU801205	MBV100426	34%	62.1%	70.4%
SAU801205	MLP101478	30%	77.8%	88.3%
SAU801205	MTU200381	34%	62.1%	70.4%
SAU801205	PMU101877	27%	41.4%	41.6%
SAU801205	PRT105176	31%	44.8%	44.4%
SAU801205	PAE205326	31%	41.4%	41.8%
SAU801205	SPA102548	27%	41.4%	41.8%
SAU801205	STY104543	27%	41.4%	41.8%
SAU801205	SAU801205	100%	100%	100%
SAU801205	SEP201475	81%	100%	100%
SAU801205	SHA102132	83%	99.5%	100%
SAU801205	SMU101057	56%	99.0%	96.2%
SAU801205	SPN400614	56%	99.0%	95.7%
SAU801205	SPY200673	55%	99.0%	96.2%
SAU801205	VCH100209	30%	41.4%	41.6%
SAU801205	YPS001414	27%	41.4%	41.4%
SAU801208	BAN107106	41%	99.6%	100%
SAU801208	BAN106675	46%	99.6%	99.8%
SAU801208	BBU100346	29%	18.4%	4.6%
SAU801208	CJU101273	27%	9.2%	35.6%
SAU801208	CAC101472	38%	98.1%	99.1%
SAU801208	CBO100220	37%	98.1%	98.6%
SAU801208	CDF100071	37%	35.9%	97.7%
SAU801208	CDF102341	38%	99.6%	99.3%
SAU801208	EFA200648	40%	99.8%	98.9%
SAU801208	EFM200633	39%	99.8%	99.6%
SAU801208	ECO203135	25%	15.6%	27.8%
SAU801208	HPY101372	24%	51.9%	63.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801208	LMO100988	42%	99.6%	99.8%
SAU801208	MAV104086	25%	18.1%	27.2%
SAU801208	PMU101771	26%	19.5%	30.8%
SAU801208	SAU801208	100%	100%	100%
SAU801208	SEP201479	82%	99.8%	99.8%
SAU801208	SHA102135	81%	99.6%	99.6%
SAU801208	SMU100348	40%	99.6%	99.8%
SAU801208	SPN400868	39%	99.8%	98.2%
SAU801208	SPY200766	40%	99.6%	99.6%
SAU801220	BAN103092	26%	38.9%	98.9%
SAU801220	BAN112197	26%	99.5%	99.7%
SAU801220	BAN100271	34%	99.5%	99.4%
SAU801220	BFR100304	33%	33.6%	84.4%
SAU801220	BCE114461	33%	32.1%	62.7%
SAU801220	BFU114300	30%	31.3%	31.3%
SAU801220	BMA103072	32%	39.5%	96.8%
SAU801220	CPN200667	31%	39.8%	31.1%
SAU801220	CTR200567	27%	39.2%	31.2%
SAU801220	CAC102901	33%	86.6%	87.8%
SAU801220	CBO101331	33%	93.5%	93.2%
SAU801220	CDF103395	33%	66.3%	80.7%
SAU801220	CDP101333	29%	80.3%	90.8%
SAU801220	EBC104702	35%	22.9%	9.6%
SAU801220	EFA201561	35%	70.3%	92.2%
SAU801220	EFM201980	38%	66.6%	92.9%
SAU801220	ECO201271	26%	38.0%	72.1%
SAU801220	KPN303489	27%	39.2%	53.4%
SAU801220	LPN102115	24%	28.5%	18.7%
SAU801220	LMO100883	37%	99.5%	99.5%
SAU801220	MAV103512	31%	86.3%	88.5%
SAU801220	MBV103463	37%	9.3%	89.9%
SAU801220	MBV106232	30%	69.4%	92.0%
SAU801220	MLP100014	31%	69.4%	92.0%
SAU801220	MTU200014	30%	69.4%	92.0%
SAU801220	MGE100111	29%	37.2%	79.6%
SAU801220	MPN100584	28%	42.3%	84.6%
SAU801220	PAE200074	31%	46.5%	28.0%
SAU801220	PPU101810	29%	30.7%	33.1%
SAU801220	PSY105556	30%	33.3%	56.9%
SAU801220	STY104340	28%	38.4%	75.1%
SAU801220	SAU801220	100%	100%	100%
SAU801220	SEP201501	67%	99.7%	99.8%
SAU801220	SHA102145	59%	99.5%	100%
SAU801220	SMU101509	31%	88.7%	97.1%
SAU801220	SPN401575	34%	92.8%	71.6%
SAU801220	SPY201251	33%	85.4%	89.4%
SAU801220	TPA100304	21%	17.3%	33.9%
SAU801220	UUR100217	27%	42.6%	84.2%
SAU801230	ABA100558	42%	96.1%	90.5%
SAU801230	BAN107404	34%	97.4%	96.9%
SAU801230	BAN106364	46%	98.1%	96.8%
SAU801230	BFR11476	42%	94.5%	99.0%
SAU801230	BPT102620	40%	93.5%	92.9%
SAU801230	BCE103323	39%	95.1%	91.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801230	BFU100683	39%	95.1%	94.5%
SAU801230	BMA100069	40%	95.1%	94.8%
SAU801230	CJU100105	37%	91.6%	92.2%
SAU801230	CPN200455	36%	96.8%	96.4%
SAU801230	CTR200502	37%	98.7%	98.4%
SAU801230	CAC103563	44%	97.7%	98.4%
SAU801230	CBO101300	43%	97.7%	95.0%
SAU801230	CDF101771	44%	99.4%	96.8%
SAU801230	EBC100252	43%	66.6%	85.4%
SAU801230	EFA200242	39%	95.5%	94.8%
SAU801230	EFM200686	39%	95.5%	95.7%
SAU801230	ECO101065	40%	92.9%	93.2%
SAU801230	HIN100149	39%	99.0%	97.8%
SAU801230	HPY100088	30%	98.1%	96.1%
SAU801230	KPN300448	42%	48.7%	87.6%
SAU801230	KPN300815	39%	92.9%	93.5%
SAU801230	LPN103175	37%	95.8%	94.6%
SAU801230	LMO101375	48%	98.1%	97.1%
SAU801230	MCA100612	35%	97.1%	96.6%
SAU801230	MAV102169	32%	96.1%	28.5%
SAU801230	MBV105147	34%	92.5%	15.6%
SAU801230	MLP100101	34%	92.5%	13.4%
SAU801230	MTU202908	34%	92.5%	17.4%
SAU801230	NGO101393	38%	92.2%	92.5%
SAU801230	NME200497	37%	98.1%	98.4%
SAU801230	PMU101915	38%	99.4%	99.0%
SAU801230	PRT100032	36%	100%	100%
SAU801230	PAE202966	38%	95.8%	95.2%
SAU801230	PPU104834	41%	96.4%	82.1%
SAU801230	PSY101698	38%	95.1%	94.6%
SAU801230	SPA100960	39%	92.9%	93.2%
SAU801230	STY102531	40%	92.9%	93.2%
SAU801230	STM102720	40%	92.9%	93.2%
SAU801230	SAU801230	100%	100%	100%
SAU801230	SEP201521	78%	99.7%	98.4%
SAU801230	SHA101737	80%	100%	98.7%
SAU801230	SMU100543	42%	99.7%	100%
SAU801230	SPN400380	40%	96.1%	96.4%
SAU801230	SPY201349	39%	98.1%	96.5%
SAU801230	VCH101992	39%	98.1%	98.4%
SAU801230	YPS003126	39%	92.9%	93.2%
SAU801231	ABA100557	50%	98.4%	97.5%
SAU801231	BAN107352	49%	96.7%	96.8%
SAU801231	BAN101218	64%	98.4%	98.4%
SAU801231	BFR10719	52%	98.4%	97.6%
SAU801231	BPT102619	53%	98.4%	95.6%
SAU801231	BCE112767	56%	97.6%	96.0%
SAU801231	BFU100684	56%	97.6%	96.0%
SAU801231	BMA106290	55%	97.6%	96.0%
SAU801231	CJU100403	46%	98.4%	98.0%
SAU801231	CPN200456	43%	97.6%	96.4%
SAU801231	CTR200501	47%	98.4%	97.6%
SAU801231	CAC102747	32%	99.2%	91.6%
SAU801231	CAC100570	55%	98.4%	97.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801231	CBO102327	55%	97.6%	95.2%
SAU801231	CDF101772	56%	97.6%	96.4%
SAU801231	CDP101282	34%	72.8%	62.8%
SAU801231	EBC100251	62%	66.7%	99.4%
SAU801231	EFA200243	51%	100%	99.2%
SAU801231	EFM201914	52%	98.4%	97.1%
SAU801231	ECO101066	55%	98.4%	97.5%
SAU801231	HIN100148	52%	98.4%	98.3%
SAU801231	HPY100554	43%	98.4%	98.0%
SAU801231	KPN300814	54%	98.4%	97.5%
SAU801231	LPN103118	51%	98.4%	97.2%
SAU801231	LMO102009	62%	98.4%	98.0%
SAU801231	MCA101812	48%	82.9%	93.1%
SAU801231	MAV103538	40%	98.4%	90.2%
SAU801231	MBV105473	41%	98.4%	97.2%
SAU801231	MLP101100	45%	99.2%	91.7%
SAU801231	MTU201333	41%	98.4%	97.2%
SAU801231	NGO101381	54%	98.4%	96.4%
SAU801231	NME200494	55%	98.4%	96.4%
SAU801231	PMU101916	52%	98.0%	97.9%
SAU801231	PRT100071	55%	98.4%	97.5%
SAU801231	PAE202965	51%	98.4%	97.6%
SAU801231	PPU101751	52%	98.4%	98.0%
SAU801231	PSY108154	50%	98.4%	97.6%
SAU801231	SPA100959	53%	98.4%	97.5%
SAU801231	STY102532	54%	98.4%	97.5%
SAU801231	STM102721	54%	98.4%	97.5%
SAU801231	SAU801231	100%	100%	100%
SAU801231	SEP200094	37%	99.2%	99.6%
SAU801231	SEP201523	92%	99.2%	100%
SAU801231	SHA101738	90%	98.4%	98.8%
SAU801231	SMU100541	46%	98.4%	97.5%
SAU801231	SPN400381	47%	98.4%	97.9%
SAU801231	SPY201348	47%	98.4%	97.5%
SAU801231	VCH101991	54%	98.4%	96.0%
SAU801231	YPS003130	54%	98.4%	97.5%
SAU801232	ABA100149	53%	55.8%	87.8%
SAU801232	BAN107311	67%	90.9%	87.5%
SAU801232	BFR100793	62%	93.5%	92.3%
SAU801232	BPT104633	60%	96.1%	94.9%
SAU801232	BBU100703	49%	92.2%	88.8%
SAU801232	BCE109854	58%	92.2%	91.1%
SAU801232	BFU104450	58%	92.2%	91.1%
SAU801232	BMA104399	58%	92.2%	91.1%
SAU801232	CJU100409	48%	100%	100%
SAU801232	CPN200457	54%	88.3%	86.1%
SAU801232	CTR200500	54%	88.3%	88.3%
SAU801232	CAC100280	61%	92.2%	92.2%
SAU801232	CBO102204	59%	92.2%	68.3%
SAU801232	CDF104494	52%	92.2%	95.9%
SAU801232	CDF102560	58%	89.6%	93.3%
SAU801232	CDP102441	36%	81.8%	65.3%
SAU801232	EBC107855	25%	93.5%	86.7%
SAU801232	EFA204896	56%	94.8%	92.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801232	EFM201177	66%	62.3%	92.3%
SAU801232	ECO101067	63%	89.6%	88.5%
SAU801232	HIN100147	58%	90.9%	92.1%
SAU801232	HPY100946	52%	90.9%	45.1%
SAU801232	HPY100552	56%	93.5%	92.3%
SAU801232	KPN301296	62%	89.6%	88.5%
SAU801232	LPN100598	58%	90.9%	85.4%
SAU801232	LMO102315	71%	94.8%	94.8%
SAU801232	MCA100571	48%	88.3%	87.2%
SAU801232	MAV103068	40%	92.2%	61.7%
SAU801232	MBV100652	39%	92.2%	61.7%
SAU801232	MLP101007	39%	92.2%	61.7%
SAU801232	MTU202210	39%	92.2%	61.7%
SAU801232	MGE100293	29%	90.9%	83.3%
SAU801232	MPN100432	28%	58.4%	53.6%
SAU801232	NGO100692	57%	96.1%	96.2%
SAU801232	NME200041	56%	96.1%	96.2%
SAU801232	PMU101917	60%	90.9%	92.1%
SAU801232	PRT100070	67%	75.3%	90.6%
SAU801232	PAE202964	60%	88.3%	87.2%
SAU801232	PPU104838	58%	90.9%	89.7%
SAU801232	PSY106594	60%	90.9%	89.7%
SAU801232	SPA100630	63%	89.6%	88.5%
SAU801232	STY107110	63%	89.6%	88.5%
SAU801232	STM102722	63%	89.6%	88.5%
SAU801232	SAU801232	100%	100%	100%
SAU801232	SEP201525	98%	100%	100%
SAU801232	SHA101739	98%	100%	100%
SAU801232	SMU100547	45%	100%	100%
SAU801232	SPN400038	52%	92.2%	90.9%
SAU801232	SPY201351	44%	100%	100%
SAU801232	TPA100800	46%	94.8%	93.6%
SAU801232	UUR100511	27%	92.2%	94.8%
SAU801232	VCH101990	61%	90.9%	63.6%
SAU801232	YPS004652	65%	90.9%	89.7%
SAU801234	ABA100578	28%	98.8%	98.8%
SAU801234	BAN103630	32%	99.1%	99.5%
SAU801234	BAN104397	40%	99.6%	99.7%
SAU801234	BFR101153	20%	43.5%	56.2%
SAU801234	BPT100686	26%	99.0%	99.1%
SAU801234	BBU100045	23%	98.7%	99.3%
SAU801234	BCE108067	26%	99.2%	98.1%
SAU801234	BFU113992	27%	99.0%	99.1%
SAU801234	BMA100428	27%	99.2%	99.5%
SAU801234	CPN200161	18%	72.6%	43.0%
SAU801234	CAC103024	34%	99.2%	99.5%
SAU801234	CBO103358	35%	99.5%	99.4%
SAU801234	CDF101890	33%	99.5%	99.7%
SAU801234	CDP101170	27%	99.9%	99.7%
SAU801234	EFA201599	41%	99.4%	99.3%
SAU801234	EFM202536	36%	85.4%	99.6%
SAU801234	LPN102310	19%	65.2%	50.6%
SAU801234	LPN101618	20%	57.2%	33.6%
SAU801234	LMO100062	41%	99.5%	99.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801234	MCA102065	25%	99.5%	99.8%
SAU801234	MAV100512	28%	48.5%	97.3%
SAU801234	MBV100832	37%	26.2%	70.0%
SAU801234	MLP100993	28%	98.7%	98.7%
SAU801234	MTU202884	27%	98.8%	92.3%
SAU801234	MGE100304	25%	12.6%	25.4%
SAU801234	MPN100415	27%	100%	99.8%
SAU801234	NGO101479	28%	98.8%	99.0%
SAU801234	NME200667	28%	98.8%	99.0%
SAU801234	PMU100609	18%	46.3%	76.5%
SAU801234	PAE201526	26%	98.8%	99.1%
SAU801234	PPU107259	28%	98.8%	99.1%
SAU801234	PSY103899	27%	98.8%	99.1%
SAU801234	SAU801234	100%	100%	100%
SAU801234	SEP201527	76%	100%	99.9%
SAU801234	SHA101741	72%	99.9%	99.9%
SAU801234	SMU100494	36%	99.5%	99.9%
SAU801234	SPN401125	37%	99.5%	99.8%
SAU801234	SPY200382	35%	99.5%	99.8%
SAU801234	TPA100363	26%	99.5%	98.8%
SAU801234	UUR100139	29%	99.2%	99.0%
SAU801235	ABA102251	46%	74.3%	84.0%
SAU801235	BAN106145	63%	73.3%	100%
SAU801235	BAN102864	68%	74.0%	93.6%
SAU801235	BFR103244	46%	71.6%	94.0%
SAU801235	BPT103145	42%	72.8%	49.8%
SAU801235	BBU100076	39%	67.5%	96.8%
SAU801235	BCE109396	44%	65.9%	77.1%
SAU801235	BFU100592	44%	64.9%	63.5%
SAU801235	BMA103170	42%	72.1%	61.1%
SAU801235	CJU101131	43%	73.1%	98.6%
SAU801235	CPN200871	37%	70.0%	97.6%
SAU801235	CTR200202	36%	67.1%	95.8%
SAU801235	CAC103551	49%	72.1%	97.7%
SAU801235	CBO103745	48%	72.1%	97.7%
SAU801235	CDF101891	46%	90.1%	92.5%
SAU801235	CDP101168	38%	90.6%	75.2%
SAU801235	EBC104170	43%	91.1%	75.9%
SAU801235	EFA201601	48%	94.0%	99.5%
SAU801235	EFM200001	60%	76.7%	95.5%
SAU801235	ECO103387	43%	91.1%	74.2%
SAU801235	HIN100748	42%	90.4%	92.0%
SAU801235	HPY100750	40%	69.2%	96.6%
SAU801235	KPN308256	46%	83.7%	68.0%
SAU801235	LMO101591	70%	75%	95.1%
SAU801235	MCA101469	48%	72.1%	95.2%
SAU801235	MAV103813	46%	65.6%	63.3%
SAU801235	MBV100063	42%	48.3%	57.8%
SAU801235	MLP100992	43%	71.9%	68.8%
SAU801235	MTU202883	46%	65.6%	64.2%
SAU801235	MGE100303	40%	76.7%	93.4%
SAU801235	MPN100416	41%	70.9%	84.8%
SAU801235	NME200274	41%	82.5%	81.2%
SAU801235	PMU101519	44%	82.7%	77.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801235	PRT100781	44%	90.4%	60.0%
SAU801235	PAE200372	46%	72.8%	66.2%
SAU801235	PPU102117	47%	74.5%	62.8%
SAU801235	PSY102772	46%	74.8%	60.6%
SAU801235	SPA100292	52%	57.0%	94.0%
SAU801235	STY101273	43%	91.1%	75.6%
SAU801235	SAU801235	100%	100%	100%
SAU801235	SEP201528	82%	98.1%	99.5%
SAU801235	SHA101742	83%	100%	100%
SAU801235	SMU100011	47%	93.8%	73.3%
SAU801235	SPN401122	48%	90.9%	84.7%
SAU801235	SPY200409	51%	90.9%	72.1%
SAU801235	TPA100571	38%	68.5%	95.3%
SAU801235	UUR100140	47%	72.8%	86.6%
SAU801235	VCH100146	44%	87.3%	94.9%
SAU801235	YPS000724	44%	87.3%	64.9%
SAU801236	BAN105732	35%	38.2%	71.2%
SAU801236	BAN103174	68%	29.1%	88.9%
SAU801236	BAN108618	57%	91.8%	91.8%
SAU801236	BFR105869	36%	50.9%	31.9%
SAU801236	CAC101521	34%	90%	87.9%
SAU801236	CBO103236	38%	85.5%	92.7%
SAU801236	EFA201152	48%	96.4%	98.2%
SAU801236	EFM202076	48%	96.4%	98.2%
SAU801236	LMO101202	47%	93.6%	97.3%
SAU801236	MPN100417	31%	80.9%	87.3%
SAU801236	SAU801236	100%	100%	100%
SAU801236	SEP201529	82%	100%	100%
SAU801236	SHA101743	80%	100%	100%
SAU801236	SMU100255	50%	96.4%	96.4%
SAU801236	SPN401166	49%	96.4%	96.4%
SAU801236	SPY200916	52%	96.4%	93.8%
SAU801236	UUR100141	40%	65.5%	72.7%
SAU801237	ABA100567	51%	98.2%	95.7%
SAU801237	BAN113732	68%	73.6%	100%
SAU801237	BAN108180	75%	75.8%	100%
SAU801237	BFR10168	53%	84.2%	99.0%
SAU801237	BPT101335	49%	95.4%	95.7%
SAU801237	BBU100693	42%	94.3%	96.0%
SAU801237	BCE112884	48%	70.3%	97.5%
SAU801237	BFU115323	49%	98.5%	99.3%
SAU801237	BMA100755	49%	97.6%	99.3%
SAU801237	CJU100659	40%	97.8%	98.2%
SAU801237	CPN200646	39%	98.2%	98.4%
SAU801237	CTR200289	40%	98.5%	98.7%
SAU801237	CAC101092	62%	96.5%	98.2%
SAU801237	CBO101744	61%	96.5%	98.4%
SAU801237	CDF103672	65%	82.0%	96.9%
SAU801237	CDP101160	48%	98.0%	89.5%
SAU801237	EBC100407	50%	76.5%	94.4%
SAU801237	EFA201155	58%	98.7%	97.9%
SAU801237	EFM202293	62%	85.3%	99.7%
SAU801237	ECO102557	50%	99.3%	98.7%
SAU801237	HIN100105	50%	98.7%	97.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801237	HPY101135	39%	98.9%	98.2%
SAU801237	KPN301264	51%	77.4%	93.0%
SAU801237	LPN101209	47%	98.7%	96.5%
SAU801237	LMO100196	72%	100%	100%
SAU801237	MCA100840	50%	98.9%	98.9%
SAU801237	MAV103395	45%	99.3%	91.1%
SAU801237	MBV102321	47%	96.9%	88.2%
SAU801237	MLP100989	47%	95.8%	85.4%
SAU801237	MTU202878	47%	96.9%	88.2%
SAU801237	MGE100048	44%	92.1%	93.5%
SAU801237	MPN100093	41%	98.9%	96.4%
SAU801237	NGO101772	48%	98.5%	98.7%
SAU801237	NME202026	50%	98.5%	98.7%
SAU801237	PMU101183	49%	98.7%	97.8%
SAU801237	PRT100858	49%	99.3%	98.7%
SAU801237	PAE203743	50%	99.6%	98.2%
SAU801237	PPU107798	51%	99.3%	99.3%
SAU801237	PSY103783	50%	99.3%	99.3%
SAU801237	SPA101887	47%	77.8%	98.6%
SAU801237	STY102223	51%	99.3%	98.7%
SAU801237	SAU801237	100%	100%	100%
SAU801237	SEP201530	94%	100%	100%
SAU801237	SHA102361	88%	24.0%	100%
SAU801237	SMU100253	55%	99.3%	88.0%
SAU801237	SPN401165	56%	96.9%	84.3%
SAU801237	SPY200915	54%	99.1%	87.9%
SAU801237	TPA100412	41%	93.8%	95.1%
SAU801237	UUR100090	44%	93.8%	94.6%
SAU801237	VCH100550	50%	98.5%	97.0%
SAU801237	YPS003448	50%	99.3%	98.7%
SAU801238	ABA100463	43%	82.4%	91.6%
SAU801238	BFR103669	51%	91.2%	38.7%
SAU801238	BPT101149	37%	80.2%	86.0%
SAU801238	BBU100694	44%	94.5%	98.8%
SAU801238	BCE101287	40%	82.4%	89.3%
SAU801238	BFU106133	40%	82.4%	68.2%
SAU801238	BMA105933	40%	82.4%	89.3%
SAU801238	CJU100660	52%	80.2%	96%
SAU801238	CPN200645	42%	72.5%	53.8%
SAU801238	CTR200290	43%	86.8%	65.5%
SAU801238	CAC102507	53%	89.0%	98.8%
SAU801238	CBO102241	57%	91.2%	96.5%
SAU801238	CDF104187	52%	100%	96.8%
SAU801238	CDP101155	51%	92.3%	52.9%
SAU801238	EFA201163	65%	100%	98.9%
SAU801238	ECO102556	39%	82.4%	92.7%
SAU801238	HIN100194	44%	82.4%	92.7%
SAU801238	HPY101134	47%	80.2%	94.7%
SAU801238	KPN203248	41%	75.8%	95.9%
SAU801238	LPN102433	42%	82.4%	88.4%
SAU801238	LMO101675	65%	100%	100%
SAU801238	MCA100471	45%	80.2%	90.2%
SAU801238	MAV103402	52%	92.3%	48.8%
SAU801238	MBV102277	51%	92.3%	51.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801238	MLP100988	51%	92.3%	51.9%
SAU801238	MTU202871	51%	92.3%	51.2%
SAU801238	MGE100455	46%	91.2%	92.1%
SAU801238	MPN100182	51%	89.0%	90.9%
SAU801238	NGO102008	40%	83.5%	95.1%
SAU801238	NME200735	40%	83.5%	95.1%
SAU801238	PRT100822	45%	75.8%	72.9%
SAU801238	PAE203742	43%	80.2%	89.2%
SAU801238	PPU107799	40%	82.4%	69.7%
SAU801238	PSY103786	41%	85.7%	92.9%
SAU801238	SPA101888	38%	82.4%	74.5%
SAU801238	STY102221	38%	82.4%	92.7%
SAU801238	SAU801238	100%	100%	100%
SAU801238	SEP201531	87%	100%	100%
SAU801238	SHA102521	94%	56.0%	100%
SAU801238	SMU100800	61%	100%	98.9%
SAU801238	SPN400682	65%	100%	100%
SAU801238	SPY200625	62%	100%	100%
SAU801238	TPA100895	50%	82.4%	61.0%
SAU801238	UUR100575	45%	97.8%	89.1%
SAU801238	VCH100551	41%	80.2%	90.2%
SAU801238	YPS003446	42%	83.5%	92.7%
SAU801240	ABA100452	44%	93.9%	96.3%
SAU801240	BFR103869	51%	91.0%	99.6%
SAU801240	BPT101155	43%	91.4%	90.7%
SAU801240	BBU100697	45%	91.8%	94.1%
SAU801240	BCE110744	46%	90.6%	86.4%
SAU801240	BFU102064	43%	91.4%	88.8%
SAU801240	BMA102082	44%	91.4%	87.1%
SAU801240	CJU100663	38%	90.2%	96.6%
SAU801240	CPN200644	50%	91.8%	61.8%
SAU801240	CTR200291	45%	91.8%	63.4%
SAU801240	CAC101341	48%	95.9%	96.3%
SAU801240	CBO102927	52%	97.1%	97.5%
SAU801240	CDF104123	50%	91.4%	98.3%
SAU801240	CDP101153	41%	100%	97.6%
SAU801240	EBC100905	44%	97.6%	94.5%
SAU801240	EFA202296	54%	97.6%	98.0%
SAU801240	ECO102554	44%	97.6%	94.5%
SAU801240	HIN100192	45%	96.3%	96.7%
SAU801240	HPY101131	37%	91.8%	99.1%
SAU801240	KPN300514	33%	45.3%	100%
SAU801240	LPN101866	44%	97.6%	96.4%
SAU801240	LMO102506	55%	97.1%	98.4%
SAU801240	MCA100037	39%	89.8%	92%
SAU801240	MAV103396	42%	90.6%	95.0%
SAU801240	MBV102286	46%	90.2%	98.3%
SAU801240	MLP100985	45%	90.2%	95.0%
SAU801240	MTU202868	46%	90.2%	98.3%
SAU801240	MGE100454	46%	94.7%	99.1%
SAU801240	MPN100183	46%	86.1%	99.0%
SAU801240	NGO102006	46%	96.7%	96.0%
SAU801240	NME200733	46%	96.3%	95.6%
SAU801240	PMU101297	45%	97.6%	98.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801240	PRT100820	42%	97.6%	96.4%
SAU801240	PAE203740	42%	96.3%	94.8%
SAU801240	PPU107801	45%	97.1%	96%
SAU801240	PSY102681	45%	97.1%	93.0%
SAU801240	SPA101890	43%	96.7%	93.7%
SAU801240	STY102217	44%	97.6%	94.5%
SAU801240	SAU801240	100%	100%	100%
SAU801240	SEP201533	81%	99.2%	99.2%
SAU801240	SMU100806	58%	97.6%	97.9%
SAU801240	SPN400687	57%	97.6%	98.3%
SAU801240	SPY200632	58%	100%	99.2%
SAU801240	TPA100898	43%	90.6%	88%
SAU801240	UUR100574	46%	91.8%	97.8%
SAU801240	VCH100553	44%	97.1%	97.2%
SAU801240	YPS003421	43%	97.6%	98.0%
SAU801241	ABA100455	64%	95.7%	91.0%
SAU801241	BFR102397	60%	83.6%	82.9%
SAU801241	BPT100242	64%	80.2%	73.8%
SAU801241	BBU100698	55%	90.5%	86.8%
SAU801241	BCE107881	53%	92.2%	82.3%
SAU801241	BFU102066	54%	92.2%	82.9%
SAU801241	BMA100174	53%	92.2%	82.9%
SAU801241	CJU100664	56%	97.4%	97.5%
SAU801241	CPN200643	48%	94.0%	90.1%
SAU801241	CTR200292	49%	94.8%	90.9%
SAU801241	CAC102258	63%	95.7%	97.4%
SAU801241	CBO102492	60%	94.8%	96.5%
SAU801241	CDF103914	67%	97.4%	97.4%
SAU801241	CDP101148	67%	95.7%	98.2%
SAU801241	EBC100906	55%	94.0%	94.8%
SAU801241	EFA202298	74%	95.7%	96.5%
SAU801241	EFM202223	76%	95.7%	96.5%
SAU801241	ECO102553	55%	94.0%	94.8%
SAU801241	HIN100191	54%	94.0%	94.0%
SAU801241	HPY101130	49%	97.4%	97.5%
SAU801241	KPN301017	55%	94.0%	94.8%
SAU801241	LPN101449	55%	98.3%	93.4%
SAU801241	LMO102632	76%	97.4%	99.1%
SAU801241	MCA100220	63%	95.7%	89.4%
SAU801241	MAV102886	65%	94.8%	97.3%
SAU801241	MBV102292	65%	94.8%	97.3%
SAU801241	MLP100984	64%	94.8%	97.3%
SAU801241	MTU202866	65%	94.8%	97.3%
SAU801241	MGE100453	48%	94.0%	90.8%
SAU801241	MPN100184	48%	94.0%	90.8%
SAU801241	NGO102004	64%	87.9%	84.3%
SAU801241	NME200732	65%	87.9%	84.3%
SAU801241	PMU101298	55%	94.0%	94.0%
SAU801241	PRT100819	55%	94.0%	93.2%
SAU801241	PAE203739	56%	98.3%	97.4%
SAU801241	PPU107802	57%	98.3%	97.4%
SAU801241	PSY103791	58%	98.3%	97.4%
SAU801241	SPA101891	55%	94.0%	94.8%
SAU801241	STY102215	55%	94.0%	94.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801241	SAU801241	100%	100%	100%
SAU801241	SEP201534	93%	100%	100%
SAU801241	SMU100257	72%	95.7%	96.5%
SAU801241	SPN401170	72%	95.7%	96.5%
SAU801241	SPY200530	71%	95.7%	96.5%
SAU801241	TPA100899	57%	93.1%	87.8%
SAU801241	UUR100573	54%	95.7%	90.2%
SAU801241	VCH100554	62%	94.0%	93.2%
SAU801241	YPS003417	54%	94.0%	94.8%
SAU801243	BAN100670	54%	94.9%	99.3%
SAU801243	BAN113498	55%	97.6%	96.6%
SAU801243	BBU100642	34%	94.2%	96.4%
SAU801243	CAC103197	43%	92.5%	95.8%
SAU801243	CBO101418	41%	97.6%	97.9%
SAU801243	CDF103392	44%	94.6%	92.0%
SAU801243	EFA201280	53%	97.6%	100%
SAU801243	EFM202454	52%	97.6%	99.0%
SAU801243	LMO101914	58%	94.9%	96.9%
SAU801243	MGE100451	30%	94.6%	96.7%
SAU801243	MPN100186	29%	94.6%	96.3%
SAU801243	NGO101947	35%	93.2%	86.3%
SAU801243	NME200873	35%	93.2%	86.3%
SAU801243	SAU801243	100%	100%	100%
SAU801243	SEP201537	82%	97.6%	100%
SAU801243	SHA101010	84%	100%	100%
SAU801243	SMU100098	46%	94.2%	95.8%
SAU801243	SPN401043	45%	95.9%	97.5%
SAU801243	SPY200887	44%	96.3%	98.2%
SAU801243	UUR100599	30%	94.2%	97.4%
SAU801243	VCH103253	41%	97.3%	88.9%
SAU801246	ABA101768	62%	97.0%	99.7%
SAU801246	BAN108859	65%	98.0%	98.7%
SAU801246	BAN107819	77%	98.0%	98.7%
SAU801246	BFR12149	55%	94.0%	98.6%
SAU801246	BPT102810	60%	94.0%	98.6%
SAU801246	BCE103851	63%	95.0%	99.7%
SAU801246	BFU103478	61%	94.0%	98.6%
SAU801246	BMA108528	62%	94.0%	98.6%
SAU801246	CJU100496	54%	94.0%	98.3%
SAU801246	CPN200869	59%	92.7%	95.6%
SAU801246	CTR200204	55%	94.0%	97.6%
SAU801246	EBC102737	65%	94.0%	98.3%
SAU801246	EFA201366	24%	68.5%	20.3%
SAU801246	ECO100712	65%	94.0%	98.3%
SAU801246	HIN101170	62%	96.4%	99.3%
SAU801246	KPN300770	63%	94.0%	98.3%
SAU801246	LPN101597	62%	94.7%	98.6%
SAU801246	MAV101285	52%	92.4%	96%
SAU801246	MBV101961	51%	92.1%	94.7%
SAU801246	MLP100114	51%	92.4%	96%
SAU801246	MTU200943	51%	92.1%	94.7%
SAU801246	NGO101261	63%	97.0%	99.7%
SAU801246	NME201066	63%	97.0%	99.7%
SAU801246	PMU100281	64%	94.0%	98.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801246	PRT102068	65%	94.0%	97.9%
SAU801246	PAE201588	65%	94.7%	96.9%
SAU801246	PPU101203	64%	94.7%	97.3%
SAU801246	PSY104865	64%	94.7%	97.6%
SAU801246	SPA103281	61%	89.7%	94.4%
SAU801246	STY101933	65%	94.0%	98.3%
SAU801246	STM101672	65%	94.0%	98.3%
SAU801246	SAU801246	100%	100%	100%
SAU801246	SEP201540	93%	100%	100%
SAU801246	SHA100180	93%	86.4%	100%
SAU801246	VCH102052	66%	94.7%	98.6%
SAU801246	YPS002067	65%	94.0%	97.9%
SAU801251	BAN112697	67%	97.9%	99.8%
SAU801251	BAN101040	72%	98.9%	94.9%
SAU801251	EFA201310	71%	97.9%	97.7%
SAU801251	EFM200985	68%	99.1%	93.9%
SAU801251	LMO102370	72%	100%	100%
SAU801251	SAU801251	100%	100%	100%
SAU801251	SEP201543	91%	100%	98.2%
SAU801251	SHA100490	93%	67.1%	100%
SAU801251	SMU100122	63%	98.2%	98.2%
SAU801251	SPN400844	66%	98.2%	98.2%
SAU801251	SPY200895	65%	97.7%	96.9%
SAU801252	BAN111598	42%	96.3%	98.0%
SAU801252	BAN106190	47%	96.3%	97.7%
SAU801252	EFA201313	46%	96.3%	97.7%
SAU801252	EFM202573	45%	96.6%	93.9%
SAU801252	LMO101828	47%	97.0%	98%
SAU801252	SAU801252	100%	100%	100%
SAU801252	SEP201545	81%	98.7%	99.3%
SAU801252	SHA100491	82%	99.7%	100%
SAU801252	SPN401046	26%	79.5%	78.1%
SAU801253	BAN106152	70%	96.7%	97.8%
SAU801253	BAN100924	73%	96.7%	97.8%
SAU801253	BPT100535	56%	96.7%	96.6%
SAU801253	BBU100295	53%	95.6%	95.6%
SAU801253	BCE107448	41%	82.3%	95.5%
SAU801253	BFU106864	53%	96.7%	97.2%
SAU801253	BMA106404	52%	96.7%	82.0%
SAU801253	CJU100619	53%	93.9%	93.9%
SAU801253	EBC104505	55%	95.6%	97.2%
SAU801253	EFA201316	63%	100%	100%
SAU801253	EFM201153	63%	100%	100%
SAU801253	ECO103838	56%	95.6%	97.2%
SAU801253	HIN100475	59%	95.6%	98.3%
SAU801253	HPY100510	51%	94.5%	96.7%
SAU801253	KPN303215	54%	95.6%	97.2%
SAU801253	LPN100752	56%	96.7%	95.1%
SAU801253	LMO102574	71%	97.2%	98.9%
SAU801253	MAV106140	26%	89.0%	58.7%
SAU801253	MBV101982	27%	89.0%	61.2%
SAU801253	MLP100822	25%	89.0%	61.2%
SAU801253	MTU202077	27%	89.0%	61.2%
SAU801253	PMU101749	58%	95.6%	97.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801253	PRT101661	54%	95.6%	97.2%
SAU801253	PAE205048	57%	95.6%	97.2%
SAU801253	PPU107338	59%	96.7%	90.1%
SAU801253	PSY103571	59%	94.5%	88.0%
SAU801253	SPA106189	66%	32.6%	98.3%
SAU801253	STY103120	55%	95.6%	97.2%
SAU801253	SAU801253	100%	100%	100%
SAU801253	SEP201546	94%	98.9%	99.4%
SAU801253	SHA100492	95%	100%	100%
SAU801253	VCH102638	58%	95.6%	92.4%
SAU801253	YPS001391	56%	95.6%	98.3%
SAU801256	ABA104000	48%	96.1%	97.6%
SAU801256	BAN100446	73%	71.0%	96.8%
SAU801256	BAN110084	77%	89.0%	97.4%
SAU801256	BFR104950	47%	92.5%	84.9%
SAU801256	BPT101108	54%	86.7%	88.8%
SAU801256	BBU100122	49%	100%	98.8%
SAU801256	BCE101166	47%	92.9%	96.3%
SAU801256	BFU101939	49%	94.1%	96%
SAU801256	BMA101604	48%	92.2%	97.1%
SAU801256	CJU101107	50%	99.2%	97.0%
SAU801256	CPN200048	46%	98.8%	91.7%
SAU801256	CTR200051	45%	94.9%	85.8%
SAU801256	CAC101756	70%	89.0%	97.9%
SAU801256	CBO103187	70%	89.0%	97.9%
SAU801256	CDF101764	69%	92.9%	99.6%
SAU801256	CDP101120	54%	100%	97.0%
SAU801256	EBC103098	52%	88.2%	93.4%
SAU801256	EFA200418	70%	99.6%	95.0%
SAU801256	ECO100169	51%	88.2%	93.4%
SAU801256	HIN100892	47%	92.5%	94.8%
SAU801256	HPY101531	51%	97.6%	94.3%
SAU801256	KPN301398	51%	83.5%	93.0%
SAU801256	LPN100646	48%	96.5%	98.8%
SAU801256	LMO100442	74%	98.8%	100%
SAU801256	MCA101251	49%	98.8%	92.3%
SAU801256	MAV106404	56%	99.2%	94.2%
SAU801256	MBV102282	61%	88.6%	78.7%
SAU801256	MLP100973	61%	88.6%	81.6%
SAU801256	MTU202852	61%	88.6%	78.7%
SAU801256	MGE100072	37%	96.5%	87.0%
SAU801256	MPN100623	36%	96.5%	84.0%
SAU801256	NGO100893	46%	92.9%	97.9%
SAU801256	NME200306	46%	92.9%	97.9%
SAU801256	PMU101984	48%	92.5%	94.4%
SAU801256	PRT105507	51%	96.1%	100%
SAU801256	PAE203654	50%	92.5%	98.4%
SAU801256	PPU107884	49%	92.9%	97.1%
SAU801256	PSY108183	51%	89.8%	85.8%
SAU801256	SPA101195	49%	96.1%	100%
SAU801256	STY103848	52%	88.2%	93.4%
SAU801256	STM103561	52%	88.2%	93.4%
SAU801256	SAU801256	100%	100%	100%
SAU801256	SEP201549	94%	100%	97.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801256	SHA100713	93%	78.8%	96.6%
SAU801256	SMU100628	62%	99.6%	96.9%
SAU801256	SPN402017	63%	99.6%	97.3%
SAU801256	SPY201599	64%	97.6%	97.3%
SAU801256	TPA100599	58%	87.5%	76.6%
SAU801256	UUR100024	43%	86.7%	63.6%
SAU801256	VCH102226	53%	92.2%	95.5%
SAU801256	YPS001127	52%	88.2%	93.4%
SAU801257	ABA106144	43%	98.3%	97.3%
SAU801257	BAN110110	57%	96.9%	99.0%
SAU801257	BAN103067	70%	99.0%	98.3%
SAU801257	BFR10353	33%	92.5%	98.5%
SAU801257	BPT101109	46%	98.3%	97.3%
SAU801257	BBU100121	34%	88.4%	92.5%
SAU801257	BCE107064	46%	99.7%	97.6%
SAU801257	BFU100280	46%	99.7%	97.6%
SAU801257	BMA107429	44%	99.7%	97.6%
SAU801257	CJU101106	37%	99.7%	100%
SAU801257	CPN200047	37%	93.5%	99.6%
SAU801257	CTR200050	35%	93.5%	99.6%
SAU801257	CAC101812	47%	99.0%	98.7%
SAU801257	CBO101301	47%	98.6%	98.4%
SAU801257	CDF101762	53%	100%	100%
SAU801257	CDP101115	41%	93.9%	99.6%
SAU801257	EBC103096	43%	100%	99.3%
SAU801257	EFA200421	62%	100%	99.7%
SAU801257	ECO100170	43%	100%	99.3%
SAU801257	HIN100893	47%	98.3%	97.2%
SAU801257	HPY101532	37%	100%	100%
SAU801257	KPN301399	43%	100%	99.3%
SAU801257	LPN100716	44%	100%	99.7%
SAU801257	LMO102014	63%	100%	99.7%
SAU801257	MCA101252	42%	98.3%	96.9%
SAU801257	MAV106405	40%	93.9%	99.6%
SAU801257	MBV102285	40%	93.9%	99.6%
SAU801257	MLP100972	38%	93.9%	99.6%
SAU801257	MTU202851	40%	93.9%	99.6%
SAU801257	MGE100443	37%	100%	99.7%
SAU801257	MPN100211	40%	100%	99.7%
SAU801257	NGO100890	44%	100%	99.6%
SAU801257	NME200305	44%	100%	99.6%
SAU801257	PMU101985	46%	100%	99.6%
SAU801257	PRT104501	45%	100%	100%
SAU801257	PAE203653	46%	99.7%	98.3%
SAU801257	PPU107887	42%	99.7%	98.3%
SAU801257	PSY104373	44%	99.7%	98.3%
SAU801257	SPA101193	43%	100%	99.3%
SAU801257	STY103870	43%	100%	99.3%
SAU801257	STM103563	43%	100%	99.3%
SAU801257	SAU801257	100%	100%	100%
SAU801257	SEP201550	91%	99.0%	99.3%
SAU801257	SHA100714	92%	99.0%	99.3%
SAU801257	SMU100627	42%	99.7%	98.3%
SAU801257	SPN402016	42%	99.7%	98.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801257	SPY201600	42%	99.7%	98.3%
SAU801257	TPA100598	31%	91.5%	95.5%
SAU801257	UUR100520	40%	98.3%	98.6%
SAU801257	VCH102225	44%	97.3%	97.1%
SAU801257	YPS001128	44%	100%	99.3%
SAU801259	ABA101326	40%	100%	99.5%
SAU801259	BAN107492	62%	95.1%	100%
SAU801259	BAN102566	62%	98.4%	97.8%
SAU801259	BFR11093	45%	98.4%	96.8%
SAU801259	BPT101111	48%	100%	98.9%
SAU801259	BBU100120	47%	93.5%	93.5%
SAU801259	BCE106939	46%	100%	98.9%
SAU801259	BFU100278	47%	94.0%	100%
SAU801259	BMA105364	47%	100%	98.9%
SAU801259	CJU100207	41%	100%	98.4%
SAU801259	CPN200045	38%	98.4%	98.9%
SAU801259	CTR200048	38%	97.8%	98.9%
SAU801259	CAC102009	52%	100%	99.5%
SAU801259	CBO101172	50%	100%	99.5%
SAU801259	CDF101758	53%	98.9%	98.4%
SAU801259	CDP101113	45%	100%	99.5%
SAU801259	EBC103092	45%	98.9%	98.4%
SAU801259	EFA200427	60%	98.9%	98.4%
SAU801259	ECO100172	46%	98.9%	98.4%
SAU801259	HIN100788	43%	98.9%	98.4%
SAU801259	HPY101239	46%	98.4%	97.8%
SAU801259	KPN301402	46%	98.9%	98.4%
SAU801259	LPN100810	47%	100%	99.5%
SAU801259	LMO100919	59%	98.9%	98.4%
SAU801259	MCA100779	42%	100%	99.5%
SAU801259	MAV106394	46%	100%	99.5%
SAU801259	MBV102301	46%	100%	99.5%
SAU801259	MLP100969	45%	100%	99.5%
SAU801259	MTU202844	46%	100%	99.5%
SAU801259	MGE100445	35%	95.7%	94.5%
SAU801259	MPN100206	35%	97.8%	96.7%
SAU801259	NGO100813	45%	100%	99.5%
SAU801259	NME200075	44%	100%	99.5%
SAU801259	PMU101987	43%	98.9%	98.4%
SAU801259	PRT101754	43%	98.9%	98.4%
SAU801259	PAE203651	44%	100%	99.5%
SAU801259	PPU101137	46%	100%	99.5%
SAU801259	PSY109122	42%	100%	99.5%
SAU801259	SPA101723	44%	98.9%	98.4%
SAU801259	STY103872	45%	98.9%	98.4%
SAU801259	STM103585	45%	98.9%	98.4%
SAU801259	SAU801259	100%	100%	100%
SAU801259	SEP201552	91%	100%	100%
SAU801259	SHA100716	89%	100%	100%
SAU801259	SMU101141	56%	98.4%	97.8%
SAU801259	SPN400846	54%	98.4%	97.8%
SAU801259	SPY200332	60%	98.4%	97.8%
SAU801259	TPA100597	44%	94.6%	95.1%
SAU801259	UUR100518	43%	97.8%	97.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801259	VCH102223	45%	100%	99.5%
SAU801259	YPS001131	43%	98.9%	98.4%
SAU801260	ABA101323	35%	91.4%	93.6%
SAU801260	BAN110276	44%	92.6%	100%
SAU801260	BAN105083	55%	96.1%	95.7%
SAU801260	BFR102222	42%	74.2%	90.4%
SAU801260	BPT101116	41%	92.6%	93.3%
SAU801260	BBU100119	33%	91.0%	99.6%
SAU801260	BCE102153	34%	89.1%	89.1%
SAU801260	BFU100277	40%	92.6%	90.8%
SAU801260	BMA102737	40%	92.6%	90.8%
SAU801260	CJU100763	32%	88.3%	97.7%
SAU801260	CPN200180	41%	93.4%	93.5%
SAU801260	CTR200725	43%	89.1%	91.7%
SAU801260	CAC100397	52%	93.0%	93.8%
SAU801260	CBO101109	49%	95.7%	96.0%
SAU801260	CDF101757	53%	94.1%	98.8%
SAU801260	CDP100541	38%	89.5%	93.5%
SAU801260	EBC103101	41%	86.3%	96.5%
SAU801260	EFA201709	55%	94.9%	93.4%
SAU801260	EFM200654	20%	43.4%	31.5%
SAU801260	EFM202480	20%	43.4%	31.5%
SAU801260	ECO100174	43%	88.3%	89.3%
SAU801260	HIN100899	44%	91.8%	98.3%
SAU801260	HPY101204	39%	90.2%	98.3%
SAU801260	KPN301405	39%	93.8%	93.0%
SAU801260	LPN100728	33%	63.7%	98.8%
SAU801260	LMO100967	52%	98.8%	100%
SAU801260	MCA100780	38%	91.0%	94.0%
SAU801260	MAV108353	41%	91.0%	78.7%
SAU801260	MBV102605	40%	85.9%	99.1%
SAU801260	MLP100397	39%	91.0%	78.7%
SAU801260	MTU202325	39%	91.0%	78.7%
SAU801260	NGO100815	44%	93.0%	93.5%
SAU801260	NME200076	44%	93.0%	93.5%
SAU801260	PMU101989	45%	93.0%	99.2%
SAU801260	PRT105689	42%	94.9%	96.4%
SAU801260	PAE203650	39%	91.0%	92.8%
SAU801260	PPU101138	39%	91.8%	93.6%
SAU801260	PSY104368	37%	91.8%	93.6%
SAU801260	SPA101725	38%	88.3%	93.7%
SAU801260	STY103874	41%	90.6%	93.7%
SAU801260	STM103587	41%	90.6%	93.7%
SAU801260	SAU801260	100%	100%	100%
SAU801260	SEP201553	78%	100%	100%
SAU801260	SHA102731	78%	100%	100%
SAU801260	SMU101088	49%	94.9%	99.2%
SAU801260	SPN400240	53%	90.6%	91.5%
SAU801260	SPY201513	55%	89.5%	93.6%
SAU801260	TPA100596	38%	89.1%	99.1%
SAU801260	VCH102222	40%	94.1%	94.1%
SAU801260	YPS001135	40%	90.6%	92.1%
SAU801261	ABA101320	45%	46.5%	44.9%
SAU801261	BAN105383	44%	98.8%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801261	BAN105024	49%	98.8%	98.9%
SAU801261	BFR103149	37%	65.4%	68.5%
SAU801261	BPT105948	35%	48.5%	46.7%
SAU801261	BCE105417	32%	98.8%	99.3%
SAU801261	BFU100276	36%	98.8%	99.3%
SAU801261	BMA102698	30%	98.8%	99.3%
SAU801261	CJU101271	42%	50%	52.3%
SAU801261	CPN200179	31%	57.7%	52.9%
SAU801261	CTR200726	27%	95%	89.5%
SAU801261	CAC100444	30%	89.6%	95.9%
SAU801261	CBO101925	31%	90.8%	98.8%
SAU801261	CDF101756	35%	95.4%	96.1%
SAU801261	CDP101112	40%	48.1%	42.8%
SAU801261	EBC103099	46%	51.9%	47.4%
SAU801261	EFA201711	42%	98.1%	98.5%
SAU801261	ECO100175	44%	51.9%	54.2%
SAU801261	HIN100898	43%	48.5%	45.1%
SAU801261	HPY100211	29%	90.4%	89.1%
SAU801261	KPN301406	43%	52.7%	52.1%
SAU801261	LPN100664	44%	47.7%	46.4%
SAU801261	LMO100426	45%	99.2%	99.6%
SAU801261	MCA100781	32%	96.5%	88.3%
SAU801261	MAV106396	40%	46.5%	38.6%
SAU801261	MBV102303	39%	51.5%	42.8%
SAU801261	MLP100968	40%	46.2%	38.1%
SAU801261	MTU202843	39%	51.5%	42.8%
SAU801261	MGE100446	26%	92.3%	76.2%
SAU801261	MPN100205	26%	87.7%	72.2%
SAU801261	NGO100817	42%	43.1%	43.0%
SAU801261	NME200077	29%	96.2%	95.5%
SAU801261	PMU101990	37%	63.1%	60.6%
SAU801261	PRT101751	35%	86.2%	73.9%
SAU801261	PAE202534	28%	96.5%	82.6%
SAU801261	PPU101140	31%	98.8%	96.7%
SAU801261	PSY104366	32%	98.8%	96.7%
SAU801261	SPA101726	45%	51.9%	54.4%
SAU801261	STY103875	45%	51.9%	47.4%
SAU801261	STM103588	45%	51.9%	47.4%
SAU801261	SAU801261	100%	100%	100%
SAU801261	SEP201554	86%	100%	100%
SAU801261	SHA100718	86%	99.6%	99.6%
SAU801261	SMU101086	41%	97.7%	98.1%
SAU801261	SPN400241	39%	98.1%	97.0%
SAU801261	SPY201512	40%	98.1%	98.5%
SAU801261	TPA100595	27%	84.6%	81.2%
SAU801261	UUR100517	30%	66.9%	56.3%
SAU801261	VCH102221	44%	49.2%	46.1%
SAU801261	YPS001137	33%	90%	78.0%
SAU801263	ABA100529	45%	98.1%	99.1%
SAU801263	BAN100354	53%	98.9%	99.6%
SAU801263	BAN103931	58%	98.9%	99.5%
SAU801263	BFR100495	27%	33.7%	4.4%
SAU801263	BPT102439	44%	99.8%	100%
SAU801263	BCE111561	55%	39.0%	99.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801263	BFU106495	45%	99.1%	98.8%
SAU801263	BMA104091	45%	99.1%	98.8%
SAU801263	CJU100505	40%	99.1%	99.5%
SAU801263	CPN200251	39%	95.6%	96.3%
SAU801263	CTR200662	36%	98.1%	96.7%
SAU801263	CAC100467	50%	98.6%	97.4%
SAU801263	CBO100123	31%	98.6%	98.7%
SAU801263	CDF100404	45%	13.4%	81.9%
SAU801263	CDF100250	47%	97.9%	97.2%
SAU801263	CDP100483	39%	95.1%	95.4%
SAU801263	EBC102546	44%	98.1%	98.6%
SAU801263	EFA200454	56%	98.8%	98.3%
SAU801263	EFM201684	55%	98.6%	98.6%
SAU801263	ECO100194	44%	99.1%	99.5%
SAU801263	HIN100709	44%	99.8%	100%
SAU801263	HPY100234	42%	93.7%	93.8%
SAU801263	KPN301911	46%	93.7%	97.8%
SAU801263	LPN102483	44%	16.6%	100%
SAU801263	LMO100624	59%	98.6%	98.8%
SAU801263	MCA101839	45%	98.4%	99.8%
SAU801263	MAV102826	40%	96.5%	97.1%
SAU801263	MBV103229	39%	96.5%	97.1%
SAU801263	MTU202807	40%	96.8%	96.7%
SAU801263	MGE100289	25%	19.8%	24.6%
SAU801263	NGO100106	49%	98.8%	99.1%
SAU801263	NME201412	49%	98.8%	99.1%
SAU801263	PMU101370	45%	99.3%	99.6%
SAU801263	PRT101177	47%	98.6%	99.1%
SAU801263	PAE200955	48%	99.1%	99.5%
SAU801263	PPU108855	47%	94.9%	98.4%
SAU801263	PSY105509	46%	99.1%	99.5%
SAU801263	SPA100809	43%	98.1%	100%
SAU801263	STY103990	45%	98.1%	98.4%
SAU801263	SAU801263	100%	100%	100%
SAU801263	SEP201556	82%	100%	100%
SAU801263	SHA101150	83%	99.8%	99.8%
SAU801263	SMU101082	47%	98.8%	99.4%
SAU801263	SPN400243	48%	98.6%	99.0%
SAU801263	SPY201510	47%	98.6%	98.9%
SAU801263	TPA100158	38%	93.1%	93.4%
SAU801263	VCH100859	45%	99.1%	99.6%
SAU801263	YPS002005	44%	99.1%	99.5%
SAU801264	BAN108834	41%	90.5%	99.1%
SAU801264	BAN108033	59%	99.9%	100%
SAU801264	CAC101590	45%	93.0%	95.0%
SAU801264	CBO102746	46%	95.2%	94.8%
SAU801264	CDF103797	46%	99.4%	99.9%
SAU801264	EFA200457	54%	99.9%	99.9%
SAU801264	EFM200946	55%	99.4%	99.4%
SAU801264	LMO102727	57%	99.6%	99.5%
SAU801264	MGE100031	37%	87.1%	89.7%
SAU801264	MPN100120	37%	85.5%	86.1%
SAU801264	SAU801264	100%	100%	100%
SAU801264	SEP201557	90%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801264	SHA103204	91%	100%	100%
SAU801264	SMU101474	49%	99.4%	99.5%
SAU801264	SPN400251	49%	99.4%	99.5%
SAU801264	SPY201509	49%	99.4%	99.5%
SAU801264	UUR100379	39%	83.1%	84.4%
SAU801269	ABA104593	42%	95.9%	77.4%
SAU801269	BAN113310	47%	98.2%	98.0%
SAU801269	BAN110029	65%	100%	100%
SAU801269	BFR11714	43%	99.0%	73.5%
SAU801269	BPT100248	47%	91.6%	73.7%
SAU801269	BBU100800	45%	90.6%	72.1%
SAU801269	BCE101969	52%	82.7%	80.2%
SAU801269	BFU100867	50%	89.2%	63.8%
SAU801269	BMA109716	48%	92.8%	67.6%
SAU801269	CJU100125	43%	15.3%	2.2%
SAU801269	CPN200434	41%	92.1%	74.4%
SAU801269	CTR200365	42%	89.8%	71.7%
SAU801269	CAC100425	52%	100%	99.7%
SAU801269	CBO103185	54%	100%	97.9%
SAU801269	CDF102888	58%	81.4%	89.3%
SAU801269	CDP100479	50%	81.6%	96.7%
SAU801269	EBC101431	48%	99.6%	79.5%
SAU801269	EFA200621	61%	9.9%	0.9%
SAU801269	EFM201052	62%	94.5%	95.8%
SAU801269	ECO103100	48%	99.6%	77.3%
SAU801269	HIN101252	47%	100%	84.8%
SAU801269	HPY101031	44%	94.6%	68.3%
SAU801269	KPN301426	48%	99.0%	83.6%
SAU801269	LPN102343	53%	61.6%	99.5%
SAU801269	LMO100282	63%	100%	99.9%
SAU801269	MCA100802	46%	93.8%	75.8%
SAU801269	MAV100286	48%	81.6%	96.1%
SAU801269	MBV104310	50%	61.6%	99.8%
SAU801269	MLP100953	49%	81.6%	63.4%
SAU801269	MTU202801	49%	81.6%	65.1%
SAU801269	MGE100144	46%	81.8%	92.9%
SAU801269	MPN100676	42%	86.4%	99.4%
SAU801269	NGO101494	47%	93.2%	84.0%
SAU801269	NME201748	48%	92.1%	68.2%
SAU801269	PMU100759	46%	100%	84.2%
SAU801269	PRT102425	52%	90.5%	68.3%
SAU801269	PAE204740	48%	92.9%	77.4%
SAU801269	PPU108488	46%	94.9%	79.4%
SAU801269	PSY104832	51%	78.6%	99.6%
SAU801269	SPA101256	53%	65.4%	99.6%
SAU801269	STY101473	48%	99.6%	77.1%
SAU801269	SAU801269	100%	100%	100%
SAU801269	SEP201562	87%	100%	98.9%
SAU801269	SHA100514	87%	100%	98.9%
SAU801269	SMU100784	57%	16.0%	4.6%
SAU801269	SPN400481	56%	16.2%	3.2%
SAU801269	SPY201321	55%	15.5%	10.2%
SAU801269	TPA100881	49%	87.7%	74.0%
SAU801269	UUR100322	48%	85.2%	98.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801269	VCH100631	48%	99.6%	76.8%
SAU801269	YPS001051	49%	96.9%	75.1%
SAU801273	ABA104153	55%	100%	100%
SAU801273	BAN112139	78%	100%	100%
SAU801273	BAN112261	78%	100%	100%
SAU801273	BFR101219	61%	34.8%	96.9%
SAU801273	BPT102559	51%	100%	100%
SAU801273	BBU100803	50%	97.8%	98.9%
SAU801273	BCE114521	53%	100%	100%
SAU801273	BFU106341	53%	98.9%	97.8%
SAU801273	BMA104593	53%	100%	100%
SAU801273	CJU100816	48%	98.9%	97.8%
SAU801273	CPN200838	49%	100%	100%
SAU801273	CTR200226	49%	100%	100%
SAU801273	CAC101338	58%	97.8%	100%
SAU801273	CBO102464	59%	100%	85.6%
SAU801273	CDF100875	71%	92.1%	96.5%
SAU801273	CDP100449	60%	100%	100%
SAU801273	EBC103888	55%	100%	100%
SAU801273	EFA202022	77%	100%	100%
SAU801273	EFM202414	76%	100%	100%
SAU801273	ECO103097	55%	100%	100%
SAU801273	HIN101437	53%	100%	100%
SAU801273	HIN101294	53%	100%	100%
SAU801273	HPY101023	50%	98.9%	97.8%
SAU801273	KPN301430	56%	100%	100%
SAU801273	LPN100705	45%	69.7%	95.4%
SAU801273	LMO101938	80%	100%	100%
SAU801273	MCA100389	53%	100%	100%
SAU801273	MAV100300	57%	100%	100%
SAU801273	MBV101245	59%	100%	100%
SAU801273	MLP100514	60%	100%	100%
SAU801273	MTU202747	59%	100%	100%
SAU801273	MGE100434	45%	91.0%	94.2%
SAU801273	MPN100220	44%	91.0%	94.2%
SAU801273	NGO100722	52%	100%	100%
SAU801273	NME200754	52%	100%	100%
SAU801273	PMU100301	53%	100%	100%
SAU801273	PRT102435	57%	100%	100%
SAU801273	PAE204737	56%	100%	100%
SAU801273	PPU105055	56%	100%	100%
SAU801273	PSY104828	55%	70.8%	100%
SAU801273	SPA101259	51%	100%	100%
SAU801273	STY101470	53%	100%	100%
SAU801273	SAU801273	100%	100%	100%
SAU801273	SEP201566	93%	100%	100%
SAU801273	SHA100171	94%	100%	100%
SAU801273	SMU101327	65%	100%	100%
SAU801273	SPN401466	67%	100%	100%
SAU801273	SPY201503	65%	100%	100%
SAU801273	TPA100877	48%	100%	100%
SAU801273	UUR100204	44%	98.9%	98.9%
SAU801273	VCH100634	59%	100%	100%
SAU801273	YPS006344	53%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801274	ABA106110	46%	98.6%	98.3%
SAU801274	BAN109088	42%	99.7%	98.9%
SAU801274	BAN100469	66%	99.7%	97.3%
SAU801274	BFR11379	47%	97.9%	89.2%
SAU801274	BPT102560	49%	99.0%	96.5%
SAU801274	BBU100804	45%	98.3%	98.6%
SAU801274	BCE107587	48%	99.1%	97.3%
SAU801274	BFU106344	47%	99.1%	97.2%
SAU801274	BMA106616	48%	97.7%	89.6%
SAU801274	CJU101178	41%	95.7%	96.9%
SAU801274	CPN200839	46%	98.1%	98.3%
SAU801274	CTR200225	46%	98.0%	98.1%
SAU801274	CAC102635	52%	98.3%	97.3%
SAU801274	CBO102281	52%	98.3%	97.6%
SAU801274	CDF100877	56%	99.3%	98.4%
SAU801274	CDP100447	44%	97.4%	95.2%
SAU801274	EBC103885	49%	99.1%	96.8%
SAU801274	EFA202028	62%	99.3%	98.6%
SAU801274	EFM200260	62%	99.3%	94.3%
SAU801274	ECO103096	49%	99.1%	93.9%
SAU801274	HIN100220	48%	98.3%	96.3%
SAU801274	HPY101196	38%	95.0%	96.2%
SAU801274	KPN301429	49%	99.1%	96.9%
SAU801274	LPN101324	50%	97.1%	92.6%
SAU801274	LMO100657	66%	99.6%	96.0%
SAU801274	MCA100390	49%	98.4%	98.7%
SAU801274	MAV100299	44%	96.8%	93.7%
SAU801274	MBV101241	45%	96.8%	94.0%
SAU801274	MLP100515	43%	96.8%	91.8%
SAU801274	MTU202745	45%	96.8%	94.0%
SAU801274	NGO102045	49%	99.7%	98.3%
SAU801274	NME200892	49%	99.3%	98.0%
SAU801274	PMU101114	48%	97.3%	95.1%
SAU801274	PRT102434	48%	98.3%	96.3%
SAU801274	PAE204736	50%	97.0%	96.4%
SAU801274	PPU105054	50%	98.3%	97.9%
SAU801274	PSY104827	47%	83.7%	97.8%
SAU801274	SPA101063	45%	11.7%	55.2%
SAU801274	STY100979	49%	98.6%	96.3%
SAU801274	SAU801274	100%	100%	100%
SAU801274	SEP201567	91%	100%	99.6%
SAU801274	SHA100393	52%	26.6%	100%
SAU801274	SHA101099	91%	99.1%	100%
SAU801274	SMU101329	58%	99.1%	94.9%
SAU801274	SPN400516	57%	99.1%	89.4%
SAU801274	SPY201498	58%	99.1%	97.6%
SAU801274	TPA100876	44%	97.0%	96.0%
SAU801274	VCH100635	49%	99.6%	97.7%
SAU801274	YPS001047	49%	98.0%	96.6%
SAU801275	BAN106546	41%	99.3%	99.1%
SAU801275	BAN109546	51%	99.3%	99.6%
SAU801275	EFA200747	46%	98.9%	97.9%
SAU801275	EFM200896	45%	98.0%	97.5%
SAU801275	LMO100794	51%	99.1%	99.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801275	SAU801275	100%	100%	100%
SAU801275	SEP201568	93%	100%	97.4%
SAU801275	SHA101100	91%	100%	98.1%
SAU801275	SMU100333	43%	98.4%	99.5%
SAU801275	SPN400538	40%	98.2%	99.3%
SAU801275	SPY200771	43%	98.4%	99.5%
SAU801279	ABA105498	21%	96.5%	45.3%
SAU801279	BAN107286	44%	97.0%	97.2%
SAU801279	BAN100894	46%	97.0%	97.0%
SAU801279	BFR10509	27%	47.2%	47.2%
SAU801279	BPT103765	24%	96.5%	44.3%
SAU801279	BBU100535	29%	58.9%	27.4%
SAU801279	CJU100744	22%	85.3%	86.1%
SAU801279	CPN200887	23%	44.6%	19.9%
SAU801279	CTR200185	25%	46.0%	20.6%
SAU801279	CAC101568	23%	67.3%	32.7%
SAU801279	CBO100728	23%	95.3%	88.2%
SAU801279	CDF103715	39%	99.8%	98.8%
SAU801279	EBC102726	21%	45.1%	26.4%
SAU801279	EFA201528	41%	96.7%	95.9%
SAU801279	EFM200625	40%	97.0%	97.2%
SAU801279	ECO101465	27%	53.0%	25.5%
SAU801279	HIN101334	23%	52.6%	24.6%
SAU801279	HPY100995	22%	85.0%	81.1%
SAU801279	KPN305142	22%	45.8%	21.1%
SAU801279	LPN100962	22%	64.5%	79.0%
SAU801279	LMO100434	41%	97.9%	97.2%
SAU801279	MCA101028	25%	58.6%	52.1%
SAU801279	MAV100298	29%	38.8%	37.2%
SAU801279	MBV101239	26%	39.7%	39.7%
SAU801279	MLP100516	27%	48.4%	47.6%
SAU801279	MTU202744	26%	39.7%	39.7%
SAU801279	PMU100804	23%	65.4%	30.8%
SAU801279	PRT105970	25%	49.5%	22.9%
SAU801279	PAE200371	23%	91.8%	91.0%
SAU801279	PPU102118	22%	82.9%	81.4%
SAU801279	PSY102770	23%	82.9%	81.6%
SAU801279	SPA102439	19%	55.1%	23.9%
SAU801279	SAU801279	100%	100%	100%
SAU801279	SEP201578	79%	99.8%	99.5%
SAU801279	SHA100451	80%	99.8%	99.8%
SAU801279	SMU101391	29%	95.3%	94.4%
SAU801279	SPN402026	33%	94.6%	93.7%
SAU801279	SPY201681	31%	93.7%	93.2%
SAU801279	TPA100024	23%	34.8%	16.7%
SAU801279	VCH100544	22%	93.0%	41.7%
SAU801279	YPS001083	21%	46.7%	20.8%
SAU801280	BAN105196	34%	98.7%	100%
SAU801280	BAN100845	38%	98.7%	97.9%
SAU801280	LMO101523	37%	98.3%	96.3%
SAU801280	SAU801280	100%	100%	100%
SAU801280	SEP201580	64%	100%	100%
SAU801280	SHA100452	66%	100%	100%
SAU801281	BAN104875	55%	86.2%	97.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801281	BAN100345	62%	93.8%	98.9%
SAU801281	SAU801281	100%	100%	100%
SAU801281	SEP201582	89%	100%	100%
SAU801281	SHA102814	88%	100%	100%
SAU801282	ABA105298	26%	57.7%	28.1%
SAU801282	BAN100109	25%	93.8%	38.1%
SAU801282	BAN102965	26%	96.2%	42.2%
SAU801282	BPT104503	26%	53.1%	41.1%
SAU801282	BCE107711	25%	57.7%	22.2%
SAU801282	BFU107885	25%	57.7%	20.3%
SAU801282	BMA105226	26%	55.4%	20%
SAU801282	CPN200766	30%	53.1%	48.3%
SAU801282	CTR200272	19%	97.7%	86.8%
SAU801282	EFA201529	38%	57.7%	26.0%
SAU801282	EFM201058	29%	93.8%	44.9%
SAU801282	ECO203392	26%	61.5%	23.7%
SAU801282	HIN100346	20%	78.5%	29.0%
SAU801282	LPN100742	21%	50%	34.4%
SAU801282	LMO100900	31%	77.7%	30.7%
SAU801282	PMU102009	21%	88.5%	36.8%
SAU801282	PAE203801	25%	94.6%	31.7%
SAU801282	PPU101372	23%	87.7%	31.3%
SAU801282	STY101725	23%	87.7%	35.8%
SAU801282	SAU801282	100%	100%	100%
SAU801282	SEP201584	62%	99.2%	99.2%
SAU801282	SHA100455	69%	53.1%	100%
SAU801282	SPN402025	29%	93.8%	46.0%
SAU801282	SPY201680	27%	76.2%	24.6%
SAU801282	TPA100330	34%	56.2%	18.0%
SAU801282	VCH100745	30%	53.8%	17.8%
SAU801282	YPS003236	24%	87.7%	33.6%
SAU801286	BAN101235	48%	99.6%	99.8%
SAU801286	BAN102202	68%	99.2%	99.6%
SAU801286	BFR11955	42%	99.0%	99.8%
SAU801286	BBU100503	45%	98.5%	98.4%
SAU801286	BCE102283	25%	13.9%	34.8%
SAU801286	CJU101134	43%	99.6%	100%
SAU801286	CTR200895	25%	24.1%	28.6%
SAU801286	CAC102280	58%	99.8%	99.2%
SAU801286	CBO100216	49%	45.7%	98.7%
SAU801286	CDF100051	76%	21.8%	93.4%
SAU801286	CDF100869	58%	99.2%	97.7%
SAU801286	EBC104561	30%	16.2%	13.2%
SAU801286	EFA201506	65%	99.6%	99.8%
SAU801286	EFM100483	63%	97.7%	100%
SAU801286	HIN100903	33%	15.8%	12.9%
SAU801286	HPY100747	38%	84.4%	92.0%
SAU801286	KPN108885	24%	27.7%	83.9%
SAU801286	LMO101581	68%	99.4%	99.2%
SAU801286	MAV108578	40%	11.2%	13.0%
SAU801286	MBV102427	23%	32.2%	70.2%
SAU801286	MLP100500	30%	17.5%	22.1%
SAU801286	MTU201661	23%	32.2%	64.9%
SAU801286	MGE100132	26%	46.2%	49.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801286	MPN100564	26%	47.2%	50.5%
SAU801286	SAU801286	100%	100%	100%
SAU801286	SEP201589	93%	100%	100%
SAU801286	SHA101288	93%	100%	100%
SAU801286	SMU101495	54%	99.6%	100%
SAU801286	SPN401582	54%	100%	100%
SAU801286	SPY201258	52%	99.6%	100%
SAU801286	TPA101008	49%	98.5%	99.2%
SAU801286	UUR100083	32%	81.9%	88.2%
SAU801296	ABA100502	35%	99.7%	87.6%
SAU801296	BAN112441	36%	98.6%	89.0%
SAU801296	BAN105004	46%	100%	88.8%
SAU801296	BFR102385	34%	99.5%	87.7%
SAU801296	BPT102145	34%	99.7%	84.4%
SAU801296	BBU100796	29%	99.2%	88.1%
SAU801296	BCE113665	36%	83.9%	86.0%
SAU801296	BFU100247	52%	18.9%	64.9%
SAU801296	BMA101183	35%	91.6%	77.6%
SAU801296	CPN200903	35%	88.4%	85.3%
SAU801296	CTR200169	34%	88.8%	86.5%
SAU801296	CAC101879	43%	100%	88.6%
SAU801296	CBO101875	42%	100%	89.3%
SAU801296	CDF101333	41%	100%	88.6%
SAU801296	EBC104328	36%	88.8%	85.7%
SAU801296	EFA201508	50%	99.9%	88.2%
SAU801296	EFM202291	49%	99.9%	88.5%
SAU801296	ECO102673	37%	88.8%	81.2%
SAU801296	HIN100686	36%	93.7%	84.7%
SAU801296	KPN300176	27%	15.8%	80.9%
SAU801296	KPN303856	36%	88.8%	81.2%
SAU801296	LPN100294	46%	29.6%	76.8%
SAU801296	LMO102476	52%	99.9%	88.5%
SAU801296	NGO100025	34%	99.9%	88.8%
SAU801296	NME200231	35%	99.9%	88.0%
SAU801296	PMU101830	35%	99.4%	87.8%
SAU801296	PRT104418	35%	99.4%	87.2%
SAU801296	PAE203618	35%	89.0%	81.4%
SAU801296	PPU106720	34%	99.7%	88.1%
SAU801296	PSY104425	36%	89.0%	81.4%
SAU801296	SPA101071	34%	87.6%	92.6%
SAU801296	STY103352	37%	88.8%	81.1%
SAU801296	STM103830	37%	88.8%	81.1%
SAU801296	SAU801296	100%	100%	100%
SAU801296	SEP201609	79%	100%	88.4%
SAU801296	SHA101666	82%	88.2%	87.8%
SAU801296	SMU101244	43%	99.9%	88.2%
SAU801296	SPN401885	43%	99.9%	86.8%
SAU801296	SPY201640	42%	99.9%	88.2%
SAU801296	TPA100324	34%	100%	87.8%
SAU801296	VCH100525	37%	88.6%	80.5%
SAU801296	YPS000071	38%	88.8%	81.4%
SAU801297	ABA100436	30%	99.4%	98.3%
SAU801297	BAN110763	44%	97.5%	100%
SAU801297	BAN112909	46%	99.9%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801297	BFR100255	29%	98.7%	98.9%
SAU801297	BPT102215	35%	99.3%	98.7%
SAU801297	BBU100210	30%	99.7%	99.8%
SAU801297	BCE101069	39%	99.3%	96.4%
SAU801297	BFU105240	39%	99.3%	95.2%
SAU801297	BMA108596	38%	99.3%	95.5%
SAU801297	CPN201040	31%	87.0%	86.4%
SAU801297	CTR200853	35%	48.7%	56.6%
SAU801297	CAC102986	33%	99.6%	99.7%
SAU801297	CBO103041	32%	99.9%	99.8%
SAU801297	CDF101334	34%	98.2%	98.0%
SAU801297	EBC102001	41%	96.4%	96.1%
SAU801297	EFA201509	43%	99.9%	99.4%
SAU801297	EFM201334	45%	99.9%	99.4%
SAU801297	ECO104060	38%	49.2%	54.5%
SAU801297	HIN100066	28%	83.0%	84.3%
SAU801297	KPN300048	43%	25.0%	99.4%
SAU801297	KPN301336	39%	50.4%	55.4%
SAU801297	LPN100571	38%	48.9%	57.3%
SAU801297	LMO100388	49%	99.6%	99.3%
SAU801297	NGO100175	31%	99.7%	99.7%
SAU801297	NME201515	30%	99.7%	99.7%
SAU801297	PMU100904	40%	48.0%	52.8%
SAU801297	PRT104001	28%	92.1%	91.9%
SAU801297	PAE204941	39%	99.4%	98.9%
SAU801297	PPU106702	40%	99.4%	98.9%
SAU801297	PSY101062	40%	99.4%	96.4%
SAU801297	SPA101227	48%	28.4%	73.3%
SAU801297	STY103745	40%	47.8%	53.4%
SAU801297	STM103526	40%	47.8%	53.4%
SAU801297	SAU801297	100%	100%	100%
SAU801297	SEP201920	75%	100%	100%
SAU801297	SHA101443	75%	100%	100%
SAU801297	SMU101239	42%	99.9%	98.0%
SAU801297	SPN400160	40%	99.9%	98.0%
SAU801297	SPY201621	41%	99.9%	98.0%
SAU801297	TPA100300	34%	99.3%	94.3%
SAU801297	UUR100579	22%	24.8%	33.6%
SAU801297	VCH100340	29%	87.9%	88.4%
SAU801297	YPS003494	39%	47.8%	51.8%
SAU801301	ABA103732	60%	98.8%	98.0%
SAU801301	BAN107568	66%	41.6%	93.2%
SAU801301	BAN110463	78%	79.1%	99.5%
SAU801301	BPT102742	50%	98.6%	97.2%
SAU801301	BBU100240	56%	97.8%	97.2%
SAU801301	BCE105610	30%	96.6%	95.3%
SAU801301	BFU103471	55%	99.2%	98.8%
SAU801301	BMA108603	55%	99.2%	95.2%
SAU801301	CAC100927	58%	99.0%	99.2%
SAU801301	CBO103256	63%	98.2%	96.1%
SAU801301	CDF103106	63%	99.8%	98.2%
SAU801301	CDP100653	50%	98.4%	98.2%
SAU801301	EBC104504	61%	98.2%	97.4%
SAU801301	EFA202255	64%	99.4%	98.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801301	EFM201617	62%	96.2%	99.8%
SAU801301	ECO103832	61%	99.4%	98.6%
SAU801301	HIN100672	58%	98.2%	97.2%
SAU801301	HPY200804	33%	10.8%	19.2%
SAU801301	KPN300967	61%	98.2%	97.2%
SAU801301	LPN100925	47%	97.6%	98.0%
SAU801301	LMO101597	69%	99.4%	99.6%
SAU801301	MAV103198	51%	98.4%	97.6%
SAU801301	MBV104620	51%	98.2%	99%
SAU801301	MLP101379	50%	98.4%	97.6%
SAU801301	MTU203642	51%	98.2%	95.7%
SAU801301	MGE100038	47%	99.4%	98.6%
SAU801301	MPN100104	48%	98.6%	97.8%
SAU801301	PMU101446	59%	99.8%	99.0%
SAU801301	PRT101873	60%	98.8%	96.7%
SAU801301	PAE203580	61%	98.8%	97.4%
SAU801301	PPU101510	61%	98.8%	97.4%
SAU801301	PSY105188	60%	98.8%	97.0%
SAU801301	SPA101671	59%	99.4%	98.8%
SAU801301	STY103131	61%	99.4%	98.8%
SAU801301	SAU801301	100%	100%	100%
SAU801301	SEP201925	86%	100%	99.8%
SAU801301	SHA100389	86%	100%	99.8%
SAU801301	SPN401988	63%	99.2%	98.4%
SAU801301	SPY201295	64%	99.8%	97.8%
SAU801301	VCH103465	58%	99.2%	97.8%
SAU801301	YPS003517	39%	97.4%	97.4%
SAU801303	BAN106168	27%	98.4%	96.8%
SAU801303	BAN103220	31%	98.4%	98.7%
SAU801303	BFR103324	24%	48.7%	37.1%
SAU801303	CAC101453	33%	35.2%	30.9%
SAU801303	CBO101891	31%	100%	99.0%
SAU801303	CDF101626	34%	39.1%	77.8%
SAU801303	CDP100635	25%	87.8%	85.8%
SAU801303	EBC103957	30%	46.4%	43.6%
SAU801303	EFA202448	32%	98.0%	98.4%
SAU801303	ECO103737	28%	40.5%	37.1%
SAU801303	HIN100626	21%	88.5%	81.8%
SAU801303	KPN303520	28%	46.4%	43.6%
SAU801303	LPN102659	25%	31.6%	31.8%
SAU801303	LMO101007	32%	97.4%	97.4%
SAU801303	MCA103128	27%	88.8%	100%
SAU801303	MAV102145	21%	90.5%	90.3%
SAU801303	NME300873	22%	46.7%	51.6%
SAU801303	PAE203299	29%	98.7%	95.6%
SAU801303	PPU108432	29%	98.7%	96.5%
SAU801303	SPA101172	28%	46.4%	42.6%
SAU801303	STY102009	30%	48.0%	44.4%
SAU801303	STM101115	30%	48.0%	44.4%
SAU801303	SAU801303	100%	100%	100%
SAU801303	SEP201929	51%	100%	99.4%
SAU801303	SHA102823	55%	98.7%	98.0%
SAU801303	VCH100134	26%	30.6%	28.4%
SAU801303	YPS001338	25%	48.0%	44.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801310	ABA100417	35%	96.9%	98.1%
SAU801310	BAN105748	72%	98.9%	99.3%
SAU801310	BAN104448	75%	98.9%	99.3%
SAU801310	BFR11190	26%	91.0%	86.4%
SAU801310	BPT102675	37%	97.3%	92.8%
SAU801310	BCE102837	39%	84.1%	85.6%
SAU801310	BFU101392	37%	93.0%	99.1%
SAU801310	BMA100200	39%	84.1%	85.6%
SAU801310	CJU100649	38%	93.0%	93.5%
SAU801310	CAC103422	34%	27.6%	19.7%
SAU801310	CBO100732	23%	85.9%	70.9%
SAU801310	CDF100645	29%	21.5%	19.9%
SAU801310	CDP100410	37%	88.8%	89.3%
SAU801310	EBC103135	40%	88.1%	89.3%
SAU801310	EFA201729	71%	100%	100%
SAU801310	EFM202549	71%	100%	100%
SAU801310	ECO103776	39%	90.6%	91.7%
SAU801310	HIN100845	39%	88.6%	89.2%
SAU801310	HPY100507	36%	93.3%	93.8%
SAU801310	KPN301351	40%	88.1%	89.3%
SAU801310	LPN101888	34%	97.8%	99.1%
SAU801310	LMO101667	75%	98.9%	99.3%
SAU801310	MCA100914	38%	87.2%	88.7%
SAU801310	MAV103088	42%	97.8%	98.7%
SAU801310	MBV103559	42%	97.8%	98.7%
SAU801310	MLP100995	43%	97.8%	98.7%
SAU801310	MTU202188	42%	97.8%	98.7%
SAU801310	NGO100777	38%	87.4%	82.0%
SAU801310	NME201965	38%	87.4%	88.8%
SAU801310	PMU101175	38%	92.6%	92.8%
SAU801310	PRT102825	39%	88.1%	89.3%
SAU801310	PAE205114	37%	95.7%	97.4%
SAU801310	PPU106798	36%	95.7%	97.6%
SAU801310	PSY103100	37%	95.7%	97.6%
SAU801310	SPA103892	39%	90.6%	91.7%
SAU801310	STY103416	40%	90.6%	91.7%
SAU801310	SAU801310	100%	100%	100%
SAU801310	SEP201943	95%	100%	100%
SAU801310	SHA100843	94%	89.2%	100%
SAU801310	SMU100694	66%	98.7%	99.3%
SAU801310	SPN400444	65%	98.7%	99.3%
SAU801310	SPY201446	64%	98.7%	99.3%
SAU801310	VCH102707	38%	92.8%	93.6%
SAU801310	YPS001320	38%	88.8%	90.0%
SAU801321	BAN105583	26%	97.8%	94.7%
SAU801321	BAN102074	29%	94.2%	90.7%
SAU801321	CAC102608	24%	88.4%	89.4%
SAU801321	EFM101112	28%	53.4%	60.4%
SAU801321	MGE100396	23%	27.8%	76.5%
SAU801321	SAU801321	100%	100%	100%
SAU801321	SEP201965	50%	97.5%	97.3%
SAU801321	SHA102754	50%	73.0%	99.3%
SAU801321	SMU101032	36%	61.2%	95.7%
SAU801321	SPN401813	30%	92.0%	91.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801321	UUR100029	23%	39.9%	56.7%
SAU801322	BAN105174	44%	79.5%	100%
SAU801322	BAN104200	45%	100%	100%
SAU801322	SAU801322	100%	100%	100%
SAU801322	SEP201967	69%	100%	100%
SAU801322	SHA100761	69%	100%	100%
SAU801322	SMU101030	49%	98%	98.5%
SAU801322	SPN401812	50%	98.5%	99.0%
SAU801330	BAN111952	38%	84.9%	91.5%
SAU801330	BAN108525	43%	90.1%	89.2%
SAU801330	CJU100123	26%	96.1%	98.6%
SAU801330	CAC103773	29%	85.5%	86.5%
SAU801330	CBO102527	33%	88.8%	87.7%
SAU801330	CDF102912	34%	93.8%	93%
SAU801330	CDP100062	31%	84.9%	84.4%
SAU801330	EBC102666	26%	89.5%	90.3%
SAU801330	EFA200377	41%	96.7%	99.3%
SAU801330	ECO100003	26%	89.5%	90%
SAU801330	HIN100087	30%	85.2%	86.3%
SAU801330	HPY101033	24%	95.7%	97.6%
SAU801330	KPN302083	27%	89.5%	90.3%
SAU801330	LMO102232	39%	96.7%	99.0%
SAU801330	MAV106529	30%	85.5%	84.6%
SAU801330	MBV105500	28%	86.5%	71.7%
SAU801330	MLP100697	30%	86.5%	84.4%
SAU801330	MTU201279	28%	86.5%	84.2%
SAU801330	PMU100114	29%	85.2%	86.3%
SAU801330	PRT105493	28%	85.2%	86.1%
SAU801330	SPA100290	26%	90.1%	91.2%
SAU801330	STY100368	26%	89.5%	90.3%
SAU801330	STM100041	26%	89.5%	90.3%
SAU801330	SAU801330	100%	100%	100%
SAU801330	SEP201983	67%	99.7%	99.0%
SAU801330	SHA100711	70%	99.7%	99.3%
SAU801330	SMU100986	40%	96.7%	98.6%
SAU801330	SPN401217	40%	96.7%	98.6%
SAU801330	VCH102328	30%	87.5%	87.4%
SAU801330	YPS000770	26%	85.2%	86.1%
SAU801331	BAN105201	34%	98.9%	100%
SAU801331	BAN104169	39%	98.9%	96.7%
SAU801331	BFR104366	30%	98.1%	94.9%
SAU801331	BFR11663	34%	98.9%	64.9%
SAU801331	BPT104731	21%	89.5%	82.6%
SAU801331	BCE113428	44%	20.2%	60%
SAU801331	BFU104191	25%	98.5%	96.3%
SAU801331	CAC103083	29%	98.9%	98.5%
SAU801331	CBO101559	29%	98.9%	98.5%
SAU801331	CDF103997	30%	98.9%	96.4%
SAU801331	EBC104368	28%	98.5%	98.1%
SAU801331	EFA201290	32%	98.5%	98.9%
SAU801331	EFM100732	29%	93.3%	98.8%
SAU801331	ECO103618	28%	97.8%	97.4%
SAU801331	HIN100003	28%	98.1%	97.7%
SAU801331	HPY200593	32%	34.8%	45.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801331	KPN302267	28%	97.8%	97.4%
SAU801331	LMO102909	33%	98.5%	98.2%
SAU801331	MCA102858	42%	26.2%	29.3%
SAU801331	PMU101555	25%	97.8%	94.4%
SAU801331	PRT100132	28%	98.5%	98.9%
SAU801331	PAE204955	27%	50.6%	30.3%
SAU801331	PPU111047	27%	40.8%	27.2%
SAU801331	SPA101786	28%	97.8%	92.0%
SAU801331	STY103971	28%	97.8%	97.4%
SAU801331	STM101116	27%	98.5%	98.5%
SAU801331	SAU801331	100%	100%	100%
SAU801331	SEP201985	71%	100%	99.6%
SAU801331	SHA100712	67%	100%	100%
SAU801331	SMU101554	31%	97.8%	97.4%
SAU801331	SPN401169	29%	97.4%	97.4%
SAU801331	SPY200445	30%	97.8%	97.4%
SAU801331	UUR100576	24%	95.9%	95.7%
SAU801331	VCH101344	31%	98.1%	96.3%
SAU801331	YPS003424	30%	98.5%	98.5%
SAU801342	ABA100381	46%	98.5%	98.0%
SAU801342	BAN111549	56%	57.1%	100%
SAU801342	BAN102492	60%	100%	97.8%
SAU801342	BFR11813	40%	98.8%	98.5%
SAU801342	BPT100911	44%	98.0%	97.6%
SAU801342	BCE113404	46%	98.0%	95.2%
SAU801342	BFU103444	46%	98.2%	96.4%
SAU801342	BMA106204	46%	98.0%	95.2%
SAU801342	CJU101551	44%	98.9%	98.9%
SAU801342	CPN200956	46%	98.0%	97.3%
SAU801342	CTR200126	45%	98.3%	97.4%
SAU801342	CAC102328	54%	98.3%	97.9%
SAU801342	CAC101106	54%	99.2%	98.8%
SAU801342	CBO103315	34%	99.1%	98.6%
SAU801342	CDF103784	36%	40.0%	93.5%
SAU801342	CDP100257	45%	98.9%	95.7%
SAU801342	EBC103706	45%	98.5%	98.6%
SAU801342	EFA201838	59%	98.5%	99.7%
SAU801342	EFM200992	29%	20.8%	23.3%
SAU801342	ECO102870	45%	98.5%	98.6%
SAU801342	HIN101002	48%	98.2%	98.2%
SAU801342	HPY101071	44%	99.5%	98.3%
SAU801342	KPN303075	45%	98.5%	98.6%
SAU801342	LPN102231	62%	27.3%	95.3%
SAU801342	LPN102506	45%	95.5%	99.1%
SAU801342	LMO101346	61%	100%	100%
SAU801342	MCA100777	45%	98.5%	96.7%
SAU801342	MAV101560	44%	98.8%	96.0%
SAU801342	MBV100248	42%	98.8%	96%
SAU801342	MLP100366	44%	98.9%	96.1%
SAU801342	MTU201430	42%	98.8%	96%
SAU801342	MGE100068	38%	97.7%	98.3%
SAU801342	MPN100073	36%	97.7%	98.3%
SAU801342	NGO100398	47%	99.1%	99.5%
SAU801342	NME201529	47%	99.1%	99.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801342	PMU101638	46%	97.6%	97.8%
SAU801342	PMU101242	46%	98.5%	98.7%
SAU801342	PRT102791	46%	98.5%	98.5%
SAU801342	PAE200547	47%	97.6%	97.4%
SAU801342	PPU104660	47%	98.5%	98.3%
SAU801342	PSY103014	46%	96.2%	98.8%
SAU801342	SPA101296	44%	98.5%	98.6%
SAU801342	STY104533	44%	98.5%	98.6%
SAU801342	STM101336	46%	97.9%	97.6%
SAU801342	SAU801342	100%	100%	100%
SAU801342	SEP202003	84%	100%	100%
SAU801342	SHA100863	84%	59.1%	98.5%
SAU801342	SMU101576	55%	98.9%	99.4%
SAU801342	SPN401839	54%	98.9%	99.4%
SAU801342	SPY201289	57%	99.8%	92.7%
SAU801342	TPA100554	45%	98.0%	97.7%
SAU801342	UUR100593	38%	98.5%	99.2%
SAU801342	VCH103347	46%	99.4%	97.1%
SAU801342	VCH100468	46%	99.7%	95.4%
SAU801342	YPS000208	47%	98.5%	98.5%
SAU801346	ABA102859	21%	79.3%	72.1%
SAU801346	BAN102851	37%	23.8%	26.1%
SAU801346	BAN105200	24%	99.7%	99.7%
SAU801346	BFR104408	21%	85.4%	96.0%
SAU801346	BBU100829	24%	95.2%	94.4%
SAU801346	CPN200747	21%	42.8%	86.4%
SAU801346	CAC102141	24%	98.6%	98.5%
SAU801346	CBO100905	21%	45.2%	90.6%
SAU801346	CBO101427	23%	69.0%	50.6%
SAU801346	CDF103294	24%	99.8%	99.1%
SAU801346	EBC101244	20%	48.6%	87.7%
SAU801346	EFA200866	25%	99.5%	99.4%
SAU801346	EFM202519	27%	99.8%	99.8%
SAU801346	ECO100389	21%	98.7%	98.4%
SAU801346	KPN305696	21%	98.7%	98.4%
SAU801346	LMO100865	27%	99.7%	99.5%
SAU801346	MCA102350	24%	66.9%	11.9%
SAU801346	PMU100774	22%	34.2%	53.5%
SAU801346	PRT101272	22%	61.2%	43.5%
SAU801346	PAE204280	23%	30.2%	2.2%
SAU801346	PPU101727	26%	39.6%	8.2%
SAU801346	PSY100720	21%	76.1%	64.9%
SAU801346	SPA100796	49%	5.5%	76.1%
SAU801346	STY100354	24%	30.0%	37.0%
SAU801346	SAU801346	100%	100%	100%
SAU801346	SEP202013	44%	100%	100%
SAU801346	SHA102750	52%	11.6%	68.4%
SAU801346	SPY100934	23%	17.0%	51.5%
SAU801346	TPA100620	22%	98.7%	98.7%
SAU801346	VCH103246	25%	99.6%	99.7%
SAU801346	YPS002049	22%	27.7%	46.2%
SAU801353	BAN110703	46%	98.0%	99.5%
SAU801353	BPT100366	38%	96.0%	90.2%
SAU801353	BCE111262	36%	98.5%	91.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801353	BFU102327	34%	98.5%	91.6%
SAU801353	BMA109316	38%	98.5%	96.1%
SAU801353	CJU100326	32%	97.0%	98.0%
SAU801353	CAC101816	33%	97.0%	99.0%
SAU801353	CBO101234	37%	97.0%	99.5%
SAU801353	CDF101093	35%	97.0%	94.6%
SAU801353	EBC100867	34%	96.0%	89.8%
SAU801353	EFA201321	41%	99.5%	93.5%
SAU801353	EFM102093	41%	89.6%	94.8%
SAU801353	ECO102993	32%	96.0%	90.2%
SAU801353	HIN100253	32%	98.5%	95.5%
SAU801353	HPY101488	32%	97.0%	79.0%
SAU801353	KPN304106	31%	96.0%	90.2%
SAU801353	LPN102283	33%	99.0%	69.7%
SAU801353	LMO102620	50%	99.0%	98.0%
SAU801353	MGE100251	33%	98.5%	95.0%
SAU801353	MPN100486	32%	98.5%	95.0%
SAU801353	NGO101160	33%	98.5%	98%
SAU801353	NME201160	33%	98.5%	98%
SAU801353	PMU101696	34%	98.5%	94.5%
SAU801353	PRT100514	34%	96.0%	84.9%
SAU801353	PAE200580	34%	96.5%	98.4%
SAU801353	PPU100641	31%	96.5%	98.4%
SAU801353	PSY103383	30%	96.5%	98.4%
SAU801353	SPA101471	34%	96.0%	88.5%
SAU801353	STY100804	34%	96.0%	91.1%
SAU801353	STM101260	34%	96.0%	91.1%
SAU801353	SAU801353	100%	100%	100%
SAU801353	SEP202027	89%	100%	100%
SAU801353	SHA100825	86%	100%	100%
SAU801353	SMU101039	43%	94.6%	90.6%
SAU801353	SPN400755	42%	99.5%	94.8%
SAU801353	SPY200679	40%	99.5%	94.8%
SAU801353	UUR100408	35%	98.0%	88.7%
SAU801353	VCH100513	32%	98.0%	90.9%
SAU801353	YPS001965	33%	96.0%	85.6%
SAU801354	BAN100279	67%	95.5%	99.5%
SAU801354	BAN106450	70%	97.9%	99.1%
SAU801354	EFA201799	71%	97.9%	95.0%
SAU801354	EFM202341	70%	95.3%	99.4%
SAU801354	LMO101322	70%	97.9%	99.1%
SAU801354	MGE100205	47%	95.6%	99.7%
SAU801354	MPN100032	45%	95.6%	99.7%
SAU801354	SAU801354	100%	100%	100%
SAU801354	SEP202029	92%	99.8%	99.7%
SAU801354	SHA100791	64%	20.3%	100%
SAU801354	SHA100826	91%	99.8%	99.7%
SAU801354	SMU101038	68%	95.6%	98.2%
SAU801354	SPN400756	69%	95.6%	98.1%
SAU801354	SPY200680	67%	95.8%	98.2%
SAU801354	UUR100471	52%	96.2%	98.8%
SAU801354	ECO102964	38%	94.1%	97.9%
SAU801354	NME201790	39%	95.0%	98.6%
SAU801354	PAE204962	38%	94.0%	97.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801354	PMU100370	38%	94.3%	98.1%
SAU801354	YPS001994	37%	94.6%	98.3%
SAU801355	BAN110308	42%	92.1%	92.2%
SAU801355	BAN106306	58%	99.6%	99.0%
SAU801355	CBO103199	45%	90.6%	96.7%
SAU801355	EFA201801	56%	99.2%	97.7%
SAU801355	EFM100902	54%	99.1%	98.0%
SAU801355	LMO102776	56%	99.5%	97.6%
SAU801355	SAU801355	100%	100%	100%
SAU801355	SEP202031	83%	99.9%	99.9%
SAU801355	SHA100827	83%	98.4%	100%
SAU801355	SMU101036	53%	96.9%	98.4%
SAU801355	SPN400757	52%	99.4%	98.3%
SAU801355	SPY200681	52%	98.9%	99.0%
SAU801355	UUR100472	41%	93.8%	88.6%
SAU801355	ECO102953	32%	92.4%	97.5%
SAU801355	MPN100031	37%	91.3%	92.5%
SAU801355	NME201659	32%	88.8%	94.6%
SAU801355	PAE204959	36%	71.0%	74.5%
SAU801355	PMU100369	32%	86.8%	91.0%
SAU801355	YPS002002	33%	86%	89.8%
SAU801362	ABA105445	44%	15.0%	65.3%
SAU801362	BCE112162	25%	16.5%	22.0%
SAU801362	CDF100773	30%	78.0%	86.2%
SAU801362	CDF100771	32%	67.3%	84.6%
SAU801362	EFA201849	42%	93.6%	78.2%
SAU801362	EFM202260	38%	89.0%	97.6%
SAU801362	LMO100807	41%	92.7%	99.0%
SAU801362	MAV108258	30%	61.5%	67.2%
SAU801362	MTU400793	25%	67.0%	51.2%
SAU801362	MTU405761	25%	67.0%	52.5%
SAU801362	SAU801362	100%	100%	100%
SAU801362	SEP202045	76%	99.4%	98.8%
SAU801362	SHA102568	70%	47.1%	100%
SAU801362	SMU100110	32%	94.8%	74.0%
SAU801362	SPN401225	30%	96.0%	83.5%
SAU801362	SPY201033	31%	93.6%	71.2%
SAU801362	TPA100731	23%	42.2%	35.4%
SAU801366	BAN105241	54%	47.8%	96.5%
SAU801366	BAN108518	61%	47.8%	98.2%
SAU801366	BAN108248	63%	98.0%	96.3%
SAU801366	CAC101350	50%	97.1%	96.8%
SAU801366	CBO102562	47%	98.3%	98.0%
SAU801366	CDF103804	43%	97.7%	92.6%
SAU801366	LMO100556	60%	98.5%	96.6%
SAU801366	MAV108484	36%	98.0%	83.0%
SAU801366	PAE203459	37%	98.5%	83.9%
SAU801366	PPU105893	36%	99.1%	87.3%
SAU801366	PSY104354	38%	96.5%	87.6%
SAU801366	SAU801366	100%	100%	100%
SAU801366	SHA101687	80%	99.4%	98.6%
SAU801366	SPN400552	55%	99.7%	99.4%
SAU801375	BFR103954	26%	35.1%	36.7%
SAU801375	SAU801375	100%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801375	SEP202067	86%	100%	100%
SAU801375	SHA101696	82%	93.8%	100%
SAU801375	SPY200443	27%	98.6%	99.0%
SAU801388	ABA103820	44%	92.9%	64.3%
SAU801388	BAN111672	45%	97.4%	100%
SAU801388	BAN112161	56%	97.4%	95.6%
SAU801388	BFR10280	36%	79.5%	60.5%
SAU801388	BPT101013	30%	84.4%	82.2%
SAU801388	BBU100215	35%	91.2%	95.0%
SAU801388	BCE106431	29%	89.9%	84.7%
SAU801388	BFU107007	30%	87.3%	85.6%
SAU801388	BMA101485	27%	90.6%	85.0%
SAU801388	CJU100575	40%	92.2%	97.7%
SAU801388	CAC102164	29%	86.4%	89.9%
SAU801388	CBO103614	32%	92.2%	97.2%
SAU801388	CDF100003	33%	29.9%	81.1%
SAU801388	CDF104102	34%	95.1%	96.1%
SAU801388	CDP100488	29%	93.2%	90.6%
SAU801388	EBC104239	28%	93.5%	95.0%
SAU801388	EFA200604	30%	96.1%	97.1%
SAU801388	ECO103648	27%	93.5%	95.0%
SAU801388	HIN101348	30%	89.6%	91.7%
SAU801388	KPN302236	27%	92.5%	94.0%
SAU801388	LMO102682	34%	93.2%	96.4%
SAU801388	MCA100488	32%	84.7%	86.2%
SAU801388	MAV105985	29%	91.6%	91.2%
SAU801388	MBV103842	30%	87.7%	89.9%
SAU801388	MLP101266	29%	90.6%	92.8%
SAU801388	MTU200926	30%	87.7%	89.9%
SAU801388	PMU100435	31%	79.2%	80.6%
SAU801388	PRT102835	28%	93.8%	95.3%
SAU801388	PPU107748	30%	90.3%	90.4%
SAU801388	PSY104957	32%	89.6%	97.2%
SAU801388	STY103903	28%	93.5%	95.0%
SAU801388	SAU801388	100%	100%	100%
SAU801388	SEP202089	83%	100%	100%
SAU801388	SHA101136	82%	100%	100%
SAU801388	SMU100943	28%	100%	99.4%
SAU801388	SPN401255	31%	88.3%	87.9%
SAU801388	SPY200954	29%	82.8%	83.0%
SAU801388	VCH102807	30%	95.5%	87.2%
SAU801388	YPS003539	28%	95.8%	97.5%
SAU801392	BAN100882	70%	88.2%	98.9%
SAU801392	BAN109532	73%	95.9%	62.1%
SAU801392	BFR10176	56%	47.3%	99.4%
SAU801392	BPT100336	44%	99.6%	90.2%
SAU801392	BBU100741	57%	95.9%	40%
SAU801392	BCE107353	46%	98.7%	43.4%
SAU801392	BFU101573	46%	99.6%	99.8%
SAU801392	BMA103267	46%	99.6%	99.8%
SAU801392	CJU100394	46%	99.1%	99.4%
SAU801392	CPN200741	39%	93.8%	40%
SAU801392	CTR200617	38%	93.8%	40.2%
SAU801392	CAC102468	68%	98.9%	99.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801392	CBO103433	66%	45.6%	99.8%
SAU801392	CDF100968	64%	48.4%	100%
SAU801392	EBC102343	45%	99.6%	99.6%
SAU801392	EFA200654	70%	100%	98.2%
SAU801392	EFM100463	71%	38.5%	99.8%
SAU801392	ECO100796	45%	99.6%	99.8%
SAU801392	HPY100840	48%	98.7%	99.2%
SAU801392	KPN302739	45%	99.6%	99.8%
SAU801392	LMO100778	74%	99.2%	99.1%
SAU801392	NGO100212	46%	99.6%	99.8%
SAU801392	NME201287	46%	99.6%	99.8%
SAU801392	PRT100022	45%	99.6%	99.6%
SAU801392	PAE201962	46%	44.1%	99.0%
SAU801392	PPU110733	46%	99.8%	99.8%
SAU801392	PSY102530	47%	98.1%	99.6%
SAU801392	SPA102072	44%	99.6%	99.6%
SAU801392	STY102394	45%	99.6%	99.6%
SAU801392	STM102165	45%	99.6%	99.8%
SAU801392	SAU801392	100%	100%	100%
SAU801392	SEP202098	94%	100%	99.6%
SAU801392	SHA100965	94%	100%	99.8%
SAU801392	SMU101414	65%	98.9%	97.6%
SAU801392	SPN402032	66%	99.6%	98.1%
SAU801392	SPY201692	66%	98.7%	97.4%
SAU801392	TPA100829	53%	47.3%	97.5%
SAU801392	VCH101496	46%	99.6%	99.6%
SAU801392	YPS002248	45%	99.6%	99.6%
SAU801394	ABA102417	23%	99.1%	99.7%
SAU801394	BAN105110	48%	66.9%	94.4%
SAU801394	BAN110285	47%	98.2%	97.1%
SAU801394	BFR101725	43%	97.9%	98.2%
SAU801394	BPT101923	23%	93.9%	95.2%
SAU801394	BCE110623	24%	93.9%	96.0%
SAU801394	BFU109219	23%	93.9%	96.0%
SAU801394	BMA107844	24%	93.9%	96.0%
SAU801394	CJU100951	43%	98.5%	98.0%
SAU801394	CPN200789	26%	94.2%	93.1%
SAU801394	CTR200632	28%	94.2%	91.6%
SAU801394	CAC102778	25%	94.2%	93.6%
SAU801394	CAC100810	27%	96.7%	96.1%
SAU801394	CBO102584	51%	98.2%	87.9%
SAU801394	CDF102483	52%	97.3%	97.0%
SAU801394	CDP101635	40%	97.3%	99.1%
SAU801394	EBC101246	28%	97.6%	97.0%
SAU801394	EFA200749	46%	96.4%	94.4%
SAU801394	EFM202572	51%	97.0%	95.8%
SAU801394	ECO102277	29%	97.6%	97.0%
SAU801394	HIN100627	22%	98.2%	99.7%
SAU801394	HPY101172	38%	95.7%	96.2%
SAU801394	KPN302836	27%	97.3%	96.7%
SAU801394	LPN102579	45%	96.4%	96.2%
SAU801394	LMO102054	45%	98.8%	99.1%
SAU801394	MCA103569	22%	93.9%	96.6%
SAU801394	MAV103165	39%	97.3%	98.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801394	MBV102870	40%	87.5%	93.8%
SAU801394	MLP101382	38%	96.4%	96.3%
SAU801394	MTU203654	39%	96.4%	97.1%
SAU801394	NGO100986	25%	97.6%	98.9%
SAU801394	NME200328	25%	97.6%	98.9%
SAU801394	PMU101632	23%	98.2%	99.7%
SAU801394	PRT101099	27%	97.6%	97.0%
SAU801394	PAE203114	25%	97.6%	97.3%
SAU801394	PPU105849	29%	97.6%	97.3%
SAU801394	PSY101677	31%	89.4%	98.0%
SAU801394	SPA102819	26%	97.6%	97.0%
SAU801394	STY101017	27%	97.6%	97.0%
SAU801394	SAU801394	100%	100%	100%
SAU801394	SEP202102	85%	99.7%	99.7%
SAU801394	SHA100967	86%	99.7%	99.7%
SAU801394	SMU100090	44%	97.0%	94.1%
SAU801394	SPN400918	42%	96.4%	93.6%
SAU801394	VCH102075	42%	97.6%	97.0%
SAU801394	YPS002391	30%	97.6%	97.0%
SAU801396	ABA105360	41%	77.1%	70.3%
SAU801396	BAN102900	25%	94.2%	87.7%
SAU801396	BAN107078	25%	94.2%	87.6%
SAU801396	BFR10828	34%	93.8%	91.7%
SAU801396	BPT102724	37%	76.7%	70.6%
SAU801396	BCE105684	35%	78.8%	73.6%
SAU801396	BMA108656	39%	79.2%	77.2%
SAU801396	CJU100185	37%	78.3%	79.8%
SAU801396	CPN200790	29%	98.3%	90.2%
SAU801396	CTR200633	34%	80%	77.2%
SAU801396	CAC100895	39%	100%	98.4%
SAU801396	CBO100936	42%	96.7%	94.0%
SAU801396	CDF100169	43%	49.2%	98.3%
SAU801396	CDF101971	40%	94.2%	86.5%
SAU801396	CDF103888	42%	100%	98.8%
SAU801396	CDP100444	25%	70.8%	72.2%
SAU801396	EBC102147	37%	77.5%	70.3%
SAU801396	EFA201878	25%	100%	99.2%
SAU801396	EFM201574	38%	100%	97.5%
SAU801396	ECO100031	37%	77.1%	70.0%
SAU801396	HIN101274	35%	76.2%	70%
SAU801396	HPY100505	31%	97.1%	97.2%
SAU801396	KPN306527	37%	90%	82.4%
SAU801396	LPN103391	26%	68.3%	68.7%
SAU801396	LMO101881	21%	100%	99.2%
SAU801396	MCA102220	38%	80.4%	74.7%
SAU801396	MAV101194	25%	74.6%	75.9%
SAU801396	MBV101254	25%	75.4%	76.7%
SAU801396	MTU202735	26%	75.4%	76.7%
SAU801396	NGO100748	35%	80.8%	74.0%
SAU801396	NME200061	36%	78.8%	72.1%
SAU801396	PMU100726	35%	76.2%	70%
SAU801396	PRT101653	36%	81.2%	73.6%
SAU801396	PAE204755	38%	79.6%	73.5%
SAU801396	PPU111382	37%	81.2%	95.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801396	PSY104750	38%	81.2%	79.2%
SAU801396	SPA101380	38%	77.1%	70.2%
SAU801396	STY101155	38%	77.1%	70.0%
SAU801396	STM100870	38%	77.1%	70.0%
SAU801396	SAU801396	100%	100%	100%
SAU801396	SEP202106	77%	100%	100%
SAU801396	SHA100969	80%	100%	100%
SAU801396	SMU100878	27%	79.2%	76.9%
SAU801396	SPN401413	27%	79.2%	76.9%
SAU801396	VCH102356	38%	78.3%	72.1%
SAU801396	YPS000815	37%	76.2%	69.2%
SAU801408	ABA100780	19%	69.3%	71.1%
SAU801408	BAN104787	27%	98.9%	100%
SAU801408	BAN111400	32%	98.9%	98.7%
SAU801408	BFU103452	21%	60.5%	65.6%
SAU801408	CDF104135	20%	72.0%	72.4%
SAU801408	EFA201494	25%	18.8%	12.8%
SAU801408	EFM201409	20%	62.3%	50.7%
SAU801408	LMO102254	27%	17.8%	40.7%
SAU801408	PAE200524	26%	30.4%	31.0%
SAU801408	SAU801408	100%	100%	100%
SAU801408	SEP200320	76%	100%	100%
SAU801408	SHA101098	77%	99.4%	100%
SAU801413	ABA105904	40%	95.2%	93.7%
SAU801413	BAN103255	42%	77.4%	75.4%
SAU801413	BAN111079	46%	96.4%	94.1%
SAU801413	BPT101840	36%	97.7%	96.1%
SAU801413	BCE108051	37%	96.2%	94.8%
SAU801413	BFU101166	36%	96.2%	94.7%
SAU801413	BMA105967	37%	96.2%	95.2%
SAU801413	CPN200372	38%	89.2%	88.3%
SAU801413	CTR200319	37%	88.1%	87.5%
SAU801413	CDF103227	21%	14.4%	50.5%
SAU801413	CDP101055	38%	89.0%	88.9%
SAU801413	EBC102740	39%	96.1%	95.2%
SAU801413	ECO100709	38%	96.1%	95.2%
SAU801413	HIN101627	36%	96.1%	93.7%
SAU801413	KPN300439	56%	16.7%	91.7%
SAU801413	KPN301278	39%	96.1%	95.2%
SAU801413	LPN103608	38%	96.1%	95.1%
SAU801413	MCA101641	38%	95.9%	94.2%
SAU801413	MAV105067	41%	88.9%	74.0%
SAU801413	MBV101835	40%	88.9%	67.9%
SAU801413	MLP100674	41%	87.8%	64.3%
SAU801413	MTU201231	40%	88.9%	67.9%
SAU801413	NGO101271	36%	96.2%	95.9%
SAU801413	NME201061	36%	96.2%	95.9%
SAU801413	PMU100277	37%	93.7%	92.9%
SAU801413	PRT102075	37%	96.1%	95.2%
SAU801413	PAE201584	38%	96.1%	95.3%
SAU801413	PPU103111	38%	93.1%	94.2%
SAU801413	PSY104853	39%	87.7%	93.8%
SAU801413	SPA103278	38%	96.1%	94.8%
SAU801413	STY101930	38%	96.1%	95.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801413	STM101669	38%	96.1%	95.2%
SAU801413	SAU801413	100%	100%	100%
SAU801413	SEP200338	81%	99.4%	99.9%
SAU801413	SHA102778	78%	72.5%	100%
SAU801413	VCH102055	38%	96.1%	95.2%
SAU801413	YPS002064	38%	96.1%	95.2%
SAU801419	BAN100510	26%	85.8%	87.1%
SAU801419	BFR100612	25%	93.5%	98.7%
SAU801419	CJU101619	33%	95.3%	91.5%
SAU801419	CAC103631	27%	96.4%	92.5%
SAU801419	CBO103591	32%	85.8%	86.0%
SAU801419	CDF104280	32%	98.8%	100%
SAU801419	CDP100572	20%	84.6%	83.1%
SAU801419	EFA200851	25%	98.8%	97.7%
SAU801419	EFM201484	22%	92.9%	93.5%
SAU801419	KPN304595	20%	84.6%	83.1%
SAU801419	LMO100047	22%	85.8%	84.3%
SAU801419	SAU801419	100%	100%	100%
SAU801419	SEP200360	65%	98.8%	100%
SAU801419	SHA101283	67%	98.8%	100%
SAU801419	SMU101216	22%	85.8%	81.0%
SAU801419	SPN401317	26%	85.8%	89.6%
SAU801419	SPY201637	26%	45.6%	68.3%
SAU801426	ABA105042	36%	88.7%	87.6%
SAU801426	BAN106373	43%	98.1%	100%
SAU801426	BFR103062	38%	97.5%	96.4%
SAU801426	BPT100703	36%	81.8%	80.6%
SAU801426	BCE101792	38%	99.4%	98.2%
SAU801426	BFU100755	37%	98.7%	97.6%
SAU801426	BMA106298	37%	99.4%	97.6%
SAU801426	CPN201094	34%	79.9%	77.6%
SAU801426	CTR200891	29%	80.5%	81.8%
SAU801426	CAC100060	39%	84.9%	90.2%
SAU801426	CDP100078	34%	71.1%	68.3%
SAU801426	EBC103149	34%	98.1%	99.4%
SAU801426	EFA201842	46%	94.3%	94.5%
SAU801426	EFM100508	46%	94.3%	88.6%
SAU801426	ECO100048	34%	98.1%	99.4%
SAU801426	HIN100879	44%	99.4%	100%
SAU801426	KPN307712	35%	98.1%	99.4%
SAU801426	LPN102439	37%	84.9%	97.9%
SAU801426	LMO102529	39%	91.2%	92.5%
SAU801426	MCA101498	37%	75.5%	74.9%
SAU801426	MAV101963	32%	74.8%	69.1%
SAU801426	MBV103478	39%	59.1%	61.0%
SAU801426	MLP100935	33%	61.0%	62.4%
SAU801426	MTU202726	39%	59.1%	61.0%
SAU801426	MGE100233	31%	69.2%	74.4%
SAU801426	MPN100515	27%	80.5%	91.9%
SAU801426	NGO101724	30%	98.7%	98.8%
SAU801426	NME202016	30%	98.7%	98.8%
SAU801426	PMU101893	41%	98.7%	97.0%
SAU801426	PRT101248	35%	100%	100%
SAU801426	PAE200349	34%	86.2%	86.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801426	PPU102745	33%	86.2%	95.5%
SAU801426	PSY108387	33%	83.0%	92.8%
SAU801426	SPA103699	35%	98.1%	99.4%
SAU801426	STY101217	34%	98.1%	99.4%
SAU801426	STM100930	35%	98.1%	99.4%
SAU801426	SAU801426	100%	100%	100%
SAU801426	SEP201187	79%	100%	98.8%
SAU801426	SEP200372	81%	100%	98.8%
SAU801426	SHA101277	86%	99.4%	99.4%
SAU801426	SMU100954	34%	95.6%	92.4%
SAU801426	SPN401428	34%	95.6%	94.0%
SAU801426	SPY200658	32%	99.4%	100%
SAU801426	UUR100113	28%	76.1%	80.1%
SAU801426	VCH100435	42%	96.2%	93.9%
SAU801426	YPS000851	39%	99.4%	100%
SAU801434	BFR100985	19%	5.8%	73.2%
SAU801434	BPT100907	21%	5.6%	93.6%
SAU801434	CJU100041	22%	22.9%	71.7%
SAU801434	CJU100788	22%	62.5%	65.0%
SAU801434	CAC100360	19%	94.0%	62.1%
SAU801434	CAC100718	18%	36.8%	67.2%
SAU801434	CDP100418	21%	2.6%	73.1%
SAU801434	HIN101341	19%	10.3%	51.3%
SAU801434	HPY100521	18%	31.5%	84.6%
SAU801434	KPN204472	22%	12.8%	89.0%
SAU801434	MAV100077	23%	48.2%	66.9%
SAU801434	MBV101083	31%	73.9%	65.4%
SAU801434	MTU202311	21%	9.4%	57.6%
SAU801434	MGE100222	20%	11.9%	98.3%
SAU801434	MPN100526	19%	30.1%	75.6%
SAU801434	PAE200410	20%	33.4%	72.4%
SAU801434	SAU801434	100%	100%	100%
SAU801434	SEP200390	22%	35.1%	95.8%
SAU801434	SEP200388	29%	95.8%	66.8%
SAU801434	UUR100500	20%	8.4%	11.1%
SAU801434	UUR100479	22%	78.5%	25.9%
SAU801434	UUR100487	19%	88.3%	21.1%
SAU801434	VCH101382	19%	3.3%	98.4%
SAU801439	ABA101540	43%	15.3%	30%
SAU801439	ABA103709	25%	93.8%	97.9%
SAU801439	BPT102239	28%	95.2%	99.7%
SAU801439	BCE106127	28%	86.3%	92%
SAU801439	BMA102767	29%	88.2%	92.9%
SAU801439	CBO102725	26%	81.7%	88.0%
SAU801439	EBC101979	27%	94.6%	72.1%
SAU801439	KPN304528	26%	94.6%	37.2%
SAU801439	LPN100345	25%	93.8%	96.3%
SAU801439	PPU102936	28%	73.9%	90.7%
SAU801439	PSY103265	28%	87.6%	72.5%
SAU801439	SAU801439	100%	100%	100%
SAU801450	ABA104514	27%	73.6%	64.5%
SAU801450	BAN111504	38%	7.2%	72.2%
SAU801450	BAN111626	37%	13.9%	88.7%
SAU801450	BAN112322	37%	24.2%	68.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801450	BAN109558	31%	36.7%	51.5%
SAU801450	BAN107365	29%	97.5%	80.5%
SAU801450	BAN100187	29%	88.7%	91.1%
SAU801450	BAN106468	33%	79.6%	98.1%
SAU801450	BAN109120	36%	90.1%	83.1%
SAU801450	BAN113112	35%	97.5%	86.2%
SAU801450	BFR12422	26%	81.4%	90.0%
SAU801450	BPT100929	28%	86.8%	87.6%
SAU801450	BBU100731	22%	76.2%	68.8%
SAU801450	BCE103115	26%	76.9%	83.5%
SAU801450	BFU113279	38%	83.6%	86.2%
SAU801450	BMA101975	27%	76.9%	74.9%
SAU801450	CJU100471	27%	81.3%	88.0%
SAU801450	CAC101849	28%	96.4%	96.0%
SAU801450	CBO102303	30%	82.7%	74.1%
SAU801450	CDF104052	29%	35.4%	69.5%
SAU801450	CDF102218	25%	99.0%	90.1%
SAU801450	CDP100789	26%	96.3%	95.2%
SAU801450	EBC100689	28%	68.2%	95.5%
SAU801450	EFA201378	31%	98.8%	93.1%
SAU801450	EFM201090	31%	88.2%	84.5%
SAU801450	ECO100149	25%	87.3%	74.3%
SAU801450	HIN101690	26%	77.0%	69.1%
SAU801450	HPY100590	24%	80.7%	87.1%
SAU801450	KPN300435	25%	22.8%	44.0%
SAU801450	KPN304206	28%	73.5%	60.3%
SAU801450	LPN102619	33%	15.1%	96.5%
SAU801450	LPN100189	37%	31.5%	77.6%
SAU801450	LMO102341	36%	98.6%	84.4%
SAU801450	MCA101332	30%	73.6%	66.3%
SAU801450	MAV101544	28%	74.1%	86.8%
SAU801450	MBV103327	27%	87.2%	76.0%
SAU801450	MLP101587	27%	87.1%	88.6%
SAU801450	MTU200050	28%	81.0%	85.7%
SAU801450	NGO101656	32%	83.9%	85.7%
SAU801450	NME200606	33%	87.8%	89.1%
SAU801450	PMU100456	27%	72.5%	65.5%
SAU801450	PRT101565	26%	73.5%	68.7%
SAU801450	PAE204696	30%	72.5%	65.6%
SAU801450	PPU108387	28%	72.5%	67.9%
SAU801450	PSY104456	30%	72.5%	67.9%
SAU801450	SPA102354	31%	43.6%	88.7%
SAU801450	STY103467	27%	73.5%	61.4%
SAU801450	STM103141	27%	73.5%	61.4%
SAU801450	SAU801450	100%	100%	100%
SAU801450	SEP200416	81%	100%	98.7%
SAU801450	SHA102710	46%	9.5%	61.7%
SAU801450	SHA101878	77%	99.0%	94.9%
SAU801450	SMU101483	32%	94.4%	97.0%
SAU801450	SPN400329	31%	95.0%	97.1%
SAU801450	SPY201271	32%	95.9%	97.8%
SAU801450	TPA100697	26%	82.0%	78.5%
SAU801450	VCH100591	25%	73.6%	66.2%
SAU801450	YPS000157	27%	73.5%	62.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801457	ABA105939	32%	48%	40.7%
SAU801457	BAN107872	38%	97.2%	99.5%
SAU801457	BAN102524	39%	97.2%	97.7%
SAU801457	BFR104611	34%	49%	43.2%
SAU801457	BPT101657	33%	50.5%	45.9%
SAU801457	BBU100705	32%	83.5%	82.7%
SAU801457	BCE100092	32%	48.2%	42.4%
SAU801457	BFU102642	31%	51%	43.3%
SAU801457	BMA109607	32%	48.2%	42.7%
SAU801457	CJU100728	27%	63.5%	69.6%
SAU801457	CPN201005	27%	96.2%	96.3%
SAU801457	CTR200077	38%	51.2%	50.2%
SAU801457	CAC103726	25%	65.8%	55.0%
SAU801457	CBO100682	43%	53.5%	48.4%
SAU801457	CDF103451	31%	95.2%	94.6%
SAU801457	CDP101606	38%	49%	41.0%
SAU801457	EBC102069	34%	55%	50.9%
SAU801457	EFA201869	37%	97%	95.1%
SAU801457	ECO100143	32%	50.8%	47.1%
SAU801457	HIN100062	29%	53.5%	49.8%
SAU801457	HPY100632	29%	98.2%	95.3%
SAU801457	KPN308697	33%	50.8%	49.1%
SAU801457	LPN103037	33%	54.2%	53.0%
SAU801457	LMO102472	37%	98.2%	98.7%
SAU801457	MCA100864	33%	40.2%	27.9%
SAU801457	MAV103429	38%	46.8%	40.4%
SAU801457	MBV106184	36%	46.8%	40.4%
SAU801457	MLP101592	38%	47%	40.3%
SAU801457	MTU203852	36%	46.8%	40.4%
SAU801457	NGO100973	31%	58.5%	52.1%
SAU801457	NME200969	30%	58.5%	51.4%
SAU801457	PMU100864	30%	54.8%	46.9%
SAU801457	PRT102520	33%	50.8%	48.2%
SAU801457	PAE204723	35%	52.8%	47.8%
SAU801457	PPU108737	35%	52.8%	48.2%
SAU801457	PSY105160	34%	52.8%	48.0%
SAU801457	SPA104027	34%	55%	51.1%
SAU801457	STY103428	34%	55%	48.9%
SAU801457	STM101254	31%	52.2%	50.4%
SAU801457	SAU801457	100%	100%	100%
SAU801457	SEP200430	56%	100%	100%
SAU801457	SHA101762	59%	100%	100%
SAU801457	SMU100881	39%	98.8%	99.2%
SAU801457	SPN401412	38%	96.8%	96.2%
SAU801457	SPY200644	38%	97.8%	98.0%
SAU801457	TPA100267	41%	48.5%	41.6%
SAU801457	VCH100583	24%	76.5%	72.6%
SAU801457	YPS000784	30%	64.8%	60.9%
SAU801458	BAN104921	44%	95.8%	99.2%
SAU801458	BAN113092	55%	99.5%	99.2%
SAU801458	BPT101918	24%	92.4%	85.8%
SAU801458	BBU100453	22%	79.2%	80.7%
SAU801458	BFU102831	23%	77.1%	71.6%
SAU801458	CPN200894	22%	77.9%	75.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801458	CTR100305	29%	13.4%	10.8%
SAU801458	CAC102137	21%	98.2%	97.2%
SAU801458	CAC100874	24%	99.5%	97.2%
SAU801458	CBO102992	25%	63.2%	58.8%
SAU801458	CBO100320	26%	78.2%	79.7%
SAU801458	CDF102815	24%	79.5%	80.7%
SAU801458	CDP100741	28%	41.1%	38.9%
SAU801458	EBC103431	30%	55%	54.9%
SAU801458	EFA200235	25%	98.7%	96.1%
SAU801458	EFM201493	23%	98.9%	94.3%
SAU801458	ECO204536	26%	45.8%	48.4%
SAU801458	HIN101663	23%	93.4%	95.8%
SAU801458	HPY100417	25%	30.3%	28.8%
SAU801458	KPN301575	27%	51.8%	53.1%
SAU801458	LPN100676	23%	95.8%	97.2%
SAU801458	LMO101281	25%	88.4%	81.3%
SAU801458	MAV103221	23%	69.5%	72.1%
SAU801458	MBV102473	23%	70%	68.7%
SAU801458	MLP100543	22%	69.7%	71.1%
SAU801458	MTU202154	23%	70%	68.7%
SAU801458	NGO100979	26%	48.2%	53.3%
SAU801458	NME200972	26%	47.1%	77.8%
SAU801458	PRT105053	27%	51.6%	52.5%
SAU801458	PAE200841	25%	50%	46.3%
SAU801458	PPU103947	27%	52.9%	50.3%
SAU801458	PSY100988	28%	46.6%	47.3%
SAU801458	SPA104080	28%	41.8%	44.9%
SAU801458	STY104620	28%	41.8%	44.9%
SAU801458	STM101647	22%	92.1%	93.9%
SAU801458	SAU801458	100%	100%	100%
SAU801458	SEP200432	80%	98.2%	98.2%
SAU801458	SHA101761	84%	98.2%	99.2%
SAU801458	SMU101081	23%	99.5%	87.4%
SAU801458	SPN400982	23%	98.4%	87.1%
SAU801458	SPY200370	24%	98.9%	86.9%
SAU801458	VCH100256	26%	75.8%	68.0%
SAU801466	ABA105177	32%	94.8%	93.9%
SAU801466	BAN111428	54%	88.7%	94.0%
SAU801466	BAN105811	58%	94.3%	98.4%
SAU801466	BAN110054	61%	97.4%	97.4%
SAU801466	BAN102027	62%	100%	100%
SAU801466	BFR11345	34%	92.0%	94.1%
SAU801466	BPT101881	33%	92.5%	94.1%
SAU801466	BCE109344	32%	96.6%	94.1%
SAU801466	BFU105028	34%	90.5%	88.5%
SAU801466	BMA108307	31%	97.2%	95.1%
SAU801466	CJU101540	33%	95.1%	95.0%
SAU801466	CPN200800	28%	93.0%	95.3%
SAU801466	CTR200637	32%	92.8%	95.0%
SAU801466	CAC102325	32%	90.7%	94.9%
SAU801466	CBO102194	45%	97.9%	95.9%
SAU801466	CDF101103	32%	90.7%	93.9%
SAU801466	CDP100371	40%	97.7%	96.0%
SAU801466	EBC103288	34%	97.7%	95.0%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801466	EFA201862	57%	100%	100%
SAU801466	EFM101478	55%	98.5%	98.5%
SAU801466	ECO102287	33%	94.8%	94.5%
SAU801466	HIN100186	36%	93.3%	95.2%
SAU801466	HPY100655	33%	96.6%	96.4%
SAU801466	KPN302822	33%	94.8%	94.5%
SAU801466	LPN100018	33%	90.5%	92.0%
SAU801466	LMO100937	56%	100%	100%
SAU801466	MCA100479	33%	94.1%	91.8%
SAU801466	MAV101894	41%	99.7%	96.5%
SAU801466	MBV101353	41%	97.7%	92.7%
SAU801466	MLP100313	42%	97.7%	93.9%
SAU801466	MTU202503	41%	97.7%	95.3%
SAU801466	NGO100523	34%	94.1%	92.3%
SAU801466	NME201788	34%	94.1%	92.3%
SAU801466	PMU100359	33%	94.1%	96.1%
SAU801466	PRT105081	34%	93.8%	93.4%
SAU801466	PAE201680	32%	94.1%	92.8%
SAU801466	PPU102947	31%	97.4%	96.4%
SAU801466	PSY104698	32%	94.1%	92.8%
SAU801466	SPA101187	34%	88.9%	90.4%
SAU801466	STY101051	33%	94.8%	94.5%
SAU801466	SAU801466	100%	100%	100%
SAU801466	SEP200448	86%	100%	100%
SAU801466	SHA101753	86%	100%	100%
SAU801466	SMU100093	56%	100%	100%
SAU801466	SPN401231	57%	98.5%	98.5%
SAU801466	SPY200602	50%	100%	100%
SAU801466	VCH102083	35%	94.8%	94.5%
SAU801466	YPS002330	33%	93.8%	93.4%
SAU801470	ABA104632	32%	94.0%	92%
SAU801470	BAN109070	32%	97.2%	96.0%
SAU801470	BAN113356	44%	97.8%	96.6%
SAU801470	BFR101349	30%	96.9%	95.4%
SAU801470	BPT102476	27%	94.0%	93.1%
SAU801470	BBU100313	27%	90.0%	85.9%
SAU801470	BCE111505	28%	98.4%	94.6%
SAU801470	BFU108244	30%	97.5%	93.9%
SAU801470	BMA107188	28%	97.2%	100%
SAU801470	CJU100503	30%	83.1%	87.2%
SAU801470	CDP100844	31%	97.2%	94.8%
SAU801470	EBC100486	29%	86.2%	99.3%
SAU801470	EFA201824	35%	94.7%	93.3%
SAU801470	EFM100877	33%	96.2%	93.9%
SAU801470	ECO103117	28%	93.4%	92.3%
SAU801470	HIN100861	29%	97.2%	94.2%
SAU801470	HPY100236	27%	90.0%	92.2%
SAU801470	KPN301067	29%	92.8%	97.0%
SAU801470	LMO100122	40%	98.4%	97.2%
SAU801470	MAV102273	32%	96.9%	90.1%
SAU801470	MBV101462	30%	96.9%	92.2%
SAU801470	MLP101355	29%	98.1%	94.8%
SAU801470	MTU200559	30%	96.9%	92.2%
SAU801470	NGO101628	31%	96.9%	95.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801470	NME201998	31%	96.9%	95.1%
SAU801470	PMU100346	29%	95.6%	92.4%
SAU801470	PRT103357	28%	90.9%	90.4%
SAU801470	PAE204567	28%	94.0%	92.9%
SAU801470	PPU109792	27%	95.6%	94.4%
SAU801470	PSY102709	26%	95.6%	94.4%
SAU801470	SPA100483	28%	53.6%	93.5%
SAU801470	STY101489	29%	93.4%	92.3%
SAU801470	STM101744	29%	93.4%	92.3%
SAU801470	SAU801470	100%	100%	100%
SAU801470	SEP200452	76%	99.7%	99.7%
SAU801470	SHA101414	73%	99.7%	100%
SAU801470	TPA100675	24%	86.8%	83.2%
SAU801470	VCH100429	30%	97.5%	89.4%
SAU801470	YPS002150	30%	85.9%	84.8%
SAU801471	ABA102453	44%	95.9%	73.7%
SAU801471	BAN101221	53%	93.4%	98.7%
SAU801471	BAN110701	64%	95.0%	97.5%
SAU801471	BFR100912	35%	93.4%	92.7%
SAU801471	BPT101405	39%	95.4%	88.4%
SAU801471	BCE105003	42%	93.4%	92.6%
SAU801471	BFU111004	38%	95.9%	95.1%
SAU801471	BMA103315	42%	93.4%	92.6%
SAU801471	CJU100293	33%	93.8%	98.3%
SAU801471	CPN200235	32%	94.6%	94.9%
SAU801471	CTR200702	29%	93.4%	92.9%
SAU801471	CAC101072	33%	55.6%	61.8%
SAU801471	CBO102321	27%	72.2%	73.5%
SAU801471	CDP100838	38%	92.5%	90.7%
SAU801471	EBC103973	42%	95.0%	92.8%
SAU801471	ECO103745	41%	93.4%	90.8%
SAU801471	HPY101462	35%	85.5%	88.2%
SAU801471	KPN303531	41%	93.4%	90.8%
SAU801471	LPN103135	38%	95.9%	93.6%
SAU801471	LMO101474	59%	96.3%	98.7%
SAU801471	MCA101080	42%	96.3%	82.8%
SAU801471	MAV102270	34%	96.3%	97.4%
SAU801471	MBV101071	36%	94.6%	94.0%
SAU801471	MLP101352	34%	91.3%	89.1%
SAU801471	MTU200555	36%	94.6%	94.0%
SAU801471	NGO101981	38%	95.9%	93.5%
SAU801471	NME200879	39%	95.9%	93.5%
SAU801471	PMU101686	41%	93.8%	85.4%
SAU801471	PRT102944	40%	95.9%	93.2%
SAU801471	PAE205058	42%	93.4%	89.1%
SAU801471	PPU109250	40%	93.4%	89.1%
SAU801471	PSY103601	42%	93.4%	89.1%
SAU801471	SPA102812	39%	93.4%	90.8%
SAU801471	STY101995	39%	93.4%	90.8%
SAU801471	STM101124	39%	93.4%	90.8%
SAU801471	SAU801471	100%	100%	100%
SAU801471	SEP200454	82%	100%	100%
SAU801471	SHA101413	82%	99.2%	100%
SAU801471	VCH100083	41%	95.9%	89.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801471	YPS000639	42%	95.0%	92.8%
SAU801473	ABA103631	58%	98.9%	98.9%
SAU801473	BAN110875	80%	100%	100%
SAU801473	BFR100422	50%	100%	100%
SAU801473	BPT100124	53%	98.9%	98.9%
SAU801473	BBU100231	32%	98.9%	88.0%
SAU801473	BCE110670	63%	100%	100%
SAU801473	BFU100991	56%	98.9%	98.9%
SAU801473	BMA101790	53%	98.9%	96.7%
SAU801473	CJU100843	53%	98.9%	90.8%
SAU801473	CPN200333	26%	100%	91%
SAU801473	CTR200531	25%	100%	91%
SAU801473	CAC100114	58%	98.9%	97.8%
SAU801473	CBO102675	58%	98.9%	79.5%
SAU801473	CDF102299	58%	98.9%	97.8%
SAU801473	EBC102270	61%	98.9%	98.9%
SAU801473	EFA201883	78%	98.9%	97.8%
SAU801473	EFM100184	79%	98.9%	90.8%
SAU801473	ECO100432	61%	98.9%	98.9%
SAU801473	HIN100410	66%	100%	66.2%
SAU801473	HPY100822	39%	100%	96.8%
SAU801473	KPN302503	58%	100%	100%
SAU801473	LPN101041	37%	94.4%	95.5%
SAU801473	LMO100364	82%	98.9%	97.8%
SAU801473	MCA101444	57%	98.9%	98.9%
SAU801473	MAV101405	39%	98.9%	42.0%
SAU801473	MBV102079	39%	98.9%	41.6%
SAU801473	MLP101029	39%	98.9%	44.5%
SAU801473	MTU202948	39%	98.9%	41.6%
SAU801473	NGO100251	51%	98.9%	100%
SAU801473	NME201722	47%	98.9%	97.8%
SAU801473	NME201276	51%	98.9%	100%
SAU801473	PMU101732	67%	100%	100%
SAU801473	PRT101499	65%	98.9%	92.7%
SAU801473	PAE201803	62%	98.9%	98.9%
SAU801473	PPU111425	61%	98.9%	98.9%
SAU801473	PSY108978	58%	98.9%	98.9%
SAU801473	SPA102996	61%	98.9%	98.9%
SAU801473	STY100727	61%	98.9%	98.9%
SAU801473	STM100440	60%	98.9%	98.9%
SAU801473	SAU801473	100%	100%	100%
SAU801473	SEP200458	100%	100%	100%
SAU801473	SHA101411	96%	100%	100%
SAU801473	SMU100719	78%	98.9%	97.8%
SAU801473	SPN401020	75%	98.9%	97.8%
SAU801473	SPY201144	78%	98.9%	97.8%
SAU801473	TPA100248	34%	94.4%	81.0%
SAU801473	UUR100284	28%	96.7%	66.9%
SAU801473	VCH100270	58%	100%	100%
SAU801473	YPS001873	61%	98.9%	98.9%
SAU801475	ABA100688	42%	98.2%	91.3%
SAU801475	BAN111369	64%	99.8%	100%
SAU801475	BAN112079	75%	100%	100%
SAU801475	BFR10077	45%	28.7%	72.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801475	BPT100007	41%	98.2%	96.5%
SAU801475	BBU100507	33%	74.5%	32.3%
SAU801475	BCE100856	37%	99.1%	96.5%
SAU801475	BFU105505	38%	98.2%	96.9%
SAU801475	BMA102074	39%	98.2%	96.9%
SAU801475	CJU100354	34%	98.6%	97.6%
SAU801475	CPN201006	31%	70.9%	27.7%
SAU801475	CTR200076	33%	69.7%	26.3%
SAU801475	CAC100098	52%	99.8%	99.5%
SAU801475	CBO101866	52%	99.8%	99.3%
SAU801475	CDF102465	52%	100%	99.1%
SAU801475	CDP101065	40%	67.2%	21.6%
SAU801475	EBC102035	41%	99.3%	95.3%
SAU801475	EFA201884	68%	99.8%	99.8%
SAU801475	ECO102462	42%	97.9%	90.1%
SAU801475	HIN100129	38%	98.9%	93.1%
SAU801475	HPY100821	34%	99.5%	97.4%
SAU801475	KPN305977	40%	99.3%	95.3%
SAU801475	LPN101429	41%	97.9%	92.0%
SAU801475	LMO102523	73%	99.8%	99.8%
SAU801475	MCA101523	41%	98.2%	90.9%
SAU801475	MAV102019	40%	99.1%	92.1%
SAU801475	MBV105348	39%	99.1%	92.7%
SAU801475	MLP100852	38%	99.1%	92.9%
SAU801475	MTU201691	39%	99.1%	92.7%
SAU801475	MGE100337	43%	98.9%	97.3%
SAU801475	MPN100366	43%	9.4%	45.2%
SAU801475	NGO101003	40%	98.2%	88.0%
SAU801475	NME200978	40%	98.2%	88.0%
SAU801475	PMU100105	38%	100%	94.1%
SAU801475	PRT102921	40%	97.9%	92.5%
SAU801475	PAE203796	38%	97.9%	90.9%
SAU801475	PPU112339	39%	97.9%	91.0%
SAU801475	PSY106808	41%	68.6%	83.2%
SAU801475	PSY103809	38%	97.9%	90.3%
SAU801475	SPA102739	43%	97.9%	90.2%
SAU801475	STY101715	42%	97.9%	92.4%
SAU801475	SAU801475	100%	100%	100%
SAU801475	SEP200461	93%	100%	100%
SAU801475	SHA101409	93%	100%	100%
SAU801475	SMU101355	62%	99.8%	99.8%
SAU801475	SPN401552	66%	99.8%	99.8%
SAU801475	SPY200248	66%	99.8%	99.8%
SAU801475	TPA100681	32%	98.9%	94.6%
SAU801475	UUR100386	44%	98.9%	98.0%
SAU801475	VCH100750	41%	97.9%	92.3%
SAU801475	YPS003216	41%	40.1%	77.2%
SAU801476	ABA101621	29%	32.2%	89.8%
SAU801476	BAN106697	46%	99.7%	100%
SAU801476	BAN102603	48%	99.7%	99.7%
SAU801476	BFR12241	34%	89.8%	42.7%
SAU801476	BPT100197	34%	88.2%	89.1%
SAU801476	BBU100126	27%	88.0%	32.2%
SAU801476	BCE109984	36%	88.2%	86.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801476	BFU102076	36%	88.2%	88.9%
SAU801476	BMA105447	36%	88.2%	90%
SAU801476	CJU100824	29%	98.2%	96.6%
SAU801476	CPN200436	31%	93.4%	91.0%
SAU801476	CTR200367	31%	88.7%	79.3%
SAU801476	CAC100711	36%	41.4%	52.0%
SAU801476	CBO101243	40%	99.5%	97.4%
SAU801476	CDF100938	31%	98.5%	96.0%
SAU801476	CDP100313	40%	88.2%	32.2%
SAU801476	EBC100136	35%	89.0%	82.0%
SAU801476	EFA201885	49%	48.8%	92.6%
SAU801476	ECO100886	35%	99.7%	99.6%
SAU801476	HIN101192	33%	88.0%	77.6%
SAU801476	HPY100395	28%	87.7%	30.0%
SAU801476	KPN302625	35%	89.3%	96.7%
SAU801476	LPN102947	36%	98.7%	98.9%
SAU801476	LMO101312	51%	99.7%	99.0%
SAU801476	MCA101969	34%	96.2%	93.1%
SAU801476	MAV106579	39%	92.3%	74.6%
SAU801476	MBV101279	39%	92.3%	66.9%
SAU801476	MLP100855	39%	92.3%	74.4%
SAU801476	MTU201609	39%	92.3%	74.4%
SAU801476	NGO100236	34%	86.7%	75.1%
SAU801476	NME201375	34%	86.7%	74.9%
SAU801476	PMU100801	33%	89.0%	79.1%
SAU801476	PRT100600	35%	95.4%	96.8%
SAU801476	PAE203160	36%	94.4%	79.4%
SAU801476	PPU100844	34%	88.5%	76.7%
SAU801476	PSY103125	35%	91.8%	77.4%
SAU801476	SPA102059	34%	94.6%	96.5%
SAU801476	STY102913	35%	99.7%	99.6%
SAU801476	STM103301	35%	99.7%	99.6%
SAU801476	SAU801476	100%	100%	100%
SAU801476	SEP200462	87%	99.7%	99.7%
SAU801476	SHA101408	86%	99.7%	99.7%
SAU801476	SMU101029	42%	88.5%	65.7%
SAU801476	SPN400764	41%	87.7%	64%
SAU801476	SPY200684	42%	91.8%	90.0%
SAU801476	TPA100276	31%	92.6%	61.5%
SAU801476	VCH101885	34%	99.7%	99.6%
SAU801476	YPS001263	35%	88.2%	92.1%
SAU801481	BPT103701	20%	53.9%	77.1%
SAU801481	BCE109402	18%	61.1%	71.8%
SAU801481	LMO100891	27%	9.7%	38.5%
SAU801481	MBV100591	29%	20.8%	45.4%
SAU801481	MTU202815	26%	20.2%	17.4%
SAU801481	MTU202128	26%	24.1%	21.1%
SAU801481	MTU201308	27%	20.0%	18.4%
SAU801481	MTU200968	28%	16.5%	8.5%
SAU801481	MTU201056	32%	18.5%	15.6%
SAU801481	MTU200278	31%	17.9%	10.2%
SAU801481	MTU203538	30%	19.1%	17.0%
SAU801481	MTU200529	30%	17.3%	13.3%
SAU801481	MTU201226	30%	19.1%	17.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801481	MTU203460	31%	17.9%	2.0%
SAU801481	MTU203301	32%	16.7%	18.6%
SAU801481	MTU200575	26%	23.7%	5.0%
SAU801481	PAE205178	31%	21.0%	64.4%
SAU801481	PPU110426	32%	21.0%	64.6%
SAU801481	PSY102383	26%	32.9%	68.6%
SAU801481	SAU801481	100%	100%	100%
SAU801481	SEP200466	41%	90.9%	19.1%
SAU801481	SHA102755	35%	88.9%	47.4%
SAU801484	BFU113561	28%	80.5%	78.9%
SAU801484	CAC101692	38%	76.8%	91.9%
SAU801484	CBO102099	38%	76.8%	89.4%
SAU801484	CDF102732	38%	76.8%	91.9%
SAU801484	CDP100996	26%	82.9%	56.2%
SAU801484	EFA201899	39%	74.4%	84.7%
SAU801484	EFM102447	34%	76.8%	86.3%
SAU801484	LMO101364	59%	87.8%	97.3%
SAU801484	MAV104191	37%	80.5%	76.9%
SAU801484	MBV100688	39%	70.7%	82.5%
SAU801484	MTU203456	39%	70.7%	82.5%
SAU801484	SAU801484	100%	100%	100%
SAU801484	SEP200469	93%	100%	100%
SAU801484	SHA100251	93%	100%	100%
SAU801484	SMU100898	28%	73.2%	87.5%
SAU801484	SPN401457	33%	79.3%	66.3%
SAU801484	SPY200593	28%	73.2%	87.7%
SAU801487	CAC101789	24%	48.7%	72.4%
SAU801487	CAC103687	25%	29.5%	20.0%
SAU801487	EFA203098	21%	29.5%	83.6%
SAU801487	KPN302263	22%	41.9%	46.0%
SAU801487	LPN100452	24%	38.6%	17.1%
SAU801487	SAU801490	83%	91.3%	94.4%
SAU801487	SAU801488	69%	98.0%	97.0%
SAU801487	SAU801487	100%	100%	100%
SAU801487	SEP201760	55%	90.3%	87.2%
SAU801489	BFR101222	29%	7.6%	21.7%
SAU801489	CBO101974	25%	18.5%	50.9%
SAU801489	ECO101555	27%	10.4%	30.6%
SAU801489	HPY101333	25%	20.4%	44.5%
SAU801489	LPN100915	23%	17.8%	21.3%
SAU801489	PRT105801	27%	21.9%	64.6%
SAU801489	SAU801489	100%	100%	100%
SAU801489	SEP204035	51%	6.2%	78.6%
SAU801489	YPS001066	19%	32.4%	48.8%
SAU801490	CAC101789	24%	47.6%	76.6%
SAU801490	LPN100452	24%	39.9%	17.1%
SAU801490	PPU112163	22%	85.8%	29.3%
SAU801490	SAU801487	83%	94.4%	91.3%
SAU801490	SAU801488	63%	95.8%	91.7%
SAU801490	SAU801486	56%	100%	91.8%
SAU801490	SAU801490	100%	100%	100%
SAU801490	SEP201760	51%	97.9%	91.4%
SAU801490	YPS002035	27%	34.7%	28.3%
SAU801491	BAN101808	29%	66.7%	96.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801491	BAN110636	34%	97.6%	98.6%
SAU801491	BFR104661	27%	68.2%	88.3%
SAU801491	BBU100419	30%	43.5%	17.7%
SAU801491	CBO100338	28%	96.9%	98.8%
SAU801491	LMO102271	33%	97.8%	98.8%
SAU801491	MGE100286	23%	26.9%	62.9%
SAU801491	STY104177	31%	19.0%	0.6%
SAU801491	STM103913	32%	19.0%	0.6%
SAU801491	SAU801491	100%	100%	100%
SAU801491	SEP200477	71%	98.8%	99.2%
SAU801491	SHA100281	68%	99.1%	99.8%
SAU801491	TPA100359	51%	6.3%	4.6%
SAU801493	ABA100571	36%	85.3%	69.1%
SAU801493	BAN106396	52%	94.3%	100%
SAU801493	BAN112374	58%	96.7%	97.9%
SAU801493	BFR101094	42%	94.7%	49.4%
SAU801493	BPT105047	36%	91.0%	38.5%
SAU801493	BCE101547	38%	63.3%	57.0%
SAU801493	BFU100864	35%	94.3%	65%
SAU801493	BMA103043	36%	93.5%	41.9%
SAU801493	CJU101613	30%	94.7%	95.7%
SAU801493	CAC103000	45%	95.9%	99.2%
SAU801493	CBO100831	45%	93.5%	96.6%
SAU801493	CDF103251	44%	95.5%	99.2%
SAU801493	CDP101061	39%	93.1%	72.0%
SAU801493	EBC103840	34%	96.7%	79.7%
SAU801493	EFA201902	52%	97.1%	100%
SAU801493	ECO103916	34%	96.7%	79.7%
SAU801493	HIN101172	34%	96.7%	68.1%
SAU801493	HPY101438	30%	92.7%	91.2%
SAU801493	KPN302620	34%	96.7%	79.4%
SAU801493	LPN101167	38%	93.5%	94.0%
SAU801493	LMO102115	58%	98.4%	98.8%
SAU801493	MCA100956	36%	85.3%	64.6%
SAU801493	MAV102015	42%	93.1%	93.5%
SAU801493	MBV105381	38%	93.1%	90.9%
SAU801493	MLP100850	39%	93.5%	90.3%
SAU801493	MTU201689	38%	93.1%	90.9%
SAU801493	NGO101107	38%	94.3%	67.1%
SAU801493	NME201432	37%	97.6%	94.9%
SAU801493	PMU100661	35%	88.2%	64.1%
SAU801493	PRT101163	34%	93.1%	76.0%
SAU801493	PAE203177	33%	94.7%	61.4%
SAU801493	PPU100429	35%	94.7%	66.8%
SAU801493	PSY103194	34%	94.7%	58.1%
SAU801493	SPA102160	36%	85.7%	89.2%
SAU801493	STY103030	34%	96.7%	83.5%
SAU801493	STM102148	32%	95.5%	78.9%
SAU801493	SAU801493	100%	100%	100%
SAU801493	SEP200481	84%	100%	100%
SAU801493	SHA100025	86%	41.2%	100%
SAU801493	SMU100469	51%	95.9%	97.9%
SAU801493	SPN401687	49%	95.9%	97.9%
SAU801493	SPY200268	47%	97.6%	99.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801493	TPA100455	29%	93.1%	92.0%
SAU801493	VCH101160	35%	96.7%	75.4%
SAU801493	YPS000890	35%	96.7%	76.4%
SAU801500	BAN111913	47%	89.7%	89.5%
SAU801500	BAN102220	49%	90.4%	90.1%
SAU801500	CDF102758	24%	85.8%	67.8%
SAU801500	NGO101868	30%	22.5%	45.4%
SAU801500	NME200254	28%	30.1%	77.0%
SAU801500	SAU801500	100%	100%	100%
SAU801500	SEP200495	77%	99.7%	99.7%
SAU801500	SHA101159	78%	99.7%	99.7%
SAU801505	BAN108522	24%	14.0%	92.4%
SAU801505	BAN109710	38%	34.6%	96.2%
SAU801505	BAN100420	36%	97.2%	100%
SAU801505	BAN107027	45%	97.0%	97.6%
SAU801505	BFR106011	42%	97.0%	96.0%
SAU801505	BBU100635	41%	97.6%	97.9%
SAU801505	BCE103506	40%	98.0%	97.4%
SAU801505	BFU110875	40%	98.6%	92.7%
SAU801505	BMA104058	38%	97.0%	97.5%
SAU801505	CPN200514	40%	97.4%	95.7%
SAU801505	CTR200450	41%	97.4%	96.4%
SAU801505	CDP100263	35%	96.8%	99.4%
SAU801505	EBC101990	37%	97.2%	97.4%
SAU801505	EFA202157	51%	97.0%	95.7%
SAU801505	EFM200783	52%	97.0%	95.5%
SAU801505	ECO101820	37%	97.2%	97.4%
SAU801505	HIN100537	40%	96.8%	96.4%
SAU801505	HPY101084	33%	92.9%	95.5%
SAU801505	KPN301980	37%	97.2%	97.4%
SAU801505	LPN101375	36%	97.8%	97.2%
SAU801505	LMO101587	58%	97.2%	97.6%
SAU801505	MAV100342	37%	97.4%	93.4%
SAU801505	MBV100250	37%	97.4%	94.2%
SAU801505	MTU201428	37%	97.4%	94.2%
SAU801505	NGO101240	40%	97.4%	98.1%
SAU801505	NME201469	39%	97.4%	98.1%
SAU801505	PMU101549	40%	96.8%	96.0%
SAU801505	PRT102542	39%	97.2%	97.4%
SAU801505	PAE205434	38%	99.0%	99.6%
SAU801505	PPU102310	40%	97.6%	99.2%
SAU801505	PSY105445	40%	97.8%	96.3%
SAU801505	SPA101656	44%	50.6%	83.5%
SAU801505	STY102250	37%	97.2%	97.4%
SAU801505	SAU801505	100%	100%	100%
SAU801505	SEP200503	89%	99.8%	99.8%
SAU801505	SHA101154	85%	65.6%	100%
SAU801505	SPN401121	44%	97.0%	96.0%
SAU801505	TPA100474	39%	97.4%	94.8%
SAU801505	VCH103615	44%	96.8%	95.2%
SAU801505	YPS003483	38%	99.0%	98.6%
SAU801507	BAN108822	57%	99.3%	99.6%
SAU801507	BAN110449	62%	100%	94.5%
SAU801507	BFR12473	25%	67.4%	62.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801507	BPT104697	28%	91.6%	87.1%
SAU801507	BFU109800	29%	94.0%	43.2%
SAU801507	BMA108112	30%	94.0%	44.1%
SAU801507	CBO101845	58%	98.9%	98.9%
SAU801507	CDP101743	32%	90.5%	88.5%
SAU801507	EFA202421	48%	99.1%	99.6%
SAU801507	EFM200113	48%	99.6%	99.1%
SAU801507	HIN101324	20%	66.8%	58.0%
SAU801507	LPN102297	30%	10.2%	6.7%
SAU801507	MAV101648	30%	91.6%	83.4%
SAU801507	MBV103520	30%	91.6%	82.0%
SAU801507	MTU404234	30%	91.6%	90.3%
SAU801507	PMU100542	22%	38.3%	31.1%
SAU801507	PAE202150	30%	94.2%	46.2%
SAU801507	PPU100890	30%	91.6%	44.7%
SAU801507	PSY102525	31%	94.4%	47.0%
SAU801507	SAU801507	100%	100%	100%
SAU801507	SEP200506	77%	99.8%	100%
SAU801507	SHA100419	79%	83.1%	100%
SAU801507	SMU100841	44%	100%	100%
SAU801507	SPN400310	43%	99.8%	99.8%
SAU801507	SPY201517	44%	99.8%	99.6%
SAU801508	BAN105249	39%	59.9%	59.9%
SAU801508	BAN103335	36%	98.8%	97.1%
SAU801508	CAC101861	29%	98.5%	94.5%
SAU801508	CBO101579	30%	98.8%	98.8%
SAU801508	EBC102003	28%	94.1%	97.8%
SAU801508	EFA202242	30%	95.9%	95.2%
SAU801508	EFM200454	28%	99.4%	98.2%
SAU801508	ECO101291	28%	92.9%	94.6%
SAU801508	LMO101532	28%	99.4%	98.2%
SAU801508	SAU801508	100%	100%	100%
SAU801508	SHA100288	41%	94.1%	99.7%
SAU801508	SMU101053	31%	99.7%	98.5%
SAU801508	SPN401919	34%	79.6%	81.7%
SAU801508	SPY200996	32%	99.7%	98.8%
SAU801511	ABA106023	23%	42.3%	63.5%
SAU801511	BAN111119	61%	11.5%	84.4%
SAU801511	BAN105234	53%	84.6%	97.8%
SAU801511	BAN113086	64%	98.9%	99.1%
SAU801511	BFR101518	51%	98.5%	95.5%
SAU801511	BPT101882	25%	44.0%	66.9%
SAU801511	BBU100560	49%	98.5%	99.4%
SAU801511	BCE101525	65%	98.9%	99.1%
SAU801511	BFU110445	62%	98.9%	99.1%
SAU801511	BMA101484	63%	99.4%	99.4%
SAU801511	CPN200393	47%	99.6%	98.1%
SAU801511	CTR200328	47%	98.7%	97.3%
SAU801511	CAC103227	24%	51.5%	77.7%
SAU801511	CDF100221	24%	47.2%	69.4%
SAU801511	CDP101096	52%	98.7%	96.5%
SAU801511	EBC100628	66%	60.0%	100%
SAU801511	EFA202110	67%	99.6%	99.2%
SAU801511	EFM201302	32%	96.6%	99%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801511	ECO101988	66%	99.4%	99.4%
SAU801511	HIN100532	56%	98.5%	95.9%
SAU801511	HPY200581	21%	45.5%	69.8%
SAU801511	KPN300636	66%	98.3%	100%
SAU801511	LPN102651	26%	43.2%	64.4%
SAU801511	LMO100124	64%	98.9%	98.3%
SAU801511	MAV102693	49%	99.1%	95.5%
SAU801511	MBV102034	50%	93.2%	99.5%
SAU801511	MLP101249	50%	99.4%	96.5%
SAU801511	MTU201811	51%	98.7%	95.9%
SAU801511	NGO102016	54%	99.4%	97.1%
SAU801511	NME200246	54%	99.4%	97.1%
SAU801511	PMU101554	56%	98.5%	95.9%
SAU801511	PRT100074	66%	54.9%	98.8%
SAU801511	PAE201575	25%	41.7%	64.6%
SAU801511	PPU102849	29%	96.4%	99.1%
SAU801511	PSY105462	31%	81.0%	98.5%
SAU801511	SPA105071	66%	99.4%	99.4%
SAU801511	STY103509	66%	99.4%	99.4%
SAU801511	STM100645	21%	60.0%	89.7%
SAU801511	SAU801511	100%	100%	100%
SAU801511	SEP200507	89%	100%	100%
SAU801511	SHA102447	83%	100%	100%
SAU801511	SHA100561	91%	100%	98.7%
SAU801511	SPN400335	66%	98.9%	98.5%
SAU801511	SPY102341	66%	16.0%	97.4%
SAU801511	TPA100327	50%	99.4%	97.1%
SAU801511	VCH103617	55%	99.4%	97.1%
SAU801511	YPS002961	68%	99.1%	99.1%
SAU801513	BAN108627	35%	95.1%	96.9%
SAU801513	BAN111615	36%	95.1%	96.6%
SAU801513	BFR11644	24%	43.6%	36.4%
SAU801513	CAC100965	31%	94.5%	96.9%
SAU801513	CBO101390	31%	94.5%	93.7%
SAU801513	CDF101701	20%	91.7%	92.3%
SAU801513	EFA202281	30%	96.3%	99.1%
SAU801513	EFM101954	28%	50%	85.9%
SAU801513	LMO100864	27%	94.8%	95.1%
SAU801513	MBV104087	21%	40.5%	39.2%
SAU801513	MTU202534	21%	40.5%	39.2%
SAU801513	PAE203357	21%	42.3%	43.5%
SAU801513	PPU111785	22%	26.4%	51.7%
SAU801513	SAU801513	100%	100%	100%
SAU801513	SEP200509	76%	99.7%	100%
SAU801513	SHA100407	70%	99.7%	100%
SAU801513	SPN401597	26%	94.5%	97.5%
SAU801513	SPY200963	24%	93.6%	96.2%
SAU801514	BAN109993	70%	97.9%	98.6%
SAU801514	SAU801514	100%	100%	100%
SAU801514	SEP200880	87%	100%	100%
SAU801514	SHA100406	88%	100%	100%
SAU801515	BAN113643	43%	99.5%	98.9%
SAU801515	BAN110237	52%	99.5%	98.9%
SAU801515	BFR11470	36%	97.9%	98.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801515	CPN200222	32%	98.3%	99.0%
SAU801515	CTR200670	30%	98.3%	93.9%
SAU801515	CDF100259	33%	69.6%	84.8%
SAU801515	CDP100400	39%	17.2%	22.2%
SAU801515	EFA201273	48%	99.8%	99.1%
SAU801515	LMO102719	56%	99.8%	99.0%
SAU801515	MBV104450	33%	46.9%	12.1%
SAU801515	MTU202181	33%	46.9%	12.1%
SAU801515	MGE100278	33%	97.6%	97.4%
SAU801515	SAU801515	100%	100%	100%
SAU801515	SEP200881	68%	100%	100%
SAU801515	SHA100405	70%	100%	100%
SAU801516	ABA101027	41%	99.7%	99.7%
SAU801516	BAN105255	43%	85.0%	90.3%
SAU801516	BAN110745	69%	100%	100%
SAU801516	BFR11469	41%	98.2%	47.0%
SAU801516	BFU108548	43%	96.3%	96.4%
SAU801516	CPN200731	43%	97.9%	47.8%
SAU801516	CTR200608	43%	97.9%	47.8%
SAU801516	CBO101881	46%	99.1%	99.7%
SAU801516	CDF100258	44%	93.9%	97.8%
SAU801516	EFA201271	56%	100%	49.6%
SAU801516	ECO100412	25%	75.2%	36.9%
SAU801516	KPN304382	26%	74.9%	75.2%
SAU801516	LMO101318	65%	100%	100%
SAU801516	MAV101952	41%	96.3%	93.2%
SAU801516	PRT104897	25%	74.3%	36.2%
SAU801516	PAE202246	43%	91.1%	88.9%
SAU801516	PSY101642	26%	70.9%	71.9%
SAU801516	SPA102152	22%	70.0%	72.5%
SAU801516	STY100985	23%	70.0%	69.4%
SAU801516	SAU801516	100%	100%	100%
SAU801516	SEP200882	89%	100%	100%
SAU801516	SHA100929	87%	75.8%	96.9%
SAU801516	SMU100292	40%	99.1%	98.0%
SAU801516	SPN401050	45%	97.9%	97.0%
SAU801516	SPY200776	44%	95.1%	94.9%
SAU801516	TPA100815	24%	73.1%	36.7%
SAU801516	VCH100873	24%	74.0%	36.7%
SAU801516	YPS003520	25%	75.2%	74.5%
SAU801517	ABA101029	33%	95.8%	98.4%
SAU801517	BAN100062	46%	97.9%	99.1%
SAU801517	BAN105443	55%	97.9%	97.6%
SAU801517	BFU114632	32%	96.7%	97.9%
SAU801517	CJU100290	23%	49.7%	33.8%
SAU801517	EFA103865	45%	96.1%	97.9%
SAU801517	LMO102895	55%	97.6%	97.9%
SAU801517	PPU103038	33%	95.8%	97.5%
SAU801517	SAU801517	100%	100%	100%
SAU801517	SEP200883	81%	99.1%	98.5%
SAU801517	SHA100928	82%	99.7%	99.1%
SAU801517	SPN401051	31%	96.4%	99.1%
SAU801518	BAN105760	32%	88.4%	93.5%
SAU801518	BAN100264	48%	99.2%	99.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801518	BFR11786	32%	96.6%	99.3%
SAU801518	BFR10034	32%	96.6%	98.9%
SAU801518	EFA201252	48%	99.2%	99.4%
SAU801518	LMO100523	46%	99.2%	99.4%
SAU801518	SAU801518	100%	100%	100%
SAU801518	SEP200884	70%	100%	100%
SAU801518	SHA100927	70%	100%	95.0%
SAU801518	SMU101480	36%	99.8%	78.5%
SAU801518	SPY200778	35%	99.8%	77.9%
SAU801521	ABA101203	40%	89.4%	87.8%
SAU801521	BAN104007	40%	90.1%	98.9%
SAU801521	BAN101637	45%	95.9%	94.9%
SAU801521	BFR11516	38%	64.2%	65.5%
SAU801521	BPT101397	37%	91.5%	89.4%
SAU801521	BCE105992	38%	97.6%	97.3%
SAU801521	BFU102595	41%	89.4%	88.7%
SAU801521	BMA106450	38%	91.5%	90.8%
SAU801521	CJU101550	42%	76.1%	78.6%
SAU801521	CPN201106	34%	66.9%	70.2%
SAU801521	CTR200905	32%	84.0%	83.2%
SAU801521	CAC100312	44%	97.6%	99.0%
SAU801521	CBO103178	44%	92.8%	91.8%
SAU801521	CDF101808	50%	76.8%	76.9%
SAU801521	EBC103067	42%	90.8%	90.3%
SAU801521	EFA202196	49%	87.7%	88.7%
SAU801521	EFM100682	48%	81.2%	89.8%
SAU801521	ECO100413	42%	90.8%	90.3%
SAU801521	HIN101407	43%	87.4%	87.5%
SAU801521	HPY100913	35%	83.3%	80.9%
SAU801521	KPN303447	42%	90.8%	90.3%
SAU801521	LPN101272	41%	82.3%	83.3%
SAU801521	LMO102568	52%	97.6%	95.9%
SAU801521	MCA102758	38%	94.5%	81.9%
SAU801521	MAV101215	32%	71.0%	53.0%
SAU801521	MBV101130	34%	70.0%	64.7%
SAU801521	MTU203338	34%	70.0%	57.1%
SAU801521	NGO100628	41%	86.0%	83.6%
SAU801521	NME202061	41%	86.0%	83.6%
SAU801521	PMU100533	40%	96.9%	96.3%
SAU801521	PRT101971	40%	96.2%	92.5%
SAU801521	PAE204040	41%	88.7%	88.5%
SAU801521	PPU108239	39%	90.8%	90.5%
SAU801521	PSY102175	40%	90.8%	90.5%
SAU801521	SPA103652	36%	90.8%	90.3%
SAU801521	STY100443	42%	90.8%	90.3%
SAU801521	SAU801521	100%	100%	100%
SAU801521	SEP200890	68%	100%	100%
SAU801521	SHA100008	69%	100%	100%
SAU801521	SMU100705	44%	95.9%	97.9%
SAU801521	SPN401086	45%	88.4%	89.7%
SAU801521	SPY201152	47%	89.1%	90.3%
SAU801521	VCH100874	44%	92.2%	92.5%
SAU801521	YPS001917	41%	91.1%	88.6%
SAU801523	ABA105166	23%	98.9%	97.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801523	BAN107094	37%	96.6%	98.2%
SAU801523	BAN107312	41%	98.2%	97.1%
SAU801523	BFR10436	22%	98.2%	99.8%
SAU801523	BCE105570	35%	36.0%	87.3%
SAU801523	BFU106862	32%	97.8%	94.1%
SAU801523	BMA103262	32%	98.2%	85.1%
SAU801523	CJU100294	35%	74.4%	85.8%
SAU801523	CPN200772	35%	97.8%	97.5%
SAU801523	CTR200597	32%	99.1%	98.1%
SAU801523	CAC102940	37%	98.2%	98.7%
SAU801523	CBO103748	39%	84.5%	95.0%
SAU801523	CDF101807	35%	98.0%	97.5%
SAU801523	CDP100939	28%	91.5%	90.1%
SAU801523	EBC102031	36%	98.0%	95.4%
SAU801523	EFA202200	42%	99.3%	98.7%
SAU801523	EFM100680	42%	98.4%	98.4%
SAU801523	ECO102460	35%	98.0%	95.6%
SAU801523	HIN100377	37%	92.4%	94.1%
SAU801523	HPY100965	42%	17.3%	63.6%
SAU801523	HPY100255	34%	98.4%	99.0%
SAU801523	KPN304083	35%	97.8%	94.0%
SAU801523	LPN102596	32%	98.2%	98.2%
SAU801523	LMO100760	39%	97.8%	96.9%
SAU801523	MCA102830	23%	98.9%	87.8%
SAU801523	MAV100804	28%	92.6%	90.4%
SAU801523	MBV104380	28%	81.6%	79.3%
SAU801523	MLP101180	29%	92.6%	88.6%
SAU801523	MTU201093	28%	81.6%	79.3%
SAU801523	NGO101103	34%	99.1%	98.6%
SAU801523	NME201434	34%	99.8%	97.6%
SAU801523	PMU100168	35%	99.1%	99.3%
SAU801523	PRT103272	34%	98.0%	94.4%
SAU801523	PAE203774	33%	92.4%	89.3%
SAU801523	PPU101396	36%	91.5%	88.5%
SAU801523	PSY103770	35%	92.6%	88.8%
SAU801523	SPA100549	38%	76.9%	91.8%
SAU801523	STY101689	35%	98.7%	97.8%
SAU801523	STM101426	35%	98.7%	97.8%
SAU801523	SAU801523	100%	100%	100%
SAU801523	SEP200892	76%	100%	100%
SAU801523	SHA100991	72%	99.3%	99.3%
SAU801523	SMU100701	41%	99.1%	98.9%
SAU801523	SPN401088	42%	99.1%	98.7%
SAU801523	SPY201154	39%	99.8%	99.8%
SAU801523	VCH100753	34%	95.7%	95.5%
SAU801523	YPS003204	33%	98.7%	95.6%
SAU801526	ABA100122	49%	99.8%	98.0%
SAU801526	BAN102154	62%	97.6%	99.5%
SAU801526	BAN113444	66%	99.1%	99.3%
SAU801526	BFR11613	50%	98.4%	87.9%
SAU801526	BFR11898	53%	98.0%	87.5%
SAU801526	BPT100134	51%	98.2%	96.9%
SAU801526	BCE104481	53%	97.8%	96.5%
SAU801526	BFU115826	52%	97.8%	96.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801526	BMA101045	52%	97.8%	96.5%
SAU801526	CJU101214	51%	98.4%	99.5%
SAU801526	CPN200575	56%	98.0%	97.1%
SAU801526	CTR200394	56%	98.2%	96.7%
SAU801526	CAC103617	60%	98.2%	98.9%
SAU801526	CBO103874	56%	98.0%	98.4%
SAU801526	CDF101399	55%	98.0%	97.4%
SAU801526	CDP100825	47%	95.1%	71.9%
SAU801526	EBC102634	49%	69.8%	99.0%
SAU801526	EFA200245	58%	99.3%	98.2%
SAU801526	EFM201807	58%	98.9%	97.2%
SAU801526	ECO103186	53%	98.2%	98.2%
SAU801526	HIN100951	54%	99.6%	99.8%
SAU801526	HPY100366	51%	98.4%	96.5%
SAU801526	KPN308876	52%	98.2%	98.2%
SAU801526	LPN102993	53%	98.2%	98.7%
SAU801526	LMO101165	68%	99.3%	98.7%
SAU801526	MCA102208	50%	98.0%	98.2%
SAU801526	MAV103606	49%	97.3%	61.9%
SAU801526	MBV101167	46%	98.0%	67.7%
SAU801526	MLP100439	47%	93.1%	69.9%
SAU801526	MTU202464	46%	98.0%	67.7%
SAU801526	MPN100138	21%	33.7%	47.6%
SAU801526	NGO101616	53%	98.0%	97.1%
SAU801526	NME200552	52%	98.0%	97.1%
SAU801526	PMU101091	54%	99.6%	99.8%
SAU801526	PRT100504	52%	98.2%	98.4%
SAU801526	PAE205431	54%	98.4%	93.6%
SAU801526	PPU102301	54%	98.4%	93.6%
SAU801526	PSY108097	51%	98.0%	98.4%
SAU801526	SPA101601	52%	98.2%	99.3%
SAU801526	STY101665	52%	98.2%	98.2%
SAU801526	STM102307	52%	98.2%	98.2%
SAU801526	SAU801526	100%	100%	100%
SAU801526	SEP200908	88%	99.6%	99.3%
SAU801526	SHA100988	88%	99.8%	99.8%
SAU801526	SMU100533	59%	96.9%	97.1%
SAU801526	SPN400385	56%	97.6%	96.9%
SAU801526	SPY201344	59%	97.6%	97.1%
SAU801526	VCH100291	54%	98.2%	98.7%
SAU801526	YPS003128	54%	98.2%	98.2%
SAU801529	SAU801529	100%	100%	100%
SAU801530	EFM102296	36%	26.2%	98.0%
SAU801530	LPN102745	26%	56.5%	28.1%
SAU801530	SAU801530	100%	100%	100%
SAU801530	SEP200922	73%	97.9%	53.0%
SAU801530	SHA100985	60%	97.9%	53.1%
SAU801530	SPN200817	50%	24.1%	76.7%
SAU801530	SPY100203	31%	34.6%	90.4%
SAU801537	ABA100533	28%	20.7%	29.6%
SAU801537	BAN111655	51%	88.7%	99.1%
SAU801537	BAN103769	52%	97.0%	96.7%
SAU801537	BFR10109	42%	97.2%	98.6%
SAU801537	BPT101499	38%	98.3%	96.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801537	BCE108544	37%	97.2%	96.0%
SAU801537	BFU101740	38%	97.8%	96.5%
SAU801537	BMA104071	39%	97.2%	96.0%
SAU801537	CBO100281	49%	97.8%	95.5%
SAU801537	EBC102214	41%	97.0%	96.4%
SAU801537	ECO102841	42%	97.0%	96.4%
SAU801537	HIN100446	29%	16.0%	20.7%
SAU801537	HPY100369	30%	23.7%	11.4%
SAU801537	KPN302317	42%	97.0%	96.4%
SAU801537	LPN102134	43%	96.7%	96.4%
SAU801537	LMO101246	51%	97.5%	97.2%
SAU801537	MCA103134	37%	97.0%	95.6%
SAU801537	MAV101181	38%	97.8%	96.5%
SAU801537	MBV103611	37%	97.2%	92.9%
SAU801537	MLP100525	36%	97.5%	96.2%
SAU801537	MTU202177	37%	97.2%	92.9%
SAU801537	NGO101406	40%	97.2%	95.9%
SAU801537	NME200699	39%	97.2%	95.4%
SAU801537	PRT102357	40%	97.0%	96.4%
SAU801537	PAE205210	40%	96.7%	96.1%
SAU801537	PPU102197	40%	97.0%	96.4%
SAU801537	PSY103024	42%	89.8%	90%
SAU801537	SPA100601	41%	80.4%	94.8%
SAU801537	STY104162	41%	97.0%	96.4%
SAU801537	SAU801537	100%	100%	100%
SAU801537	SEP200945	76%	100%	100%
SAU801537	SHA100726	78%	66.1%	100%
SAU801537	YPS000179	41%	97.0%	96.2%
SAU801552	BAN111435	27%	10.4%	98.6%
SAU801552	BAN111478	36%	61.2%	99.8%
SAU801552	BAN101568	36%	95.5%	97.6%
SAU801552	BAN101801	44%	68.0%	99.8%
SAU801552	BAN109554	36%	96.8%	96.5%
SAU801552	BAN100977	45%	84.9%	98.2%
SAU801552	BAN112527	41%	97.7%	97.1%
SAU801552	BAN109997	42%	99.1%	98.4%
SAU801552	EFA200268	37%	95.8%	95.9%
SAU801552	EFM202382	38%	94.5%	93.6%
SAU801552	LMO101809	40%	99.4%	96.0%
SAU801552	SAU801552	100%	100%	100%
SAU801552	SEP200968	84%	99.6%	98.6%
SAU801552	SHA101019	79%	99.1%	99.9%
SAU801552	SMU100731	33%	97.4%	98.3%
SAU801552	SPN401516	32%	95.9%	97.7%
SAU801552	SPY102094	27%	28.1%	100%
SAU801554	BAN103376	41%	94.9%	97.7%
SAU801554	BAN106361	45%	98.5%	98.5%
SAU801554	EFA200380	41%	97.8%	93.8%
SAU801554	LMO100045	51%	98.5%	95.7%
SAU801554	SAU801554	100%	100%	100%
SAU801554	SEP200986	85%	99.3%	97.1%
SAU801554	SHA101073	83%	99.3%	96.4%
SAU801557	BAN104029	74%	91.2%	98.5%
SAU801557	BAN112485	72%	99.3%	99.0%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801557	BFR10491	33%	86.8%	92.4%
SAU801557	BFU108696	48%	13.2%	11.6%
SAU801557	CPN200013	32%	87.5%	89.1%
SAU801557	CTR200902	33%	87.5%	90.6%
SAU801557	CAC100742	27%	54.4%	57.4%
SAU801557	CBO101029	24%	77.4%	82.3%
SAU801557	CDF102470	40%	94.6%	97.1%
SAU801557	EBC100541	26%	33.8%	93.5%
SAU801557	EFA201039	70%	100%	99.7%
SAU801557	EFM200108	69%	97.6%	96.3%
SAU801557	ECO102118	32%	86.8%	90.9%
SAU801557	KPN302671	34%	86.8%	91.2%
SAU801557	LMO101207	71%	98.3%	98.0%
SAU801557	MAV102930	29%	61.1%	84.6%
SAU801557	MBV100817	31%	81.4%	86.9%
SAU801557	MLP101143	31%	81.4%	86.9%
SAU801557	MTU200667	31%	81.4%	86.9%
SAU801557	MGE100240	36%	94.6%	95.2%
SAU801557	MPN100508	41%	94.6%	96.9%
SAU801557	PRT103078	34%	86.8%	92.2%
SAU801557	SPA101840	33%	80.4%	85.5%
SAU801557	STY104295	33%	86.8%	90.9%
SAU801557	STM104044	33%	86.8%	90.9%
SAU801557	SAU801557	100%	100%	100%
SAU801557	SEP200992	86%	100%	100%
SAU801557	SHA101070	85%	100%	99.0%
SAU801557	UUR100308	44%	100%	98.0%
SAU801557	VCH102325	33%	87.2%	90.9%
SAU801557	YPS001104	32%	86.8%	90.9%
SAU801558	BAN101728	35%	95.5%	100%
SAU801558	BAN104506	45%	95.5%	98.6%
SAU801558	EFA202379	44%	98.4%	97.8%
SAU801558	EFM202075	45%	98.4%	99.3%
SAU801558	LMO101935	42%	96.0%	98.9%
SAU801558	SAU801558	100%	100%	100%
SAU801558	SEP200994	82%	99.6%	99.8%
SAU801558	SHA101069	81%	100%	100%
SAU801558	SMU101455	44%	98.7%	99.1%
SAU801558	SPN400670	43%	98.7%	99.1%
SAU801558	SPY201279	41%	98.7%	99.1%
SAU801558	UUR100589	34%	96.4%	96.8%
SAU801565	BAN102454	62%	99.1%	100%
SAU801565	BAN109844	74%	99.1%	99.3%
SAU801565	BFR10455	50%	97.8%	96.1%
SAU801565	BBU100370	49%	97.8%	96.4%
SAU801565	CAC103604	68%	99.4%	99.1%
SAU801565	CBO100196	69%	99.6%	99.1%
SAU801565	CDP100533	48%	98.5%	97.8%
SAU801565	MAV106180	50%	99.8%	92.5%
SAU801565	MBV102613	51%	99.8%	94.4%
SAU801565	MLP100499	48%	99.8%	98.7%
SAU801565	MTU202321	51%	99.8%	98.7%
SAU801565	MGE100255	42%	97.8%	98.0%
SAU801565	MPN100482	41%	98.1%	97.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801565	SAU801565	100%	100%	100%
SAU801565	SEP201018	93%	100%	100%
SAU801565	SHA101653	92%	100%	100%
SAU801565	TPA100664	45%	98.9%	98.9%
SAU801565	UUR100498	52%	98.9%	96.6%
SAU801567	ABA104706	41%	98.0%	89.2%
SAU801567	BAN106100	53%	95.7%	99.7%
SAU801567	BAN104384	66%	98.7%	98.0%
SAU801567	BFR10151	44%	98.3%	99.7%
SAU801567	BPT102612	36%	97.7%	98.3%
SAU801567	BBU100659	37%	96.3%	99.0%
SAU801567	BCE103799	39%	98.0%	97.7%
SAU801567	BFU101300	38%	98.0%	97.7%
SAU801567	BMA106167	40%	98.0%	97.7%
SAU801567	CJU100617	33%	96.3%	97.9%
SAU801567	CAC100901	50%	97.0%	97.6%
SAU801567	CBO100020	51%	97.0%	98.0%
SAU801567	CDF104210	56%	97.0%	98.3%
SAU801567	CDP100545	39%	90.0%	100%
SAU801567	EBC102411	38%	80.9%	98.0%
SAU801567	EFA200395	63%	99.3%	99%
SAU801567	EFM200497	62%	99.7%	99.7%
SAU801567	ECO102517	39%	97.3%	97.0%
SAU801567	HIN100012	40%	97.3%	96.7%
SAU801567	HPY100512	32%	98.7%	98.0%
SAU801567	KPN303149	40%	99.3%	99.7%
SAU801567	LPN101153	39%	96.3%	97.6%
SAU801567	LMO100968	58%	98.3%	98.0%
SAU801567	MCA101618	40%	97.0%	91.2%
SAU801567	MAV106432	44%	98.3%	100%
SAU801567	MBV102618	43%	98.3%	97.1%
SAU801567	MLP100395	42%	98.3%	99.3%
SAU801567	MTU202328	43%	98.3%	100%
SAU801567	MPN100274	24%	90.0%	93.1%
SAU801567	NGO101005	38%	97.0%	89.8%
SAU801567	NME200824	38%	97.0%	94.8%
SAU801567	PMU100060	38%	97.3%	95.4%
SAU801567	PRT105132	39%	97.3%	96.7%
SAU801567	PAE200770	38%	97.0%	95.1%
SAU801567	PPU107911	39%	97.0%	96.7%
SAU801567	PSY102356	40%	98.0%	97.7%
SAU801567	SPA103313	39%	97.3%	97.0%
SAU801567	STY102109	39%	97.3%	97.0%
SAU801567	SAU801567	100%	100%	100%
SAU801567	SEP201022	94%	100%	100%
SAU801567	SHA101651	92%	100%	100%
SAU801567	SMU101127	61%	97.0%	97.3%
SAU801567	SPN400871	62%	97.7%	98.0%
SAU801567	SPY200342	60%	98.3%	99.0%
SAU801567	TPA100535	30%	97.0%	97.5%
SAU801567	UUR100496	34%	97.0%	96.4%
SAU801567	VCH102424	40%	97.3%	90.2%
SAU801567	YPS002232	38%	97.3%	96.4%
SAU801572	ECO101986	22%	65.1%	43.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801572	SPA101417	27%	41.8%	43.4%
SAU801572	STY102068	27%	41.8%	43.9%
SAU801572	SAU801572	100%	100%	100%
SAU801572	SEP201028	46%	100%	100%
SAU801572	SHA101646	42%	100%	100%
SAU801580	ABA101828	59%	82.5%	100%
SAU801580	BAN105420	62%	40.5%	99.6%
SAU801580	BAN112806	79%	57.5%	100%
SAU801580	BAN101659	75%	99.5%	99.8%
SAU801580	BFR104209	60%	99.2%	100%
SAU801580	BPT102710	57%	99.5%	99.8%
SAU801580	BBU100517	61%	100%	100%
SAU801580	BCE103385	55%	99.5%	100%
SAU801580	BFU102634	55%	99.5%	100%
SAU801580	BMA105956	55%	96.1%	93.8%
SAU801580	CJU100698	57%	98.4%	99.7%
SAU801580	CPN200248	57%	99.7%	98.9%
SAU801580	CTR200665	58%	98.9%	97.9%
SAU801580	CAC101902	64%	99.8%	100%
SAU801580	CBO102574	64%	99.5%	99.8%
SAU801580	CDF100724	66%	99.5%	99.8%
SAU801580	CDP101465	60%	99.8%	99.3%
SAU801580	EBC103112	37%	95.6%	96.3%
SAU801580	EFA200573	77%	99.8%	100%
SAU801580	EFM201964	82%	8.5%	100%
SAU801580	ECO100014	55%	99.3%	99.7%
SAU801580	HIN101209	53%	99.5%	99.8%
SAU801580	HPY100107	55%	99.7%	98.9%
SAU801580	KPN301135	54%	94.9%	99.0%
SAU801580	LPN102089	55%	100%	100%
SAU801580	LMO100117	76%	100%	99.7%
SAU801580	MCA103113	55%	99.3%	99.8%
SAU801580	MAV101249	63%	76.2%	100%
SAU801580	MBV102185	58%	100%	99.7%
SAU801580	MLP101485	58%	100%	99.7%
SAU801580	MTU200349	58%	100%	99.7%
SAU801580	MGE100311	57%	95.2%	98.8%
SAU801580	MPN100407	56%	95.2%	98.8%
SAU801580	NGO101449	56%	99.8%	100%
SAU801580	NME200678	56%	99.8%	100%
SAU801580	PMU100736	57%	99.5%	99.8%
SAU801580	PRT105582	53%	100%	100%
SAU801580	PAE204757	56%	99.5%	99.8%
SAU801580	PPU100111	56%	100%	100%
SAU801580	PSY104756	55%	99.3%	99.7%
SAU801580	SPA100920	53%	99.3%	99.7%
SAU801580	STY100388	55%	99.3%	99.7%
SAU801580	STM100061	55%	99.3%	99.7%
SAU801580	SAU801580	100%	100%	100%
SAU801580	SEP201054	90%	100%	99.8%
SAU801580	SHA100529	91%	100%	99.8%
SAU801580	SMU101376	72%	99.7%	99.3%
SAU801580	SPN400455	74%	98.9%	99.8%
SAU801580	SPY201356	74%	98.9%	99.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801580	TPA100214	58%	100%	100%
SAU801580	UUR100341	56%	98.4%	99.2%
SAU801580	VCH100839	55%	99.8%	100%
SAU801580	YPS000806	54%	99.3%	99.7%
SAU801593	BAN110580	35%	93.8%	96.8%
SAU801593	BAN111416	42%	93.8%	95.2%
SAU801593	CAC102263	43%	87.6%	89.4%
SAU801593	CBO100870	36%	92.3%	89%
SAU801593	CDF103337	40%	94.3%	96.3%
SAU801593	EFA200252	40%	88.7%	86.7%
SAU801593	EFM200106	37%	88.7%	87.2%
SAU801593	LMO100476	39%	88.1%	88.5%
SAU801593	MGE100245	32%	63.4%	41.4%
SAU801593	MPN100500	32%	65.5%	42.6%
SAU801593	SAU801593	100%	100%	100%
SAU801593	SEP201082	81%	100%	100%
SAU801593	SHA101365	79%	100%	100%
SAU801593	SMU101104	35%	94.8%	92.4%
SAU801593	SPN401589	36%	89.2%	86.8%
SAU801593	SPY200226	32%	92.8%	91.4%
SAU801593	TPA100732	32%	63.9%	68.1%
SAU801596	ABA104791	36%	92.5%	95.4%
SAU801596	BAN105708	35%	98.9%	98.9%
SAU801596	BAN100439	43%	98.9%	98.6%
SAU801596	BFR100940	32%	91.8%	98.4%
SAU801596	BPT102959	32%	98.5%	95.8%
SAU801596	BCE113860	30%	94.4%	93.3%
SAU801596	BFU107002	32%	92.9%	88.2%
SAU801596	BMA107935	33%	94.4%	93.3%
SAU801596	CJU100373	33%	98.9%	98.9%
SAU801596	CPN200802	29%	91.4%	49.5%
SAU801596	CTR200639	30%	91.0%	48.7%
SAU801596	CAC100326	28%	93.7%	68.1%
SAU801596	CBO101162	30%	90.7%	94.6%
SAU801596	CDF100361	32%	95.1%	94.8%
SAU801596	CDP100373	27%	98.9%	94.5%
SAU801596	EBC103139	29%	57.1%	87.6%
SAU801596	EFA201865	32%	95.9%	94.8%
SAU801596	ECO101660	31%	95.9%	95.8%
SAU801596	HIN100636	31%	98.5%	97.4%
SAU801596	HPY101232	34%	90.7%	90.5%
SAU801596	KPN301549	34%	95.1%	96.1%
SAU801596	LPN102392	32%	91.8%	92.5%
SAU801596	LMO101551	46%	99.3%	98.9%
SAU801596	MCA103619	32%	95.5%	98.5%
SAU801596	MAV103673	24%	95.5%	98.1%
SAU801596	MBV100973	25%	97.0%	96.6%
SAU801596	MLP100312	24%	97.0%	94.2%
SAU801596	MTU202515	25%	97.0%	96.3%
SAU801596	NGO100780	32%	94.4%	91.0%
SAU801596	NME201966	33%	94.4%	93.7%
SAU801596	PMU101271	32%	91.8%	93.3%
SAU801596	PRT105310	30%	94.8%	94.9%
SAU801596	PAE200243	27%	94.8%	93.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801596	PPU111361	30%	94.8%	94.3%
SAU801596	PSY102591	31%	94.4%	93.3%
SAU801596	SPA104338	34%	91.4%	91.5%
SAU801596	STY101862	34%	91.4%	91.5%
SAU801596	SAU801596	100%	100%	100%
SAU801596	SEP201086	71%	100%	99.6%
SAU801596	SHA101362	67%	99.6%	99.6%
SAU801596	SMU100089	33%	98.9%	96.5%
SAU801596	SPN401233	34%	92.5%	91.2%
SAU801596	SPY201222	34%	95.1%	93.8%
SAU801596	VCH100056	32%	91.8%	89.9%
SAU801596	YPS002545	35%	99.6%	97.8%
SAU801597	BAN105757	48%	99.5%	100%
SAU801597	BAN111582	52%	100%	100%
SAU801597	EFA200249	48%	100%	100%
SAU801597	EFM202278	48%	98.9%	99.5%
SAU801597	LMO102317	49%	100%	100%
SAU801597	SAU801597	100%	100%	100%
SAU801597	SEP201087	84%	100%	100%
SAU801597	SHA101361	83%	100%	100%
SAU801597	SMU101110	46%	98.9%	99.2%
SAU801597	SPN401592	48%	100%	100%
SAU801597	SPY200223	47%	98.9%	99.2%
SAU801597	UUR100473	29%	96.2%	95.8%
SAU801599	ABA100279	24%	84.6%	72.8%
SAU801599	BAN101650	46%	89.5%	88.9%
SAU801599	BAN108836	47%	99.6%	98.7%
SAU801599	BFR104094	28%	81.6%	87.2%
SAU801599	BPT102655	20%	68.0%	31.7%
SAU801599	BBU100587	35%	98.7%	89.1%
SAU801599	BBU100374	36%	98.7%	98.7%
SAU801599	BCE100924	30%	96.5%	90.2%
SAU801599	BFU109681	30%	96.5%	76.0%
SAU801599	BMA103603	29%	96.5%	90.8%
SAU801599	CJU100106	33%	99.6%	98.7%
SAU801599	CPN200522	22%	68.4%	60.6%
SAU801599	CAC100045	40%	99.6%	99.1%
SAU801599	CBO101197	40%	99.6%	99.1%
SAU801599	CDF101106	43%	96.9%	96.1%
SAU801599	CDP102826	24%	78.5%	83.7%
SAU801599	EBC102139	52%	98.7%	96.6%
SAU801599	EFA200856	47%	99.6%	98.7%
SAU801599	EFM202072	46%	99.6%	98.7%
SAU801599	ECO100159	54%	99.6%	97.8%
SAU801599	HIN101188	53%	99.6%	99.1%
SAU801599	HPY100087	36%	99.6%	98.3%
SAU801599	KPN306028	52%	99.6%	97.8%
SAU801599	LMO102202	50%	99.6%	99.1%
SAU801599	MBV102135	30%	99.6%	97.3%
SAU801599	MTU200091	30%	99.6%	97.3%
SAU801599	NGO100042	47%	99.6%	97.9%
SAU801599	NME200901	45%	99.6%	97.9%
SAU801599	PMU100194	52%	99.6%	99.1%
SAU801599	PRT104077	48%	99.6%	96.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801599	PAE203967	24%	75.4%	35.3%
SAU801599	PPU107143	29%	80.7%	86.7%
SAU801599	PSY105099	24%	75.4%	36.1%
SAU801599	SPA102658	53%	99.6%	97.8%
SAU801599	STY103498	53%	99.6%	97.8%
SAU801599	SAU801599	100%	100%	100%
SAU801599	SEP201090	71%	100%	100%
SAU801599	SHA101359	71%	100%	100%
SAU801599	SMU101154	42%	96.5%	95.2%
SAU801599	SPN400894	43%	99.6%	98.7%
SAU801599	SPY200320	41%	99.6%	98.3%
SAU801599	TPA100168	35%	95.2%	89.2%
SAU801599	UUR100475	40%	50%	95.8%
SAU801599	VCH102344	53%	99.6%	98.7%
SAU801599	YPS000146	50%	99.6%	97.4%
SAU801605	ABA100484	46%	99.2%	97.6%
SAU801605	BAN111697	60%	17.2%	70.5%
SAU801605	BAN107867	55%	66.4%	98.2%
SAU801605	BAN106428	54%	93.6%	92.9%
SAU801605	BPT101355	52%	98.8%	98.8%
SAU801605	BCE104528	36%	95.2%	91.0%
SAU801605	BCE107667	44%	98.8%	89.0%
SAU801605	BFU103189	46%	99.6%	94.6%
SAU801605	BMA104515	44%	99.6%	93.1%
SAU801605	CJU101450	55%	99.6%	97.6%
SAU801605	CDF102700	49%	98.4%	90.8%
SAU801605	EBC100474	43%	55.6%	98.5%
SAU801605	ECO100696	45%	98%	98.4%
SAU801605	HIN101694	45%	98.4%	93.8%
SAU801605	KPN300310	33%	46%	69.0%
SAU801605	KPN300091	36%	28.4%	93.4%
SAU801605	KPN302568	42%	99.6%	98.8%
SAU801605	MAV102722	40%	98.8%	98.0%
SAU801605	MLP100225	40%	98.8%	98.0%
SAU801605	NME200029	44%	99.2%	99.2%
SAU801605	PRT102094	47%	98.4%	97.2%
SAU801605	PAE202110	42%	94.4%	96.8%
SAU801605	PPU106297	38%	98.4%	95.7%
SAU801605	PSY104029	44%	98.4%	96.1%
SAU801605	SPA102223	40%	96%	98.7%
SAU801605	STY101893	45%	94.8%	95.1%
SAU801605	STM101632	44%	98.8%	99.2%
SAU801605	SAU801605	100%	100%	100%
SAU801605	SEP201114	74%	100%	100%
SAU801605	SHA100233	78%	100%	100%
SAU801605	VCH103496	39%	95.2%	97.2%
SAU801605	YPS001546	46%	98.8%	98.8%
SAU801606	KPN105172	57%	27.8%	97.7%
SAU801606	SAU801606	100%	100%	100%
SAU801606	SEP201117	80%	99.8%	99.8%
SAU801606	SHA100232	84%	93.4%	100%
SAU801615	BAN102459	37%	86.3%	94.6%
SAU801615	BAN105001	37%	86.3%	91.6%
SAU801615	CBO101692	29%	81.4%	89.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801615	CDF103625	29%	97.1%	82.3%
SAU801615	EFA200710	48%	100%	82.4%
SAU801615	EFM202242	46%	100%	97.0%
SAU801615	LMO102296	40%	94.1%	89%
SAU801615	SAU801615	100%	100%	100%
SAU801615	SEP201157	89%	100%	100%
SAU801615	SHA101193	89%	100%	100%
SAU801615	SMU101202	41%	97.1%	97.0%
SAU801615	SPN400177	42%	98.0%	97.0%
SAU801615	SPY201612	40%	97.1%	97.0%
SAU801616	ABA100403	30%	74.8%	62.3%
SAU801616	BAN104572	59%	98.4%	87.6%
SAU801616	BAN108104	61%	98.4%	87.6%
SAU801616	BFR12028	31%	98.4%	97.5%
SAU801616	BCE103090	27%	86.2%	70.5%
SAU801616	CPN200515	38%	83.7%	67.5%
SAU801616	CTR200449	39%	75.6%	63.5%
SAU801616	CAC101999	49%	99.2%	88.1%
SAU801616	CBO100417	50%	99.2%	86.9%
SAU801616	CDF100891	55%	97.6%	83.0%
SAU801616	CDP100379	27%	98.4%	75.4%
SAU801616	EBC103406	26%	91.9%	79.7%
SAU801616	EFA200711	54%	98.4%	86.4%
SAU801616	EFM201893	55%	97.6%	83.9%
SAU801616	ECO102884	26%	91.9%	79.7%
SAU801616	HIN100291	26%	71.5%	62.6%
SAU801616	KPN302112	26%	91.9%	79.1%
SAU801616	LPN100282	29%	71.5%	62.6%
SAU801616	LMO101308	56%	98.4%	87.0%
SAU801616	MCA100969	26%	89.4%	70.3%
SAU801616	MAV104478	31%	91.1%	45.6%
SAU801616	MBV100969	37%	65.0%	47.1%
SAU801616	MLP100310	31%	96.7%	63.6%
SAU801616	MTU202517	37%	65.0%	47.1%
SAU801616	NGO100112	35%	64.2%	51.7%
SAU801616	NME201410	34%	64.2%	51.7%
SAU801616	PRT104009	31%	75.6%	66.2%
SAU801616	PAE200403	25%	91.1%	77.1%
SAU801616	PPU109370	23%	92.7%	80.9%
SAU801616	PSY105925	24%	91.9%	80.1%
SAU801616	SPA102544	27%	72.4%	63.8%
SAU801616	STY104576	27%	72.4%	63.8%
SAU801616	STM100595	27%	72.4%	63.8%
SAU801616	SAU801616	100%	100%	100%
SAU801616	SEP201160	86%	99.2%	85.9%
SAU801616	SHA101192	83%	99.2%	85.9%
SAU801616	SMU101205	52%	99.2%	87.8%
SAU801616	SPN400176	52%	97.6%	86.3%
SAU801616	SPY201613	48%	97.6%	86.3%
SAU801616	UUR100372	34%	100%	87.8%
SAU801616	VCH100461	22%	77.2%	67.9%
SAU801616	YPS000228	29%	75.6%	65.7%
SAU801617	BAN109872	57%	100%	98.9%
SAU801617	BAN111284	57%	100%	98.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801617	CAC103316	46%	89.5%	89.5%
SAU801617	CBO101837	48%	89.5%	92.8%
SAU801617	CDF100893	43%	96.5%	97.6%
SAU801617	EFA200713	58%	89.5%	86.5%
SAU801617	EFM200709	55%	89.5%	87.5%
SAU801617	LMO101635	54%	95.3%	92.2%
SAU801617	SAU801617	100%	100%	100%
SAU801617	SEP201163	87%	96.5%	96.5%
SAU801617	SHA101191	83%	100%	100%
SAU801617	SMU101208	56%	90.7%	87.6%
SAU801617	SPN400175	53%	93.0%	90.9%
SAU801617	SPY201614	56%	90.7%	87.6%
SAU801618	ABA102548	51%	8.7%	92.7%
SAU801618	ABA101894	43%	99.4%	99.2%
SAU801618	BAN112993	42%	12.2%	96.4%
SAU801618	BAN112360	57%	73.3%	100%
SAU801618	BAN110893	59%	100%	99.8%
SAU801618	BFR11415	40%	98.5%	98.9%
SAU801618	BPT101143	44%	99.3%	99.5%
SAU801618	BBU100219	38%	79.1%	98.8%
SAU801618	BCE107013	46%	47.8%	94.4%
SAU801618	BFU114595	42%	99.5%	99.8%
SAU801618	BMA107024	43%	99.4%	99.7%
SAU801618	CJU100469	42%	98.1%	98.6%
SAU801618	CPN200957	36%	96.9%	97.0%
SAU801618	CTR200124	36%	99.1%	99.2%
SAU801618	CAC100475	43%	100%	99.8%
SAU801618	CBO102316	44%	100%	99.8%
SAU801618	CDF100894	45%	99.8%	99.5%
SAU801618	CDP100382	38%	99.0%	99.4%
SAU801618	EBC101519	44%	98.4%	100%
SAU801618	EFA202378	55%	99.9%	99.9%
SAU801618	EFM102001	56%	14.2%	100%
SAU801618	ECO102637	45%	99.0%	98.9%
SAU801618	HIN100794	44%	99.3%	99.5%
SAU801618	HPY101224	39%	98.6%	98.9%
SAU801618	KPN301584	45%	99.0%	99.0%
SAU801618	LPN103164	42%	99.7%	100%
SAU801618	LMO101358	56%	99.8%	99.5%
SAU801618	MCA100516	45%	99.7%	99.4%
SAU801618	MAV102135	38%	97.7%	99.2%
SAU801618	MBV100967	38%	99.3%	99.2%
SAU801618	MLP100309	38%	99.3%	99.6%
SAU801618	MTU202518	38%	99.3%	99.2%
SAU801618	MGE100298	36%	89.6%	87.3%
SAU801618	MPN100422	34%	94.4%	92.6%
SAU801618	NGO101407	42%	99.3%	99.4%
SAU801618	NME201646	43%	99.3%	99.4%
SAU801618	PMU101287	44%	99.1%	99.2%
SAU801618	PRT101312	42%	99.2%	99.2%
SAU801618	PAE200902	45%	99.4%	99.7%
SAU801618	PPU106922	45%	98.6%	98.9%
SAU801618	PSY103114	44%	94.3%	99.2%
SAU801618	SPA101276	44%	99.0%	99.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801618	STY102766	44%	99.0%	98.9%
SAU801618	SAU801618	100%	100%	100%
SAU801618	SEP201165	83%	100%	100%
SAU801618	SHA101190	83%	100%	99.7%
SAU801618	SMU100824	49%	99.4%	99.8%
SAU801618	SPN401239	50%	99.2%	99.5%
SAU801618	SPY201063	50%	99.7%	100%
SAU801618	TPA101007	38%	79.9%	98.7%
SAU801618	UUR100371	36%	99.9%	99.9%
SAU801618	VCH100535	43%	99.3%	99.3%
SAU801618	YPS003498	45%	99.0%	99.0%
SAU801619	ABA105938	24%	55.9%	85.9%
SAU801619	BAN100190	32%	87.2%	91.9%
SAU801619	BAN101468	48%	89.1%	94.5%
SAU801619	BFR100242	22%	46.4%	93.4%
SAU801619	BBU100631	27%	53.6%	72.1%
SAU801619	BCE106437	25%	30.2%	26.6%
SAU801619	BFU102756	29%	46.9%	70.7%
SAU801619	BMA100166	32%	18.3%	51.2%
SAU801619	CPN200638	31%	89.1%	98.1%
SAU801619	CTR200297	33%	79.3%	85.6%
SAU801619	CAC103106	35%	90.2%	99.6%
SAU801619	CBO101836	35%	86.8%	95.4%
SAU801619	CDF101471	34%	87.5%	96.3%
SAU801619	EBC102604	23%	55.2%	82.2%
SAU801619	EFA200908	41%	98.7%	98.7%
SAU801619	EFM101108	42%	98.2%	98.3%
SAU801619	ECO102756	22%	55.8%	82.7%
SAU801619	HIN101288	24%	47.2%	69.8%
SAU801619	HPY200724	26%	13.1%	20.9%
SAU801619	KPN305146	23%	52.1%	77.7%
SAU801619	LPN102124	22%	47.4%	45.5%
SAU801619	LPN101988	22%	47.4%	45.5%
SAU801619	LMO102542	46%	98.4%	97.5%
SAU801619	MCA101482	25%	53.3%	68.8%
SAU801619	MAV103656	27%	46.4%	69.5%
SAU801619	MBV100278	26%	45.9%	68.5%
SAU801619	MTU200626	26%	45.9%	68.5%
SAU801619	NGO100235	26%	49.7%	76.7%
SAU801619	NME201279	26%	49.5%	77.8%
SAU801619	PMU100517	23%	52.5%	75.8%
SAU801619	PRT102296	23%	61.2%	84.5%
SAU801619	PAE204281	36%	45.1%	63.5%
SAU801619	PPU101090	33%	46.2%	66.9%
SAU801619	PSY102739	33%	45.1%	65.9%
SAU801619	SPA100178	22%	25.8%	97.4%
SAU801619	STY103973	22%	55.2%	81.5%
SAU801619	SAU801619	100%	100%	100%
SAU801619	SEP201166	80%	100%	100%
SAU801619	SHA101579	76%	45.0%	98.7%
SAU801619	SMU101281	39%	97.3%	98.1%
SAU801619	SPN400363	40%	91.6%	95.4%
SAU801619	SPY201419	39%	97.3%	97.9%
SAU801619	VCH102285	25%	47.6%	65.0%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801619	YPS001085	34%	45.7%	68.9%
SAU801621	ABA105138	55%	94.6%	96.3%
SAU801621	BAN108754	63%	98.7%	100%
SAU801621	BAN107731	73%	98.1%	97.6%
SAU801621	BFR101806	39%	93.3%	98.0%
SAU801621	BPT102222	50%	94.6%	97.3%
SAU801621	BBU100681	37%	94.9%	98.6%
SAU801621	BCE109535	54%	94.9%	93.1%
SAU801621	BFU101559	55%	94.9%	93.4%
SAU801621	BMA105040	56%	94.9%	93.2%
SAU801621	CJU100046	33%	95.2%	100%
SAU801621	CPN200310	48%	94.6%	96.7%
SAU801621	CTR200552	52%	94.4%	92.8%
SAU801621	CAC103620	43%	94.6%	98.9%
SAU801621	CBO100620	42%	95.2%	98.3%
SAU801621	CBO101941	44%	94.9%	98.1%
SAU801621	CDF100895	42%	94.9%	97.8%
SAU801621	CDP100137	34%	94.9%	98.4%
SAU801621	EBC102862	54%	96.0%	97.0%
SAU801621	EFA201802	69%	99.2%	99.2%
SAU801621	EFM201233	72%	99.2%	99.2%
SAU801621	ECO101106	55%	96.5%	94.3%
SAU801621	HIN100165	54%	95.7%	85.6%
SAU801621	HPY101317	35%	94.9%	94.7%
SAU801621	KPN301143	55%	96.5%	93.0%
SAU801621	LPN102566	54%	96.0%	99.2%
SAU801621	LMO100858	77%	99.5%	98.9%
SAU801621	MCA100336	55%	95.7%	93.9%
SAU801621	MAV103827	35%	94.9%	98.6%
SAU801621	MBV105909	35%	94.9%	96.2%
SAU801621	MLP101048	35%	94.9%	98.6%
SAU801621	MTU202984	35%	94.9%	96.2%
SAU801621	MGE100301	37%	94.4%	98.1%
SAU801621	MPN100419	37%	96.2%	98.6%
SAU801621	NGO101275	51%	95.7%	91.9%
SAU801621	NME201603	52%	95.7%	91.9%
SAU801621	PMU101336	56%	97.0%	94.8%
SAU801621	PRT100592	56%	96.0%	97.8%
SAU801621	PAE202624	58%	94.9%	94.1%
SAU801621	PPU110350	57%	94.9%	94.4%
SAU801621	PSY104084	56%	96.2%	95.5%
SAU801621	SPA104236	55%	96.5%	98.1%
SAU801621	STY102569	55%	96.5%	98.1%
SAU801621	SAU801621	100%	100%	100%
SAU801621	SEP201168	89%	100%	100%
SAU801621	SHA100752	89%	100%	100%
SAU801621	SMU101360	71%	97.6%	97.6%
SAU801621	SPN400122	72%	98.4%	93.6%
SAU801621	SPY201672	71%	97.3%	97.3%
SAU801621	UUR100405	47%	98.4%	97.4%
SAU801621	VCH101109	54%	96.5%	97.6%
SAU801621	YPS003264	54%	96.0%	96.8%
SAU801624	SAU801624	100%	100%	100%
SAU801624	SEP203376	72%	95.8%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801625	BAN103970	45%	85%	77.3%
SAU801625	BAN109777	54%	53.3%	82.9%
SAU801625	BCE109299	38%	95%	47.2%
SAU801625	BFU108906	39%	88.3%	74.6%
SAU801625	CDP102360	38%	71.7%	94.2%
SAU801625	EBC104212	34%	86.7%	75.4%
SAU801625	EFA204368	39%	96.7%	61.0%
SAU801625	EFM202444	30%	83.3%	74.6%
SAU801625	ECO103939	47%	56.7%	49.3%
SAU801625	KPN304718	44%	56.7%	49.3%
SAU801625	LMO100321	32%	88.3%	90.2%
SAU801625	MAV107307	35%	83.3%	73.1%
SAU801625	MAV106390	37%	68.3%	54.4%
SAU801625	MAV109056	36%	78.3%	63.6%
SAU801625	PAE204734	28%	91.7%	90.8%
SAU801625	PPU109566	45%	66.7%	81.6%
SAU801625	PSY104361	34%	78.3%	74.6%
SAU801625	SPA103512	44%	56.7%	48.6%
SAU801625	STY101943	44%	56.7%	48.6%
SAU801625	STM102797	44%	56.7%	48.6%
SAU801625	SAU800840	79%	98.3%	92.2%
SAU801625	SAU801625	100%	100%	100%
SAU801625	SEP203695	71%	93.3%	88.9%
SAU801625	SPN401624	40%	98.3%	88.1%
SAU801625	SPN401384	44%	98.3%	92.2%
SAU801625	SPY201542	38%	95%	86.4%
SAU801625	SPY200970	46%	85%	81.8%
SAU801626	ABA104591	43%	57.1%	51.0%
SAU801626	BAN106612	60%	100%	100%
SAU801626	BAN110626	64%	100%	100%
SAU801626	BPT100530	33%	89.3%	80%
SAU801626	BCE101233	31%	89.3%	75.4%
SAU801626	BFU111916	34%	89.3%	76.7%
SAU801626	BMA105369	31%	89.3%	75.4%
SAU801626	CJU100815	24%	86.4%	93.4%
SAU801626	CAC101137	39%	89.3%	94.2%
SAU801626	CBO101126	40%	89.3%	89.2%
SAU801626	CDF100898	44%	86.4%	86.5%
SAU801626	EBC103621	31%	64.3%	63.1%
SAU801626	ECO102482	33%	95.7%	84.6%
SAU801626	HIN100358	48%	57.1%	53.3%
SAU801626	KPN306316	32%	95.7%	84.0%
SAU801626	LPN100480	30%	95.7%	91.5%
SAU801626	LMO102363	64%	100%	100%
SAU801626	MCA100831	33%	95.7%	84.5%
SAU801626	MAV100728	30%	87.1%	81.1%
SAU801626	MBV105554	30%	88.6%	81.4%
SAU801626	MTU201270	30%	88.6%	81.4%
SAU801626	NGO101056	35%	89.3%	88.5%
SAU801626	NME201452	35%	89.3%	88.5%
SAU801626	PMU100317	35%	89.3%	85.1%
SAU801626	PRT105219	30%	95.7%	84.1%
SAU801626	PAE203812	45%	57.1%	49.1%
SAU801626	PPU104025	31%	93.6%	75.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801626	FSY108566	42%	57.1%	49.1%
SAU801626	SPA100194	33%	95.7%	84.0%
SAU801626	STY105174	33%	95.7%	83.5%
SAU801626	STM103542	31%	83.6%	85.8%
SAU801626	SAU801626	100%	100%	100%
SAU801626	SEP201571	91%	100%	100%
SAU801626	SIA102530	88%	90%	100%
SAU801626	VCH100734	34%	85.7%	67.0%
SAU801626	YPS003291	32%	95.7%	85.4%
SAU801630	ABA101157	52%	99.3%	98.5%
SAU801630	BAN109213	47%	99.7%	100%
SAU801630	BAN103380	66%	99.7%	99.0%
SAU801630	BNR10266	52%	77.7%	98.7%
SAU801630	BFT101790	51%	99.5%	99.2%
SAU801630	BBU100445	48%	85.2%	98.8%
SAU801630	BCE104313	40%	16.3%	76.6%
SAU801630	BCE111669	52%	99.8%	98.8%
SAU801630	BFU111015	53%	99.8%	99.0%
SAU801630	BMA100432	52%	99.8%	98.8%
SAU801630	CUU100601	51%	97.3%	97.1%
SAU801630	OPN200083	46%	99.7%	99.7%
SAU801630	CTR200818	44%	99.7%	100%
SAU801630	CAC102618	55%	99.3%	97.6%
SAU801630	CBO100008	54%	99.1%	97.6%
SAU801630	ODF100502	52%	99.3%	97.8%
SAU801630	ODP100396	46%	98.3%	97.0%
SAU801630	BBC102309	54%	99.1%	98.6%
SAU801630	BFA202213	63%	99.7%	99.2%
SAU801630	BEM202626	62%	99.7%	99.2%
SAU801630	BCO101834	54%	99.1%	98.6%
SAU801630	BIN100302	51%	99.1%	99.0%
SAU801630	BFY100610	50%	99.3%	99.7%
SAU801630	KTN301306	59%	52.6%	96.8%
SAU801630	LIN101576	53%	99.1%	98.7%
SAU801630	LMO101015	64%	99.3%	98.6%
SAU801630	MCA100604	50%	99.3%	98.8%
SAU801630	MAV103031	45%	87.6%	99.6%
SAU801630	MBV101554	45%	98.3%	94.8%
SAU801630	MLP100306	44%	98.3%	97.8%
SAU801630	MTU202535	45%	98.3%	97.1%
SAU801630	MGE100036	35%	97.3%	96.9%
SAU801630	MFN100108	36%	98.1%	96.6%
SAU801630	NGO101633	52%	99.1%	99.3%
SAU801630	NME201865	52%	99.3%	98.3%
SAU801630	PMU100983	51%	99.1%	99.0%
SAU801630	PKF100115	53%	99.1%	100%
SAU801630	PAE200962	53%	99.3%	98.6%
SAU801630	PFU112195	52%	99.3%	98.6%
SAU801630	PSY106866	53%	90.1%	97.6%
SAU801630	SPA102449	52%	65.1%	98.0%
SAU801630	STY102265	54%	99.1%	98.6%
SAU801630	SAU801630	100%	100%	100%
SAU801630	SEP201575	88%	100%	100%
SAU801630	SIA100663	89%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801630	SMU101272	57%	99.3%	98.0%
SAU801630	SPN401921	57%	99.3%	98.3%
SAU801630	SPY201648	56%	99.3%	99.1%
SAU801630	TPA100975	44%	99.3%	96.8%
SAU801630	UUR100288	42%	99.0%	99.3%
SAU801630	VCH101147	52%	99.3%	98.6%
SAU801630	YPS003419	52%	99.1%	97.3%
SAU801631	ABA101469	49%	15%	78.8%
SAU801631	ABA100694	40%	98.1%	96.7%
SAU801631	BAN108710	37%	96.4%	97.9%
SAU801631	BAN104310	58%	99.0%	89.8%
SAU801631	BFR11762	23%	98.1%	97.6%
SAU801631	BPT100013	40%	94.3%	90.1%
SAU801631	BBU100134	23%	99.5%	97.2%
SAU801631	BCE114784	40%	98.1%	93.7%
SAU801631	BFU113972	40%	93.8%	88.1%
SAU801631	BMA106479	40%	98.1%	93.7%
SAU801631	CJU100704	36%	98.6%	99.0%
SAU801631	CPN200082	38%	98.8%	98.1%
SAU801631	CTR200819	39%	96.0%	94.6%
SAU801631	CAC100205	26%	97.1%	97.4%
SAU801631	CBO102641	47%	99.5%	99.5%
SAU801631	CDF100504	50%	100%	99.3%
SAU801631	CDP100409	44%	98.6%	96.5%
SAU801631	EBC102800	38%	99.5%	98.1%
SAU801631	EFA202211	49%	98.6%	95.6%
SAU801631	EFM201250	47%	98.6%	96.3%
SAU801631	ECO102465	38%	99.5%	98.1%
SAU801631	HIN100348	40%	99.5%	98.3%
SAU801631	HPY101173	27%	95.7%	94.1%
SAU801631	KPN309062	39%	99.5%	98.1%
SAU801631	LPN101194	38%	97.6%	95.5%
SAU801631	LMO101789	54%	98.8%	97.4%
SAU801631	MCA101520	42%	96.9%	97.2%
SAU801631	MAV103034	44%	97.9%	96.4%
SAU801631	MBV101555	44%	97.9%	95.7%
SAU801631	MLP100305	41%	97.9%	94.8%
SAU801631	MTU202543	44%	97.9%	95.7%
SAU801631	MGE100035	32%	95%	94.4%
SAU801631	MPN100109	34%	98.1%	97.6%
SAU801631	NGO101009	43%	95.2%	93.5%
SAU801631	NME200980	43%	95.2%	93.5%
SAU801631	PMU102011	41%	99.5%	98.3%
SAU801631	PRT104870	38%	98.8%	97.4%
SAU801631	PAE203799	43%	98.1%	96.3%
SAU801631	PPU103989	43%	98.6%	96.7%
SAU801631	PSY103800	42%	98.1%	96.3%
SAU801631	SPA101921	43%	70.7%	98.0%
SAU801631	STY101721	38%	99.5%	98.1%
SAU801631	SAU801631	100%	100%	100%
SAU801631	SEP201577	84%	99.8%	98.8%
SAU801631	SHA100662	85%	100%	99.3%
SAU801631	SMU101274	45%	97.6%	95.1%
SAU801631	SPN401928	48%	99.0%	96.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801631	SPY201649	46%	98.6%	96.7%
SAU801631	TPA100633	24%	76.2%	75.1%
SAU801631	UUR100287	37%	97.6%	97.6%
SAU801631	VCH100747	40%	97.1%	96.0%
SAU801631	YPS003230	40%	97.1%	95.8%
SAU801632	BAN100228	29%	55.3%	47.5%
SAU801632	BAN110524	28%	62.2%	49.5%
SAU801632	BAN102171	29%	62.5%	49.0%
SAU801632	BAN111103	29%	61.9%	38.1%
SAU801632	BAN102482	29%	61.9%	37.8%
SAU801632	BAN101459	33%	60.1%	75.2%
SAU801632	BFR103557	24%	55.0%	51.9%
SAU801632	BPT102223	27%	58.8%	48.2%
SAU801632	BBU100665	27%	54.6%	61.7%
SAU801632	BCE110660	27%	57.0%	47.8%
SAU801632	BFU102333	27%	60.8%	45.0%
SAU801632	BMA100078	28%	58.8%	43.2%
SAU801632	CJU101194	26%	72.2%	38.4%
SAU801632	CPN200332	32%	59.5%	70.5%
SAU801632	CTR200532	34%	58.8%	67.9%
SAU801632	CAC100830	33%	58.8%	83.1%
SAU801632	CBO103642	28%	58.8%	100%
SAU801632	CBO102707	34%	57.0%	18.3%
SAU801632	CDF100779	34%	61.9%	79.7%
SAU801632	CDP101644	26%	58.4%	45.5%
SAU801632	EBC100856	28%	58.1%	74.5%
SAU801632	EFM202599	36%	64.9%	66.0%
SAU801632	ECO102754	30%	58.1%	49.0%
SAU801632	HIN100065	29%	58.4%	52.1%
SAU801632	HPY100759	26%	58.8%	50.2%
SAU801632	KPN305150	28%	58.1%	52.5%
SAU801632	LPN100769	29%	60.5%	48.2%
SAU801632	LMO100827	38%	32.6%	13.6%
SAU801632	MAV106636	24%	58.4%	45.1%
SAU801632	MBV103480	24%	58.4%	45.1%
SAU801632	MLP101597	24%	58.4%	45.1%
SAU801632	MTU203860	24%	58.4%	45.1%
SAU801632	NGO101686	29%	62.9%	56.7%
SAU801632	NME201874	27%	62.9%	57.5%
SAU801632	PMU100903	27%	57.7%	54.5%
SAU801632	PRT102294	26%	58.1%	52.8%
SAU801632	PAE204942	27%	59.8%	48.8%
SAU801632	PPU106701	29%	57.7%	46.6%
SAU801632	PSY101064	30%	57.7%	54.3%
SAU801632	SPA104044	28%	61.2%	52.9%
SAU801632	STY103967	29%	58.1%	52.5%
SAU801632	STM101271	27%	61.2%	78.9%
SAU801632	SAU801632	100%	100%	100%
SAU801632	SEP201579	71%	100%	100%
SAU801632	SHA100124	68%	84.9%	100%
SAU801632	TPA100244	25%	56.4%	59.7%
SAU801632	VCH100339	25%	62.5%	41.3%
SAU801632	YPS001087	28%	58.1%	52.6%
SAU801636	ABA101961	31%	73.1%	98.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801636	BAN104770	29%	99.6%	98.9%
SAU801636	BAN102480	40%	99.6%	98.6%
SAU801636	BFR100673	32%	65.5%	99.2%
SAU801636	BPT101805	31%	70.0%	93.6%
SAU801636	BBU100253	32%	73.3%	99.2%
SAU801636	BFU108641	31%	72.5%	99.1%
SAU801636	BMA106924	31%	70.3%	96.3%
SAU801636	CJU100028	34%	69.6%	98.3%
SAU801636	CPN200184	27%	71.6%	94.7%
SAU801636	CTR200722	28%	72.7%	97.1%
SAU801636	CAC102562	33%	69.9%	95.9%
SAU801636	CBO101432	35%	73.2%	98.8%
SAU801636	CDF100497	38%	73.1%	68.6%
SAU801636	EBC102952	38%	47.8%	84.8%
SAU801636	EFA201172	38%	99.3%	99.2%
SAU801636	EFM100083	43%	38.3%	99.7%
SAU801636	ECO102828	32%	70.3%	96.0%
SAU801636	HIN101186	34%	65.7%	90.8%
SAU801636	HPY100344	30%	65.3%	94.0%
SAU801636	KPN303321	32%	70.5%	96.4%
SAU801636	LPN103347	31%	71.9%	98.1%
SAU801636	LMO102252	37%	99.9%	98.1%
SAU801636	MCA101569	29%	72.8%	96.3%
SAU801636	NGO100971	32%	65.1%	89.4%
SAU801636	NME200968	33%	65.1%	89.4%
SAU801636	PMU100192	31%	65.7%	90.8%
SAU801636	PRT103507	30%	70.1%	95.8%
SAU801636	PAE203722	32%	65.8%	91.2%
SAU801636	PPU107844	32%	65.3%	90.5%
SAU801636	PSY104923	32%	65.8%	91.2%
SAU801636	SPA102978	30%	70.1%	95.8%
SAU801636	STY104138	32%	70.1%	95.8%
SAU801636	SAU801636	100%	100%	100%
SAU801636	SEP201590	66%	100%	100%
SAU801636	SHA101075	68%	99.7%	99.7%
SAU801636	SMU100405	39%	98.3%	97.5%
SAU801636	SPN400537	38%	99.3%	98.9%
SAU801636	SPY200696	37%	96.2%	95.9%
SAU801636	TPA100696	27%	0.5%	20.1%
SAU801636	VCH102382	30%	70.1%	95.5%
SAU801636	YPS000162	29%	71.3%	97.4%
SAU801643	CAC103297	30%	94.1%	91.6%
SAU801643	CBO102699	28%	93.4%	94%
SAU801643	SAU801643	100%	100%	100%
SAU801643	SEP201603	74%	99.3%	100%
SAU801643	SHA100641	82%	99.3%	100%
SAU801644	ABA102020	45%	79.3%	84.2%
SAU801644	BAN108425	53%	99.8%	100%
SAU801644	BAN110337	64%	100%	100%
SAU801644	BFR10585	42%	80.5%	94.5%
SAU801644	BPT102468	45%	79.1%	91.8%
SAU801644	BBU100780	39%	74.4%	96.0%
SAU801644	BCE109750	47%	79.3%	93.2%
SAU801644	BFU106483	44%	85.3%	98.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801644	BMA107520	47%	77.2%	90.3%
SAU801644	CJU100085	41%	77.4%	98%
SAU801644	CPN200205	42%	76.3%	97.1%
SAU801644	CTR200689	45%	76.7%	100%
SAU801644	CAC103735	49%	100%	100%
SAU801644	CBO102816	48%	99.8%	99.8%
SAU801644	CDF101736	51%	99.5%	98.8%
SAU801644	CDP101218	43%	99.3%	86.0%
SAU801644	EBC102677	45%	75.1%	83.4%
SAU801644	EFA201920	61%	100%	99.5%
SAU801644	EFM201911	60%	88.8%	97.5%
SAU801644	ECO103113	47%	69.8%	77.7%
SAU801644	HIN100857	45%	75.6%	84.1%
SAU801644	HPY100299	48%	68.1%	80.6%
SAU801644	KPN300686	43%	79.3%	87.2%
SAU801644	LPN101316	48%	64.9%	99.3%
SAU801644	LMO102191	65%	100%	100%
SAU801644	MCA101313	46%	77.2%	82.9%
SAU801644	MAV104121	43%	97.7%	86.6%
SAU801644	MBV104432	43%	99.3%	88.6%
SAU801644	MLP100902	42%	99.3%	90.2%
SAU801644	MTU202404	43%	99.3%	89.6%
SAU801644	MGE100395	37%	98.4%	98.2%
SAU801644	MPN100279	38%	98.4%	98.2%
SAU801644	NGO100959	44%	83.0%	97.7%
SAU801644	NME200322	43%	83.0%	97.7%
SAU801644	PMU100351	44%	79.3%	88.7%
SAU801644	PRT100791	44%	79.8%	89.7%
SAU801644	PAE204564	47%	76.5%	82.0%
SAU801644	PPU110997	45%	79.1%	87.5%
SAU801644	PSY102705	46%	65.6%	78.9%
SAU801644	SPA100458	44%	75.1%	89.3%
SAU801644	STY101485	44%	75.1%	83.6%
SAU801644	SAU801644	100%	100%	100%
SAU801644	SEP201605	90%	100%	100%
SAU801644	SHA100640	88%	85.1%	100%
SAU801644	SMU100127	58%	100%	99.5%
SAU801644	SPN400984	59%	100%	99.5%
SAU801644	SPY201023	60%	100%	99.5%
SAU801644	TPA100734	40%	74.2%	84.0%
SAU801644	UUR100466	37%	99.8%	99.5%
SAU801644	VCH100432	39%	84.9%	96.2%
SAU801644	YPS002137	42%	86.3%	98.7%
SAU801645	ABA101804	61%	73.7%	85.9%
SAU801645	BAN111062	82%	94.9%	100%
SAU801645	BAN102544	84%	94.9%	97.9%
SAU801645	BFR10883	53%	80.8%	89.9%
SAU801645	BPT102470	59%	82.8%	96.5%
SAU801645	BBU100779	56%	80.8%	97.5%
SAU801645	BCE103036	55%	84.8%	96.6%
SAU801645	BFU106480	57%	78.8%	89.7%
SAU801645	BMA101618	55%	84.8%	96.6%
SAU801645	CJU100084	59%	81.8%	96.4%
SAU801645	CPN200204	58%	73.7%	86.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801645	CTR200690	61%	80.8%	94.0%
SAU801645	CAC103330	67%	92.9%	92%
SAU801645	CBO102962	75%	92.9%	92%
SAU801645	CDF101911	68%	93.9%	96.9%
SAU801645	CDP101220	63%	80.8%	89.8%
SAU801645	EBC100461	60%	82.8%	97.6%
SAU801645	EFA202214	81%	93.9%	94.9%
SAU801645	EFM200824	80%	94.9%	96.9%
SAU801645	ECO103115	60%	82.8%	97.6%
SAU801645	HIN100859	58%	80.8%	94.1%
SAU801645	HPY100293	60%	80.8%	90.9%
SAU801645	KPN300596	59%	82.8%	97.6%
SAU801645	LPN100139	51%	80.8%	88.0%
SAU801645	LMO100798	85%	90.9%	93.8%
SAU801645	MCA101440	55%	82.8%	97.6%
SAU801645	MAV104122	57%	85.9%	95.5%
SAU801645	MBV104431	63%	80.8%	91.9%
SAU801645	MLP100903	61%	83.8%	93.2%
SAU801645	MTU202405	63%	80.8%	91.9%
SAU801645	MGE100239	63%	87.9%	83.7%
SAU801645	MPN100509	67%	89.9%	87.5%
SAU801645	NGO101635	58%	80.8%	90%
SAU801645	NME202000	56%	80.8%	90%
SAU801645	PMU100348	60%	82.8%	97.6%
SAU801645	PRT100790	59%	82.8%	97.6%
SAU801645	PAE204565	62%	82.8%	97.6%
SAU801645	PPU109793	56%	82.8%	97.6%
SAU801645	PSY102707	51%	85.9%	94.5%
SAU801645	SPA100460	60%	82.8%	97.6%
SAU801645	STY101487	60%	82.8%	97.6%
SAU801645	SAU801645	100%	100%	100%
SAU801645	SEP201610	92%	100%	100%
SAU801645	SHA100024	92%	100%	100%
SAU801645	SMU100757	82%	90.9%	92.8%
SAU801645	SPN401014	79%	89.9%	100%
SAU801645	SPY200612	80%	90.9%	92.8%
SAU801645	TPA100735	60%	80.8%	93.1%
SAU801645	UUR100211	65%	85.9%	85%
SAU801645	VCH100431	60%	80.8%	94.2%
SAU801645	YPS002142	60%	82.8%	97.6%
SAU801646	BAN108189	37%	92.0%	93.9%
SAU801646	BAN100435	37%	92.0%	93.9%
SAU801646	CBO101665	32%	83.9%	88.0%
SAU801646	CDF103326	30%	92.0%	97.1%
SAU801646	EFA202216	36%	82.1%	85.1%
SAU801646	EFM200511	35%	84.8%	87.7%
SAU801646	ECO101034	30%	41.1%	56.8%
SAU801646	LMO102819	33%	94.6%	100%
SAU801646	MGE100238	40%	40.2%	39.4%
SAU801646	MPN100510	48%	22.3%	25%
SAU801646	SAU801646	100%	100%	100%
SAU801646	SEP201611	89%	94.6%	100%
SAU801646	SHA100023	86%	94.6%	100%
SAU801646	SMU100756	32%	82.1%	86.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801646	SPN401013	24%	83.0%	86.0%
SAU801646	SPY200611	28%	85.7%	90.7%
SAU801646	TPA100736	29%	92.0%	94.4%
SAU801646	UUR100212	29%	78.6%	80.4%
SAU801647	ABA105440	47%	99.0%	99.0%
SAU801647	BAN108298	72%	100%	100%
SAU801647	BAN107763	72%	100%	100%
SAU801647	BFR10884	46%	100%	86.8%
SAU801647	BPT104764	47%	100%	42.0%
SAU801647	BBU100777	37%	98.0%	98.1%
SAU801647	BCE111959	49%	100%	100%
SAU801647	BFU106477	50%	100%	83.1%
SAU801647	BMA107479	48%	100%	100%
SAU801647	CJU100083	36%	100%	100%
SAU801647	CPN200203	40%	97.1%	95.3%
SAU801647	CTR200691	41%	94.1%	92.5%
SAU801647	CAC100327	53%	100%	100%
SAU801647	CBO100385	54%	100%	78.2%
SAU801647	CDF101910	54%	100%	97.2%
SAU801647	CDP101222	38%	98.0%	99.0%
SAU801647	EBC100460	34%	31.4%	100%
SAU801647	EFA202217	62%	100%	96.2%
SAU801647	EFM200259	64%	100%	100%
SAU801647	ECO103116	41%	100%	100%
SAU801647	HIN100860	46%	100%	100%
SAU801647	HPY100292	40%	99.0%	98.1%
SAU801647	KPN300595	40%	87.3%	100%
SAU801647	LPN100481	43%	98.0%	98.1%
SAU801647	LMO101855	75%	100%	100%
SAU801647	MCA101422	43%	100%	100%
SAU801647	MAV102387	34%	97.1%	96.1%
SAU801647	MBV104430	34%	97.1%	95.2%
SAU801647	MLP100904	34%	97.1%	96.1%
SAU801647	MTU202406	34%	97.1%	95.2%
SAU801647	MGE100237	40%	95.1%	94%
SAU801647	MPN100511	42%	95.1%	94%
SAU801647	NGO101632	43%	95.1%	86.0%
SAU801647	NME201999	43%	95.1%	96.1%
SAU801647	PMU100347	46%	100%	100%
SAU801647	PRT100789	45%	98.0%	99.0%
SAU801647	PAE204566	49%	100%	100%
SAU801647	PPU108773	47%	99.0%	65.0%
SAU801647	PSY108282	49%	100%	64.8%
SAU801647	SPA100461	38%	69.6%	100%
SAU801647	STY101488	41%	100%	100%
SAU801647	SAU801647	100%	100%	100%
SAU801647	SEP201612	94%	100%	100%
SAU801647	SMU100215	60%	99.0%	97.1%
SAU801647	SPN401012	57%	99.0%	97.1%
SAU801647	SPY200610	60%	99.0%	97.1%
SAU801647	TPA100737	43%	98.0%	97.1%
SAU801647	UUR100213	51%	99.0%	98%
SAU801647	VCH100430	50%	100%	100%
SAU801647	YPS002148	42%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801648	ABA104912	24%	52.8%	37.8%
SAU801648	BAN104044	23%	83.0%	88.6%
SAU801648	BAN108789	21%	95.5%	92.8%
SAU801648	CBO103951	21%	75%	76.5%
SAU801648	EBC106824	27%	37.5%	62.9%
SAU801648	EFA202030	25%	85.8%	91.1%
SAU801648	EFM200541	20%	85.8%	89.9%
SAU801648	LPN102451	25%	46.0%	24.5%
SAU801648	LMO101092	21%	81.2%	79.7%
SAU801648	MGE100319	22%	73.3%	42.9%
SAU801648	SPA102371	24%	68.2%	90.2%
SAU801648	STY102480	22%	72.2%	80.9%
SAU801648	STM102604	22%	72.2%	80.9%
SAU801648	SAU801648	100%	100%	100%
SAU801648	SEP201613	68%	97.7%	99.4%
SAU801648	SHA102804	50%	94.3%	98.2%
SAU801648	SMU101227	20%	88.1%	91.2%
SAU801648	SPN402019	23%	79.5%	89.0%
SAU801648	UUR100272	25%	91.5%	74.4%
SAU801663	ABA101795	41%	99.3%	98.5%
SAU801663	BAN107436	52%	99.3%	98.8%
SAU801663	BAN109623	68%	99.3%	98.8%
SAU801663	BFR103128	42%	99.9%	99.8%
SAU801663	BPT100020	38%	99.2%	97.9%
SAU801663	BBU100737	43%	99.3%	99.0%
SAU801663	BCE114033	40%	99.3%	99.1%
SAU801663	BFU109684	40%	99.1%	98.2%
SAU801663	BMA104351	39%	99.3%	99.1%
SAU801663	CJU100714	40%	99.2%	99.8%
SAU801663	CPN200668	36%	97.4%	97.4%
SAU801663	CTR200568	36%	99.1%	99.0%
SAU801663	CAC100067	51%	99.8%	99.4%
SAU801663	CBO100672	51%	99.8%	99.4%
SAU801663	CDF100033	36%	26.0%	98.7%
SAU801663	CDF102611	51%	99.3%	98.6%
SAU801663	CDP101232	42%	99.8%	99.3%
SAU801663	EBC104048	40%	97.5%	97.8%
SAU801663	EFA200179	65%	99.4%	98.9%
SAU801663	EFM201966	66%	99.7%	99.0%
SAU801663	ECO104148	40%	98.2%	98.4%
SAU801663	HIN101359	40%	99.9%	99.4%
SAU801663	HPY101136	39%	99.9%	99.5%
SAU801663	KPN303513	40%	97.1%	99.6%
SAU801663	LPN102949	43%	93.9%	100%
SAU801663	LMO102840	66%	99.9%	99.0%
SAU801663	MCA101259	41%	99.5%	99.2%
SAU801663	MAV104126	44%	94.1%	100%
SAU801663	MBV101058	43%	99.7%	100%
SAU801663	MLP100909	44%	99.8%	99.0%
SAU801663	MTU202412	43%	99.7%	100%
SAU801663	MGE100341	36%	99.1%	98.3%
SAU801663	MPN100361	36%	99.2%	98.4%
SAU801663	NGO100851	40%	99.2%	99.8%
SAU801663	NME200089	40%	99.7%	99.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801663	PMU100818	40%	99.9%	99.4%
SAU801663	PRT105161	42%	97.0%	96.3%
SAU801663	PAE203831	41%	98.2%	98.4%
SAU801663	PPU109466	41%	97.7%	98.5%
SAU801663	PSY104286	42%	98.2%	98.4%
SAU801663	SPA100729	34%	67.4%	98.4%
SAU801663	STY104006	40%	98.2%	98.4%
SAU801663	SAU801663	100%	100%	100%
SAU801663	SEP201629	89%	100%	100%
SAU801663	SHA100785	89%	100%	100%
SAU801663	SMU100583	60%	99.8%	99.2%
SAU801663	SPN400492	59%	99.8%	99.2%
SAU801663	SPY201210	61%	99.8%	99.3%
SAU801663	TPA101025	40%	97.5%	96.0%
SAU801663	UUR100269	41%	99.8%	99.2%
SAU801663	VCH102467	41%	99.8%	99.5%
SAU801663	YPS000947	41%	97.0%	96.0%
SAU801668	ABA100700	43%	96.3%	88.7%
SAU801668	BAN101055	53%	100%	99.7%
SAU801668	BAN100517	63%	100%	97.9%
SAU801668	BPT100922	45%	98.8%	95.6%
SAU801668	BCE101370	45%	98.1%	96.7%
SAU801668	BFU101599	45%	98.1%	96.7%
SAU801668	BMA104829	46%	98.1%	96.7%
SAU801668	CJU100923	50%	98.8%	98.5%
SAU801668	CPN200001	43%	98.1%	95.8%
SAU801668	CTR200001	42%	98.1%	95.5%
SAU801668	CAC102676	55%	98.8%	99.4%
SAU801668	CBO101832	54%	98.8%	98.1%
SAU801668	CDF102168	56%	98.8%	98.5%
SAU801668	CDP100775	48%	98.1%	97.9%
SAU801668	EBC102698	54%	67.3%	96.0%
SAU801668	ECO100361	49%	96.9%	92.8%
SAU801668	HPY100160	51%	99.4%	99.4%
SAU801668	KPN308372	49%	96.9%	96.0%
SAU801668	LPN101016	48%	98.5%	96.1%
SAU801668	LMO100837	66%	99.7%	99.1%
SAU801668	MCA101135	45%	98.5%	96.4%
SAU801668	MAV107884	45%	98.1%	97.9%
SAU801668	MBV102362	46%	98.1%	97.6%
SAU801668	MLP101436	44%	98.1%	97.0%
SAU801668	MTU200510	46%	98.1%	97.0%
SAU801668	NGO100861	43%	98.8%	95.3%
SAU801668	NME200933	44%	98.8%	95.3%
SAU801668	PMU101692	45%	98.1%	94.4%
SAU801668	PRT102370	49%	96.9%	95.7%
SAU801668	PAE205238	45%	98.8%	95.5%
SAU801668	PPU110651	47%	97.5%	96.6%
SAU801668	PSY101277	45%	96.0%	93.2%
SAU801668	SPA101546	46%	84.9%	94.7%
SAU801668	STY104591	49%	96.9%	96.0%
SAU801668	SAU801668	100%	100%	100%
SAU801668	SEP201642	90%	100%	100%
SAU801668	SHA101765	86%	62.3%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801668	VCH100105	45%	98.1%	92.5%
SAU801668	YPS000599	46%	98.1%	94.4%
SAU801669	BAN100994	40%	34.7%	32.9%
SAU801669	BAN107924	32%	80.6%	76.4%
SAU801669	CJU101006	23%	78.4%	81.3%
SAU801669	CDP100774	25%	82.4%	36.2%
SAU801669	LPN101520	24%	57.7%	54.8%
SAU801669	LMO101547	27%	87.8%	33.3%
SAU801669	MAV108772	27%	80.6%	36.2%
SAU801669	MBV102363	27%	80.6%	36.3%
SAU801669	MLP101437	26%	83.3%	36.6%
SAU801669	MTU200509	27%	80.6%	35.4%
SAU801669	SAU801669	100%	100%	100%
SAU801669	SEP201643	64%	99.5%	97.8%
SAU801669	SHA100589	55%	99.1%	97.3%
SAU801670	ABA104490	46%	98.7%	98.4%
SAU801670	BAN106158	43%	99.4%	99.7%
SAU801670	BAN110595	57%	99.4%	99.0%
SAU801670	BPT102803	42%	98.7%	96.8%
SAU801670	BCE100543	43%	97.7%	91.0%
SAU801670	BFU106232	45%	97.7%	91.6%
SAU801670	BMA109200	42%	97.7%	92.4%
SAU801670	CJU100507	40%	97.7%	98.0%
SAU801670	CPN200711	32%	56.5%	73.5%
SAU801670	CTR200564	33%	56.2%	70.7%
SAU801670	CAC102785	36%	94.8%	99.0%
SAU801670	CBO103439	44%	80.8%	83.4%
SAU801670	CDF103801	42%	96.1%	99.0%
SAU801670	CDP100772	33%	96.8%	99.0%
SAU801670	EBC102514	45%	96.8%	93.1%
SAU801670	ECO103717	45%	96.8%	93.1%
SAU801670	HPY100233	38%	98.4%	98.7%
SAU801670	KPN308138	43%	96.8%	95.2%
SAU801670	LPN101369	41%	97.1%	93.5%
SAU801670	LMO101599	52%	98.4%	98.4%
SAU801670	MCA101397	45%	98.7%	97.2%
SAU801670	MAV106921	35%	96.1%	94.7%
SAU801670	MBV102364	35%	96.1%	96.5%
SAU801670	MLP101438	34%	96.1%	94.7%
SAU801670	MTU200508	35%	96.1%	97.4%
SAU801670	NGO101908	46%	97.4%	96.5%
SAU801670	NME200661	46%	97.4%	96.5%
SAU801670	PMU101812	44%	98.4%	96.8%
SAU801670	PRT102814	44%	96.1%	94.6%
SAU801670	PAE205255	45%	97.7%	96.2%
SAU801670	PPU105501	44%	98.4%	96.8%
SAU801670	PSY101227	46%	97.7%	96.2%
SAU801670	SPA101514	44%	96.8%	94.0%
SAU801670	STY102055	46%	96.8%	95.2%
SAU801670	SAU801670	100%	100%	100%
SAU801670	SEP201644	82%	99.4%	99.4%
SAU801670	SHA100588	84%	99.7%	99.0%
SAU801670	VCH100120	43%	98.4%	95.6%
SAU801670	YPS001422	42%	96.1%	94.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801671	ABA100570	23%	94.5%	95.5%
SAU801671	BAN106101	27%	73.4%	77.6%
SAU801671	BAN113250	30%	95.9%	93.9%
SAU801671	BPT100926	21%	90.0%	52.5%
SAU801671	BCE109235	18%	75.3%	51.8%
SAU801671	BFU105613	18%	75.3%	50.9%
SAU801671	BMA103662	17%	92.6%	65.4%
SAU801671	CDP100805	24%	48.7%	43.5%
SAU801671	EBC102475	21%	90.4%	83.0%
SAU801671	ECO102558	22%	90.4%	83.0%
SAU801671	HIN101070	23%	63.1%	21.6%
SAU801671	HPY100374	20%	76.4%	21.3%
SAU801671	KPN301265	21%	72.0%	66.6%
SAU801671	MCA103521	23%	82.3%	84.8%
SAU801671	MAV108685	22%	82.3%	70.5%
SAU801671	MBV103201	24%	84.1%	70.7%
SAU801671	MLP101430	23%	84.1%	70.6%
SAU801671	MTU200526	24%	84.1%	70.7%
SAU801671	NGO101770	23%	56.5%	59.3%
SAU801671	NME202025	23%	56.5%	59.3%
SAU801671	PRT100857	20%	72.7%	66.1%
SAU801671	PAE203744	24%	82.3%	82.7%
SAU801671	PPU103412	26%	94.1%	92.2%
SAU801671	PSY103780	26%	49.1%	70.4%
SAU801671	SPA101534	20%	90.4%	83.0%
SAU801671	STY102227	20%	90.4%	90.9%
SAU801671	STM102478	20%	90.4%	90.9%
SAU801671	SAU801671	100%	100%	100%
SAU801671	SEP201645	73%	99.3%	99.6%
SAU801671	SHA100587	72%	99.3%	99.6%
SAU801671	SPN203453	20%	66.8%	62.4%
SAU801671	UUR100525	23%	69.4%	29.5%
SAU801671	VCH100549	24%	69.7%	68.9%
SAU801671	YPS003452	19%	72.0%	64.0%
SAU801677	SAU801677	100%	100%	100%
SAU801677	SEP201661	81%	100%	99.5%
SAU801677	SHA102781	72%	30.2%	98.4%
SAU801678	ABA102501	57%	99.2%	98.3%
SAU801678	BAN104202	58%	97.5%	96.6%
SAU801678	BAN110178	77%	97.5%	97.5%
SAU801678	BFR104064	55%	98.3%	100%
SAU801678	BPT100292	56%	99.2%	98.3%
SAU801678	BBU100187	50%	96.6%	99.1%
SAU801678	BCE102715	58%	99.2%	98.3%
SAU801678	BFU102443	59%	99.2%	98.3%
SAU801678	BMA107401	58%	99.2%	98.3%
SAU801678	CJU100217	52%	99.2%	100%
SAU801678	CPN200847	46%	100%	97.5%
SAU801678	CTR200218	48%	100%	95.9%
SAU801678	CAC101951	57%	96.6%	95.8%
SAU801678	CDF102735	55%	99.2%	99.2%
SAU801678	CDP100976	48%	99.2%	92.1%
SAU801678	EBC102984	61%	99.2%	99.2%
SAU801678	EFA200358	71%	99.2%	98.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801678	EFM201307	69%	99.2%	98.3%
SAU801678	ECO101684	61%	99.2%	99.2%
SAU801678	HIN101286	62%	99.2%	100%
SAU801678	HPY100124	47%	97.5%	99.1%
SAU801678	KPN301692	60%	99.2%	99.2%
SAU801678	LPN101410	58%	99.2%	98.3%
SAU801678	LMO100743	70%	99.2%	98.3%
SAU801678	MAV106548	50%	99.2%	89.3%
SAU801678	MBV101274	50%	99.2%	90.7%
SAU801678	MLP100866	50%	99.2%	90.7%
SAU801678	MTU201622	50%	99.2%	90.7%
SAU801678	MGE100200	51%	94.9%	90.3%
SAU801678	MPN100037	56%	94.9%	88.2%
SAU801678	NGO101855	63%	99.2%	98.3%
SAU801678	NME200857	63%	99.2%	98.3%
SAU801678	PMU100604	61%	99.2%	100%
SAU801678	PRT101306	62%	99.2%	99.2%
SAU801678	PAE202739	58%	99.2%	99.2%
SAU801678	PPU111376	58%	99.2%	99.2%
SAU801678	PSY109131	57%	99.2%	99.2%
SAU801678	SPA100657	60%	97.5%	95.8%
SAU801678	STY101118	61%	99.2%	99.2%
SAU801678	STM103448	61%	99.2%	99.2%
SAU801678	SAU801678	100%	100%	100%
SAU801678	SEP201662	94%	100%	100%
SAU801678	SHA100082	93%	100%	100%
SAU801678	SMU100912	63%	99.2%	98.3%
SAU801678	SPN400863	63%	99.2%	98.3%
SAU801678	SPY200598	63%	99.2%	98.3%
SAU801678	TPA100839	50%	89.0%	86.1%
SAU801678	UUR100231	54%	93.2%	96.7%
SAU801678	VCH103020	63%	99.2%	100%
SAU801678	YPS003061	62%	99.2%	99.2%
SAU801679	ABA102503	48%	97.0%	85.1%
SAU801679	BAN113355	72%	93.9%	93.9%
SAU801679	BAN109536	72%	93.9%	93.9%
SAU801679	BFR104500	46%	95.5%	100%
SAU801679	BPT100293	45%	97.0%	98.5%
SAU801679	BBU100188	41%	93.9%	93.9%
SAU801679	BCE106262	42%	92.4%	98.4%
SAU801679	BFU102444	40%	92.4%	98.4%
SAU801679	BMA105698	45%	97.0%	98.5%
SAU801679	CJU100216	40%	93.9%	96.8%
SAU801679	CPN200848	45%	93.9%	96.9%
SAU801679	CTR200217	41%	93.9%	96.9%
SAU801679	CAC101588	56%	97.0%	98.5%
SAU801679	CBO102406	57%	97.0%	98.5%
SAU801679	CDF104095	60%	97.0%	100%
SAU801679	CDP100973	50%	90.9%	93.8%
SAU801679	EBC102982	53%	97.0%	98.5%
SAU801679	EFA203061	66%	100%	100%
SAU801679	EFM202134	65%	100%	100%
SAU801679	ECO101685	48%	97.0%	98.5%
SAU801679	HIN101285	50%	97.0%	71.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801679	HPY100123	43%	93.9%	95.3%
SAU801679	KPN301691	48%	97.0%	98.5%
SAU801679	LPN101798	48%	92.4%	100%
SAU801679	LMO101064	66%	100%	100%
SAU801679	MAV106547	45%	93.9%	96.9%
SAU801679	MBV101273	43%	93.9%	96.9%
SAU801679	MLP100865	45%	93.9%	96.9%
SAU801679	MTU201621	43%	93.9%	96.9%
SAU801679	MGE100199	57%	89.4%	100%
SAU801679	MPN100038	55%	89.4%	100%
SAU801679	NGO101853	45%	97.0%	98.5%
SAU801679	NME200856	45%	97.0%	98.5%
SAU801679	PMU100603	50%	97.0%	98.5%
SAU801679	PRT103408	51%	97.0%	98.5%
SAU801679	PAE202740	54%	93.9%	95.3%
SAU801679	PPU103712	54%	93.9%	88.4%
SAU801679	PSY107471	51%	93.9%	95.3%
SAU801679	SPA100656	48%	97.0%	98.5%
SAU801679	STY101126	48%	97.0%	98.5%
SAU801679	STM103447	48%	97.0%	98.5%
SAU801679	SAU801679	100%	100%	100%
SAU801679	SEP201663	95%	100%	100%
SAU801679	SHA100081	93%	100%	100%
SAU801679	SMU100910	59%	100%	100%
SAU801679	SPN400862	59%	100%	100%
SAU801679	SPY200597	64%	93.9%	95.4%
SAU801679	TPA100840	41%	93.9%	93.9%
SAU801679	UUR100230	50%	90.9%	93.8%
SAU801679	VCH103019	43%	97.0%	98.4%
SAU801679	YPS003064	53%	97.0%	98.5%
SAU801680	ABA102498	43%	65.1%	100%
SAU801680	BAN104142	63%	100%	100%
SAU801680	BAN107901	63%	100%	87.7%
SAU801680	BFR100214	46%	96.5%	83.3%
SAU801680	BPT101959	52%	88.4%	92.7%
SAU801680	BBU100189	44%	97.7%	90.3%
SAU801680	BCE106172	46%	90.7%	100%
SAU801680	BFU107897	47%	90.7%	100%
SAU801680	BMA109299	48%	90.7%	100%
SAU801680	CJU100195	42%	97.7%	98.3%
SAU801680	CPN200849	45%	96.5%	89.2%
SAU801680	CTR200216	46%	94.2%	87.1%
SAU801680	CAC103337	52%	93.6%	92%
SAU801680	CBO100172	50%	93.6%	87.5%
SAU801680	CDF100791	52%	79.1%	96.5%
SAU801680	CDP100970	48%	82.6%	95.9%
SAU801680	EBC102980	51%	80.2%	96.5%
SAU801680	EFA200363	72%	100%	98.8%
SAU801680	EFM200354	73%	48.8%	94.4%
SAU801680	ECO101686	53%	94.2%	90.6%
SAU801680	HIN101284	50%	76.2%	97.8%
SAU801680	HPY100122	38%	100%	84.7%
SAU801680	KPN301690	52%	80.2%	96.5%
SAU801680	LMO102427	69%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801680	MCA103235	47%	84.9%	100%
SAU801680	MAV106545	46%	78.5%	78.0%
SAU801680	MBV103903	45%	87.2%	81.5%
SAU801680	MLP100864	46%	87.2%	81.1%
SAU801680	MTU201620	45%	95.3%	81.6%
SAU801680	MGE100198	28%	92.4%	87.8%
SAU801680	MPN100039	35%	77.9%	66.7%
SAU801680	NGO101851	50%	88.4%	98.1%
SAU801680	NME200855	50%	95.3%	94.8%
SAU801680	PMU100602	50%	87.2%	98.1%
SAU801680	PRT100107	49%	62.8%	97.3%
SAU801680	PAE202741	48%	99.4%	93.4%
SAU801680	PPU111378	47%	99.4%	93.4%
SAU801680	PSY102598	49%	99.4%	96.6%
SAU801680	SPA100655	51%	94.2%	90.6%
SAU801680	STY101129	52%	94.2%	90.6%
SAU801680	STM103446	53%	80.2%	96.5%
SAU801680	SAU801680	100%	100%	100%
SAU801680	SEP201664	94%	100%	98.3%
SAU801680	SMU100907	59%	100%	86%
SAU801680	SPN400861	61%	100%	88.2%
SAU801680	SPY200596	59%	100%	97.7%
SAU801680	TPA100841	44%	96.5%	92.7%
SAU801680	UUR100229	40%	89.5%	86.5%
SAU801680	YPS003067	53%	94.2%	90.7%
SAU801681	SAU801681	100%	100%	100%
SAU801682	KPN101788	53%	87.9%	98.2%
SAU801682	SAU801682	100%	100%	100%
SAU801682	SEP201665	87%	93.3%	58.8%
SAU801683	ABA102500	42%	97.2%	97.0%
SAU801683	BAN108871	64%	94.6%	96.9%
SAU801683	BAN105353	70%	97.5%	98.0%
SAU801683	BFR103141	45%	79.8%	99.4%
SAU801683	BPT101956	42%	99.4%	98.6%
SAU801683	BBU100719	40%	89.5%	98.6%
SAU801683	BCE105528	43%	98.8%	99.4%
SAU801683	BFU105096	43%	98.8%	97.4%
SAU801683	BMA106934	43%	99.2%	99.8%
SAU801683	CJU100194	42%	94.9%	99.8%
SAU801683	CPN201046	40%	96.3%	96.2%
SAU801683	CTR200859	40%	97.5%	97.8%
SAU801683	CAC102528	45%	99.1%	99.2%
SAU801683	CBO100249	47%	99.1%	95.2%
SAU801683	CDF102396	47%	99.2%	93.6%
SAU801683	CDP100262	40%	88.8%	87.3%
SAU801683	EBC102990	43%	98.4%	98.1%
SAU801683	EFA200266	67%	98.6%	98.9%
SAU801683	EFM200127	67%	98.8%	98.9%
SAU801683	ECO101687	43%	98.4%	98.1%
SAU801683	HIN101333	41%	98.9%	98.4%
SAU801683	HPY100121	41%	90.2%	93.5%
SAU801683	KPN300773	43%	95.7%	98.4%
SAU801683	LPN100924	45%	94.9%	99.7%
SAU801683	LMO102823	72%	98.6%	99.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801683	MCA103158	43%	99.5%	99.4%
SAU801683	MAV102514	41%	90.1%	88.2%
SAU801683	MBV100785	40%	92.1%	88.5%
SAU801683	MLP100282	39%	96.3%	91.0%
SAU801683	MTU202577	40%	92.1%	89.2%
SAU801683	MGE100386	42%	81.6%	92.7%
SAU801683	MPN100289	41%	82.3%	93.6%
SAU801683	NGO101849	44%	98.6%	97.1%
SAU801683	NME200854	44%	98.6%	98.7%
SAU801683	PMU100593	41%	98.9%	98.4%
SAU801683	PRT105628	42%	98.4%	98.1%
SAU801683	PAE202742	41%	97.1%	96.9%
SAU801683	PPU103710	41%	97.2%	97.0%
SAU801683	PSY102599	42%	97.1%	96.9%
SAU801683	SPA100654	41%	75.0%	96.1%
SAU801683	STY101132	43%	98.4%	98.1%
SAU801683	STM103445	43%	98.4%	98.1%
SAU801683	SAU801683	100%	100%	100%
SAU801683	SEP201666	89%	100%	100%
SAU801683	SHA100279	92%	75.8%	100%
SAU801683	SMU101079	64%	99.1%	98.8%
SAU801683	SPN401471	63%	99.1%	97.1%
SAU801683	SPY200371	63%	99.1%	98.8%
SAU801683	TPA100828	41%	85.1%	92.4%
SAU801683	UUR100540	49%	88.5%	98.8%
SAU801683	VCH103018	42%	98.9%	98.8%
SAU801683	YPS003070	42%	98.4%	98.1%
SAU801687	ABA101897	42%	94.4%	97.9%
SAU801687	BAN112255	62%	98.5%	98.8%
SAU801687	BFR105929	48%	95.6%	98.8%
SAU801687	BPT100913	48%	98.2%	100%
SAU801687	BBU100057	50%	95.0%	98.8%
SAU801687	BCE100315	50%	95.3%	97.9%
SAU801687	BMA104624	49%	95.3%	97.9%
SAU801687	CBO101733	52%	97.4%	99.7%
SAU801687	CDF104406	52%	97.4%	99.7%
SAU801687	EBC101178	50%	94.1%	96.7%
SAU801687	ECO101747	47%	96.2%	99.4%
SAU801687	HIN100001	46%	96.2%	98.5%
SAU801687	HPY101328	41%	96.2%	99.1%
SAU801687	KPN301260	49%	94.1%	96.7%
SAU801687	LPN102268	52%	96.2%	99.1%
SAU801687	MCA100654	37%	95.9%	95.3%
SAU801687	NGO100736	49%	97.1%	98.3%
SAU801687	NME200057	48%	97.1%	98.3%
SAU801687	PRT101067	46%	96.2%	99.4%
SAU801687	PAE203193	50%	96.8%	99.1%
SAU801687	PPU103462	51%	94.7%	97.3%
SAU801687	PSY104227	51%	94.7%	97.3%
SAU801687	SPA101906	43%	97.1%	99.1%
SAU801687	STY101244	48%	96.2%	99.4%
SAU801687	SAU801687	100%	100%	100%
SAU801687	SEP201680	82%	99.7%	99.7%
SAU801687	TPA100835	41%	95.0%	98.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801694	ABA105254	61%	99.3%	96.9%
SAU801694	BAN112004	77%	99.5%	97.7%
SAU801694	BFR10209	60%	99.1%	99.2%
SAU801694	BPT102694	62%	99.1%	97.1%
SAU801694	BCE100542	64%	84.6%	96.6%
SAU801694	BFU100077	62%	57.1%	96.2%
SAU801694	BMA102395	63%	99.3%	97.1%
SAU801694	CAC100329	38%	95.0%	98.2%
SAU801694	CBO103577	37%	95.0%	98.5%
SAU801694	CDF102339	38%	94.5%	98.2%
SAU801694	EBC103518	62%	99.1%	97.4%
SAU801694	ECO101109	62%	99.1%	97.4%
SAU801694	HPY100026	61%	99.1%	96.7%
SAU801694	KPN301139	64%	85.5%	93.0%
SAU801694	LPN103112	66%	31.5%	100%
SAU801694	LMO101307	77%	99.1%	99.5%
SAU801694	PMU101606	61%	99.1%	97.6%
SAU801694	PRT100717	50%	11.8%	100%
SAU801694	PRT100403	64%	98.8%	97.1%
SAU801694	PAE202621	62%	99.5%	97.6%
SAU801694	PPU100885	61%	98.8%	96.9%
SAU801694	SPA104215	59%	99.1%	98.1%
SAU801694	STY102941	62%	99.1%	97.4%
SAU801694	STM102772	62%	99.1%	97.4%
SAU801694	SAU801694	100%	100%	100%
SAU801694	SEP201686	93%	100%	100%
SAU801694	SHA100973	92%	100%	100%
SAU801694	SMU100855	56%	99.3%	98.5%
SAU801694	YPS000338	61%	99.1%	97.4%
SAU801695	ABA106072	35%	97.9%	95.3%
SAU801695	BAN107073	56%	98.4%	98.9%
SAU801695	BFR11387	33%	99.2%	94.8%
SAU801695	BPT101641	35%	97.9%	91.8%
SAU801695	BCE115034	36%	97.9%	94.1%
SAU801695	BFU102001	35%	97.9%	94.3%
SAU801695	BFU100604	36%	98.1%	93.2%
SAU801695	BMA104539	37%	97.9%	94.1%
SAU801695	CJU101587	35%	97.6%	90.3%
SAU801695	CDP100042	36%	99.7%	91.1%
SAU801695	EBC101675	34%	96.5%	88.1%
SAU801695	ECO100325	36%	98.1%	94.6%
SAU801695	HPY100025	34%	95.2%	89.7%
SAU801695	KPN302561	34%	96.5%	88.5%
SAU801695	LPN101295	37%	99.7%	99.7%
SAU801695	LMO101744	54%	98.9%	99.2%
SAU801695	MCA103218	38%	94.1%	85.6%
SAU801695	MAV103161	38%	96.8%	96.5%
SAU801695	MBV104689	38%	97.1%	91.9%
SAU801695	MLP101277	34%	93.0%	84.2%
SAU801695	MTU201116	38%	97.1%	91.9%
SAU801695	NGO100564	37%	97.9%	95.5%
SAU801695	NME201898	37%	97.9%	95.6%
SAU801695	PMU100276	33%	92.8%	84.3%
SAU801695	PRT102070	33%	96.5%	88.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801695	PAE200794	41%	98.1%	97.3%
SAU801695	PPU111305	41%	98.1%	97.3%
SAU801695	PSY105567	39%	98.1%	96.3%
SAU801695	SPA102598	34%	93.6%	95.9%
SAU801695	STY104558	36%	97.9%	94.3%
SAU801695	STM104272	35%	97.9%	94.3%
SAU801695	SAU801695	100%	100%	100%
SAU801695	SEP201687	85%	99.7%	99.7%
SAU801695	SHA100972	82%	99.7%	100%
SAU801695	SMU100854	49%	99.7%	100%
SAU801695	VCH101317	37%	98.1%	97.1%
SAU801695	YPS002059	35%	96.5%	88.3%
SAU801697	BAN102623	60%	100%	100%
SAU801697	BFR102996	41%	81.4%	96.5%
SAU801697	BPT102404	37%	80.2%	96.9%
SAU801697	BBU100347	43%	80.9%	97.9%
SAU801697	BCE107531	40%	80.9%	85.7%
SAU801697	BFU103511	40%	80.9%	75.2%
SAU801697	BMA100592	39%	80.9%	99.2%
SAU801697	CJU100360	44%	80.2%	97.5%
SAU801697	CPN200665	39%	81.7%	98.6%
SAU801697	CTR200601	42%	76.9%	93.8%
SAU801697	CAC102744	53%	80.7%	99.8%
SAU801697	CBO103563	49%	100%	100%
SAU801697	CDF101154	50%	100%	99.3%
SAU801697	CDP101191	41%	81.2%	98.9%
SAU801697	EBC101988	38%	80.7%	99.2%
SAU801697	EFA202113	60%	99.1%	99.1%
SAU801697	EFM201839	52%	99.1%	99.2%
SAU801697	ECO101644	48%	80.7%	100%
SAU801697	HIN101541	40%	77.8%	95.8%
SAU801697	KPN306162	51%	73.2%	100%
SAU801697	LPN100837	36%	76.4%	99.1%
SAU801697	LMO101206	58%	99.1%	99.1%
SAU801697	MAV106549	40%	81.0%	99.2%
SAU801697	MBV101766	38%	76.6%	99.5%
SAU801697	MLP100794	39%	81.0%	99.2%
SAU801697	MTU201596	38%	81.0%	99.2%
SAU801697	MGE100220	40%	58.3%	72.2%
SAU801697	MPN100533	41%	58.3%	72.2%
SAU801697	NGO101773	40%	79.7%	96.3%
SAU801697	NME200171	40%	79.7%	96.3%
SAU801697	PMU100653	39%	79.1%	97.3%
SAU801697	PRT102320	47%	80.7%	100%
SAU801697	PAE201497	37%	81.5%	99.0%
SAU801697	PPU107170	39%	80%	98.3%
SAU801697	PSY105033	39%	81.4%	99.4%
SAU801697	SPA101649	53%	45.0%	100%
SAU801697	STY101028	47%	80.7%	100%
SAU801697	STM101984	38%	80.2%	98.3%
SAU801697	SAU801697	100%	100%	100%
SAU801697	SEP201702	89%	100%	100%
SAU801697	SHA100298	88%	77.8%	100%
SAU801697	SMU101016	42%	80.5%	99.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801697	SPN400797	42%	80.5%	99.4%
SAU801697	SPY200985	42%	80.5%	99.4%
SAU801697	UUR100186	38%	56.9%	75.3%
SAU801697	VCH100480	50%	80.7%	100%
SAU801697	YPS002962	47%	80.7%	100%
SAU801698	BAN100067	60%	100%	95.3%
SAU801698	BFR11519	47%	100%	90.9%
SAU801698	BBU100726	26%	90.6%	71.0%
SAU801698	CPN200599	24%	68.1%	41.2%
SAU801698	CTR200472	23%	64.8%	39.1%
SAU801698	CAC100105	50%	99.7%	95.0%
SAU801698	CBO101518	47%	99.7%	92.7%
SAU801698	CDF101157	57%	100%	95.3%
SAU801698	CDP100166	35%	93.8%	90.6%
SAU801698	EBC106796	50%	99.3%	94.7%
SAU801698	EFA202114	53%	99.7%	95%
SAU801698	EFM200509	54%	99.7%	95%
SAU801698	ECO103822	48%	99.3%	94.7%
SAU801698	HIN100963	47%	99.3%	94.7%
SAU801698	KPN300184	56%	7.5%	41.1%
SAU801698	KPN306771	48%	99.3%	94.7%
SAU801698	LPN100265	25%	83.1%	64.5%
SAU801698	LMO100385	59%	100%	95.3%
SAU801698	MAV101408	36%	90.6%	87.8%
SAU801698	MBV103661	37%	90.6%	87.8%
SAU801698	MLP101042	36%	90.6%	87.8%
SAU801698	MTU202972	37%	90.6%	87.8%
SAU801698	MGE100219	35%	93.8%	89.8%
SAU801698	MPN100534	38%	93.8%	88.4%
SAU801698	PMU100069	46%	99.3%	94.7%
SAU801698	PRT100706	47%	99.3%	93.8%
SAU801698	SPA101674	49%	99.3%	94.7%
SAU801698	STY103207	49%	99.3%	94.7%
SAU801698	STM101597	49%	99.3%	94.7%
SAU801698	SAU801698	100%	100%	100%
SAU801698	SEP201703	84%	100%	100%
SAU801698	SHA100297	81%	100%	95.3%
SAU801698	SMU101017	50%	90.9%	82.8%
SAU801698	SPN400796	56%	90.9%	83.0%
SAU801698	SPY200986	53%	90.9%	82.8%
SAU801698	TPA100107	25%	95.1%	74.2%
SAU801698	UUR100185	24%	92.5%	89.4%
SAU801698	VCH102652	50%	99.3%	91.5%
SAU801698	YPS001617	48%	99.3%	94.8%
SAU801700	ABA100308	52%	83.8%	96.0%
SAU801700	BAN105768	63%	98.4%	95.4%
SAU801700	BPT101398	52%	99.7%	97.5%
SAU801700	BCE106451	53%	99.7%	96.9%
SAU801700	BFU100947	53%	99.7%	96.9%
SAU801700	BMA107589	53%	99.7%	96.9%
SAU801700	CJU100411	51%	99.7%	98.4%
SAU801700	CPN200335	48%	99.4%	96.3%
SAU801700	CTR200529	48%	99.4%	96.3%
SAU801700	CAC100492	60%	84.1%	96.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801700	CBO102220	56%	88.9%	50.3%
SAU801700	CDF101403	55%	95.5%	95.5%
SAU801700	EBC102554	53%	98.4%	97.8%
SAU801700	EFA200247	53%	80.6%	96.6%
SAU801700	EFM200190	56%	80.6%	96.9%
SAU801700	ECO100185	52%	98.4%	97.8%
SAU801700	HIN100386	53%	98.4%	97.8%
SAU801700	HPY100550	48%	99.7%	97.8%
SAU801700	KPN301921	53%	98.4%	97.8%
SAU801700	LPN101352	52%	85.0%	98.9%
SAU801700	LMO100159	60%	99.0%	97.8%
SAU801700	MCA100190	53%	80.3%	98.4%
SAU801700	MLP101010	25%	44.9%	29.0%
SAU801700	NGO100369	50%	99.7%	98.1%
SAU801700	NME201237	50%	99.7%	98.1%
SAU801700	PMU100292	53%	98.4%	97.8%
SAU801700	PRT100667	51%	98.4%	97.8%
SAU801700	PRT101241	51%	98.4%	97.8%
SAU801700	PAE203637	52%	98.7%	98.1%
SAU801700	PPU101171	51%	98.4%	98.1%
SAU801700	PSY108491	50%	98.4%	97.5%
SAU801700	SPA100816	47%	89.2%	99.3%
SAU801700	STY103916	53%	98.4%	97.8%
SAU801700	STM103628	53%	98.4%	97.8%
SAU801700	SAU801700	100%	100%	100%
SAU801700	SEP201704	85%	100%	100%
SAU801700	SHA100923	86%	100%	99.7%
SAU801700	SMU100529	56%	79.0%	95.3%
SAU801700	SPN400387	56%	79.9%	96.9%
SAU801700	SPY201342	56%	79.0%	95.3%
SAU801700	VCH102210	52%	98.4%	97.8%
SAU801700	YPS001157	54%	98.4%	97.8%
SAU801701	ABA101266	42%	86.3%	83.2%
SAU801701	BAN103283	66%	98.6%	96.9%
SAU801701	BFR11219	27%	65.3%	34.0%
SAU801701	BFR11611	29%	76.8%	89.6%
SAU801701	BFR11899	29%	64.6%	33.9%
SAU801701	BPT100791	46%	94.0%	94.5%
SAU801701	BCE105100	57%	44.9%	94.1%
SAU801701	BFU114977	42%	91.6%	91.4%
SAU801701	BMA103750	43%	90.2%	89.7%
SAU801701	CJU100116	46%	97.2%	97.5%
SAU801701	CPN200705	46%	86.3%	80.8%
SAU801701	CTR200558	46%	86.3%	88.0%
SAU801701	CAC103552	58%	95.1%	98.2%
SAU801701	CDF101011	50%	98.9%	100%
SAU801701	CDP100046	35%	76.5%	43.1%
SAU801701	EBC101249	46%	83.9%	96.0%
SAU801701	EFA200246	53%	95.1%	96.5%
SAU801701	EFM200144	51%	95.8%	96.2%
SAU801701	ECO102274	47%	91.6%	86.8%
SAU801701	HIN101232	47%	90.5%	88.2%
SAU801701	HPY100934	47%	96.8%	95.5%
SAU801701	KPN302817	46%	91.6%	86.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801701	LPN101645	49%	66.0%	85.8%
SAU801701	LMO101514	60%	98.2%	95.6%
SAU801701	MCA101005	47%	63.2%	95.7%
SAU801701	MAV105603	37%	76.8%	44.3%
SAU801701	MBV105423	38%	74.0%	42.2%
SAU801701	MLP100072	31%	64.9%	78.9%
SAU801701	MTU200895	38%	74.0%	42.2%
SAU801701	NGO100954	44%	90.2%	89.7%
SAU801701	NME200815	44%	90.5%	90%
SAU801701	PMU100636	47%	90.5%	85.9%
SAU801701	PRT103138	29%	29.5%	70.2%
SAU801701	PRT100424	46%	91.6%	82.5%
SAU801701	PAE203110	45%	90.9%	90.3%
SAU801701	PPU105860	45%	90.2%	87.5%
SAU801701	PSY101722	44%	90.2%	85.0%
SAU801701	SPA100127	43%	47.7%	61.8%
SAU801701	STY101011	46%	91.6%	86.8%
SAU801701	SAU801701	100%	100%	100%
SAU801701	SEP201705	90%	99.6%	99.6%
SAU801701	SHA100922	88%	100%	99.3%
SAU801701	SMU100531	50%	95.1%	96.9%
SAU801701	SPN400386	48%	95.4%	96.9%
SAU801701	SPY201343	47%	95.1%	96.9%
SAU801701	VCH100983	46%	91.6%	85.7%
SAU801701	YPS002401	46%	91.6%	86.8%
SAU801703	ABA101411	32%	91.1%	87.3%
SAU801703	BAN112326	40%	93.0%	92.9%
SAU801703	BFR102018	32%	71.5%	61.8%
SAU801703	BPT101552	31%	94.5%	93.1%
SAU801703	BBU100578	33%	98.2%	96.8%
SAU801703	BCE115231	33%	90.6%	88.1%
SAU801703	BFU107633	33%	90.6%	86.9%
SAU801703	BMA101634	33%	90.6%	88.3%
SAU801703	CJU100668	36%	8.8%	11.4%
SAU801703	CPN200079	35%	10.0%	15.6%
SAU801703	CTR200821	31%	94.2%	91.0%
SAU801703	CAC103161	35%	91.9%	91.9%
SAU801703	CBO100607	32%	99.7%	99.3%
SAU801703	CBO101196	32%	99.6%	98.7%
SAU801703	CDF101163	35%	92.4%	90.7%
SAU801703	CDP101233	36%	14.1%	16.2%
SAU801703	EBC102553	32%	93.8%	93.0%
SAU801703	EFA202115	37%	97.0%	96.8%
SAU801703	EFM200294	38%	91.1%	90.8%
SAU801703	ECO100184	33%	93.8%	93.0%
SAU801703	HIN100720	32%	93.8%	92.9%
SAU801703	HPY101439	30%	93.4%	91.7%
SAU801703	KPN301922	32%	93.8%	93.0%
SAU801703	LPN102982	33%	97.5%	97.0%
SAU801703	LMO100629	40%	95.8%	97.4%
SAU801703	MCA102321	33%	83.2%	81.0%
SAU801703	MAV103371	32%	92.0%	92.1%
SAU801703	MBV102577	31%	92.0%	93.1%
SAU801703	MLP100747	32%	92.0%	92.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801703	MTU201526	31%	92.0%	91.8%
SAU801703	MGE100266	31%	77.2%	95.5%
SAU801703	MPN100459	33%	72.3%	89.2%
SAU801703	NGO101860	31%	92.8%	92.4%
SAU801703	NME200585	32%	92.8%	92.4%
SAU801703	PMU100034	32%	93.8%	92.9%
SAU801703	PRT101242	33%	92.0%	92.9%
SAU801703	PAE203638	32%	90.6%	90.5%
SAU801703	PPU100137	32%	93.9%	93.4%
SAU801703	PSY104339	31%	90.6%	90.5%
SAU801703	SPA100912	31%	93.8%	93.7%
SAU801703	STY103914	33%	93.8%	93.0%
SAU801703	STM103627	33%	93.8%	93.0%
SAU801703	SAU801703	100%	100%	100%
SAU801703	SEP201707	70%	100%	100%
SAU801703	SHA100359	68%	99.7%	97.1%
SAU801703	SMU101018	33%	92.8%	93.5%
SAU801703	SPN400795	34%	92.4%	92.3%
SAU801703	SPY200987	34%	92.4%	93.1%
SAU801703	TPA100661	34%	93.7%	90.8%
SAU801703	UUR100419	35%	87.5%	94.8%
SAU801703	VCH102211	31%	94.5%	93.3%
SAU801703	YPS001155	33%	92.9%	91.5%
SAU801712	BAN110414	35%	96.8%	98.8%
SAU801712	EFA202191	33%	71.4%	95.6%
SAU801712	EFM201485	35%	80.3%	76.4%
SAU801712	HIN100304	26%	31.4%	40.7%
SAU801712	LMO102042	34%	99.0%	100%
SAU801712	PMU100985	25%	31.4%	40.7%
SAU801712	PAE201895	23%	30.2%	21.1%
SAU801712	SAU801712	100%	100%	100%
SAU801712	SEP201729	83%	100%	100%
SAU801712	SHA100433	82%	100%	100%
SAU801712	SMU100537	30%	94.3%	89.3%
SAU801712	SPN401853	35%	79.0%	77.0%
SAU801712	SPY200081	33%	82.2%	80.1%
SAU801719	ABA100128	47%	100%	100%
SAU801719	BAN103804	78%	100%	100%
SAU801719	BFR10425	48%	100%	100%
SAU801719	BPT100895	43%	100%	100%
SAU801719	BBU100614	39%	100%	98.6%
SAU801719	BCE103241	44%	100%	100%
SAU801719	BFU101595	44%	100%	100%
SAU801719	BMA100015	44%	100%	100%
SAU801719	CJU101500	46%	100%	100%
SAU801719	CPN200012	40%	99.5%	98.6%
SAU801719	CTR200903	43%	99.5%	98.6%
SAU801719	CAC102218	42%	100%	100%
SAU801719	CBO101434	44%	100%	100%
SAU801719	CDF103315	49%	86.5%	90.6%
SAU801719	CDP100020	50%	100%	100%
SAU801719	EBC103653	47%	100%	100%
SAU801719	EFA202012	66%	100%	99.0%
SAU801719	ECO103219	47%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801719	HIN100782	47%	100%	100%
SAU801719	HPY101276	47%	100%	100%
SAU801719	KPN300702	47%	100%	100%
SAU801719	LMO100680	75%	100%	100%
SAU801719	MCA100425	46%	100%	100%
SAU801719	MAV101010	48%	100%	100%
SAU801719	MBV100325	46%	100%	100%
SAU801719	MLP101195	47%	100%	100%
SAU801719	MTU203411	46%	100%	100%
SAU801719	MGE100317	42%	99%	98.0%
SAU801719	MPN100395	44%	99%	98.0%
SAU801719	NGO100887	47%	100%	100%
SAU801719	NME200098	47%	100%	100%
SAU801719	PMU101391	48%	100%	100%
SAU801719	PRT104446	48%	100%	100%
SAU801719	PAE204237	46%	100%	100%
SAU801719	PPU108168	47%	100%	100%
SAU801719	PSY107923	42%	100%	100%
SAU801719	SPA104316	47%	100%	100%
SAU801719	STY101827	47%	100%	100%
SAU801719	SAU801719	100%	100%	100%
SAU801719	SEP201745	93%	100%	100%
SAU801719	SHA100142	92%	100%	100%
SAU801719	SMU101344	66%	100%	99.0%
SAU801719	SPN400078	65%	100%	99.0%
SAU801719	SPY201664	65%	100%	99.0%
SAU801719	TPA100303	41%	94%	94.6%
SAU801719	UUR100503	48%	100%	99.0%
SAU801719	VCH102535	47%	100%	100%
SAU801719	YPS002492	45%	100%	100%
SAU801722	BFU111473	28%	73.0%	55.5%
SAU801722	KPN305062	23%	86.5%	88.8%
SAU801722	SAU801722	100%	100%	100%
SAU801722	SEP201747	65%	96.6%	97.9%
SAU801722	SHA101468	65%	90.5%	100%
SAU801723	ABA103811	23%	93.0%	91.1%
SAU801723	BAN112134	22%	77.9%	82.1%
SAU801723	BAN108173	23%	91.2%	96.4%
SAU801723	BFR11044	24%	91.2%	97.5%
SAU801723	BCE109919	27%	89.4%	96.3%
SAU801723	BFU103313	28%	86.5%	90.2%
SAU801723	BMA103073	28%	89.4%	96.3%
SAU801723	CAC101326	28%	91.9%	98.3%
SAU801723	CBO103823	29%	91.9%	98.0%
SAU801723	CDF100905	29%	91.9%	97.8%
SAU801723	EBC100388	22%	53.0%	98.0%
SAU801723	EFA202078	25%	95.8%	96.5%
SAU801723	EFM101508	25%	49.6%	96.0%
SAU801723	ECO100882	22%	50.6%	55.0%
SAU801723	HPY100724	31%	92.7%	94.0%
SAU801723	KPN302433	23%	92.7%	90.8%
SAU801723	MCA100242	26%	53.2%	56%
SAU801723	PRT102617	21%	71.4%	76.0%
SAU801723	PAE201309	23%	69.6%	71.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801723	PPU111438	22%	93.0%	97.3%
SAU801723	SPA103653	26%	77.1%	81.2%
SAU801723	STY100702	24%	91.2%	96.2%
SAU801723	STM100412	25%	91.2%	96.2%
SAU801723	SAU801723	100%	100%	100%
SAU801723	SEP201749	75%	99.7%	100%
SAU801723	SHA100581	70%	99.2%	99.2%
SAU801723	SMU101221	20%	44.9%	52.9%
SAU801723	VCH100387	28%	87.5%	91.7%
SAU801723	YPS001257	23%	50.6%	54.8%
SAU801726	EBC101577	48%	98.8%	100%
SAU801726	EFA201939	51%	99.6%	72.6%
SAU801726	EFM200960	51%	99.6%	72.7%
SAU801726	KPN100130	42%	65.4%	98.4%
SAU801726	PMU100876	49%	99.4%	98.8%
SAU801726	PRT101158	48%	98.0%	71.2%
SAU801726	SAU801726	100%	100%	100%
SAU801726	SEP202071	77%	100%	99.8%
SAU801726	SHA100570	76%	100%	100%
SAU801726	YPS001239	48%	98.0%	71.5%
SAU801727	ABA100079	26%	70.7%	77.9%
SAU801727	BAN103991	44%	80%	83.2%
SAU801727	BAN111056	44%	96.6%	97.5%
SAU801727	BFR105109	25%	62.4%	46.1%
SAU801727	BPT101209	24%	73.7%	64.9%
SAU801727	BBU100037	24%	82.9%	72%
SAU801727	BCE112943	25%	67.8%	27.5%
SAU801727	BFU101555	27%	77.1%	64.7%
SAU801727	BMA102538	29%	78.0%	63.7%
SAU801727	CJU100479	25%	56.1%	50.9%
SAU801727	CPN200177	23%	93.2%	92.5%
SAU801727	CTR200728	24%	78.5%	78.2%
SAU801727	CAC103311	25%	96.1%	83.8%
SAU801727	CBO103145	25%	88.3%	77.5%
SAU801727	CDF100095	34%	81.0%	82.3%
SAU801727	CDP101961	30%	73.2%	24.9%
SAU801727	EBC100878	23%	81.0%	70.1%
SAU801727	EFA200862	34%	91.2%	93.8%
SAU801727	EFM200018	33%	96.6%	88.6%
SAU801727	ECO102952	23%	81.0%	69.8%
SAU801727	HIN100714	26%	83.4%	75%
SAU801727	HPY101330	32%	62.4%	54.2%
SAU801727	KPN305544	25%	55.1%	49.0%
SAU801727	LPN102983	30%	79.0%	69.5%
SAU801727	LMO100144	41%	97.1%	97.0%
SAU801727	MAV103253	25%	72.7%	60%
SAU801727	MBV105256	31%	62.4%	51.0%
SAU801727	MLP100059	25%	72.7%	59.5%
SAU801727	MTU203761	31%	62.4%	51.0%
SAU801727	MGE100216	25%	63.4%	53.0%
SAU801727	MPN100537	22%	70.2%	56.0%
SAU801727	NGO100013	30%	65.9%	55.5%
SAU801727	NME200377	31%	69.3%	58.3%
SAU801727	PMU102001	22%	73.2%	76.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801727	PRT101005	25%	86.8%	75.1%
SAU801727	PAE200005	29%	59.5%	47.9%
SAU801727	PPU103632	25%	71.7%	59.4%
SAU801727	PSY103533	29%	70.2%	58.2%
SAU801727	SPA103206	25%	46.3%	95.1%
SAU801727	STY100460	23%	81.0%	69.8%
SAU801727	SAU801727	100%	100%	100%
SAU801727	SEP202072	80%	100%	99.0%
SAU801727	SHA100569	80%	100%	99.0%
SAU801727	SMU100763	32%	96.1%	78%
SAU801727	SPN401464	34%	95.6%	73.5%
SAU801727	SPY201080	32%	96.1%	71.7%
SAU801727	VCH101936	26%	66.8%	22.7%
SAU801727	YPS002560	28%	63.9%	62.9%
SAU801729	ABA100977	27%	94.0%	92.2%
SAU801729	BAN112022	61%	98.8%	99.5%
SAU801729	BFR102131	47%	98.1%	98.6%
SAU801729	BPT102833	27%	90.5%	86.8%
SAU801729	BBU100369	40%	98.8%	99.3%
SAU801729	BCE105055	26%	94.5%	93.2%
SAU801729	BFU103526	26%	90.5%	85.1%
SAU801729	BMA103960	27%	94.5%	81.4%
SAU801729	CJU101196	26%	94.0%	93.8%
SAU801729	CPN200392	39%	90.7%	91.7%
SAU801729	CTR200327	39%	97.4%	97.6%
SAU801729	CAC102127	43%	99.3%	99.3%
SAU801729	CBO100352	46%	98.6%	98.5%
SAU801729	CDF100316	26%	94.3%	97.7%
SAU801729	CDP101017	44%	98.8%	99.0%
SAU801729	EBC101794	48%	98.3%	98.1%
SAU801729	EFA201026	58%	99.8%	100%
SAU801729	EFM101163	56%	98.1%	98.3%
SAU801729	ECO101607	48%	98.3%	98.1%
SAU801729	HIN101577	28%	98.8%	96.8%
SAU801729	HPY100761	28%	94.0%	93.5%
SAU801729	KPN300735	41%	83.3%	99.2%
SAU801729	LPN101252	27%	91.2%	89.8%
SAU801729	LMO100615	59%	99.0%	99.5%
SAU801729	MCA103163	27%	96.7%	94.6%
SAU801729	MAV104042	44%	98.1%	98.1%
SAU801729	MBV103086	43%	97.4%	97.9%
SAU801729	MLP100838	44%	98.1%	98.1%
SAU801729	MTU201668	43%	98.1%	97.9%
SAU801729	MGE100464	34%	99.3%	96.1%
SAU801729	MPN100173	36%	99.3%	98.2%
SAU801729	NGO101762	48%	98.3%	98.8%
SAU801729	NME200576	49%	98.3%	98.8%
SAU801729	PMU100755	28%	98.8%	98.2%
SAU801729	PRT103206	48%	92.9%	98.5%
SAU801729	PAE204135	39%	97.6%	96.1%
SAU801729	PPU102660	30%	88.8%	89.0%
SAU801729	PSY103333	31%	86.2%	85.4%
SAU801729	SPA102382	48%	98.3%	99.0%
SAU801729	STY100579	48%	98.3%	98.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801729	STM104067	48%	98.3%	98.1%
SAU801729	SAU801729	100%	100%	100%
SAU801729	SEP202075	89%	100%	99.8%
SAU801729	SHA101242	86%	100%	100%
SAU801729	SMU100562	55%	98.8%	99.5%
SAU801729	SPN401907	52%	98.8%	99.5%
SAU801729	SPY200069	55%	98.8%	99.5%
SAU801729	TPA100825	38%	97.9%	95.4%
SAU801729	UUR100116	44%	98.3%	98.1%
SAU801729	VCH100460	49%	99.0%	96.1%
SAU801729	YPS002930	48%	98.8%	98.6%
SAU801731	BAN111612	27%	13.2%	11.7%
SAU801731	BAN104612	23%	20.1%	70.9%
SAU801731	BAN104171	27%	11.2%	68.4%
SAU801731	BAN109296	23%	29.2%	47.3%
SAU801731	CAC102751	23%	22.3%	33.1%
SAU801731	LMO100495	23%	59.6%	62.7%
SAU801731	SAU801129	42%	0.7%	37.1%
SAU801731	SAU801731	100%	100%	100%
SAU801731	SMU100069	26%	10.2%	13.5%
SAU801733	ABA104697	39%	97.4%	90.0%
SAU801733	BAN107191	68%	100%	99.8%
SAU801733	BPT101744	36%	94.2%	87.1%
SAU801733	BCE108358	31%	8.1%	38.2%
SAU801733	BCE107626	38%	91.7%	81.5%
SAU801733	BFU102771	37%	94.2%	87.3%
SAU801733	BMA105405	39%	91.7%	85%
SAU801733	CJU101446	37%	95.2%	88.0%
SAU801733	EBC104475	39%	97.4%	86.1%
SAU801733	ECO103963	38%	99.3%	90.6%
SAU801733	HPY101028	37%	94.2%	86.7%
SAU801733	KPN304710	38%	99.3%	91.2%
SAU801733	LPN103537	38%	91.2%	86.4%
SAU801733	MAV102747	38%	95.4%	88.8%
SAU801733	MBV104988	38%	95.4%	89.2%
SAU801733	MTU203613	38%	95.4%	89.2%
SAU801733	PMU100692	39%	94.2%	87.1%
SAU801733	PRT105882	37%	93.7%	84.1%
SAU801733	PAE204729	40%	93.8%	87.3%
SAU801733	PPU108448	36%	95.2%	89.6%
SAU801733	PSY103165	38%	93.7%	90.2%
SAU801733	SPA101860	35%	99.3%	91.5%
SAU801733	STY102326	37%	99.3%	90.6%
SAU801733	STM104274	28%	93.8%	90.8%
SAU801733	SAU801733	100%	100%	100%
SAU801733	SHA101238	83%	100%	99.8%
SAU801733	VCH100294	37%	93.7%	84.7%
SAU801733	YPS002593	38%	98.6%	91.0%
SAU801738	ABA106084	26%	79.9%	39.5%
SAU801738	BCE103763	21%	53.5%	73.2%
SAU801738	BFU115601	24%	43.8%	28.5%
SAU801738	CJU101364	29%	42.9%	51.9%
SAU801738	CTR200035	22%	83.8%	24.6%
SAU801738	EBC102124	26%	72.6%	60.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801738	ECO100722	28%	76.1%	60.6%
SAU801738	HPY100318	22%	88.3%	34.1%
SAU801738	KPN300668	29%	35.8%	60.4%
SAU801738	MCA101042	18%	72.1%	92.1%
SAU801738	MAV108037	27%	31.0%	47.2%
SAU801738	MAV100245	25%	41.2%	56.0%
SAU801738	NGO101025	22%	23.5%	77.5%
SAU801738	PMU100968	26%	86.1%	36.2%
SAU801738	PAE200970	23%	81.4%	47.6%
SAU801738	PPU108649	28%	88.1%	40.1%
SAU801738	PSY105487	24%	82.7%	58.0%
SAU801738	SPA100196	27%	86.3%	62.8%
SAU801738	STY101950	26%	87.2%	60.4%
SAU801738	STM101679	27%	85.2%	57.2%
SAU801738	SAU801738	100%	100%	100%
SAU801738	SEP202090	34%	94.7%	92.4%
SAU801738	SHA103272	46%	21.2%	36.5%
SAU801738	SPN400121	23%	69.9%	23.9%
SAU801738	SPN401992	21%	79.9%	61.3%
SAU801738	TPA100466	23%	26.1%	66.7%
SAU801738	VCH101807	23%	40.7%	57.3%
SAU801738	YPS002074	26%	73.9%	49.5%
SAU801740	ABA100629	33%	95.7%	92.1%
SAU801740	BAN108290	64%	98.6%	98.9%
SAU801740	BFR104492	27%	96.3%	98.7%
SAU801740	BPT102999	32%	96.1%	96.8%
SAU801740	BBU100816	32%	86.3%	85.9%
SAU801740	BCE114835	30%	95.7%	95.5%
SAU801740	BFU100404	30%	92.4%	97.1%
SAU801740	BMA107598	31%	95.7%	95.5%
SAU801740	CJU100982	29%	99.5%	99.5%
SAU801740	CTR200138	29%	97.5%	52.3%
SAU801740	CAC101140	33%	97.5%	97.2%
SAU801740	CBO102681	34%	97.7%	96.7%
SAU801740	CDF104436	33%	97.5%	99.3%
SAU801740	CDP101264	29%	98.6%	98.1%
SAU801740	EBC101801	28%	96.3%	91.9%
SAU801740	EFA202282	61%	97.0%	95.5%
SAU801740	EFM200546	60%	97.0%	95.7%
SAU801740	ECO100091	29%	96.3%	91.9%
SAU801740	HIN101113	28%	95.9%	93.5%
SAU801740	HPY100615	29%	95.2%	94.4%
SAU801740	KPN301848	29%	96.3%	91.9%
SAU801740	LPN102520	33%	95.9%	94.5%
SAU801740	LMO102778	59%	97.7%	95.5%
SAU801740	MCA100897	32%	96.6%	90.9%
SAU801740	MAV103971	30%	61.3%	86.7%
SAU801740	MBV100529	28%	98.4%	94.7%
SAU801740	MLP100570	29%	95.2%	91.9%
SAU801740	MTU202118	28%	98.4%	94.7%
SAU801740	NGO100584	31%	98.2%	97.9%
SAU801740	NME201905	32%	98.2%	90.7%
SAU801740	PMU100143	28%	95.9%	92.1%
SAU801740	PRT102633	29%	96.3%	92.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801740	PAE204409	32%	96.6%	91.2%
SAU801740	PPU111777	33%	96.6%	90.9%
SAU801740	PSY103843	33%	96.6%	91.4%
SAU801740	SPA101847	27%	98.2%	96.0%
SAU801740	STY103177	27%	98.9%	93.9%
SAU801740	STM102889	27%	98.9%	93.9%
SAU801740	SAU801740	100%	100%	100%
SAU801740	SEP202092	84%	100%	100%
SAU801740	SHA100218	80%	56.3%	100%
SAU801740	SMU100523	50%	97.7%	97.1%
SAU801740	SPN401372	49%	97.0%	96.4%
SAU801740	SPY200251	50%	97.9%	97.3%
SAU801740	TPA100337	29%	85.1%	82.7%
SAU801740	VCH102365	29%	95.9%	87.7%
SAU801740	YPS001016	28%	96.3%	91.9%
SAU801741	ABA100229	33%	57.5%	81.4%
SAU801741	BAN106567	33%	99.5%	99.8%
SAU801741	BCE110599	42%	38.9%	96.3%
SAU801741	BFU105081	43%	36.7%	36.5%
SAU801741	BMA101290	45%	35.2%	86.1%
SAU801741	CJU100817	33%	65.9%	82.8%
SAU801741	EBC100487	38%	36.7%	64.3%
SAU801741	ECO100865	38%	45.9%	48.8%
SAU801741	HIN101559	45%	36.0%	92.8%
SAU801741	HPY101073	39%	41.6%	64.9%
SAU801741	KPN100639	46%	25.0%	99.4%
SAU801741	LPN100195	41%	39.5%	71.8%
SAU801741	LMO102204	45%	56.3%	96.8%
SAU801741	MCA100556	43%	35.2%	99.4%
SAU801741	PMU100255	35%	53.1%	78.2%
SAU801741	PRT100386	34%	55.6%	85.9%
SAU801741	SPA103466	44%	36.3%	97.1%
SAU801741	STY102893	41%	40.4%	41.3%
SAU801741	STM102713	38%	45.1%	45.4%
SAU801741	SAU801741	100%	100%	100%
SAU801741	SEP202093	54%	100%	100%
SAU801741	SHA101435	51%	100%	100%
SAU801741	VCH101873	40%	43.6%	66.1%
SAU801742	BAN102341	53%	99.0%	97.5%
SAU801742	EFA202054	46%	97.0%	96.1%
SAU801742	EFM200975	56%	74.2%	96.1%
SAU801742	LMO100772	53%	99.0%	97.1%
SAU801742	MGE100458	42%	63.1%	85.4%
SAU801742	MPN100179	35%	89.4%	76.1%
SAU801742	SAU801742	100%	100%	100%
SAU801742	SEP202095	76%	100%	100%
SAU801742	SHA101433	77%	100%	100%
SAU801742	SMU100522	42%	97.0%	94.2%
SAU801742	SPN401724	40%	97.0%	94.2%
SAU801742	SPY101819	41%	97.0%	94.2%
SAU801742	UUR100192	30%	99.0%	96.4%
SAU801749	BAN106147	46%	98.5%	97.7%
SAU801749	BFU115607	25%	21.3%	15.8%
SAU801749	BMA109525	38%	20.5%	15.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801749	CBO101598	22%	43.0%	38.3%
SAU801749	EFA201131	40%	89.0%	90.7%
SAU801749	EFM202567	39%	95.1%	96.2%
SAU801749	HIN101506	28%	33.1%	35.2%
SAU801749	LPN101017	18%	45.2%	40.3%
SAU801749	LMO101148	44%	87.5%	88.5%
SAU801749	MAV102537	26%	34.6%	24.1%
SAU801749	MGE100366	18%	68.4%	57.5%
SAU801749	PPU110551	23%	45.2%	36.9%
SAU801749	PSY102492	30%	22.4%	17.2%
SAU801749	SAU801749	100%	100%	100%
SAU801749	SEP202110	89%	100%	100%
SAU801749	SHA101330	89%	100%	100%
SAU801749	SMU100768	30%	90.5%	91.9%
SAU801749	SPN400475	30%	90.5%	90.5%
SAU801749	SPY201327	31%	82.1%	82.5%
SAU801749	YPS003183	19%	77.9%	74.3%
SAU801751	BAN104199	42%	98.9%	99.1%
SAU801751	BFR100617	37%	14.9%	16.1%
SAU801751	CAC102647	36%	98.5%	98.5%
SAU801751	CBO100026	35%	98.1%	98.3%
SAU801751	CDF102762	35%	98.7%	97.1%
SAU801751	EFA201202	40%	98.9%	98.7%
SAU801751	EFM200248	36%	65.5%	98.4%
SAU801751	LMO100797	44%	98.9%	98.5%
SAU801751	PPU110017	24%	89.3%	76.0%
SAU801751	PSY104220	24%	96.6%	73.9%
SAU801751	SAU801751	100%	100%	100%
SAU801751	SEP202112	82%	100%	100%
SAU801751	SHA101328	82%	99.8%	99.8%
SAU801751	SMU100171	38%	98.9%	98.7%
SAU801751	SPN400547	39%	98.3%	97.9%
SAU801751	SPY200812	38%	98.9%	98.5%
SAU801753	ABA100431	35%	97.0%	96.6%
SAU801753	BAN104776	48%	98.7%	96.3%
SAU801753	BBU100128	28%	98.3%	92.4%
SAU801753	BCE110410	32%	98.7%	97.1%
SAU801753	BFU113278	33%	98.7%	89.3%
SAU801753	BMA108257	34%	98.7%	96.2%
SAU801753	CPN200986	36%	96.1%	94.0%
SAU801753	CTR200096	34%	97.8%	93.8%
SAU801753	CAC103133	48%	99.6%	97.5%
SAU801753	CBO100292	46%	98.3%	97.9%
SAU801753	CDF102819	48%	96.5%	95%
SAU801753	EBC102915	36%	97.0%	96.2%
SAU801753	EFA201204	47%	100%	98.0%
SAU801753	EFM200797	46%	100%	100%
SAU801753	ECO102142	37%	97.0%	97.8%
SAU801753	HIN101215	40%	98.7%	99.1%
SAU801753	KPN301779	37%	96.1%	93.7%
SAU801753	LMO101945	50%	100%	100%
SAU801753	MCA103178	35%	98.3%	99.6%
SAU801753	NGO100244	36%	95.2%	97.8%
SAU801753	NME201373	36%	95.2%	97.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801753	PMU100003	38%	99.1%	99.6%
SAU801753	PRT101140	39%	99.1%	98.7%
SAU801753	PAE200732	35%	97.0%	98.3%
SAU801753	PPU103373	36%	97.0%	98.3%
SAU801753	PSY102334	36%	95.2%	96.5%
SAU801753	SPA100233	38%	97.0%	97.8%
SAU801753	STY104331	38%	97.0%	97.8%
SAU801753	SAU801753	100%	100%	100%
SAU801753	SEP202114	72%	98.7%	99.1%
SAU801753	SHA101326	70%	99.6%	100%
SAU801753	SMU100796	39%	99.6%	99.2%
SAU801753	SPN400256	46%	98.7%	97.9%
SAU801753	SPY201026	45%	98.7%	96.3%
SAU801753	VCH101608	40%	97.0%	97.4%
SAU801753	YPS000335	40%	97.0%	96.2%
SAU801754	ABA105833	19%	93.3%	96.1%
SAU801754	BAN113336	39%	76.7%	98.3%
SAU801754	BAN106207	39%	82.8%	97.6%
SAU801754	BAN104835	37%	99.3%	97.6%
SAU801754	BCE109401	18%	72.7%	70.2%
SAU801754	BFU100360	18%	72.7%	70.2%
SAU801754	BMA106132	17%	64.2%	51.7%
SAU801754	CAC101941	26%	94.4%	95.3%
SAU801754	CBO100125	25%	95.3%	97.3%
SAU801754	CDF100053	35%	13.4%	62.4%
SAU801754	CDF102528	25%	98.7%	96.3%
SAU801754	EBC101202	21%	38.9%	41.9%
SAU801754	EFA201206	28%	99.1%	97.1%
SAU801754	EFM200105	28%	99.5%	97.6%
SAU801754	ECO101042	20%	33.3%	35.6%
SAU801754	KPN302527	19%	38.9%	40.8%
SAU801754	LPN101130	18%	96.4%	95.3%
SAU801754	LMO100220	38%	99.3%	99.8%
SAU801754	MCA103523	18%	96.0%	98.1%
SAU801754	MAV108372	19%	30.7%	54.9%
SAU801754	NGO101881	17%	78.5%	77.9%
SAU801754	NME202045	18%	78.5%	77.9%
SAU801754	PMU101660	19%	84.8%	88.8%
SAU801754	PRT101541	21%	40.5%	43.8%
SAU801754	PAE204560	21%	40.5%	43.8%
SAU801754	PPU112503	19%	36.9%	38.9%
SAU801754	PSY102688	19%	36.9%	40.4%
SAU801754	SPA100422	21%	40.7%	41.9%
SAU801754	STY102506	20%	38.9%	43.1%
SAU801754	STM102672	20%	38.9%	40.8%
SAU801754	SAU801754	100%	100%	100%
SAU801754	SEP202115	83%	100%	100%
SAU801754	SHA101325	71%	100%	100%
SAU801754	SMU100383	26%	99.3%	98.2%
SAU801754	SPN401382	27%	99.1%	98.3%
SAU801754	SPY200284	27%	99.3%	98.2%
SAU801754	TPA100512	19%	66.5%	65.2%
SAU801754	VCH100667	18%	80.8%	81.0%
SAU801755	ABA103848	35%	79.3%	60.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801755	BAN100407	63%	92.0%	68.6%
SAU801755	BPT101495	29%	80.6%	61.8%
SAU801755	BCE105916	29%	80.3%	61.1%
SAU801755	BFU102587	30%	80.3%	61.0%
SAU801755	BMA109065	28%	87.6%	65.8%
SAU801755	CAC101518	41%	86.6%	66.9%
SAU801755	CBO101797	38%	93.9%	70.3%
SAU801755	CDF102335	40%	90.8%	68.6%
SAU801755	EBC103756	30%	93.0%	89.7%
SAU801755	EFA202331	52%	89.2%	72.4%
SAU801755	EFM200487	46%	94.3%	70.7%
SAU801755	ECO103415	31%	93.0%	70%
SAU801755	HIN100912	30%	88.5%	65.8%
SAU801755	KPN306630	29%	93.0%	70.5%
SAU801755	LPN102418	32%	79.3%	82.5%
SAU801755	LMO100816	55%	94.6%	70.8%
SAU801755	MCA101549	35%	79.0%	60.1%
SAU801755	PMU100031	32%	79.3%	60.9%
SAU801755	PRT104499	30%	93.9%	70.6%
SAU801755	PAE200558	30%	79.3%	61.0%
SAU801755	PPU109267	35%	79.3%	61.1%
SAU801755	PSY103648	34%	79.3%	57.2%
SAU801755	SPA101798	30%	93.0%	70.4%
SAU801755	STY100869	30%	93.0%	70%
SAU801755	SAU801755	100%	100%	100%
SAU801755	SEP202116	75%	96.5%	70.8%
SAU801755	SHA101324	79%	95.5%	71.4%
SAU801755	SMU100726	40%	94.6%	71.5%
SAU801755	SPN400651	43%	89.2%	66.0%
SAU801755	SPY201435	43%	94.6%	71.7%
SAU801755	VCH100080	32%	93.0%	70.4%
SAU801755	YPS002475	31%	93.9%	71.1%
SAU801758	BPT101066	20%	20.8%	79.8%
SAU801758	MPN100367	18%	43.7%	86.2%
SAU801758	PMU101507	23%	15.8%	73.6%
SAU801758	SAU801758	100%	100%	100%
SAU801758	SEP202646	35%	99.6%	29.7%
SAU801758	SHA100633	28%	73.7%	83.4%
SAU801758	SHA100651	33%	12.8%	80.4%
SAU801758	SHA101983	28%	99.9%	40.6%
SAU801758	SHA101424	30%	82.9%	58.1%
SAU801760	ABA105508	41%	99.5%	98.9%
SAU801760	BAN102826	74%	99.9%	99.9%
SAU801760	BFR10298	45%	99.8%	99.9%
SAU801760	BPT102350	38%	99.5%	99.4%
SAU801760	BBU100250	52%	99.8%	99.6%
SAU801760	BCE103321	39%	98.9%	98.8%
SAU801760	BMA109061	39%	98.9%	93.5%
SAU801760	CJU101017	40%	100%	100%
SAU801760	CPN200606	50%	99.8%	99.9%
SAU801760	CTR200474	52%	99.8%	99.9%
SAU801760	CAC101070	48%	100%	100%
SAU801760	CBO100961	48%	99.9%	99.8%
SAU801760	CDF103555	48%	99.8%	99.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801760	CDP101454	45%	99.3%	97.2%
SAU801760	EBC100539	37%	53.0%	99.6%
SAU801760	EFA200538	72%	99.9%	99.9%
SAU801760	EFM200610	72%	99.9%	99.9%
SAU801760	ECO100632	42%	99.5%	99.3%
SAU801760	HIN100900	43%	99.8%	99.4%
SAU801760	HPY101524	40%	98.9%	99.1%
SAU801760	KPN300581	40%	13.9%	68.9%
SAU801760	KPN302684	42%	99.5%	99.5%
SAU801760	LPN103327	43%	99.5%	99.3%
SAU801760	LMO100611	69%	99.9%	99.9%
SAU801760	MCA102972	39%	99.6%	98.7%
SAU801760	MAV103767	44%	99.0%	94.3%
SAU801760	MBV104696	43%	99.0%	96.3%
SAU801760	MLP100028	43%	99.0%	96.5%
SAU801760	MTU200041	43%	99.0%	96.5%
SAU801760	MGE100272	44%	99.8%	99.7%
SAU801760	MPN100453	44%	99.8%	99.6%
SAU801760	NGO100059	41%	99.6%	99.3%
SAU801760	NME200518	39%	99.5%	99.5%
SAU801760	PMU101214	42%	99.8%	99.5%
SAU801760	PRT102887	42%	99.5%	99.3%
SAU801760	PAE203984	40%	99.6%	99.4%
SAU801760	PPU108817	41%	99.6%	99.4%
SAU801760	PSY105072	42%	99.6%	99.4%
SAU801760	SPA100430	46%	62.3%	97.8%
SAU801760	STY101466	42%	99.5%	99.3%
SAU801760	SAU801760	100%	100%	100%
SAU801760	SEP202121	87%	100%	100%
SAU801760	SHA100631	86%	100%	100%
SAU801760	SMU100492	65%	99.8%	99.6%
SAU801760	SPN400235	66%	99.8%	99.6%
SAU801760	SPY200128	65%	99.8%	99.6%
SAU801760	TPA100579	47%	99.8%	99.9%
SAU801760	UUR100373	53%	99.5%	99.8%
SAU801760	VCH100940	43%	99.6%	95.4%
SAU801760	YPS001199	41%	99.5%	99.3%
SAU801769	ABA104921	34%	93.6%	97.9%
SAU801769	BAN106809	47%	99.5%	99.2%
SAU801769	BAN107259	53%	99.5%	99.2%
SAU801769	BFR101499	44%	100%	98.3%
SAU801769	BPT100010	33%	91.6%	81.4%
SAU801769	BCE107847	38%	71.8%	76.5%
SAU801769	BCE114560	36%	89.6%	91.8%
SAU801769	BFU105494	36%	89.6%	92.3%
SAU801769	BMA104123	35%	89.6%	66.6%
SAU801769	CJU100533	36%	92.6%	98.2%
SAU801769	CPN200978	41%	99.0%	94.3%
SAU801769	CTR200104	44%	98.5%	92.5%
SAU801769	CAC101077	50%	99.7%	98.8%
SAU801769	CBO102459	53%	99.7%	98.5%
SAU801769	CDF101260	56%	99.5%	96.3%
SAU801769	CDP100293	42%	98.7%	90.4%
SAU801769	EBC103923	44%	50.1%	91.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801769	ECO102975	44%	50.9%	92.6%
SAU801769	HIN100202	44%	48.3%	86.6%
SAU801769	HPY100791	35%	94.1%	100%
SAU801769	KPN306827	43%	50.9%	92.6%
SAU801769	LPN102962	45%	72.0%	97.3%
SAU801769	MCA101128	33%	93.9%	99.7%
SAU801769	MAV100813	46%	99.2%	91.6%
SAU801769	MBV102147	45%	99.2%	94.4%
SAU801769	MLP100345	45%	99.2%	92.2%
SAU801769	MTU201396	45%	99.2%	94.4%
SAU801769	NGO101214	35%	91.3%	78.4%
SAU801769	NME201304	36%	91.3%	96.1%
SAU801769	PMU101385	43%	49.6%	91.6%
SAU801769	PRT102178	44%	50.6%	92.2%
SAU801769	PAE204051	34%	93.1%	98.6%
SAU801769	PPU110431	35%	93.6%	97.9%
SAU801769	PSY102199	35%	93.6%	99.2%
SAU801769	SPA102485	43%	50.6%	91.7%
SAU801769	STY100768	43%	50.9%	92.6%
SAU801769	STM101319	48%	47.1%	95.9%
SAU801769	SAU801769	100%	100%	100%
SAU801769	SEP202140	75%	100%	100%
SAU801769	SHA101040	73%	100%	100%
SAU801769	SPN400162	49%	100%	98.8%
SAU801769	VCH102235	39%	90.6%	96.2%
SAU801769	YPS001985	45%	49.4%	89.9%
SAU801770	ABA101512	38%	93.8%	90.0%
SAU801770	BAN111761	44%	90.5%	91.4%
SAU801770	BAN112258	46%	92.9%	91.1%
SAU801770	BFR10686	33%	91.9%	98.5%
SAU801770	BPT102166	33%	87.1%	80.3%
SAU801770	BCE102163	39%	92.4%	96.2%
SAU801770	BFU114695	39%	93.8%	100%
SAU801770	BMA105732	35%	93.8%	100%
SAU801770	CJU101143	30%	100%	99.0%
SAU801770	CPN200217	30%	89.0%	92%
SAU801770	CTR200675	31%	89.0%	91.9%
SAU801770	CAC101867	40%	92.4%	90.1%
SAU801770	CBO100822	37%	100%	94.3%
SAU801770	CDF101262	40%	95.7%	91.0%
SAU801770	CDP100296	38%	91.9%	98.0%
SAU801770	EBC101113	34%	88.6%	42.1%
SAU801770	ECO101632	35%	88.6%	42.3%
SAU801770	HIN101580	33%	91.9%	97.5%
SAU801770	HPY101551	37%	93.8%	91.3%
SAU801770	KPN300802	34%	88.6%	63.8%
SAU801770	LPN103102	36%	91.9%	94.1%
SAU801770	MCA101660	35%	100%	99.1%
SAU801770	MAV100811	39%	92.9%	100%
SAU801770	MBV102153	41%	91.9%	98.0%
SAU801770	MLP100344	40%	91.9%	95.2%
SAU801770	MTU201393	41%	91.9%	98.0%
SAU801770	NGO100198	29%	87.1%	71.4%
SAU801770	NME201294	29%	87.1%	84.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801770	PMU100650	31%	87.1%	90.7%
SAU801770	PRT102318	37%	87.1%	84.9%
SAU801770	PAE204052	37%	93.8%	90.4%
SAU801770	PPU104479	36%	93.8%	89.6%
SAU801770	PSY102201	37%	93.8%	90%
SAU801770	SPA100334	33%	39.5%	75%
SAU801770	STY100625	32%	88.6%	42.3%
SAU801770	STM104015	32%	88.6%	42.3%
SAU801770	SAU801770	100%	100%	100%
SAU801770	SEP202141	77%	100%	100%
SAU801770	SHA101041	68%	100%	100%
SAU801770	SPN400163	46%	100%	100%
SAU801770	VCH102236	38%	94.3%	91.7%
SAU801770	YPS002958	34%	88.6%	41.3%
SAU801771	ABA103798	36%	98.0%	98.0%
SAU801771	BAN112131	35%	98.0%	97.0%
SAU801771	BAN106315	40%	98.0%	94.9%
SAU801771	BFR10090	31%	87.3%	89.3%
SAU801771	BPT102814	33%	97.4%	90.9%
SAU801771	BCE111009	34%	89.0%	89.3%
SAU801771	BFU111851	34%	97.4%	87.1%
SAU801771	BMA106009	33%	89.0%	85.5%
SAU801771	CJU101528	27%	68.9%	77.4%
SAU801771	CPN200979	31%	97.7%	93.6%
SAU801771	CTR200103	29%	97.4%	88.4%
SAU801771	CAC102186	31%	94.2%	90.9%
SAU801771	CBO103939	32%	97.1%	93.1%
SAU801771	CDF101264	30%	97.1%	94.6%
SAU801771	CDP100306	32%	85.9%	78.1%
SAU801771	EBC101279	34%	87.3%	87.7%
SAU801771	EFM102196	24%	37.8%	100%
SAU801771	ECO100406	36%	87.3%	87.7%
SAU801771	HIN100923	34%	99.1%	96.8%
SAU801771	HPY101484	24%	56.2%	65.4%
SAU801771	KPN303443	35%	87.9%	88.3%
SAU801771	LPN101462	28%	91.9%	91.3%
SAU801771	MCA103171	30%	98.6%	95.7%
SAU801771	MAV100828	33%	87.3%	84.8%
SAU801771	MBV102159	35%	88.5%	86.4%
SAU801771	MLP100341	33%	87.3%	85.3%
SAU801771	MTU201390	34%	88.5%	86.4%
SAU801771	NGO101603	34%	98.6%	96.2%
SAU801771	NME200596	33%	98.6%	96.2%
SAU801771	PMU100749	36%	87.3%	85.4%
SAU801771	PRT100794	48%	33.1%	76.5%
SAU801771	PAE204053	35%	87.9%	87.1%
SAU801771	PPU104478	33%	87.9%	85.4%
SAU801771	PSY102203	35%	87.9%	86.0%
SAU801771	SPA103220	32%	87.3%	87.7%
SAU801771	STY100425	33%	87.3%	87.7%
SAU801771	STM100096	33%	87.3%	87.7%
SAU801771	SAU801771	100%	100%	100%
SAU801771	SEP202142	65%	100%	100%
SAU801771	SHA101042	62%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801771	SPN400164	34%	89.3%	88.0%
SAU801771	VCH102237	33%	99.4%	96.7%
SAU801771	YPS002513	34%	99.1%	98.1%
SAU801781	BAN102026	30%	83.5%	90.4%
SAU801781	BAN100029	32%	83.5%	87.9%
SAU801781	BFR102578	30%	84.0%	89.0%
SAU801781	BCE112831	23%	91.1%	72.6%
SAU801781	CAC102703	34%	84.8%	89.3%
SAU801781	CBO102369	59%	98.7%	96.7%
SAU801781	CDF102721	32%	96.2%	98.6%
SAU801781	CDP100260	26%	48.5%	41.4%
SAU801781	EBC104147	23%	84.8%	88.2%
SAU801781	EFA200734	28%	83.5%	85.3%
SAU801781	EFM202614	23%	94.1%	91.3%
SAU801781	ECO103852	25%	84.8%	88.2%
SAU801781	KPN303236	26%	84.8%	88.2%
SAU801781	LMO102295	33%	94.1%	95.4%
SAU801781	PRT102648	24%	84.8%	88.2%
SAU801781	SPA101828	25%	84.8%	88.2%
SAU801781	STY102761	25%	84.8%	88.2%
SAU801781	STM100053	27%	60.3%	53.9%
SAU801781	SAU801781	100%	100%	100%
SAU801781	SEP202149	88%	100%	100%
SAU801781	SHA101204	94%	100%	100%
SAU801781	SMU101539	26%	87.8%	91.0%
SAU801781	SPN400233	24%	83.1%	86.5%
SAU801781	SPY201499	53%	99.2%	96.3%
SAU801781	YPS000933	28%	84.4%	87.3%
SAU801788	BAN109240	49%	97.1%	96.4%
SAU801788	BAN109986	53%	97.5%	96.1%
SAU801788	BAN101451	53%	97.5%	96.1%
SAU801788	BAN108570	55%	97.1%	95.7%
SAU801788	BPT100139	47%	97.5%	86.9%
SAU801788	BFU106841	30%	91.3%	90.7%
SAU801788	BMA101899	29%	93.9%	93.2%
SAU801788	CBO103560	46%	95.7%	86%
SAU801788	CDP100048	39%	98.6%	94.1%
SAU801788	EFA201398	48%	99.3%	98.2%
SAU801788	EFM100053	44%	32.5%	96.8%
SAU801788	LMO102538	49%	96.8%	95.6%
SAU801788	MAV101886	40%	97.1%	95.0%
SAU801788	MBV105140	43%	98.6%	95.0%
SAU801788	MLP101019	40%	98.6%	95.0%
SAU801788	MTU202933	43%	98.6%	95.0%
SAU801788	PSY101323	30%	91.0%	91.9%
SAU801788	SAU801788	100%	100%	100%
SAU801788	SEP202180	72%	100%	99.6%
SAU801788	SHA101201	74%	100%	99.6%
SAU801788	YPS002012	43%	97.1%	95.3%
SAU801790	ABA100383	61%	97.7%	97.9%
SAU801790	BAN108106	75%	99.0%	99.0%
SAU801790	BFR103242	50%	97.7%	98.6%
SAU801790	BPT100493	60%	98.7%	99.2%
SAU801790	BBU100375	51%	97.7%	96.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801790	BCE104520	60%	98.5%	99.2%
SAU801790	BFU106887	60%	98.5%	93.6%
SAU801790	BMA102515	60%	98.5%	97.0%
SAU801790	CJU101022	41%	97.2%	98.7%
SAU801790	CAC100015	69%	97.7%	99.0%
SAU801790	CDF101475	69%	98.5%	99.0%
SAU801790	CDP100317	57%	98.2%	97.1%
SAU801790	EBC106045	63%	96.5%	98.4%
SAU801790	EFA200562	72%	98.5%	98.7%
SAU801790	EFM102997	76%	12.8%	91.1%
SAU801790	ECO102877	62%	98.2%	98.4%
SAU801790	HIN101146	61%	97.7%	97.9%
SAU801790	HPY100194	58%	97.2%	97.4%
SAU801790	KPN303051	63%	98.2%	98.4%
SAU801790	LPN103398	58%	99.2%	100%
SAU801790	LMO101989	70%	99.5%	99.5%
SAU801790	MCA100501	58%	98.7%	99.7%
SAU801790	MAV103344	58%	99.5%	100%
SAU801790	MBV103088	57%	98.2%	98.0%
SAU801790	MLP100335	57%	99.5%	100%
SAU801790	MTU201374	57%	99.5%	100%
SAU801790	MGE100047	38%	98.0%	96.1%
SAU801790	MPN100094	39%	98.0%	96.1%
SAU801790	NGO101704	62%	97.7%	98.2%
SAU801790	NME200613	62%	97.7%	98.2%
SAU801790	PMU101027	61%	98.5%	98.7%
SAU801790	PRT101183	61%	97.7%	97.9%
SAU801790	PAE200545	57%	97.7%	98.0%
SAU801790	PPU109309	57%	97.7%	98.0%
SAU801790	PSY103013	57%	97.7%	98.0%
SAU801790	SPA102476	63%	97.5%	98.2%
SAU801790	STY104545	63%	98.2%	98.4%
SAU801790	STM100571	63%	98.2%	98.4%
SAU801790	SAU801790	100%	100%	100%
SAU801790	SEP202182	88%	99.7%	99.5%
SAU801790	SHA101199	90%	99.7%	99.7%
SAU801790	SMU101066	66%	99.5%	99.7%
SAU801790	SPN400671	66%	99.5%	100%
SAU801790	SPY201042	65%	99.5%	99.2%
SAU801790	TPA100786	53%	98.0%	96.5%
SAU801790	UUR100416	48%	99.0%	98.7%
SAU801790	VCH100467	61%	98.0%	97.9%
SAU801790	YPS000215	61%	98.2%	98.4%
SAU801791	BAN102885	63%	97.2%	97.5%
SAU801791	BFR105535	50%	90%	89.7%
SAU801791	CJU100862	54%	91.7%	92.6%
SAU801791	EBC103850	52%	91.3%	90.4%
SAU801791	ECO103326	52%	91.7%	91.3%
SAU801791	HIN100789	49%	90.9%	89.8%
SAU801791	KPN309152	51%	92.5%	92.0%
SAU801791	PMU101542	52%	90%	88.8%
SAU801791	PRT103276	68%	11.9%	98.5%
SAU801791	PRT102605	52%	90%	88.9%
SAU801791	PAE205187	46%	92.6%	95.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801791	PPU109983	46%	92.6%	96.6%
SAU801791	PSY103061	49%	93.2%	95.9%
SAU801791	SPA102215	50%	54.2%	87.2%
SAU801791	STY101369	53%	89.8%	88.7%
SAU801791	STM102905	53%	89.8%	88.7%
SAU801791	SAU801791	100%	100%	100%
SAU801791	SEP202183	83%	100%	93.1%
SAU801791	SHA100255	86%	100%	100%
SAU801791	SMU101955	23%	77.2%	72.9%
SAU801791	SPY100767	22%	22.8%	45.4%
SAU801791	VCH102699	49%	96.4%	94.3%
SAU801791	YPS001562	52%	89.8%	88.7%
SAU801800	CBO103265	28%	37.5%	71.5%
SAU801800	CBO101981	35%	22.7%	48.1%
SAU801800	EFM200873	31%	39.6%	69.1%
SAU801800	MBV105157	30%	19.9%	30.3%
SAU801800	MTU408706	30%	19.9%	30.3%
SAU801800	NME301036	20%	62.2%	47.3%
SAU801800	SAU801800	100%	100%	100%
SAU801800	SEP202377	32%	50.2%	83.4%
SAU801800	SHA103321	32%	51.4%	83.4%
SAU801801	CBO102312	27%	40.9%	41.3%
SAU801801	PRT103680	26%	42.3%	26.6%
SAU801801	SAU801801	100%	100%	100%
SAU801801	SEP201425	42%	80.8%	98.9%
SAU801812	BFR103731	35%	22.9%	7.8%
SAU801812	BFU106944	27%	75.8%	16.1%
SAU801812	EFA200509	27%	65.8%	59.2%
SAU801812	MBV105595	24%	61.2%	43.4%
SAU801812	MTU201032	24%	61.2%	43.4%
SAU801812	MPN100256	34%	37.1%	21.3%
SAU801812	SAU801813	48%	100%	100%
SAU801812	SAU801809	54%	100%	100%
SAU801812	SAU801810	54%	100%	100%
SAU801812	SAU801811	61%	100%	100%
SAU801812	SAU801812	100%	100%	100%
SAU801812	SEP200474	32%	75.8%	63.1%
SAU801812	SHA103193	24%	61.7%	33.5%
SAU801812	SPN201991	23%	86.7%	9.6%
SAU801812	UUR100028	55%	14.2%	3.9%
SAU801819	BAN101272	26%	93.4%	100%
SAU801819	BAN107130	26%	94.3%	100%
SAU801819	BCE101717	24%	22.6%	25.3%
SAU801819	MGE100328	24%	66.3%	19.4%
SAU801819	SAU801163	30%	92.5%	98.1%
SAU801819	SAU801820	32%	84.9%	89.1%
SAU801819	SAU802419	33%	84.9%	89.0%
SAU801819	SAU802005	29%	95.2%	96.3%
SAU801819	SAU802420	29%	95.5%	99.4%
SAU801819	SAU802004	39%	94.3%	95.6%
SAU801819	SAU802421	76%	95.8%	97.8%
SAU801819	SAU801819	100%	100%	100%
SAU801831	ABA105109	31%	98.9%	85.5%
SAU801831	LPN100617	23%	94.0%	90.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801831	PRT100970	29%	94.0%	91.7%
SAU801831	PSY105329	26%	47.3%	52.5%
SAU801831	SAU801831	100%	100%	100%
SAU801831	SEP202203	69%	100%	100%
SAU801831	SHA100944	57%	100%	100%
SAU801842	BAN105878	50%	95.8%	95.9%
SAU801842	BAN106784	50%	98.4%	98.1%
SAU801842	BFU105060	27%	40.6%	63.4%
SAU801842	CAC102817	36%	98.1%	96.3%
SAU801842	CBO103612	27%	93.3%	94.3%
SAU801842	EFA201160	42%	99.0%	99.4%
SAU801842	EFM201438	44%	99.7%	100%
SAU801842	LMO101135	55%	95.8%	95.8%
SAU801842	SAU801842	100%	100%	100%
SAU801842	SEP202225	82%	100%	100%
SAU801842	SHA100193	81%	100%	100%
SAU801842	SMU100680	42%	99.4%	96.9%
SAU801842	SPN401792	43%	98.1%	92.5%
SAU801842	SPY200197	44%	97.8%	98.7%
SAU801843	BAN110707	25%	18.4%	25%
SAU801843	BAN101656	20%	73.8%	95.8%
SAU801843	BCE102515	25%	14.7%	44.6%
SAU801843	EBC105222	20%	31.0%	79.7%
SAU801843	EFA201162	22%	97.5%	97.2%
SAU801843	EFM202044	24%	99.7%	99.2%
SAU801843	LMO101860	28%	97.6%	98.2%
SAU801843	PMU100358	22%	37.4%	32.4%
SAU801843	SAU801843	100%	100%	100%
SAU801843	SEP202243	69%	100%	99.7%
SAU801843	SHA101351	56%	63.4%	91.0%
SAU801844	BAN112727	33%	72.9%	98.0%
SAU801844	BAN108010	34%	99.5%	94.4%
SAU801844	BCE105254	28%	83.7%	82.4%
SAU801844	BFU106002	24%	26.4%	25.5%
SAU801844	CTR100444	26%	23.4%	33.8%
SAU801844	CDP101084	24%	59.0%	62.5%
SAU801844	EFA201164	35%	57.8%	56.2%
SAU801844	EFM200739	28%	99.5%	99.5%
SAU801844	LMO101049	34%	96.0%	95.4%
SAU801844	MAV100736	23%	47.2%	50.7%
SAU801844	MLP100687	23%	47.2%	50.7%
SAU801844	MTU201260	24%	55.5%	53.5%
SAU801844	SAU801844	100%	100%	100%
SAU801844	SEP202229	79%	100%	100%
SAU801844	SHA100337	72%	96.5%	98.5%
SAU801864	BAN106235	40%	98.6%	99.5%
SAU801864	BAN106367	70%	99.8%	99.1%
SAU801864	LMO102085	67%	99.8%	99.1%
SAU801864	SAU801864	100%	100%	100%
SAU801864	SEP200493	90%	100%	100%
SAU801864	SHA100850	90%	100%	100%
SAU801885	BAN105284	41%	53.6%	61.1%
SAU801885	BAN109052	39%	95.1%	95.7%
SAU801885	BFR101331	53%	8.1%	29.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801885	BFR101263	30%	56.5%	47.4%
SAU801885	CAC100128	25%	78.1%	64.6%
SAU801885	CBO100759	26%	62.2%	57.1%
SAU801885	CDF103262	22%	91.6%	76.6%
SAU801885	CDP100733	28%	57.6%	46.7%
SAU801885	EFA200214	35%	98.0%	97.3%
SAU801885	EFM100401	38%	84.1%	98.1%
SAU801885	HIN100254	25%	79.8%	52.4%
SAU801885	KPN101258	30%	49.6%	80.6%
SAU801885	LMO101432	40%	88.2%	88.1%
SAU801885	MCA103333	24%	76.9%	41.2%
SAU801885	MAV102966	29%	55.6%	23.1%
SAU801885	PRT102089	27%	58.8%	34.0%
SAU801885	PSY102913	34%	57.1%	51.8%
SAU801885	SPA103134	26%	55.6%	32.8%
SAU801885	STM101354	28%	58.2%	36.6%
SAU801885	SAU801885	100%	100%	100%
SAU801885	SEP200524	92%	99.1%	98.9%
SAU801885	SHA102846	88%	100%	100%
SAU801885	SMU101513	36%	66.6%	71.0%
SAU801885	SPN400343	32%	94.8%	97.0%
SAU801885	SPY201249	30%	95.7%	97.0%
SAU801885	YPS002615	25%	55.9%	33.2%
SAU801891	BFR103387	25%	79.0%	39.9%
SAU801891	BCE102350	26%	42.0%	21.8%
SAU801891	BFU101626	25%	56.4%	27.9%
SAU801891	BMA107339	28%	45.7%	23.2%
SAU801891	CAC100871	44%	97.9%	99.6%
SAU801891	CBO102328	46%	97.1%	98.0%
SAU801891	CDF103937	25%	84.0%	45.0%
SAU801891	CDP101577	35%	85.2%	90%
SAU801891	EFA201623	39%	86.0%	92.6%
SAU801891	EFM202615	40%	86.4%	92.2%
SAU801891	KPN305163	24%	75.7%	40.4%
SAU801891	LMO102346	29%	72.4%	35.6%
SAU801891	MAV103150	35%	81.1%	85.1%
SAU801891	MBV105752	35%	87.2%	92.6%
SAU801891	MLP101386	33%	87.2%	93.0%
SAU801891	MTU203659	35%	87.2%	92.6%
SAU801891	PAE201276	30%	41.2%	21.0%
SAU801891	PPU104541	31%	40.3%	20.9%
SAU801891	PSY104520	26%	56.4%	28.8%
SAU801891	SPA101593	25%	63.4%	32.7%
SAU801891	STY102862	25%	63.4%	32.6%
SAU801891	SAU801891	100%	100%	100%
SAU801891	SEP200530	86%	99.2%	100%
SAU801891	SHA100327	87%	65.0%	100%
SAU801891	SMU100316	37%	86.8%	82.1%
SAU801891	SPN401443	39%	86.4%	82.3%
SAU801891	SPY200781	42%	86.8%	81.7%
SAU801891	VCH103448	26%	59.7%	31.0%
SAU801892	CAC103089	37%	83.5%	85.3%
SAU801892	CBO103928	33%	88.3%	87.0%
SAU801892	CDP101579	27%	89.9%	90.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801892	EFA201624	35%	88.8%	88.2%
SAU801892	EFM201524	33%	90.6%	91.1%
SAU801892	MAV103153	28%	95.7%	95.9%
SAU801892	MBV103349	24%	70.3%	99.3%
SAU801892	MILP101385	28%	98.4%	98.8%
SAU801892	MTU203658	28%	95.7%	95.9%
SAU801892	SAU801892	100%	100%	100%
SAU801892	SEP200540	84%	100%	100%
SAU801892	SHA100326	86%	91.5%	100%
SAU801892	SMU100305	38%	83.1%	82.3%
SAU801892	SPN401442	35%	92.9%	92.4%
SAU801892	SPY200782	35%	88.1%	87.4%
SAU801898	ABA102906	25%	93.0%	97.1%
SAU801898	BAN101717	37%	83.5%	87.6%
SAU801898	BAN104028	51%	93.3%	97.7%
SAU801898	BFR103264	21%	87.6%	91.6%
SAU801898	BPT102594	36%	33.7%	35.2%
SAU801898	CAC101539	32%	93.3%	99.3%
SAU801898	CBO100610	29%	91.4%	97.6%
SAU801898	CDF100046	31%	91.7%	97.0%
SAU801898	CDP100495	27%	93.7%	91.4%
SAU801898	EBC101306	32%	82.9%	87.0%
SAU801898	EFA201025	50%	95.6%	84.8%
SAU801898	EFM201626	34%	92.7%	99.7%
SAU801898	ECO102045	31%	82.9%	87.0%
SAU801898	KPN304484	30%	82.9%	86.6%
SAU801898	LPN102533	27%	87.6%	94.8%
SAU801898	LMO101117	54%	94.0%	95.8%
SAU801898	MAV101449	25%	86.0%	88.4%
SAU801898	MBV102765	22%	90.5%	93.2%
SAU801898	MTU202218	22%	90.5%	93.2%
SAU801898	PRT102330	32%	82.9%	87.5%
SAU801898	PAE203021	29%	82.5%	85.1%
SAU801898	PPU103228	26%	82.5%	85.8%
SAU801898	PSY100248	33%	40.3%	92.6%
SAU801898	PSY102861	27%	86.3%	87.2%
SAU801898	SPA100769	27%	82.9%	86.9%
SAU801898	STM103922	29%	82.9%	87.0%
SAU801898	SAU801898	100%	100%	100%
SAU801898	SEP200546	89%	98.4%	98.1%
SAU801898	SHA101107	86%	100%	95.5%
SAU801898	SMU101024	46%	96.8%	90.2%
SAU801898	SPN400947	33%	92.4%	92.6%
SAU801898	SPY200551	45%	99.0%	93.2%
SAU801898	YPS003168	33%	82.9%	87.8%
SAU801899	ABA101192	49%	98.5%	96.9%
SAU801899	BAN113289	55%	98.1%	98.1%
SAU801899	BAN103118	77%	100%	100%
SAU801899	BPT102505	47%	99.4%	99.8%
SAU801899	BBU100340	41%	99.4%	99.4%
SAU801899	BCE113424	47%	74.7%	94.3%
SAU801899	BFU106894	45%	98.9%	98.4%
SAU801899	BMA107258	47%	98.9%	99.2%
SAU801899	CJU101122	48%	98.9%	99.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801899	CPN200756	42%	99.4%	98.4%
SAU801899	CTR200267	41%	98.1%	97.1%
SAU801899	CAC103172	51%	100%	100%
SAU801899	CBO100777	53%	99.8%	99.8%
SAU801899	CDF102772	25%	25.5%	84%
SAU801899	CDP100169	44%	98.9%	96.4%
SAU801899	EFA201028	72%	100%	100%
SAU801899	EFM100482	77%	22.9%	100%
SAU801899	HPY100650	46%	99.4%	99.6%
SAU801899	LPN102938	40%	99.4%	99.8%
SAU801899	LMO100253	75%	100%	100%
SAU801899	MCA100584	46%	98.5%	97.1%
SAU801899	MAV106350	42%	98.1%	95.0%
SAU801899	MBV101310	42%	98.1%	93.9%
SAU801899	MLP101041	40%	98.1%	93.9%
SAU801899	MTU202971	42%	98.1%	93.9%
SAU801899	MGE100102	36%	97.7%	96.4%
SAU801899	MPN100593	38%	97.7%	96.2%
SAU801899	NGO101113	46%	99.4%	99.8%
SAU801899	NME201429	46%	99.4%	99.8%
SAU801899	PAE204482	48%	99.6%	99.8%
SAU801899	PPU103969	48%	99.6%	99.8%
SAU801899	PSY104801	48%	99.6%	95.0%
SAU801899	SAU801899	100%	100%	100%
SAU801899	SEP200547	92%	100%	100%
SAU801899	SHA101106	93%	100%	100%
SAU801899	SMU101137	64%	99.8%	99.4%
SAU801899	SPN400393	63%	99.8%	99.2%
SAU801899	SPY201364	63%	99.8%	99.4%
SAU801899	TPA101011	37%	99.4%	94.9%
SAU801899	UUR100550	36%	99.6%	99.6%
SAU801899	VCH100444	27%	25.1%	20.9%
SAU801900	ABA101195	47%	97.5%	96.3%
SAU801900	BAN102336	47%	96.3%	96.8%
SAU801900	BAN100349	61%	98.8%	98.8%
SAU801900	BFR100886	24%	18.6%	27.2%
SAU801900	BPT102507	47%	90.7%	89.8%
SAU801900	BBU100341	39%	91.8%	89.7%
SAU801900	BCE103922	49%	90.7%	91.3%
SAU801900	BFU106893	49%	91.8%	92.3%
SAU801900	BMA103667	49%	90.7%	91.3%
SAU801900	CJU100987	46%	89.7%	98.5%
SAU801900	CPN200757	44%	99.2%	97.2%
SAU801900	CTR200266	44%	98.8%	97.1%
SAU801900	CAC100524	54%	97.9%	99.8%
SAU801900	CBO102412	49%	98.8%	98.8%
SAU801900	CDP100148	46%	96.3%	96.4%
SAU801900	EBC101332	32%	93.0%	92.3%
SAU801900	EFA201041	61%	97.7%	96.5%
SAU801900	EFM202258	24%	95.9%	96.7%
SAU801900	HPY100817	48%	92.4%	96.7%
SAU801900	KPN302436	31%	97.5%	97.0%
SAU801900	LPN101348	50%	91.8%	91.9%
SAU801900	LMO101334	62%	97.5%	97.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801900	MCA100258	47%	98.4%	97.8%
SAU801900	MAV101410	48%	95.5%	95.7%
SAU801900	MBV100289	47%	95.5%	95.7%
SAU801900	MLP101043	47%	95.5%	95.0%
SAU801900	MTU202973	47%	95.5%	95.7%
SAU801900	MGE100101	32%	97.1%	99.4%
SAU801900	MPN100594	33%	88.5%	91.6%
SAU801900	NGO101120	46%	96.3%	96.9%
SAU801900	NME201427	47%	96.1%	96.7%
SAU801900	PRT104598	24%	28.9%	44.3%
SAU801900	PAE204481	50%	95.9%	95.9%
SAU801900	PPU101392	48%	95.9%	96.1%
SAU801900	PSY105880	47%	95.9%	96.1%
SAU801900	SAU801900	100%	100%	100%
SAU801900	SEP200550	90%	100%	100%
SAU801900	SHA100413	89%	77.9%	98.4%
SAU801900	SMU101138	56%	98.8%	97.7%
SAU801900	SPN400394	56%	98.8%	97.7%
SAU801900	SPY201365	56%	98.8%	97.7%
SAU801900	TPA101010	46%	83.1%	81.6%
SAU801900	UUR100551	32%	94.0%	95.2%
SAU801900	YPS002788	31%	93.0%	92.3%
SAU801901	ABA101198	33%	89%	85.6%
SAU801901	BAN111216	40%	88%	94.6%
SAU801901	BAN108238	44%	95%	99.0%
SAU801901	BPT102508	35%	92%	97.1%
SAU801901	BCE104390	28%	92%	97.0%
SAU801901	BFU106892	28%	92%	86.5%
SAU801901	BMA103771	27%	92%	97.0%
SAU801901	CPN200758	28%	90%	92.1%
SAU801901	CTR200265	25%	92%	94%
SAU801901	CAC100906	30%	93%	93.9%
SAU801901	CBO103651	29%	93%	93.9%
SAU801901	CDP100146	32%	99%	100%
SAU801901	EFA201044	38%	97%	89.8%
SAU801901	EFM100480	39%	97%	96.0%
SAU801901	LPN103589	25%	95%	96.9%
SAU801901	LMO100749	46%	97%	100%
SAU801901	MCA100257	27%	92%	96.8%
SAU801901	MAV101412	38%	98%	100%
SAU801901	MBV101316	34%	98%	81.7%
SAU801901	MLP101044	35%	97%	98.0%
SAU801901	MTU202974	35%	98%	99.0%
SAU801901	NGO101123	29%	94%	97.9%
SAU801901	NME201426	27%	94%	97.9%
SAU801901	PAE204480	34%	90%	93.8%
SAU801901	PPU103938	34%	90%	94.7%
SAU801901	PSY108279	33%	90%	94.7%
SAU801901	SAU801901	100%	100%	100%
SAU801901	SEP200560	95%	100%	100%
SAU801901	SHA100412	90%	100%	100%
SAU801901	SMU101140	44%	95%	95%
SAU801901	SPN400395	41%	95%	95%
SAU801901	SPY201366	40%	95%	95%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801904	ABA100577	42%	97.9%	96.5%
SAU801904	BAN102650	47%	98.7%	100%
SAU801904	BAN110615	60%	98.7%	98.8%
SAU801904	BFR102809	40%	98.4%	99.1%
SAU801904	BPT100689	44%	96.1%	96.1%
SAU801904	BBU100551	33%	97.3%	97.7%
SAU801904	BCE104345	46%	97.5%	96.2%
SAU801904	BFU101944	46%	96.1%	94.9%
SAU801904	BMA104881	46%	96.1%	94.9%
SAU801904	CJU100547	35%	96.7%	97.4%
SAU801904	CPN200612	41%	96.9%	96.8%
SAU801904	CTR200416	38%	97.5%	97.6%
SAU801904	CAC101086	38%	97.6%	98.3%
SAU801904	CAC101820	38%	98.8%	98.7%
SAU801904	CBO101063	39%	98.2%	98.8%
SAU801904	CDF103325	49%	98.5%	96.9%
SAU801904	CDP100142	37%	98.5%	97.9%
SAU801904	EBC101052	43%	98.8%	99.6%
SAU801904	EFA201047	56%	98.4%	96.5%
SAU801904	EFM100886	58%	30.6%	95.8%
SAU801904	ECO102362	44%	98.8%	99.3%
SAU801904	HIN101074	45%	98.8%	97.9%
SAU801904	HPY100608	40%	97.8%	97.9%
SAU801904	KPN300317	41%	20.7%	81.8%
SAU801904	KPN301038	44%	98.8%	99.3%
SAU801904	LPN101707	40%	98.4%	98.5%
SAU801904	LMO102553	60%	99.0%	98.5%
SAU801904	MCA101464	42%	98.1%	95.2%
SAU801904	MAV101428	38%	97.3%	95.4%
SAU801904	MBV102830	38%	97.2%	95.5%
SAU801904	MLP101046	38%	97.3%	95.2%
SAU801904	MTU202976	38%	97.2%	95.5%
SAU801904	MGE100258	36%	98.2%	99.4%
SAU801904	MPN100479	37%	97.5%	98.8%
SAU801904	NGO100904	43%	98.8%	99.5%
SAU801904	NME200800	44%	98.2%	96.4%
SAU801904	PMU101716	43%	97.8%	97.8%
SAU801904	PRT102270	45%	98.5%	98.5%
SAU801904	PAE201528	42%	97.6%	97.4%
SAU801904	PPU107257	44%	98.1%	98.2%
SAU801904	PSY103902	43%	85.2%	94.1%
SAU801904	SPA103528	42%	98.8%	99.4%
SAU801904	STY101179	43%	98.8%	99.3%
SAU801904	SAU801904	100%	100%	100%
SAU801904	SEP200563	82%	99.4%	99.7%
SAU801904	SHA100321	83%	97.8%	100%
SAU801904	SMU101026	51%	97.8%	99.1%
SAU801904	SPN401024	51%	97.8%	99.1%
SAU801904	SPY200550	51%	97.8%	99.1%
SAU801904	TPA100627	27%	98.7%	77.5%
SAU801904	UUR100120	41%	99.4%	99.7%
SAU801904	VCH100955	43%	99.0%	99.6%
SAU801904	YPS000606	43%	98.8%	99.3%
SAU801905	ABA100705	40%	87.0%	94.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801905	BAN105739	39%	99.2%	99.5%
SAU801905	BAN105118	58%	99.3%	98.7%
SAU801905	BFR10181	43%	91.2%	95.7%
SAU801905	BPT100444	37%	99.0%	96.3%
SAU801905	BBU100606	38%	87.1%	97.1%
SAU801905	BCE114095	37%	86.6%	100%
SAU801905	BFU114667	35%	99.9%	100%
SAU801905	BMA108211	34%	99.9%	100%
SAU801905	CJU101027	36%	96.8%	97.4%
SAU801905	CPN201081	40%	87.0%	98.9%
SAU801905	CTR200887	40%	87.3%	99.5%
SAU801905	CAC100746	44%	98.5%	98.9%
SAU801905	CBO101783	48%	99.0%	99.5%
SAU801905	CDF102800	43%	99.2%	98.7%
SAU801905	CDP100108	42%	99.2%	94.4%
SAU801905	EBC102904	39%	86.2%	94.6%
SAU801905	EFA201050	57%	99.5%	99.3%
SAU801905	EFM200737	25%	86.0%	88.9%
SAU801905	ECO103725	39%	99.0%	99.0%
SAU801905	HIN101161	40%	99.6%	99.3%
SAU801905	HPY101457	33%	95.5%	94.6%
SAU801905	KPN303539	39%	99.0%	98.8%
SAU801905	LPN100488	37%	89.3%	98.2%
SAU801905	LMO100030	60%	99.6%	99.9%
SAU801905	MCA101054	37%	87.3%	93.8%
SAU801905	MAV107704	43%	99.2%	97.8%
SAU801905	MBV101967	43%	99.2%	97.5%
SAU801905	MLP100111	41%	99.6%	98.2%
SAU801905	MTU200940	43%	99.2%	97.5%
SAU801905	MGE100248	28%	94.9%	96.0%
SAU801905	MPN100496	33%	92.3%	95.7%
SAU801905	MPN100495	29%	94.8%	94.8%
SAU801905	NGO100682	37%	99.0%	98.5%
SAU801905	NME200026	37%	99.0%	98.5%
SAU801905	PMU100411	39%	99.6%	99.4%
SAU801905	PRT102802	38%	99.0%	99.3%
SAU801905	PAE205438	38%	99.5%	99.2%
SAU801905	PPU102313	38%	99.5%	99.0%
SAU801905	PSY103224	37%	94.5%	99.6%
SAU801905	SPA103752	39%	86.2%	93.9%
SAU801905	STY102029	39%	99.0%	99.0%
SAU801905	STM101095	39%	99.0%	99.0%
SAU801905	SAU801905	100%	100%	100%
SAU801905	SEP200564	89%	100%	99.9%
SAU801905	SHA100319	87%	98.5%	100%
SAU801905	SMU100987	52%	99.7%	100%
SAU801905	SPN400995	53%	99.7%	99.9%
SAU801905	SPY200975	52%	99.7%	100%
SAU801905	TPA100101	41%	87.7%	96.7%
SAU801905	UUR100506	37%	97.7%	97.4%
SAU801905	VCH100188	40%	99.2%	99.0%
SAU801905	YPS001400	39%	99.0%	99.0%
SAU801908	ABA105090	26%	98.4%	97.1%
SAU801908	BAN108908	61%	99.1%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801908	BAN107339	72%	99.8%	99.3%
SAU801908	BFR11423	26%	67.7%	67.9%
SAU801908	BPT102211	25%	70.3%	66.0%
SAU801908	BCE106246	32%	52.4%	62.8%
SAU801908	BFU107381	27%	96.1%	89.5%
SAU801908	BMA109025	28%	95.8%	90.5%
SAU801908	CJU100023	48%	99.1%	99.3%
SAU801908	CAC101025	28%	95.4%	89.7%
SAU801908	CBO102979	27%	95.8%	89.9%
SAU801908	CDF100139	26%	16.9%	81.5%
SAU801908	CDF100863	28%	97.4%	90.6%
SAU801908	CDP100537	24%	95.8%	89.1%
SAU801908	EBC102864	25%	76.3%	73.7%
SAU801908	EFA200867	70%	99.8%	99.8%
SAU801908	EFM201242	68%	99.8%	99.8%
SAU801908	ECO101104	27%	74.0%	71.5%
SAU801908	HIN100620	24%	79.6%	76.8%
SAU801908	HPY101095	46%	99.1%	99.3%
SAU801908	KPN304553	30%	94.0%	93.4%
SAU801908	LPN100438	25%	68.7%	67.1%
SAU801908	LMO102395	72%	99.8%	100%
SAU801908	MCA100711	26%	81.9%	78.8%
SAU801908	MAV104228	27%	87.5%	81.6%
SAU801908	MBV105328	27%	87.5%	82.0%
SAU801908	MLP101330	28%	87.5%	82.0%
SAU801908	MTU200771	27%	87.5%	82.0%
SAU801908	NGO101832	26%	80.5%	80.7%
SAU801908	NME202038	24%	90.3%	90.1%
SAU801908	PMU101851	27%	85.8%	81.3%
SAU801908	PRT104726	25%	95.8%	91.7%
SAU801908	PRT105429	33%	97.4%	94.3%
SAU801908	PAE203514	29%	98.1%	88.6%
SAU801908	PAE203515	32%	95.1%	87.2%
SAU801908	PPU101118	29%	98.4%	96%
SAU801908	PSY102568	29%	87.0%	95.1%
SAU801908	SPA104234	26%	68.7%	65.0%
SAU801908	STY102567	26%	74.0%	71.5%
SAU801908	SAU801908	100%	100%	100%
SAU801908	SEP200567	92%	100%	100%
SAU801908	SHA100373	93%	99.8%	99.8%
SAU801908	SMU101297	66%	99.8%	99.5%
SAU801908	SPN400056	66%	99.8%	99.5%
SAU801908	SPY200028	66%	99.8%	100%
SAU801908	VCH101107	27%	65.7%	63.8%
SAU801908	YPS003261	26%	76.6%	75.2%
SAU801912	ABA100328	25%	83.5%	42.9%
SAU801912	BAN108683	47%	85.7%	85.7%
SAU801912	BAN108744	50%	95.2%	95.6%
SAU801912	BFR106001	25%	59.0%	24.2%
SAU801912	BPT101105	23%	76.2%	37.3%
SAU801912	BCE104452	45%	97.8%	96.1%
SAU801912	BFU114829	46%	97.8%	94.8%
SAU801912	BMA100850	44%	96.7%	94.4%
SAU801912	CJU100749	27%	85.7%	92.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801912	CAC102721	26%	67.0%	27.6%
SAU801912	CBO100735	26%	67.4%	28.5%
SAU801912	CDF103692	31%	81.0%	87.3%
SAU801912	CDP101431	50%	95.2%	96.3%
SAU801912	EBC101020	58%	98.5%	99.3%
SAU801912	EFA201596	55%	97.4%	97.5%
SAU801912	EFM200649	56%	95.2%	95.6%
SAU801912	ECO101708	58%	98.5%	99.3%
SAU801912	HPY100325	31%	80.6%	78.8%
SAU801912	KPN302800	60%	98.5%	99.3%
SAU801912	LMO101503	58%	96.7%	97.1%
SAU801912	MCA102959	24%	80.6%	38.5%
SAU801912	MGE100394	28%	86.8%	91.1%
SAU801912	MPN100280	27%	88.3%	92.3%
SAU801912	NGO101101	25%	79.5%	81.0%
SAU801912	NME201435	25%	79.9%	78.4%
SAU801912	PRT106200	27%	83.9%	42.9%
SAU801912	PAE204915	45%	96.3%	98.5%
SAU801912	PPU107581	45%	97.1%	99.3%
SAU801912	PSY101011	45%	97.1%	99.3%
SAU801912	SPA103120	60%	96.3%	96.4%
SAU801912	STY101195	58%	98.5%	99.3%
SAU801912	SAU801912	100%	100%	100%
SAU801912	SEP200570	80%	99.6%	98.9%
SAU801912	SHA100109	80%	100%	100%
SAU801912	SMU101467	57%	95.2%	95.6%
SAU801912	SPN401275	55%	96.3%	96.7%
SAU801912	SPY201273	57%	96.3%	96.7%
SAU801912	TPA100772	24%	76.2%	28.9%
SAU801912	UUR100465	30%	87.2%	91.0%
SAU801912	VCH102941	50%	97.1%	99.6%
SAU801912	YPS003346	27%	76.6%	37.8%
SAU801913	ABA104064	24%	62.8%	82.4%
SAU801913	BAN100917	56%	98.0%	99.2%
SAU801913	BAN111422	64%	98.8%	99.2%
SAU801913	BFR12483	24%	61.3%	83.0%
SAU801913	BBU100634	40%	95.1%	97.9%
SAU801913	BFU104396	21%	56.2%	76.7%
SAU801913	CJU100203	44%	78.9%	84.0%
SAU801913	CAC102082	46%	96.1%	96.7%
SAU801913	CAC102201	45%	95.5%	95.5%
SAU801913	CBO101220	43%	96.1%	96.1%
SAU801913	CDF101027	49%	95.5%	98.3%
SAU801913	CDP101373	33%	90.4%	94.7%
SAU801913	EBC100632	24%	37.4%	64.1%
SAU801913	EFA201594	59%	99.2%	98.4%
SAU801913	EFM200699	59%	98.6%	98.6%
SAU801913	ECO100906	20%	66.3%	87%
SAU801913	KPN301496	21%	57.5%	77%
SAU801913	LPN101555	44%	95.9%	98.1%
SAU801913	LMO102099	61%	97.8%	96.8%
SAU801913	MAV103522	30%	89.4%	92.1%
SAU801913	MBV100308	37%	92.6%	91.1%
SAU801913	MTU200570	37%	92.6%	91.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801913	MPN100107	21%	61.1%	76.1%
SAU801913	NGO100225	25%	71.2%	93.0%
SAU801913	NME201565	25%	71.2%	89.3%
SAU801913	PRT101956	22%	40.9%	54.2%
SAU801913	PAE204374	23%	31.7%	44.0%
SAU801913	PPU107582	24%	54.2%	72.1%
SAU801913	PSY101887	25%	31.7%	43.0%
SAU801913	SPA102570	21%	66.3%	87%
SAU801913	STY102950	21%	66.3%	87%
SAU801913	SAU801913	100%	100%	100%
SAU801913	SEP200580	85%	100%	100%
SAU801913	SHA101008	87%	84.0%	96.9%
SAU801913	SMU101465	58%	98.0%	98.6%
SAU801913	SPN401276	59%	98.6%	99.4%
SAU801913	SPY201274	62%	95.3%	96.3%
SAU801913	TPA100621	38%	92.2%	95.3%
SAU801913	UUR100278	22%	54.8%	78.2%
SAU801913	YPS002092	21%	66.3%	87.0%
SAU801919	BAN106385	61%	66.3%	99.5%
SAU801919	BAN103886	53%	98.4%	99.7%
SAU801919	CAC101085	43%	98.1%	97.4%
SAU801919	CBO102972	42%	76.7%	86.5%
SAU801919	CDF100963	46%	2.6%	44.5%
SAU801919	EFA201809	57%	98.7%	99.0%
SAU801919	EFM101283	48%	65.0%	100%
SAU801919	LMO102809	52%	100%	100%
SAU801919	SAU801919	100%	100%	100%
SAU801919	SEP200585	82%	100%	100%
SAU801919	SHA100533	81%	100%	100%
SAU801919	SMU100407	48%	99.0%	99.0%
SAU801919	SPN401388	49%	99.0%	99.0%
SAU801919	SPY200277	48%	99.0%	99.0%
SAU801919	VCH101659	34%	97.7%	98.7%
SAU801933	BAN110157	40%	95.3%	100%
SAU801933	BAN100669	41%	95.3%	97.9%
SAU801933	BFR12250	29%	72.1%	73.6%
SAU801933	CBO103408	43%	92.6%	97.2%
SAU801933	CDF102635	40%	95.0%	99.3%
SAU801933	HPY101203	30%	75.8%	97.8%
SAU801933	SAU801933	100%	100%	100%
SAU801933	SEP200625	67%	98.0%	96.1%
SAU801933	SHA100899	61%	95.3%	95.0%
SAU801933	SMU101571	40%	76.8%	93.4%
SAU801933	SPN401558	35%	68.5%	82.5%
SAU801933	SPY200989	35%	68.5%	86.2%
SAU801934	ABA105859	30%	78.6%	38%
SAU801934	BAN104444	47%	97.6%	100%
SAU801934	BAN112958	52%	100%	97.7%
SAU801934	BCE102018	42%	55.6%	51.9%
SAU801934	CAC102154	36%	75.4%	81.0%
SAU801934	CBO102232	49%	96.0%	98.4%
SAU801934	CDF100819	47%	98.4%	100%
SAU801934	EFA204644	29%	100%	96.1%
SAU801934	KPN103820	29%	70.6%	40.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU801934	LMO101932	31%	88.9%	85.5%
SAU801934	MAV100931	39%	54.8%	57.0%
SAU801934	MBV100745	29%	88.9%	87.6%
SAU801934	MTU201137	29%	88.9%	87.6%
SAU801934	PRT106136	43%	49.2%	23.8%
SAU801934	STM101603	28%	81.0%	41.2%
SAU801934	SAU801934	100%	100%	100%
SAU801934	SEP200626	80%	98.4%	99.2%
SAU801934	SHA100898	78%	98.4%	98.4%
SAU801934	SMU101019	31%	88.9%	90.2%
SAU801934	SPN401557	32%	84.9%	87.6%
SAU801934	VCH102380	38%	50%	24.6%
SAU801934	YPS002665	38%	53.2%	26.3%
SAU802004	BAN101272	25%	94.7%	98.4%
SAU802004	BAN107130	26%	95.9%	98.7%
SAU802004	SAU801163	28%	89.6%	92.8%
SAU802004	SAU802419	29%	91.1%	92.2%
SAU802004	SAU801820	29%	84.9%	88.1%
SAU802004	SAU802420	30%	83.4%	85.7%
SAU802004	SAU802005	33%	90.5%	82.9%
SAU802004	SAU802421	40%	96.4%	97.2%
SAU802004	SAU801819	39%	95.6%	94.3%
SAU802004	SAU802004	100%	100%	100%
SAU802004	VCH100912	22%	30.2%	43.2%
SAU802047	ABA100982	31%	99.7%	97.5%
SAU802047	BAN106801	29%	95.3%	98.4%
SAU802047	BAN104276	47%	99.4%	99.7%
SAU802047	BFR103776	37%	93.6%	57.0%
SAU802047	BFR10042	34%	99.7%	99.1%
SAU802047	BCE113553	30%	99.7%	99.4%
SAU802047	BFU107062	30%	99.7%	99.4%
SAU802047	BMA104615	31%	99.7%	99.4%
SAU802047	CAC100348	38%	99.4%	99.1%
SAU802047	CBO100372	39%	99.7%	98.9%
SAU802047	CDF101542	40%	99.2%	99.7%
SAU802047	EBC102419	32%	43.6%	86.1%
SAU802047	EFA201584	46%	100%	98.9%
SAU802047	EFM201350	46%	100%	99.2%
SAU802047	ECO103275	31%	45.0%	87.8%
SAU802047	HIN100639	31%	87.7%	42.5%
SAU802047	KPN301152	31%	46.1%	88.9%
SAU802047	LMO101290	46%	100%	99.5%
SAU802047	MCA100657	31%	99.7%	99.7%
SAU802047	PMU101582	31%	86.3%	40.9%
SAU802047	PRT102660	31%	86.3%	40.7%
SAU802047	STY101770	32%	82.6%	37.6%
SAU802047	STM102482	32%	82.6%	37.6%
SAU802047	SAU802047	100%	100%	100%
SAU802047	SEP201282	79%	100%	100%
SAU802047	SHA101969	80%	100%	100%
SAU802047	SMU100319	45%	100%	99.7%
SAU802047	SPN401021	47%	100%	100%
SAU802047	SPY200774	44%	100%	99.7%
SAU802049	ABA100056	43%	85.9%	93.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802049	BAN102312	39%	90.3%	92.4%
SAU802049	BAN108913	63%	98.5%	98.3%
SAU802049	BAN103034	63%	98.5%	100%
SAU802049	BFR100429	40%	96.8%	99.1%
SAU802049	BPT100362	42%	95.9%	86.6%
SAU802049	BBU100768	42%	96.2%	94.2%
SAU802049	BCE114776	43%	78.9%	86.2%
SAU802049	BFU102589	45%	91.5%	88.7%
SAU802049	BMA105419	44%	90.6%	88.0%
SAU802049	CJU101268	36%	93.8%	94.6%
SAU802049	CPN200562	40%	92.4%	92.4%
SAU802049	CTR200463	43%	91.8%	92.6%
SAU802049	CAC103068	52%	98.8%	99.7%
SAU802049	CBO100390	55%	98.8%	99.7%
SAU802049	CDF101563	53%	97.9%	96.6%
SAU802049	CDP100064	45%	92.7%	93.1%
SAU802049	EBC100417	42%	94.4%	96.1%
SAU802049	EFA200289	58%	98.5%	97.1%
SAU802049	EFM201462	58%	97.4%	98.8%
SAU802049	ECO102998	41%	97.9%	99.1%
SAU802049	HIN100509	44%	94.4%	95.6%
SAU802049	HPY101561	34%	93.8%	95.6%
SAU802049	KPN306799	37%	54.8%	97.9%
SAU802049	LPN103299	43%	83.6%	92.2%
SAU802049	LMO102931	59%	98.8%	98.5%
SAU802049	MCA101243	40%	94.1%	94.5%
SAU802049	MAV102882	48%	51.9%	97.3%
SAU802049	MBV101140	44%	92.1%	92.7%
SAU802049	MLP100243	44%	91.2%	90.3%
SAU802049	MTU203373	44%	92.1%	92.7%
SAU802049	MGE100046	33%	97.4%	100%
SAU802049	MPN100095	36%	97.4%	100%
SAU802049	NGO101700	40%	93.0%	94.9%
SAU802049	NME200611	39%	93.0%	94.9%
SAU802049	PMU101238	43%	97.9%	98.8%
SAU802049	PRT100528	41%	97.9%	98.2%
SAU802049	PAE200579	44%	90.0%	91.2%
SAU802049	PPU107523	45%	97.7%	98.8%
SAU802049	PSY103381	43%	98.2%	99.4%
SAU802049	SPA101473	35%	62.5%	89.4%
SAU802049	STY100806	41%	97.9%	99.1%
SAU802049	SAU802049	100%	100%	100%
SAU802049	SEP201284	80%	99.4%	98.3%
SAU802049	SHA101340	78%	100%	100%
SAU802049	SMU100718	53%	97.7%	98.5%
SAU802049	SPN400131	55%	97.1%	97.9%
SAU802049	SPY201441	53%	98.2%	97.4%
SAU802049	TPA100672	40%	92.1%	89.2%
SAU802049	UUR100415	37%	92.7%	96.6%
SAU802049	YPS001964	43%	90.0%	91.1%
SAU802054	ABA105924	43%	94.1%	98.4%
SAU802054	BAN113044	53%	93.0%	99.8%
SAU802054	BAN109521	54%	95.8%	99.5%
SAU802054	BFR10273	41%	89.1%	99.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802054	BPT102555	42%	93.5%	98.2%
SAU802054	BCE111312	45%	93.4%	89.3%
SAU802054	BFU106339	44%	93.4%	95.1%
SAU802054	BMA108273	44%	93.4%	95.1%
SAU802054	CJU100535	44%	93.5%	97.7%
SAU802054	CAC100732	43%	93.5%	98.7%
SAU802054	CDF100458	43%	92.0%	97.3%
SAU802054	CDP100196	42%	93.7%	86.2%
SAU802054	EBC103122	42%	93.5%	99.3%
SAU802054	ECO100077	42%	94.1%	93.5%
SAU802054	HIN101552	43%	93.5%	97.6%
SAU802054	KPN302040	42%	93.5%	98.9%
SAU802054	LPN103264	22%	83.2%	83.5%
SAU802054	LMO101325	59%	96.6%	99.7%
SAU802054	MCA100916	43%	95.9%	94.6%
SAU802054	MAV101431	43%	93.7%	90.5%
SAU802054	MBV101317	43%	93.7%	91.1%
SAU802054	MLP101038	43%	95.1%	91.4%
SAU802054	MTU202965	43%	93.7%	91.1%
SAU802054	NGO101351	43%	93.5%	97.4%
SAU802054	NME201625	43%	93.5%	97.4%
SAU802054	PMU100870	43%	93.5%	97.6%
SAU802054	PRT105730	42%	93.5%	98.9%
SAU802054	PAE204692	41%	92.4%	96.7%
SAU802054	PPU111169	43%	87.3%	98.5%
SAU802054	PSY104459	41%	84.7%	98.3%
SAU802054	SPA102770	42%	93.5%	98.9%
SAU802054	STY102149	42%	93.5%	98.9%
SAU802054	STM101000	42%	93.5%	98.9%
SAU802054	SAU802054	100%	100%	100%
SAU802054	SEP201291	81%	94.1%	95.0%
SAU802054	SHA101346	79%	94.7%	94.4%
SAU802054	SMU101464	56%	94.9%	98.4%
SAU802054	SPN400401	54%	95.1%	98.6%
SAU802054	VCH102447	43%	94.1%	98.4%
SAU802054	YPS000964	41%	94.1%	98.4%
SAU802055	ABA105739	28%	88.1%	44.8%
SAU802055	BAN101552	40%	88.1%	43.8%
SAU802055	BFR103117	33%	67.9%	30.1%
SAU802055	BPT102556	24%	88.1%	44.8%
SAU802055	BCE113712	30%	96.4%	44.6%
SAU802055	BFU106342	31%	88.1%	44.8%
SAU802055	BMA102494	30%	96.4%	47.9%
SAU802055	CJU100536	28%	98.8%	53.9%
SAU802055	EBC101943	33%	88.1%	44.8%
SAU802055	ECO100078	32%	88.1%	44.8%
SAU802055	HIN101551	28%	88.1%	44.8%
SAU802055	KPN301558	31%	88.1%	42.2%
SAU802055	LMO101469	36%	97.6%	49.1%
SAU802055	MCA100917	26%	85.7%	39.4%
SAU802055	MAV101430	34%	86.9%	42.9%
SAU802055	MBV101315	34%	86.9%	42.9%
SAU802055	MTU202964	34%	86.9%	42.9%
SAU802055	NGO101348	29%	88.1%	44.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802055	NME201624	29%	88.1%	44.8%
SAU802055	PMU100869	27%	88.1%	44.8%
SAU802055	PAE204691	27%	96.4%	46.0%
SAU802055	PPU100092	28%	96.4%	46.0%
SAU802055	PSY104460	27%	96.4%	46.0%
SAU802055	SPA102565	32%	88.1%	83.9%
SAU802055	STY103145	32%	88.1%	44.5%
SAU802055	STM102857	32%	88.1%	44.8%
SAU802055	SAU802055	100%	100%	100%
SAU802055	SEP204150	61%	89.3%	97.4%
SAU802055	SHA102434	62%	89.3%	93.8%
SAU802055	SMU101466	32%	96.4%	49.4%
SAU802055	SPN400402	30%	96.4%	47.6%
SAU802055	VCH102446	30%	89.3%	45.1%
SAU802055	YPS000965	31%	85.7%	43.3%
SAU802056	ABA105073	53%	98.5%	97.6%
SAU802056	BAN104049	60%	97.3%	99.7%
SAU802056	BAN109399	66%	98.8%	98.2%
SAU802056	BFR11737	36%	84.4%	82.4%
SAU802056	BPT102557	54%	98.5%	97.6%
SAU802056	BCE101787	57%	99.1%	98.5%
SAU802056	BFU106345	57%	99.1%	98.5%
SAU802056	BMA102817	57%	99.1%	98.5%
SAU802056	CJU100593	59%	98.8%	97.4%
SAU802056	CAC103323	56%	97.0%	96.4%
SAU802056	CDF103947	61%	98.2%	99.4%
SAU802056	CDP100202	58%	97.0%	96.4%
SAU802056	EBC102901	33%	94.0%	91.9%
SAU802056	EFM100577	60%	30.8%	98.1%
SAU802056	ECO103688	33%	94.0%	91.9%
SAU802056	HIN100663	31%	94.0%	91.9%
SAU802056	HPY100326	43%	95.2%	96.7%
SAU802056	KPN302041	33%	94.0%	91.9%
SAU802056	LMO100212	77%	98.2%	99.1%
SAU802056	MCA100918	54%	98.5%	97.1%
SAU802056	MAV101429	56%	97.0%	97.6%
SAU802056	MBV101313	56%	97.0%	97.6%
SAU802056	MLP101036	54%	98.8%	99.4%
SAU802056	MTU202963	56%	97.0%	97.6%
SAU802056	NGO101342	56%	98.5%	97.6%
SAU802056	NME201622	56%	98.5%	97.6%
SAU802056	PMU101284	32%	95.2%	92.9%
SAU802056	PRT103939	31%	95.2%	92.7%
SAU802056	PAE204690	56%	98.5%	97.6%
SAU802056	PPU100091	55%	98.5%	97.6%
SAU802056	PSY104461	55%	98.5%	97.6%
SAU802056	SPA103746	31%	62.3%	94.9%
SAU802056	STY102126	33%	94.0%	91.9%
SAU802056	STM101019	33%	94.0%	91.9%
SAU802056	SAU802056	100%	100%	100%
SAU802056	SEP201300	89%	100%	100%
SAU802056	SHA101347	88%	100%	100%
SAU802056	SMU101468	67%	96.4%	94.7%
SAU802056	SPN400403	68%	96.4%	94.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802056	VCH100160	30%	95.2%	92.7%
SAU802056	YPS001623	32%	94.0%	91.9%
SAU802059	ABA104781	55%	98.9%	99.2%
SAU802059	BAN100313	64%	98.9%	100%
SAU802059	BAN100367	66%	99.3%	97.8%
SAU802059	BFR12153	48%	99.1%	99.6%
SAU802059	BPT101910	54%	99.1%	97.3%
SAU802059	BCE108881	54%	99.6%	99.8%
SAU802059	BFU100662	55%	98.5%	91.7%
SAU802059	BMA104026	54%	99.1%	61.9%
SAU802059	CJU101621	56%	99.3%	98.7%
SAU802059	CAC102015	36%	99.1%	98.8%
SAU802059	CDF100900	33%	99.8%	100%
SAU802059	CDP100261	54%	97.1%	94.8%
SAU802059	EBC102532	55%	99.6%	100%
SAU802059	ECO100072	54%	99.6%	99.8%
SAU802059	HIN100969	54%	100%	99.8%
SAU802059	HPY100766	25%	75.2%	40.9%
SAU802059	KPN301553	54%	99.6%	99.8%
SAU802059	LMO100765	75%	100%	98.9%
SAU802059	MCA100223	54%	98.9%	99.2%
SAU802059	MAV108159	54%	97.4%	95.8%
SAU802059	MBV102077	52%	97.4%	96.4%
SAU802059	MLP101031	54%	97.8%	95.3%
SAU802059	MTU202950	52%	97.4%	96.4%
SAU802059	NGO101165	54%	98.7%	98.7%
SAU802059	NME201321	54%	98.7%	98.7%
SAU802059	PMU101960	54%	99.6%	99.4%
SAU802059	PRT101170	56%	99.1%	98.7%
SAU802059	PAE203119	55%	99.6%	99.4%
SAU802059	PPU103214	55%	99.6%	98.5%
SAU802059	PSY104878	55%	99.3%	98.7%
SAU802059	SPA102560	54%	97.4%	100%
SAU802059	STY103139	54%	99.6%	99.8%
SAU802059	STM104156	45%	99.3%	98.5%
SAU802059	SAU802059	100%	100%	100%
SAU802059	SEP201303	89%	100%	100%
SAU802059	SHA102193	80%	59.9%	100%
SAU802059	SMU100436	65%	99.3%	98.5%
SAU802059	VCH102456	55%	98.9%	98.9%
SAU802059	YPS000958	55%	99.1%	97.3%
SAU802063	ABA100497	40%	98.7%	90.4%
SAU802063	BAN103890	51%	97.2%	98.3%
SAU802063	BAN110897	57%	99.4%	99.2%
SAU802063	BFR10814	49%	35.3%	87.7%
SAU802063	BFR10451	47%	97.1%	97.5%
SAU802063	BPT101858	42%	96.8%	89.3%
SAU802063	BCE100683	42%	98.9%	88.0%
SAU802063	BFU102354	43%	98.9%	91.8%
SAU802063	BMA107964	43%	98.9%	87.3%
SAU802063	CAC102993	53%	98.2%	98.7%
SAU802063	CBO101100	50%	98.6%	98.8%
SAU802063	CDF101569	52%	98.6%	99.0%
SAU802063	CDP101150	43%	98.3%	92.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802063	EBC103842	42%	99.3%	92.5%
SAU802063	EFA200142	56%	99.2%	98.4%
SAU802063	EFM202462	56%	99.7%	99.2%
SAU802063	ECO103330	42%	94.8%	92.7%
SAU802063	HIN100547	42%	99.3%	94.4%
SAU802063	KPN300029	38%	25.3%	96.1%
SAU802063	KPN307162	42%	99.3%	92.5%
SAU802063	LPN100520	41%	98.2%	89.6%
SAU802063	LMO101697	57%	99.9%	99.0%
SAU802063	MCA100121	39%	99.3%	88.6%
SAU802063	NGO101872	42%	96.8%	91.4%
SAU802063	NME200185	42%	96.8%	91.4%
SAU802063	PMU101448	42%	99.3%	90.9%
SAU802063	PRT102821	42%	99.3%	92.4%
SAU802063	PAE205196	42%	96.9%	90.0%
SAU802063	PPU110008	42%	98.6%	92.2%
SAU802063	PSY103044	42%	98.6%	92.4%
SAU802063	SPA103543	41%	98.2%	99.9%
SAU802063	STY101364	42%	99.3%	92.5%
SAU802063	STM102920	42%	99.3%	92.6%
SAU802063	SAU802063	100%	100%	100%
SAU802063	SEP201321	76%	100%	100%
SAU802063	SHA100107	86%	42.7%	100%
SAU802063	SMU100019	49%	99.6%	99.6%
SAU802063	SPN400808	51%	97.6%	96.6%
SAU802063	SPY200418	49%	100%	99.7%
SAU802063	TPA100914	42%	99.2%	90.0%
SAU802063	UUR100027	41%	99.3%	99.7%
SAU802063	VCH102678	42%	99.3%	93.0%
SAU802063	YPS001556	41%	99.3%	90.8%
SAU802070	ABA104714	34%	93.5%	98.0%
SAU802070	BAN108606	28%	74.1%	73.6%
SAU802070	BAN113034	40%	95.3%	94.6%
SAU802070	BFR100168	31%	94.0%	43.0%
SAU802070	BPT100200	30%	88.7%	90.1%
SAU802070	BBU100159	28%	93.7%	96.2%
SAU802070	BCE100962	30%	85.9%	93.2%
SAU802070	BCE103071	30%	91.4%	95.5%
SAU802070	BFU105069	28%	92.4%	96.6%
SAU802070	BMA104109	30%	91.4%	95.5%
SAU802070	CJU100836	28%	87.4%	91.2%
SAU802070	CAC101046	27%	93.2%	90.9%
SAU802070	CAC102016	38%	95.5%	96.1%
SAU802070	CBO102786	36%	95.5%	94.3%
SAU802070	CDF103831	37%	97.6%	97.1%
SAU802070	CDP100053	31%	93.2%	94.5%
SAU802070	EBC104213	32%	95.3%	99.7%
SAU802070	EFA200474	38%	95.5%	98.9%
SAU802070	EFM101678	32%	94.2%	100%
SAU802070	ECO103947	32%	95.3%	99.7%
SAU802070	HIN101543	32%	95.3%	99.2%
SAU802070	HPY100925	33%	94.8%	98.9%
SAU802070	KPN308841	32%	95.3%	99.7%
SAU802070	LPN103528	31%	56.5%	99.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802070	LMO100444	40%	95.3%	98.4%
SAU802070	MCA100312	29%	95.3%	97.4%
SAU802070	MAV105645	33%	93.7%	93.4%
SAU802070	MBV101134	32%	94.8%	99.7%
SAU802070	MLP100239	31%	93.7%	94.1%
SAU802070	MTU203377	32%	94.8%	90.4%
SAU802070	NGO101532	33%	93.2%	97.7%
SAU802070	NME201757	33%	93.2%	97.7%
SAU802070	PMU100413	33%	92.7%	96.4%
SAU802070	PRT101882	32%	95.3%	99.2%
SAU802070	PAE204925	33%	94.8%	99.2%
SAU802070	PPU103159	34%	94.8%	98.9%
SAU802070	PSY101164	33%	95.3%	99.4%
SAU802070	SPA101756	31%	94.0%	98.6%
SAU802070	STY102270	31%	95.3%	99.7%
SAU802070	STM102809	31%	95.3%	99.7%
SAU802070	SAU802070	100%	100%	100%
SAU802070	SEP201329	70%	100%	100%
SAU802070	SHA101048	68%	100%	100%
SAU802070	SMU101166	39%	98.2%	99.7%
SAU802070	SPN401539	38%	93.5%	94.9%
SAU802070	SPY201387	37%	96.3%	100%
SAU802070	TPA100673	33%	86.6%	96.4%
SAU802070	VCH100367	33%	96.3%	96.3%
SAU802070	YPS002811	31%	94.8%	98.9%
SAU802071	BAN108531	48%	22.7%	35.1%
SAU802071	BAN107463	51%	99.2%	99.2%
SAU802071	BPT102423	32%	96.6%	83.7%
SAU802071	BBU100010	30%	93.3%	96.8%
SAU802071	BCE113308	32%	98.3%	90.3%
SAU802071	BFU105262	28%	95.8%	80.4%
SAU802071	BMA102365	33%	95.8%	88.8%
SAU802071	CJU101328	33%	92.4%	97.4%
SAU802071	CPN200439	37%	95.0%	95.9%
SAU802071	CTR200370	35%	94.1%	93.6%
SAU802071	CAC100902	37%	96.6%	98.4%
SAU802071	CBO101228	39%	96.6%	97.6%
SAU802071	CDF100783	40%	94.1%	94.4%
SAU802071	CDP101322	31%	92.4%	96.9%
SAU802071	EBC102618	37%	95.8%	97.6%
SAU802071	EFA203222	48%	96.6%	98.3%
SAU802071	ECO102514	38%	95.8%	97.6%
SAU802071	HPY100795	34%	95.0%	97.5%
SAU802071	KPN303138	38%	95.8%	97.6%
SAU802071	LMO100718	46%	96.6%	99.2%
SAU802071	MAV106414	25%	95.8%	96.9%
SAU802071	MBV101363	25%	95.8%	96.9%
SAU802071	MLP100741	28%	95.8%	96.9%
SAU802071	MTU202486	25%	95.8%	96.9%
SAU802071	MGE100215	34%	53.8%	55.3%
SAU802071	MPN100538	36%	54.6%	55.5%
SAU802071	NGO101699	41%	77.3%	72%
SAU802071	NME201879	36%	97.5%	100%
SAU802071	PRT105767	40%	96.6%	98.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802071	SPA103323	39%	95.8%	97.6%
SAU802071	STY102100	39%	95.8%	97.6%
SAU802071	SAU802071	100%	100%	100%
SAU802071	SEP201331	70%	98.3%	99.1%
SAU802071	SHA101047	75%	97.5%	98.3%
SAU802071	SMU101169	34%	98.3%	98.3%
SAU802071	SPN401540	37%	98.3%	97.5%
SAU802071	SPY201388	41%	96.6%	97.5%
SAU802071	TPA100819	32%	96.6%	96.8%
SAU802071	UUR100396	32%	95.0%	92.2%
SAU802071	VCH102421	41%	97.5%	99.2%
SAU802071	YPS003414	34%	95.8%	97.6%
SAU802075	ABA101351	40%	98.4%	91.5%
SAU802075	BPT102678	39%	97.8%	93.5%
SAU802075	EBC100703	36%	99.5%	99.0%
SAU802075	ECO100679	36%	100%	100%
SAU802075	KPN302575	37%	100%	99.5%
SAU802075	PPU106278	36%	97.3%	97.8%
SAU802075	STY101873	39%	97.8%	95.4%
SAU802075	SAU802075	100%	100%	100%
SAU802075	YPS001486	39%	97.8%	93%
SAU802076	ABA101353	55%	99.6%	99.0%
SAU802076	BAN101555	47%	99.3%	100%
SAU802076	BAN105989	60%	99.3%	96.1%
SAU802076	BFR10818	54%	98.8%	98.5%
SAU802076	BPT102676	51%	99.0%	95.3%
SAU802076	BFU106360	57%	45.9%	97.8%
SAU802076	BMA100646	54%	98.4%	94.4%
SAU802076	CJU100628	59%	98.5%	97.7%
SAU802076	CAC103333	61%	98.8%	97.8%
SAU802076	CDF103879	61%	99.0%	97.4%
SAU802076	EBC100702	55%	54.8%	99.2%
SAU802076	EFA201049	54%	97.8%	98.8%
SAU802076	EFM100911	24%	86.5%	76.0%
SAU802076	ECO100680	55%	98.4%	97.9%
SAU802076	KPN302573	54%	97.9%	97.5%
SAU802076	LMO102824	55%	97.3%	97.9%
SAU802076	MAV101812	53%	96.4%	93.4%
SAU802076	MBV104268	53%	98.4%	95.3%
SAU802076	MTU201019	53%	98.4%	95.2%
SAU802076	PRT102410	53%	98.4%	98.4%
SAU802076	PAE201633	54%	97.2%	94.5%
SAU802076	PPU106277	54%	97.2%	98.9%
SAU802076	PSY105755	55%	97.2%	94.2%
SAU802076	SPA100439	44%	95.6%	98.8%
SAU802076	STY101874	58%	16.4%	0.7%
SAU802076	SAU800073	71%	100%	100%
SAU802076	SAU802076	100%	100%	100%
SAU802076	SEP200654	71%	100%	100%
SAU802076	YPS001489	55%	99.3%	98.8%
SAU802081	ABA101163	40%	70.4%	60%
SAU802081	BAN102211	42%	95.3%	99.4%
SAU802081	BAN103847	50%	98.4%	95.5%
SAU802081	BFR10255	37%	88.7%	72.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802081	BPT100457	40%	71.7%	64.3%
SAU802081	BCE107115	39%	76.1%	93.7%
SAU802081	BFU107954	39%	74.3%	81.6%
SAU802081	BMA103404	40%	75.1%	84.7%
SAU802081	CAC103020	44%	83.6%	80.7%
SAU802081	CBO102910	46%	81.8%	84.3%
SAU802081	CDF103369	41%	88.9%	84.0%
SAU802081	CDP101075	39%	92.3%	83.7%
SAU802081	EBC103897	40%	90.3%	73.9%
SAU802081	EFA200476	49%	97.0%	96.5%
SAU802081	EFM201829	50%	95.7%	99.6%
SAU802081	ECO103094	39%	92.5%	73.2%
SAU802081	HIN100222	37%	93.3%	76.0%
SAU802081	HPY100243	35%	92.7%	95.5%
SAU802081	KPN300133	44%	29.1%	99.3%
SAU802081	KPN301427	39%	92.1%	73.9%
SAU802081	LPN103085	38%	97.6%	84.6%
SAU802081	LMO100391	50%	98.4%	98.1%
SAU802081	MCA100979	33%	97.0%	85.5%
SAU802081	MAV100272	39%	87.4%	78.1%
SAU802081	MBV105490	38%	90.7%	79.4%
SAU802081	MLP100490	32%	92.5%	90.3%
SAU802081	MTU201236	38%	90.7%	79.4%
SAU802081	MGE100435	32%	71.3%	82.2%
SAU802081	MPN100219	34%	72.1%	83.1%
SAU802081	NGO101914	38%	71.1%	87.4%
SAU802081	NME201494	38%	71.1%	80.5%
SAU802081	PMU101112	39%	93.3%	76.4%
SAU802081	PRT102432	39%	90.7%	75.1%
SAU802081	PAE202838	39%	90.7%	81.5%
SAU802081	PPU101891	40%	90.1%	79.8%
SAU802081	PSY103180	39%	91.7%	81.9%
SAU802081	SPA101061	40%	79.4%	86.7%
SAU802081	STY100977	39%	92.5%	73.2%
SAU802081	STM102125	37%	72.5%	82.2%
SAU802081	SAU802081	100%	100%	100%
SAU802081	SEP201342	87%	100%	100%
SAU802081	SHA100953	87%	100%	100%
SAU802081	SMU100751	48%	97.2%	95.9%
SAU802081	SPN401439	47%	96.2%	96.6%
SAU802081	SPY201084	46%	98.2%	94.4%
SAU802081	TPA100762	38%	84.0%	65.6%
SAU802081	VCH103524	36%	99.2%	72.2%
SAU802081	YPS001037	39%	92.7%	71.7%
SAU802082	ABA100930	31%	96.0%	93.3%
SAU802082	BAN107253	30%	74.6%	76.8%
SAU802082	BAN102625	49%	36.5%	67.5%
SAU802082	BAN103946	49%	37.2%	98.2%
SAU802082	BAN106298	45%	99.6%	99.8%
SAU802082	BFR103444	40%	44.7%	86.4%
SAU802082	BPT104540	34%	22.1%	40%
SAU802082	BBU100303	28%	94.5%	94.4%
SAU802082	BCE104414	30%	81.6%	97.7%
SAU802082	BFU100824	30%	94.5%	91.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802082	BMA104638	31%	99.6%	97.2%
SAU802082	CJU100734	26%	60.2%	55.2%
SAU802082	CPN200950	29%	97.1%	98.2%
SAU802082	CTR200132	28%	96.2%	94.5%
SAU802082	CAC101153	41%	93.8%	93.4%
SAU802082	CBO102608	39%	99.6%	98.7%
SAU802082	CDF103288	38%	94.7%	94.7%
SAU802082	CDP101279	29%	93.8%	93.8%
SAU802082	EBC102572	33%	99.6%	98.7%
SAU802082	EFA200478	42%	94.2%	94.1%
SAU802082	EFM201777	39%	99.3%	99.1%
SAU802082	ECO100086	31%	99.6%	98.7%
SAU802082	HIN101108	33%	94.7%	94.1%
SAU802082	HPY100728	25%	59.3%	52.9%
SAU802082	KPN301858	31%	99.6%	98.7%
SAU802082	LMO101402	41%	95.8%	95.6%
SAU802082	MCA100820	31%	92.7%	91.5%
SAU802082	MAV103997	26%	59.1%	91.1%
SAU802082	MLP100565	26%	99.8%	98.6%
SAU802082	MTU202123	28%	100%	98.2%
SAU802082	NGO100600	35%	94.7%	98.4%
SAU802082	NME201912	34%	94.7%	94.9%
SAU802082	PMU100138	32%	99.6%	98.7%
SAU802082	PRT102642	34%	98.7%	97.2%
SAU802082	PAE204414	32%	93.8%	92.8%
SAU802082	PPU111733	35%	93.6%	92.5%
SAU802082	PSY103854	35%	93.8%	93.6%
SAU802082	SPA102755	32%	99.6%	98.7%
SAU802082	STY103172	32%	99.6%	98.7%
SAU802082	STM102864	32%	99.6%	98.7%
SAU802082	SAU802082	100%	100%	100%
SAU802082	SEP201343	71%	99.8%	100%
SAU802082	SHA100952	73%	99.8%	100%
SAU802082	SMU100741	37%	99.3%	99.6%
SAU802082	SPN401513	33%	95.1%	94.5%
SAU802082	SPY201087	38%	94.5%	92.7%
SAU802082	TPA100382	32%	92.9%	92.6%
SAU802082	VCH102370	33%	99.6%	98.9%
SAU802082	YPS000994	32%	99.6%	98.7%
SAU802083	ABA100626	31%	94.9%	96.1%
SAU802083	BAN104177	35%	86.5%	99.7%
SAU802083	BAN100572	50%	96.9%	99.7%
SAU802083	BFR105381	28%	94.7%	98.8%
SAU802083	BPT102997	31%	93.0%	92.7%
SAU802083	BBU100199	36%	96.3%	98.0%
SAU802083	BCE105651	28%	94.1%	95.2%
SAU802083	BFU100405	31%	94.1%	94.3%
SAU802083	BMA105987	32%	69.9%	81.3%
SAU802083	CJU100737	29%	86.5%	87.0%
SAU802083	CPN200944	32%	97.5%	42.5%
SAU802083	CTR100467	31%	97.8%	42.7%
SAU802083	CAC100277	44%	96.3%	99.1%
SAU802083	CBO101170	28%	94.9%	98.3%
SAU802083	CDF102256	34%	95.5%	99.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802083	CDP100271	37%	94.4%	94.5%
SAU802083	EBC102757	43%	96.9%	96.7%
SAU802083	EFA200480	47%	95.2%	98.9%
SAU802083	EFM201399	47%	96.6%	97.5%
SAU802083	ECO100373	42%	96.9%	97.3%
SAU802083	HIN101114	30%	95.8%	99.0%
SAU802083	HPY100726	27%	97.2%	99.1%
SAU802083	KPN306468	42%	96.9%	97.3%
SAU802083	LPN102747	35%	93.0%	98.0%
SAU802083	LMO102338	48%	99.4%	99.5%
SAU802083	MCA100898	29%	93.5%	86.8%
SAU802083	MAV101441	36%	95.2%	96.5%
SAU802083	MBV102041	36%	94.4%	98.6%
SAU802083	MLP101024	38%	95.2%	93.8%
SAU802083	MTU202943	36%	95.2%	95.4%
SAU802083	NGO100582	29%	94.4%	97.0%
SAU802083	NME201904	29%	94.4%	97.0%
SAU802083	PMU100144	30%	96.3%	98.7%
SAU802083	PRT104171	43%	100%	99.7%
SAU802083	PAE204198	30%	97.8%	98.0%
SAU802083	PPU100215	35%	95.2%	96.9%
SAU802083	PSY105197	47%	77.2%	83.8%
SAU802083	SPA103191	43%	96.9%	97.2%
SAU802083	STY104599	43%	96.9%	97.3%
SAU802083	STM102890	32%	94.9%	99.0%
SAU802083	SAU802083	100%	100%	100%
SAU802083	SEP201344	86%	100%	99.7%
SAU802083	SHA100951	84%	100%	100%
SAU802083	SMU100736	47%	98.6%	99.4%
SAU802083	SPN401514	46%	97.5%	98.6%
SAU802083	SPY201088	45%	98.6%	99.4%
SAU802083	TPA100662	37%	95.5%	88.4%
SAU802083	VCH103296	29%	94.9%	97.6%
SAU802083	YPS001018	35%	94.9%	99.0%
SAU802087	ABA104996	31%	85.6%	87.9%
SAU802087	BAN100950	43%	73.2%	84.5%
SAU802087	BAN106687	42%	91.8%	89%
SAU802087	BCE103740	37%	83.5%	89.0%
SAU802087	BFU100478	34%	90.7%	97.8%
SAU802087	CAC102114	38%	75.3%	76.8%
SAU802087	CBO100308	38%	91.8%	97.8%
SAU802087	CDF100513	40%	99.0%	100%
SAU802087	EBC103158	38%	61.9%	65.9%
SAU802087	ECO102064	31%	90.7%	97.8%
SAU802087	KPN302400	23%	90.7%	77.2%
SAU802087	LMO101992	41%	82.5%	81.4%
SAU802087	MAV104011	47%	97.9%	87.4%
SAU802087	MBV102694	56%	74.2%	75%
SAU802087	MLP101543	51%	81.4%	58.5%
SAU802087	MTU200189	56%	74.2%	75%
SAU802087	PAE201297	35%	84.5%	90.1%
SAU802087	PPU106096	31%	80.4%	83.2%
SAU802087	PSY106346	28%	99.0%	97.9%
SAU802087	SPA103443	30%	90.7%	97.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802087	STY104085	31%	90.7%	97.8%
SAU802087	SAU802087	100%	100%	100%
SAU802087	SEP201349	84%	100%	100%
SAU802087	SHA100794	87%	100%	100%
SAU802090	ABA100996	31%	68.6%	31.4%
SAU802090	BAN110101	33%	42.8%	98.4%
SAU802090	BAN111360	27%	84.1%	92.3%
SAU802090	BAN113573	32%	84.1%	92.5%
SAU802090	BFR11357	28%	69.3%	33.3%
SAU802090	BPT100635	24%	70.7%	33.4%
SAU802090	BBU100441	25%	67.6%	36.9%
SAU802090	BCE114096	27%	70%	34.9%
SAU802090	BFU101036	27%	66.2%	32.1%
SAU802090	BMA108265	29%	66.2%	31.7%
SAU802090	CJU100888	31%	77.2%	39.6%
SAU802090	CPN200442	29%	72.1%	27.3%
SAU802090	CTR200515	30%	71.7%	27.4%
SAU802090	CAC102265	31%	82.1%	87.8%
SAU802090	CBO101415	31%	73.8%	92.6%
SAU802090	CDF102839	31%	70.7%	89.4%
SAU802090	CDP101656	29%	33.8%	27.1%
SAU802090	EBC104228	29%	65.2%	32.0%
SAU802090	EFA200401	37%	86.2%	80%
SAU802090	EFM202652	32%	95.9%	97.7%
SAU802090	ECO103626	29%	70.7%	34.5%
SAU802090	HIN100982	29%	70%	34.4%
SAU802090	HPY101429	29%	71.0%	35.1%
SAU802090	KPN302215	28%	65.2%	32.6%
SAU802090	LMO100776	36%	92.8%	98.5%
SAU802090	MCA103022	33%	71.4%	35.1%
SAU802090	MAV100557	30%	38.6%	28.6%
SAU802090	MBV106261	30%	38.6%	27.6%
SAU802090	MLP101603	29%	38.6%	26.6%
SAU802090	MTU203866	30%	38.6%	27.6%
SAU802090	MGE100473	23%	80.3%	67.8%
SAU802090	MPN100162	22%	69.7%	57.4%
SAU802090	NGO101427	32%	72.4%	36.1%
SAU802090	NME200508	31%	72.4%	36.1%
SAU802090	PMU101165	29%	70%	34.4%
SAU802090	PRT103088	27%	65.2%	32.7%
SAU802090	PAE205563	27%	72.8%	34.3%
SAU802090	PPU103675	26%	73.1%	35.5%
SAU802090	PSY103555	26%	65.2%	31.0%
SAU802090	SPA101311	29%	70.7%	35.4%
SAU802090	STY103946	28%	70.7%	34.5%
SAU802090	STM100542	28%	70.7%	34.5%
SAU802090	SAU802090	100%	100%	100%
SAU802090	SEP201891	83%	100%	100%
SAU802090	SHA100992	74%	59.3%	100%
SAU802090	SMU100510	35%	96.9%	91.9%
SAU802090	SPN401788	29%	100%	95.8%
SAU802090	SPY200255	35%	81.0%	75.2%
SAU802090	TPA100939	25%	70.7%	31.9%
SAU802090	UUR100609	22%	77.2%	64.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802090	VCH100004	29%	70%	34.4%
SAU802090	YPS003474	28%	65.2%	32.1%
SAU802091	ABA103813	30%	84.5%	86.7%
SAU802091	BAN109630	50%	53.1%	86.7%
SAU802091	BAN104683	47%	93.9%	90.4%
SAU802091	BFR11309	29%	83.6%	88.7%
SAU802091	BPT102398	32%	81.7%	81.6%
SAU802091	BCE108732	26%	79.8%	62.7%
SAU802091	BFU102896	27%	68.1%	40.1%
SAU802091	BMA102974	27%	84.0%	48.8%
SAU802091	CJU101007	31%	93.4%	91.0%
SAU802091	CAC102203	29%	83.1%	86.7%
SAU802091	CAC102661	37%	86.4%	85.3%
SAU802091	CBO102722	36%	86.4%	88.3%
SAU802091	CDF102363	39%	34.3%	45.7%
SAU802091	CDF103547	36%	92.5%	91.9%
SAU802091	CDP101293	30%	91.5%	89.2%
SAU802091	EBC103905	26%	80.8%	81.3%
SAU802091	EFA200774	29%	93.0%	91.0%
SAU802091	EFM201656	34%	19.2%	24.0%
SAU802091	ECO103891	28%	79.8%	79.6%
SAU802091	HIN100397	41%	96.7%	95.1%
SAU802091	HPY100830	40%	93.4%	94.5%
SAU802091	KPN302487	28%	79.8%	79.6%
SAU802091	LMO100703	47%	95.3%	95.8%
SAU802091	MCA101998	26%	72.8%	70.5%
SAU802091	MAV101591	30%	81.7%	80.7%
SAU802091	MBV106116	34%	80.3%	80.2%
SAU802091	MLP100208	32%	79.8%	76.6%
SAU802091	MTU200413	34%	80.3%	80.2%
SAU802091	NGO101027	28%	83.1%	85.4%
SAU802091	NME200337	28%	85.0%	87.3%
SAU802091	PMU101260	43%	93.9%	94.1%
SAU802091	PRT101551	29%	81.7%	80%
SAU802091	PAE203973	27%	86.4%	87.6%
SAU802091	PPU107618	29%	85.9%	86.5%
SAU802091	PSY105102	32%	85.9%	87.3%
SAU802091	SPA100267	29%	62.9%	63.8%
SAU802091	STY102650	28%	79.8%	79.6%
SAU802091	SAU802091	100%	100%	100%
SAU802091	SEP201892	61%	99.1%	99.1%
SAU802091	SHA100076	64%	92.5%	100%
SAU802091	SPN400630	52%	98.1%	99.5%
SAU802091	VCH100062	26%	85.9%	43.9%
SAU802091	YPS000460	29%	82.2%	80.5%
SAU802092	ABA100604	38%	94.7%	89.8%
SAU802092	BAN109533	33%	90.9%	89.2%
SAU802092	BAN107336	40%	90.9%	89.2%
SAU802092	CAC103654	34%	93.5%	93.4%
SAU802092	CBO102672	34%	98.5%	97.7%
SAU802092	CDF103521	36%	94.3%	93.9%
SAU802092	EBC100699	40%	95.1%	96.5%
SAU802092	EFA200773	32%	81.4%	80.9%
SAU802092	ECO102063	40%	91.3%	90.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802092	HIN100395	41%	98.5%	97.7%
SAU802092	HPY100832	36%	92.0%	89.0%
SAU802092	KPN308180	42%	91.3%	91.8%
SAU802092	LMO102897	38%	98.1%	95.9%
SAU802092	PMU101262	40%	97.7%	97.0%
SAU802092	SPA101206	30%	90.1%	91.7%
SAU802092	STY104191	41%	93.5%	91.7%
SAU802092	SAU802092	100%	100%	100%
SAU802092	SEP201893	66%	99.6%	100%
SAU802092	SHA100807	73%	55.1%	99.3%
SAU802092	SPN400629	41%	98.9%	97.4%
SAU802094	ABA101933	26%	96.5%	97.3%
SAU802094	BAN101414	26%	95.6%	97.8%
SAU802094	BAN108931	27%	97.4%	96.1%
SAU802094	CJU100408	21%	95.6%	98.2%
SAU802094	EFA200784	26%	96.5%	99.1%
SAU802094	HIN100338	21%	93.4%	98.6%
SAU802094	HPY101269	22%	93.9%	98.6%
SAU802094	KPN303112	22%	93.4%	94.4%
SAU802094	LMO101829	24%	90.0%	89.7%
SAU802094	PMU101264	21%	95.2%	99.5%
SAU802094	SAU802094	100%	100%	100%
SAU802094	SEP201895	62%	100%	100%
SAU802094	SHA100805	62%	99.6%	99.6%
SAU802094	SPN400634	26%	96.9%	92.2%
SAU802098	ABA101324	50%	91.8%	95.8%
SAU802098	BAN112058	68%	61.0%	98.9%
SAU802098	BAN101529	66%	97.9%	99.3%
SAU802098	BFR100706	45%	97.9%	30.8%
SAU802098	BPT101129	47%	96.6%	97.4%
SAU802098	BCE105358	46%	94.5%	91.0%
SAU802098	BFU107782	44%	95.2%	91.0%
SAU802098	BFU105730	46%	94.5%	90.9%
SAU802098	BMA107929	45%	95.2%	91.6%
SAU802098	CJU100245	40%	96.6%	99.3%
SAU802098	CPN200094	47%	97.3%	94.8%
SAU802098	CTR200808	46%	95.2%	92.8%
SAU802098	CAC102008	52%	91.8%	95.0%
SAU802098	CBO103374	61%	97.3%	98.6%
SAU802098	CDF104046	51%	26.7%	97.5%
SAU802098	CDF101479	59%	58.9%	96.6%
SAU802098	CDF100018	61%	82.9%	100%
SAU802098	EBC103090	60%	30.8%	60%
SAU802098	EBC100023	56%	45.2%	65.7%
SAU802098	EBC100020	56%	45.2%	65.7%
SAU802098	EFA203430	53%	91.8%	95.0%
SAU802098	EFM202041	61%	91.8%	96.4%
SAU802098	ECO100180	46%	91.1%	89.4%
SAU802098	HIN101039	45%	94.5%	93.9%
SAU802098	HPY101356	39%	98.6%	94.3%
SAU802098	KPN301913	46%	91.1%	89.4%
SAU802098	LPN101746	44%	89.7%	92.4%
SAU802098	LMO100873	61%	97.3%	98.6%
SAU802098	MCA100038	43%	95.2%	81.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802098	NGO100839	53%	84.9%	84.6%
SAU802098	NME200083	53%	84.9%	84.6%
SAU802098	PMU101995	49%	94.5%	91.4%
SAU802098	PRT101246	48%	91.1%	78.5%
SAU802098	PAE203643	46%	94.5%	97.3%
SAU802098	PPU101164	45%	94.5%	97.3%
SAU802098	PSY104344	46%	94.5%	97.3%
SAU802098	SPA100773	46%	91.1%	89.4%
SAU802098	STY103910	46%	91.1%	89.4%
SAU802098	STM103593	46%	91.1%	89.4%
SAU802098	SAU802098	100%	100%	100%
SAU802098	SEP204192	93%	98.6%	99.3%
SAU802098	SHA100083	91%	39.0%	98.3%
SAU802098	SMU100534	53%	95.2%	98.6%
SAU802098	SPN400384	56%	95.2%	98.6%
SAU802098	SPY201345	55%	93.2%	97.1%
SAU802098	VCH102215	46%	91.1%	88.2%
SAU802098	YPS001148	47%	91.1%	74.6%
SAU802099	SAU802099	100%	100%	100%
SAU802100	ABA104194	50%	93.7%	85.4%
SAU802100	BAN100780	56%	95.3%	83.1%
SAU802100	BAN104280	61%	94.8%	83.2%
SAU802100	BPT102115	49%	95.8%	86.3%
SAU802100	BFU102916	50%	95.0%	79.5%
SAU802100	BMA104589	52%	58.2%	93.3%
SAU802100	CJU100797	46%	93.7%	85.2%
SAU802100	CPN200175	39%	88.5%	74.2%
SAU802100	CTR200730	39%	91.4%	79.4%
SAU802100	CAC103585	46%	96.1%	87.6%
SAU802100	CBO100954	51%	93.7%	85.4%
SAU802100	CDF100485	56%	34.7%	100%
SAU802100	CDF102163	58%	54.6%	97.4%
SAU802100	CDP101476	44%	93.5%	84.7%
SAU802100	EFA201611	58%	94.8%	83.8%
SAU802100	EFM201945	58%	94.8%	83.6%
SAU802100	HIN101057	48%	95.0%	85.6%
SAU802100	KPN103684	47%	95.0%	86.4%
SAU802100	LPN103006	49%	93.7%	85.1%
SAU802100	LMO101018	60%	94.8%	83.7%
SAU802100	MCA100762	48%	93.7%	85.2%
SAU802100	MAV106518	45%	51.4%	98.0%
SAU802100	MBV100208	43%	93.5%	84.7%
SAU802100	MLP100716	43%	93.5%	84.7%
SAU802100	MTU201298	43%	93.5%	84.7%
SAU802100	NME200242	49%	95.0%	86.3%
SAU802100	PMU100180	48%	95.0%	85.4%
SAU802100	PPU109849	49%	93.7%	85.3%
SAU802100	SPA100963	47%	41.8%	99.4%
SAU802100	SAU802100	100%	100%	100%
SAU802100	SEP202410	88%	94.8%	86.2%
SAU802100	SHA101060	86%	88.0%	100%
SAU802100	SMU100515	55%	93.7%	85.1%
SAU802100	SPN401779	56%	93.7%	84.3%
SAU802100	SPY200561	56%	93.7%	85.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802100	VCH102478	50%	48.8%	93.3%
SAU802105	ABA102336	55%	95.0%	94.9%
SAU802105	BAN102895	65%	100%	100%
SAU802105	BAN104850	79%	100%	100%
SAU802105	BFR12383	55%	95.8%	95.8%
SAU802105	BPT102265	60%	98.8%	99.2%
SAU802105	BCE113271	58%	99.0%	99.4%
SAU802105	BFU111824	59%	99.0%	99.4%
SAU802105	BMA104609	58%	99.0%	99.4%
SAU802105	CJU100094	64%	98.6%	99.2%
SAU802105	CAC101220	64%	100%	99.8%
SAU802105	CBO103759	63%	99.2%	99.2%
SAU802105	CDF103688	67%	99.2%	99.2%
SAU802105	CDP100092	55%	100%	92.6%
SAU802105	EBC104234	53%	99.4%	99.8%
SAU802105	EFA201608	72%	99.4%	96.3%
SAU802105	EFM200643	72%	99.2%	96.1%
SAU802105	ECO103655	54%	96.2%	96.3%
SAU802105	HIN100461	57%	96.8%	96.9%
SAU802105	HPY101117	60%	99.2%	99.4%
SAU802105	KPN301117	54%	96.2%	96.9%
SAU802105	LPN101363	62%	74.1%	99.2%
SAU802105	LMO102357	77%	100%	99.6%
SAU802105	MCA100632	57%	98.2%	98.4%
SAU802105	MAV106522	58%	99.4%	91.9%
SAU802105	MBV105525	57%	99.4%	92.7%
SAU802105	MLP100709	57%	99.4%	91.2%
SAU802105	MTU201291	57%	99.4%	92.7%
SAU802105	MGE100413	55%	91.6%	88.8%
SAU802105	MPN100242	56%	91.6%	88.8%
SAU802105	NGO101344	57%	99.4%	99.4%
SAU802105	NME200481	57%	99.4%	99.4%
SAU802105	PMU101492	55%	96.8%	96.9%
SAU802105	PRT105365	55%	95.4%	95.5%
SAU802105	PAE205551	56%	95.8%	95.7%
SAU802105	PPU103565	56%	95.8%	95.7%
SAU802105	PSY106861	59%	86.9%	95.9%
SAU802105	SPA103402	53%	42.2%	99.5%
SAU802105	STY103858	55%	96.2%	96.3%
SAU802105	SAU802105	100%	100%	100%
SAU802105	SEP201899	94%	100%	99.8%
SAU802105	SHA101055	94%	100%	100%
SAU802105	SMU101004	72%	98.6%	98.8%
SAU802105	SPN401361	72%	98.4%	98.6%
SAU802105	SPY200556	72%	98.8%	98.8%
SAU802105	UUR100131	57%	97.0%	61.0%
SAU802105	VCH102727	57%	96.2%	94.5%
SAU802105	YPS003553	55%	96.2%	96.3%
SAU802106	ABA105713	25%	97.2%	96.6%
SAU802106	BAN113283	31%	97.2%	96.1%
SAU802106	BPT104652	28%	94.4%	93.9%
SAU802106	BCE113381	29%	96.1%	95.5%
SAU802106	BFU106431	28%	96.1%	95.5%
SAU802106	BMA109247	28%	96.1%	95.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802106	CAC100509	20%	93.3%	92.7%
SAU802106	CBO103858	24%	93.3%	92.7%
SAU802106	CDF100340	24%	97.8%	96.7%
SAU802106	CDP100090	19%	91.1%	59.0%
SAU802106	EBC104237	27%	95.0%	94.4%
SAU802106	EFA203407	21%	95.5%	94.4%
SAU802106	EFM202376	21%	97.2%	96.1%
SAU802106	ECO103656	25%	95.0%	94.4%
SAU802106	HIN100462	23%	98.3%	97.7%
SAU802106	KPN301116	28%	95.0%	94.4%
SAU802106	LPN103596	27%	93.9%	93.3%
SAU802106	LMO101750	30%	97.8%	97.2%
SAU802106	MCA100631	24%	96.1%	95.6%
SAU802106	MGE100414	22%	95.5%	97.7%
SAU802106	MPN100241	20%	96.1%	97.2%
SAU802106	NGO103629	28%	93.9%	93.2%
SAU802106	NME200480	27%	93.9%	93.2%
SAU802106	PMU101491	22%	98.3%	97.7%
SAU802106	PRT104944	25%	93.9%	93.2%
SAU802106	PAE205552	23%	95.5%	94.9%
SAU802106	PPU103564	26%	66.5%	79.7%
SAU802106	PSY103436	24%	93.9%	96.5%
SAU802106	SPA103404	26%	95.0%	94.4%
SAU802106	STY107267	27%	95.0%	94.4%
SAU802106	SAU802106	100%	100%	100%
SAU802106	SEP201900	64%	100%	100%
SAU802106	SHA101054	58%	100%	100%
SAU802106	SMU101006	21%	96.6%	96.1%
SAU802106	SPN401362	24%	93.3%	92.7%
SAU802106	SPY200555	22%	90.5%	89.9%
SAU802106	UUR100133	19%	96.6%	96.6%
SAU802106	VCH102728	23%	95.5%	94.9%
SAU802106	YPS003556	24%	95.0%	94.4%
SAU802107	ABA102339	24%	84.4%	93.6%
SAU802107	BAN100824	42%	94.8%	96.4%
SAU802107	BAN112818	42%	94.8%	96.4%
SAU802107	BFR102691	28%	87.3%	92.1%
SAU802107	BPT104649	23%	84.4%	93.6%
SAU802107	BCE107096	24%	83.8%	99.3%
SAU802107	BFU106432	24%	86.7%	96.2%
SAU802107	BMA103063	24%	83.8%	99.3%
SAU802107	CJU100091	20%	74.6%	91.5%
SAU802107	CPN200676	36%	41.6%	35.1%
SAU802107	CAC100986	31%	87.9%	95.6%
SAU802107	CBO100440	29%	87.3%	95.0%
SAU802107	CDF103938	31%	91.3%	91.8%
SAU802107	CDP100088	25%	93.1%	83.5%
SAU802107	EBC105501	28%	86.7%	96.2%
SAU802107	EFA203406	35%	88.4%	86.9%
SAU802107	EFM201470	34%	96.0%	95.4%
SAU802107	ECO103657	26%	86.7%	96.2%
SAU802107	HIN100463	23%	86.7%	96.2%
SAU802107	HPY201061	21%	66.5%	72.2%
SAU802107	KPN306143	28%	42.8%	45.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802107	LPN102324	21%	89.0%	60.7%
SAU802107	LMO102155	35%	94.8%	95.3%
SAU802107	MCA100630	25%	84.4%	94.2%
SAU802107	MAV106520	21%	79.2%	77.0%
SAU802107	MBV105523	21%	86.7%	33.9%
SAU802107	MLP100708	24%	86.7%	33.9%
SAU802107	MTU201290	21%	86.7%	33.9%
SAU802107	MGE100415	25%	85.5%	71.2%
SAU802107	MPN100240	25%	85.5%	71.5%
SAU802107	NGO103626	24%	86.7%	96.2%
SAU802107	NME200479	24%	86.7%	96.2%
SAU802107	PMU101490	23%	86.7%	96.2%
SAU802107	PRT106151	26%	86.7%	96.2%
SAU802107	PAE205553	26%	86.7%	96.2%
SAU802107	PPU112306	26%	86.7%	96.2%
SAU802107	PSY103435	25%	86.7%	96.2%
SAU802107	SPA103406	27%	86.7%	96.2%
SAU802107	STY107265	27%	86.7%	96.2%
SAU802107	SAU802107	100%	100%	100%
SAU802107	SEP201901	82%	100%	100%
SAU802107	SHA101818	86%	49.7%	100%
SAU802107	SMU101008	36%	91.3%	95.8%
SAU802107	SPN401363	31%	89.0%	93.9%
SAU802107	SPY200554	35%	89.0%	93.9%
SAU802107	UUR100134	28%	85.5%	72.2%
SAU802107	YPS003559	26%	86.7%	96.2%
SAU802109	ABA102343	30%	77.3%	71.1%
SAU802109	BAN101337	53%	12.4%	65.2%
SAU802109	BAN109723	66%	12.4%	83.3%
SAU802109	BAN111963	55%	56.6%	94.4%
SAU802109	BAN106879	55%	93.4%	95.4%
SAU802109	BFR102190	27%	87.6%	59.3%
SAU802109	BPT104642	29%	96.3%	89.1%
SAU802109	BCE101199	27%	94.2%	89.0%
SAU802109	BFU111209	26%	97.5%	93.1%
SAU802109	BFU108338	27%	90.1%	83.5%
SAU802109	BMA102656	26%	97.9%	65.9%
SAU802109	CJU101129	25%	90.9%	91.2%
SAU802109	CAC101894	26%	96.7%	95.9%
SAU802109	CBO100509	33%	100%	100%
SAU802109	CDF102803	31%	89.7%	92.7%
SAU802109	CDP100087	32%	92.6%	74.7%
SAU802109	EBC104246	32%	99.2%	88.6%
SAU802109	EFA203403	50%	93.0%	94.6%
SAU802109	EFM200212	49%	93.0%	94.6%
SAU802109	ECO103659	34%	85.5%	80.4%
SAU802109	HIN100465	32%	87.2%	85.5%
SAU802109	HPY100815	26%	87.6%	87.2%
SAU802109	KPN301113	34%	85.5%	80.4%
SAU802109	LPN100590	35%	64.9%	59.6%
SAU802109	LMO102867	58%	100%	100%
SAU802109	MCA100628	30%	83.5%	77.5%
SAU802109	MAV106517	36%	92.1%	88.5%
SAU802109	MBV105517	35%	92.1%	89.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802109	MLP100705	35%	94.2%	91.2%
SAU802109	MTU201287	35%	92.1%	89.6%
SAU802109	MGE100417	22%	94.6%	81.5%
SAU802109	MPN100238	25%	94.6%	81.2%
SAU802109	NGO101341	27%	94.2%	86.1%
SAU802109	NME200477	28%	94.2%	86.1%
SAU802109	PMU101488	31%	89.3%	86.7%
SAU802109	PRT105765	32%	93.0%	84.7%
SAU802109	PAE205555	28%	89.3%	82.0%
SAU802109	PPU103681	28%	86.8%	92.8%
SAU802109	PSY103433	27%	86.4%	79.6%
SAU802109	SPA103408	32%	97.9%	87.5%
SAU802109	STY103856	32%	97.9%	87.5%
SAU802109	SAU802109	100%	100%	100%
SAU802109	SEP201902	87%	100%	100%
SAU802109	SHA100056	83%	100%	100%
SAU802109	SMU101010	40%	91.7%	91.6%
SAU802109	SPN401364	37%	91.7%	92.4%
SAU802109	SPY200553	36%	91.7%	92.4%
SAU802109	UUR100136	24%	100%	87.3%
SAU802109	VCH102731	30%	63.6%	60%
SAU802109	YPS000004	32%	97.9%	86.5%
SAU802111	ABA105452	42%	96.0%	98.7%
SAU802111	BAN106286	54%	19.7%	94.9%
SAU802111	BAN110258	39%	88.8%	92.9%
SAU802111	BAN112148	60%	96.8%	96.3%
SAU802111	BAN107002	60%	96.8%	98.4%
SAU802111	BFR104545	49%	95.5%	98.9%
SAU802111	BFR12295	46%	96.0%	99.5%
SAU802111	CJU101068	24%	77.9%	79.0%
SAU802111	CAC103461	52%	99.2%	97.9%
SAU802111	CAC103778	55%	97.9%	98.4%
SAU802111	CBO100630	53%	99.2%	94.7%
SAU802111	CDF100919	58%	95.5%	96.3%
SAU802111	EFA200201	60%	99.2%	98.2%
SAU802111	EFM201136	23%	97.3%	96.3%
SAU802111	KPN301893	50%	95.7%	98.1%
SAU802111	LMO102015	60%	99.2%	98.4%
SAU802111	NME200190	50%	94.7%	97.8%
SAU802111	PPU108280	48%	90.7%	96.1%
SAU802111	SAU802111	100%	100%	100%
SAU802111	SEP201903	72%	100%	98.4%
SAU802111	SHA100639	66%	99.7%	99.5%
SAU802111	SMU100328	56%	99.2%	97.9%
SAU802111	SPN300337	57%	95.5%	98.4%
SAU802111	VCH100901	50%	95.5%	98.9%
SAU802111	YPS001517	51%	95.7%	98.1%
SAU802112	ABA105256	52%	81.8%	97.7%
SAU802112	BAN112213	72%	100%	100%
SAU802112	BFR103881	33%	95.2%	94.5%
SAU802112	BPT100985	48%	98.1%	84.4%
SAU802112	BCE107019	56%	97.6%	94.4%
SAU802112	BFU100449	54%	64.6%	100%
SAU802112	BMA105302	56%	97.6%	94.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802112	CJU101210	47%	99.5%	99.5%
SAU802112	CTR200822	52%	99.5%	68.6%
SAU802112	CAC100474	70%	100%	100%
SAU802112	CBO100953	70%	100%	100%
SAU802112	CDF104480	66%	100%	100%
SAU802112	CDP100815	43%	99.0%	97.6%
SAU802112	EBC102719	51%	99.0%	99.5%
SAU802112	EFA201665	70%	100%	100%
SAU802112	EFM100705	72%	54.1%	100%
SAU802112	ECO102449	51%	99.0%	95.4%
SAU802112	HIN101200	52%	96.2%	96.6%
SAU802112	KPN309030	51%	99.0%	99.5%
SAU802112	LPN102459	60%	99.5%	97.2%
SAU802112	LMO102461	71%	100%	100%
SAU802112	MCA103555	52%	98.6%	95.8%
SAU802112	MAV100235	44%	97.6%	79.0%
SAU802112	MBV100852	44%	99.0%	99.5%
SAU802112	MTU203266	44%	99.0%	99.5%
SAU802112	MGE100030	46%	96.2%	97.1%
SAU802112	MPN100121	46%	84.7%	98.9%
SAU802112	NGO100075	50%	98.6%	99.0%
SAU802112	NME200908	50%	98.6%	99.0%
SAU802112	PMU100019	53%	96.2%	96.6%
SAU802112	PRT104353	53%	99.0%	99.5%
SAU802112	PAE204643	53%	98.6%	97.2%
SAU802112	PPU104022	53%	96.2%	94.8%
SAU802112	PSY102376	53%	96.2%	94.8%
SAU802112	SPA103099	50%	99.0%	98.6%
SAU802112	STY101654	51%	99.0%	99.5%
SAU802112	SAU802112	100%	100%	100%
SAU802112	SEP201904	94%	100%	100%
SAU802112	SHA100638	94%	100%	100%
SAU802112	SMU100374	70%	100%	100%
SAU802112	SPN400655	71%	100%	96.8%
SAU802112	SPY200285	70%	100%	100%
SAU802112	TPA100444	34%	42.1%	25%
SAU802112	UUR100115	54%	97.6%	98.6%
SAU802112	VCH102191	52%	99.0%	99.5%
SAU802112	YPS002584	52%	99.0%	99.5%
SAU802113	ABA104851	60%	99.0%	98.1%
SAU802113	BAN101706	68%	99.3%	99.3%
SAU802113	BAN109367	70%	99.8%	99.3%
SAU802113	BFR11177	57%	98.5%	99.3%
SAU802113	BPT102825	62%	98.1%	96.9%
SAU802113	BBU100600	55%	98.1%	99.5%
SAU802113	BCE107637	61%	99.8%	98.6%
SAU802113	BFU111760	56%	99.0%	97.4%
SAU802113	BMA102315	60%	99.8%	83.0%
SAU802113	CJU100370	55%	98.3%	97.6%
SAU802113	CPN200229	44%	97.3%	90.5%
SAU802113	CTR200706	44%	97.3%	90.5%
SAU802113	CAC101420	64%	99.3%	98.8%
SAU802113	CBO101302	65%	98.3%	97.3%
SAU802113	CDF100075	65%	17.7%	83.0%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802113	CDF100511	66%	99.3%	97.6%
SAU802113	CDP100921	54%	99.3%	96.0%
SAU802113	EBC100017	57%	27.4%	97.5%
SAU802113	EBC102113	57%	99.0%	97.6%
SAU802113	EFA201664	66%	99.8%	99.8%
SAU802113	EFM103325	62%	11.7%	95.9%
SAU802113	ECO102502	59%	99.0%	98.1%
SAU802113	HIN100869	57%	99.0%	97.9%
SAU802113	HPY100180	53%	99.8%	98.8%
SAU802113	KPN305968	58%	98.1%	97.1%
SAU802113	LPN101884	55%	50.2%	97.7%
SAU802113	LMO102513	70%	99.8%	99.3%
SAU802113	MCA101556	59%	98.3%	96.7%
SAU802113	MAV100777	56%	98.3%	95.8%
SAU802113	MBV106196	54%	99.0%	96.9%
SAU802113	MLP101190	53%	99.0%	96.5%
SAU802113	MTU200070	54%	99.0%	96.9%
SAU802113	MGE100406	54%	96.6%	97.0%
SAU802113	MPN100266	53%	97.6%	98.0%
SAU802113	NGO101181	60%	99.0%	97.8%
SAU802113	NME201154	60%	99.0%	97.8%
SAU802113	PMU100225	57%	99.0%	98.1%
SAU802113	PRT105514	56%	99.0%	98.1%
SAU802113	PAE204600	60%	99.0%	97.8%
SAU802113	PPU107530	60%	98.3%	97.4%
SAU802113	PSY105291	60%	99.0%	97.8%
SAU802113	SPA103023	55%	96.6%	96.2%
SAU802113	STY102040	58%	99.0%	98.1%
SAU802113	SAU802113	100%	100%	100%
SAU802113	SEP201905	87%	99.8%	99.8%
SAU802113	SHA100637	84%	100%	100%
SAU802113	SMU100311	59%	98.3%	96.7%
SAU802113	SPN400928	61%	98.3%	97.1%
SAU802113	SPY200872	60%	98.3%	97.1%
SAU802113	TPA100325	44%	93.4%	72.6%
SAU802113	VCH103010	61%	98.3%	94.0%
SAU802113	YPS003331	57%	99.0%	98.1%
SAU802118	ABA105579	53%	97.8%	96.4%
SAU802118	BAN113068	61%	94.7%	99.1%
SAU802118	BAN100929	65%	98.0%	99.2%
SAU802118	BFR11151	45%	98.3%	97.6%
SAU802118	BPT101750	50%	99.2%	98.3%
SAU802118	BBU100195	47%	98.0%	98.6%
SAU802118	BCE108751	49%	98.9%	98.1%
SAU802118	BFU107325	50%	98.9%	98.1%
SAU802118	BMA103540	50%	99.7%	98.9%
SAU802118	CJU101518	54%	98.0%	98.6%
SAU802118	CPN200648	51%	91.9%	94.7%
SAU802118	CTR200287	52%	92.5%	93.0%
SAU802118	CAC101625	54%	99.2%	99.2%
SAU802118	CBO100481	57%	98.6%	98.9%
SAU802118	CDF101347	58%	97.8%	99.2%
SAU802118	CDP100071	47%	96.6%	97.2%
SAU802118	EBC100920	56%	68.7%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802118	EFA201655	63%	99.4%	100%
SAU802118	EFM200375	61%	99.4%	100%
SAU802118	ECO101184	50%	98.9%	98.1%
SAU802118	HIN101530	51%	98.0%	97.0%
SAU802118	HPY100075	51%	96.4%	97.7%
SAU802118	KPN303478	50%	98.9%	98.1%
SAU802118	LPN101572	54%	96.1%	95.3%
SAU802118	LMO101439	64%	99.2%	99.4%
SAU802118	MCA100127	55%	96.4%	95.8%
SAU802118	MAV106507	42%	97.2%	97.8%
SAU802118	MBV105506	40%	97.2%	97.8%
SAU802118	MLP100700	40%	97.5%	98.1%
SAU802118	MTU201282	40%	97.2%	97.8%
SAU802118	MGE100263	48%	98.3%	97.5%
SAU802118	MPN100475	47%	97.8%	96.9%
SAU802118	NGO100540	53%	99.2%	98.9%
SAU802118	NME201794	53%	99.2%	98.9%
SAU802118	PMU100555	51%	98.9%	98.1%
SAU802118	PRT101055	52%	98.0%	97.2%
SAU802118	PAE204662	52%	99.2%	98.9%
SAU802118	PPU109700	52%	99.2%	98.9%
SAU802118	PSY102423	50%	98.6%	98.3%
SAU802118	SPA100352	44%	98.9%	98.0%
SAU802118	STY101661	50%	98.9%	98.1%
SAU802118	SAU802118	100%	100%	100%
SAU802118	SEP201909	93%	100%	100%
SAU802118	SHA100601	90%	100%	100%
SAU802118	SMU100318	58%	98.9%	99.2%
SAU802118	SPN400924	58%	98.9%	99.2%
SAU802118	SPY200868	57%	99.2%	99.4%
SAU802118	TPA100050	46%	96.6%	98.9%
SAU802118	UUR100003	52%	92.5%	92.2%
SAU802118	VCH102146	52%	98.6%	97.8%
SAU802118	YPS003258	51%	98.0%	97.2%
SAU802119	BAN102071	61%	84.9%	97.7%
SAU802119	BAN101436	63%	95.0%	97.4%
SAU802119	BFR10775	46%	91.5%	87.9%
SAU802119	BBU100790	26%	83.9%	52.3%
SAU802119	CAC102314	60%	95.0%	96.9%
SAU802119	CBO102085	60%	95.0%	99.0%
SAU802119	EBC100656	29%	86.4%	76.3%
SAU802119	EFA201653	28%	92.5%	95.9%
SAU802119	EFM201540	27%	86.9%	90.7%
SAU802119	ECO101209	29%	86.4%	86.3%
SAU802119	HIN100508	29%	86.4%	91.7%
SAU802119	KPN300816	29%	86.4%	86.3%
SAU802119	LPN103251	27%	86.4%	85.2%
SAU802119	LMO102848	29%	88.9%	94.8%
SAU802119	MGE100034	46%	90.5%	83.1%
SAU802119	MPN100110	47%	89.9%	91.1%
SAU802119	PMU101236	29%	86.4%	92.2%
SAU802119	PRT105114	28%	92.5%	95.5%
SAU802119	SPA100526	30%	86.4%	87.2%
SAU802119	STY102989	30%	86.4%	86.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802119	SAU802119	100%	100%	100%
SAU802119	SEP201910	86%	100%	100%
SAU802119	SHA100600	84%	100%	100%
SAU802119	SMU100321	27%	88.9%	91.8%
SAU802119	SPN400922	26%	92.5%	94.0%
SAU802119	SPY200867	29%	86.9%	93.1%
SAU802119	UUR100601	44%	91.5%	83.4%
SAU802119	VCH101148	27%	86.4%	92.2%
SAU802119	YPS000765	27%	86.4%	90.3%
SAU802120	ABA103769	50%	92.9%	91.7%
SAU802120	BAN113559	70%	96.4%	100%
SAU802120	BAN104117	72%	96.4%	100%
SAU802120	BFR11933	43%	94.0%	95.2%
SAU802120	BPT100219	50%	92.9%	61.6%
SAU802120	BBU100228	47%	92.9%	96.3%
SAU802120	BCE110175	49%	98.8%	95.3%
SAU802120	BFU100113	50%	97.6%	92.0%
SAU802120	BMA100597	49%	98.8%	94.3%
SAU802120	CJU100144	35%	96.4%	100%
SAU802120	CPN200649	52%	92.9%	70.6%
SAU802120	CTR200286	47%	92.9%	71.3%
SAU802120	CAC103101	36%	98.8%	98.6%
SAU802120	CBO102930	34%	100%	97.2%
SAU802120	CDF104012	37%	66.7%	79.2%
SAU802120	CDP100131	51%	94.0%	89.8%
SAU802120	EBC103974	49%	94.0%	90.7%
SAU802120	EFA201303	70%	100%	94.4%
SAU802120	ECO100288	46%	94.0%	89.7%
SAU802120	HIN100738	41%	97.6%	97.1%
SAU802120	HPY100544	40%	96.4%	100%
SAU802120	KPN303881	48%	48.8%	71.9%
SAU802120	LMO100203	74%	96.4%	100%
SAU802120	MCA100984	53%	94.0%	90.7%
SAU802120	MAV106531	35%	94.0%	82.5%
SAU802120	MBV105505	34%	94.0%	82.5%
SAU802120	MLP100699	34%	94.0%	78.6%
SAU802120	MTU201281	34%	94.0%	82.5%
SAU802120	MGE100262	28%	92.9%	68.0%
SAU802120	MPN100476	28%	92.9%	68.0%
SAU802120	NGO101307	52%	52.4%	80%
SAU802120	NME201050	45%	92.9%	87.9%
SAU802120	PMU100220	46%	94.0%	90.9%
SAU802120	PRT104831	51%	94.0%	95.1%
SAU802120	PAE203599	51%	92.9%	89.7%
SAU802120	PPU102065	35%	95.2%	93.0%
SAU802120	PSY107166	46%	92.9%	83.9%
SAU802120	SPA100819	45%	94.0%	90.7%
SAU802120	STY104986	46%	94.0%	90.7%
SAU802120	STM100496	46%	94.0%	90.7%
SAU802120	SAU802120	100%	100%	100%
SAU802120	SEP204230	95%	100%	98.8%
SAU802120	SHA102245	81%	65.5%	100%
SAU802120	SMU100284	70%	96.4%	100%
SAU802120	SPN401176	70%	96.4%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802120	SPY200525	67%	100%	96.5%
SAU802120	TPA100252	28%	96.4%	98.5%
SAU802120	VCH100862	50%	94.0%	91.8%
SAU802120	YPS001792	48%	94.0%	90.7%
SAU802121	ABA100304	49%	91.6%	97.1%
SAU802121	BAN105100	51%	94.7%	97.6%
SAU802121	BAN113042	66%	94.7%	97.9%
SAU802121	BFR103103	54%	84.2%	55.7%
SAU802121	BPT100264	51%	91.6%	97.1%
SAU802121	BBU100229	53%	87.4%	74.8%
SAU802121	BCE104048	50%	92.9%	98.1%
SAU802121	BFU105309	51%	90.0%	94.4%
SAU802121	BMA101995	50%	92.9%	98.1%
SAU802121	CJU101081	51%	94.1%	97.7%
SAU802121	CPN200135	53%	91.8%	87.3%
SAU802121	CTR200767	53%	91.3%	96.2%
SAU802121	CAC102868	58%	82.6%	75.4%
SAU802121	CBO103912	55%	96.1%	87.1%
SAU802121	CDF100058	61%	76.7%	67.6%
SAU802121	CDP100068	53%	82.9%	54.4%
SAU802121	EBC103271	59%	60.3%	100%
SAU802121	EFA201306	65%	92.0%	93.7%
SAU802121	ECO103697	52%	93.2%	98.6%
SAU802121	HIN100281	53%	93.2%	98.6%
SAU802121	HPY100543	51%	95.9%	96.6%
SAU802121	KPN301899	53%	86.1%	95%
SAU802121	LMO101598	66%	92.9%	96.7%
SAU802121	MCA100009	40%	42.5%	96.4%
SAU802121	MAV106530	54%	82.6%	61.6%
SAU802121	MBV105502	52%	86.5%	64.0%
SAU802121	MLP100698	51%	86.5%	63.1%
SAU802121	MTU201280	52%	86.5%	64.0%
SAU802121	NGO100759	52%	91.3%	96.7%
SAU802121	NME200762	52%	91.3%	96.7%
SAU802121	PMU101920	52%	93.2%	98.6%
SAU802121	PRT102841	52%	93.2%	98.6%
SAU802121	PAE205234	53%	91.6%	96.9%
SAU802121	PPU100260	52%	90.4%	99.5%
SAU802121	PSY100590	52%	91.6%	96.9%
SAU802121	SPA103748	52%	93.2%	98.6%
SAU802121	STY102102	52%	93.2%	98.6%
SAU802121	STM101036	52%	93.2%	98.6%
SAU802121	SAU802121	100%	100%	100%
SAU802121	SEP201911	95%	100%	100%
SAU802121	SHA100146	94%	99.1%	96.0%
SAU802121	TPA100251	53%	89.0%	75.5%
SAU802121	VCH100303	52%	92.9%	98.3%
SAU802121	YPS001531	51%	93.2%	98.6%
SAU802124	BAN108367	44%	84.2%	83.4%
SAU802124	BAN107764	59%	98.8%	96.7%
SAU802124	BFR11634	34%	97.1%	98.2%
SAU802124	BBU100471	34%	97.1%	94.1%
SAU802124	BCE107676	42%	91.9%	98.2%
SAU802124	CAC102006	50%	98.3%	98.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802124	CBO103182	53%	97.6%	97.6%
SAU802124	EBC101214	42%	97.4%	97.6%
SAU802124	EFA201309	54%	97.6%	95.6%
SAU802124	ECO103119	42%	97.4%	97.6%
SAU802124	HPY100640	40%	98.1%	98.3%
SAU802124	KPN301069	42%	97.4%	97.6%
SAU802124	LMO102733	57%	97.1%	96.2%
SAU802124	MAV102894	37%	52.7%	98.2%
SAU802124	NGO102024	43%	97.6%	98.1%
SAU802124	PRT100966	42%	97.4%	97.4%
SAU802124	PAE204448	44%	97.1%	97.6%
SAU802124	PSY104793	43%	90.7%	98.7%
SAU802124	SPA100481	39%	43.9%	96.9%
SAU802124	STY101491	43%	97.4%	97.6%
SAU802124	SAU802124	100%	100%	100%
SAU802124	SEP201914	85%	100%	100%
SAU802124	SHA101919	83%	100%	100%
SAU802124	SMU101064	51%	97.6%	98.1%
SAU802124	SPN400989	52%	97.6%	98.1%
SAU802124	SPY201041	52%	97.6%	98.1%
SAU802124	TPA100028	31%	98.1%	98.8%
SAU802124	YPS002303	43%	97.4%	97.6%
SAU802125	ABA100914	33%	99.7%	95.4%
SAU802125	BAN112047	72%	97.2%	100%
SAU802125	BAN107884	76%	99.7%	100%
SAU802125	BFR11934	38%	98.6%	96.7%
SAU802125	BPT102002	38%	99.7%	92.9%
SAU802125	BBU100444	26%	94.8%	93.0%
SAU802125	BCE111090	35%	97.9%	92.8%
SAU802125	BFU111409	34%	99.7%	92.7%
SAU802125	BMA102172	35%	97.9%	92.8%
SAU802125	CJU100558	26%	95.1%	93.2%
SAU802125	CAC101944	53%	99.0%	99.7%
SAU802125	CBO101028	43%	96.9%	96.8%
SAU802125	CDF100408	44%	99.3%	99.6%
SAU802125	CDF101639	43%	99.7%	97.9%
SAU802125	CDP101376	30%	92.7%	92.4%
SAU802125	EBC104459	41%	99.7%	100%
SAU802125	EFA201312	48%	99.7%	100%
SAU802125	EFM201171	39%	96.2%	94.8%
SAU802125	ECO102055	42%	99.7%	99.3%
SAU802125	HIN100503	26%	93.0%	91.4%
SAU802125	HPY100173	43%	98.6%	99.3%
SAU802125	KPN306125	51%	98.6%	99.3%
SAU802125	LMO100774	65%	99.7%	100%
SAU802125	MCA100353	34%	99.7%	95.4%
SAU802125	MBV102190	27%	92.7%	92.4%
SAU802125	MLP100198	29%	92.7%	92.2%
SAU802125	MTU200362	27%	92.7%	92.4%
SAU802125	MGE100023	44%	99.0%	99.7%
SAU802125	MPN100129	45%	99.0%	99.7%
SAU802125	NGO101574	35%	99.7%	92.9%
SAU802125	NME200544	35%	99.7%	92.9%
SAU802125	PMU101373	37%	99.7%	98.0%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802125	PRT102752	40%	96.9%	97.2%
SAU802125	PAE200554	34%	99.7%	92.9%
SAU802125	PPU104672	34%	99.7%	94.3%
SAU802125	PSY100210	34%	99.7%	92.9%
SAU802125	SPA103912	43%	97.9%	98.2%
SAU802125	STY100942	43%	97.9%	98.2%
SAU802125	STM101386	43%	97.9%	98.2%
SAU802125	SAU802125	100%	100%	100%
SAU802125	SEP201915	95%	100%	100%
SAU802125	SHA101918	93%	100%	100%
SAU802125	SMU101408	45%	99.7%	100%
SAU802125	SPN400530	44%	99.7%	100%
SAU802125	SPY201455	45%	99.7%	100%
SAU802125	TPA100654	39%	99.0%	97.6%
SAU802125	UUR100603	43%	99.7%	99.3%
SAU802125	VCH100473	26%	89.5%	88.5%
SAU802125	YPS000084	41%	99.3%	99.6%
SAU802130	BAN113149	31%	46.8%	97.0%
SAU802130	BAN107309	36%	97.8%	95.7%
SAU802130	EFA202449	23%	54.7%	10.6%
SAU802130	PSY101953	20%	63.7%	37.3%
SAU802130	SAU802130	100%	100%	100%
SAU802130	SEP201922	75%	99.3%	97.4%
SAU802130	SHA102983	77%	99.3%	99.6%
SAU802133	BAN111842	44%	37.3%	96.7%
SAU802133	BAN109593	58%	49.7%	92.9%
SAU802133	BAN105036	53%	99.2%	97.8%
SAU802133	CAC101783	22%	97.7%	99.5%
SAU802133	CBO102190	27%	97.0%	96.9%
SAU802133	CDF101111	30%	96.7%	93.6%
SAU802133	CDF101575	35%	93.1%	94.2%
SAU802133	CDF100587	38%	97.0%	98.2%
SAU802133	EBC100570	34%	66.5%	63.3%
SAU802133	EFM202575	45%	98.7%	96.6%
SAU802133	ECO101308	33%	66.0%	57.4%
SAU802133	KPN304546	31%	67.0%	58.2%
SAU802133	MAV100227	33%	99.0%	97.2%
SAU802133	MBV100846	33%	95.4%	95.2%
SAU802133	MTU203263	33%	95.4%	95.2%
SAU802133	SAU802133	100%	100%	100%
SAU802133	SEP201928	85%	100%	100%
SAU802133	SHA101910	86%	100%	100%
SAU802137	BAN109977	64%	91.8%	100%
SAU802137	BAN102250	66%	95.9%	95.1%
SAU802137	BFR12234	34%	70.9%	55.4%
SAU802137	BCE105592	55%	57.7%	98.4%
SAU802137	BFU103022	31%	68.6%	47.6%
SAU802137	BFU108762	30%	72.3%	50%
SAU802137	BMA104956	36%	92.3%	81.2%
SAU802137	CAC100384	63%	95.9%	98.6%
SAU802137	CBO100256	58%	96.4%	100%
SAU802137	CDF100310	48%	98.2%	97.7%
SAU802137	CDP101627	45%	95.9%	95.9%
SAU802137	EBC103572	32%	92.7%	84.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802137	EFA202355	63%	96.8%	97.3%
SAU802137	EFM201549	62%	96.8%	97.3%
SAU802137	ECO104267	34%	92.7%	83.8%
SAU802137	HIN101089	55%	96.4%	94.6%
SAU802137	KPN308783	35%	92.7%	83.1%
SAU802137	LPN101764	30%	81.8%	72.8%
SAU802137	LMO101987	64%	96.8%	96.0%
SAU802137	MAV103921	45%	48.6%	96.6%
SAU802137	MBV102346	45%	95.9%	95.1%
SAU802137	MLP101461	42%	95.9%	95.1%
SAU802137	MTU200476	45%	95.9%	95.1%
SAU802137	MGE100050	45%	95.9%	94.2%
SAU802137	MPN100091	46%	95.5%	93.3%
SAU802137	PMU101343	55%	96.4%	94.6%
SAU802137	PRT101388	53%	98.6%	98.2%
SAU802137	PAE201382	27%	51.4%	20.5%
SAU802137	PSY100190	32%	76.8%	68.3%
SAU802137	SPA100057	34%	70.5%	83.5%
SAU802137	STY104584	32%	93.2%	82.3%
SAU802137	STM100357	33%	92.7%	81.9%
SAU802137	SAU800138	97%	100%	100%
SAU802137	SAU802137	100%	100%	100%
SAU802137	SEP201938	78%	100%	100%
SAU802137	SHA101905	84%	100%	100%
SAU802137	SMU100919	60%	100%	100%
SAU802137	SPN400745	59%	100%	100%
SAU802137	SPY201436	45%	97.7%	96.0%
SAU802137	TPA100261	41%	93.6%	95.4%
SAU802137	UUR100592	46%	93.2%	95.3%
SAU802137	VCH102315	34%	86.4%	78.0%
SAU802137	YPS001140	53%	97.7%	96.4%
SAU802139	BAN113297	49%	96.6%	98.6%
SAU802139	BAN110089	51%	97.3%	97.9%
SAU802139	BFR12031	33%	82.3%	87.7%
SAU802139	BPT102735	32%	95.2%	75.3%
SAU802139	BBU100689	25%	93.2%	73.5%
SAU802139	BCE107273	33%	98.6%	89.5%
SAU802139	BFU102626	31%	98.6%	67.1%
SAU802139	BMA103777	32%	98.6%	89.5%
SAU802139	CJU101443	27%	95.2%	94.6%
SAU802139	CDP100814	28%	98.6%	90.1%
SAU802139	EBC100875	22%	97.3%	84.4%
SAU802139	EFA200810	28%	92.5%	89.0%
SAU802139	EFA200155	34%	91.8%	88.4%
SAU802139	EFM200208	33%	48.3%	72.4%
SAU802139	ECO100788	23%	97.3%	84.4%
SAU802139	HIN101315	32%	94.6%	86.9%
SAU802139	HPY100239	32%	96.6%	97.2%
SAU802139	KPN300031	20%	78.9%	87.0%
SAU802139	KPN303559	20%	97.3%	84.4%
SAU802139	LMO102910	43%	98.0%	93.6%
SAU802139	MAV101663	24%	92.5%	74.7%
SAU802139	PMU100817	34%	95.9%	88.7%
SAU802139	PRT106088	23%	92.5%	74.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802139	PAE200961	31%	95.9%	90.4%
SAU802139	PPU108680	30%	98.0%	91.7%
SAU802139	PSY105983	33%	98.0%	91.7%
SAU802139	SPA101972	23%	97.3%	84.4%
SAU802139	STY102376	23%	97.3%	84.4%
SAU802139	SAU802139	100%	100%	100%
SAU802139	SEP201942	84%	99.3%	98.6%
SAU802139	SHA101903	84%	98.0%	98.6%
SAU802139	SMU100064	33%	92.5%	78.9%
SAU802139	SPN401429	35%	92.5%	77.0%
SAU802139	SPY201180	33%	91.2%	77.7%
SAU802139	TPA101028	29%	95.2%	79.7%
SAU802139	VCH100138	29%	98.6%	92.9%
SAU802139	YPS000339	23%	93.2%	80.8%
SAU802152	BFR101055	28%	97.9%	98.5%
SAU802152	HPY100644	26%	43.5%	59.4%
SAU802152	SAU802152	100%	100%	100%
SAU802152	SEP201959	69%	99.3%	99.3%
SAU802152	SHA102869	66%	74.0%	99.5%
SAU802152	SPN401123	26%	100%	99.6%
SAU802154	ABA103622	43%	100%	100%
SAU802154	BAN106917	49%	100%	100%
SAU802154	BAN102903	70%	100%	100%
SAU802154	BFR105590	56%	8.2%	33.6%
SAU802154	BPT101720	40%	100%	100%
SAU802154	BCE109254	39%	100%	100%
SAU802154	BFU109440	44%	17.5%	77.9%
SAU802154	BFU103182	40%	100%	100%
SAU802154	BMA102722	39%	100%	100%
SAU802154	CJU101290	36%	100%	100%
SAU802154	CPN200876	38%	100%	100%
SAU802154	CTR200198	38%	100%	100%
SAU802154	CAC103586	45%	100%	100%
SAU802154	CBO102655	43%	100%	100%
SAU802154	CDF100284	44%	100%	100%
SAU802154	CDP100523	40%	96.2%	100%
SAU802154	EBC104245	41%	100%	100%
SAU802154	EFA201749	58%	100%	100%
SAU802154	EFM200906	23%	55.6%	94.0%
SAU802154	ECO103650	41%	100%	100%
SAU802154	HIN100409	39%	100%	100%
SAU802154	HPY101510	37%	100%	100%
SAU802154	KPN300721	40%	100%	100%
SAU802154	LPN102850	38%	100%	100%
SAU802154	LMO101794	65%	100%	100%
SAU802154	MCA103570	37%	100%	100%
SAU802154	MAV105640	40%	100%	96.1%
SAU802154	MBV101159	39%	97.2%	100%
SAU802154	MLP100237	39%	100%	100%
SAU802154	MTU203389	39%	100%	100%
SAU802154	NGO101887	38%	100%	100%
SAU802154	NME200260	38%	100%	100%
SAU802154	PMU101731	39%	100%	100%
SAU802154	PRT104794	42%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802154	PAE205544	42%	100%	100%
SAU802154	PPU102151	43%	100%	100%
SAU802154	PSY103460	42%	100%	100%
SAU802154	SPA101582	38%	100%	100%
SAU802154	STY103864	41%	100%	100%
SAU802154	STM100312	19%	55.9%	94.3%
SAU802154	SAU802154	100%	100%	100%
SAU802154	SEP201962	89%	100%	100%
SAU802154	SHA100979	88%	100%	100%
SAU802154	SMU101007	56%	100%	100%
SAU802154	SPN400245	57%	100%	100%
SAU802154	SPY200983	57%	100%	100%
SAU802154	TPA100852	37%	100%	100%
SAU802154	VCH100482	39%	100%	100%
SAU802154	YPS003544	41%	100%	100%
SAU802158	CAC102954	48%	97.9%	97.3%
SAU802158	CDF104113	44%	100%	99.3%
SAU802158	EBC101475	39%	91.0%	35.1%
SAU802158	EFA201285	44%	93.8%	95.9%
SAU802158	EFM202400	44%	90.3%	92.4%
SAU802158	ECO102128	42%	81.9%	31.6%
SAU802158	HIN100428	40%	89.6%	26.1%
SAU802158	KPN102504	38%	88.9%	67.9%
SAU802158	MPN100189	28%	89.6%	90.2%
SAU802158	PAE100175	41%	84.7%	33.2%
SAU802158	SAU802158	100%	100%	100%
SAU802158	SMU101001	38%	96.5%	98.6%
SAU802158	SPN400358	40%	93.1%	95.2%
SAU802158	YPS001090	36%	92.4%	35.5%
SAU802159	ABA105269	26%	40.5%	44.3%
SAU802159	BCE113957	28%	38.0%	40.6%
SAU802159	BFU102350	25%	56.8%	49.4%
SAU802159	BMA101585	27%	59.5%	47.8%
SAU802159	CAC102601	36%	96.5%	95.3%
SAU802159	CDF104333	39%	98.6%	97.9%
SAU802159	EBC103811	37%	99.5%	98.7%
SAU802159	EFA201284	42%	96.2%	94.8%
SAU802159	EFM200126	42%	96.2%	95.0%
SAU802159	ECO103522	37%	99.7%	99.7%
SAU802159	KPN305795	38%	99.2%	98.4%
SAU802159	MAV108334	28%	58.7%	49.9%
SAU802159	MPN100190	24%	92.1%	90.7%
SAU802159	PMU101062	38%	99.7%	99.2%
SAU802159	PAE202340	24%	45.7%	38.5%
SAU802159	PSY101120	27%	47.6%	39.8%
SAU802159	SPA103111	37%	99.5%	99.5%
SAU802159	STY100406	38%	99.5%	99.5%
SAU802159	STM104137	38%	99.5%	99.5%
SAU802159	SAU802159	100%	100%	100%
SAU802159	SMU100999	41%	99.5%	99.2%
SAU802159	SPN400359	39%	97.8%	98.7%
SAU802159	VCH103762	41%	98.1%	96.1%
SAU802159	YPS003325	37%	99.7%	98.4%
SAU802160	BFR11305	19%	46.2%	73.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802160	BFU115165	25%	6.6%	67.1%
SAU802160	BFU101113	21%	70.6%	97.6%
SAU802160	BMA106913	27%	1.5%	75.4%
SAU802160	EFA200160	23%	20.0%	68.3%
SAU802160	KPN107267	19%	31.6%	61.3%
SAU802160	LMO102026	20%	13.1%	47.4%
SAU802160	MAV105337	19%	21.6%	59.6%
SAU802160	MBV105545	20%	6.9%	59.3%
SAU802160	MLP100688	20%	28.7%	82.7%
SAU802160	MTU201261	20%	6.9%	59.3%
SAU802160	MGE100398	17%	20.0%	48.3%
SAU802160	NME200837	20%	64.2%	38.7%
SAU802160	PPU102763	36%	4.8%	9.4%
SAU802160	PSY104388	20%	7.7%	76.4%
SAU802160	SAU802160	100%	100%	100%
SAU802160	SHA100633	25%	86.9%	70.1%
SAU802160	SHA100651	34%	50.7%	55.8%
SAU802160	SHA101424	30%	35.6%	99.9%
SAU802160	SHA101983	30%	88.4%	10.3%
SAU802160	SPN400581	18%	36.0%	23.2%
SAU802160	SPN401042	20%	6.4%	26.2%
SAU802160	SPY200538	21%	77.2%	47.8%
SAU802161	ABA104792	42%	98.2%	98.7%
SAU802161	BAN112515	62%	76.9%	76.2%
SAU802161	BAN107998	67%	99.8%	100%
SAU802161	BFR11957	24%	96.9%	97.6%
SAU802161	BPT101024	41%	97.3%	98.2%
SAU802161	BCE111154	40%	94.7%	97.9%
SAU802161	BFU108542	38%	64.1%	87.1%
SAU802161	BMA109028	41%	98.0%	98.5%
SAU802161	CJU100328	37%	98.0%	98.0%
SAU802161	CPN200877	43%	98.9%	97.6%
SAU802161	CTR200197	44%	98.4%	96.9%
SAU802161	CAC102696	49%	98.9%	99.6%
SAU802161	CBO100852	48%	99.1%	98.9%
SAU802161	CDF100285	51%	98.7%	95.1%
SAU802161	CDP100049	49%	98.2%	98.7%
SAU802161	EBC102674	45%	98.0%	98.7%
SAU802161	EFA201741	61%	99.8%	100%
SAU802161	EFM202621	25%	93.1%	92.2%
SAU802161	ECO103106	44%	98.0%	98.7%
SAU802161	HIN101431	47%	98.0%	98.4%
SAU802161	HIN101303	47%	98.0%	98.4%
SAU802161	HPY100073	38%	97.3%	98.2%
SAU802161	KPN300882	45%	69.4%	98.4%
SAU802161	LPN103638	45%	97.3%	95.6%
SAU802161	LMO100393	66%	99.8%	99.8%
SAU802161	MCA101170	40%	98.4%	99.1%
SAU802161	MAV103417	48%	98.2%	99.1%
SAU802161	MBV101154	47%	98.2%	99.1%
SAU802161	MLP100234	48%	98.2%	95.2%
SAU802161	MTU203394	47%	98.2%	99.1%
SAU802161	NGO100553	43%	97.8%	98.4%
SAU802161	NME201798	43%	97.8%	98.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802161	PMU100440	47%	98.0%	98.6%
SAU802161	PRT100621	47%	98.0%	98.4%
SAU802161	PAE204745	45%	98.2%	98.7%
SAU802161	PPU108507	45%	97.8%	98.2%
SAU802161	PSY104836	44%	98.2%	98.4%
SAU802161	SPA100515	46%	58.1%	98.5%
SAU802161	STY101478	44%	98.0%	98.7%
SAU802161	SAU802161	100%	100%	100%
SAU802161	SEP201964	92%	100%	100%
SAU802161	SHA100977	88%	99.8%	100%
SAU802161	SMU100302	59%	99.6%	100%
SAU802161	SPN401416	60%	99.8%	100%
SAU802161	SPY200785	60%	99.8%	99.8%
SAU802161	TPA100409	39%	19.3%	13.4%
SAU802161	VCH100627	43%	98.2%	98.4%
SAU802161	YPS001055	45%	98.0%	98.4%
SAU802162	BAN107590	24%	98.1%	66.4%
SAU802162	BAN101871	27%	100%	62.1%
SAU802162	CAC101443	24%	97.7%	74.2%
SAU802162	CBO101794	26%	78.7%	57.7%
SAU802162	CDF103998	23%	97.4%	74.3%
SAU802162	EFA201739	26%	92.6%	74.7%
SAU802162	EFM101102	22%	91.6%	73.5%
SAU802162	LMO100488	34%	41.9%	96.9%
SAU802162	MBV101680	34%	13.9%	12.6%
SAU802162	MTU200828	34%	13.9%	12.6%
SAU802162	NME104849	21%	74.8%	44.1%
SAU802162	SAU802162	100%	100%	100%
SAU802162	SEP201966	70%	100%	99.7%
SAU802162	SHA100469	69%	71.6%	100%
SAU802162	SMU100303	27%	91.0%	89.9%
SAU802162	SPN401417	22%	68.4%	83.4%
SAU802162	SPY200784	23%	93.2%	92.5%
SAU802170	ABA101286	32%	88.6%	93.9%
SAU802170	BAN111561	26%	30.3%	94.5%
SAU802170	BAN110295	30%	88.6%	92.2%
SAU802170	BFR103995	34%	88.2%	95.4%
SAU802170	BBU100117	26%	99.6%	98.7%
SAU802170	BCE107682	31%	86.8%	96.1%
SAU802170	BFU103494	28%	86.8%	96.1%
SAU802170	BMA100077	24%	40.8%	93.1%
SAU802170	CAC102285	35%	89.0%	95.7%
SAU802170	CBO101117	37%	89.0%	94.4%
SAU802170	CDF103680	31%	89.0%	96.3%
SAU802170	CDP100520	24%	83.3%	84.8%
SAU802170	EBC102963	34%	89.9%	93.6%
SAU802170	EFA201192	35%	87.7%	93.1%
SAU802170	EFM100507	33%	87.7%	93.1%
SAU802170	ECO102835	32%	89.9%	93.6%
SAU802170	KPN303348	32%	89.9%	93.6%
SAU802170	LMO101419	31%	92.1%	99.5%
SAU802170	MAV100786	31%	81.1%	56.2%
SAU802170	MBV104176	27%	86.0%	91.7%
SAU802170	MTU201073	27%	86.0%	91.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802170	NGO101498	32%	74.6%	83.2%
SAU802170	NME201751	32%	74.6%	83.2%
SAU802170	PRT102034	30%	36.8%	25.6%
SAU802170	PAE204828	32%	87.3%	96.1%
SAU802170	PPU109350	32%	89.5%	98.5%
SAU802170	PSY103607	34%	71.9%	99.4%
SAU802170	SPA102067	35%	89.0%	94.9%
SAU802170	STY104155	34%	89.9%	93.6%
SAU802170	SAU802170	100%	100%	100%
SAU802170	SEP201988	82%	99.6%	100%
SAU802170	SHA100595	85%	99.6%	100%
SAU802170	SMU100942	54%	93.9%	97.7%
SAU802170	SPN401319	55%	90.4%	95.3%
SAU802170	SPY200885	54%	93.9%	98.6%
SAU802170	TPA101027	38%	88.2%	85.3%
SAU802170	VCH100040	35%	89.5%	94.9%
SAU802170	YPS000173	33%	89.5%	87.6%
SAU802171	CPN200994	30%	97.5%	84.8%
SAU802171	CTR200088	30%	99.0%	86.4%
SAU802171	CAC100688	25%	22.8%	34.9%
SAU802171	EFM202390	26%	22.3%	47.6%
SAU802171	SAU802171	100%	100%	100%
SAU802171	SEP201990	77%	100%	100%
SAU802171	SHA100594	69%	100%	100%
SAU802176	BFR10841	33%	30.9%	98.2%
SAU802176	BFR12085	27%	56.6%	88.4%
SAU802176	BFR102986	27%	93.9%	97.9%
SAU802176	BFR100727	28%	91.8%	96.4%
SAU802176	ECO203932	33%	94.2%	99.4%
SAU802176	KPN103323	29%	88.9%	96.3%
SAU802176	PRT101434	33%	91.3%	96.7%
SAU802176	PSY102146	33%	82.2%	86.6%
SAU802176	SAU802176	100%	100%	100%
SAU802176	SEP202002	72%	100%	100%
SAU802176	SHA100066	71%	100%	100%
SAU802176	SPN400935	35%	94.5%	96.8%
SAU802176	YPS002673	34%	90.7%	94.9%
SAU802177	BAN107236	33%	74.0%	92.0%
SAU802177	BAN102502	33%	88.7%	90.4%
SAU802177	BCE100353	25%	78.3%	75.7%
SAU802177	BFU107408	25%	86.9%	79.7%
SAU802177	BMA101385	44%	29.1%	23.9%
SAU802177	EBC103345	37%	86.2%	89.3%
SAU802177	ECO104179	36%	86.2%	88.7%
SAU802177	KPN304212	25%	76.5%	81.1%
SAU802177	PMU100131	36%	88.4%	92.6%
SAU802177	PSY102144	36%	87.2%	91.6%
SAU802177	SPA100028	29%	33.6%	99.1%
SAU802177	STY103490	26%	73.7%	78.4%
SAU802177	STM103176	26%	73.7%	78.4%
SAU802177	SAU802177	100%	100%	100%
SAU802177	SEP202004	72%	100%	98.8%
SAU802177	SHA100119	69%	52.3%	100%
SAU802177	SPN200521	31%	51.4%	88.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802177	VCH100200	25%	86.2%	85.6%
SAU802181	PRT104884	25%	60.6%	62.1%
SAU802181	STM104876	23%	10.2%	38.1%
SAU802181	SAU802181	100%	100%	100%
SAU802181	SEP202012	59%	100%	99.8%
SAU802181	SHA102033	56%	97.7%	98.2%
SAU802183	CBO101399	36%	67.1%	57.6%
SAU802183	EFA203038	29%	77.2%	96.8%
SAU802183	EFM200451	42%	58.2%	75.8%
SAU802183	SAU802183	100%	100%	100%
SAU802183	SEP202016	83%	100%	100%
SAU802183	SHA102688	77%	100%	100%
SAU802183	SPN401622	30%	58.2%	82.1%
SAU802183	SPY200972	36%	77.2%	98.4%
SAU802184	ABA104072	23%	64.6%	95.9%
SAU802184	EFA202511	27%	70.2%	70.4%
SAU802184	MBV100432	45%	17.4%	20.8%
SAU802184	MTU202703	45%	17.4%	20.8%
SAU802184	SAU802184	100%	100%	100%
SAU802184	SEP202018	86%	100%	100%
SAU802184	SHA102031	85%	100%	100%
SAU802186	ABA104325	41%	99.7%	99.4%
SAU802186	BAN104489	40%	23.9%	96.4%
SAU802186	BAN104922	50%	55.2%	98.9%
SAU802186	BAN107319	41%	99.4%	99.7%
SAU802186	BPT100756	31%	59.7%	60.2%
SAU802186	BCE108257	44%	99.7%	94.1%
SAU802186	BFU114209	43%	99.4%	98.5%
SAU802186	BMA103723	26%	91.3%	73.9%
SAU802186	CDP101649	25%	94.3%	95.9%
SAU802186	EBC103573	39%	91.9%	92.5%
SAU802186	EFA202428	31%	83.9%	83.5%
SAU802186	EFM202451	41%	99.7%	96.8%
SAU802186	ECO103945	33%	54.6%	54.4%
SAU802186	KPN306077	40%	91.9%	91.3%
SAU802186	LPN102544	36%	99.7%	98.5%
SAU802186	LMO100089	44%	99.4%	98.8%
SAU802186	MAV101562	32%	55.8%	55.2%
SAU802186	MBV100928	35%	54.3%	54.3%
SAU802186	MLP100086	26%	53.7%	52.1%
SAU802186	MTU201433	35%	54.3%	54.3%
SAU802186	PRT101880	34%	53.7%	53.5%
SAU802186	PAE203565	37%	99.4%	99.1%
SAU802186	PPU100559	38%	99.4%	98.5%
SAU802186	PSY102165	37%	99.4%	99.1%
SAU802186	SAU802186	100%	100%	100%
SAU802186	SEP202019	65%	100%	99.7%
SAU802186	SHA102028	69%	100%	99.7%
SAU802186	SMU100802	27%	71.9%	76.1%
SAU802186	VCH100542	27%	92.5%	86.1%
SAU802186	YPS000359	27%	91.9%	89.9%
SAU802187	ABA101379	44%	34.5%	82.7%
SAU802187	BCE113538	43%	98.8%	97.3%
SAU802187	BFU101504	42%	98.8%	97.0%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802187	BMA105219	45%	98.8%	96.5%
SAU802187	EBC101789	47%	74.5%	93.9%
SAU802187	ECO101420	45%	99.1%	89.1%
SAU802187	KPN304015	48%	96.1%	94.2%
SAU802187	MAV106640	39%	100%	98.8%
SAU802187	MBV104295	23%	80.8%	14.5%
SAU802187	MTU403167	23%	80.8%	20.7%
SAU802187	PMU101940	21%	56.2%	78.0%
SAU802187	PAE202195	44%	98.8%	96.8%
SAU802187	PPU103733	43%	99.4%	97.7%
SAU802187	PSY104709	46%	83.8%	99.6%
SAU802187	SPA100754	43%	99.7%	96.3%
SAU802187	STY103772	43%	99.7%	97.7%
SAU802187	SAU802187	100%	100%	100%
SAU802187	SEP202022	72%	99.4%	99.1%
SAU802189	BFU102156	34%	96.0%	75.9%
SAU802189	CAC101421	57%	98.5%	97.3%
SAU802189	EBC104273	32%	97.7%	98.2%
SAU802189	EFM201273	59%	98.9%	99.1%
SAU802189	KPN304023	38%	97.4%	98.0%
SAU802189	LMO102257	38%	97.9%	97.4%
SAU802189	SPA103555	32%	98.9%	98.9%
SAU802189	STY104414	33%	98.9%	98.9%
SAU802189	STM100091	32%	98.9%	98.9%
SAU802189	SAU802189	100%	100%	100%
SAU802189	SEP202028	93%	100%	100%
SAU802189	SHA102024	91%	99.6%	99.8%
SAU802189	SMU100441	82%	99.8%	98.7%
SAU802189	SPN401068	81%	99.8%	99.8%
SAU802189	SPY201475	83%	100%	100%
SAU802190	BAN109819	30%	70.4%	95.7%
SAU802190	BAN102068	32%	72.1%	95.3%
SAU802190	CAC103704	53%	98.6%	98.8%
SAU802190	CBO100029	30%	70.2%	90.9%
SAU802190	CDF101451	31%	73.3%	95.9%
SAU802190	EBC100969	35%	71.6%	95.4%
SAU802190	EFA201919	32%	74.7%	99.3%
SAU802190	EFM200856	55%	99.6%	100%
SAU802190	ECO101705	26%	75.8%	99.8%
SAU802190	KPN307137	33%	74.4%	95.5%
SAU802190	LPN103127	29%	10%	9.9%
SAU802190	LMO102762	28%	73.0%	95.7%
SAU802190	PRT105426	24%	69.1%	98.1%
SAU802190	SPA103123	26%	75.8%	99.8%
SAU802190	STY101186	26%	75.8%	99.8%
SAU802190	STM103427	26%	75.8%	99.8%
SAU802190	SAU802190	100%	100%	100%
SAU802190	SEP202030	80%	99.8%	100%
SAU802190	SHA102023	82%	98.6%	100%
SAU802190	SMU100447	76%	99.8%	100%
SAU802190	SPN401069	73%	99.6%	100%
SAU802190	SPY201476	75%	99.8%	100%
SAU802190	VCH101263	33%	73.5%	93.9%
SAU802190	YPS001429	25%	75.6%	98.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802191	BAN110520	38%	89.3%	86.0%
SAU802191	BAN108150	38%	89.3%	86.8%
SAU802191	BAN100622	41%	82.5%	97.7%
SAU802191	BAN112662	39%	89.3%	86.0%
SAU802191	BAN106129	36%	96.1%	94.3%
SAU802191	CAC103163	54%	99.0%	98.1%
SAU802191	CBO103254	42%	87.4%	91.8%
SAU802191	CDF101623	36%	79.6%	70.1%
SAU802191	CDF101453	43%	95.1%	93.1%
SAU802191	EBC103915	33%	96.1%	94.3%
SAU802191	EFA202140	37%	87.4%	84.9%
SAU802191	EFM201537	45%	99.0%	97.1%
SAU802191	ECO101704	34%	96.1%	85.3%
SAU802191	KPN306848	43%	94.2%	91.3%
SAU802191	LMO102156	40%	86.4%	89%
SAU802191	PRT104730	32%	96.1%	86.1%
SAU802191	SPA103124	32%	96.1%	86.1%
SAU802191	STY101178	31%	96.1%	86.1%
SAU802191	STM103428	32%	96.1%	86.1%
SAU802191	SAU802191	100%	100%	100%
SAU802191	SEP202032	74%	100%	99.0%
SAU802191	SHA102022	82%	99.0%	98.1%
SAU802191	SMU100449	75%	100%	99.0%
SAU802191	SPN401070	82%	100%	98.1%
SAU802191	SPY201477	76%	100%	98.1%
SAU802191	VCH101264	34%	94.2%	87.4%
SAU802191	YPS001431	34%	87.4%	78.3%
SAU802192	ABA105994	27%	29.1%	41.8%
SAU802192	BMA106286	27%	38.3%	13.2%
SAU802192	EFA200527	64%	96.9%	95.2%
SAU802192	EFM200718	60%	98.8%	97.0%
SAU802192	ECO103787	24%	84.7%	87.7%
SAU802192	LMO100537	55%	96.9%	93.2%
SAU802192	PAE202357	26%	31.3%	27.7%
SAU802192	PAE202352	34%	18.7%	16.0%
SAU802192	PPU105679	32%	18.7%	16.3%
SAU802192	PSY104152	31%	18.7%	16.3%
SAU802192	SPA103925	25%	84.7%	87.7%
SAU802192	STY103378	25%	84.7%	87.7%
SAU802192	SAU802192	100%	100%	100%
SAU802192	SEP202034	90%	99.7%	100%
SAU802192	SHA102021	91%	99.7%	100%
SAU802192	SMU101449	72%	99.7%	98.8%
SAU802192	SPN401072	75%	99.7%	99.7%
SAU802192	SPY201309	70%	95.1%	95.4%
SAU802192	SPY201478	73%	98.8%	98.2%
SAU802194	BAN108863	32%	84.8%	98.6%
SAU802194	BFR11814	33%	79.5%	94.4%
SAU802194	BMA104191	30%	90.6%	96.3%
SAU802194	CJU100855	34%	74.9%	86.9%
SAU802194	CAC100548	62%	98.8%	98.3%
SAU802194	CBO103215	43%	80.1%	94.5%
SAU802194	CDF103094	39%	86.5%	99.3%
SAU802194	CDF102622	39%	84.8%	96.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802194	CDP101246	39%	70.8%	84.7%
SAU802194	EFA200479	74%	100%	100%
SAU802194	ECO103984	38%	80.7%	92.6%
SAU802194	KPN204541	33%	86.0%	96.7%
SAU802194	LMO101140	40%	83.0%	97.3%
SAU802194	MAV102295	31%	90.1%	96.2%
SAU802194	MBV101530	33%	86.5%	93.7%
SAU802194	MLP100915	32%	90.1%	94.4%
SAU802194	MTU202429	33%	86.5%	92.0%
SAU802194	PMU101645	34%	85.4%	96.0%
SAU802194	PRT105715	26%	73.7%	78.5%
SAU802194	SAU802194	100%	100%	100%
SAU802194	SEP202038	82%	100%	100%
SAU802194	SHA102019	81%	100%	100%
SAU802194	SMU100454	80%	100%	100%
SAU802194	SPN401074	84%	100%	100%
SAU802194	SPY201310	84%	100%	100%
SAU802194	UUR100004	34%	86.5%	98.1%
SAU802194	YPS000070	34%	87.7%	99.3%
SAU802195	CAC101036	47%	99.3%	99.3%
SAU802195	EFA200477	60%	99.3%	99.3%
SAU802195	HPY100567	30%	97.2%	91.4%
SAU802195	KPN100143	29%	45.1%	87.7%
SAU802195	MGE100408	33%	95.8%	92.1%
SAU802195	MPN100247	32%	93.7%	89.5%
SAU802195	SAU802195	100%	100%	100%
SAU802195	SEP202039	78%	100%	100%
SAU802195	SHA102018	78%	100%	100%
SAU802195	SMU100455	76%	100%	100%
SAU802195	SPN401075	74%	99.3%	99.3%
SAU802195	SPY201481	73%	100%	100%
SAU802199	SAU802199	100%	100%	100%
SAU802200	BFR100129	38%	85.8%	91.7%
SAU802200	ECO200334	42%	95.0%	93.5%
SAU802200	KPN302330	40%	95.0%	94.5%
SAU802200	LPN102510	25%	80.1%	90.6%
SAU802200	LPN102953	28%	82.6%	91.8%
SAU802200	LMO101510	64%	100%	100%
SAU802200	SPA104129	40%	95.0%	94.5%
SAU802200	STY103649	41%	96.8%	96.9%
SAU802200	SAU802200	100%	100%	100%
SAU802200	SMU100871	51%	98.2%	99.3%
SAU802200	SPN401331	42%	90.8%	95%
SAU802200	YPS002514	56%	100%	95.3%
SAU802206	BAN105885	29%	99.1%	96.7%
SAU802206	BAN112573	36%	99.1%	92.1%
SAU802206	CAC103299	32%	99.1%	96.6%
SAU802206	CDP101034	33%	99.1%	94.3%
SAU802206	EFA200693	51%	98.3%	97.9%
SAU802206	EFM200265	53%	98.7%	98.3%
SAU802206	LMO101689	41%	99.1%	97.1%
SAU802206	PRT100919	32%	98.3%	82.7%
SAU802206	SAU802206	100%	100%	100%
SAU802206	SEP201253	81%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802206	SHA101838	77%	100%	100%
SAU802207	BAN108476	45%	98.7%	99.6%
SAU802207	BAN112629	56%	99.3%	97.9%
SAU802207	BCE111852	29%	89.7%	93.2%
SAU802207	BFU107623	31%	96.4%	96.9%
SAU802207	BMA102225	30%	96.4%	96.9%
SAU802207	CAC100215	35%	98.0%	95.4%
SAU802207	EBC100415	48%	53.4%	97.0%
SAU802207	EFA200703	64%	98.0%	98.5%
SAU802207	EFM202328	65%	99.8%	99.8%
SAU802207	KPN304223	45%	49.6%	95.9%
SAU802207	LMO102636	56%	98.7%	97.0%
SAU802207	MAV102134	29%	97.7%	94.7%
SAU802207	PRT100920	46%	96.8%	96.6%
SAU802207	PAE204177	32%	96.9%	97.3%
SAU802207	PPU111700	32%	97.8%	98.2%
SAU802207	PPU108615	32%	97.8%	98.2%
SAU802207	SAU802207	100%	100%	100%
SAU802207	SEP201255	87%	100%	100%
SAU802207	SHA101837	84%	100%	100%
SAU802207	SMU100357	62%	99.5%	99.1%
SAU802207	VCH101566	43%	97.1%	94.9%
SAU802217	ABA100673	49%	94.6%	96.1%
SAU802217	BAN112009	71%	100%	100%
SAU802217	BAN109246	73%	100%	100%
SAU802217	BFR11427	50%	93.1%	94.5%
SAU802217	BPT102858	51%	94.6%	94.6%
SAU802217	BBU100337	54%	94.6%	90.4%
SAU802217	BCE104886	50%	94.6%	94.6%
SAU802217	BFU103523	48%	94.6%	94.6%
SAU802217	BMA104857	49%	94.6%	94.6%
SAU802217	CJU101395	48%	93.8%	95.3%
SAU802217	CPN200506	51%	93.8%	91.8%
SAU802217	CTR200396	45%	93.8%	91.7%
SAU802217	CAC102494	68%	100%	100%
SAU802217	CBO103462	70%	100%	100%
SAU802217	CDF100063	66%	100%	100%
SAU802217	CDP100047	47%	93.1%	68.4%
SAU802217	EBC102179	50%	100%	100%
SAU802217	EFA200812	72%	100%	100%
SAU802217	EFM201820	73%	100%	100%
SAU802217	ECO103160	50%	100%	100%
SAU802217	HIN101411	49%	100%	100%
SAU802217	HPY100081	45%	93.8%	95.3%
SAU802217	KPN302005	50%	100%	100%
SAU802217	LPN102542	46%	96.9%	96.5%
SAU802217	LMO100441	73%	100%	100%
SAU802217	MCA100086	52%	94.6%	96.1%
SAU802217	MAV103416	50%	93.1%	72.9%
SAU802217	MBV101153	49%	93.1%	80.1%
SAU802217	MLP100233	52%	93.1%	79.1%
SAU802217	MTU203395	49%	93.1%	80.1%
SAU802217	MGE100427	50%	100%	100%
SAU802217	MPN100226	56%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802217	NGO102668	54%	96.2%	96.2%
SAU802217	NME200353	54%	96.2%	96.2%
SAU802217	PMU100521	52%	100%	100%
SAU802217	PRT100490	51%	100%	100%
SAU802217	PAE204430	50%	100%	100%
SAU802217	PPU105982	51%	100%	100%
SAU802217	PSY108021	50%	100%	100%
SAU802217	SPA100957	50%	100%	100%
SAU802217	STY101559	50%	100%	100%
SAU802217	SAU802217	100%	100%	100%
SAU802217	SEP202046	96%	100%	100%
SAU802217	SHA100041	98%	100%	100%
SAU802217	SMU101370	71%	100%	100%
SAU802217	SPN400272	70%	100%	100%
SAU802217	SPY201485	71%	100%	100%
SAU802217	TPA101014	55%	94.6%	95.3%
SAU802217	UUR100583	55%	97.7%	95.5%
SAU802217	VCH100561	50%	100%	100%
SAU802217	YPS002276	52%	100%	100%
SAU802218	ABA100676	53%	94.5%	96.5%
SAU802218	BAN101291	69%	100%	100%
SAU802218	BAN111521	69%	100%	100%
SAU802218	BFR11426	44%	97.2%	93.5%
SAU802218	BPT102861	52%	96.6%	98.6%
SAU802218	BBU100338	48%	93.1%	92.5%
SAU802218	BCE107311	54%	97.2%	80.1%
SAU802218	BFU103522	55%	97.2%	99.3%
SAU802218	BMA107182	55%	97.2%	78.8%
SAU802218	CJU101396	53%	91.7%	95.0%
SAU802218	CPN200505	48%	93.8%	91.9%
SAU802218	CTR200395	50%	89.0%	86.7%
SAU802218	CAC102148	48%	97.9%	98.6%
SAU802218	CBO103121	52%	99.3%	99.3%
SAU802218	CDF100062	46%	94.5%	95.8%
SAU802218	CDP100045	49%	97.2%	95.9%
SAU802218	EBC102180	58%	94.5%	96.5%
SAU802218	EFA200811	69%	95.2%	94.5%
SAU802218	EFM201491	69%	95.9%	79.0%
SAU802218	ECO103161	58%	94.5%	96.5%
SAU802218	HIN101412	56%	94.5%	96.5%
SAU802218	HPY100082	47%	91.7%	94.3%
SAU802218	KPN301994	56%	94.5%	96.5%
SAU802218	LPN102178	51%	97.2%	97.9%
SAU802218	LMO100177	70%	100%	100%
SAU802218	MCA103453	53%	98.6%	100%
SAU802218	MAV103415	48%	97.2%	95.9%
SAU802218	MBV101152	50%	97.2%	72.3%
SAU802218	MLP100232	46%	97.2%	95.9%
SAU802218	MTU203396	50%	97.2%	95.9%
SAU802218	MGE100428	38%	95.2%	95.9%
SAU802218	MPN100225	40%	95.2%	95.9%
SAU802218	NGO101071	55%	97.9%	99.3%
SAU802218	NME200352	55%	97.9%	99.3%
SAU802218	PMU100520	56%	94.5%	96.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802218	PRT100489	59%	94.5%	96.5%
SAU802218	PAE204431	55%	97.2%	99.3%
SAU802218	PPU105984	54%	97.2%	99.3%
SAU802218	PSY103838	58%	93.8%	95.8%
SAU802218	SPA100958	58%	94.5%	96.5%
SAU802218	STY101563	58%	94.5%	96.5%
SAU802218	SAU802218	100%	100%	100%
SAU802218	SEP202048	93%	100%	100%
SAU802218	SHA100040	89%	77.2%	100%
SAU802218	SMU101369	59%	99.3%	97.3%
SAU802218	SPN400271	64%	99.3%	97.3%
SAU802218	SPY201486	64%	99.3%	97.3%
SAU802218	TPA101015	46%	93.8%	95.8%
SAU802218	UUR100584	48%	90.3%	88.5%
SAU802218	VCH100560	57%	94.5%	96.5%
SAU802218	YPS002279	56%	94.5%	96.5%
SAU802221	BAN100298	34%	90.2%	97.1%
SAU802221	BAN111331	41%	95.5%	93.2%
SAU802221	CAC101129	31%	85.0%	99.2%
SAU802221	CAC103558	35%	87.8%	87.1%
SAU802221	CAC102762	38%	95.8%	95.5%
SAU802221	CBO103078	39%	99.7%	98.6%
SAU802221	CDF103575	38%	97.9%	97.2%
SAU802221	EFA201971	46%	90.6%	92.0%
SAU802221	EFM200592	43%	90.9%	90.0%
SAU802221	LMO100639	43%	94.8%	94.1%
SAU802221	MGE100183	39%	87.4%	82.2%
SAU802221	MPN100637	39%	87.4%	82.5%
SAU802221	SAU802221	100%	100%	100%
SAU802221	SEP202054	63%	100%	100%
SAU802221	SHA102409	44%	19.9%	92.1%
SAU802221	SHA103167	63%	14.3%	100%
SAU802221	SHA100340	65%	100%	100%
SAU802221	SMU101386	44%	97.9%	99.3%
SAU802221	SPN402022	44%	87.4%	89.2%
SAU802221	SPY201677	45%	88.5%	90%
SAU802221	UUR100544	43%	2.8%	30.0%
SAU802222	BAN102912	37%	92.6%	90.1%
SAU802222	BAN100224	50%	96.3%	88.3%
SAU802222	CAC103684	42%	89.2%	87.2%
SAU802222	CBO102095	42%	98.5%	97.2%
SAU802222	CDF103552	42%	92.6%	91.0%
SAU802222	EFA201972	52%	97.8%	96.4%
SAU802222	EFM200542	50%	97.8%	96.4%
SAU802222	KPN102440	34%	89.2%	90.2%
SAU802222	LMO101349	50%	98.1%	96.4%
SAU802222	MGE100182	43%	98.9%	96.0%
SAU802222	MPN100638	42%	99.3%	96.4%
SAU802222	SPA101594	32%	89.2%	88.6%
SAU802222	SAU802222	100%	100%	100%
SAU802222	SEP202056	63%	100%	100%
SAU802222	SHA101370	64%	69.9%	100%
SAU802222	SMU101388	47%	92.9%	86.6%
SAU802222	SPN402023	47%	98.1%	97.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802222	SPY201678	44%	100%	92.9%
SAU802222	UUR100545	47%	94.1%	85.7%
SAU802223	ABA100130	47%	96.7%	86.4%
SAU802223	BAN103288	73%	100%	100%
SAU802223	BAN102478	73%	100%	100%
SAU802223	BFR100896	43%	98.4%	68.3%
SAU802223	BPT100897	50%	99.2%	84.7%
SAU802223	BBU100502	36%	100%	91.1%
SAU802223	BCE109774	47%	99.2%	84.7%
SAU802223	BFU101597	48%	99.2%	85.4%
SAU802223	BMA104335	48%	99.2%	84.7%
SAU802223	CJU101502	45%	99.2%	94.9%
SAU802223	CPN200120	41%	96.7%	93.0%
SAU802223	CTR200782	40%	96.7%	93.0%
SAU802223	CAC100809	57%	99.2%	97.4%
SAU802223	CBO102497	59%	99.2%	98.2%
SAU802223	CDF102169	50%	98.4%	97.3%
SAU802223	CDP100024	44%	96.7%	68.8%
SAU802223	EBC103646	47%	97.5%	85.8%
SAU802223	EFA201974	65%	100%	99.2%
SAU802223	EFM201685	69%	100%	100%
SAU802223	ECO103217	47%	97.5%	85.8%
SAU802223	HIN100784	48%	97.5%	85.2%
SAU802223	HPY101274	46%	99.2%	95.7%
SAU802223	KPN300813	47%	97.5%	85.2%
SAU802223	LMO100340	66%	100%	100%
SAU802223	MCA100427	45%	96.7%	90.8%
SAU802223	MAV101006	44%	96.7%	74.0%
SAU802223	MBV100492	44%	96.7%	60%
SAU802223	MLP101193	42%	96.7%	63.5%
SAU802223	MTU203409	44%	96.7%	60%
SAU802223	MGE100181	35%	96.7%	92.7%
SAU802223	MPN100639	36%	95.9%	91.1%
SAU802223	NGO100883	50%	99.2%	91.0%
SAU802223	NME200096	49%	99.2%	91.0%
SAU802223	PMU101389	47%	97.5%	84.5%
SAU802223	PRT101773	46%	97.5%	85.2%
SAU802223	PAE204235	45%	97.5%	84.5%
SAU802223	PPU104535	47%	97.5%	85.2%
SAU802223	PSY105785	47%	97.5%	85.2%
SAU802223	SPA104312	47%	97.5%	85.8%
SAU802223	STY101829	47%	97.5%	85.8%
SAU802223	SAU802223	100%	100%	100%
SAU802223	SEP202058	95%	100%	100%
SAU802223	SHA100503	98%	100%	99.2%
SAU802223	SMU100584	65%	100%	100%
SAU802223	SPN400216	67%	100%	100%
SAU802223	SPY101855	67%	100%	100%
SAU802223	TPA100211	41%	99.2%	67.7%
SAU802223	UUR100260	41%	96.7%	95.8%
SAU802223	VCH102533	47%	97.5%	85.2%
SAU802223	YPS002494	47%	97.5%	84.5%
SAU802224	ABA100129	41%	93.3%	87.8%
SAU802224	BAN107601	56%	99.7%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802224	BAN108468	78%	100%	100%
SAU802224	BFR10426	41%	98.1%	95.2%
SAU802224	BPT100896	41%	97.1%	93.3%
SAU802224	BBU100501	40%	97.8%	91.9%
SAU802224	BCE103299	40%	97.1%	93.8%
SAU802224	BFU101596	40%	97.1%	93.8%
SAU802224	BMA100053	41%	97.1%	93.8%
SAU802224	CJU101501	34%	94.6%	87.5%
SAU802224	CPN200119	39%	93.0%	79.8%
SAU802224	CTR200783	37%	93.0%	79.2%
SAU802224	CAC100456	62%	100%	99.7%
SAU802224	CBO100600	63%	100%	99.7%
SAU802224	CDF104551	63%	100%	99.1%
SAU802224	CDP100022	47%	93.9%	87.0%
SAU802224	EBC103650	42%	98.1%	93.6%
SAU802224	EFA201975	71%	100%	100%
SAU802224	EFM200465	70%	100%	100%
SAU802224	ECO103218	42%	98.1%	93.6%
SAU802224	HIN100783	42%	98.1%	93.6%
SAU802224	HPY101275	35%	91.1%	84.6%
SAU802224	KPN300703	44%	76.4%	95.7%
SAU802224	LMO100649	75%	100%	100%
SAU802224	MCA100426	45%	93.3%	88.0%
SAU802224	MAV101008	50%	92.4%	83.6%
SAU802224	MBV100494	48%	92.4%	83.6%
SAU802224	MLP101194	48%	92.4%	83.6%
SAU802224	MTU203410	48%	92.4%	83.6%
SAU802224	MGE100180	37%	93.0%	93.0%
SAU802224	MPN100640	34%	96.8%	96.9%
SAU802224	NGO100885	39%	98.1%	93.6%
SAU802224	NME200097	39%	98.1%	93.6%
SAU802224	PMU101390	42%	98.1%	93.6%
SAU802224	PRT101775	42%	98.1%	93.6%
SAU802224	PAE204236	42%	98.1%	92.2%
SAU802224	PPU104534	42%	98.1%	92.2%
SAU802224	PSY100281	40%	46.2%	86.6%
SAU802224	SPA104314	42%	98.1%	93.6%
SAU802224	STY101828	42%	98.1%	93.6%
SAU802224	SAU802224	100%	100%	100%
SAU802224	SEP202059	98%	100%	100%
SAU802224	SHA100502	98%	100%	100%
SAU802224	SMU100586	57%	99.7%	99.7%
SAU802224	SPN400215	58%	99.0%	99.4%
SAU802224	SPY200063	57%	99.7%	99.7%
SAU802224	TPA100210	36%	98.7%	91.5%
SAU802224	UUR100259	40%	95.2%	95.4%
SAU802224	VCH102534	42%	98.1%	93.6%
SAU802224	YPS002493	42%	98.1%	93.6%
SAU802225	ABA100127	60%	97.7%	98.4%
SAU802225	BAN102381	81%	100%	100%
SAU802225	BAN110714	86%	100%	100%
SAU802225	BFR10424	58%	100%	100%
SAU802225	BPT100894	64%	93.8%	91.0%
SAU802225	BBU100500	55%	99.2%	95.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802225	BCE109619	63%	93.8%	91.0%
SAU802225	BFU101594	65%	93.8%	90.3%
SAU802225	BMA109746	64%	93.8%	91.0%
SAU802225	CJU101499	59%	100%	100%
SAU802225	CPN200118	62%	99.2%	96.2%
SAU802225	CTR200784	64%	93.8%	91.7%
SAU802225	CAC100574	77%	98.4%	96.9%
SAU802225	CBO101814	76%	95.3%	93.2%
SAU802225	CDF101597	75%	98.4%	97.0%
SAU802225	CDP100018	67%	95.3%	91.8%
SAU802225	EBC103656	62%	100%	100%
SAU802225	EFA201976	85%	100%	100%
SAU802225	EFM200112	83%	100%	100%
SAU802225	ECO103220	62%	100%	100%
SAU802225	HIN100781	63%	100%	100%
SAU802225	HPY101277	60%	100%	100%
SAU802225	KPN300701	62%	100%	100%
SAU802225	LMO102707	84%	100%	100%
SAU802225	MCA100424	60%	100%	100%
SAU802225	MAV101012	66%	98.4%	92.0%
SAU802225	MBV100327	66%	99.2%	92.1%
SAU802225	MLP101196	66%	98.4%	92.0%
SAU802225	MTU203412	67%	99.2%	92.1%
SAU802225	MGE100179	41%	87.6%	86.3%
SAU802225	MPN100641	47%	92.2%	98.3%
SAU802225	NGO100889	60%	93.8%	92.4%
SAU802225	NME200099	60%	93.8%	92.4%
SAU802225	PMU101392	64%	100%	100%
SAU802225	PRT105644	62%	100%	100%
SAU802225	PAE204238	61%	100%	100%
SAU802225	PPU104532	62%	100%	100%
SAU802225	PSY106472	61%	100%	100%
SAU802225	SPA104318	60%	99.2%	100%
SAU802225	STY101826	62%	100%	100%
SAU802225	SAU802225	100%	100%	100%
SAU802225	SEP200240	99%	100%	100%
SAU802225	SHA100501	100%	100%	100%
SAU802225	SMU100588	84%	95.3%	96.9%
SAU802225	SPN400214	84%	95.3%	96.9%
SAU802225	SPY200062	85%	95.3%	96.9%
SAU802225	TPA100209	61%	96.1%	98.4%
SAU802225	UUR100258	56%	92.2%	98.3%
SAU802225	VCH102536	62%	100%	100%
SAU802225	YPS002491	62%	100%	100%
SAU802226	ABA100126	57%	95.9%	97.5%
SAU802226	BAN113421	85%	33.9%	100%
SAU802226	BAN112977	78%	100%	100%
SAU802226	BFR10423	66%	98.3%	95.2%
SAU802226	BPT100893	58%	100%	100%
SAU802226	BBU100499	55%	99.2%	96.8%
SAU802226	BCE106205	54%	100%	100%
SAU802226	BFU100384	55%	100%	100%
SAU802226	BMA110016	54%	100%	100%
SAU802226	CJU101498	59%	98.3%	99.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802226	CPN200117	54%	100%	100%
SAU802226	CTR200785	53%	100%	100%
SAU802226	CAC101837	66%	100%	99.2%
SAU802226	CBO102219	67%	100%	99.2%
SAU802226	CDF103596	65%	100%	99.2%
SAU802226	CDP100016	59%	100%	100%
SAU802226	EBC103659	53%	95.9%	98.3%
SAU802226	EFA201977	75%	100%	100%
SAU802226	EFM200415	75%	100%	100%
SAU802226	ECO103221	53%	95.9%	98.3%
SAU802226	HIN100780	51%	99.2%	98.4%
SAU802226	HPY101278	58%	98.3%	100%
SAU802226	KPN300700	51%	81.8%	98.0%
SAU802226	LMO102428	78%	100%	100%
SAU802226	MCA100423	58%	95.9%	98.3%
SAU802226	MAV101014	57%	100%	98.4%
SAU802226	MBV100329	54%	100%	98.4%
SAU802226	MLP101197	59%	100%	98.4%
SAU802226	MTU203413	54%	100%	98.4%
SAU802226	MGE100178	65%	99.2%	96.8%
SAU802226	MPN100642	65%	99.2%	96.8%
SAU802226	NGO100891	58%	99.2%	100%
SAU802226	NME200100	58%	99.2%	100%
SAU802226	PMU101393	55%	95.9%	98.3%
SAU802226	PRT100020	52%	88.4%	98.2%
SAU802226	PAE204239	60%	95.9%	98.3%
SAU802226	PPU104531	59%	95.9%	98.3%
SAU802226	PSY105783	60%	60.3%	96.1%
SAU802226	SPA104321	52%	95.9%	98.3%
SAU802226	STY101825	52%	95.9%	98.3%
SAU802226	SAU802226	100%	100%	100%
SAU802226	SEP200241	95%	100%	100%
SAU802226	SHA100500	95%	100%	100%
SAU802226	SMU100590	74%	100%	100%
SAU802226	SPN400213	73%	100%	100%
SAU802226	SPY200061	73%	100%	100%
SAU802226	TPA100208	61%	100%	100%
SAU802226	UUR100257	65%	99.2%	97.0%
SAU802226	VCH102537	53%	95.9%	98.3%
SAU802226	YPS002490	54%	95.9%	98.3%
SAU802227	ABA100104	63%	100%	100%
SAU802227	BPT104512	70%	100%	100%
SAU802227	BBU100498	80%	97.3%	92.3%
SAU802227	BCE112105	68%	100%	100%
SAU802227	BFU103878	68%	100%	100%
SAU802227	BMA103855	68%	100%	100%
SAU802227	CJU101497	78%	100%	100%
SAU802227	CAC101480	97%	100%	100%
SAU802227	CBO103541	94%	100%	97.4%
SAU802227	CDF103770	97%	100%	100%
SAU802227	EBC103975	52%	64.9%	54.3%
SAU802227	EFA203137	84%	100%	100%
SAU802227	EFM202440	84%	100%	100%
SAU802227	ECO103222	63%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802227	HIN100779	64%	100%	100%
SAU802227	HPY101279	70%	100%	100%
SAU802227	KPN202806	52%	64.9%	54.3%
SAU802227	LMO101459	91%	100%	100%
SAU802227	MCA102164	42%	86.5%	71.7%
SAU802227	MBV104764	72%	100%	100%
SAU802227	MLP101198	70%	100%	100%
SAU802227	MTU203414	72%	100%	100%
SAU802227	MGE100177	67%	100%	100%
SAU802227	MPN100643	70%	100%	100%
SAU802227	NGO101308	42%	97.3%	97.6%
SAU802227	NME200101	59%	100%	100%
SAU802227	PMU101394	64%	100%	100%
SAU802227	PRT103159	63%	100%	100%
SAU802227	PAE204240	63%	100%	100%
SAU802227	PSY103480	63%	100%	67.9%
SAU802227	SPA100818	52%	64.9%	54.3%
SAU802227	STY104823	63%	100%	100%
SAU802227	STM104443	52%	64.9%	54.3%
SAU802227	SAU802227	100%	100%	100%
SAU802227	SEP202480	97%	100%	100%
SAU802227	SHA100499	97%	100%	100%
SAU802227	SMU100592	84%	100%	100%
SAU802227	SPN400212	84%	100%	100%
SAU802227	SPY200060	84%	100%	100%
SAU802227	TPA100207	72%	100%	100%
SAU802227	UUR100256	70%	100%	100%
SAU802227	VCH102538	75%	100%	100%
SAU802227	YPS003891	65%	100%	100%
SAU802228	ABA102422	69%	94.4%	93.2%
SAU802228	BAN103338	88%	59.7%	100%
SAU802228	BFR100583	70%	100%	100%
SAU802228	BPT100892	68%	100%	100%
SAU802228	BBU100168	62%	97.2%	77.8%
SAU802228	BCE109557	66%	100%	100%
SAU802228	BFU100382	66%	100%	94.7%
SAU802228	BMA107769	65%	100%	100%
SAU802228	CJU101496	69%	100%	100%
SAU802228	CPN200690	54%	97.2%	95.9%
SAU802228	CTR200589	57%	97.2%	95.9%
SAU802228	CAC103209	77%	100%	100%
SAU802228	CBO100838	77%	100%	100%
SAU802228	CDF104286	80%	100%	100%
SAU802228	CDP100014	69%	100%	100%
SAU802228	EBC100928	72%	97.2%	97.2%
SAU802228	EFA205225	84%	100%	100%
SAU802228	EFM200666	83%	100%	100%
SAU802228	ECO100859	71%	97.2%	97.2%
SAU802228	HIN100527	71%	97.2%	83.3%
SAU802228	HPY101280	59%	100%	100%
SAU802228	KPN301361	70%	86.1%	96.9%
SAU802228	LPN102139	68%	100%	98.6%
SAU802228	LMO101112	83%	100%	100%
SAU802228	MCA100273	72%	97.2%	95.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802228	MAV101015	69%	100%	100%
SAU802228	MBV100332	69%	100%	100%
SAU802228	MLP101199	69%	100%	100%
SAU802228	MTU203415	69%	100%	100%
SAU802228	MGE100176	48%	94.4%	97.1%
SAU802228	MPN100644	53%	95.8%	88.5%
SAU802228	NGO100894	67%	97.2%	97.2%
SAU802228	NME200102	67%	97.2%	97.2%
SAU802228	PMU101031	70%	97.2%	97.2%
SAU802228	PRT101847	72%	97.2%	97.2%
SAU802228	PAE202617	71%	97.2%	97.2%
SAU802228	PPU110129	71%	97.2%	97.2%
SAU802228	PSY108380	71%	97.2%	97.2%
SAU802228	SPA101389	71%	97.2%	97.2%
SAU802228	STY102886	71%	97.2%	97.2%
SAU802228	SAU802228	100%	100%	100%
SAU802228	SEP200242	98%	100%	100%
SAU802228	SHA100498	98%	100%	98.6%
SAU802228	SMU100596	83%	100%	100%
SAU802228	SPN400211	81%	100%	80%
SAU802228	SPY200059	81%	100%	100%
SAU802228	TPA100096	58%	97.2%	97.2%
SAU802228	UUR100255	55%	100%	97.3%
SAU802228	VCH101709	75%	97.2%	97.2%
SAU802228	YPS003792	72%	97.2%	97.2%
SAU802229	ABA102578	49%	99.1%	99.5%
SAU802229	BAN108855	54%	98.6%	97.7%
SAU802229	BAN106781	64%	98.6%	97.7%
SAU802229	BFR10586	39%	100%	99.5%
SAU802229	BPT101280	48%	86.5%	83.5%
SAU802229	BBU100416	43%	98.6%	98.1%
SAU802229	BCE114693	54%	86.5%	82.7%
SAU802229	BFU106856	54%	86.5%	82.4%
SAU802229	BMA102106	54%	86.5%	82.7%
SAU802229	CJU100600	28%	97.2%	94.3%
SAU802229	CPN200508	34%	95.8%	94.4%
SAU802229	CTR200398	34%	97.7%	86.2%
SAU802229	CAC102891	53%	100%	100%
SAU802229	CBO103787	53%	98.6%	98.1%
SAU802229	CDF102350	56%	98.6%	95.9%
SAU802229	CDP100003	40%	98.6%	98.9%
SAU802229	EBC103984	47%	98.6%	99.5%
SAU802229	EFA201978	64%	99.1%	99.1%
SAU802229	EFM200623	62%	99.1%	99.5%
SAU802229	ECO100465	47%	98.6%	99.5%
SAU802229	HIN100331	51%	98.6%	99.5%
SAU802229	HPY100611	29%	95.3%	92.7%
SAU802229	KPN303865	47%	98.6%	99.5%
SAU802229	LPN102084	42%	99.1%	99.5%
SAU802229	LMO102187	66%	98.6%	98.6%
SAU802229	MCA101231	47%	98.6%	98.6%
SAU802229	MAV102071	38%	94.9%	94.5%
SAU802229	MBV101628	37%	94.9%	94.5%
SAU802229	MLP101114	35%	94.9%	94.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802229	MTU200730	37%	94.9%	94.5%
SAU802229	MGE100174	36%	89.8%	88.3%
SAU802229	MPN100646	31%	89.8%	88.8%
SAU802229	NGO100911	47%	98.6%	99.1%
SAU802229	NME200954	47%	98.6%	99.1%
SAU802229	PMU100284	50%	98.6%	99.5%
SAU802229	PRT104973	47%	98.6%	99.5%
SAU802229	PAE203684	47%	98.6%	99.5%
SAU802229	PPU107935	49%	98.6%	99.5%
SAU802229	PSY104919	45%	81.9%	97.8%
SAU802229	SPA100230	47%	94.9%	88.3%
SAU802229	STY100842	47%	98.6%	99.5%
SAU802229	STM100555	47%	98.6%	99.5%
SAU802229	SAU802229	100%	100%	100%
SAU802229	SEP200243	91%	100%	100%
SAU802229	SHA100179	91%	100%	99.5%
SAU802229	SMU100597	56%	100%	99.5%
SAU802229	SPN400210	56%	100%	99.5%
SAU802229	SPY200058	57%	96.7%	96.2%
SAU802229	TPA100588	44%	94.9%	94.3%
SAU802229	UUR100253	37%	98.6%	98.1%
SAU802229	VCH100969	49%	98.6%	99.5%
SAU802229	YPS001716	45%	98.6%	99.5%
SAU802230	ABA100105	40%	96.0%	91.6%
SAU802230	BAN100422	54%	54.4%	100%
SAU802230	BAN100831	41%	98.8%	98.6%
SAU802230	BAN109756	56%	99.3%	98.8%
SAU802230	BAN106840	58%	99.3%	99.3%
SAU802230	BFR12413	38%	98.8%	95.1%
SAU802230	BPT100873	39%	96.5%	93.4%
SAU802230	BBU100497	34%	98.6%	96.8%
SAU802230	BCE109015	37%	94.4%	96%
SAU802230	BFU100380	36%	96.0%	92.4%
SAU802230	BMA107419	37%	94.4%	96.0%
SAU802230	CJU101592	40%	96.3%	97.9%
SAU802230	CPN200116	36%	97.9%	95.7%
SAU802230	CTR200786	36%	98.4%	97.2%
SAU802230	CAC102097	36%	99.3%	99.3%
SAU802230	CBO103220	36%	99.3%	99.5%
SAU802230	CDF103985	38%	99.3%	99.5%
SAU802230	CDP100001	39%	97.2%	97.7%
SAU802230	EBC103637	41%	96.0%	93.2%
SAU802230	EFA201979	46%	99.3%	99.3%
SAU802230	EFM200235	48%	99.3%	99.5%
SAU802230	ECO103223	41%	96.0%	93.2%
SAU802230	HIN100778	38%	96.7%	95.9%
SAU802230	HPY101282	38%	96.3%	97.9%
SAU802230	KPN300616	40%	78.4%	95.2%
SAU802230	LPN101432	38%	84.2%	98.1%
SAU802230	LMO101544	54%	99.3%	99.5%
SAU802230	MCA100141	37%	95.8%	92.7%
SAU802230	MAV102070	39%	99.3%	96.9%
SAU802230	MBV101627	39%	99.3%	99.5%
SAU802230	MLP101115	38%	99.3%	99.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802230	MTU200729	39%	99.3%	99.5%
SAU802230	MGE100173	35%	98.4%	90.1%
SAU802230	MPN100647	35%	98.4%	89.7%
SAU802230	NGO100896	38%	95.8%	93.3%
SAU802230	NME200103	38%	95.8%	93.3%
SAU802230	PMU101395	39%	97.2%	96.4%
SAU802230	PRT100105	39%	47.0%	95.3%
SAU802230	PAE204241	38%	96.0%	92.5%
SAU802230	PPU112340	37%	97.0%	95.3%
SAU802230	PSY100299	37%	97.0%	95.0%
SAU802230	SPA104324	41%	94.0%	94.4%
SAU802230	STY101824	40%	96.0%	93.2%
SAU802230	SAU802230	100%	100%	100%
SAU802230	SEP200245	89%	100%	100%
SAU802230	SHA100178	82%	86.0%	100%
SAU802230	SMU100598	45%	98.4%	97.7%
SAU802230	SPN400209	47%	97.9%	97.2%
SAU802230	SPY200057	46%	99.1%	98.4%
SAU802230	TPA100206	35%	98.1%	93.8%
SAU802230	UUR100252	33%	97.7%	91.7%
SAU802230	VCH102539	38%	96.0%	93.2%
SAU802230	YPS002488	40%	96.0%	93.2%
SAU802231	ABA100106	45%	98.6%	97.9%
SAU802231	BAN100388	59%	100%	100%
SAU802231	BAN101282	76%	100%	100%
SAU802231	BFR100671	50%	96.6%	96.6%
SAU802231	BPT100871	47%	97.3%	96.6%
SAU802231	BBU100496	51%	89.7%	90.3%
SAU802231	BCE108533	46%	97.3%	97.9%
SAU802231	BFU100391	47%	97.3%	97.9%
SAU802231	BMA101533	47%	97.3%	97.9%
SAU802231	CJU101593	35%	88.4%	98.5%
SAU802231	CPN200115	34%	81.5%	84.0%
SAU802231	CTR200787	41%	84.9%	87.5%
SAU802231	CAC101804	66%	100%	100%
SAU802231	CBO103582	71%	100%	100%
SAU802231	CDF100735	62%	100%	98%
SAU802231	CDP101730	50%	97.3%	94.6%
SAU802231	EBC103640	45%	98.6%	99.3%
SAU802231	EFA201980	78%	100%	100%
SAU802231	EFM201975	77%	100%	100%
SAU802231	ECO103224	46%	98.6%	99.3%
SAU802231	HIN100777	45%	98.6%	99.3%
SAU802231	HPY101283	39%	89.7%	96.3%
SAU802231	KPN300615	44%	95.2%	99.3%
SAU802231	LPN100259	40%	98.6%	99.3%
SAU802231	LMO102003	82%	100%	100%
SAU802231	MCA100140	43%	98.6%	97.9%
SAU802231	MAV102081	51%	97.3%	95.9%
SAU802231	MBV101609	47%	97.3%	95.9%
SAU802231	MLP101118	48%	97.3%	95.9%
SAU802231	MTU200720	48%	97.3%	95.9%
SAU802231	MGE100172	42%	100%	99.3%
SAU802231	MPN100648	39%	100%	98.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802231	NGO100899	41%	99.3%	100%
SAU802231	NME200104	42%	99.3%	100%
SAU802231	PMU101396	46%	98.6%	99.3%
SAU802231	PRT103332	43%	98.6%	99.3%
SAU802231	PAE204242	42%	98.6%	99.3%
SAU802231	PPU104529	45%	98.6%	99.3%
SAU802231	PSY107337	47%	98.6%	99.3%
SAU802231	SPA104326	47%	98.6%	99.3%
SAU802231	STY101823	47%	98.6%	99.3%
SAU802231	SAU802231	100%	100%	100%
SAU802231	SEP200247	94%	100%	100%
SAU802231	SHA100093	82%	58.9%	100%
SAU802231	SMU100599	80%	100%	100%
SAU802231	SPN400208	83%	100%	100%
SAU802231	SPY200056	78%	100%	100%
SAU802231	TPA100205	46%	97.9%	94.1%
SAU802231	UUR100251	48%	93.2%	92.6%
SAU802231	VCH102540	48%	98.6%	99.3%
SAU802231	YPS002485	45%	98.6%	99.3%
SAU802232	ABA100108	37%	98.3%	100%
SAU802232	BAN104365	76%	94.9%	93.3%
SAU802232	BFR100963	44%	94.9%	96.6%
SAU802232	BPT104115	48%	94.9%	91.8%
SAU802232	BBU100495	32%	93.2%	54.5%
SAU802232	BFU104042	49%	89.8%	84.1%
SAU802232	BMA107387	47%	89.8%	84.1%
SAU802232	CAC103086	52%	96.6%	100%
SAU802232	CBO100965	53%	98.3%	98.3%
SAU802232	CDF102795	62%	98.3%	95.1%
SAU802232	CDP102962	49%	93.2%	90.2%
SAU802232	EBC103644	47%	98.3%	100%
SAU802232	EFA205229	62%	98.3%	98.3%
SAU802232	EFM200795	65%	98.3%	98.3%
SAU802232	ECO103225	50%	98.3%	100%
SAU802232	HIN100776	42%	98.3%	100%
SAU802232	KPN300492	45%	94.9%	100%
SAU802232	LPN102267	51%	94.9%	91.8%
SAU802232	LMO100063	75%	98.3%	98.3%
SAU802232	MCA102911	36%	98.3%	98.3%
SAU802232	MAV102080	48%	94.9%	78.9%
SAU802232	MBV101607	49%	96.6%	87.7%
SAU802232	MLP101119	49%	96.6%	80.3%
SAU802232	MTU200719	49%	96.6%	87.7%
SAU802232	NGO102470	40%	93.2%	90.2%
SAU802232	NME200105	41%	93.2%	90.2%
SAU802232	PMU101397	42%	98.3%	100%
SAU802232	PRT100559	49%	98.3%	96.7%
SAU802232	PAE204243	42%	96.6%	98.3%
SAU802232	PPU108173	40%	96.6%	98.3%
SAU802232	PSY107474	38%	96.6%	98.3%
SAU802232	SPA106249	47%	98.3%	100%
SAU802232	STY105107	47%	98.3%	100%
SAU802232	SAU802232	100%	100%	100%
SAU802232	SEP202555	94%	100%	98.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802232	SHA100092	96%	100%	100%
SAU802232	SMU102834	67%	98.3%	96.7%
SAU802232	SPN400207	68%	98.3%	96.7%
SAU802232	SPY200055	65%	98.3%	96.7%
SAU802232	VCH102541	48%	98.3%	100%
SAU802232	YPS004281	44%	98.3%	100%
SAU802233	ABA100109	53%	95.8%	96.4%
SAU802233	BAN111381	75%	98.8%	99.4%
SAU802233	BAN112822	77%	98.8%	98.8%
SAU802233	BFR10783	52%	94.0%	90.7%
SAU802233	BPT100869	48%	98.2%	95.3%
SAU802233	BBU100494	54%	92.2%	92.7%
SAU802233	BCE102110	48%	75.9%	92.6%
SAU802233	BFU100390	48%	96.4%	93.0%
SAU802233	BMA101481	49%	96.4%	94.7%
SAU802233	CJU101594	58%	84.3%	95.2%
SAU802233	CPN200114	42%	98.2%	98.8%
SAU802233	CTR200788	44%	94.6%	95.8%
SAU802233	CAC100146	64%	97.6%	98.2%
SAU802233	CBO100463	63%	97.6%	98.2%
SAU802233	CDF100733	66%	93.4%	91.7%
SAU802233	CDP101728	59%	97.6%	77.9%
SAU802233	EBC103648	55%	98.8%	98.8%
SAU802233	EFA201981	72%	93.4%	93.4%
SAU802233	EFM200438	72%	93.4%	93.4%
SAU802233	ECO103226	55%	98.8%	98.2%
SAU802233	HIN100775	55%	98.8%	98.8%
SAU802233	HPY101284	62%	86.7%	94.1%
SAU802233	KPN300491	55%	98.8%	98.2%
SAU802233	LPN100995	56%	92.8%	91.7%
SAU802233	LMO101368	78%	93.4%	92.8%
SAU802233	MCA100160	55%	95.8%	96.4%
SAU802233	MAV102079	56%	97.0%	71.6%
SAU802233	MBV101605	57%	97.0%	73.2%
SAU802233	MLP101120	58%	93.4%	71.4%
SAU802233	MTU200718	57%	97.0%	73.2%
SAU802233	MGE100171	50%	93.4%	73.5%
SAU802233	MPN100649	50%	93.4%	70.8%
SAU802233	NGO100919	49%	96.4%	93.0%
SAU802233	NME200106	49%	96.4%	93.0%
SAU802233	PMU101398	56%	98.8%	98.8%
SAU802233	PRT100558	54%	98.8%	98.8%
SAU802233	PAE204244	52%	98.8%	99.4%
SAU802233	PPU104527	49%	99.4%	100%
SAU802233	PSY105833	49%	98.8%	99.4%
SAU802233	SPA104328	56%	98.8%	98.2%
SAU802233	STY101822	55%	98.8%	98.2%
SAU802233	SAU802233	100%	100%	100%
SAU802233	SEP200249	98%	100%	100%
SAU802233	SHA100091	98%	100%	100%
SAU802233	SMU100600	67%	96.4%	97.6%
SAU802233	SPN400206	65%	96.4%	97.6%
SAU802233	SPY200054	67%	96.4%	97.6%
SAU802233	TPA100204	54%	94.6%	91.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802233	UUR100250	53%	97.6%	80.3%
SAU802233	VCH102542	54%	98.8%	98.8%
SAU802233	YPS002482	53%	98.8%	98.2%
SAU802234	ABA100110	46%	95.8%	98.3%
SAU802234	BAN106991	70%	100%	100%
SAU802234	BFR100058	59%	74.8%	100%
SAU802234	BPT100868	42%	96.6%	100%
SAU802234	BBU100493	37%	89.9%	89.9%
SAU802234	BCE113907	44%	96.6%	100%
SAU802234	BFU100389	40%	96.6%	100%
SAU802234	BMA109275	44%	96.6%	100%
SAU802234	CJU101595	43%	93.3%	91.5%
SAU802234	CPN200113	41%	95.0%	94.3%
SAU802234	CTR200789	43%	95.0%	94.3%
SAU802234	CAC102283	60%	96.6%	99.1%
SAU802234	CBO100811	54%	100%	97.5%
SAU802234	CDF103929	58%	100%	100%
SAU802234	CDP101725	54%	91.6%	81.5%
SAU802234	EBC103652	43%	96.6%	100%
SAU802234	EFA201982	68%	100%	100%
SAU802234	EFM200146	70%	100%	100%
SAU802234	ECO103227	45%	96.6%	100%
SAU802234	HIN100774	42%	96.6%	100%
SAU802234	HPY101285	40%	93.3%	90.8%
SAU802234	KPN300490	45%	96.6%	100%
SAU802234	LPN101342	44%	89.9%	98.3%
SAU802234	LMO102391	70%	100%	100%
SAU802234	MCA100159	49%	95.8%	98.3%
SAU802234	MAV102077	50%	91.6%	81.5%
SAU802234	MBV101604	51%	91.6%	90.2%
SAU802234	MLP101121	49%	91.6%	90.9%
SAU802234	MTU200717	51%	91.6%	90.2%
SAU802234	MGE100170	37%	99.2%	100%
SAU802234	MPN100650	37%	95.0%	97.4%
SAU802234	NGO100921	45%	96.6%	100%
SAU802234	NME200107	45%	96.6%	100%
SAU802234	PMU101399	42%	96.6%	100%
SAU802234	PRT100557	45%	96.6%	100%
SAU802234	PAE204245	48%	95.0%	97.4%
SAU802234	PPU104526	47%	95.8%	98.3%
SAU802234	PSY105780	51%	78.2%	95.9%
SAU802234	SPA104494	41%	96.6%	100%
SAU802234	STY101821	45%	96.6%	100%
SAU802234	SAU802234	100%	100%	100%
SAU802234	SEP200251	88%	100%	100%
SAU802234	SHA100055	90%	100%	100%
SAU802234	SMU100601	65%	100%	100%
SAU802234	SPN400205	66%	100%	100%
SAU802234	SPY200053	67%	100%	100%
SAU802234	TPA100203	41%	95.8%	95%
SAU802234	UUR100249	45%	98.3%	95.0%
SAU802234	VCH102543	38%	96.6%	100%
SAU802234	YPS002455	43%	96.6%	100%
SAU802235	ABA100111	44%	98.3%	98.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802235	BAN102950	57%	98.3%	99.4%
SAU802235	BAN110172	62%	100%	100%
SAU802235	BFR10781	45%	98.9%	97.9%
SAU802235	BPT100867	41%	98.3%	98.9%
SAU802235	BBU100492	42%	99.4%	98.3%
SAU802235	BCE105068	42%	98.3%	98.9%
SAU802235	BFU100388	43%	98.3%	98.9%
SAU802235	BMA103347	42%	98.3%	98.9%
SAU802235	CJU101596	43%	100%	99.4%
SAU802235	CPN200112	45%	100%	97.8%
SAU802235	CTR200790	44%	100%	97.8%
SAU802235	CAC101071	56%	100%	100%
SAU802235	CBO102597	59%	100%	99.4%
SAU802235	CDF100753	57%	100%	99.4%
SAU802235	CDP101722	55%	100%	100%
SAU802235	EBC103655	44%	98.3%	98.9%
SAU802235	EFA201983	63%	100%	100%
SAU802235	EFM201241	65%	100%	100%
SAU802235	ECO103228	44%	98.3%	98.9%
SAU802235	HIN100773	46%	98.3%	98.9%
SAU802235	HPY101286	42%	100%	99.4%
SAU802235	KPN300489	59%	18.0%	91.4%
SAU802235	LPN100869	45%	98.3%	98.9%
SAU802235	LMO102101	65%	100%	100%
SAU802235	MCA100158	45%	98.3%	98.9%
SAU802235	MAV102075	50%	100%	100%
SAU802235	MBV101643	50%	100%	100%
SAU802235	MLP101122	50%	100%	100%
SAU802235	MTU200716	50%	100%	100%
SAU802235	MGE100169	45%	100%	98.4%
SAU802235	MPN100651	43%	100%	98.4%
SAU802235	NGO100923	44%	98.3%	98.9%
SAU802235	NME200108	43%	98.3%	98.9%
SAU802235	PMU101400	45%	98.3%	98.9%
SAU802235	PRT100556	45%	98.3%	98.9%
SAU802235	PAE204246	43%	98.3%	98.9%
SAU802235	PPU104525	47%	98.3%	98.9%
SAU802235	PSY100295	45%	98.3%	98.9%
SAU802235	SPA104330	44%	98.3%	98.9%
SAU802235	STY101820	44%	98.3%	98.9%
SAU802235	SAU802235	100%	100%	100%
SAU802235	SEP200253	92%	100%	100%
SAU802235	SHA100054	87%	60.1%	100%
SAU802235	SMU100602	60%	100%	100%
SAU802235	SPN400204	58%	100%	100%
SAU802235	SPY200052	61%	100%	100%
SAU802235	TPA100202	45%	99.4%	98.9%
SAU802235	UUR100248	37%	98.9%	97.3%
SAU802235	VCH102544	44%	98.3%	98.9%
SAU802235	YPS002454	44%	98.3%	98.9%
SAU802236	ABA100112	47%	99.2%	99.2%
SAU802236	BAN113611	80%	98.5%	95.6%
SAU802236	BAN101892	79%	100%	100%
SAU802236	BFR10780	52%	98.5%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802236	BPT100866	47%	99.2%	99.2%
SAU802236	BBU100491	43%	100%	100%
SAU802236	BCE101537	49%	99.2%	99.2%
SAU802236	BFU100387	48%	99.2%	99.2%
SAU802236	BMA101128	51%	99.2%	99.2%
SAU802236	CJU101597	41%	98.5%	99.2%
SAU802236	CPN200111	41%	97.7%	97.0%
SAU802236	CTR200791	42%	97.7%	97.0%
SAU802236	CAC102421	62%	100%	100%
SAU802236	CBO102964	63%	100%	100%
SAU802236	CDF100752	68%	100%	100%
SAU802236	CDP101719	59%	100%	100%
SAU802236	EBC103658	51%	99.2%	99.2%
SAU802236	EFA201984	78%	100%	100%
SAU802236	EFM200970	76%	100%	100%
SAU802236	ECO103229	51%	99.2%	99.2%
SAU802236	HIN100772	47%	99.2%	99.2%
SAU802236	HPY101287	43%	98.5%	99.2%
SAU802236	KPN300573	50%	87.1%	98.3%
SAU802236	LPN100471	43%	99.2%	99.2%
SAU802236	LMO100791	78%	100%	100%
SAU802236	MCA100157	46%	99.2%	99.2%
SAU802236	MAV102073	56%	100%	100%
SAU802236	MBV101642	56%	100%	100%
SAU802236	MLP101123	56%	100%	100%
SAU802236	MTU200715	56%	100%	100%
SAU802236	MGE100168	45%	97.0%	92.2%
SAU802236	MPN100652	46%	97.0%	91.5%
SAU802236	NGO100925	48%	99.2%	99.2%
SAU802236	NME200109	48%	99.2%	99.2%
SAU802236	PMU101401	48%	99.2%	99.2%
SAU802236	PRT100555	47%	99.2%	99.2%
SAU802236	PAE204247	43%	100%	100%
SAU802236	PPU108197	44%	100%	100%
SAU802236	PSY108276	43%	100%	100%
SAU802236	SPA104332	51%	99.2%	99.2%
SAU802236	STY101809	51%	99.2%	99.2%
SAU802236	SAU802236	100%	100%	100%
SAU802236	SEP200255	96%	100%	100%
SAU802236	SHA101609	90%	72.7%	100%
SAU802236	SMU100603	72%	100%	100%
SAU802236	SPN400203	75%	100%	100%
SAU802236	SPY200051	78%	100%	100%
SAU802236	TPA100201	50%	100%	100%
SAU802236	UUR100247	46%	97.0%	97.7%
SAU802236	VCH102545	48%	99.2%	99.2%
SAU802236	YPS002453	51%	99.2%	99.2%
SAU802237	BAN104895	83%	100%	100%
SAU802237	BAN100258	83%	100%	100%
SAU802237	BBU100490	52%	100%	82.4%
SAU802237	CJU101598	60%	100%	100%
SAU802237	CAC102855	63%	100%	100%
SAU802237	CBO101206	59%	100%	100%
SAU802237	CDF102552	80%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802237	EFA202953	77%	100%	100%
SAU802237	EFM201806	77%	100%	100%
SAU802237	HPY101288	65%	100%	100%
SAU802237	LMO100535	83%	100%	100%
SAU802237	MAV102072	60%	100%	100%
SAU802237	MBV101641	60%	100%	100%
SAU802237	MLP101124	59%	100%	100%
SAU802237	MTU200714	60%	100%	100%
SAU802237	MGE100167	60%	100%	100%
SAU802237	MPN100653	62%	100%	100%
SAU802237	SAU802237	100%	100%	100%
SAU802237	SEP202534	98%	100%	100%
SAU802237	SHA103188	100%	100%	100%
SAU802237	SMU102003	77%	100%	100%
SAU802237	SPY200050	75%	100%	100%
SAU802237	TPA100200	55%	100%	100%
SAU802237	UUR100246	72%	100%	100%
SAU802238	ABA100107	62%	85.5%	100%
SAU802238	BAN113536	73%	100%	100%
SAU802238	BAN110693	84%	100%	100%
SAU802238	BFR10778	52%	97.8%	94.1%
SAU802238	BPT100865	59%	99.4%	99.4%
SAU802238	BBU100489	58%	97.2%	95.6%
SAU802238	BCE101479	60%	99.4%	99.4%
SAU802238	BFU100385	61%	99.4%	99.4%
SAU802238	BMA102975	61%	99.4%	99.4%
SAU802238	CJU101599	52%	100%	98.9%
SAU802238	CPN200110	49%	100%	98.9%
SAU802238	CTR200792	50%	100%	98.9%
SAU802238	CAC100782	66%	97.8%	97.2%
SAU802238	CBO103765	66%	100%	99.4%
SAU802238	CDF100751	69%	99.4%	98.9%
SAU802238	CDP101582	58%	98.9%	94.7%
SAU802238	EBC103664	60%	100%	100%
SAU802238	EFA201985	83%	100%	100%
SAU802238	EFM200921	82%	100%	100%
SAU802238	ECO103231	60%	100%	100%
SAU802238	HIN100770	60%	100%	100%
SAU802238	HPY101289	49%	98.3%	97.2%
SAU802238	KPN300575	64%	79.3%	100%
SAU802238	LPN102846	56%	41.3%	93.7%
SAU802238	LMO101852	79%	100%	100%
SAU802238	MCA100155	55%	99.4%	100%
SAU802238	MAV102069	56%	98.9%	94.7%
SAU802238	MBV101640	57%	98.9%	94.7%
SAU802238	MLP101125	58%	98.9%	94.7%
SAU802238	MTU200713	57%	98.9%	94.7%
SAU802238	MGE100166	56%	100%	99.4%
SAU802238	MPN100654	56%	100%	99.4%
SAU802238	NGO100929	58%	99.4%	99.4%
SAU802238	NME200111	58%	99.4%	99.4%
SAU802238	PMU101403	60%	100%	100%
SAU802238	PRT100553	60%	100%	94.2%
SAU802238	PAE204249	60%	99.4%	99.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802238	FFU104523	58%	99.4%	99.4%
SAU802238	PSY100243	66%	46.4%	98.8%
SAU802238	SPA104334	60%	100%	100%
SAU802238	STY101807	60%	100%	100%
SAU802238	SAU802238	100%	100%	100%
SAU802238	SEP200260	96%	100%	100%
SAU802238	SHA100780	94%	100%	100%
SAU802238	SMU100604	76%	99.4%	98.9%
SAU802238	SPN400201	76%	99.4%	98.9%
SAU802238	SPY200049	76%	99.4%	98.9%
SAU802238	TPA100199	54%	98.3%	95.1%
SAU802238	UUR100245	57%	98.3%	95.7%
SAU802238	VCH102547	62%	100%	100%
SAU802238	YPS002451	59%	100%	100%
SAU802239	ABA102168	52%	84.8%	96.7%
SAU802239	BAN110382	68%	94.3%	96.1%
SAU802239	BAN104944	71%	94.3%	96.1%
SAU802239	BFR103505	55%	97.1%	97.2%
SAU802239	BPT104094	47%	92.4%	91.5%
SAU802239	BBU100488	39%	94.3%	96.0%
SAU802239	BCE110380	45%	91.4%	92.2%
SAU802239	BFU100383	41%	96.2%	97.1%
SAU802239	BMA108868	47%	91.4%	92.2%
SAU802239	CJU101600	55%	64.8%	88.3%
SAU802239	CPN200109	45%	81.9%	73.9%
SAU802239	CTR200793	47%	78.1%	70.3%
SAU802239	CAC102906	45%	94.3%	94.3%
SAU802239	CBO100250	49%	94.3%	95.2%
SAU802239	CDF103678	55%	96.2%	99.0%
SAU802239	CDP101580	54%	96.2%	100%
SAU802239	EBC103629	53%	95.2%	96.2%
SAU802239	EFA205255	65%	94.3%	96.1%
SAU802239	EFM201757	66%	94.3%	96.1%
SAU802239	ECO103232	53%	95.2%	96.2%
SAU802239	HIN100769	52%	94.3%	96.1%
SAU802239	HPY101290	58%	63.8%	91.8%
SAU802239	KPN305017	53%	95.2%	96.2%
SAU802239	LMO101665	70%	96.2%	98.1%
SAU802239	MCA100154	51%	94.3%	94.3%
SAU802239	MAV102067	49%	96.2%	100%
SAU802239	MBV101639	50%	96.2%	100%
SAU802239	MLP101126	48%	96.2%	100%
SAU802239	MTU200712	50%	96.2%	100%
SAU802239	MGE100165	34%	94.3%	97.2%
SAU802239	MPN100655	36%	94.3%	97.3%
SAU802239	NGO100931	48%	94.3%	95.3%
SAU802239	NME200112	49%	94.3%	95.3%
SAU802239	PMU101404	55%	94.3%	96.1%
SAU802239	PRT103501	47%	34.3%	89.7%
SAU802239	PAE204250	49%	96.2%	97.1%
SAU802239	PPU104522	47%	94.3%	95.2%
SAU802239	PSY100105	47%	94.3%	95.2%
SAU802239	SPA104335	51%	95.2%	96.2%
SAU802239	STY101806	53%	95.2%	96.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802239	SAU802239	100%	100%	100%
SAU802239	SEP200261	94%	100%	100%
SAU802239	SHA101599	92%	67.6%	100%
SAU802239	SMU100605	65%	94.3%	97.0%
SAU802239	SPN400200	68%	94.3%	97.0%
SAU802239	SPY200048	63%	94.3%	97.0%
SAU802239	TPA100198	51%	92.4%	92.2%
SAU802239	UUR100244	48%	97.1%	95.5%
SAU802239	VCH102548	52%	97.1%	96.2%
SAU802239	YPS002450	53%	95.2%	96.2%
SAU802240	ABA102167	65%	91.0%	96.5%
SAU802240	BAN108009	88%	100%	100%
SAU802240	BFR100659	64%	100%	100%
SAU802240	BPT100864	63%	100%	100%
SAU802240	BBU100487	59%	100%	98.4%
SAU802240	BCE113728	68%	100%	100%
SAU802240	BFU100381	68%	100%	100%
SAU802240	BMA101057	67%	100%	100%
SAU802240	CJU101601	68%	100%	100%
SAU802240	CPN200108	63%	100%	100%
SAU802240	CTR200794	64%	100%	100%
SAU802240	CAC101685	73%	100%	100%
SAU802240	CBO100636	77%	100%	100%
SAU802240	CDF102312	81%	100%	100%
SAU802240	CDP101578	75%	100%	100%
SAU802240	EBC103643	67%	100%	100%
SAU802240	EFA201986	90%	100%	100%
SAU802240	EFM201996	91%	100%	100%
SAU802240	ECO103233	66%	100%	100%
SAU802240	HIN100768	69%	100%	100%
SAU802240	HPY101291	62%	100%	100%
SAU802240	KPN305016	69%	66.4%	98.8%
SAU802240	LMO100716	92%	100%	100%
SAU802240	MCA100153	67%	100%	100%
SAU802240	MAV102065	75%	100%	100%
SAU802240	MBV101638	75%	100%	100%
SAU802240	MLP101127	73%	92.6%	100%
SAU802240	MTU200711	75%	100%	100%
SAU802240	MGE100164	60%	100%	100%
SAU802240	MPN100656	61%	100%	100%
SAU802240	NGO100934	65%	100%	100%
SAU802240	NME200113	65%	100%	100%
SAU802240	PMU101405	69%	100%	100%
SAU802240	PRT103251	65%	97.5%	100%
SAU802240	PAE204251	66%	100%	100%
SAU802240	PPU108200	65%	100%	100%
SAU802240	PSY100106	65%	100%	100%
SAU802240	SPA104303	67%	100%	100%
SAU802240	STY101805	67%	100%	100%
SAU802240	SAU802240	100%	100%	100%
SAU802240	SEP200262	97%	100%	100%
SAU802240	SHA100778	99%	100%	85.3%
SAU802240	SMU100606	90%	100%	100%
SAU802240	SPN400199	89%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802240	SPY200047	88%	100%	100%
SAU802240	TPA100197	63%	100%	100%
SAU802240	UUR100243	63%	100%	100%
SAU802240	VCH102549	66%	100%	100%
SAU802240	YPS002449	68%	100%	100%
SAU802241	BAN105005	88%	100%	100%
SAU802241	BFR100428	53%	96.6%	98.8%
SAU802241	BPT104067	49%	93.1%	87.1%
SAU802241	BBU100486	51%	92.0%	95.2%
SAU802241	BCE100913	51%	93.1%	90%
SAU802241	BFU103897	61%	39.1%	75.6%
SAU802241	BMA102592	54%	93.1%	90%
SAU802241	CJU101602	45%	85.1%	89.2%
SAU802241	CPN200107	53%	89.7%	89.5%
SAU802241	CTR200795	52%	89.7%	92.8%
SAU802241	CAC101333	62%	94.3%	97.6%
SAU802241	CBO101908	57%	94.3%	97.6%
SAU802241	CDF102812	64%	93.1%	96.4%
SAU802241	CDP102662	54%	94.3%	89.1%
SAU802241	EBC103647	49%	86.2%	89.3%
SAU802241	EFA205257	80%	97.7%	89.5%
SAU802241	EFM201704	77%	96.6%	95.5%
SAU802241	ECO103234	49%	86.2%	89.3%
SAU802241	HIN100766	53%	86.2%	88.2%
SAU802241	HPY101292	46%	86.2%	87.2%
SAU802241	KPN204999	49%	86.2%	89.3%
SAU802241	LMO101712	77%	100%	100%
SAU802241	MCA101811	55%	90.8%	87.8%
SAU802241	MAV102052	55%	93.1%	69.2%
SAU802241	MBV101010	55%	93.1%	59.6%
SAU802241	MLP101128	56%	93.1%	63.8%
SAU802241	MTU200707	55%	93.1%	59.6%
SAU802241	MGE100163	50%	94.3%	97.6%
SAU802241	MPN100657	55%	94.3%	97.6%
SAU802241	NGO102122	53%	96.6%	96.6%
SAU802241	NME200114	53%	96.6%	96.6%
SAU802241	PMU101406	56%	86.2%	88.2%
SAU802241	PRT103498	42%	78.2%	100%
SAU802241	PAE204252	53%	89.7%	88.6%
SAU802241	PPU104520	55%	89.7%	86.7%
SAU802241	PSY107655	52%	89.7%	88.6%
SAU802241	SPA104305	36%	83.9%	86.9%
SAU802241	STY101804	49%	86.2%	89.3%
SAU802241	SAU802241	100%	100%	100%
SAU802241	SEP200263	96%	100%	100%
SAU802241	SHA100777	97%	100%	100%
SAU802241	SMU100607	74%	97.7%	98.8%
SAU802241	SPN400198	77%	97.7%	98.8%
SAU802241	SPY200046	74%	97.7%	98.8%
SAU802241	TPA100196	56%	94.3%	97.6%
SAU802241	UUR100242	54%	94.3%	97.6%
SAU802241	VCH102550	50%	88.5%	91.7%
SAU802241	YPS002447	45%	86.2%	89.3%
SAU802243	ABA100087	52%	81.2%	98.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802243	BAN105442	79%	100%	100%
SAU802243	BFR12478	57%	94.4%	94.4%
SAU802243	BPT104060	55%	93.1%	97.1%
SAU802243	BBU100484	59%	95.1%	99.3%
SAU802243	BCE110254	55%	93.8%	97.8%
SAU802243	BFU100274	55%	93.8%	97.8%
SAU802243	BMA108797	56%	93.8%	97.8%
SAU802243	CJU101604	62%	93.8%	95.7%
SAU802243	CPN200105	58%	94.4%	98.6%
SAU802243	CTR200797	59%	94.4%	98.6%
SAU802243	CAC102622	63%	99.3%	99.3%
SAU802243	CBO103643	66%	99.3%	99.3%
SAU802243	CDF100749	69%	97.2%	100%
SAU802243	CDP101572	63%	50.7%	97.3%
SAU802243	EBC103654	55%	93.1%	97.8%
SAU802243	EFA201987	74%	99.3%	99.3%
SAU802243	EFM200770	73%	99.3%	99.3%
SAU802243	ECO103236	54%	93.1%	97.8%
SAU802243	HIN100764	55%	93.1%	97.8%
SAU802243	HPY101294	55%	93.8%	95.7%
SAU802243	KPN300638	53%	86.8%	100%
SAU802243	LMO101423	74%	100%	100%
SAU802243	MCA100019	57%	93.1%	97.8%
SAU802243	MAV102093	55%	94.4%	98.6%
SAU802243	MBV101012	55%	94.4%	98.6%
SAU802243	MLP101130	56%	94.4%	98.6%
SAU802243	MTU200705	57%	94.4%	98.6%
SAU802243	MGE100161	55%	94.4%	98.6%
SAU802243	MPN100659	56%	95.1%	98.6%
SAU802243	NGO100936	56%	93.8%	97.8%
SAU802243	NME200116	56%	93.8%	97.8%
SAU802243	PMU101408	55%	93.1%	97.8%
SAU802243	PRT100078	55%	93.1%	97.8%
SAU802243	PAE204254	58%	93.1%	97.8%
SAU802243	PPU104518	57%	93.1%	97.8%
SAU802243	PSY103397	56%	93.1%	97.8%
SAU802243	SPA104307	54%	93.1%	97.8%
SAU802243	STY101803	54%	93.1%	97.8%
SAU802243	SAU802243	100%	100%	100%
SAU802243	SEP200265	97%	100%	100%
SAU802243	SHA100775	99%	100%	100%
SAU802243	SMU100608	75%	93.8%	98.5%
SAU802243	SPN400196	74%	93.8%	98.5%
SAU802243	SPY200044	74%	93.8%	98.5%
SAU802243	TPA100194	53%	92.4%	95.7%
SAU802243	UUR100240	57%	94.4%	98.6%
SAU802243	VCH102552	54%	93.8%	98.5%
SAU802243	YPS002443	58%	93.1%	97.8%
SAU802244	ABA100086	54%	95.4%	90.0%
SAU802244	BAN112122	74%	83.4%	100%
SAU802244	BAN102487	75%	100%	100%
SAU802244	BFR10672	54%	94.9%	84.4%
SAU802244	BPT100851	50%	95.4%	79.1%
SAU802244	BBU100483	47%	100%	75.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802244	BCE110191	51%	95.4%	78.2%
SAU802244	BFU100273	51%	95.4%	90.8%
SAU802244	BMA108753	51%	95.4%	78.2%
SAU802244	CJU101605	52%	95.4%	89.3%
SAU802244	CPN200104	50%	94.5%	92.4%
SAU802244	CTR200798	47%	98.6%	96.9%
SAU802244	CAC103109	64%	96.8%	95.5%
SAU802244	CBO100517	61%	96.8%	95.1%
SAU802244	CDF100748	58%	97.2%	78.6%
SAU802244	CDP101570	50%	98.2%	83.6%
SAU802244	EBC103657	55%	95.4%	89.3%
SAU802244	EFA201993	77%	100%	100%
SAU802244	EFM201332	76%	100%	100%
SAU802244	ECO103237	55%	95.4%	89.3%
SAU802244	HIN100763	58%	95.4%	88.5%
SAU802244	HPY101295	54%	95.4%	88.9%
SAU802244	KPN300639	55%	95.4%	89.7%
SAU802244	LMO101810	77%	100%	100%
SAU802244	MCA100254	52%	98.2%	89.2%
SAU802244	MAV102092	50%	96.8%	75.4%
SAU802244	MBV101013	50%	96.8%	77.0%
SAU802244	MLP101131	50%	96.8%	75.1%
SAU802244	MTU200704	50%	96.8%	77.0%
SAU802244	MGE100160	42%	94.9%	78.4%
SAU802244	MPN100660	41%	94.9%	76.9%
SAU802244	NGO100939	52%	93.1%	88.3%
SAU802244	NME200117	53%	93.1%	88.3%
SAU802244	PMU101409	58%	95.4%	88.5%
SAU802244	PRT103066	55%	95.4%	89.3%
SAU802244	PAE204255	57%	95.4%	91.2%
SAU802244	PPU104517	56%	95.4%	87.8%
SAU802244	PSY103396	56%	95.4%	91.2%
SAU802244	SPA104309	55%	95.4%	89.3%
SAU802244	STY101802	55%	95.4%	89.3%
SAU802244	SAU802244	100%	100%	100%
SAU802244	SEP200267	96%	100%	100%
SAU802244	SHA100774	97%	100%	100%
SAU802244	SMU100609	72%	100%	100%
SAU802244	SPN400195	74%	100%	100%
SAU802244	SPY200043	74%	100%	100%
SAU802244	TPA100193	53%	94.0%	83.8%
SAU802244	UUR100239	47%	96.8%	83.3%
SAU802244	VCH102553	55%	95.4%	89.3%
SAU802244	YPS002439	56%	95.4%	89.7%
SAU802245	ABA100085	50%	91.5%	97.3%
SAU802245	BAN109858	63%	95.7%	99.1%
SAU802245	BAN111310	73%	95.7%	99.1%
SAU802245	BFR102815	40%	88.0%	89.0%
SAU802245	BPT104052	43%	91.5%	98.2%
SAU802245	BBU100482	34%	92.3%	90.8%
SAU802245	BCE103775	43%	93.2%	100%
SAU802245	BFU100272	42%	93.2%	100%
SAU802245	BMA104499	43%	93.2%	100%
SAU802245	CJU101606	36%	97.4%	78.0%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802245	CPN200103	39%	90.6%	95.5%
SAU802245	CTR200799	38%	90.6%	95.5%
SAU802245	CAC102305	59%	93.2%	98.2%
SAU802245	CBO100872	53%	93.2%	98.2%
SAU802245	CDF103249	54%	94.9%	93.3%
SAU802245	CDP102437	57%	96.6%	94.2%
SAU802245	EBC103660	54%	93.2%	99.1%
SAU802245	EFA201995	66%	91.5%	91.5%
SAU802245	EFM202159	67%	91.5%	93.0%
SAU802245	ECO103238	54%	93.2%	99.1%
SAU802245	HIN100762	54%	93.2%	99.1%
SAU802245	HPY101296	40%	94.0%	86.9%
SAU802245	KPN300640	60%	36.8%	87.8%
SAU802245	LMO100543	74%	94.0%	93.2%
SAU802245	MCA100253	48%	93.2%	100%
SAU802245	MAV102091	53%	89.7%	58.3%
SAU802245	MBV101014	51%	89.7%	53.3%
SAU802245	MLP101132	52%	89.7%	60%
SAU802245	MTU200703	51%	89.7%	53.3%
SAU802245	MGE100159	41%	98.3%	79.9%
SAU802245	MPN100661	46%	91.5%	58.2%
SAU802245	NGO102695	46%	93.2%	100%
SAU802245	NME200118	46%	93.2%	100%
SAU802245	PMU101410	54%	93.2%	99.1%
SAU802245	PRT103067	53%	93.2%	99.1%
SAU802245	PAE204256	47%	93.2%	99.1%
SAU802245	FPU104507	47%	93.2%	99.1%
SAU802245	FSY107686	48%	77.8%	98.9%
SAU802245	SPA104311	54%	93.2%	99.1%
SAU802245	STY101801	54%	93.2%	99.1%
SAU802245	SAU802245	100%	100%	100%
SAU802245	SEP200269	99%	100%	100%
SAU802245	SHA100773	99%	100%	100%
SAU802245	SMU100610	63%	91.5%	93.9%
SAU802245	SPN400194	62%	91.5%	93.9%
SAU802245	SPY200042	65%	91.5%	93.9%
SAU802245	TPA100192	32%	90.6%	86.3%
SAU802245	UUR100238	44%	99.1%	37.6%
SAU802245	VCH102554	50%	93.2%	99.1%
SAU802245	YPS001865	53%	93.2%	99.1%
SAU802246	ABA100084	64%	98.9%	100%
SAU802246	BAN101977	68%	95.7%	96.6%
SAU802246	BAN110916	82%	100%	100%
SAU802246	BFR104321	64%	96.7%	100%
SAU802246	BPT104048	68%	98.9%	100%
SAU802246	BBU100481	58%	100%	100%
SAU802246	BCE112635	72%	95.7%	96.7%
SAU802246	BFU104367	72%	95.7%	96.7%
SAU802246	BMA100281	72%	95.7%	96.7%
SAU802246	CUU101607	61%	96.7%	95.7%
SAU802246	CPN200102	65%	90.2%	94.3%
SAU802246	CTR200800	65%	90.2%	94.3%
SAU802246	CAC101096	65%	97.8%	96.8%
SAU802246	CBO102193	60%	98.9%	86.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802246	CDF103424	67%	100%	98.9%
SAU802246	CDP101567	77%	100%	100%
SAU802246	EBC103663	65%	100%	100%
SAU802246	EFA201997	83%	100%	100%
SAU802246	EFM202484	82%	100%	100%
SAU802246	ECO103239	65%	100%	100%
SAU802246	HIN100761	65%	95.7%	96.7%
SAU802246	HPY101297	63%	96.7%	95.7%
SAU802246	KPN300699	64%	100%	100%
SAU802246	LMO100277	82%	100%	100%
SAU802246	MCA100252	59%	98.9%	100%
SAU802246	MAV102090	78%	100%	98.9%
SAU802246	MBV101015	78%	100%	98.9%
SAU802246	MLP101133	77%	100%	98.9%
SAU802246	MTU200702	78%	100%	98.9%
SAU802246	MGE100158	63%	93.5%	98.9%
SAU802246	MPN100662	66%	93.5%	98.9%
SAU802246	NGO102970	65%	100%	100%
SAU802246	NME200119	65%	100%	100%
SAU802246	PMU101411	65%	95.7%	96.7%
SAU802246	PRT100323	66%	100%	100%
SAU802246	PAE204257	62%	98.9%	100%
SAU802246	PPU111002	62%	98.9%	100%
SAU802246	PSY101086	61%	98.9%	100%
SAU802246	SPA104313	64%	100%	100%
SAU802246	STY101800	64%	100%	100%
SAU802246	SAU802246	100%	100%	100%
SAU802246	SEP200271	96%	100%	100%
SAU802246	SHA100772	96%	100%	100%
SAU802246	SMU102869	86%	41.3%	95%
SAU802246	SPN400192	85%	100%	98.9%
SAU802246	SPY200041	85%	100%	100%
SAU802246	TPA100191	52%	100%	100%
SAU802246	UUR100237	65%	90.2%	94.3%
SAU802246	VCH102555	63%	100%	100%
SAU802246	YPS001864	65%	100%	100%
SAU802247	ABA100083	54%	100%	100%
SAU802247	BAN100305	80%	58.1%	98.8%
SAU802247	BFR10675	60%	99.6%	100%
SAU802247	BPT100850	57%	99.6%	100%
SAU802247	BBU100480	57%	99.6%	100%
SAU802247	BCE100228	57%	99.6%	100%
SAU802247	BFU100271	59%	99.6%	100%
SAU802247	BMA102202	60%	99.6%	100%
SAU802247	CJU101608	59%	100%	100%
SAU802247	CPN200101	52%	98.6%	99.3%
SAU802247	CTR200801	51%	98.6%	99.3%
SAU802247	CAC101509	66%	100%	100%
SAU802247	CBO101184	68%	100%	100%
SAU802247	CDF100747	66%	99.6%	100%
SAU802247	CDP101565	63%	99.3%	97.5%
SAU802247	EBC103628	58%	99.6%	100%
SAU802247	EFA201999	78%	99.6%	100%
SAU802247	EFM200310	76%	83.0%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802247	ECO103240	58%	99.6%	100%
SAU802247	HIN100760	60%	99.6%	100%
SAU802247	HPY101298	57%	100%	100%
SAU802247	KPN300698	58%	99.6%	100%
SAU802247	LMO100597	84%	100%	100%
SAU802247	MCA100251	58%	100%	100%
SAU802247	MAV102089	62%	99.3%	97.5%
SAU802247	MBV101016	62%	99.3%	97.5%
SAU802247	MLP101134	60%	99.3%	97.5%
SAU802247	MTU200701	62%	99.3%	97.5%
SAU802247	MGE100157	60%	99.3%	98.6%
SAU802247	MPN100663	57%	99.3%	98.6%
SAU802247	NGO101613	62%	98.9%	98.2%
SAU802247	NME200120	62%	98.9%	98.2%
SAU802247	PMU101412	61%	99.6%	100%
SAU802247	PRT100324	60%	99.6%	100%
SAU802247	PAE204258	60%	99.3%	100%
SAU802247	PPU104505	59%	99.3%	100%
SAU802247	PSY107059	61%	99.3%	100%
SAU802247	SPA104315	57%	99.6%	100%
SAU802247	STY101789	57%	99.6%	100%
SAU802247	SAU802247	100%	100%	100%
SAU802247	SEP200273	95%	100%	100%
SAU802247	SHA100771	96%	100%	100%
SAU802247	SPN400191	76%	100%	100%
SAU802247	SPY200040	78%	100%	100%
SAU802247	TPA100190	57%	99.3%	100%
SAU802247	UUR100236	63%	99.3%	100%
SAU802247	VCH102556	61%	99.6%	100%
SAU802247	YPS001863	60%	100%	100%
SAU802248	ABA100082	40%	87.9%	76.4%
SAU802248	BFR102748	38%	94.5%	95.8%
SAU802248	BPT104043	39%	87.9%	82.7%
SAU802248	BBU100479	38%	98.9%	95.1%
SAU802248	BCE100645	41%	87.9%	77.9%
SAU802248	BFU103900	41%	87.9%	77.9%
SAU802248	BMA108040	41%	87.9%	77.9%
SAU802248	CJU101609	29%	86.8%	84.9%
SAU802248	CPN200100	34%	89.0%	91.9%
SAU802248	CTR200802	32%	89.0%	91.9%
SAU802248	CAC102428	51%	92.3%	85.7%
SAU802248	CBO102507	48%	90.1%	84.5%
SAU802248	CDF101975	49%	93.4%	88.5%
SAU802248	CDP102947	45%	97.8%	90.1%
SAU802248	EBC101608	37%	87.9%	81.8%
SAU802248	EFA205285	68%	97.8%	92.7%
SAU802248	ECO103241	38%	87.9%	81%
SAU802248	HIN100759	37%	87.9%	81.8%
SAU802248	KPN300697	38%	87.9%	81%
SAU802248	LMO100631	68%	97.8%	94.7%
SAU802248	MCA100250	43%	89.0%	76.1%
SAU802248	MAV102088	49%	97.8%	91%
SAU802248	MBV101017	50%	97.8%	91%
SAU802248	MLP101135	50%	97.8%	91%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802248	MTU200700	50%	97.8%	91%
SAU802248	MGE100156	38%	93.4%	83.0%
SAU802248	MPN100664	34%	93.4%	37.1%
SAU802248	NGO102702	42%	83.5%	74.0%
SAU802248	NME200121	38%	87.9%	76.4%
SAU802248	PMU101413	39%	87.9%	81%
SAU802248	PRT100325	39%	87.9%	81%
SAU802248	PAE204259	38%	87.9%	81.8%
SAU802248	PPU102891	41%	87.9%	81.8%
SAU802248	PSY107072	35%	87.9%	81.8%
SAU802248	SPA104317	38%	87.9%	81%
SAU802248	STY101788	38%	87.9%	81%
SAU802248	SAU802248	100%	100%	100%
SAU802248	SEP200275	92%	100%	100%
SAU802248	SHA100770	93%	100%	100%
SAU802248	SPN400190	53%	98.9%	94.9%
SAU802248	SPY200039	56%	98.9%	94.9%
SAU802248	TPA100189	40%	93.4%	90.4%
SAU802248	UUR100235	30%	93.4%	84.8%
SAU802248	VCH102557	40%	87.9%	81%
SAU802248	YPS005095	38%	87.9%	81%
SAU802249	ABA100081	42%	94.7%	98%
SAU802249	BFR10676	45%	97.6%	98.1%
SAU802249	BPT100849	37%	95.7%	96.6%
SAU802249	BBU100478	40%	96.1%	96.2%
SAU802249	BCE103118	36%	97.1%	97.6%
SAU802249	BFU100270	36%	97.1%	97.6%
SAU802249	BMA104332	40%	62.3%	97.0%
SAU802249	CJU101610	35%	91.8%	92.2%
SAU802249	CPN200099	37%	94.7%	92.9%
SAU802249	CTR200803	40%	94.7%	92.8%
SAU802249	CAC100377	48%	99.0%	99.0%
SAU802249	CBO103307	47%	99.0%	99.0%
SAU802249	CDF100746	54%	99.0%	94.5%
SAU802249	CDP101562	43%	93.7%	89.9%
SAU802249	EBC101609	41%	90.8%	93.0%
SAU802249	EFA202001	61%	99.5%	99.5%
SAU802249	ECO103242	40%	92.3%	94.5%
SAU802249	HIN100758	38%	96.6%	99.5%
SAU802249	HPY101300	38%	91.8%	91.2%
SAU802249	KPN300696	39%	92.3%	94.5%
SAU802249	LMO102640	60%	99.5%	99.5%
SAU802249	MCA100249	40%	96.6%	99.5%
SAU802249	MAV102087	45%	93.7%	92.2%
SAU802249	MBV101018	43%	93.7%	87.4%
SAU802249	MLP101136	46%	93.7%	84.8%
SAU802249	MTU200699	43%	93.7%	87.4%
SAU802249	MGE100155	38%	99.5%	99.5%
SAU802249	MPN100665	37%	98.1%	98.1%
SAU802249	NGO101615	37%	96.1%	96.6%
SAU802249	NME200122	36%	96.1%	96.6%
SAU802249	PMU101414	39%	96.6%	99.5%
SAU802249	PRT103342	41%	92.8%	95.0%
SAU802249	PAE204260	46%	97.1%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802249	PPU104504	43%	97.1%	100%
SAU802249	PSY108736	43%	97.1%	100%
SAU802249	SPA104319	40%	92.3%	95%
SAU802249	STY101787	40%	92.3%	94.5%
SAU802249	SAU802249	100%	100%	100%
SAU802249	SEP200280	90%	99.5%	99.5%
SAU802249	SHA100769	89%	100%	100%
SAU802249	SMU101861	48%	15.0%	100%
SAU802249	SPN400189	63%	99.5%	99.5%
SAU802249	SPY200038	61%	99.5%	99.5%
SAU802249	TPA100188	38%	96.1%	92.1%
SAU802249	UUR100234	36%	98.6%	100%
SAU802249	VCH102558	44%	93.2%	96%
SAU802249	YPS001862	40%	92.8%	95.0%
SAU802250	ABA100080	50%	43.2%	98.0%
SAU802250	BFR10677	49%	94.5%	98.0%
SAU802250	BPT100848	46%	96.8%	91.3%
SAU802250	BBU100477	48%	96.8%	99.0%
SAU802250	BCE112456	45%	100%	99.5%
SAU802250	BFU100269	45%	98.2%	96.3%
SAU802250	BMA106660	45%	98.2%	96.3%
SAU802250	CJU101611	34%	92.7%	95.3%
SAU802250	CPN200098	41%	95.5%	95.9%
SAU802250	CTR200804	44%	95.5%	95.0%
SAU802250	CAC103369	55%	98.2%	99.5%
SAU802250	CBO101061	56%	98.2%	96.3%
SAU802250	CDF100745	57%	97.3%	98.1%
SAU802250	CDP100915	48%	98.2%	95.9%
SAU802250	EBC101610	42%	96.8%	98.6%
SAU802250	EFA202003	64%	98.2%	99.0%
SAU802250	ECO103243	43%	96.8%	98.6%
SAU802250	HIN100757	45%	96.8%	98.6%
SAU802250	HPY101301	33%	90%	92.7%
SAU802250	KPN300695	41%	40.9%	98.9%
SAU802250	LMO102018	66%	98.2%	99.0%
SAU802250	MCA100248	45%	98.2%	99.5%
SAU802250	MAV102086	49%	99.1%	98.6%
SAU802250	MBV100990	48%	99.1%	98.6%
SAU802250	MLP101137	49%	99.1%	98.2%
SAU802250	MTU200698	48%	99.1%	98.6%
SAU802250	MGE100154	39%	99.1%	82.9%
SAU802250	MPN100666	41%	97.7%	73.2%
SAU802250	NGO101617	46%	99.1%	99.5%
SAU802250	NME200123	46%	99.1%	99.5%
SAU802250	PMU101415	46%	96.8%	98.6%
SAU802250	PRT102977	45%	96.8%	98.6%
SAU802250	PAE204261	46%	98.2%	98.6%
SAU802250	PPU111511	45%	98.2%	98.6%
SAU802250	PSY106254	46%	98.2%	93.7%
SAU802250	SPA104320	43%	90.9%	92.3%
SAU802250	STY101786	45%	90.9%	92.3%
SAU802250	SAU802250	100%	100%	100%
SAU802250	SEP200281	91%	100%	100%
SAU802250	SHA100768	90%	59.5%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802250	SMU100611	65%	98.2%	98.6%
SAU802250	SPN400188	65%	99.1%	99.5%
SAU802250	SPY200037	64%	98.2%	98.6%
SAU802250	TPA100187	43%	97.3%	98.1%
SAU802250	UUR100233	44%	98.6%	90.1%
SAU802250	VCH102559	48%	96.8%	98.6%
SAU802250	YPS001861	43%	96.8%	98.6%
SAU802251	ABA100720	56%	64.7%	100%
SAU802251	BAN112470	86%	82.4%	100%
SAU802251	BFR102501	63%	97.1%	98.0%
SAU802251	BPT104019	64%	100%	85.7%
SAU802251	BBU100476	54%	99.0%	98.1%
SAU802251	BCE114850	65%	100%	82.3%
SAU802251	BFU100268	65%	100%	71.3%
SAU802251	BMA104676	65%	100%	99.0%
SAU802251	CJU101612	53%	96.1%	95.1%
SAU802251	CPN200200	65%	97.1%	94.3%
SAU802251	CTR200710	66%	97.1%	94.3%
SAU802251	CAC101769	78%	100%	100%
SAU802251	CBO101448	76%	100%	100%
SAU802251	CDF104153	80%	61.8%	100%
SAU802251	CDP100914	71%	99.0%	100%
SAU802251	EBC101611	64%	100%	99.0%
SAU802251	EFA205288	86%	100%	100%
SAU802251	ECO103244	62%	100%	99.0%
SAU802251	HIN100756	64%	100%	86.4%
SAU802251	HPY101302	58%	95.1%	93.3%
SAU802251	KPN304660	64%	100%	94.4%
SAU802251	LMO100137	88%	100%	100%
SAU802251	MCA101858	61%	100%	99.0%
SAU802251	MAV102085	71%	99.0%	100%
SAU802251	MBV100992	71%	99.0%	100%
SAU802251	MLP101138	71%	99.0%	100%
SAU802251	MTU200697	71%	99.0%	100%
SAU802251	MGE100153	43%	92.2%	88.7%
SAU802251	MPN100667	42%	92.2%	87.0%
SAU802251	NGO102546	65%	100%	99.0%
SAU802251	NME200127	65%	100%	99.0%
SAU802251	PMU101416	64%	100%	99.0%
SAU802251	PRT100142	64%	100%	99.0%
SAU802251	PAE204262	62%	100%	99.0%
SAU802251	PPU104502	61%	91.2%	98.9%
SAU802251	PSY106273	62%	100%	82.3%
SAU802251	SPA104323	54%	100%	94.6%
SAU802251	STY101785	64%	100%	99.0%
SAU802251	SAU802251	100%	100%	100%
SAU802251	SEP200282	99%	100%	100%
SAU802251	SHA102423	96%	100%	100%
SAU802251	SMU100612	75%	100%	100%
SAU802251	SPN400187	77%	100%	100%
SAU802251	SPY200036	76%	100%	100%
SAU802251	TPA100186	51%	99.0%	99.0%
SAU802251	UUR100232	51%	97.1%	98.0%
SAU802251	VCH102560	62%	100%	99.0%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802251	YPS005092	64%	100%	99.0%
SAU802254	BAN106323	36%	98.5%	100%
SAU802254	BAN107719	48%	99.6%	99.3%
SAU802254	BFR11341	34%	83.5%	87.4%
SAU802254	BPT100056	35%	84.8%	72.3%
SAU802254	BCE103151	34%	84.8%	90.6%
SAU802254	BFU100507	34%	84.8%	70.8%
SAU802254	BMA106704	35%	76.9%	91.9%
SAU802254	CAC102331	44%	99.6%	98.6%
SAU802254	CBO102358	46%	99.2%	98.5%
SAU802254	CDF103201	48%	99.6%	99.3%
SAU802254	EBC101583	28%	48.0%	82.8%
SAU802254	EFA201812	40%	97.6%	97.1%
SAU802254	EFM200904	35%	41.6%	100%
SAU802254	ECO101731	29%	80.0%	90.8%
SAU802254	HIN100424	31%	81.2%	93.7%
SAU802254	KPN302957	29%	80.0%	91.5%
SAU802254	LMO102705	47%	99.9%	99.4%
SAU802254	PMU100207	31%	81.2%	94.6%
SAU802254	PRT106061	29%	81.7%	92.4%
SAU802254	PPU110370	29%	68.2%	89.2%
SAU802254	PSY104995	30%	74.0%	88.2%
SAU802254	SPA100636	33%	24.6%	72.4%
SAU802254	STY102434	30%	87.6%	96.7%
SAU802254	STM103402	29%	80.0%	91.4%
SAU802254	SAU802254	100%	100%	100%
SAU802254	SEP200287	72%	100%	100%
SAU802254	SHA100701	73%	99.9%	99.6%
SAU802254	VCH102013	32%	79.0%	91.3%
SAU802254	YPS000729	29%	82.4%	95.0%
SAU802261	ABA100532	26%	98.2%	97.7%
SAU802261	BAN104054	25%	96.0%	98.2%
SAU802261	BAN111342	33%	99.7%	98.7%
SAU802261	BAN113400	37%	99.1%	49.8%
SAU802261	BAN109301	45%	99.8%	100%
SAU802261	BFR11719	25%	49.6%	97.6%
SAU802261	BPT102713	23%	97.4%	96.4%
SAU802261	BBU100139	26%	99.5%	48.9%
SAU802261	BCE101292	24%	97.1%	48.4%
SAU802261	BFU109876	23%	97.3%	50.7%
SAU802261	BFU100767	24%	97.1%	45.9%
SAU802261	BMA103699	23%	99.8%	97.6%
SAU802261	CJU100961	23%	51.4%	99.9%
SAU802261	CAC102232	36%	55.5%	9.3%
SAU802261	CDF100351	30%	29.3%	100%
SAU802261	CDF103505	27%	98.6%	95.9%
SAU802261	EBC101480	24%	97.5%	97.9%
SAU802261	EFA103690	20%	31.3%	93.3%
SAU802261	EFM200039	20%	31.3%	93.3%
SAU802261	ECO102034	24%	98.6%	97.0%
SAU802261	HIN100875	24%	98.2%	97.0%
SAU802261	HPY100600	23%	98.3%	97.9%
SAU802261	KPN304473	24%	98.7%	97.6%
SAU802261	LPN100210	22%	99.1%	97.0%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802261	LPN100247	22%	98.8%	98.4%
SAU802261	MCA102709	23%	98.6%	98.7%
SAU802261	NGO100607	22%	98.7%	97.1%
SAU802261	NME201818	23%	98.7%	97.1%
SAU802261	PMU101132	23%	97.6%	96.5%
SAU802261	PRT102325	24%	97.4%	95.7%
SAU802261	PAE202524	24%	98.3%	46.8%
SAU802261	PPU103094	25%	98.3%	98.8%
SAU802261	PSY102999	24%	98.9%	98.3%
SAU802261	SPA104062	22%	96.5%	97.5%
SAU802261	STY104173	24%	98.6%	97.0%
SAU802261	STM103910	23%	98.6%	97.0%
SAU802261	SAU802261	100%	100%	100%
SAU802261	SEP200295	75%	100%	99.7%
SAU802261	SHA100824	74%	99.1%	94.8%
SAU802261	VCH100898	23%	98.7%	97.1%
SAU802261	YPS003137	24%	50.4%	96.9%
SAU802262	BFR104711	26%	22.3%	25.9%
SAU802262	BBU100585	21%	93.6%	95.1%
SAU802262	CAC101449	29%	23.8%	32.4%
SAU802262	SAU802262	100%	100%	100%
SAU802262	SEP200301	80%	100%	100%
SAU802262	SHA100823	78%	100%	100%
SAU802262	SPN400540	26%	98.8%	98.3%
SAU802262	SPY200444	29%	91.9%	92.2%
SAU802273	ABA105779	30%	92.4%	94.2%
SAU802273	BAN100337	38%	97.6%	99.3%
SAU802273	BAN108929	48%	92.6%	98.5%
SAU802273	BAN104661	48%	98.8%	97.4%
SAU802273	BAN112052	50%	98.6%	95.9%
SAU802273	BAN113492	52%	97.4%	96.0%
SAU802273	BPT101119	31%	86.9%	89.5%
SAU802273	BCE114366	32%	90.2%	89.3%
SAU802273	BFU101148	33%	82.3%	83.0%
SAU802273	BMA103156	33%	83.8%	76.8%
SAU802273	CJU101433	28%	90.0%	93.2%
SAU802273	CAC103575	31%	88.3%	90.9%
SAU802273	CBO100240	28%	94.7%	97.8%
SAU802273	CDF101730	34%	90.2%	93.9%
SAU802273	CDP101687	29%	84.0%	86.8%
SAU802273	EBC102785	30%	94.7%	96.1%
SAU802273	EFA202358	31%	91.9%	95.8%
SAU802273	ECO100803	29%	90.0%	90.8%
SAU802273	HIN101417	33%	89.3%	91.8%
SAU802273	HPY100169	27%	87.4%	90.8%
SAU802273	KPN302747	31%	76.1%	76.4%
SAU802273	LMO100059	36%	97.6%	99.8%
SAU802273	MCA101689	35%	93.1%	94.1%
SAU802273	MAV101757	32%	90.7%	93.8%
SAU802273	MBV106113	32%	86.9%	93.6%
SAU802273	MLP100130	25%	94.3%	97.6%
SAU802273	MTU200437	31%	90.9%	94.8%
SAU802273	PMU100694	33%	94.7%	97.8%
SAU802273	PRT102031	28%	95.2%	95.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802273	PAE203911	30%	83.1%	84.3%
SAU802273	PAE203026	30%	90.5%	91.1%
SAU802273	PPU103226	30%	85.0%	86.0%
SAU802273	PSY102581	32%	78.8%	80.2%
SAU802273	SPA100308	26%	76.1%	89.3%
SAU802273	STY102410	30%	76.1%	76.0%
SAU802273	SAU802273	100%	100%	100%
SAU802273	SEP200335	74%	100%	100%
SAU802273	SHA101561	77%	100%	100%
SAU802273	VCH101503	31%	90.2%	61.6%
SAU802273	YPS002254	27%	95.2%	93.4%
SAU802275	BAN104975	53%	92.9%	91.7%
SAU802275	BPT101121	40%	86.3%	82.7%
SAU802275	BCE102933	33%	75%	63.9%
SAU802275	BFU100752	32%	75%	59.2%
SAU802275	BMA109380	35%	75%	62.6%
SAU802275	CJU100675	35%	83.9%	78.9%
SAU802275	CAC100345	36%	88.7%	89.1%
SAU802275	CBO103886	34%	85.1%	87.7%
SAU802275	CDF101203	41%	58.3%	58.7%
SAU802275	EBC102209	43%	87.5%	85.3%
SAU802275	EFA202344	32%	91.7%	93.1%
SAU802275	ECO100758	44%	87.5%	85.3%
SAU802275	HIN100319	32%	89.9%	77.2%
SAU802275	HPY100786	35%	84.5%	81.2%
SAU802275	KPN303581	43%	87.5%	85.3%
SAU802275	LMO101377	45%	92.9%	95.1%
SAU802275	MCA101697	47%	86.9%	76.2%
SAU802275	MAV104045	30%	92.3%	95%
SAU802275	MBV100621	30%	80.4%	73.5%
SAU802275	MLP100125	30%	91.7%	83.4%
SAU802275	MTU200973	30%	80.4%	73.5%
SAU802275	PMU102003	31%	85.7%	75.5%
SAU802275	PRT105678	31%	84.5%	73.3%
SAU802275	PAE203912	38%	86.3%	77.3%
SAU802275	PAE203027	44%	86.3%	79.9%
SAU802275	PPU101702	43%	86.3%	79.9%
SAU802275	PSY109125	43%	86.3%	79.9%
SAU802275	SPA102733	45%	87.5%	85.3%
SAU802275	STY102331	45%	87.5%	85.3%
SAU802275	STM102090	45%	87.5%	85.3%
SAU802275	SAU802275	100%	100%	100%
SAU802275	SEP200340	66%	98.8%	95.5%
SAU802275	SHA101559	73%	100%	98.2%
SAU802275	VCH101006	47%	86.3%	84.1%
SAU802275	YPS000774	28%	89.9%	77.9%
SAU802276	ABA105442	31%	65.6%	84.1%
SAU802276	BAN103191	31%	99.1%	99.4%
SAU802276	BAN103239	35%	98.8%	99.1%
SAU802276	BAN100839	43%	94.6%	95.0%
SAU802276	BAN102602	44%	94.6%	95.0%
SAU802276	BAN107456	42%	98.8%	99.1%
SAU802276	BAN112551	43%	99.1%	99.4%
SAU802276	BAN105516	43%	99.4%	99.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802276	BFR102200	32%	41.9%	61.3%
SAU802276	BPT100891	29%	71.6%	90.9%
SAU802276	BCE105273	28%	37.7%	72.9%
SAU802276	BFU102717	32%	60.8%	81.0%
SAU802276	BMA107045	32%	60.8%	81.0%
SAU802276	CDP101620	31%	65.6%	64.8%
SAU802276	EBC102784	31%	71.6%	96.7%
SAU802276	EFA202445	31%	45.5%	40.3%
SAU802276	ECO103890	33%	71.6%	96.7%
SAU802276	HIN101418	32%	60.5%	82.7%
SAU802276	HPY100801	32%	53.9%	69.4%
SAU802276	KPN302744	31%	71.6%	94.8%
SAU802276	LPN101229	33%	60.2%	53.6%
SAU802276	LMO101764	34%	98.8%	99.4%
SAU802276	MCA103599	32%	71.3%	90.2%
SAU802276	MCA100944	30%	71.6%	93.3%
SAU802276	MAV102617	29%	61.1%	52.3%
SAU802276	MBV102230	30%	72.8%	62.5%
SAU802276	MLP100495	29%	61.1%	52.7%
SAU802276	MTU203076	30%	72.8%	62.5%
SAU802276	NGO101068	31%	71.6%	93.4%
SAU802276	NME200347	31%	71.6%	93.4%
SAU802276	PMU100695	33%	60.5%	84.5%
SAU802276	PRT101552	39%	62.0%	82.7%
SAU802276	PAE204660	34%	60.8%	80.6%
SAU802276	PPU109704	36%	60.8%	80.9%
SAU802276	PSY102406	34%	60.8%	78.4%
SAU802276	SPA100132	29%	71.6%	95.6%
SAU802276	STY102652	32%	71.6%	94.0%
SAU802276	SAU802276	100%	100%	100%
SAU802276	SEP200343	68%	99.4%	99.7%
SAU802276	SHA101558	72%	100%	100%
SAU802276	SPN400608	32%	36.8%	37.7%
SAU802276	VCH103341	31%	71.3%	93.7%
SAU802276	YPS000463	29%	71.6%	94.0%
SAU802288	ABA104364	64%	100%	48.3%
SAU802288	BPT101328	64%	100%	100%
SAU802288	BCE114774	65%	99%	47.8%
SAU802288	BFU110403	65%	99%	81.8%
SAU802288	BMA101403	63%	99%	43.4%
SAU802288	EBC101014	62%	100%	38.3%
SAU802288	ECO201397	61%	100%	100%
SAU802288	ECO205623	61%	100%	100%
SAU802288	HIN100520	58%	99%	99%
SAU802288	KPN300384	60%	66%	80.5%
SAU802288	KPN307408	63%	100%	100%
SAU802288	MBV102038	62%	99%	99%
SAU802288	MTU201815	62%	99%	99%
SAU802288	PAE204860	66%	99%	99%
SAU802288	PPU110641	64%	99%	47.4%
SAU802288	PSY101839	61%	99%	99%
SAU802288	SAU802288	100%	100%	100%
SAU802288	SEP101087	92%	100%	48.3%
SAU802288	UUR100439	59%	99%	98.0%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802288	YPS001366	52%	99%	99%
SAU802290	ABA103748	60%	99.5%	99.8%
SAU802290	BPT101319	57%	99.5%	99.6%
SAU802290	BCE105583	60%	100%	100%
SAU802290	BFU110328	60%	100%	100%
SAU802290	BMA103367	60%	100%	100%
SAU802290	EBC100116	66%	50.8%	98.3%
SAU802290	EFM200086	28%	12.4%	13.9%
SAU802290	ECO205553	62%	100%	100%
SAU802290	ECO201399	62%	100%	100%
SAU802290	HIN100518	59%	100%	100%
SAU802290	HPY100070	57%	99.5%	99.6%
SAU802290	KPN304109	62%	99.3%	99.5%
SAU802290	LMO100028	36%	22.1%	19.5%
SAU802290	MBV102006	55%	99.5%	99.7%
SAU802290	MTU201817	55%	99.5%	99.7%
SAU802290	PRT105539	61%	99.3%	72.4%
SAU802290	PAE204863	59%	99.5%	99.8%
SAU802290	PPU110642	59%	99.3%	99.5%
SAU802290	PSY100871	60%	99.5%	99.8%
SAU802290	SAU802290	100%	100%	100%
SAU802290	SEP200371	90%	100%	70.4%
SAU802290	UUR100437	57%	99.6%	99.8%
SAU802290	YPS001373	54%	99.1%	99.3%
SAU802292	ABA102930	22%	97.4%	59.2%
SAU802292	BPT101315	21%	65.9%	76.3%
SAU802292	BCE112587	23%	96.5%	96.5%
SAU802292	BFU110332	23%	96.5%	96.5%
SAU802292	BMA109613	25%	96.5%	56.0%
SAU802292	EBC101190	21%	97.4%	96.9%
SAU802292	ECO201401	19%	97.4%	96.9%
SAU802292	ECO205579	19%	97.4%	96.9%
SAU802292	HIN100516	22%	80.8%	97.4%
SAU802292	HPY100067	26%	96.5%	86.6%
SAU802292	KPN304125	20%	97.4%	96.9%
SAU802292	MBV102008	24%	47.6%	49.3%
SAU802292	MTU201818	24%	47.6%	49.3%
SAU802292	PRT104531	25%	81.2%	89.3%
SAU802292	PAE204887	26%	95.6%	96.4%
SAU802292	PPU110665	20%	97.4%	96.9%
SAU802292	PSY100980	20%	96.5%	97.3%
SAU802292	STY101858	35%	24.5%	37.3%
SAU802292	SAU802292	100%	100%	100%
SAU802292	SEP200375	76%	100%	100%
SAU802292	UUR100435	40%	97.4%	90%
SAU802292	YPS001379	23%	96.5%	96.5%
SAU802293	ABA102567	60%	97.5%	97.5%
SAU802293	BPT100743	61%	97.5%	93.0%
SAU802293	BCE100299	62%	96.6%	91.6%
SAU802293	BFU110334	62%	97.1%	91.2%
SAU802293	BMA101911	61%	96.6%	91.2%
SAU802293	CJU100584	30%	78.9%	61.1%
SAU802293	CBO101376	28%	90.2%	78.0%
SAU802293	CDP100866	31%	92.2%	71.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802293	EBC101191	58%	94.1%	94.6%
SAU802293	ECO102667	27%	89.2%	59.3%
SAU802293	HIN100515	62%	99.5%	90.2%
SAU802293	HPY100066	61%	96.6%	99.0%
SAU802293	KPN304128	63%	97.1%	96.6%
SAU802293	LPN100384	30%	88.7%	67.9%
SAU802293	MBV102011	51%	98.0%	89.3%
SAU802293	MTU201819	51%	98.0%	89.3%
SAU802293	PRT102194	62%	93.6%	93.2%
SAU802293	PAE204888	58%	97.5%	97.5%
SAU802293	PPU110666	64%	93.6%	92.3%
SAU802293	PSY106880	57%	97.5%	97.1%
SAU802293	SPA101916	26%	89.2%	59.3%
SAU802293	STY102828	26%	89.2%	59.3%
SAU802293	STM103657	26%	89.2%	59.3%
SAU802293	SAU802293	100%	100%	100%
SAU802293	SEP200377	90%	100%	100%
SAU802293	UUR100434	71%	96.1%	95.6%
SAU802293	YPS001381	58%	95.1%	89.5%
SAU802308	BAN111346	23%	75.8%	96%
SAU802308	BAN104126	26%	68.8%	95.6%
SAU802308	BAN104809	28%	93.6%	92.5%
SAU802308	LMO101374	28%	96.2%	95.6%
SAU802308	SAU802308	100%	100%	100%
SAU802308	SHA101510	78%	100%	99.4%
SAU802309	ABA105410	27%	70.5%	78.5%
SAU802309	BAN111819	47%	98.6%	100%
SAU802309	BAN104504	48%	97.1%	98.0%
SAU802309	BAN108797	55%	98.6%	98.9%
SAU802309	BAN107861	56%	99.2%	99.5%
SAU802309	BFR102378	31%	7.2%	8.6%
SAU802309	BPT101897	29%	72.7%	94.8%
SAU802309	BCE100301	33%	86.3%	95.5%
SAU802309	BFU109099	33%	94.7%	91.4%
SAU802309	BMA102600	32%	99.1%	95.1%
SAU802309	CJU101426	27%	52.6%	58.4%
SAU802309	CAC102909	27%	20.4%	34.9%
SAU802309	CBO103110	26%	20.8%	36.6%
SAU802309	CDF102669	33%	53.9%	94.8%
SAU802309	EBC104465	34%	69.4%	96.4%
SAU802309	EFA202359	33%	95.2%	99.0%
SAU802309	ECO103973	35%	69.4%	96.2%
SAU802309	HIN101025	23%	49.8%	65.5%
SAU802309	HPY101249	22%	44.7%	46.1%
SAU802309	KPN300210	34%	8.1%	59.9%
SAU802309	KPN300277	25%	11.7%	93.5%
SAU802309	KPN300272	37%	14.4%	82.4%
SAU802309	KPN303260	32%	69.4%	96.2%
SAU802309	LPN103373	23%	76.1%	84.0%
SAU802309	LMO101763	54%	98.5%	97.1%
SAU802309	MCA101207	20%	83.2%	82.2%
SAU802309	MAV100466	29%	18.0%	93.3%
SAU802309	MAV103718	30%	20.1%	97.2%
SAU802309	MAV102918	30%	31.8%	32.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802309	MAV102797	32%	48.8%	97.0%
SAU802309	MBV102300	27%	34.2%	44.8%
SAU802309	MTU202862	27%	34.2%	44.8%
SAU802309	NGO100650	23%	75.2%	82.1%
SAU802309	NME200010	23%	75.2%	82.1%
SAU802309	PMU101594	28%	69.2%	95.3%
SAU802309	PRT106150	34%	69.1%	95.0%
SAU802309	PAE201778	30%	69.4%	77.3%
SAU802309	PPU106426	34%	94.2%	94.3%
SAU802309	PSY105562	29%	68.9%	76.8%
SAU802309	SPA101768	35%	69.1%	100%
SAU802309	STY102346	35%	69.4%	96.2%
SAU802309	STM101130	22%	63.4%	84.5%
SAU802309	SAU802309	100%	100%	100%
SAU802309	SHA101509	84%	90.5%	100%
SAU802309	VCH103400	28%	66.8%	91.9%
SAU802309	YPS003389	33%	69.5%	96.2%
SAU802310	BAN106020	40%	96.2%	99.7%
SAU802310	BAN100582	40%	96.8%	99.0%
SAU802310	CAC101564	31%	93.7%	90.0%
SAU802310	CAC101142	32%	94.9%	93.2%
SAU802310	CBO100290	30%	98.4%	72.9%
SAU802310	CDP100702	36%	55.6%	39.7%
SAU802310	EFA200704	36%	97.1%	99.0%
SAU802310	EFM200695	38%	98.1%	97.5%
SAU802310	LMO102536	33%	99.4%	97.8%
SAU802310	MAV105446	29%	69.5%	35.9%
SAU802310	MBV101890	26%	58.4%	33.5%
SAU802310	MLP100452	30%	60.6%	47.2%
SAU802310	MTU200816	26%	58.4%	33.5%
SAU802310	SAU802310	100%	100%	100%
SAU802310	SEP200407	76%	99.7%	99.4%
SAU802310	SHA101993	49%	98.1%	98.7%
SAU802310	SMU100754	29%	93.0%	74.9%
SAU802310	SPN401757	29%	94.0%	90.2%
SAU802310	SPY201332	30%	97.1%	75%
SAU802328	ABA103559	40%	91.1%	91.4%
SAU802328	BAN100208	35%	98.0%	97.9%
SAU802328	BAN105602	43%	98.3%	99.3%
SAU802328	BCE104059	55%	47.1%	75.8%
SAU802328	BCE105925	52%	86.3%	100%
SAU802328	BFU103430	45%	97.3%	98.6%
SAU802328	BMA102007	42%	92.5%	94.4%
SAU802328	CAC103127	44%	96.9%	93.0%
SAU802328	CBO102575	42%	93.2%	92.5%
SAU802328	EBC103168	57%	96.2%	97.6%
SAU802328	EFA200150	50%	99.0%	97.6%
SAU802328	EFM200978	49%	98.6%	97.3%
SAU802328	ECO102937	60%	97.6%	97.3%
SAU802328	KPN305078	55%	94.2%	90.2%
SAU802328	LMO101848	60%	100%	99.7%
SAU802328	MAV106410	45%	67.9%	97.5%
SAU802328	PAE202140	40%	96.6%	97.9%
SAU802328	PPU105455	45%	96.6%	98.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802328	PSY101078	46%	94.9%	96.5%
SAU802328	SPA103631	59%	97.3%	96.9%
SAU802328	STY100437	60%	97.3%	96.9%
SAU802328	STM101187	60%	97.3%	96.9%
SAU802328	SAU802328	100%	100%	100%
SAU802328	SEP200449	82%	100%	100%
SAU802328	SHA100524	84%	100%	100%
SAU802331	ABA105800	62%	98.6%	97.7%
SAU802331	BAN106204	54%	98.2%	98.9%
SAU802331	BAN105173	68%	98.4%	98.6%
SAU802331	BFR10261	34%	94.2%	81.8%
SAU802331	BCE104672	58%	58.2%	100%
SAU802331	BFU113421	61%	99.1%	97.5%
SAU802331	BMA109225	62%	99.1%	97.5%
SAU802331	EBC100807	58%	59.3%	100%
SAU802331	KPN301790	60%	98.4%	96.8%
SAU802331	LPN101472	60%	98.6%	98.2%
SAU802331	MCA101940	58%	98.7%	100%
SAU802331	PAE205095	62%	98.6%	97.5%
SAU802331	PPU106762	61%	98.6%	97.8%
SAU802331	PSY101331	62%	96.9%	94.4%
SAU802331	SPA101433	57%	98.2%	99.4%
SAU802331	STY102299	60%	98.4%	97.0%
SAU802331	STM101870	38%	9.9%	6.8%
SAU802331	SAU802331	100%	100%	100%
SAU802331	SPN400943	29%	11.6%	31.5%
SAU802331	SPY201590	36%	94.0%	79.9%
SAU802331	VCH101184	60%	98.9%	96.3%
SAU802331	YPS002693	60%	98.6%	96.8%
SAU802332	BPT100588	25%	97.6%	90.9%
SAU802332	BFU102473	22%	92.9%	91.4%
SAU802332	CBO102863	25%	97.3%	97.3%
SAU802332	EBC101843	25%	82.7%	82.5%
SAU802332	EFM102228	25%	78.6%	92.7%
SAU802332	ECO201939	26%	82.7%	82.3%
SAU802332	KPN307471	23%	94.9%	96.0%
SAU802332	MAV102104	23%	87.8%	81.9%
SAU802332	MBV105077	23%	79.3%	75.3%
SAU802332	MLP101570	23%	79.3%	76.8%
SAU802332	MTU200117	23%	79.3%	75.8%
SAU802332	PPU109373	29%	20.7%	20.5%
SAU802332	PPU101916	24%	92.5%	93.3%
SAU802332	PSY104413	24%	97.3%	94.2%
SAU802332	SPA103068	25%	80.6%	77.0%
SAU802332	STY104272	25%	80.6%	81.0%
SAU802332	STM101851	26%	81.0%	77.6%
SAU802332	SAU802332	100%	100%	100%
SAU802333	BAN111465	58%	98.6%	100%
SAU802333	BAN104289	58%	98.6%	100%
SAU802333	BAN108891	65%	99.3%	99.3%
SAU802333	BAN102504	64%	99.3%	100%
SAU802333	BCE105683	26%	78.4%	92.9%
SAU802333	BFU114968	32%	80.6%	20.6%
SAU802333	CBO102493	39%	51.1%	87.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802333	EBC103002	34%	96.4%	92.9%
SAU802333	EFA201396	28%	79.1%	93.5%
SAU802333	EFM201766	28%	81.3%	96.7%
SAU802333	ECO100187	29%	83.5%	89.9%
SAU802333	HIN100307	30%	79.9%	88.9%
SAU802333	KPN302981	35%	93.5%	92.1%
SAU802333	LPN101860	46%	23.0%	61.5%
SAU802333	LMO101925	35%	93.5%	100%
SAU802333	NGO101565	26%	78.4%	87.4%
SAU802333	NME201984	27%	78.4%	85.5%
SAU802333	PRT100522	28%	84.2%	96.9%
SAU802333	PAE201128	35%	94.2%	93.3%
SAU802333	PPU108454	24%	82.0%	83.2%
SAU802333	SPA101410	27%	79.1%	88.1%
SAU802333	STY100607	27%	79.1%	88.1%
SAU802333	SAU802333	100%	100%	100%
SAU802333	SEP202219	62%	98.6%	96.5%
SAU802333	SMU101103	25%	79.1%	90%
SAU802333	SPN400864	24%	83.5%	85.3%
SAU802333	YPS002942	27%	79.1%	88.1%
SAU802335	CBO103499	20%	58.0%	68.6%
SAU802335	CDF103594	24%	43.2%	87.3%
SAU802335	SAU802335	100%	100%	100%
SAU802335	SEP200455	58%	100%	99.5%
SAU802335	SHA103355	56%	100%	99.7%
SAU802341	ABA100592	34%	72.6%	18.3%
SAU802341	BAN106164	42%	18.1%	53.5%
SAU802341	BAN101097	46%	98.0%	99.3%
SAU802341	BFR10398	27%	92.0%	97.2%
SAU802341	BPT100190	32%	70.2%	61.0%
SAU802341	BCE110810	30%	75.6%	91.9%
SAU802341	BFU103371	31%	70.2%	84.7%
SAU802341	BMA108770	30%	75.6%	91.9%
SAU802341	CJU100624	32%	78.3%	98.8%
SAU802341	CAC101062	27%	98.7%	98.4%
SAU802341	CAC101497	28%	99.3%	99.0%
SAU802341	CBO100997	30%	98.0%	97.4%
SAU802341	CDF103190	30%	97.0%	97.7%
SAU802341	CDP101422	32%	77.6%	85.3%
SAU802341	EBC103391	27%	99.3%	97.7%
SAU802341	EFA202336	42%	99.0%	99.3%
SAU802341	EFM200486	41%	99.3%	99.7%
SAU802341	ECO100770	31%	97.3%	4.8%
SAU802341	HPY100705	32%	71.9%	91.7%
SAU802341	KPN303592	30%	97.3%	4.8%
SAU802341	LMO100853	48%	98.7%	98.7%
SAU802341	MCA101024	30%	75.6%	95.9%
SAU802341	MAV103194	30%	96.0%	89.8%
SAU802341	MBV100156	30%	96.0%	90.7%
SAU802341	MTU201201	30%	96.0%	90.7%
SAU802341	MPN100502	28%	76.9%	72.1%
SAU802341	NGO101385	34%	72.9%	70.8%
SAU802341	NME200704	36%	66.2%	91.7%
SAU802341	PMU100171	29%	77.6%	98.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802341	PRT103445	28%	75.6%	96.3%
SAU802341	PAE203670	31%	97.0%	97.4%
SAU802341	PAE204034	33%	71.6%	70.1%
SAU802341	PPU104145	29%	77.6%	98.8%
SAU802341	PSY100293	30%	77.6%	98.8%
SAU802341	SPA102971	29%	97.3%	5.0%
SAU802341	STM103062	26%	99.3%	97.7%
SAU802341	SAU802341	100%	100%	100%
SAU802341	SMU100271	35%	72.9%	75.2%
SAU802341	SPN401561	40%	96.3%	97.0%
SAU802341	SPY200545	29%	94.0%	93.2%
SAU802341	UUR100092	32%	70.2%	89.8%
SAU802341	VCH102491	32%	77.6%	98.8%
SAU802346	ABA104933	22%	51.6%	44.6%
SAU802346	BAN109344	42%	97.4%	100%
SAU802346	BAN107706	43%	97.4%	97.4%
SAU802346	BBU100683	27%	94.3%	92.8%
SAU802346	BCE111066	25%	23.5%	21.5%
SAU802346	BFU102030	29%	24.4%	20.5%
SAU802346	CBO101704	22%	88.3%	85.2%
SAU802346	CDF103639	24%	46.1%	41.8%
SAU802346	EBC103192	22%	49.3%	43.0%
SAU802346	EFA200385	46%	96.6%	97.4%
SAU802346	EFM202514	45%	96.8%	95.5%
SAU802346	ECO103527	24%	49.3%	41.2%
SAU802346	HIN101704	24%	42.7%	34.1%
SAU802346	KPN305761	21%	53.6%	45.2%
SAU802346	LPN100706	36%	36.7%	70.6%
SAU802346	LPN100340	32%	92.6%	97.4%
SAU802346	LMO101142	43%	98.6%	96.6%
SAU802346	MCA101122	26%	35.0%	26.1%
SAU802346	MAV101346	30%	86.5%	91.6%
SAU802346	MBV104099	24%	36.4%	28.0%
SAU802346	MTU200691	24%	36.4%	28.0%
SAU802346	NGO101059	25%	45.6%	35.6%
SAU802346	NME201451	25%	45.6%	35.6%
SAU802346	PMU100288	23%	31.8%	30.7%
SAU802346	PAE204767	22%	49.3%	42.8%
SAU802346	PPU108584	23%	49.3%	42.8%
SAU802346	STY100378	21%	49.3%	41.2%
SAU802346	STM104153	22%	49.3%	41.2%
SAU802346	SAU802346	100%	100%	100%
SAU802346	SEP200052	76%	99.7%	99.7%
SAU802346	SEP200853	76%	99.7%	99.7%
SAU802346	SHA102078	79%	100%	100%
SAU802346	SMU100940	40%	90.5%	94.0%
SAU802346	SPN400341	40%	90.5%	92.6%
SAU802346	SPY200654	42%	90.5%	94.5%
SAU802346	VCH103702	26%	33.8%	33.3%
SAU802346	YPS003024	24%	43.3%	34.6%
SAU802359	BAN112546	46%	98.2%	100%
SAU802359	BAN108719	49%	98.2%	97.8%
SAU802359	BMA108659	36%	99.5%	94.4%
SAU802359	CDP101457	42%	93.7%	91.0%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802359	LMO101705	48%	100%	100%
SAU802359	SAU802359	100%	100%	100%
SAU802359	SEP200905	70%	99.1%	98.6%
SAU802359	SHA101961	68%	99.1%	99.1%
SAU802360	BFR101675	24%	30.2%	27.9%
SAU802360	BFR101280	28%	31.3%	34.9%
SAU802360	BFR105907	25%	28.2%	25%
SAU802360	BMA100570	24%	33.6%	32.0%
SAU802360	CDF100955	21%	98.9%	44.4%
SAU802360	CDF102346	19%	100%	99.2%
SAU802360	ECO101089	20%	44.7%	41.4%
SAU802360	MTU202526	18%	98.6%	98.6%
SAU802360	SAU802360	100%	100%	100%
SAU802360	SEP200907	53%	100%	100%
SAU802360	SHA102644	56%	100%	100%
SAU802360	VCH103501	30%	33.3%	15.2%
SAU802365	BAN104884	56%	93.5%	96.2%
SAU802365	BAN101178	62%	95.7%	98%
SAU802365	BCE112448	51%	91.4%	89.5%
SAU802365	CJU100361	24%	84.1%	92.4%
SAU802365	CDP100511	49%	95.9%	98.4%
SAU802365	EBC106483	48%	95.7%	89.8%
SAU802365	ECO102168	50%	91.8%	86.1%
SAU802365	HPY100084	23%	84.1%	91.3%
SAU802365	KPN301561	47%	96.1%	90.8%
SAU802365	MAV102823	46%	94.7%	96.4%
SAU802365	MBV100580	46%	94.1%	99.4%
SAU802365	MTU202814	47%	95.1%	98.6%
SAU802365	NGO100920	49%	94.7%	99.2%
SAU802365	NME200310	50%	94.7%	99.2%
SAU802365	PRT100644	49%	94.5%	97.2%
SAU802365	PAE203450	53%	94.5%	93.1%
SAU802365	PPU104014	51%	94.1%	96.0%
SAU802365	PSY100602	49%	94.5%	96.4%
SAU802365	SAU802365	100%	100%	100%
SAU802365	SEP200913	79%	96.3%	100%
SAU802365	SHA101955	77%	96.3%	100%
SAU802365	VCH102882	31%	10.6%	12.9%
SAU802368	SAU802368	100%	100%	100%
SAU802368	SEP200934	44%	99.5%	99.5%
SAU802369	BAN103259	36%	97.7%	97.1%
SAU802369	BAN112183	36%	97.7%	97.1%
SAU802369	BPT100938	43%	26.9%	28.6%
SAU802369	BCE107689	29%	97.1%	95.0%
SAU802369	BFU103812	35%	37.4%	36.8%
SAU802369	BMA103339	24%	60.2%	60.6%
SAU802369	EBC105348	22%	89.5%	89.4%
SAU802369	EFA202072	42%	98.8%	99.4%
SAU802369	EFM200209	35%	97.7%	96.5%
SAU802369	KPN303262	31%	98.2%	97.7%
SAU802369	LMO102096	40%	98.2%	100%
SAU802369	MAV105704	28%	93.6%	89.0%
SAU802369	MBV105099	26%	93.6%	98.1%
SAU802369	MTU202632	26%	93.6%	98.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802369	NME200232	28%	43.3%	42.9%
SAU802369	PRT106021	25%	78.9%	79.1%
SAU802369	PPU108805	28%	48.0%	49.7%
SAU802369	PSY102532	24%	97.1%	94.3%
SAU802369	SPA102323	26%	67.8%	72.3%
SAU802369	STY103987	32%	46.8%	46.2%
SAU802369	SAU802369	100%	100%	100%
SAU802369	SEP202650	51%	97.7%	93.3%
SAU802369	SHA100368	52%	100%	100%
SAU802369	SMU100484	36%	97.7%	96.5%
SAU802369	SPN400508	36%	98.2%	99.4%
SAU802369	SPY101945	37%	93.0%	97.0%
SAU802369	VCH101321	34%	32.2%	34.8%
SAU802369	YPS000948	31%	46.8%	47.3%
SAU802371	BAN103862	34%	36.8%	32.2%
SAU802371	BFR102730	26%	59.4%	52.7%
SAU802371	BCE108880	26%	70.7%	61.2%
SAU802371	BFU115699	25%	65.4%	63.9%
SAU802371	CAC101368	28%	89.5%	86.4%
SAU802371	EBC104604	29%	39.8%	32.6%
SAU802371	KPN302220	43%	91.7%	86.3%
SAU802371	LMO101023	42%	94.7%	92.7%
SAU802371	PRT104530	29%	66.2%	28.2%
SAU802371	SAU802371	100%	100%	100%
SAU802371	SEP200943	68%	100%	100%
SAU802371	SHA101897	60%	100%	100%
SAU802371	SMU100213	38%	35.3%	26.1%
SAU802371	SPN400237	30%	49.6%	47.8%
SAU802372	BAN103594	38%	32.9%	85.8%
SAU802372	BAN100580	37%	63.1%	98.6%
SAU802372	BAN108168	43%	99.1%	94.0%
SAU802372	BFU101355	27%	91.8%	85.6%
SAU802372	EFA200225	31%	93.1%	90.2%
SAU802372	EFM200250	32%	91.5%	89.5%
SAU802372	LMO102184	33%	96.1%	94.3%
SAU802372	SAU802372	100%	100%	100%
SAU802372	SHA101896	68%	99.7%	96.2%
SAU802372	SMU100809	34%	91.8%	90.4%
SAU802372	SPN401420	32%	93.1%	92.9%
SAU802372	SPY200633	34%	91.8%	90.9%
SAU802378	PRT102873	30%	41.8%	29.1%
SAU802378	SAU802378	100%	100%	100%
SAU802378	SEP200955	54%	65.2%	82.4%
SAU802378	SHA100322	56%	65.2%	83.1%
SAU802378	SPY200567	35%	50.6%	65.6%
SAU802389	BAN103843	25%	58.9%	77.4%
SAU802389	BAN108506	23%	68.1%	74.8%
SAU802389	CDF101015	40%	98.4%	95%
SAU802389	SAU802389	100%	100%	100%
SAU802389	SEP100573	38%	15.1%	50%
SAU802389	SMU101334	42%	97.4%	97.7%
SAU802389	UUR100585	22%	79.6%	44.1%
SAU802390	ABA100515	30%	38.2%	92.2%
SAU802390	BAN111977	22%	93.5%	98.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802390	BAN110775	23%	93.5%	96.3%
SAU802390	BPT104469	25%	39.0%	71.5%
SAU802390	BCE109138	32%	37.0%	44.2%
SAU802390	BMA105986	34%	37.0%	63.9%
SAU802390	CAC101199	26%	93.5%	97.9%
SAU802390	CBO101857	24%	95.9%	98.8%
SAU802390	CDF102948	27%	58.5%	55.3%
SAU802390	CDF101305	33%	46.3%	41.6%
SAU802390	CDF102920	26%	93.1%	96.4%
SAU802390	CDP101417	21%	92.7%	94.1%
SAU802390	EBC101808	30%	40.7%	97.1%
SAU802390	EFA201158	26%	95.5%	98.4%
SAU802390	EFM202323	24%	93.1%	97.6%
SAU802390	KPN307759	31%	37.0%	93.9%
SAU802390	LMO101047	25%	94.7%	98.8%
SAU802390	MAV100400	29%	40.2%	33.1%
SAU802390	PRT100890	31%	38.6%	94.1%
SAU802390	PPU110548	26%	46.7%	89.8%
SAU802390	STM103457	28%	38.2%	90.9%
SAU802390	SAU802390	100%	100%	100%
SAU802390	SEP200173	33%	96.3%	98.8%
SAU802390	SHA101547	30%	94.7%	95.4%
SAU802390	SMU101335	41%	95.1%	98.4%
SAU802390	SPN400649	30%	47.6%	56.4%
SAU802390	VCH100958	24%	40.7%	77.0%
SAU802390	YPS003904	24%	52.0%	45.5%
SAU802397	BAN101011	45%	99.0%	99.3%
SAU802397	BAN102461	58%	99.6%	99.1%
SAU802397	BMA109820	49%	98.9%	92.5%
SAU802397	CDP101676	60%	26.0%	97.0%
SAU802397	EBC101930	47%	57.4%	98.3%
SAU802397	ECO101197	49%	99.3%	98.2%
SAU802397	KPN305068	48%	99.4%	98.3%
SAU802397	MCA101683	49%	99.5%	98.2%
SAU802397	MAV100250	49%	98.9%	95.3%
SAU802397	MBV101452	49%	98.9%	98.1%
SAU802397	MTU201146	49%	98.9%	98.1%
SAU802397	PRT105206	49%	97.9%	96.5%
SAU802397	PAE203872	49%	99.6%	97.9%
SAU802397	SPA102910	47%	52.2%	100%
SAU802397	STY102963	50%	98.7%	97.5%
SAU802397	STM100368	49%	98.0%	96.9%
SAU802397	SAU802397	100%	100%	100%
SAU802397	SEP202550	86%	100%	100%
SAU802397	SHA101605	86%	100%	100%
SAU802398	ABA103247	41%	73.5%	52.3%
SAU802398	BAN106629	40%	73.8%	75.5%
SAU802398	BANI12655	41%	73.8%	50.6%
SAU802398	BFR12474	22%	74.5%	39.6%
SAU802398	BPT100993	36%	73.5%	48.7%
SAU802398	BCE103181	34%	74.5%	98.8%
SAU802398	BFU106371	39%	71.1%	91.6%
SAU802398	BMA101721	38%	71.7%	83.1%
SAU802398	CAC103696	37%	73.8%	48.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802398	CBO100144	36%	73.5%	49.0%
SAU802398	CDF102901	38%	83.1%	54.4%
SAU802398	CDP100485	40%	64.9%	98.6%
SAU802398	EBC103863	36%	76.3%	53.6%
SAU802398	ECO103291	37%	76.3%	53.6%
SAU802398	KPN306621	38%	71.7%	49.0%
SAU802398	LMO101561	35%	85.5%	56.8%
SAU802398	MCA103517	38%	72.3%	52.3%
SAU802398	MAV102832	34%	72.3%	59.1%
SAU802398	MBV103227	34%	72%	58.3%
SAU802398	MTU202809	34%	72%	58.3%
SAU802398	NME201254	38%	77.8%	53.1%
SAU802398	PRT104849	36%	73.5%	51.3%
SAU802398	PAE202609	41%	71.7%	50.1%
SAU802398	PPU100873	41%	72.9%	51.2%
SAU802398	PSY104166	41%	73.8%	51.7%
SAU802398	SPA103180	35%	76.3%	53.6%
SAU802398	STY101423	35%	76.3%	53.6%
SAU802398	STM102832	36%	76.3%	53.6%
SAU802398	SAU802398	100%	100%	100%
SAU802398	SEP201014	60%	94.2%	97.7%
SAU802398	SHA101604	59%	96.3%	99.7%
SAU802398	SPY100086	33%	38.8%	40.9%
SAU802398	VCH102524	38%	71.7%	77.3%
SAU802398	YPS000102	37%	78.5%	53.6%
SAU802399	ABA103234	36%	80.8%	83.2%
SAU802399	BAN109784	56%	98.1%	82.9%
SAU802399	BAN101731	56%	98.1%	86.4%
SAU802399	BPT100852	27%	94.2%	95.1%
SAU802399	BCE102364	37%	60.6%	59.3%
SAU802399	BMA104059	41%	94.2%	63.6%
SAU802399	EBC103872	29%	92.3%	94.4%
SAU802399	ECO103289	31%	90.4%	92.6%
SAU802399	KPN303056	35%	75%	72.9%
SAU802399	LPN102471	32%	52.9%	47.0%
SAU802399	MAV106074	31%	90.4%	81.0%
SAU802399	MBV100699	68%	18.3%	6.2%
SAU802399	MTU203475	40%	42.3%	11.4%
SAU802399	PAE201779	36%	94.2%	90.7%
SAU802399	PSY107850	41%	30.8%	43.6%
SAU802399	SAU802399	100%	100%	100%
SAU802399	SEP201015	69%	100%	100%
SAU802399	SHA101603	76%	100%	100%
SAU802399	YPS000211	28%	92.3%	90.6%
SAU802400	ABA101297	35%	99.0%	94.9%
SAU802400	BAN105525	60%	21.7%	97.8%
SAU802400	BAN103462	47%	99.8%	100%
SAU802400	BAN107337	57%	77.7%	99.4%
SAU802400	BPT100841	31%	35.8%	68.6%
SAU802400	BCE101590	33%	70.4%	75.8%
SAU802400	BFU104746	33%	99.3%	93.3%
SAU802400	BMA109485	49%	97.8%	97.2%
SAU802400	CAC102162	30%	48.6%	97.1%
SAU802400	CBO101506	28%	45.8%	89.0%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802400	CDF102934	28%	48.7%	45.6%
SAU802400	EBC103870	35%	99.0%	95.2%
SAU802400	ECO103288	35%	99.0%	95.2%
SAU802400	KPN300216	41%	12.2%	79.4%
SAU802400	KPN303469	33%	99.4%	97.1%
SAU802400	MCA101622	28%	41.4%	71.9%
SAU802400	MAV102348	33%	93.4%	91.2%
SAU802400	MBV104807	33%	97.8%	82.6%
SAU802400	MTU200251	33%	98.0%	93.4%
SAU802400	PRT105408	35%	99.4%	95.0%
SAU802400	PAE201780	48%	99.5%	98.8%
SAU802400	PPU107970	33%	94.6%	90.1%
SAU802400	PSY104967	34%	94.3%	79.7%
SAU802400	SPA103178	36%	39.0%	65.3%
SAU802400	STY101426	35%	99.5%	95.4%
SAU802400	STM102828	35%	99.0%	95.2%
SAU802400	SAU802400	100%	100%	100%
SAU802400	SEP201017	82%	100%	100%
SAU802400	SHA101602	84%	99.8%	100%
SAU802400	YPS001671	34%	99.4%	95.0%
SAU802401	BAN101769	25%	49.4%	73.3%
SAU802401	BAN106436	21%	88.1%	91.1%
SAU802401	BAN106118	20%	97.9%	95.2%
SAU802401	BAN109894	27%	96.7%	97.9%
SAU802401	BCE113179	19%	49.8%	96.9%
SAU802401	BFU104281	25%	42.0%	78.2%
SAU802401	BMA108024	20%	41.6%	80.5%
SAU802401	MAV101627	25%	85.2%	86.1%
SAU802401	SAU802401	100%	100%	100%
SAU802401	SEP201019	55%	98.4%	100%
SAU802401	SHA101601	49%	97.5%	98.7%
SAU802401	YPS002784	31%	33.3%	9.3%
SAU802418	LPN101927	20%	49.1%	32.6%
SAU802418	PSY104376	28%	21.0%	32.1%
SAU802418	SAU802418	100%	100%	100%
SAU802418	SAU800111	28%	37.9%	49.8%
SAU802418	VCH101393	28%	19.6%	14.9%
SAU802419	BAN101272	21%	87.1%	89.5%
SAU802419	BAN107130	21%	88.3%	89.9%
SAU802419	SAU801819	33%	89.0%	84.9%
SAU802419	SAU802421	29%	98.1%	95.4%
SAU802419	SAU802004	29%	92.2%	91.1%
SAU802419	SAU801163	25%	95.5%	96.9%
SAU802419	SAU802005	34%	87.4%	77.8%
SAU802419	SAU802420	67%	98.4%	99.0%
SAU802419	SAU801820	70%	98.4%	99.0%
SAU802419	SAU802419	100%	100%	100%
SAU802425	ABA100387	33%	89.9%	91.8%
SAU802425	BAN102051	49%	94.3%	96.9%
SAU802425	BAN104523	52%	94.3%	95.2%
SAU802425	BPT101142	33%	87.5%	87.4%
SAU802425	BCE111317	34%	82.1%	78.5%
SAU802425	BFU107999	31%	95.2%	87.6%
SAU802425	BMA105033	33%	88.7%	87.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802425	CJU101589	33%	80.3%	97.1%
SAU802425	CPN200793	31%	89.3%	90.9%
SAU802425	CAC101689	37%	94.3%	97.3%
SAU802425	CBO100552	37%	93.4%	97.5%
SAU802425	CDF101504	38%	94.6%	98.5%
SAU802425	CDP101447	34%	93.4%	94.9%
SAU802425	EBC101268	33%	85.1%	86.8%
SAU802425	ECO100751	33%	85.1%	83.5%
SAU802425	HIN101001	30%	85.7%	86.5%
SAU802425	HPY101386	30%	80.3%	96.8%
SAU802425	KPN301793	33%	89.0%	87.3%
SAU802425	LPN101546	35%	84.8%	90.3%
SAU802425	MCA102956	34%	90.1%	89.3%
SAU802425	MAV100547	33%	92.2%	79.9%
SAU802425	MBV101758	32%	92.2%	85.2%
SAU802425	MLP100755	33%	92.2%	89.9%
SAU802425	MTU201568	32%	92.2%	89.1%
SAU802425	NGO100345	29%	80.3%	77.4%
SAU802425	NME201245	30%	82.1%	79.4%
SAU802425	PMU100379	31%	88.4%	88.7%
SAU802425	PRT105537	33%	85.1%	83.8%
SAU802425	PAE200499	31%	90.7%	86.4%
SAU802425	PPU105080	33%	83.3%	79.8%
SAU802425	PSY103312	33%	83.6%	80.1%
SAU802425	SPA100245	33%	71.3%	92.7%
SAU802425	STY102313	34%	85.1%	83.5%
SAU802425	STM102072	34%	85.1%	83.5%
SAU802425	SAU802425	100%	100%	100%
SAU802425	SEP202217	77%	94.9%	99.1%
SAU802425	SHA101398	76%	94.9%	99.1%
SAU802425	VCH101093	33%	83.9%	80.9%
SAU802425	YPS002123	31%	85.1%	83.8%
SAU802426	ABA100566	35%	94.5%	95.5%
SAU802426	BAN105329	49%	97.3%	100%
SAU802426	BAN100374	50%	99.1%	97.2%
SAU802426	BFR105798	33%	96.9%	55.9%
SAU802426	BPT100802	34%	92.0%	97.4%
SAU802426	BBU100339	31%	10.4%	17.5%
SAU802426	BCE102714	33%	94.7%	93.3%
SAU802426	BCE101562	34%	93.4%	95.3%
SAU802426	BFU107996	33%	92.7%	91.4%
SAU802426	BMA105498	36%	83.2%	80.2%
SAU802426	CJU100276	35%	96.9%	99.1%
SAU802426	CPN200796	35%	93.8%	94.8%
SAU802426	CAC103102	39%	98.5%	99.8%
SAU802426	CDP101053	30%	97.8%	96.3%
SAU802426	ECO100750	32%	96.5%	96.7%
SAU802426	HIN101523	33%	95.6%	95.8%
SAU802426	HPY100960	36%	96.7%	97.0%
SAU802426	KPN301795	32%	96.5%	95.4%
SAU802426	MCA100377	35%	96.0%	94.1%
SAU802426	MAV103992	34%	92.9%	87.7%
SAU802426	MBV102582	32%	92.9%	91.5%
SAU802426	MLP100752	34%	83.8%	84.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802426	MTU201547	32%	92.9%	91.5%
SAU802426	NGO101913	35%	88.1%	93.1%
SAU802426	NME200866	35%	92.9%	92.4%
SAU802426	PMU101900	33%	95.8%	88.2%
SAU802426	PRT101762	35%	96.2%	97.4%
SAU802426	PAE200419	39%	96.5%	93.4%
SAU802426	PPU109348	37%	98.2%	83.1%
SAU802426	PSY103605	37%	98.2%	94.9%
SAU802426	STY102312	33%	96.5%	96.7%
SAU802426	SAU802426	100%	100%	100%
SAU802426	SEP200097	76%	99.8%	100%
SAU802426	VCH101092	33%	96.2%	96.7%
SAU802426	YPS002121	36%	91.6%	93.1%
SAU802439	BCE107747	30%	77.0%	98.2%
SAU802439	CAC103752	23%	19.5%	31.6%
SAU802439	CBO102950	23%	64.9%	85.5%
SAU802439	CDP101057	24%	61.1%	75.2%
SAU802439	MBV101962	28%	60.7%	73.6%
SAU802439	MTU202253	28%	60.7%	73.6%
SAU802439	NGO101840	24%	44.9%	52.8%
SAU802439	SAU802439	100%	100%	100%
SAU802439	SHA101133	63%	99.3%	99.0%
SAU802439	SPN400573	25%	98.3%	96.3%
SAU802439	SPY101946	37%	28.5%	92.9%
SAU802442	BFU112290	35%	18.0%	17.2%
SAU802442	BFU101947	40%	22.3%	20.2%
SAU802442	EBC101408	25%	85.5%	85.0%
SAU802442	KPN302715	26%	56.2%	51.2%
SAU802442	LPN102898	25%	61.1%	36.1%
SAU802442	PRT102223	25%	86.2%	86.1%
SAU802442	SAU802442	100%	100%	100%
SAU802442	SHA102938	79%	100%	100%
SAU802442	VCH101669	25%	60.1%	61.2%
SAU802444	MGE100123	21%	24.2%	33.3%
SAU802444	SAU802444	100%	100%	100%
SAU802444	SEP201112	80%	100%	100%
SAU802444	SHA101626	68%	98.9%	98.9%
SAU802448	BFR102635	36%	85.4%	86.0%
SAU802448	BPT102384	34%	86.1%	83.6%
SAU802448	BCE102560	46%	72.0%	77.3%
SAU802448	BFU103281	42%	88.3%	90.8%
SAU802448	BMA103809	50%	55.4%	72.8%
SAU802448	CAC100655	43%	88.8%	96.6%
SAU802448	CBO102037	44%	88.8%	94.3%
SAU802448	CDF102723	47%	88.8%	96.6%
SAU802448	CDP101406	52%	58.5%	87.7%
SAU802448	EBC101184	41%	88.3%	97.9%
SAU802448	EFA200443	60%	93.9%	98.7%
SAU802448	EFM101077	34%	90%	98.2%
SAU802448	ECO102088	43%	73.2%	98.7%
SAU802448	KPN308726	40%	75.1%	99.0%
SAU802448	LMO100952	61%	94.9%	98.2%
SAU802448	MAV103175	38%	88.8%	98.1%
SAU802448	MBV105820	39%	88.0%	95.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802448	MTU203703	39%	88.0%	95.2%
SAU802448	PRT102695	32%	84.4%	87.2%
SAU802448	PAE203888	40%	88.3%	94.1%
SAU802448	PPU103929	43%	87.8%	93.5%
SAU802448	PSY108132	43%	87.8%	93.5%
SAU802448	SPA101282	41%	73.2%	96.5%
SAU802448	STY104336	41%	88.3%	95.5%
SAU802448	STM103203	35%	84.4%	87%
SAU802448	SAU802448	100%	100%	100%
SAU802448	SEP201147	78%	98.8%	97.6%
SAU802448	SHA100819	76%	99.8%	86.4%
SAU802448	SMU101306	56%	91.0%	97.4%
SAU802448	SPY100277	34%	79.3%	98.3%
SAU802448	YPS000240	45%	73.2%	97.8%
SAU802452	ABA103825	24%	94.4%	90.3%
SAU802452	BAN112396	28%	25.6%	73.2%
SAU802452	BAN105354	34%	44.6%	95.1%
SAU802452	BAN111201	29%	90.6%	89.7%
SAU802452	BFR104989	19%	90.9%	90.8%
SAU802452	BPT100181	24%	93.7%	92.4%
SAU802452	BCE102642	28%	95.2%	88.5%
SAU802452	BFU108139	27%	89.1%	88.4%
SAU802452	BMA102629	27%	94.7%	93.8%
SAU802452	CJU101166	25%	98.7%	97.2%
SAU802452	CDP100795	20%	95.4%	88.3%
SAU802452	EBC101460	25%	85.3%	95.4%
SAU802452	EFA200778	28%	95.4%	93.7%
SAU802452	ECO101499	26%	94.9%	92.4%
SAU802452	HIN100128	24%	94.7%	92.7%
SAU802452	HPY101168	26%	97.0%	94.9%
SAU802452	KPN301059	26%	95.4%	94.4%
SAU802452	LPN100988	24%	89.4%	89.5%
SAU802452	LMO100724	26%	97.0%	97.4%
SAU802452	MAV104012	23%	90.9%	86.5%
SAU802452	MBV102693	21%	89.1%	89.3%
SAU802452	MTU200190	21%	93.4%	89.3%
SAU802452	NGO102033	20%	95.2%	99.2%
SAU802452	PMU100949	25%	94.9%	90.6%
SAU802452	PRT100064	26%	95.4%	82.5%
SAU802452	PAE203301	32%	91.4%	90.3%
SAU802452	PPU111526	25%	95.2%	95.6%
SAU802452	PSY101770	25%	95.2%	94.8%
SAU802452	SPA101640	26%	96.2%	96.4%
SAU802452	STY104274	26%	94.9%	92.4%
SAU802452	STM103712	26%	96.2%	95.4%
SAU802452	SAU802452	100%	100%	100%
SAU802452	SEP201161	77%	98.7%	99.5%
SAU802452	SHA101184	72%	98.7%	99.7%
SAU802452	YPS002886	29%	94.7%	94.8%
SAU802459	ABA104623	35%	97.1%	85.3%
SAU802459	BAN110218	39%	91.4%	94.1%
SAU802459	BAN106937	47%	96%	96.6%
SAU802459	BPT100094	34%	92.6%	79.8%
SAU802459	BCE110085	36%	96.2%	85.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802459	BFU101558	35%	95.0%	86.9%
SAU802459	BMA107414	37%	95.0%	88.2%
SAU802459	CDF100518	31%	28.8%	86.1%
SAU802459	CDF103659	31%	64.6%	66.9%
SAU802459	LPN101703	36%	93.9%	87.2%
SAU802459	MCA101185	35%	98.5%	87.7%
SAU802459	PAE203600	36%	94.7%	86.2%
SAU802459	PPU110002	36%	93.0%	81.8%
SAU802459	SAU802459	100%	100%	100%
SAU802459	SEP200972	78%	100%	100%
SAU802459	SHA101719	75%	99.8%	99.6%
SAU802464	PRT104892	41%	97.0%	97.8%
SAU802464	SAU802464	100%	100%	100%
SAU802464	SEP200047	69%	98.9%	98.9%
SAU802467	ABA100843	20%	73.5%	75.7%
SAU802467	BAN108463	24%	64.8%	70%
SAU802467	BAN105979	26%	93.6%	93.1%
SAU802467	BPT102300	26%	79.9%	78.2%
SAU802467	BCE113024	27%	65.0%	72.8%
SAU802467	BFU100703	27%	94.4%	94.6%
SAU802467	BMA100152	25%	23.5%	45.6%
SAU802467	BMA105680	27%	72.6%	74.3%
SAU802467	CJU101490	27%	91.9%	93.2%
SAU802467	CBO100751	24%	96.1%	95.3%
SAU802467	CBO101097	23%	95.9%	95.1%
SAU802467	CBO101308	25%	92.7%	88.8%
SAU802467	CDF101830	20%	96.1%	95.4%
SAU802467	CDF101269	25%	91.0%	89.3%
SAU802467	CDP100600	27%	55.5%	51.7%
SAU802467	EBC100767	25%	95.3%	96.6%
SAU802467	ECO103399	34%	93.2%	94.3%
SAU802467	HIN100833	22%	93.2%	93.3%
SAU802467	HPY100294	25%	89.1%	87.1%
SAU802467	KPN300173	48%	16.0%	77.0%
SAU802467	KPN304736	31%	93.0%	94.4%
SAU802467	LPN103438	24%	59.2%	79.0%
SAU802467	LMO100125	23%	92.7%	92.0%
SAU802467	MAV103759	24%	77.3%	79.2%
SAU802467	MLP100689	20%	76.9%	78.1%
SAU802467	PMU100236	25%	96.4%	96.4%
SAU802467	PRT101741	41%	94.4%	95.0%
SAU802467	PAE204498	24%	94.7%	94.7%
SAU802467	PAE204494	25%	84.2%	84.5%
SAU802467	PPU106604	34%	93.0%	99.2%
SAU802467	PSY102116	26%	85.9%	84.7%
SAU802467	SPA102842	26%	90.2%	94.6%
SAU802467	STY100765	26%	95.3%	96.6%
SAU802467	SAU802467	100%	100%	100%
SAU802467	SEP200050	82%	100%	100%
SAU802467	SHA102504	27%	97.6%	96.7%
SAU802467	SHA102341	28%	95.7%	95.4%
SAU802467	SPY201537	27%	76.5%	74.4%
SAU802467	VCH100169	26%	75.4%	70.3%
SAU802467	YPS002641	26%	85.2%	85.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802468	PAE204830	31%	96.5%	94.7%
SAU802468	SAU802468	100%	100%	100%
SAU802468	SEP200060	61%	98.4%	99.1%
SAU802468	YPS001170	29%	91.2%	91.7%
SAU802469	PAE204831	25%	84.6%	87.1%
SAU802469	SAU802469	100%	100%	100%
SAU802469	SEP200061	62%	99.3%	99.6%
SAU802469	YPS001169	28%	65.8%	67.9%
SAU802472	BFR11509	39%	90.8%	98.0%
SAU802472	BPT101439	41%	93.0%	98.8%
SAU802472	BFU103591	40%	93.0%	89.8%
SAU802472	CAC101364	36%	92.6%	94.8%
SAU802472	CDF100553	36%	92.3%	94.7%
SAU802472	EFA200981	37%	93.8%	95.9%
SAU802472	EFA201256	36%	93.0%	95.0%
SAU802472	EFM202362	37%	93.8%	95.9%
SAU802472	KPN103715	36%	91.5%	98.4%
SAU802472	MAV106724	36%	91.2%	95.7%
SAU802472	MBV102804	39%	93.4%	98.0%
SAU802472	MLP100673	29%	84.9%	83.0%
SAU802472	MTU201908	39%	93.4%	98.0%
SAU802472	PAE201648	39%	93.0%	98.8%
SAU802472	PPU101577	35%	94.9%	95.8%
SAU802472	SAU802472	100%	100%	100%
SAU802472	SEP200975	76%	99.3%	99.3%
SAU802472	SHA101724	77%	100%	100%
SAU802472	SPN400290	35%	92.6%	93.4%
SAU802472	SPY200457	35%	93.8%	97.0%
SAU802472	VCH101567	37%	93.4%	96.8%
SAU802473	BFR12135	33%	93.8%	98.8%
SAU802473	BPT101434	22%	72.9%	85.3%
SAU802473	CTR100501	44%	9.2%	7.8%
SAU802473	CDF101113	40%	97.5%	100%
SAU802473	CDF103684	41%	99.4%	98.6%
SAU802473	CDP101707	32%	88.7%	98.1%
SAU802473	EBC100434	33%	71.5%	91.4%
SAU802473	EFA201330	27%	27.0%	26.8%
SAU802473	ECO101307	35%	95.3%	94.9%
SAU802473	KPN304537	36%	95.3%	95.3%
SAU802473	MCA101881	37%	98.2%	94.0%
SAU802473	NGO100614	37%	97.1%	97.3%
SAU802473	NME201822	37%	97.1%	97.3%
SAU802473	PMU101104	37%	99.4%	98.9%
SAU802473	PRT100243	37%	97.3%	98.5%
SAU802473	SAU802473	100%	100%	100%
SAU802473	SHA101725	74%	99.4%	99.2%
SAU802473	SPY200100	23%	65.6%	68.3%
SAU802473	VCH100864	36%	99.2%	97.0%
SAU802473	YPS001074	31%	95.5%	95.2%
SAU802481	CBO103036	28%	47.0%	37.8%
SAU802481	SAU802486	82%	97.3%	100%
SAU802481	SAU802481	100%	100%	100%
SAU802481	SEP200591	74%	88.3%	98.7%
SAU802481	SEP200552	71%	97.7%	98.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802481	SEP200589	73%	98.1%	99.2%
SAU802481	SEP200598	60%	87.9%	99.1%
SAU802481	SEP200593	62%	87.5%	97.1%
SAU802481	SEP200083	59%	93.6%	99.6%
SAU802481	SEP200597	60%	97.7%	99.2%
SAU802481	SEP200616	60%	97.7%	99.6%
SAU802481	SEP200553	66%	97.0%	98.8%
SAU802481	SHA101524	83%	67.8%	98.4%
SAU802488	ABA100783	23%	17.9%	16.1%
SAU802488	ABA100144	24%	19.8%	17.3%
SAU802488	EBC102917	30%	19.8%	16.7%
SAU802488	ECO102143	32%	19.8%	16.7%
SAU802488	HPY101500	34%	52.2%	39.5%
SAU802488	HPY100585	21%	69.2%	34.5%
SAU802488	KPN301786	31%	20.6%	17.5%
SAU802488	PRT101141	36%	15.5%	13.1%
SAU802488	STY104333	31%	19.8%	16.7%
SAU802488	STM100155	31%	19.8%	16.7%
SAU802488	SAU802488	100%	100%	100%
SAU802488	SEP201002	64%	99.8%	52.0%
SAU802488	SPY101669	29%	20.4%	22.5%
SAU802488	YPS000334	33%	20.0%	16.1%
SAU802491	BAN105883	33%	91.6%	96.2%
SAU802491	BAN103235	39%	91.6%	96.5%
SAU802491	BFR101582	36%	90.7%	93.3%
SAU802491	BBU100834	32%	87.8%	92.3%
SAU802491	BFU111711	22%	84.2%	75.5%
SAU802491	BFU102625	22%	84.2%	85.9%
SAU802491	CPN200707	34%	85.2%	85.1%
SAU802491	CTR200560	33%	85.9%	86.0%
SAU802491	CAC102619	37%	89.4%	92.7%
SAU802491	CBO103621	39%	90.6%	93.9%
SAU802491	CDF104307	34%	92.6%	97.0%
SAU802491	CDF100956	35%	96.6%	95.5%
SAU802491	CDP101629	32%	88.2%	90%
SAU802491	EFA200367	40%	91.9%	96.7%
SAU802491	EFM101685	35%	93.1%	97.6%
SAU802491	HIN100721	32%	82.7%	94.2%
SAU802491	LMO102655	38%	91.6%	96.2%
SAU802491	MAV100233	28%	91.9%	96.2%
SAU802491	MBV100850	29%	90.7%	94.8%
SAU802491	MLP100433	28%	91.1%	94.6%
SAU802491	MTU203265	29%	90.7%	94.8%
SAU802491	MGE100053	29%	90.4%	94%
SAU802491	MPN100088	28%	86.1%	89.4%
SAU802491	PMU101074	33%	88.9%	89.8%
SAU802491	PRT100549	22%	84.2%	87.8%
SAU802491	PPU110293	23%	84.2%	88.3%
SAU802491	PSY105678	24%	87.7%	91.1%
SAU802491	STM101606	22%	84.6%	88.3%
SAU802491	SAU802491	100%	100%	100%
SAU802491	SEP201006	66%	93.1%	99.6%
SAU802491	SHA102495	55%	93.3%	99.3%
SAU802491	SMU100294	38%	88.0%	92.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802491	SPN401350	36%	87.1%	91.6%
SAU802491	SPY200938	38%	88.0%	92.5%
SAU802491	TPA100634	33%	89.4%	92.5%
SAU802491	UUR100536	29%	88.2%	90.8%
SAU802491	VCH103757	33%	90.1%	93.7%
SAU802496	BMA100689	34%	8.4%	10.3%
SAU802496	CBO102378	29%	5.3%	29.8%
SAU802496	CDF100714	32%	10.1%	26.9%
SAU802496	CDF102419	29%	44.8%	45.1%
SAU802496	SAU802496	100%	100%	100%
SAU802496	SEP202577	60%	93.0%	4.9%
SAU802496	SHA102996	55%	71.4%	76.9%
SAU802496	SPN401042	23%	95.4%	20.8%
SAU802496	SPN400581	26%	83.4%	22.3%
SAU802496	SPY100688	30%	13.5%	21.7%
SAU802496	UUR100377	20%	56%	71.6%
SAU802502	ABA105088	40%	11.7%	31.9%
SAU802502	BAN109365	16%	27.4%	32.3%
SAU802502	BAN100965	21%	29.1%	17.2%
SAU802502	BAN111001	19%	23.2%	12.6%
SAU802502	BPT105763	30%	12.2%	37.3%
SAU802502	BPT105804	40%	5.2%	14.2%
SAU802502	BBU100545	16%	19.0%	70.6%
SAU802502	BCE111297	41%	13.5%	13.5%
SAU802502	BFU107405	42%	8.1%	53.4%
SAU802502	BMA109637	37%	6.1%	59.8%
SAU802502	CJU101536	29%	12.2%	50.7%
SAU802502	CPN200033	19%	22.1%	25.6%
SAU802502	CPN200268	39%	7.8%	8.9%
SAU802502	CTR200876	22%	8.8%	35.4%
SAU802502	CDF103752	27%	8.8%	56.4%
SAU802502	CDF102641	30%	38.5%	41.7%
SAU802502	CDP102558	27%	9.3%	7.8%
SAU802502	CDP101521	30%	8.9%	13.9%
SAU802502	EBC100323	28%	11.8%	45.4%
SAU802502	EFA201300	46%	9.9%	47.8%
SAU802502	EFA200083	45%	15.1%	90.2%
SAU802502	EFA202388	39%	18.2%	85.1%
SAU802502	EFA203524	21%	28.8%	44.4%
SAU802502	EFA200038	42%	64.3%	66.7%
SAU802502	EFM201584	29%	21.7%	36.8%
SAU802502	ECO102908	34%	5.8%	10.4%
SAU802502	ECO101223	36%	6.9%	23.4%
SAU802502	HPY101323	29%	13.4%	43.9%
SAU802502	HPY100575	31%	12.5%	31.5%
SAU802502	KPN201031	32%	11.8%	21.2%
SAU802502	LPN101461	21%	18.3%	52.1%
SAU802502	LMO101802	34%	15.1%	29.1%
SAU802502	LMO101963	29%	15.3%	35.8%
SAU802502	MCA102006	28%	4.7%	25.8%
SAU802502	MBV106185	38%	9.9%	24.2%
SAU802502	MLP100033	28%	11.1%	25.8%
SAU802502	MTU203821	33%	10.8%	9.5%
SAU802502	MTU203824	37%	10.3%	25.5%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802502	MGE100323	22%	25.8%	53.4%
SAU802502	MPN100275	27%	88.8%	52.7%
SAU802502	MPN100388	29%	8.2%	55.8%
SAU802502	NGO100382	20%	17.2%	36.2%
SAU802502	NGO101515	20%	17.2%	50%
SAU802502	NGO100447	20%	17.2%	36.2%
SAU802502	NGO101440	20%	17.2%	36.2%
SAU802502	NGO101563	29%	13.4%	19.4%
SAU802502	NME201654	22%	17.3%	29.3%
SAU802502	NME200717	30%	8.4%	15.5%
SAU802502	PMU100098	28%	66.5%	29.9%
SAU802502	PRT100444	30%	5.7%	49.5%
SAU802502	PRT105010	39%	13.0%	38.3%
SAU802502	PAE203113	27%	10.0%	10.8%
SAU802502	PAE200196	41%	7.3%	39.6%
SAU802502	PPU102161	31%	8.9%	42.4%
SAU802502	PSY102683	33%	8.1%	6.7%
SAU802502	PSY104998	41%	11.2%	15.8%
SAU802502	SPA103530	23%	14.6%	48.9%
SAU802502	STY101188	24%	14.6%	49.1%
SAU802502	SAU800563	19%	99.4%	98.2%
SAU802502	SAU802630	21%	90.4%	65.7%
SAU802502	SAU800561	21%	99.4%	98.0%
SAU802502	SAU800811	22%	99.7%	99.4%
SAU802502	SAU802503	66%	100%	100%
SAU802502	SAU802502	100%	100%	100%
SAU802502	SEP200110	20%	96.6%	87.8%
SAU802502	SHA100540	23%	15.7%	88.6%
SAU802502	SHA102998	24%	18.9%	71.5%
SAU802502	SHA100562	23%	78.7%	84.7%
SAU802502	SMU100238	40%	14.6%	19.7%
SAU802502	SMU100747	22%	19.7%	29.2%
SAU802502	SMU100749	44%	6.5%	5.8%
SAU802502	SPN401402	39%	66.8%	88.1%
SAU802502	SPY201545	29%	62.2%	35.1%
SAU802502	TPA100365	33%	12.2%	17.4%
SAU802502	VCH100756	50%	2.3%	7.7%
SAU802502	YPS002256	39%	5.0%	22.1%
SAU802503	ABA105088	30%	11.0%	40.3%
SAU802503	BAN109365	16%	27.2%	34.7%
SAU802503	BAN111001	19%	74.9%	41.9%
SAU802503	BPT105763	24%	3.8%	23.5%
SAU802503	BPT105804	41%	13.4%	14.1%
SAU802503	BBU100545	25%	12.1%	45.8%
SAU802503	BCE111297	45%	13.3%	16.6%
SAU802503	BFU107405	45%	10.2%	78.4%
SAU802503	BMA109637	50%	2.6%	47.5%
SAU802503	CJU101103	22%	35.8%	64.9%
SAU802503	CPN200033	19%	17.5%	22.0%
SAU802503	CPN200268	34%	6.0%	8.5%
SAU802503	CTR200876	33%	13.4%	40.4%
SAU802503	CBO103272	23%	28.7%	56.4%
SAU802503	CDF103752	27%	13.1%	53.5%
SAU802503	CDF102641	29%	7.6%	12.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802503	CDP101521	33%	11.9%	6.8%
SAU802503	EBC103874	27%	16.6%	39.4%
SAU802503	EBC100323	29%	7.4%	52.7%
SAU802503	EFA202388	52%	10.0%	47.9%
SAU802503	EFA200083	50%	14.3%	29.1%
SAU802503	EFA201300	48%	16.7%	89.6%
SAU802503	EFA200038	37%	59.2%	87.4%
SAU802503	EFM201584	28%	16.1%	49.4%
SAU802503	ECO102908	37%	8.2%	9.8%
SAU802503	ECO103311	24%	94.5%	35.7%
SAU802503	ECO101223	40%	7.9%	29.7%
SAU802503	HPY101323	32%	11.7%	53.0%
SAU802503	HPY100575	31%	14.4%	55.2%
SAU802503	KPN201031	24%	12.0%	39.9%
SAU802503	LPN101461	24%	12.8%	43.5%
SAU802503	LMO101963	31%	6.4%	27.1%
SAU802503	LMO101802	34%	15.7%	29.3%
SAU802503	MCA102006	40%	6.6%	26.1%
SAU802503	MBV106185	39%	10.3%	27.8%
SAU802503	MLP100033	28%	6.1%	23.5%
SAU802503	MTU203824	38%	9.5%	21.8%
SAU802503	MTU203821	37%	11.8%	50.6%
SAU802503	MGE100323	21%	21.9%	55.8%
SAU802503	MPN100275	23%	22.8%	15.5%
SAU802503	MPN100388	27%	12.0%	55.1%
SAU802503	NGO101440	20%	15.9%	36.2%
SAU802503	NGO101515	20%	15.9%	50%
SAU802503	NGO100447	20%	15.9%	36.2%
SAU802503	NGO100382	20%	15.9%	36.2%
SAU802503	NGO101563	28%	9.8%	17.0%
SAU802503	NME201654	22%	21.8%	36.7%
SAU802503	NME200717	31%	8.1%	13.7%
SAU802503	PMU100098	28%	92.6%	35.8%
SAU802503	PRT105010	36%	14.7%	38.3%
SAU802503	PRT100444	35%	6.0%	35.4%
SAU802503	PAE203113	25%	9.6%	10.9%
SAU802503	PAE200196	36%	6.3%	45.9%
SAU802503	PPU102161	33%	5.3%	40.3%
SAU802503	PSY108790	31%	6.9%	4.8%
SAU802503	PSY102683	43%	10.2%	6.7%
SAU802503	PSY104998	37%	11.4%	31.5%
SAU802503	SPA103530	22%	17.7%	47.7%
SAU802503	STY101188	22%	16.6%	52.1%
SAU802503	SAU802630	20%	99.3%	97.9%
SAU802503	SAU800561	21%	99.4%	98.0%
SAU802503	SAU800563	20%	99.4%	98.2%
SAU802503	SAU800811	22%	85.1%	96.7%
SAU802503	SAU802502	65%	100%	100%
SAU802503	SAU802503	100%	100%	100%
SAU802503	SEP200110	20%	95.6%	92.8%
SAU802503	SHA100540	21%	16.3%	85.1%
SAU802503	SHA100562	23%	17.3%	15.2%
SAU802503	SHA102998	23%	18.5%	71.8%
SAU802503	SMU100238	23%	19.0%	33.8%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802503	SMU100747	21%	37.7%	61.4%
SAU802503	SMU100749	40%	14.5%	6.5%
SAU802503	SPN401402	39%	4.8%	4.0%
SAU802503	SPY201545	34%	13.5%	19.3%
SAU802503	TPA100365	35%	14.0%	17.4%
SAU802503	VCH100756	58%	5.7%	5.9%
SAU802503	YPS002256	38%	9.8%	5.9%
SAU802506	BAN112425	42%	97.9%	100%
SAU802506	BAN111510	60%	98.3%	98.8%
SAU802506	BFR11473	25%	74.9%	77.2%
SAU802506	BCE101565	30%	95.9%	96.6%
SAU802506	BFU100630	27%	89.9%	85.9%
SAU802506	BMA108610	28%	95.9%	98.1%
SAU802506	CAC102691	31%	97.7%	99.8%
SAU802506	CDF101648	31%	96.9%	97.3%
SAU802506	EBC104555	27%	95.2%	98.6%
SAU802506	EFA200809	39%	98.1%	99.6%
SAU802506	EFM202150	36%	98.5%	100%
SAU802506	ECO103486	25%	95.2%	98.6%
SAU802506	HIN101086	24%	87.6%	87.9%
SAU802506	KPN309070	26%	87.0%	90.1%
SAU802506	LMO101414	41%	98.1%	98.0%
SAU802506	PMU101371	25%	94.4%	98.6%
SAU802506	PRT101395	25%	94.4%	97.7%
SAU802506	STY100699	26%	95.2%	98.6%
SAU802506	STM104115	22%	93.6%	96.4%
SAU802506	SAU802506	100%	100%	100%
SAU802506	SEP201009	76%	99.2%	100%
SAU802506	SHA100834	81%	98.8%	99.8%
SAU802506	YPS000393	27%	97.7%	99.2%
SAU802507	ABA101570	30%	61.9%	56.1%
SAU802507	BAN111763	36%	85.8%	81.1%
SAU802507	BAN106500	46%	100%	93.0%
SAU802507	BPT103130	25%	83.6%	87.7%
SAU802507	BCE107345	29%	61.1%	57.7%
SAU802507	BFU100176	21%	88.5%	74.8%
SAU802507	BFU104257	27%	61.5%	52.8%
SAU802507	BFU103403	21%	88.1%	78.9%
SAU802507	CAC102025	23%	78.8%	81.5%
SAU802507	CDF104417	31%	64.2%	65.8%
SAU802507	CDF100440	27%	81.9%	76.1%
SAU802507	CDP100432	25%	81.9%	83.3%
SAU802507	EBC103251	22%	88.1%	85.5%
SAU802507	EFA200682	32%	31.9%	31.6%
SAU802507	ECO101511	22%	87.6%	85.1%
SAU802507	KPN306069	23%	87.6%	85.1%
SAU802507	MAV104574	32%	23.0%	21.2%
SAU802507	MAV103382	25%	66.4%	61.6%
SAU802507	MAV101336	24%	87.2%	84.1%
SAU802507	MBV102645	25%	57.5%	49.4%
SAU802507	MTU200164	25%	57.5%	49.6%
SAU802507	PRT100638	20%	92.5%	94.1%
SAU802507	PAE200796	21%	93.4%	87.5%
SAU802507	PPU106554	26%	63.3%	66.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802507	PSY105573	22%	84.5%	78.5%
SAU802507	SPA101683	21%	79.6%	60.2%
SAU802507	STY104298	22%	88.1%	85.5%
SAU802507	STM104445	21%	79.6%	60.2%
SAU802507	SAU802507	100%	100%	100%
SAU802507	SEP201029	73%	99.6%	99.6%
SAU802507	SHA100833	74%	98.2%	96.9%
SAU802507	SMU100140	23%	61.5%	61.1%
SAU802507	SPY102945	32%	21.7%	52.5%
SAU802507	VCH101315	25%	82.3%	92.3%
SAU802507	YPS003104	24%	54.4%	56.4%
SAU802510	BAN101366	23%	53.1%	26.2%
SAU802510	BMA100274	45%	21.6%	60.3%
SAU802510	CBO102568	26%	64.8%	13.5%
SAU802510	CBO100474	28%	78.4%	16.5%
SAU802510	EFA200549	40%	40.7%	44%
SAU802510	EFM100539	43%	40.7%	44.6%
SAU802510	LMO102593	50%	32.7%	91.4%
SAU802510	PAE201642	28%	73.5%	36.3%
SAU802510	SAU802510	100%	100%	100%
SAU802510	SEP201035	34%	84.6%	99.3%
SAU802510	SHA100027	51%	43.2%	63.1%
SAU802511	ABA101187	32%	25.0%	21.5%
SAU802511	BPT102628	28%	28.3%	30.1%
SAU802511	BCE107041	29%	25.0%	28.6%
SAU802511	BFU102753	24%	32.3%	21.7%
SAU802511	BMA106189	21%	72.7%	66.9%
SAU802511	CJU100519	28%	29.0%	8.0%
SAU802511	EBC103859	24%	43.3%	75.1%
SAU802511	EFA200764	23%	28.2%	49.1%
SAU802511	EFA200374	31%	26.9%	46.2%
SAU802511	ECO103281	23%	92.6%	85.6%
SAU802511	HIN101645	21%	93.9%	85.8%
SAU802511	KPN301327	21%	92.6%	86.1%
SAU802511	LPN101554	19%	43.7%	77.7%
SAU802511	LPN103586	22%	39.7%	88.8%
SAU802511	MCA100529	35%	8.9%	15.0%
SAU802511	MAV101852	23%	27.3%	21.9%
SAU802511	NGO101970	21%	65.2%	63.7%
SAU802511	NME200209	20%	66.7%	64.4%
SAU802511	PMU100392	21%	90.1%	84.2%
SAU802511	PRT101407	24%	51.7%	44.9%
SAU802511	PAE203303	21%	20.4%	19.4%
SAU802511	PAE201269	20%	23.4%	21.6%
SAU802511	PPU109268	24%	33.1%	29.4%
SAU802511	PSY101807	21%	22.9%	21.1%
SAU802511	SPA103296	23%	52.4%	48.6%
SAU802511	STY103605	29%	24.4%	20.2%
SAU802511	STM102815	22%	98.2%	91.9%
SAU802511	SAU802511	100%	100%	100%
SAU802511	SEP201036	61%	99.3%	94.8%
SAU802511	SHA101790	61%	85.7%	98.3%
SAU802511	VCH103439	27%	28.5%	23.4%
SAU802511	YPS001766	19%	85.5%	79.0%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802518	ABA105593	29%	50.8%	39.2%
SAU802518	BAN110972	45%	82.2%	91.6%
SAU802518	BAN100218	45%	93.4%	91.6%
SAU802518	BBU100645	26%	63.5%	35.5%
SAU802518	BCE107415	21%	88.8%	81.5%
SAU802518	BFU112947	22%	98.5%	92.7%
SAU802518	CTR100655	27%	58.4%	45.2%
SAU802518	CDF100729	25%	58.9%	39.1%
SAU802518	EFA201235	55%	93.4%	92%
SAU802518	EFM200131	42%	93.4%	91.5%
SAU802518	LPN100583	24%	74.1%	73.5%
SAU802518	LMO102230	42%	93.4%	92.1%
SAU802518	PAE200542	26%	82.7%	51.9%
SAU802518	PPU111804	30%	52.3%	52.8%
SAU802518	PSY105127	30%	80.2%	69.2%
SAU802518	SAU802518	100%	100%	100%
SAU802518	SHA101221	72%	86.3%	98.3%
SAU802520	BAN108403	43%	71.5%	100%
SAU802520	BAN112352	46%	91.7%	89.2%
SAU802520	BFR105372	33%	52.8%	70%
SAU802520	BPT102354	27%	75%	65.3%
SAU802520	BFU110972	30%	77.8%	66.5%
SAU802520	BMA102527	28%	51.4%	46.2%
SAU802520	CAC103017	25%	95.8%	90.3%
SAU802520	CDP101090	30%	79.2%	86.0%
SAU802520	EBC101510	27%	75.7%	63.1%
SAU802520	EFA201241	44%	97.9%	99.3%
SAU802520	EFM101277	27%	52.8%	49.7%
SAU802520	ECO102629	28%	75.7%	63.1%
SAU802520	KPN304419	27%	75.7%	63.1%
SAU802520	LMO100103	26%	79.9%	81.2%
SAU802520	MBV101633	28%	54.2%	48.5%
SAU802520	MLP101283	22%	69.4%	69.9%
SAU802520	MTU200734	28%	54.2%	48.5%
SAU802520	PRT102689	28%	77.8%	65.1%
SAU802520	STY102739	28%	75.7%	63.1%
SAU802520	STM103221	28%	75.7%	63.1%
SAU802520	SAU802520	100%	100%	100%
SAU802520	SHA100070	77%	100%	100%
SAU802520	SMU101475	31%	92.4%	89.3%
SAU802520	SPN401598	26%	82.6%	89.4%
SAU802520	SPY201508	36%	90.3%	91.5%
SAU802520	YPS002793	28%	75.7%	65.3%
SAU802522	ABA102625	29%	25%	23.0%
SAU802522	BAN101372	31%	86.9%	84.3%
SAU802522	BAN110637	34%	86.9%	81.6%
SAU802522	BCE111951	27%	42.9%	36.2%
SAU802522	BFU108797	23%	79.1%	60.2%
SAU802522	EFA201248	39%	40.3%	94.0%
SAU802522	KPN303068	30%	46.6%	40.9%
SAU802522	LMO101465	38%	92.9%	90.7%
SAU802522	PRT103713	24%	42.9%	93.7%
SAU802522	PAE203501	28%	47.0%	60.2%
SAU802522	PPU109159	25%	43.7%	91.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802522	SPA100901	26%	42.9%	94.6%
SAU802522	STM103633	26%	42.9%	94.6%
SAU802522	SAU802522	100%	100%	100%
SAU802522	SEP201068	61%	96.6%	97.7%
SAU802522	SHA100686	63%	77.6%	99.0%
SAU802522	SPN400066	34%	81.7%	77.1%
SAU802522	SPY201605	32%	89.2%	83.9%
SAU802528	BAN103721	26%	97.1%	97.6%
SAU802528	CAC100274	29%	89.3%	91.2%
SAU802528	CDP100640	26%	66.5%	50.2%
SAU802528	CDP101493	34%	36.9%	22.5%
SAU802528	CDP100638	26%	67.5%	41.2%
SAU802528	CDP101495	40%	36.4%	23.4%
SAU802528	CDP100684	31%	64.1%	45.0%
SAU802528	EFA202035	28%	70.4%	58.2%
SAU802528	EFM200204	23%	92.7%	57.4%
SAU802528	LMO101005	27%	88.3%	86.0%
SAU802528	SAU802528	100%	100%	100%
SAU802528	SEP201093	71%	99.5%	99.5%
SAU802528	SHA102510	79%	99.5%	99.5%
SAU802528	SMU100891	28%	59.7%	50.4%
SAU802528	SPN300435	33%	59.2%	43.1%
SAU802528	SPY200880	27%	88.8%	78.7%
SAU802539	BFR102568	31%	95.9%	95.7%
SAU802539	BCE113546	30%	96.2%	94.4%
SAU802539	BFU115336	32%	93.3%	87.7%
SAU802539	BFU112943	33%	93.3%	93.3%
SAU802539	BMA108339	31%	96.4%	97.2%
SAU802539	CDP100580	30%	95.0%	95.2%
SAU802539	EBC102312	33%	94.6%	96.1%
SAU802539	EFM100662	36%	91.2%	100%
SAU802539	ECO100847	33%	94.6%	95.5%
SAU802539	KPN301806	33%	94.6%	95.5%
SAU802539	LMO100148	57%	100%	100%
SAU802539	MAV104239	33%	92.9%	92.8%
SAU802539	PRT102417	31%	98.1%	98.8%
SAU802539	PAE202106	34%	93.1%	94.1%
SAU802539	PSY105421	30%	94.6%	95.6%
SAU802539	STY102871	32%	94.6%	95.5%
SAU802539	SAU802539	100%	100%	100%
SAU802539	SEP201171	84%	100%	100%
SAU802539	SHA102199	81%	100%	100%
SAU802539	SPN400642	31%	97.9%	96.6%
SAU802539	YPS001186	32%	94.6%	95.5%
SAU802545	BBU100684	34%	91.8%	87.9%
SAU802545	BCE107302	50%	37.9%	82.1%
SAU802545	BMA103982	27%	23.1%	54.0%
SAU802545	EFM100738	56%	37.6%	100%
SAU802545	LPN103488	35%	99.1%	96.8%
SAU802545	LMO100989	41%	100%	99.8%
SAU802545	PAE110993	24%	48.9%	30.6%
SAU802545	SAU802545	100%	100%	100%
SAU802545	SEP201177	81%	99.8%	99.8%
SAU802545	SHA101318	82%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802545	SMU100946	44%	96.5%	99.8%
SAU802545	SPN401568	42%	97.9%	98.1%
SAU802545	SPY200655	43%	96.7%	96%
SAU802547	ABA105572	39%	90.8%	97.5%
SAU802547	BAN101922	36%	76.3%	90.4%
SAU802547	BAN104869	42%	90.8%	98%
SAU802547	BFR100765	43%	71.1%	68.0%
SAU802547	BPT103019	37%	86.7%	77.9%
SAU802547	BCE103848	40%	89.6%	88.7%
SAU802547	BFU110234	38%	86.7%	64.2%
SAU802547	BMA101458	44%	26.0%	71.4%
SAU802547	BMA108546	39%	60.7%	27.5%
SAU802547	CJU100775	36%	91.9%	98.7%
SAU802547	CPN200150	30%	64.7%	60.7%
SAU802547	CTR200751	26%	48.0%	43.9%
SAU802547	CAC103117	37%	88.4%	92.9%
SAU802547	CBO100820	33%	87.3%	92.3%
SAU802547	CDF100241	49%	97.1%	97.2%
SAU802547	CDP100500	32%	69.9%	83.7%
SAU802547	EBC100683	45%	60.7%	60.1%
SAU802547	EFA201894	37%	65.9%	65.0%
SAU802547	EFM201553	37%	87.3%	96.7%
SAU802547	ECO101306	43%	60.7%	59.1%
SAU802547	HIN100382	46%	98.8%	87.9%
SAU802547	HPY100668	37%	90.2%	88.1%
SAU802547	KPN302255	39%	74.6%	36.6%
SAU802547	LPN100954	37%	88.4%	92.3%
SAU802547	LMO102205	33%	90.8%	46.6%
SAU802547	MCA101470	41%	65.9%	55.8%
SAU802547	MAV102898	41%	90.8%	92.1%
SAU802547	MBV100407	44%	86.7%	88.5%
SAU802547	MLP100717	44%	86.7%	88.5%
SAU802547	MTU201299	44%	86.7%	88.5%
SAU802547	NGO100306	42%	61.8%	35.3%
SAU802547	NME201587	41%	61.8%	35.3%
SAU802547	PMU101068	44%	98.3%	95.6%
SAU802547	PRT106182	32%	93.1%	99.4%
SAU802547	PAE200994	36%	86.7%	86.7%
SAU802547	PPU110616	38%	86.1%	89.2%
SAU802547	PSY102798	40%	54.9%	40.5%
SAU802547	SPA102006	41%	59.0%	57.3%
SAU802547	STY103674	42%	59.0%	57.3%
SAU802547	STM100933	42%	59.0%	57.3%
SAU802547	SAU802547	100%	100%	100%
SAU802547	SEP201179	60%	98.8%	99.4%
SAU802547	SHA101314	58%	100%	100%
SAU802547	SMU101210	42%	93.1%	98.2%
SAU802547	SPN401316	40%	97.1%	96.0%
SAU802547	TPA100140	36%	57.8%	53.7%
SAU802547	VCH103735	40%	90.8%	98.1%
SAU802547	YPS001868	43%	59.0%	57.0%
SAU802548	SPA102343	38%	93.6%	82.7%
SAU802548	STM102687	38%	93.6%	80.2%
SAU802548	SAU802548	100%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802548	SMU100972	64%	98.6%	98.1%
SAU802548	SPN400307	62%	100%	99.9%
SAU802548	SPY200663	63%	98.6%	97.9%
SAU802555	ABA106035	32%	54.3%	54.2%
SAU802555	BAN106994	48%	40.7%	95.3%
SAU802555	BFR11792	51%	93.5%	95.4%
SAU802555	BCE103747	41%	82.4%	88.6%
SAU802555	BFU112906	30%	53.8%	51.9%
SAU802555	CJU100202	33%	45.7%	40.7%
SAU802555	CPN200095	27%	50.3%	30.8%
SAU802555	CTR200807	31%	50.3%	30.7%
SAU802555	CAC101718	48%	94.0%	91.2%
SAU802555	CBO101588	44%	94.0%	84.5%
SAU802555	CDF103080	40%	92.0%	98.9%
SAU802555	CDF103398	47%	93.0%	99.5%
SAU802555	CDP101537	45%	65.3%	92.3%
SAU802555	EBC103982	40%	91.5%	98.4%
SAU802555	EFA204780	39%	99.5%	69.8%
SAU802555	EFM202301	33%	84.4%	95.8%
SAU802555	ECO100334	42%	93.5%	91.1%
SAU802555	KPN303887	40%	91.5%	95.7%
SAU802555	LMO101588	39%	92.5%	96.8%
SAU802555	MAV101369	34%	56.3%	42.5%
SAU802555	MBV105847	36%	56.3%	30.7%
SAU802555	MLP101056	34%	55.8%	43.7%
SAU802555	MTU202994	36%	56.3%	36%
SAU802555	NGO101296	43%	54.3%	62.2%
SAU802555	NME200459	42%	54.3%	62.9%
SAU802555	PMU101056	44%	92.5%	90.6%
SAU802555	PPU102678	38%	87.4%	96.1%
SAU802555	PSY104038	36%	56.3%	31.0%
SAU802555	SPA100218	40%	91.5%	98.4%
SAU802555	STY100785	40%	91.5%	98.4%
SAU802555	SAU802555	100%	100%	100%
SAU802555	SHA101210	67%	95.0%	99.0%
SAU802555	SPN300070	41%	92.0%	97.3%
SAU802555	SPY200807	56%	93.5%	98.9%
SAU802555	VCH103556	34%	97.0%	97.9%
SAU802557	ABA101879	45%	97.9%	97.7%
SAU802557	BAN105978	59%	60.2%	99.8%
SAU802557	BAN110321	61%	70.9%	100%
SAU802557	BFR10291	40%	0.9%	8.6%
SAU802557	BPT102136	43%	4.2%	12.6%
SAU802557	BCE110602	45%	75.2%	97.9%
SAU802557	BFU101728	44%	90.5%	96.7%
SAU802557	BMA106854	46%	74.8%	73.3%
SAU802557	CJU101080	31%	93.1%	92.9%
SAU802557	CPN200982	31%	82.0%	93.6%
SAU802557	CTR200100	30%	82.0%	97.0%
SAU802557	CAC100879	48%	17.1%	8.6%
SAU802557	CBO102754	47%	16.6%	8.1%
SAU802557	CDF102644	49%	98.3%	98.6%
SAU802557	CDP100778	43%	0.4%	9.2%
SAU802557	EBC104530	46%	78.9%	95.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802557	EFA201855	49%	8.1%	16.4%
SAU802557	EFM201092	51%	1.4%	7.8%
SAU802557	ECO100475	38%	99.5%	99.9%
SAU802557	HIN100276	37%	0.4%	9.3%
SAU802557	HPY101055	37%	1.5%	7.8%
SAU802557	KPN308679	39%	97.3%	100%
SAU802557	LPN101141	45%	78.9%	88.6%
SAU802557	LPN101253	45%	78.9%	88.3%
SAU802557	LMO100878	51%	1.1%	8.3%
SAU802557	MCA100406	38%	0.9%	8.6%
SAU802557	MAV100988	33%	88.0%	95.4%
SAU802557	MBV103852	51%	75.7%	76.1%
SAU802557	MLP101210	43%	79.9%	84.5%
SAU802557	MTU200960	51%	75.7%	78.3%
SAU802557	MGE100073	25%	62.8%	66.7%
SAU802557	MPN100622	25%	67.5%	69.6%
SAU802557	NGO100160	39%	0.2%	9.7%
SAU802557	NME201398	39%	0.2%	9.7%
SAU802557	PMU101892	39%	0.7%	8.8%
SAU802557	PRT105848	44%	99.0%	98.6%
SAU802557	PAE203917	43%	98.9%	99.5%
SAU802557	PPU108258	44%	7.9%	16.1%
SAU802557	PSY102170	44%	0.1%	9.1%
SAU802557	SPA101217	38%	89.3%	100%
SAU802557	STY100871	38%	99.5%	99.9%
SAU802557	STM104228	45%	0.7%	8.0%
SAU802557	SAU802557	100%	100%	100%
SAU802557	SEP201193	73%	99.1%	100%
SAU802557	SHA100292	69%	76.4%	100%
SAU802557	SMU100795	45%	1.0%	8.4%
SAU802557	SPN400641	45%	81.2%	86.5%
SAU802557	SPY201317	43%	1.4%	8.0%
SAU802557	TPA101026	35%	89.9%	99.2%
SAU802557	UUR100203	31%	80.2%	94.5%
SAU802557	VCH102181	42%	5.2%	5.5%
SAU802557	YPS001578	40%	8.4%	17.0%
SAU802558	BAN109810	45%	83.8%	98.3%
SAU802558	BFU109224	40%	88.2%	72.2%
SAU802558	EBC100081	41%	88.2%	75%
SAU802558	EFM202554	38%	86.8%	85.5%
SAU802558	HIN100277	42%	89.7%	88.2%
SAU802558	HIN100278	42%	89.7%	88.2%
SAU802558	HPY101056	32%	89.7%	90.9%
SAU802558	KPN304604	38%	88.2%	65.9%
SAU802558	LMO102528	41%	98.5%	98.5%
SAU802558	MCA101196	42%	97.1%	94.3%
SAU802558	MAV101708	32%	89.7%	85.7%
SAU802558	NGO102035	40%	97.1%	94.3%
SAU802558	PMU101891	47%	98.5%	95.7%
SAU802558	PPU102427	41%	91.2%	90.8%
SAU802558	PSY107623	37%	91.2%	90.8%
SAU802558	SPA101034	40%	63.2%	59.5%
SAU802558	SAU802558	100%	100%	100%
SAU802558	SEP201194	61%	98.5%	94.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802558	SHA101777	62%	98.5%	98.5%
SAU802558	UUR100202	24%	95.6%	86.5%
SAU802564	BAN107558	26%	29.2%	33.1%
SAU802564	BAN112682	21%	44.5%	43.9%
SAU802564	BAN101794	21%	44.5%	44.1%
SAU802564	BMA102467	36%	8.9%	44.4%
SAU802564	LMO100571	26%	99.2%	98.6%
SAU802564	PAE200420	24%	54.3%	48.0%
SAU802564	SAU802564	100%	100%	100%
SAU802564	SHA101771	69%	99.0%	98.0%
SAU802565	SAU802565	100%	100%	100%
SAU802565	SHA103208	47%	41.2%	88.3%
SAU802567	BFU100798	25%	57.2%	94.4%
SAU802567	BMA109603	32%	58.2%	48.1%
SAU802567	CTR200330	25%	16.3%	20.0%
SAU802567	EFM201158	21%	29.5%	65.2%
SAU802567	ECO203243	27%	18.4%	30.2%
SAU802567	HIN100372	29%	36.5%	89.8%
SAU802567	KPN206582	24%	60.7%	96.5%
SAU802567	LPN100851	30%	13.9%	19.0%
SAU802567	LPN101642	31%	62.0%	53.8%
SAU802567	LMO102084	41%	96.7%	98.7%
SAU802567	MAV107021	31%	61.7%	94.2%
SAU802567	MBV105112	33%	57.9%	58.8%
SAU802567	MLP101575	34%	61.9%	59.2%
SAU802567	MTU200111	34%	61.9%	57.5%
SAU802567	NGO101829	27%	95.0%	96.1%
SAU802567	PRT104518	30%	57.7%	51.1%
SAU802567	PAE203155	33%	56.7%	51.4%
SAU802567	PPU103844	22%	57.4%	93.3%
SAU802567	SPA103154	31%	58.2%	53.0%
SAU802567	STY101087	30%	58.2%	53.0%
SAU802567	SAU802567	100%	100%	100%
SAU802567	SEP201198	64%	98.8%	99.2%
SAU802567	SMU101308	26%	95.5%	97.0%
SAU802567	SPN401865	26%	95.2%	97.2%
SAU802567	SPY200033	26%	95.2%	96.8%
SAU802580	BFR10064	24%	86.6%	86.0%
SAU802580	BPT100834	33%	82.1%	85.3%
SAU802580	BCE103008	24%	73.8%	70.3%
SAU802580	BFU100508	22%	69.6%	67.3%
SAU802580	BFU104873	25%	83.9%	70.6%
SAU802580	BFU103585	28%	82.4%	74.7%
SAU802580	BFU103576	29%	73.5%	67.0%
SAU802580	KPN302051	31%	76.5%	79.8%
SAU802580	LPN102617	32%	83.0%	82.9%
SAU802580	LMO102915	42%	98.8%	100%
SAU802580	MAV103755	39%	98.2%	99.4%
SAU802580	MBV100078	24%	71.4%	73.0%
SAU802580	MTU203462	24%	71.4%	73.0%
SAU802580	SAU802580	100%	100%	100%
SAU802580	SHA101214	73%	69.0%	100%
SAU802581	BAN101204	26%	48.9%	56.7%
SAU802581	BAN103460	27%	93.5%	90.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802581	BFU105217	23%	43.8%	39.6%
SAU802581	BFU103369	23%	43.8%	39.5%
SAU802581	CDF100605	26%	57.2%	55.6%
SAU802581	CDF103586	25%	48.6%	52.0%
SAU802581	LMO101378	66%	100%	100%
SAU802581	MAV108594	30%	44.6%	39.1%
SAU802581	SAU802581	100%	100%	100%
SAU802581	SHA102890	70%	99.6%	99.6%
SAU802581	SMU100172	31%	46.7%	34.9%
SAU802581	TPA100942	26%	42.0%	33.3%
SAU802585	BAN105638	33%	58.2%	61.8%
SAU802585	BAN113350	30%	75.5%	87.8%
SAU802585	BAN112732	30%	75.5%	87.8%
SAU802585	CAC102695	34%	89.8%	66.4%
SAU802585	CAC101396	34%	89.8%	66.4%
SAU802585	SAU802585	100%	100%	100%
SAU802585	SEP200238	78%	100%	100%
SAU802586	CBO101009	37%	38.5%	3.6%
SAU802586	EFA102043	24%	80.3%	84.2%
SAU802586	SAU802586	100%	100%	100%
SAU802587	SAU802587	100%	100%	100%
SAU802590	SAU802590	100%	100%	100%
SAU802590	SEP201225	49%	93.4%	86.7%
SAU802599	ABA105729	42%	97.1%	100%
SAU802599	BAN109585	45%	96.7%	96.1%
SAU802599	BAN103122	55%	96.7%	95.3%
SAU802599	BFR101138	43%	94.9%	95.6%
SAU802599	BPT102100	38%	91.5%	89.9%
SAU802599	BCE108792	39%	94.9%	95.6%
SAU802599	BFU102636	39%	94.9%	95.6%
SAU802599	BMA109222	39%	94.9%	95.6%
SAU802599	CJU100267	47%	95.2%	94.9%
SAU802599	CAC102467	44%	97.8%	98.2%
SAU802599	CBO102096	47%	95.2%	95.3%
SAU802599	CDF100322	43%	94.9%	94.9%
SAU802599	CDP101560	40%	77.9%	100%
SAU802599	EBC103390	44%	94.9%	98.1%
SAU802599	EFA200426	50%	93.0%	93.1%
SAU802599	EFM200299	50%	93.0%	93.1%
SAU802599	ECO100134	44%	94.9%	98.1%
SAU802599	HPY101041	39%	93.0%	94.1%
SAU802599	KPN305802	45%	94.9%	98.1%
SAU802599	LMO101566	54%	92.3%	91.7%
SAU802599	MCA100866	39%	94.9%	93.9%
SAU802599	MAV103092	43%	92.3%	88.8%
SAU802599	MBV104454	44%	90.1%	87.9%
SAU802599	MLP100998	42%	92.3%	88.5%
SAU802599	MTU202191	44%	90.1%	87.9%
SAU802599	NGO101061	42%	95.6%	99.2%
SAU802599	NME201002	42%	95.6%	99.2%
SAU802599	PRT102516	42%	94.9%	98.1%
SAU802599	PAE204725	41%	94.9%	97.7%
SAU802599	PPU108442	41%	94.9%	92.9%
SAU802599	PSY105156	42%	94.9%	97.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802599	SPA104023	39%	94.9%	97.7%
SAU802599	STY103388	43%	94.9%	97.7%
SAU802599	SAU802599	100%	100%	100%
SAU802599	SEP201249	75%	100%	100%
SAU802599	SHA101527	74%	100%	100%
SAU802599	VCH100581	40%	94.5%	97.7%
SAU802599	YPS000790	46%	95.2%	98.1%
SAU802601	EBC102039	34%	77.8%	87.6%
SAU802601	EFM100783	70%	20.5%	73.8%
SAU802601	KPN304221	32%	99.1%	89.6%
SAU802601	SAU802601	100%	100%	100%
SAU802601	SMU100354	42%	99.6%	99.2%
SAU802601	SPN401248	42%	98.3%	95.9%
SAU802601	SPY101115	40%	47.4%	92%
SAU802601	VCH101565	30%	98.3%	88.1%
SAU802605	BCE111163	23%	63.8%	65.2%
SAU802605	EFA202884	32%	42.8%	28.2%
SAU802605	SAU802605	100%	100%	100%
SAU802605	SEP201630	47%	97.8%	94.4%
SAU802605	SHA103206	40%	93.5%	91.5%
SAU802605	YPS004171	25%	52.9%	56.5%
SAU802606	LPN100635	28%	61.1%	53.0%
SAU802606	MAV102533	61%	98.6%	98.7%
SAU802606	STY101723	32%	15.5%	12.4%
SAU802606	SAU802606	100%	100%	100%
SAU802606	SEP201634	92%	100%	100%
SAU802606	SHA101827	93%	44.3%	100%
SAU802610	BAN105148	30%	61.9%	56.1%
SAU802610	BAN112430	33%	61.9%	54.5%
SAU802610	BFU101996	28%	51.0%	63.1%
SAU802610	CBO103389	30%	37.4%	54.9%
SAU802610	CDP101315	23%	55.8%	80.2%
SAU802610	LMO101650	18%	56.5%	49.1%
SAU802610	MAV100914	23%	46.9%	90.8%
SAU802610	MBV100112	23%	63.3%	88.6%
SAU802610	MLP101168	25%	53.7%	75.2%
SAU802610	MTU203540	23%	63.3%	88.6%
SAU802610	PRT104693	25%	53.7%	52.3%
SAU802610	SAU802610	100%	100%	100%
SAU802610	SEP203908	63%	99.3%	98.6%
SAU802610	SHA101334	65%	99.3%	93.6%
SAU802612	ABA105055	52%	95.8%	98.9%
SAU802612	BPT101787	34%	75.6%	97.9%
SAU802612	BCE100989	49%	86.5%	95.0%
SAU802612	BFU106253	51%	94.0%	95.0%
SAU802612	BMA100271	50%	95.8%	96.1%
SAU802612	CJU100383	29%	13.5%	13.8%
SAU802612	CDP100617	62%	96.3%	92.1%
SAU802612	EBC100717	53%	48.2%	94.8%
SAU802612	ECO100303	49%	95.4%	97.7%
SAU802612	KPN300102	52%	24.4%	100%
SAU802612	KPN304388	50%	96.0%	98.6%
SAU802612	MAV102913	33%	94.0%	99.4%
SAU802612	MBV105546	37%	93.0%	98.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802612	MTU201262	37%	93.0%	98.9%
SAU802612	PRT102375	50%	96.0%	98.4%
SAU802612	PAE205367	49%	96.5%	97.9%
SAU802612	PPU102034	51%	96.5%	97.2%
SAU802612	PSY102763	51%	96.0%	96.1%
SAU802612	SAU802612	100%	100%	100%
SAU802612	SEP201650	88%	99.6%	99.5%
SAU802612	SHA101538	89%	99.6%	99.5%
SAU802612	YPS002162	52%	96.0%	96.3%
SAU802613	ABA104044	41%	95.0%	95.9%
SAU802613	BAN108237	36%	95.8%	93.5%
SAU802613	BAN113091	41%	96.0%	97.3%
SAU802613	BAN112735	41%	96.8%	96.4%
SAU802613	BAN113417	44%	96.0%	95.5%
SAU802613	BFR103003	30%	23.8%	85.5%
SAU802613	BFU102984	38%	97.6%	98.4%
SAU802613	BFU103241	39%	97.4%	94.1%
SAU802613	BFU100165	42%	96.6%	98.8%
SAU802613	BMA103749	40%	96.0%	88.6%
SAU802613	CJU100455	34%	79.2%	99.5%
SAU802613	CAC103154	33%	96.0%	97.5%
SAU802613	CDP100607	51%	97.6%	94.3%
SAU802613	EBC101625	41%	95.6%	96.5%
SAU802613	ECO100304	41%	95.6%	96.5%
SAU802613	KPN304386	40%	95.6%	96.5%
SAU802613	LPN101129	47%	97.8%	99.2%
SAU802613	LMO102125	39%	96.6%	97.3%
SAU802613	MCA100475	37%	95.8%	94.2%
SAU802613	MAV101782	41%	94.8%	94.0%
SAU802613	MAV103466	41%	94.8%	93.0%
SAU802613	MLP101520	30%	90.3%	96.9%
SAU802613	NGO100472	36%	91.3%	91.4%
SAU802613	NME200446	36%	96.0%	98.5%
SAU802613	PPU109546	42%	95.4%	95.5%
SAU802613	PSY103463	41%	95.6%	96.5%
SAU802613	SPA103863	35%	95.4%	97.3%
SAU802613	STY103756	38%	95.0%	96.7%
SAU802613	SAU802613	100%	100%	100%
SAU802613	SEP201652	89%	100%	100%
SAU802613	SHA101537	87%	100%	100%
SAU802613	SMU101316	31%	91.3%	97.4%
SAU802613	SPY200809	30%	91.7%	96.1%
SAU802613	YPS002165	40%	95.6%	96.5%
SAU802627	BAN110806	44%	75.1%	96.9%
SAU802627	BAN110948	47%	98.9%	96.7%
SAU802627	BFR101036	31%	88.6%	94.0%
SAU802627	BCE114143	31%	88.6%	91.7%
SAU802627	BMA108016	31%	88.6%	75.0%
SAU802627	CAC102470	23%	36.5%	49.1%
SAU802627	EBC102822	37%	64.1%	75.4%
SAU802627	EFA202089	46%	97.0%	95.5%
SAU802627	ECO100375	36%	61.8%	69.0%
SAU802627	KPN304876	35%	72.4%	81.9%
SAU802627	PRT105117	33%	71.7%	78.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802627	PAE203294	37%	59.9%	69.7%
SAU802627	SAU802627	100%	100%	100%
SAU802627	SEP201696	66%	99.8%	98.2%
SAU802627	SHA101994	63%	99.8%	97.8%
SAU802627	YPS001866	36%	60.3%	69.4%
SAU802628	ABA105164	19%	63.7%	55.6%
SAU802628	ABA104704	17%	73.2%	74.7%
SAU802628	BAN106975	45%	82.2%	83.1%
SAU802628	BAN103536	45%	82.2%	83.1%
SAU802628	BFU101239	26%	65.0%	77.4%
SAU802628	BFU102576	25%	65.6%	77.0%
SAU802628	BMA109935	22%	73.2%	86.5%
SAU802628	CBO101313	29%	70.1%	75.9%
SAU802628	EBC103824	20%	68.2%	66.7%
SAU802628	EFA202071	20%	73.2%	80%
SAU802628	KPN300786	37%	33.1%	69.1%
SAU802628	LMO101624	44%	86.6%	92.1%
SAU802628	MAV105204	24%	70.1%	69.9%
SAU802628	PAE201652	36%	80.3%	82.3%
SAU802628	SPA102320	28%	59.2%	67.1%
SAU802628	STY100589	28%	59.2%	68.1%
SAU802628	STM104051	29%	59.2%	67.1%
SAU802628	SAU802628	100%	100%	100%
SAU802628	SEP201738	74%	94.3%	100%
SAU802628	SHA101864	73%	94.9%	100%
SAU802632	BFR105563	27%	32.0%	27.9%
SAU802632	BFU113817	42%	95.7%	99.0%
SAU802632	CBO100615	47%	95.7%	94.2%
SAU802632	EFA202434	54%	92.2%	94.5%
SAU802632	EFM201460	51%	96.3%	98.4%
SAU802632	LPN102484	27%	35.1%	32.9%
SAU802632	LMO102628	51%	96.6%	99.0%
SAU802632	PMU101896	29%	35.1%	32.4%
SAU802632	PRT105732	38%	95.7%	98.3%
SAU802632	SPA100561	39%	95.3%	98.3%
SAU802632	STM100668	39%	95.3%	98.3%
SAU802632	SAU802632	100%	100%	100%
SAU802632	SMU101540	48%	96.3%	98.4%
SAU802632	SPN200887	49%	81.1%	98.5%
SAU802632	SPY201189	49%	96.3%	98.4%
SAU802638	BAN107918	24%	65.7%	61.7%
SAU802638	SAU802638	100%	100%	100%
SAU802638	SEP202299	24%	72%	72.5%
SAU802638	SEP202175	32%	84%	89.4%
SAU802638	SHA100151	47%	100%	100%
SAU802641	BBU100407	43%	98.9%	3.7%
SAU802641	CPN200703	33%	19.7%	81.0%
SAU802641	CAC101724	45%	70.9%	98.7%
SAU802641	CDF103357	38%	99.2%	98.0%
SAU802641	EFM200703	52%	99.8%	99.7%
SAU802641	KPN103840	44%	46.6%	94.5%
SAU802641	MCA101148	20%	33.4%	75.1%
SAU802641	PMU101795	40%	22.8%	71.4%
SAU802641	SPA101839	42%	72.2%	87.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802641	SAU802641	100%	100%	100%
SAU802641	SEP201763	75%	100%	100%
SAU802641	VCH101790	30%	19.4%	84.9%
SAU802641	VCH101791	41%	5.4%	94.6%
SAU802641	VCH101792	40%	80.6%	5.2%
SAU802641	VCH101796	49%	99.5%	2.8%
SAU802642	BBU100406	35%	32.1%	26.6%
SAU802642	CAC102434	34%	98.7%	93.9%
SAU802642	CBO103509	30%	97.8%	92.9%
SAU802642	CDF100717	51%	98.7%	98.7%
SAU802642	CDP100913	29%	33.3%	28.0%
SAU802642	EFA201620	52%	99.4%	98.1%
SAU802642	EFM200644	52%	99.4%	98.4%
SAU802642	LMO100517	53%	99.4%	98.1%
SAU802642	MAV101383	33%	21.8%	17.4%
SAU802642	MBV104868	31%	22.4%	17.9%
SAU802642	MTU203212	31%	22.4%	17.9%
SAU802642	PMU100829	27%	30.8%	24%
SAU802642	SAU802642	100%	100%	100%
SAU802642	SEP201764	67%	99.0%	97.8%
SAU802642	SMU101180	54%	98.7%	97.5%
SAU802642	SPN400647	55%	99.0%	98.7%
SAU802642	SPY201392	53%	99.0%	97.5%
SAU802642	UUR100534	29%	26.6%	29.4%
SAU802642	VCH101797	33%	27.9%	23.7%
SAU802642	VCH100266	30%	28.2%	23.3%
SAU802642	YPS001750	27%	34.0%	28.1%
SAU802643	BAN103063	24%	97.3%	100%
SAU802643	BAN108458	30%	99.8%	99.8%
SAU802643	BFU109734	25%	33.9%	46.8%
SAU802643	CAC100500	26%	10.2%	46.0%
SAU802643	CBO100159	32%	0.5%	41.6%
SAU802643	CDF100068	36%	15.5%	91.1%
SAU802643	CDF103782	30%	0.4%	38.4%
SAU802643	CDP102624	20%	28.9%	62.2%
SAU802643	CDP101471	21%	95.0%	94.6%
SAU802643	CDP100399	22%	93.3%	90.2%
SAU802643	EFA200464	25%	99.8%	96.3%
SAU802643	EFM100294	34%	28.0%	94.6%
SAU802643	ECO103408	23%	16.5%	46.1%
SAU802643	HPY100285	27%	13.7%	4.5%
SAU802643	HPY100077	21%	7.4%	48.4%
SAU802643	HPY100225	22%	21.5%	45.8%
SAU802643	HPY101140	20%	62.3%	10.7%
SAU802643	HPY101226	22%	24.9%	32.5%
SAU802643	LMO102022	28%	99.8%	99.8%
SAU802643	MAV104113	21%	95.7%	94.0%
SAU802643	MLP101538	25%	17.0%	36.6%
SAU802643	PAE202571	19%	25.9%	45.6%
SAU802643	PSY103089	22%	24.1%	42.7%
SAU802643	SPA103375	26%	14.6%	21.8%
SAU802643	STY102351	21%	15.7%	44.6%
SAU802643	SAU802643	100%	100%	100%
SAU802643	SEP201765	66%	100%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802643	SHA101169	63%	100%	100%
SAU802643	SMU101323	23%	96.8%	98.3%
SAU802643	SPN402036	27%	13.3%	54.1%
SAU802643	SPY201662	22%	96.8%	98.7%
SAU802643	YPS002077	25%	11.2%	47.6%
SAU802646	CTR100723	23%	21.7%	29.7%
SAU802646	SAU802646	100%	100%	100%
SAU802646	SEP201767	36%	98.1%	98.8%
SAU802646	SHA101749	33%	98.6%	98.1%
SAU802649	SAU802649	100%	100%	100%
SAU802649	SEP201787	64%	99.0%	99.0%
SAU802649	SHA102155	65%	100%	100%
SAU802649	SPN301641	44%	98.7%	99.1%
SAU802651	BAN102391	24%	20.3%	12.4%
SAU802651	EFA200259	31%	14.2%	25.1%
SAU802651	MAV106301	34%	13.8%	24.6%
SAU802651	SAU802651	100%	100%	100%
SAU802651	SEP201789	54%	99.4%	100%
SAU802651	SHA102153	56%	98.3%	98.7%
SAU802651	SPN301643	39%	98.3%	99.4%
SAU802651	SPY100103	44%	24.7%	100%
SAU802652	EBC103319	28%	17.0%	42.8%
SAU802652	MBV100249	23%	37.1%	54.4%
SAU802652	MTU201429	23%	37.1%	54.4%
SAU802652	SAU802652	100%	100%	100%
SAU802652	SEP201795	43%	99.2%	99.0%
SAU802652	SHA102150	41%	100%	100%
SAU802652	SPN301644	29%	98.8%	98.5%
SAU802652	SPY100024	44%	14.3%	39.9%
SAU802654	ABA105043	16%	61.1%	92.9%
SAU802654	BAN110387	21%	11.0%	67.1%
SAU802654	BAN112878	20%	60.3%	43.8%
SAU802654	BAN100594	20%	3.7%	27.2%
SAU802654	BAN103564	19%	7.7%	57.2%
SAU802654	BAN103966	20%	13.9%	37.7%
SAU802654	BAN106993	18%	11.8%	94.8%
SAU802654	BAN112238	17%	72.5%	19.9%
SAU802654	BFR100872	28%	49.2%	38.4%
SAU802654	BPT103725	21%	30.9%	38.8%
SAU802654	BCE107896	17%	6.2%	97.0%
SAU802654	BCE112211	26%	61.3%	91.7%
SAU802654	BCE114917	29%	18.7%	92.8%
SAU802654	BFU110407	15%	4.4%	99.1%
SAU802654	BFU101138	18%	91.2%	16.1%
SAU802654	BMA107841	21%	18.3%	94.5%
SAU802654	CJU101583	20%	14.5%	69.2%
SAU802654	CJU100590	20%	7.0%	88.4%
SAU802654	CPN200209	18%	10.4%	74.5%
SAU802654	CTR200684	21%	25.9%	74.6%
SAU802654	CTR200685	20%	4.0%	83.8%
SAU802654	CAC100010	16%	13.0%	98.6%
SAU802654	CBO100803	19%	39.0%	50.1%
SAU802654	CDF103991	17%	26.3%	87.2%
SAU802654	CDF104259	16%	16.8%	96.1%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802654	CDF102976	19%	30.9%	59.2%
SAU802654	CDF100770	18%	19.3%	66.5%
SAU802654	CDF100757	21%	37.3%	47.0%
SAU802654	CDF103200	17%	16.6%	86.6%
SAU802654	CDF100494	18%	24.5%	63.5%
SAU802654	CDF102075	18%	59.8%	95.2%
SAU802654	CDF100184	27%	15.1%	91.5%
SAU802654	CDF104552	17%	17.5%	88.7%
SAU802654	CDP102193	22%	14.6%	99.4%
SAU802654	EBC100399	19%	25.1%	67.8%
SAU802654	EBC100820	20%	54.4%	83.4%
SAU802654	EBC100805	17%	22.1%	98.2%
SAU802654	EBC101205	18%	15.9%	99.2%
SAU802654	EFA203174	27%	4.7%	40.4%
SAU802654	EFM202396	19%	13.4%	62.3%
SAU802654	EFM200591	19%	26.6%	67.6%
SAU802654	ECO101518	28%	35.1%	42.5%
SAU802654	ECO101343	20%	32.9%	86.5%
SAU802654	HIN100971	18%	37.6%	21.1%
SAU802654	HPY100603	15%	15.5%	17.9%
SAU802654	HPY100313	18%	12.1%	36.5%
SAU802654	HPY100602	19%	25.3%	48.7%
SAU802654	HPY101160	17%	18.5%	63.3%
SAU802654	HPY101226	17%	22.9%	56.8%
SAU802654	HPY100897	22%	1.2%	47.6%
SAU802654	HPY100077	22%	16.2%	65.0%
SAU802654	HPY100906	17%	59.6%	75.7%
SAU802654	HPY101140	19%	21.4%	43.5%
SAU802654	HPY100285	18%	86.7%	16.1%
SAU802654	KPN305221	17%	5.0%	25.9%
SAU802654	LPN102929	17%	12.8%	64.8%
SAU802654	LPN100835	19%	32.7%	84.0%
SAU802654	LPN102554	19%	22.0%	95.2%
SAU802654	LPN101177	19%	53.0%	83.2%
SAU802654	MCA100348	17%	58.9%	94.1%
SAU802654	MAV107352	19%	33.2%	95.6%
SAU802654	MBV103437	18%	40.3%	83.1%
SAU802654	MLP100263	27%	32.9%	48.3%
SAU802654	MTU201527	19%	20.0%	52.7%
SAU802654	MGE100347	16%	17.3%	20.7%
SAU802654	MPN100397	17%	11.0%	72.4%
SAU802654	NGO101220	16%	21.5%	66.1%
SAU802654	NME200634	18%	43.8%	46.9%
SAU802654	PMU100714	16%	13.2%	85.6%
SAU802654	PRT105107	16%	10.7%	92.9%
SAU802654	PAE201873	17%	66.9%	93.2%
SAU802654	PPU104136	17%	35.4%	37.4%
SAU802654	PSY108622	16%	73.8%	22.1%
SAU802654	PSY106453	19%	50.7%	87.8%
SAU802654	SPA103107	19%	25.2%	98.9%
SAU802654	STY100387	19%	26.4%	91.8%
SAU802654	STM104147	19%	6.4%	97.4%
SAU802654	SAU802654	100%	100%	100%
SAU802654	SEP201799	54%	98.8%	71.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802654	SHA102148	56%	10.7%	89.4%
SAU802654	SHA103225	61%	24.3%	97.0%
SAU802654	SPN301653	43%	94.5%	7.0%
SAU802654	SPY200509	16%	52.0%	89.0%
SAU802654	TPA100484	21%	27.1%	39.4%
SAU802654	YPS002407	18%	61.5%	83.5%
SAU802655	BFR105074	22%	73.9%	84.7%
SAU802655	BCE107142	38%	90%	96.2%
SAU802655	BFU100048	43%	89.1%	98.0%
SAU802655	EBC101089	38%	72.2%	100%
SAU802655	EFM102193	42%	46.5%	99.0%
SAU802655	KPN303589	43%	82.2%	87.7%
SAU802655	PPU103404	39%	90%	98.5%
SAU802655	PSY103942	41%	82.6%	87.0%
SAU802655	SAU802655	100%	100%	100%
SAU802655	SEP201777	93%	99.1%	99.6%
SAU802658	SAU802658	100%	100%	100%
SAU802658	SEP201781	72%	99.2%	100%
SAU802658	SHA100132	66%	100%	100%
SAU802662	BFR102810	23%	65.5%	68.1%
SAU802662	CAC101079	35%	78.8%	79.1%
SAU802662	CAC101508	33%	99.6%	99.2%
SAU802662	CBO100561	36%	78.8%	78.2%
SAU802662	EFM202294	43%	82.0%	82.7%
SAU802662	SAU802662	100%	100%	100%
SAU802681	CAC101008	23%	48.4%	63.1%
SAU802681	CDF102990	31%	19.3%	28.0%
SAU802681	EFM102460	38%	61.8%	99.2%
SAU802681	SAU802681	100%	100%	100%
SAU802681	SHA103018	64%	99.7%	100%
SAU802681	SPN300982	23%	20.9%	18.3%
SAU802686	CDF102022	36%	17.7%	18.1%
SAU802686	ECO204773	48%	97.9%	91.7%
SAU802686	HPY100700	49%	97.9%	91.7%
SAU802686	LMO101556	57%	97.2%	97.9%
SAU802686	SAU802686	100%	100%	100%
SAU802686	SMU100471	52%	97.9%	98.2%
SAU802686	SPN400428	53%	97.9%	94.8%
SAU802689	ABA104423	38%	71.7%	72.6%
SAU802689	BAN106956	65%	91.8%	93.6%
SAU802689	BAN108132	66%	94.7%	94.4%
SAU802689	BPT101446	35%	70.8%	93.4%
SAU802689	BCE111516	32%	56.6%	91.7%
SAU802689	BFU112966	31%	70.8%	73.7%
SAU802689	BMA107217	31%	71.7%	78.6%
SAU802689	CPN200011	35%	91.2%	89.2%
SAU802689	CTR200904	37%	92.8%	89.6%
SAU802689	CDP100811	35%	83.6%	88.8%
SAU802689	EBC101390	30%	88.1%	80.5%
SAU802689	EFA200985	75%	96.9%	97.5%
SAU802689	EFM201522	70%	97.2%	98.7%
SAU802689	ECO101028	32%	88.1%	80.3%
SAU802689	KPN300416	27%	34.6%	71.3%
SAU802689	KPN302517	32%	89.0%	80.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802689	LPN102475	44%	39.0%	97.7%
SAU802689	LMO100379	69%	96.5%	95.6%
SAU802689	PAE200857	37%	71.7%	72.8%
SAU802689	PPU109900	39%	71.7%	73.2%
SAU802689	PSY103191	39%	71.7%	71.6%
SAU802689	SPA101128	33%	65.7%	85.8%
SAU802689	STY102479	30%	88.1%	80.3%
SAU802689	STM102282	30%	88.1%	80.3%
SAU802689	SAU802689	100%	100%	100%
SAU802689	SEP202172	77%	99.7%	99.1%
SAU802689	SHA102497	82%	100%	99.4%
SAU802689	SPN400084	63%	95.9%	94.5%
SAU802689	SPY200686	64%	95.9%	94.5%
SAU802689	VCH101240	35%	72.3%	69.0%
SAU802689	YPS003127	31%	87.4%	78.6%
SAU802701	ABA102929	41%	87.3%	96.5%
SAU802701	BAN109528	29%	25.8%	95.5%
SAU802701	BAN100158	36%	38.5%	79.9%
SAU802701	BAN112678	26%	80.2%	78.6%
SAU802701	BAN110028	50%	40.9%	99.0%
SAU802701	BAN108206	48%	87.3%	22.2%
SAU802701	BAN101564	51%	69.8%	97.8%
SAU802701	BAN109552	43%	87.7%	95.7%
SAU802701	BAN111328	45%	97.2%	98.8%
SAU802701	BAN110379	47%	96.8%	96.8%
SAU802701	BAN108174	48%	97.2%	97.6%
SAU802701	BAN101135	49%	98.8%	100%
SAU802701	BAN112693	49%	100%	98.1%
SAU802701	BAN108774	51%	99.6%	97.7%
SAU802701	BCE101081	43%	86.5%	94.4%
SAU802701	BFU106323	40%	86.5%	72.9%
SAU802701	CAC100479	49%	100%	99.6%
SAU802701	CDF101638	49%	98.0%	99.2%
SAU802701	CDP101466	47%	81.0%	91.0%
SAU802701	EFA200808	49%	97.2%	96.1%
SAU802701	ECO100486	38%	87.7%	97.4%
SAU802701	KPN302594	39%	88.1%	95.7%
SAU802701	LMO102938	50%	99.6%	98.8%
SAU802701	MBV100633	36%	91.3%	93.1%
SAU802701	MTU200975	36%	91.3%	93.1%
SAU802701	MGE100067	45%	80.6%	43.1%
SAU802701	MPN100074	44%	80.6%	43.2%
SAU802701	PMU100448	41%	90.1%	96.9%
SAU802701	SPA101078	36%	80.2%	98.1%
SAU802701	SAU802701	100%	100%	100%
SAU802701	SEP201315	71%	100%	100%
SAU802701	SHA102331	72%	100%	100%
SAU802701	SPY201472	44%	94.4%	96.3%
SAU802701	VCH103502	39%	88.5%	98.7%
SAU802710	ABA100898	30%	79.1%	85.7%
SAU802710	BAN112555	58%	97.5%	100%
SAU802710	BAN106936	64%	98.7%	99.2%
SAU802710	BFR100717	35%	59.4%	66.5%
SAU802710	BPT103217	29%	67.4%	71.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802710	BBU100176	26%	72.0%	81.2%
SAU802710	BCE112346	30%	87.4%	89.9%
SAU802710	BFU105165	30%	84.5%	92.5%
SAU802710	BMA104306	30%	73.2%	76.3%
SAU802710	CJU100925	26%	68.2%	82.4%
SAU802710	CAC102710	43%	95.8%	96.2%
SAU802710	CBO101450	39%	93.3%	93.7%
SAU802710	CDF100026	49%	36.8%	88.1%
SAU802710	CDF104563	50%	89.1%	100%
SAU802710	CDP101653	40%	52.3%	59.2%
SAU802710	EBC100304	32%	78.2%	96.2%
SAU802710	EFA200737	62%	98.7%	99.6%
SAU802710	EFM200318	61%	98.7%	97.5%
SAU802710	ECO103661	34%	85.8%	93.7%
SAU802710	HIN100467	32%	87.4%	97.5%
SAU802710	HPY101046	33%	64.9%	83.7%
SAU802710	KPN301111	35%	87.4%	97.5%
SAU802710	LPN100764	33%	62.8%	69.2%
SAU802710	LMO101197	59%	98.7%	99.6%
SAU802710	MCA101113	31%	72.0%	76.9%
SAU802710	MAV100553	33%	49.8%	47.6%
SAU802710	MBV105240	32%	46.0%	48.7%
SAU802710	MLP101601	30%	69.5%	65.7%
SAU802710	MTU203864	31%	46.0%	48.7%
SAU802710	MGE100391	30%	62.8%	76.6%
SAU802710	MPN100284	28%	63.2%	77.5%
SAU802710	NGO100788	29%	84.5%	92.3%
SAU802710	NME200072	28%	84.9%	92.8%
SAU802710	PMU101486	34%	85.8%	92.4%
SAU802710	PRT105128	35%	74.1%	82.7%
SAU802710	PAE205559	28%	87.4%	93.0%
SAU802710	PPU102171	28%	89.5%	94.9%
SAU802710	PSY102503	29%	73.2%	79.0%
SAU802710	SPA103410	31%	89.1%	97.6%
SAU802710	STY103852	31%	89.1%	97.6%
SAU802710	SAU802710	100%	100%	100%
SAU802710	SEP201294	81%	99.6%	99.6%
SAU802710	SHA101597	82%	98.7%	98.3%
SAU802710	SMU100460	55%	98.7%	100%
SAU802710	SPN401163	53%	98.7%	96.7%
SAU802710	SPY200240	55%	98.7%	100%
SAU802710	TPA100936	27%	66.1%	70.7%
SAU802710	UUR100038	33%	88.7%	99.1%
SAU802710	VCH102735	32%	87.0%	94.3%
SAU802710	YPS000008	34%	83.7%	92.2%
SAU802711	ABA101587	49%	98.9%	98.6%
SAU802711	BAN106565	54%	99.0%	99.7%
SAU802711	BAN109722	76%	99.4%	98.7%
SAU802711	BFR10096	45%	97.6%	98.9%
SAU802711	BPT100036	48%	98.4%	97.8%
SAU802711	BBU100177	48%	98.6%	97.4%
SAU802711	BCE103020	47%	99.0%	96.2%
SAU802711	BFU109113	48%	98.4%	96.2%
SAU802711	BMA106271	48%	99.0%	96.0%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802711	CJU101113	46%	98.4%	99.4%
SAU802711	CPN200128	48%	98.1%	98.2%
SAU802711	CTR200774	47%	98.2%	98.5%
SAU802711	CAC101884	54%	98.1%	97.9%
SAU802711	CBO102626	55%	98.2%	97.0%
SAU802711	CDF103119	56%	98.2%	97.3%
SAU802711	EBC101931	52%	98.1%	99.0%
SAU802711	EFA200717	66%	99.4%	98.7%
SAU802711	EFM202552	66%	99.4%	98.4%
SAU802711	ECO103662	51%	98.9%	98.7%
SAU802711	HIN100562	50%	99.2%	99.0%
SAU802711	HPY100209	46%	99.0%	99.7%
SAU802711	KPN300377	54%	29.6%	93.4%
SAU802711	KPN301110	50%	95.4%	100%
SAU802711	LPN101818	49%	98.9%	99.0%
SAU802711	LMO102246	71%	99.2%	98.6%
SAU802711	MCA101156	47%	98.9%	97.6%
SAU802711	MGE100390	44%	97.6%	98.9%
SAU802711	MPN100285	41%	97.9%	99.2%
SAU802711	NGO100779	47%	98.2%	97.8%
SAU802711	NME200069	47%	98.2%	98.2%
SAU802711	PMU101485	51%	99.2%	99.0%
SAU802711	PRT103989	51%	99.2%	98.9%
SAU802711	PAE205560	50%	98.1%	97.3%
SAU802711	PPU103677	50%	97.8%	98.2%
SAU802711	PSY103430	49%	57.1%	97.0%
SAU802711	SPA103411	50%	98.9%	99.7%
SAU802711	STY103850	51%	98.9%	98.7%
SAU802711	SAU802711	100%	100%	100%
SAU802711	SEP201293	93%	99.7%	99.7%
SAU802711	SHA101596	94%	100%	100%
SAU802711	SMU101356	63%	98.2%	97.8%
SAU802711	SPN400124	63%	99.5%	98.0%
SAU802711	SPY201670	63%	99.2%	98.7%
SAU802711	TPA100043	42%	98.2%	99.0%
SAU802711	UUR100037	46%	98.9%	99.7%
SAU802711	VCH102736	49%	98.4%	97.8%
SAU802711	YPS000011	50%	99.0%	98.9%
SAU802713	ABA100989	26%	83.5%	73.7%
SAU802713	BAN108182	50%	89.6%	90.4%
SAU802713	BAN113266	51%	91.3%	89.1%
SAU802713	BFR101294	30%	64.3%	55.8%
SAU802713	BPT105773	40%	35.7%	34.1%
SAU802713	BBU100440	23%	82.6%	82.4%
SAU802713	BMA108699	29%	69.6%	51.0%
SAU802713	CJU100890	23%	95.7%	99.1%
SAU802713	CPN200910	34%	72.2%	59.0%
SAU802713	CTR200162	26%	71.3%	68.9%
SAU802713	CAC102336	38%	91.3%	89.9%
SAU802713	CBO103162	37%	94.8%	99.1%
SAU802713	CDF103808	40%	86.1%	87.7%
SAU802713	CDP101660	29%	54.8%	53.8%
SAU802713	EBC100049	28%	70.4%	89.0%
SAU802713	BFA200678	44%	96.5%	94.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802713	EFM102258	42%	60.9%	97.3%
SAU802713	ECO103625	26%	83.5%	80.7%
SAU802713	HIN100980	28%	69.6%	67.2%
SAU802713	HPY101427	27%	94.8%	80.7%
SAU802713	KPN302213	32%	55.7%	54.6%
SAU802713	LPN100279	32%	96.5%	96.5%
SAU802713	LMO102928	52%	98.3%	95.8%
SAU802713	MCA103188	32%	73.0%	62.0%
SAU802713	MBV103340	24%	88.7%	81.6%
SAU802713	MLP101604	21%	89.6%	92.5%
SAU802713	MTU203868	24%	88.7%	81.6%
SAU802713	MGE100474	28%	86.1%	89.8%
SAU802713	NGO101432	28%	88.7%	85.1%
SAU802713	NME200510	28%	88.7%	85.1%
SAU802713	PMU101163	29%	64.3%	56.9%
SAU802713	PRT102997	33%	55.7%	54.6%
SAU802713	PAE205564	31%	70.4%	60.7%
SAU802713	PPU102196	38%	42.6%	30.3%
SAU802713	PSY107592	33%	64.3%	43.6%
SAU802713	STY104781	27%	83.5%	80.7%
SAU802713	STM104793	27%	83.5%	80.7%
SAU802713	SAU802713	100%	100%	100%
SAU802713	SEP201290	83%	100%	100%
SAU802713	SHA100141	83%	100%	100%
SAU802713	SMU100665	44%	97.4%	93.3%
SAU802713	SPN401851	45%	97.4%	91.1%
SAU802713	SPY200178	46%	97.4%	93.3%
SAU802713	UUR100610	31%	93.0%	92.9%
SAU802713	VCH100006	33%	76.5%	74.6%
SAU802713	YPS003466	33%	56.5%	55.5%
SAU802714	ABA100986	62%	95.6%	97.7%
SAU802714	BAN102648	88%	97.8%	100%
SAU802714	BAN102568	88%	97.8%	100%
SAU802714	BFR106080	62%	95.6%	91.5%
SAU802714	BPT100632	53%	95.6%	97.7%
SAU802714	BBU100439	55%	95.6%	84.3%
SAU802714	BCE105407	55%	95.6%	97.7%
SAU802714	BMA109034	55%	95.6%	97.7%
SAU802714	CJU100891	60%	95.6%	97.7%
SAU802714	CPN200909	64%	93.3%	93.3%
SAU802714	CTR200163	61%	93.3%	93.3%
SAU802714	CAC101976	70%	91.1%	93.2%
SAU802714	CBO101345	63%	91.1%	70.7%
SAU802714	CDF104319	70%	97.8%	97.8%
SAU802714	CDP101663	58%	95.6%	86%
SAU802714	EBC100048	62%	95.6%	93.5%
SAU802714	EFA202663	86%	97.8%	100%
SAU802714	ECO103624	62%	95.6%	93.5%
SAU802714	HIN100979	70%	97.8%	100%
SAU802714	HPY101426	60%	95.6%	97.7%
SAU802714	KPN204278	62%	95.6%	93.5%
SAU802714	LPN103600	61%	97.8%	100%
SAU802714	LMO100377	84%	97.8%	100%
SAU802714	MCA103596	60%	95.6%	97.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
SAU802714	MBV102731	59%	93.3%	91.3%
SAU802714	MLP101605	58%	95.6%	91.5%
SAU802714	MTU203869	60%	95.6%	91.5%
SAU802714	MGE100475	58%	95.6%	89.6%
SAU802714	MPN100160	58%	95.6%	89.6%
SAU802714	NGO103743	55%	95.6%	97.7%
SAU802714	NME200511	55%	95.6%	97.7%
SAU802714	PMU101162	70%	97.8%	100%
SAU802714	PRT102996	60%	95.6%	91.5%
SAU802714	PAE205565	65%	95.6%	97.7%
SAU802714	PPU102199	62%	95.6%	97.7%
SAU802714	SPA101308	62%	95.6%	93.5%
SAU802714	STY104683	62%	95.6%	93.5%
SAU802714	STM104752	62%	95.6%	93.5%
SAU802714	SAU802714	100%	100%	100%
SAU802714	SEP201288	100%	100%	100%
SAU802714	SHA100140	100%	100%	100%
SAU802714	SMU102293	72%	97.8%	100%
SAU802714	SPN401805	72%	97.8%	100%
SAU802714	SPY200181	75%	97.8%	100%
SAU802714	TPA100941	55%	95.6%	84.3%
SAU802714	UUR100611	72%	95.6%	89.6%
SAU802714	VCH100007	63%	97.8%	97.8%
SAU802714	YPS003462	60%	95.6%	93.5%
STM100137	BPT103857	29%	85.4%	59.3%
STM100137	BFU113310	31%	82.2%	80.5%
STM100137	BMA106841	30%	83.6%	48.9%
STM100137	PAE111701	33%	15.5%	64.5%
STM100137	PPU102760	32%	23.2%	28.5%
STM100137	SPA106841	87%	7.0%	70.9%
STM100137	STM100137	100%	100%	100%
STM100137	SAU501115	27%	19.6%	25.6%
STM100227	BCE105792	22%	31.0%	52.5%
STM100227	BCE101253	29%	25.5%	38.4%
STM100227	BFU102165	29%	15.8%	32.0%
STM100227	KPN109637	48%	15.6%	92.1%
STM100227	STM100227	100%	100%	100%
STM100227	SAU502668	32%	7.2%	20.1%
STM100229	BCE113297	41%	41.4%	100%
STM100229	BMA101920	35%	95.7%	91.3%
STM100229	CDP102420	32%	12.3%	94.7%
STM100229	KPN112130	68%	29.7%	89.1%
STM100229	MAV107220	28%	93.7%	93.8%
STM100229	PAE111649	34%	78.5%	92.8%
STM100229	SPA106013	100%	13.6%	74.4%
STM100229	STM100229	100%	100%	100%
STM100229	SMU101194	24%	17.2%	21.3%
STM100274	ABA101013	37%	89.8%	93.7%
STM100274	ABA100365	41%	89.8%	93.7%
STM100274	BPT100083	36%	96.5%	100%
STM100274	BCE104632	39%	81.9%	100%
STM100274	BFU102105	41%	92.7%	96.1%
STM100274	BMA108617	42%	90.5%	94.0%
STM100274	EBC100961	77%	99.7%	98.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
STM100274	ECO101491	84%	98.7%	96.9%
STM100274	KPN306347	56%	96.5%	100%
STM100274	LPN103390	29%	69.5%	95.5%
STM100274	MCA100493	34%	96.5%	100%
STM100274	MLP100143	35%	15.2%	8.4%
STM100274	PRT101607	55%	94.0%	100%
STM100274	PPU106304	37%	94.3%	98.0%
STM100274	PSY103291	29%	81.3%	90.3%
STM100274	SPA103363	96%	98.7%	96.9%
STM100274	STY104266	99%	100%	100%
STM100274	STM100274	100%	100%	100%
STM100541	MAV101179	24%	26.4%	27.1%
STM100541	STM100541	100%	100%	100%
STM100580	BPT103484	40%	96.2%	68.4%
STM100580	BCE114868	44%	86.6%	96.9%
STM100580	BMA108364	24%	49.4%	48.6%
STM100580	PPU111837	30%	91.7%	71.4%
STM100580	SPA107052	72%	11.8%	86.0%
STM100580	STM100580	100%	100%	100%
STM100637	BMA101649	23%	82.3%	55.3%
STM100637	EBC104360	25%	17.3%	15.9%
STM100637	ECO103620	25%	14.5%	13.2%
STM100637	KPN301149	25%	17.3%	30.6%
STM100637	PRT102211	27%	11.9%	10.9%
STM100637	STY103968	25%	17.3%	15.9%
STM100637	STM101609	40%	97.6%	95.8%
STM100637	STM100637	100%	100%	100%
STM100638	BCE104424	35%	13.2%	39.6%
STM100638	STM100638	100%	100%	100%
STM100693	STM100290	28%	79.6%	80.3%
STM100693	STM100693	100%	100%	100%
STM100723	ABA104878	49%	99.2%	99.0%
STM100723	BAN106141	34%	43.8%	99.7%
STM100723	BAN102570	46%	43.8%	96.9%
STM100723	BFR101415	47%	42.9%	93.2%
STM100723	BPT101834	29%	44.5%	42.5%
STM100723	BBU100588	35%	42.6%	91.5%
STM100723	BCE113410	44%	36.6%	95.4%
STM100723	BFU103363	44%	44.3%	93.9%
STM100723	BMA102976	32%	43.7%	41.4%
STM100723	CJU100638	49%	45.4%	64.9%
STM100723	CAC102832	45%	44.1%	97.0%
STM100723	CBO102063	55%	22.4%	90.4%
STM100723	CDF100616	23%	44.4%	97.6%
STM100723	CDF100432	24%	43.8%	96.0%
STM100723	CDP101294	43%	59.5%	91.4%
STM100723	EBC104962	91%	99.9%	100%
STM100723	EFA202248	44%	42.6%	93.6%
STM100723	EFM200028	38%	26.9%	93.7%
STM100723	ECO102255	96%	99.9%	100%
STM100723	HIN101176	68%	99.6%	100%
STM100723	HPY200837	50%	30.5%	6.7%
STM100723	KPN305976	95%	99.3%	100%
STM100723	LPN102073	27%	26.3%	41.0%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
STM100723	LMO100950	47%	42.7%	93.8%
STM100723	MCA101508	64%	23.8%	1.4%
STM100723	MAV101929	36%	99.3%	98.6%
STM100723	MBV102834	36%	99.2%	98.8%
STM100723	MTU200407	36%	99.2%	98.8%
STM100723	MGE100305	35%	44.7%	97.5%
STM100723	MPN100413	36%	44.0%	97.2%
STM100723	NGO100804	70%	17.5%	8.2%
STM100723	NME200777	70%	17.5%	8.2%
STM100723	PMU100705	69%	99.6%	100%
STM100723	PRT100628	81%	99.3%	100%
STM100723	PAE200834	55%	98.9%	98.9%
STM100723	PPU103956	50%	98.6%	100%
STM100723	PSY102379	52%	97.5%	99.4%
STM100723	SPA102048	91%	70.3%	93.3%
STM100723	STY100983	99%	100%	100%
STM100723	STM100723	100%	100%	100%
STM100723	SAU800588	42%	43.0%	94.8%
STM100723	SEP200137	44%	43.0%	94.8%
STM100723	SHA101700	45%	43.0%	94.8%
STM100723	SMU100210	45%	42.6%	92.4%
STM100723	SPN401007	48%	43.1%	95.1%
STM100723	SPY200858	44%	43.3%	94.0%
STM100723	TPA100093	41%	43.3%	95.5%
STM100723	UUR100064	24%	35.4%	82.9%
STM100723	VCH101078	73%	100%	100%
STM100723	YPS000496	86%	99.6%	99.2%
STM100724	BAN104006	29%	73.1%	91.0%
STM100724	BAN106594	29%	97.8%	96.6%
STM100724	BFR103701	31%	95.7%	97.4%
STM100724	BPT103061	21%	19.2%	22.9%
STM100724	BBU100842	29%	95.7%	96.3%
STM100724	BMA107628	29%	77.9%	72.5%
STM100724	CTR100660	29%	20.8%	36.2%
STM100724	CBO103750	28%	98.4%	98.8%
STM100724	CDF101574	35%	76.5%	87.3%
STM100724	CDF101198	35%	98.0%	97.0%
STM100724	CDP101707	39%	11.5%	12.1%
STM100724	EBC103307	30%	96.0%	98.3%
STM100724	EFA202432	26%	80.6%	87.0%
STM100724	EFM200181	50%	5.1%	15.1%
STM100724	ECO102256	91%	100%	98.6%
STM100724	HIN100573	28%	97.2%	97.8%
STM100724	HPY100684	24%	35.2%	38.1%
STM100724	MCA100770	21%	72.7%	73.0%
STM100724	PMU101104	23%	34.0%	34.4%
STM100724	PRT100826	29%	96.4%	96.4%
STM100724	SPA102153	96%	97.8%	100%
STM100724	STY100984	100%	100%	100%
STM100724	STM100724	100%	100%	100%
STM100724	SAU801171	29%	97.6%	97.3%
STM100724	SEP202232	28%	97.4%	96.5%
STM100724	SHA102381	30%	97.6%	98.1%
STM100724	SMU100142	21%	76.7%	79.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
STM100724	SPN401956	28%	98.2%	98.2%
STM100724	SPY201191	27%	98.2%	99.4%
STM100724	VCH100864	23%	43.1%	41.8%
STM100724	YPS002032	19%	20.6%	39.7%
STM100866	BPT101006	33%	97.9%	91.7%
STM100866	BCE100250	33%	52.9%	98.0%
STM100866	BFU108046	30%	97.2%	99.7%
STM100866	BFU106928	32%	95.5%	94.2%
STM100866	BFU101670	31%	95.8%	97.1%
STM100866	BFU102611	33%	97.2%	94.9%
STM100866	BFU110913	33%	95.2%	95.9%
STM100866	BFU114233	33%	96.2%	97.3%
STM100866	BMA106862	28%	95.8%	92.0%
STM100866	CDP100121	25%	97.6%	96.4%
STM100866	EBC102104	73%	98.6%	98.3%
STM100866	EFA200698	55%	97.6%	95.6%
STM100866	ECO100606	63%	99.7%	94.5%
STM100866	HIN100022	61%	100%	99.7%
STM100866	KPN201811	89%	100%	100%
STM100866	MCA100880	23%	95.5%	97.0%
STM100866	MAV100316	30%	97.9%	95.2%
STM100866	MBV101161	31%	88.2%	86.8%
STM100866	MTU202461	31%	88.2%	86.8%
STM100866	PRT106096	26%	96.9%	97.5%
STM100866	PAE200882	30%	97.6%	97.5%
STM100866	PPU100881	28%	30.1%	11.6%
STM100866	SPA101729	96%	92.7%	100%
STM100866	STY101151	99%	100%	100%
STM100866	STM100866	100%	100%	100%
STM100866	SMU100150	56%	99.0%	95.7%
STM100866	SPY200907	57%	99.0%	97.3%
STM100866	VCH100784	65%	98.6%	96.6%
STM100866	YPS002471	30%	97.9%	96.1%
STM101115	BAN112350	30%	33.4%	40.1%
STM101115	BCE100786	33%	27.5%	28.5%
STM101115	BFU102061	27%	36.4%	39.9%
STM101115	BMA109995	30%	35.2%	35.3%
STM101115	CAC101453	33%	88.5%	81.3%
STM101115	CBO101891	30%	31.1%	33.8%
STM101115	CDF103042	31%	25.1%	48.3%
STM101115	CDP100635	25%	76.3%	82.6%
STM101115	EBC103957	84%	97.6%	100%
STM101115	EFA201896	22%	30.5%	33.6%
STM101115	ECO103737	81%	99.4%	98.8%
STM101115	HIN100626	30%	93.8%	98.4%
STM101115	KPN303520	81%	97.0%	99.4%
STM101115	LMO101007	29%	29.0%	32.4%
STM101115	MAV102145	25%	39.9%	47.3%
STM101115	MBV102643	28%	39.9%	47.0%
STM101115	MLP101539	23%	83.7%	92.8%
STM101115	MTU200182	28%	39.9%	40.6%
STM101115	MPN100368	48%	10.4%	13.1%
STM101115	PMU101631	28%	93.5%	97.5%
STM101115	PRT104544	48%	95.9%	97.3%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
STM101115	PAE203299	28%	28.4%	30.4%
STM101115	PPU108432	30%	28.4%	30.6%
STM101115	SPA101172	97%	100%	100%
STM101115	STY102009	99%	100%	100%
STM101115	STM101115	100%	100%	100%
STM101115	SAU801303	30%	44.4%	48.0%
STM101115	SEP201929	29%	35.2%	39.3%
STM101115	SHA102823	29%	29.9%	31.9%
STM101115	VCH100134	37%	93.8%	92.9%
STM101115	YPS001338	57%	97.6%	97.9%
STM101116	BAN105201	25%	87.6%	89.6%
STM101116	BAN104169	29%	90.2%	89.0%
STM101116	BBU100068	31%	97.7%	96.2%
STM101116	BCE113428	43%	30.5%	90%
STM101116	BFU104191	37%	99.2%	97.1%
STM101116	BMA100853	37%	99.2%	96.0%
STM101116	CPN200343	24%	89.5%	88.8%
STM101116	CTR200373	21%	89.8%	88.6%
STM101116	CAC101546	26%	90.2%	90.2%
STM101116	CAC100913	27%	88.3%	86.9%
STM101116	CAC101334	27%	90.2%	90%
STM101116	CBO101559	24%	89.8%	90.3%
STM101116	CDF102915	26%	89.5%	87.9%
STM101116	EBC103959	89%	99.6%	97.8%
STM101116	EFA202119	26%	90.6%	91.0%
STM101116	EFM200109	29%	90.2%	91.0%
STM101116	ECO103738	90%	57.5%	89.5%
STM101116	HIN100576	42%	98.9%	97.1%
STM101116	KPN303521	81%	99.6%	99.6%
STM101116	LMO102621	27%	90.6%	91.3%
STM101116	MAV103247	25%	98.9%	98.5%
STM101116	MBV102452	26%	87.2%	87.2%
STM101116	MLP100060	26%	96.6%	92.9%
STM101116	MTU203758	26%	87.2%	87.2%
STM101116	MPN100414	27%	80.5%	79.7%
STM101116	NGO100507	38%	34.2%	80.7%
STM101116	PMU101629	40%	98.9%	97.1%
STM101116	PRT105543	62%	99.2%	99.2%
STM101116	SPA101171	99%	75.2%	100%
STM101116	STY102007	100%	100%	100%
STM101116	STM101116	100%	100%	100%
STM101116	SAU801331	27%	98.5%	98.5%
STM101116	SEP200102	28%	90.6%	90.1%
STM101116	SHA100656	26%	98.1%	95.6%
STM101116	SMU100748	27%	98.5%	100%
STM101116	SPN400263	30%	98.9%	98.9%
STM101116	SPY201336	28%	98.9%	98.9%
STM101116	TPA100287	25%	89.1%	88.4%
STM101116	UUR100174	26%	88.7%	88.0%
STM101116	VCH100133	49%	97.4%	94.9%
STM101116	YPS001335	73%	99.6%	98.5%
STM101278	EBC107120	29%	17.1%	60.9%
STM101278	NME105091	31%	15.2%	17.7%
STM101278	PSY106217	25%	53.1%	52.6%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
STM101278	STM101278	100%	100%	100%
STM101278	SEP200437	28%	24.6%	34.2%
STM101278	SEP200202	28%	24.6%	34.2%
STM101278	SEP200828	28%	24.6%	34.2%
STM101278	SEP204358	36%	12.4%	36.5%
STM101278	SEP200771	28%	24.6%	34.2%
STM101278	SEP201864	28%	24.6%	34.2%
STM101278	SEP200165	28%	24.6%	34.2%
STM101278	SEP201913	28%	24.6%	34.2%
STM101278	SEP200187	28%	24.6%	34.2%
STM101278	SEP200347	28%	24.6%	34.2%
STM101278	SEP203770	28%	24.6%	34.2%
STM101278	SEP200222	28%	24.6%	34.2%
STM101923	BFR104413	56%	97.8%	95.5%
STM101923	BPT102042	44%	96.9%	95.0%
STM101923	BCE112542	59%	97.8%	97.8%
STM101923	BFU104304	58%	96.9%	93.0%
STM101923	BMA105070	57%	97.8%	97.4%
STM101923	CAC101675	30%	89.3%	84.0%
STM101923	CBO102946	31%	87.5%	83.9%
STM101923	CDF104256	28%	90.2%	89.3%
STM101923	CDP100150	30%	98.7%	97.9%
STM101923	EBC101616	89%	38.7%	100%
STM101923	EFA202385	30%	91.9%	88.7%
STM101923	ECO101796	90%	100%	92.5%
STM101923	KPN301541	79%	99.3%	99.6%
STM101923	MAV103783	30%	88.8%	74.1%
STM101923	MBV105656	29%	88.2%	77.6%
STM101923	MTU202299	29%	88.2%	75.6%
STM101923	PAE200245	30%	89.7%	82.8%
STM101923	SPA100492	98%	98.9%	100%
STM101923	STM101923	100%	100%	100%
STM101923	VCH101573	28%	88.6%	84.9%
STM101923	YPS000541	69%	98.9%	99.3%
STM101955	SPA104151	96%	100%	100%
STM101955	STM101955	100%	100%	100%
STM102011	STM102011	100%	100%	100%
STM102089	ABA104944	29%	76.3%	81.9%
STM102089	BAN113702	44%	45.9%	72.6%
STM102089	BAN111016	34%	98.2%	100%
STM102089	BAN102075	36%	93.0%	90.5%
STM102089	BAN106548	36%	100%	99.4%
STM102089	BAN111025	34%	100%	100%
STM102089	BFR100859	25%	46.2%	35.5%
STM102089	BFR102551	26%	49.8%	38.2%
STM102089	BPT101117	35%	98.2%	91.8%
STM102089	BCE102679	33%	98.8%	92.7%
STM102089	BFU105518	35%	86.6%	79.7%
STM102089	BMA107904	35%	98.8%	100%
STM102089	CJU100150	33%	92.7%	93.1%
STM102089	CPN200938	28%	20.4%	18.7%
STM102089	CAC101752	32%	98.8%	100%
STM102089	CBO102636	31%	98.8%	99.7%
STM102089	CDF101204	30%	98.8%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
STM102089	CDP101688	31%	86.0%	98.0%
STM102089	EBC102210	89%	100%	100%
STM102089	EFA202347	35%	98.8%	100%
STM102089	ECO100757	92%	100%	100%
STM102089	HIN101641	60%	99.4%	96.7%
STM102089	HPY100755	28%	98.8%	99.7%
STM102089	KPN303579	87%	100%	100%
STM102089	LMO102857	33%	98.8%	99.1%
STM102089	MCA103672	44%	99.1%	89.5%
STM102089	MAV105594	35%	95.1%	87.4%
STM102089	MBV102851	33%	92.4%	83.4%
STM102089	MTU203069	33%	92.4%	85.5%
STM102089	PMU100625	61%	98.8%	96.1%
STM102089	PRT104379	72%	99.1%	99.4%
STM102089	PAE201504	35%	99.4%	99.1%
STM102089	PPU106301	36%	93.3%	92.2%
STM102089	PSY105427	35%	98.2%	99.7%
STM102089	SPA102732	99%	100%	100%
STM102089	STY102330	100%	100%	100%
STM102089	STM102089	100%	100%	100%
STM102089	SAU802268	33%	100%	100%
STM102089	SEP200319	32%	100%	100%
STM102089	SHA101565	31%	100%	100%
STM102089	SPN400676	25%	48.6%	47.9%
STM102089	VCH101005	64%	100%	98.5%
STM102089	YPS002149	76%	99.1%	99.4%
STM102090	BAN104975	42%	84.7%	85.8%
STM102090	BFR102256	23%	81.2%	38.5%
STM102090	BPT101121	52%	91.8%	90.2%
STM102090	EBC102209	91%	100%	100%
STM102090	ECO100758	95%	100%	100%
STM102090	KPN303581	92%	100%	100%
STM102090	LMO101377	38%	87.1%	91.4%
STM102090	MCA101697	58%	95.9%	86.2%
STM102090	MBV100621	31%	81.8%	76.8%
STM102090	MLP100125	33%	81.2%	76.2%
STM102090	MTU200973	31%	81.8%	76.8%
STM102090	PAE203912	58%	97.1%	89.2%
STM102090	PAE203027	58%	95.9%	91.1%
STM102090	PPU101063	57%	97.6%	96.5%
STM102090	PSY109125	54%	99.4%	94.4%
STM102090	SPA102733	99%	100%	100%
STM102090	STY102331	100%	100%	100%
STM102090	STM102090	100%	100%	100%
STM102090	SAU802275	45%	85.3%	87.5%
STM102090	SEP200340	42%	85.9%	85.2%
STM102090	SHA101559	46%	84.1%	84.8%
STM102090	SMU101232	25%	56.5%	21.3%
STM102090	SPN401756	29%	51.8%	19.4%
STM102090	VCH101006	63%	98.8%	98.8%
STM102366	STM102366	100%	100%	100%
STM102401	BPT105648	41%	100%	42.0%
STM102401	BCE107576	40%	99.4%	73.4%
STM102401	BFU113002	41%	45.3%	33.2%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
STM102401	BMA104672	37%	99.4%	47.0%
STM102401	MAV108057	34%	99.4%	76.8%
STM102401	MBV105368	35%	99.4%	80.3%
STM102401	MTU409357	35%	99.4%	80.3%
STM102401	PAE109984	40%	99.4%	89.1%
STM102401	PSY100104	42%	95.0%	95.6%
STM102401	STM102401	100%	100%	100%
STM102419	BPT105323	33%	92.8%	49.0%
STM102419	PAE111918	43%	64.0%	51.8%
STM102419	PSY103395	35%	91.9%	54.3%
STM102419	SPA106234	100%	100%	82.2%
STM102419	STM102419	100%	100%	100%
STM102422	CDP102587	30%	73.9%	35.2%
STM102422	EBC105759	91%	48.9%	100%
STM102422	KPN206188	95%	48.9%	100%
STM102422	STM102422	100%	100%	100%
STM102449	BFU104448	49%	99.2%	67.8%
STM102449	MBV100454	32%	99.2%	80%
STM102449	MTU411274	32%	99.2%	80%
STM102449	FRT105025	61%	48%	88.6%
STM102449	PAE111567	48%	23.2%	96.7%
STM102449	STM102449	100%	100%	100%
STM102449	SPY103286	52%	38.4%	98.0%
STM102672	ABA105833	40%	96.4%	99.4%
STM102672	BAN101367	20%	65.6%	68.2%
STM102672	BPT101286	48%	97.5%	99.2%
STM102672	BBU100809	25%	96.6%	97.5%
STM102672	BCE109401	52%	97.1%	99.6%
STM102672	BFU100360	52%	97.1%	99.6%
STM102672	BMA106132	50%	98.1%	81.1%
STM102672	CIU100740	31%	86.3%	92.5%
STM102672	CPN200015	23%	82.6%	78.1%
STM102672	CTR200901	22%	88.4%	83.6%
STM102672	CAC103368	27%	82.8%	82.5%
STM102672	CBO100146	25%	84.4%	93.0%
STM102672	CDF100314	28%	23.1%	87.4%
STM102672	CDF100311	26%	70.2%	91.0%
STM102672	CDF103058	27%	95.6%	95.6%
STM102672	CDP101613	25%	77.9%	37.2%
STM102672	EBC101202	91%	97.5%	100%
STM102672	EFA201075	21%	72.5%	75.7%
STM102672	EFM201627	23%	43.9%	42.0%
STM102672	ECO101042	94%	97.3%	99.8%
STM102672	HIN100943	39%	93.5%	98.4%
STM102672	HPY100871	28%	83.8%	98.0%
STM102672	KPN302527	90%	100%	100%
STM102672	LPN102528	45%	87.0%	98.7%
STM102672	LMO100585	23%	36.6%	33.5%
STM102672	MCA103523	43%	95.4%	97.7%
STM102672	MBV102833	27%	79.8%	37.1%
STM102672	MLP101595	27%	91.6%	40.0%
STM102672	MTU203855	27%	80.7%	36.7%
STM102672	NGO101881	64%	96.9%	99.4%
STM102672	NME202045	63%	96.9%	99.4%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
STM102672	PMU101660	40%	93.5%	98.4%
STM102672	PRT101541	76%	97.1%	99.6%
STM102672	PAE204560	76%	97.1%	99.4%
STM102672	PPU112503	71%	97.1%	99.4%
STM102672	PSY102688	74%	93.5%	99.4%
STM102672	SPA100422	94%	100%	100%
STM102672	STY102506	99%	94.8%	100%
STM102672	STM102672	100%	100%	100%
STM102672	SAU801754	20%	40.8%	38.9%
STM102672	SEP202115	20%	40.3%	38.5%
STM102672	SHA101207	19%	78.4%	75.0%
STM102672	SMU100383	21%	40.8%	38.2%
STM102672	SPN401382	24%	26.0%	25.2%
STM102672	TPA100512	25%	89.5%	88.4%
STM102672	VCH100667	41%	97.9%	99.0%
STM102672	YPS003371	85%	97.3%	99.8%
STM102789	ABA101658	46%	92.6%	91.1%
STM102789	BAN113740	23%	69.7%	78.7%
STM102789	BAN102304	24%	87.7%	91.5%
STM102789	BFR10945	29%	87.7%	82.8%
STM102789	BPT100037	45%	96.7%	89.4%
STM102789	BCE110334	52%	91.0%	62.7%
STM102789	BFU105764	51%	91.0%	48.1%
STM102789	BMA107802	48%	91.0%	61.3%
STM102789	CJU100229	41%	86.1%	89.0%
STM102789	CAC100848	21%	89.3%	47.0%
STM102789	CBO101544	27%	92.6%	48.7%
STM102789	CDF103965	27%	88.5%	45.2%
STM102789	EBC104206	81%	100%	100%
STM102789	EFA200393	24%	87.7%	80.5%
STM102789	EFM201127	27%	83.6%	77.9%
STM102789	ECO103936	86%	99.2%	99.2%
STM102789	HIN100318	45%	93.4%	96.6%
STM102789	HPY100691	41%	88.5%	84.4%
STM102789	KPN306685	80%	28.7%	97.2%
STM102789	KPN306067	78%	34.4%	97.7%
STM102789	KPN301864	83%	99.2%	99.2%
STM102789	LMO102033	29%	86.1%	80.2%
STM102789	NGO101285	40%	88.5%	85.0%
STM102789	NME201605	40%	87.7%	84.3%
STM102789	PMU101864	50%	93.4%	96.6%
STM102789	PRT101484	64%	99.2%	98.4%
STM102789	PAE203601	50%	91.8%	91.1%
STM102789	PPU101143	50%	91.8%	92.6%
STM102789	PSY104412	45%	91.8%	92.6%
STM102789	SPA103524	99%	100%	100%
STM102789	STY101940	100%	100%	100%
STM102789	STM102789	100%	100%	100%
STM102789	SAU801569	28%	90.2%	96.5%
STM102789	SEP201025	31%	81.1%	83.9%
STM102789	SHA101649	34%	57.4%	97.2%
STM102789	SMU101129	38%	77.0%	70.1%
STM102789	SPN400870	34%	82.0%	77.9%
STM102789	SPY200341	31%	91.0%	85.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
STM102789	VCH103435	58%	95.9%	99.2%
STM102789	YPS002785	67%	98.4%	97.6%
STM102835	BAN100006	22%	40.4%	67.4%
STM102835	BFR106009	25%	50.8%	36.6%
STM102835	BPT100671	23%	68.2%	40.9%
STM102835	BCE102211	26%	1.3%	30.4%
STM102835	BCE104738	24%	53.1%	59.1%
STM102835	BCE103017	25%	40.6%	90.6%
STM102835	BCE110445	26%	35.6%	94.0%
STM102835	BCE103623	26%	1.6%	96.7%
STM102835	BCE110366	23%	13.5%	38.0%
STM102835	BCE101250	24%	61.2%	55.7%
STM102835	BCE100403	25%	3.8%	94.4%
STM102835	BFU113446	21%	12.9%	55.0%
STM102835	BFU106257	21%	16.8%	73.7%
STM102835	BFU112017	23%	53.6%	73.3%
STM102835	BFU104375	23%	53.6%	42.8%
STM102835	BFU106700	23%	46.7%	39.2%
STM102835	BFU112565	21%	69.6%	66.3%
STM102835	BFU109807	23%	53.3%	69.1%
STM102835	BFU108657	22%	54.3%	87.1%
STM102835	BMA108282	26%	58.6%	88.4%
STM102835	CJU101583	22%	16.3%	57.3%
STM102835	CJU100590	22%	61.9%	1.7%
STM102835	CTR200684	18%	40.1%	78.3%
STM102835	CBO102757	30%	3.9%	10.6%
STM102835	CDF101661	31%	8.4%	12.5%
STM102835	CDP101991	22%	13.8%	24.4%
STM102835	EFA201471	23%	63.7%	34.5%
STM102835	EFM200844	23%	57.8%	25.0%
STM102835	ECO101376	47%	12.6%	66.5%
STM102835	HPY200552	22%	40.9%	61.1%
STM102835	HPY200273	20%	48.7%	23.6%
STM102835	HPY200815	19%	41.3%	64.1%
STM102835	HPY200852	21%	1.4%	6.3%
STM102835	KPN206267	23%	9.4%	28.1%
STM102835	MAV104123	30%	5.6%	60.7%
STM102835	MBV102102	23%	63.2%	14.2%
STM102835	MTU200354	21%	56.0%	88.8%
STM102835	MTU200303	23%	17.8%	78.1%
STM102835	NME200634	21%	47.9%	41.9%
STM102835	SPA103181	85%	35.0%	97.7%
STM102835	STM102835	100%	100%	100%
STM102835	SAU800561	24%	12.7%	16.7%
STM102835	SAU800562	22%	30.5%	2.5%
STM102835	SAU800563	26%	10.9%	15.7%
STM102835	SAU800811	21%	12.4%	34.5%
STM102835	SAU802630	27%	8.3%	16.1%
STM102835	SEP100151	29%	7.2%	19.9%
STM102835	SEP100719	25%	7.7%	2.1%
STM102835	SHA100562	19%	79.5%	4.8%
STM102835	SMU101698	19%	49.7%	91.5%
STM102835	SPY201332	21%	7.1%	32.8%
STM102835	VCH101430	20%	22.5%	81.9%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
STM103180	BFR14231	25%	13.8%	43.0%
STM103180	BCE105486	36%	92.0%	95.5%
STM103180	EBC101869	50%	79.4%	98.6%
STM103180	ECO102296	58%	65.4%	100%
STM103180	PRT104898	38%	90.4%	98.7%
STM103180	PRT104430	46%	93.8%	93.3%
STM103180	PRT100691	48%	96.8%	97.2%
STM103180	SPA103176	90%	93.9%	100%
STM103180	STY103516	53%	98.9%	97.2%
STM103180	STM103180	100%	100%	100%
STM103180	YPS002772	44%	92.5%	97.5%
STM103235	CAC102031	25%	13.4%	43.5%
STM103235	CBO103445	29%	9.5%	35.5%
STM103235	ECO103932	20%	51.5%	84.6%
STM103235	KPN301199	31%	12.1%	13.0%
STM103235	SPA103638	95%	76.5%	100%
STM103235	STM103235	100%	100%	100%
STM103235	YPS000110	32%	12.1%	13.0%
STM103247	BCE107517	29%	82.1%	70.2%
STM103247	BMA103289	32%	58.0%	58.2%
STM103247	KPN207172	50%	10.1%	58.3%
STM103247	PPU107587	30%	79.8%	76%
STM103247	PSY106811	32%	81.8%	84.1%
STM103247	SPA106549	94%	14.6%	59.1%
STM103247	STM103247	100%	100%	100%
STM103274	BFU113111	30%	27.2%	15.5%
STM103274	STM103274	100%	100%	100%
STM103418	EBC106113	76%	98.4%	52.1%
STM103418	STM103418	100%	100%	100%
STM103506	KPN200136	32%	27.7%	23.2%
STM103506	SPA105363	92%	11.8%	65.1%
STM103506	STM103506	100%	100%	100%
STM103802	BMA103619	25%	42.7%	73.4%
STM103802	BMA106999	27%	87.2%	94.5%
STM103802	HPY201193	24%	11.9%	69.1%
STM103802	STM103802	100%	100%	100%
STM103805	ABA102812	33%	16.9%	22.1%
STM103805	ABA105767	23%	62.4%	49.5%
STM103805	ABA106133	25%	63.4%	49.3%
STM103805	BFR100630	24%	29.9%	36.1%
STM103805	BCE104450	37%	39.2%	94.1%
STM103805	BCE111308	33%	80.9%	94.6%
STM103805	BFU107929	43%	79.0%	88.5%
STM103805	BFU100791	45%	78.7%	82.5%
STM103805	BFU102584	45%	80.4%	90.2%
STM103805	BMA104805	46%	71.3%	78.0%
STM103805	EBC102287	37%	80.2%	67.4%
STM103805	ECO200602	33%	74.3%	84.2%
STM103805	ECO202018	32%	77.5%	76.6%
STM103805	ECO200236	32%	78.7%	78.0%
STM103805	KPN305296	25%	69.4%	61.5%
STM103805	MBV100192	36%	12.2%	27.2%
STM103805	MTU202980	35%	11.2%	20.3%
STM103805	PKI100729	28%	77.0%	77.7%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
STM103805	PRT101866	27%	95.9%	91.5%
STM103805	PAE202683	38%	77.6%	77.4%
STM103805	PAE200091	37%	83.8%	94.2%
STM103805	PAE200095	39%	81.6%	96.0%
STM103805	PPU110472	34%	80.9%	95.3%
STM103805	PSY102082	32%	83.8%	90%
STM103805	SPA102886	79%	97.7%	100%
STM103805	STY104093	99%	100%	100%
STM103805	STM103805	100%	100%	100%
STM103805	VCH102859	27%	82.7%	60.0%
STM103805	VCH101395	30%	79.8%	50.5%
STM103805	VCH102754	31%	78.5%	83.4%
STM103805	YPS002256	38%	85.7%	72.9%
STM103815	STM103815	100%	100%	100%
STM103908	BCE114708	28%	99.6%	99.3%
STM103908	BFU100174	28%	51.3%	97.9%
STM103908	BFU100103	29%	99.6%	99.3%
STM103908	BMA108675	29%	99.6%	99.0%
STM103908	EBC102778	81%	82.2%	94.6%
STM103908	ECO102028	88%	100%	95.5%
STM103908	KPN301730	84%	100%	95.3%
STM103908	PRT101397	53%	100%	100%
STM103908	PAE204868	29%	97.8%	96.0%
STM103908	PPU100478	27%	97.8%	95.5%
STM103908	PSY101023	29%	97.6%	95.7%
STM103908	SPA100063	86%	68.7%	100%
STM103908	STY104171	99%	100%	100%
STM103908	STM103908	100%	100%	100%
STM103908	VCH101366	54%	100%	100%
STM103908	YPS003105	71%	100%	100%
STM103938	ABA104340	34%	47.1%	38.6%
STM103938	BCE100985	29%	51.9%	43.2%
STM103938	BFU111670	34%	47.1%	37.4%
STM103938	BMA108444	33%	51.9%	42.9%
STM103938	EBC101816	63%	99.0%	98.2%
STM103938	ECO102066	80%	100%	64.0%
STM103938	KPN304485	70%	99.0%	98.1%
STM103938	PPU110423	34%	84.6%	83.3%
STM103938	PSY105412	32%	48.1%	51.5%
STM103938	SPA103081	100%	100%	95.4%
STM103938	STY104192	100%	100%	100%
STM103938	STM103938	100%	100%	100%
STM104133	BPT105409	27%	81.1%	76.7%
STM104133	BCE103874	31%	67.7%	49.1%
STM104133	BMA103613	24%	87.6%	98.4%
STM104133	STM104133	100%	100%	100%
STM104223	EFA203072	34%	13.4%	11.1%
STM104223	MLP101303	26%	24.4%	26.9%
STM104223	STM104223	100%	100%	100%
STM104237	STM104237	100%	100%	100%
STM104276	EBC106188	44%	98.6%	84.5%
STM104276	KPN109099	52%	78.6%	75.2%
STM104276	STM104276	100%	100%	100%
STM104686	BCE110467	45%	98.6%	100%

Query LocusID	Homolog LocusID	Identity	Query Coverage	Homolog Coverage
STM104686	BFU102583	27%	81.8%	78.5%
STM104686	BMA102061	28%	86.5%	72.5%
STM104686	EBC104891	25%	89.2%	89.0%
STM104686	KPN107511	36%	38.5%	58.1%
STM104686	PRT103753	26%	96.6%	98.6%
STM104686	PAE200094	33%	41.9%	43.8%
STM104686	PPU110480	40%	94.6%	80.3%
STM104686	STY104879	100%	100%	100%
STM104686	STM104686	100%	100%	100%
STM104686	YPS004196	35%	94.6%	89.5%

The data in Table IV demonstrates the methods described herein identified genes required for proliferation in several species which share homology.

EXAMPLE 9

Identification of Genes and their Corresponding Operons Affected by Antisense Inhibition

5 Once the genes involved in *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium*
10 *botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus*
15 *mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* proliferation are identified as described above, the operons in which these genes lie may be identified by comparison with known microbial genomes. Since bacterial genes are
20 transcribed in a polycistronic manner, the antisense inhibition of a single gene in an operon might affect the expression of all the other genes on the operon or the genes downstream from the single gene identified. Accordingly, each of the genes contained within an operon may be analyzed for their effect on proliferation.

Operons are predicted by looking for all adjacent genes in a genomic region that lie in the
25 same orientation with no large noncoding gaps in between. First, full-length ORFs complementary to the antisense molecules are identified as described above. Adjacent ORFs are then identified and their relative orientation determined either by directly analyzing the genomic sequences surrounding the ORFs complementary to the antisense clones or by extracting adjacent ORFs from the collection obtained through whole genome ORF analysis described above followed by ORF
30 alignment. Operons predicted in this way may be confirmed by comparison to the arrangement of the homologous nucleic acids in the *Bacillus subtilis* complete genome sequence, as reported by the genome database compiled at Institut Pasteur Subtilist Release R15.1 (June 24, 1999) which can be found at <http://bioweb.pasteur.fr/GenoList/Subtilist/>. The *Bacillus subtilis* genome is the only fully
35 sequenced and annotated genome from a Gram positive microorganism, and appears to have a high level of similarity to *Staphylococcus aureus* both at the level of conservation of gene sequence and genomic organization including operon structure. Operons for *Salmonella typhimurium* and *Klebsiella pneumoniae* may be identified by comparison with *E. coli*, *Haemophilus*, or

Pseudomonas sequences. The *Pseudomonas aeruginosa* web site (<http://www.pseudomonas.com>) can also be used to help predict operon organization in this bacterium.

Extensive DNA sequences of *Salmonella typhimurium* are available through the Salmonella Genome Center (Washington University, St. Louis, MO) the Sanger Centre (United Kingdom) and the PathoSeq database (Incyte). Annotation of some of the DNA sequences in some of the
5 the aforementioned databases is lacking, but comparisons may be made to *E. coli* using tools such as BLASTX.

Public or proprietary databases may be used to analyzed *E. faecalis* sequences as well as sequences from the organisms listed above.

10 The analysis of the operons on which essential genes lie may be conducted for each of the sequences which are listed in Table IA which inhibit proliferation and the ORFs listed in Table IC. Once the full length ORFs and/or the operons containing them have been identified using the methods described above, they can be obtained from a genomic library by performing a PCR
15 amplification using primers at each end of the desired sequence. Those skilled in the art will appreciate that a comparison of the ORFs to homologous sequences in other cells or microorganisms will facilitate confirmation of the start and stop codons at the ends of the ORFs.

In some embodiments, the primers may contain restriction sites which facilitate the insertion of the gene or operon into a desired vector. For example, the gene may be inserted into an expression vector and used to produce the proliferation-required protein as described below. Other
20 methods for obtaining the full length ORFs and/or operons are familiar to those skilled in the art. For example, natural restriction sites may be employed to insert the full length ORFs and/or operons into a desired vector.

EXAMPLE 10

Identification of Individual Genes within an Operon Required for Proliferation

25 The following example illustrates a method for determining if a targeted gene within an operon is required for cell proliferation by replacing the targeted allele in the chromosome with an in-frame deletion of the coding region of the targeted gene.

Deletion inactivation of a chromosomal copy of a gene in *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*,
30 *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*,

Salmonella typhi, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* can be accomplished by integrative gene replacement. The principles of this method were described in Xia, M., et al. 1999 Plasmid 42:144-149 and Hamilton, C. M., et al 1989. *J. Bacteriol.* 171: 4617-4622. A similar gene disruption method is available for *Pseudomonas aeruginosa*, except the counter selectable marker is *sacB* (Schweizer, H. P., Klassen, T. and Hoang, T. (1996) *Mol. Biol. of Pseudomonas*. ASM press, 229-237. In this approach, a mutant allele of the targeted gene is constructed by way of an in-frame deletion and introduced into the chromosome using a suicide vector. This results in a tandem duplication comprising a deleted (null) allele and a wild type allele of the target gene. Cells in which the vector sequences have been deleted are isolated using a counter-selection technique. Removal of the vector sequence from the chromosomal insertion results in either restoration of the wild-type target sequence or replacement of the wild type sequence with the deletion (null) allele. *E. faecalis* genes can be disrupted using a suicide vector that contains an internal fragment to a gene of interest. With the appropriate selection this plasmid will homologously recombine into the chromosome (Nallapareddy, S. R., X. Qin, G. M. Weinstock, M. Hook, B. E. Murray. 2000. *Infect. Immun.* 68:5218-5224.

The resultant population of *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* colonies can then be evaluated to determine whether the target sequence is required for proliferation by PCR amplification of the affected target sequence. If the targeted gene is not required for proliferation, then PCR analysis will show that roughly equal numbers of colonies have retained either the wild-type or the mutant allele. If the targeted gene is required for proliferation, then only wild-type alleles will be recovered in the PCR analysis.

The method of cross-over PCR is used to generate the mutant allele by amplification of nucleotide sequences flanking but not including the coding region of the gene of interest, using specifically designed primers such that overlap between the resulting two PCR amplification

products allows them to hybridize. Further PCR amplification of this hybridization product using primers representing the extreme 5' and 3' ends can produce an amplification product containing an in-frame deletion of the coding region but retaining substantial flanking sequences.

For *Staphylococcus aureus*, this amplification product is subcloned into the suicide vector pSA3182 (Xia, M., et al. 1999 Plasmid 42:144-149, which is host-dependent for autonomous replication. This vector includes a *tetC* tetracycline-resistance marker and the origin of replication of the well-known *Staphylococcus aureus* plasmid pT181 (Mojumdar, M and Kahn, S.A., Characterisation of the Tetracycline Resistance Gene of Plasmid pT181, J. Bacteriol. 170: 5522 (1988). The vector lacks the *repC* gene which is required for autonomous replication of the vector at the pT181 origin. This vector can be propagated in a *Staphylococcus aureus* host strain such as SA3528, which expresses *repC* in trans. Once the amplified truncated target gene sequence is cloned and propagated in the pSA3182 vector, it can then be introduced into a *repC* minus strain such as RN4220 (Kreiswirth, B.N. et al., The Toxic Shock Syndrome Exotoxin Structural Gene is Not Detectably Transmitted by a Prophage, Nature 305:709-712 (1983), by electroporation with selection for tetracycline resistance. In this strain, the vector must integrate by homologous recombination at the targeted gene in the chromosome to impart drug resistance. This results in an inserted truncated copy of the allele, followed by pSA3182 vector sequence, and finally an intact and functional allele of the targeted gene.

Once a tetracycline resistant *Staphylococcus aureus* strain is isolated using the above technique and shown to include truncated and wild-type alleles of the targeted gene as described above, a second plasmid, pSA7592 (Xia, M., et al. 1999 Plasmid 42:144-149, is introduced into the strain by electroporation. This gene includes an erythromycin resistance gene and a *repC* gene that is expressed at high levels. Expression of *repC* in these transformants is toxic due to interference of normal chromosomal replication at the integrated pT181 origin of replication. This selects for strains that have removed the vector sequence by homologous recombination, resulting in either of two outcomes: The selected cells either possess a wild-type allele of the targeted gene or a gene in which the wild-type allele has been replaced by the engineered in-frame deletion of the truncated allele.

PCR amplification can be used to determine the genetic outcome of the above process in the resulting erythromycin resistant, tet sensitive transformant colonies. If the targeted gene is not required for cellular replication, then PCR evidence for both wild-type and mutant alleles will be found among the population of resultant transformants. However, if the targeted gene is required for cellular proliferation, then only the wild-type form of the gene will be evident among the resulting transformants.

Similarly, for *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia*

pneumoniae, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*,
 5 *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or
 10 *Yersinia pestis* the PCR products containing the mutant allele of the target sequence may be introduced into an appropriate knockout vector and cells in which the wild type target has been disrupted are selected using the appropriate methodology.

The above methods have the advantage that insertion of an in-frame deletion mutation is far less likely to cause downstream polar effects on genes in the same operon as the targeted gene.
 15 However, it will be appreciated that other methods for disrupting *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*,
 20 *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*,
 25 *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* genes which are familiar to those skilled in the art may also be used.

30 Each gene in the operon may be disrupted using the methodology above to determine whether it is required for proliferation.

EXAMPLE 11

Expression of the Proteins Encoded by Genes Identified as Required for *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*,
 35 *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium*

diphtheriae, Enterobacter cloacae, Enterococcus faecium, Haemophilus influenzae, Helicobacter pylori, Legionella pneumophila, Listeria monocytogenes, Moraxella catarrhalis, Mycobacterium avium, Mycobacterium bovis, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma genitalium, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis, Pasteurella multocida, Proteus mirabilis, Pseudomonas putida, Pseudomonas syringae, Salmonella paratyphi, Salmonella typhi, Staphylococcus epidermidis, Staphylococcus haemolyticus, Streptococcus mutans, Streptococcus pneumoniae, Streptococcus pyogenes, Treponema pallidum, Ureaplasma urealyticum, Vibrio cholerae, Yersinia pestis Proliferation

The following is provided as one exemplary method to express the proliferation-required proteins identified as described above. The proliferation-required proteins may be expressed using any of the bacterial, insect, yeast, or mammalian expression systems known in the art. In some embodiments, the proliferation-required proteins encoded by the identified nucleotide sequences described above (including the proteins of SEQ ID NOs.: 42398-78581 encoded by the nucleic acids of SEQ ID NOs.: 6214-42397 are expressed using expression systems designed either for *E. coli* or for *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis*. First, the initiation and termination codons for the gene are identified. If desired, methods for improving translation or expression of the protein are well known in the art. For example, if the nucleic acid encoding the polypeptide to be expressed lacks a methionine codon to serve as the initiation site, a strong Shine-Delgarno sequence, or a stop codon, these nucleotide sequences can be added. Similarly, if the identified nucleic acid lacks a transcription termination signal, this nucleotide sequence can be added to the construct by, for example, splicing out such a sequence from an appropriate donor sequence. In addition, the coding sequence may be operably linked to a strong constitutive promoter or an inducible promoter if desired. The identified nucleic acid or portion thereof encoding the polypeptide to be expressed is obtained by, for example, PCR from the bacterial expression vector or genome using oligonucleotide primers complementary to the identified nucleic acid or portion thereof and containing restriction endonuclease sequences appropriate for inserting the coding sequences into the vector such that the coding sequences can be

expressed from the vector's promoter. Alternatively, other conventional cloning techniques may be used to place the coding sequence under the control of the promoter. In some embodiments, a termination signal may be located downstream of the coding sequence such that transcription of the coding sequence ends at an appropriate position.

5 Several expression vector systems for protein expression in *E. coli* are well known and available to those knowledgeable in the art. The coding sequence may be inserted into any of these vectors and placed under the control of the promoter. The expression vector may then be transformed into DH5 α or some other *E. coli* strain suitable for the over expression of proteins.

Alternatively, an expression vector encoding a protein required for proliferation of
 10 *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*,
 15 *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*,
 20 *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* may be introduced into *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*,
 25 *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*,
 30 *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*,
 35 *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis*. Protocols for introducing nucleic acids into these organisms are well known in the art. For example, the protocols described in J.C.Lee "Electroporation of Staphylococci" from Methods in Molecular Biology vol 47: Electroporation Protocols for Microorganisms Edited by :

J.A. Nickoloff Humana Press Inc., Totowa, NJ. pp209-216, may be used to introduce nucleic acids into *Staphylococcus aureus*. Nucleic acids may also be introduced into *Salmonella typhimurium*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* or *Enterococcus faecalis* using methods familiar to those skilled in the art. Positive transformants are selected after growing the transformed cells on
5 plates containing an antibiotic to which the vector confers resistance. In one embodiment, *Staphylococcus aureus* is transformed with an expression vector in which the coding sequence is operably linked to the T5 promoter containing a xylose operator such that expression of the encoded protein is inducible with xylose.

In one embodiment, the protein is expressed and maintained in the cytoplasm as the native
10 sequence. In an alternate embodiment, the expressed protein can be modified to include a protein tag that allows for differential cellular targeting, such as to the periplasmic space of Gram negative or Gram positive expression hosts or to the exterior of the cell (i.e., into the culture medium). In some embodiments, the osmotic shock cell lysis method described in Chapter 16 of **Current Protocols in Molecular Biology**, Vol. 2, (Ausubel, et al., Eds.) John Wiley & Sons, Inc. (1997) may
15 be used to liberate the polypeptide from the cell. In still another embodiment, such a protein tag could also facilitate purification of the protein from either fractionated cells or from the culture medium by affinity chromatography. Each of these procedures can be used to express a proliferation-required protein.

Expressed proteins, whether in the culture medium or liberated from the periplasmic space or
20 the cytoplasm, are then purified or enriched from the supernatant using conventional techniques such as ammonium sulfate precipitation, standard chromatography, immunoprecipitation, immunochromatography, size exclusion chromatography, ion exchange chromatography, and HPLC. Alternatively, the polypeptide may be secreted from the host cell in a sufficiently enriched or pure state in the supernatant or growth media of the host cell to permit it to be used for its intended purpose
25 without further enrichment. The purity of the protein product obtained can be assessed using techniques such as SDS PAGE, which is a protein resolving technique well known to those skilled in the art. Coomassie, silver staining or staining with an antibody are typical methods used to visualize the protein of interest.

Antibodies capable of specifically recognizing the protein of interest can be generated using
30 synthetic peptides using methods well known in the art. See, **Antibodies: A Laboratory Manual**, (Harlow and Lane, Eds.) Cold Spring Harbor Laboratory (1988). For example, 15-mer peptides having an amino acid sequence encoded by the appropriate identified gene sequence of interest or portion thereof can be chemically synthesized. The synthetic peptides are injected into mice to generate antibodies to the polypeptide encoded by the identified nucleic acid sequence of interest or portion
35 thereof. Alternatively, samples of the protein expressed from the expression vectors discussed above can be purified and subjected to amino acid sequencing analysis to confirm the identity of the recombinantly expressed protein and subsequently used to raise antibodies. An Example describing in detail the generation of monoclonal and polyclonal antibodies appears in Example 12.

The protein encoded by the identified nucleic acid of interest or portion thereof can be purified using standard immunochromatography techniques. In such procedures, a solution containing the secreted protein, such as the culture medium or a cell extract, is applied to a column having antibodies against the secreted protein attached to the chromatography matrix. The secreted protein is allowed to
 5 bind the immunochromatography column. Thereafter, the column is washed to remove non-specifically bound proteins. The specifically-bound secreted protein is then released from the column and recovered using standard techniques. These procedures are well known in the art.

In an alternative protein purification scheme, the identified nucleic acid of interest or portion thereof can be incorporated into expression vectors designed for use in purification schemes employing
 10 chimeric polypeptides. In such strategies the coding sequence of the identified nucleic acid of interest or portion thereof is inserted in-frame with the gene encoding the other half of the chimera. The other half of the chimera can be maltose binding protein (MBP) or a nickel binding polypeptide encoding sequence. A chromatography matrix having maltose or nickel attached thereto is then used to purify the chimeric protein. Protease cleavage sites can be engineered between the MBP gene or the nickel
 15 binding polypeptide and the identified expected gene of interest, or portion thereof. Thus, the two polypeptides of the chimera can be separated from one another by protease digestion.

One useful expression vector for generating maltose binding protein fusion proteins is pMAL (New England Biolabs), which encodes the *malE* gene. In the pMal protein fusion system, the cloned gene is inserted into a pMal vector downstream from the *malE* gene. This results in the expression of
 20 an MBP-fusion protein. The fusion protein is purified by affinity chromatography. These techniques as described are well known to those skilled in the art of molecular biology.

EXAMPLE 12

Production of an Antibody to an isolated *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter*
 25 *baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria*
 30 *monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus*
 35 *pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* Protein

Substantially pure protein or polypeptide (including one of the polypeptides of SEQ ID NOs.: 42398-78581) is isolated from the transformed cells as described in Example 11. The concentration of

protein in the final preparation is adjusted, for example, by concentration on a 10,000 molecular weight cut off AMICON filter device (Millipore, Bedford, MA), to the level of a few micrograms/ml. Monoclonal or polyclonal antibody to the protein can then be prepared as follows:

Monoclonal Antibody Production by Hybridoma Fusion

5 Monoclonal antibody to epitopes of any of the peptides identified and isolated as described can be prepared from murine hybridomas according to the classical method of Kohler, G. and Milstein, C., *Nature* 256:495 (1975) or any of the well-known derivative methods thereof. Briefly, a mouse is repetitively inoculated with a few micrograms of the selected protein or peptides derived therefrom over a period of a few weeks. The mouse is then sacrificed, and the antibody-producing cells of the
10 spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells are destroyed by growth of the system on selective medium comprising aminopterin (HAT medium). The successfully-fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay
15 procedures, such as ELISA, as described by Engvall, E., "Enzyme immunoassay ELISA and EMIT," *Meth. Enzymol.* 70:419 (1980), and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Davis, L. et al. *Basic Methods in Molecular Biology* Elsevier, New York. Section 21-2.

20 Polyclonal Antibody Production by Immunization

Polyclonal antiserum containing antibodies to heterogeneous epitopes of a single protein or a peptide can be prepared by immunizing suitable animals with the expressed protein or peptides derived therefrom described above, which can be unmodified or modified to enhance immunogenicity. Effective polyclonal antibody production is affected by many factors related both to the antigen and the
25 host species. For example, small molecules tend to be less immunogenic than larger molecules and can require the use of carriers and adjuvant. Also, host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable. An effective immunization protocol for rabbits can be found in Vaitukaitis, J. et al. *J. Clin. Endocrinol. Metab.*
30 33:988-991 (1971).

Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony, O. et al., Chap. 19 in: *Handbook of Experimental Immunology* D. Wier (ed) Blackwell (1973). Plateau
35 concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12 μ M). Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher, D., Chap. 42 in: *Manual of Clinical Immunology*, 2d Ed. (Rose and Friedman, Eds.) Amer. Soc. For Microbiol., Washington, D.C. (1980).

Antibody preparations prepared according to either protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies can also be used in therapeutic compositions for killing bacterial cells
5 expressing the protein.

EXAMPLE 13

Construction of Strains Which Overexpress or Underexpress Gene Products Required for Proliferation by Promoter Replacement

Strains which overexpress or underexpress gene products required for proliferation may
10 also be constructed by replacing the promoters which naturally direct transcription of these gene products with promoters which provide the desired level of expression. As described above, such strains are useful in methods for identifying essential genes, in methods for identifying compounds which inhibit cellular proliferation, in methods for identifying the targets of compounds which inhibit proliferation, as well as in methods for identifying genes encoding gene products required
15 for proliferation. Some embodiments of the present invention contemplate the use of a vector that comprises a regulatable fusion promoter selected from a suite of fusion promoters wherein the promoter suite is useful for modulating both the basal and maximal levels of transcription of a nucleic acid over a wide dynamic range thus allowing the desired level of production of a transcript which corresponds to a nucleic acid described herein. Such promoters are described in U.S. Patent
20 Application Serial Number 10/032,393, filed December 21, 2001, the disclosure of which is incorporated herein by reference in its entirety.

For example, in some embodiments, the natural promoter may be replaced using techniques which employ homologous recombination to exchange a promoter present on the chromosome of the cell with the desired promoter. In such methodology, a nucleic acid comprising a promoter
25 replacement cassette is introduced into the cell. As illustrated in Figure 1A, the promoter replacement cassette comprises a 5' region homologous to the sequence which is 5' of the natural promoter in the chromosome, the promoter which is to replace the chromosomal promoter and a 3' region which is homologous to sequences 3' of the natural promoter in the chromosome. In some embodiments, the promoter replacement cassette may also include a nucleic acid encoding an
30 identifiable or selectable marker disposed between the 5' region which is homologous to the sequence 5' of the natural promoter and the promoter which is to replace the chromosomal promoter. If desired, the promoter replacement cassette may also contain a transcriptional terminator 3' of the gene encoding an identifiable or selectable marker, as illustrated in Figure 1B. As illustrated in Figure 1A and 1B, homologous recombination is allowed to occur between the
35 chromosomal region containing the natural promoter and the promoter replacement cassette. Cells in which the promoter replacement cassette has integrated into the chromosome are identified or selected. To confirm that homologous recombination has occurred, the chromosomal structure of the cells may be verified by Southern analysis or PCR.

In some embodiments, the promoter replacement cassette may be introduced into the cell as a linear nucleic acid, such a PCR product or a restriction fragment. Alternatively, the promoter replacement may be introduced into the cell on a plasmid. Figures 1A and 1B illustrates the replacement of a chromosomal promoter with a desired promoter through homologous recombination.

In some embodiments, the cell into which the promoter replacement cassette is introduced may carry mutations which enhance its ability to be transformed with linear DNA or which enhance the frequency of homologous recombination. For example, if the cell is an *Escherichia coli* cell it may have a mutation in the gene encoding Exonuclease V of the RecBCD recombination complex. If the cell is an *Escherichia coli* cell it may have a mutation that activates the RecET recombinase of the λ prophage and/or a mutation that enhances recombination through the RecF pathway. For example, the *Escherichia coli* cells may be RecB or RecC mutants carrying an *sbcA* or *sbcB* mutation. Alternatively, the *Escherichia coli* cells may be *recD* mutants. In other embodiments the *Escherichia coli* cells may express the λ Red recombination genes. For example, *Escherichia coli* cells suitable for use in techniques employing homologous recombination have been described in Datsenko, K.A. and Wanner, B.L., PNAS 97:6640-6645 (2000); Murphy, K.C., J. Bact 180: 2053-2071 (1998); Zhang, Y., et al., Nature Genetics 20: 123-128 (1998); and Muirers, J.P.P. et al., Genes & Development 14: 1971-1982 (2000). It will be appreciated that cells carrying mutations in similar genes may be constructed in organisms other than *Escherichia coli*.

In some embodiments, the methods described in U.S. Patent Application Serial Number 09/948,993, may be used to place the gene required for proliferation under the control of a regulatable promoter.

If the organism in which promoter replacement is to be performed is diploid, strains in which genes encoding gene products required for proliferation are under the control of a desired promoter may be constructed by inactivating one chromosomal copy of a gene encoding a gene product required for proliferation. For example, the gene may be inactivated by insertion of or replacement by a nucleotide sequence encoding a selectable or detectable gene product, such as a polypeptide which provides resistance to a drug or which allows growth under certain culture conditions. The other chromosomal copy of the gene encoding a gene product required for proliferation is placed under the control of a regulatable promoter, such as the tetracycline regulatable promoter similar to that described in Gari et al., (1997) *Yeast* 13:837-848 and Nagahashi et al., (1997) *Mol. Gen. Genet.* 255:372-375, by homologous recombination. The resultant strains may be used to identify genes which encode gene products required for proliferation and in the methods of the present invention.

The method may also be applied to haploid organisms by modifying the single allele of the gene via recombination of the allele with a promoter replacement fragment comprising a nucleotide sequence encoding a heterologous promoter, such that the expression of the gene is conditionally regulated by the heterologous promoter. By repeating this process for a preferred subset of genes in

a haploid pathogenic organism, or its entire genome, a collection or a complete set of conditional mutant strains can be obtained.

It will be appreciated that the means to achieve conditional expression are not restricted to the promoters discussed above and can be performed with other conditional promoters. Such
5 conditional promoter may, for example, be regulated by a repressor which repress transcription from the promoter under particular condition or by a transactivator which increases transcription from the promoter, such as, when in the presence of an inducer.

Although not mandatory, performing the gene disruption first enables heterozygous strains to be constructed and separately collected as a heterozygote strain collection during the process of
10 drug target validation. Heterozygous strains for a given gene express approximately half the normal diploid level of a particular gene product. Consequently, these strains provide constructions having a diminished level of the encoded gene product, and they may be used in the methods described herein. However, it is clear to those skilled in the art that the order of allele modification followed in this embodiment of the invention is not critical, and that it is feasible to
15 perform these steps in a different order such that the conditional-expressing allele is constructed first and the disruption of the remaining wild type gene allele be performed subsequently. However, where the promoter replacement step is carried out first, it is preferable to delete sequences homologous to those employed in the gene disruption step.

Alternatively, conditional expression could be achieved by means other than the reliance of
20 conditional promoters. For example, conditional expression could be achieved by the replacement of the wild type allele in haploid or heterozygous strains with temperature sensitive alleles derived *in vitro*, and their phenotype would then be analyzed at the nonpermissive temperature. In a related approach, in heterozygous strains, insertion of a ubiquitination signal into the remaining wild type allele to destabilize the gene product during activation conditions can be adopted to examine
25 phenotypic effects resulting from gene inactivation.

In another alternative, a constitutive promoter regulated by an excisable transactivator can be used. The promoter is placed upstream to a target gene to repress expression to the basal level characteristic of the promoter. For example, if the strains are fungal organisms, a heterologous promoter containing *lexA* operator elements may be used in combination with a fusion protein
30 composed of the *lexA* DNA binding domain and any transcriptional activator domain (e.g. GAL4, HAP4, VP16) to provide constitutive expression of a target gene. Counterselection mediated by 5-FOA can be used to select those cells which have excised the gene encoding the fusion protein. This procedure enables an examination of the phenotype associated with repression of the target gene to the basal level of expression provided by the *lexA* heterologous promoter in the absence of
35 a functional transcription activator. The strains generated by this approach may be used in the present invention.

Alternatively, conditional expression of a target gene can be achieved without the use of a transactivator containing a DNA binding, transcriptional activator domain. A cassette could be

assembled to contain a heterologous constitutive promoter downstream of, for example, the URA3 selectable marker, which is flanked with a direct repeat containing homologous sequences to the 5' portion of the target gene. Additional homologous sequences upstream of the target, when added to this cassette would facilitate homologous recombination and replacement of the native promoter with e above-described heterologous promoter cassette immediately upstream of the start codon of the target gene or open reading frame. Conditional expression is achieved by selecting strains, by using 5-FOA containing media, which have excised the heterologous constitutive promoter and URA3 marker (and consequently lack those regulatory sequences upstream of the target gene required for expression of the gene) and examining the growth of the resulting strain *versus* a wild type strain grown under identical conditions.

EXAMPLE 14

Promoter Replacement to Generate Cells Capable of Overexpressing or Underexpressing a Gene Encoding a Gene Product Required for Proliferation

A target for promoter replacement is selected. A promoter replacement cassette is obtained by inserting a nucleic acid comprising the rrnBT1T2 transcriptional terminator followed by the lac promoter into pACYC184 such that the rrnB terminator and lac promoter are positioned 3' of the CAT gene. The promoter replacement cassette (CAT-rrnBT1T2-plac) is amplified by PCR. The PCR product is used as the template for another round of PCR using primers with 60-80 bp of homology to a target promoter (i.e. a promoter which directs expression of a gene encoding a gene product required for proliferation) and 20 bp of homology to the CAT/rrnBT1T2/plac template as described above. The region of homology is chosen such that upon homologous recombination, the CAT/rrnBT1T2/plac cassette replaces the promoter of the target gene but leaves its Shine-Delgarno motif untouched.

The promoter replacement cassette is transformed into competent JC8679. JC8679 is available from the E. coli genetics stock center. JC8679 allows recombination of short linear DNAs and also contains a lacY mutation which allows titratable regulation of the lac promoter. The transformed cells are plated onto LB/chloramphenicol plates containing various levels of IPTG to assure that the correct level of expression is achieved to allow survival. The correct integration of the promoter replacement cassette is confirmed by colony PCR. If desired, proper regulation of the target gene by the inserted promoter may be confirmed by testing the integrants for growth defects when inducer is absent or present at levels lower than that at which the original colonies were obtained. The inability to grow in the absence of inducer (IPTG) or in the presence of lower levels of the inducer than were used to obtain the clones confirms that the target gene is properly regulated by the inserted promoter. It will be appreciated that although the lac promoter and the strain JC8679 are used as examples, the method may be performed using any suitable regulatable promoter and organism or strain to generate cells which are capable of overexpressing or underexpressing a gene encoding a gene product required for proliferation. Examples of promoters that are useful for the regulating the expression of gene products in Gram-positive organisms over a

wide dynamic range are described in U.S. Patent Application Serial Number 10/032,393, filed December 21, 2001.

The following example describes one method for promoter replacement in a prokaryotic cell. It will be appreciated that promoter replacement can be used in a variety of organisms as previously indicated.

EXAMPLE 15

Operator Insertion to Generate Cells Capable of Overexpressing or Underexpressing a Gene Encoding a Gene Product Required for Proliferation

An oligonucleotide comprising a lac operator flanked on each side by 40 nucleotides homologous to the target promoter is designed. The target promoter is the promoter which drives expression of a gene encoding a gene product required for proliferation, such as the *yabB yabC ftsL ftsI murE* genes in an operon. The sequence of the oligonucleotide (SEQ ID NO. 78582) and locations of the regions homologous to the promoter are illustrated in Figure 6. The sequence of the promoter is also shown with the locations of the -10 and -35 regions indicated (SEQ ID NO. 78583). The single stranded oligonucleotide is transformed into a bacterium expressing the λ Beta and Gam proteins. The cells in the transformation mixture are diluted and plated on medium containing IPTG. Colonies in which the lac operator has integrated into the target promoter are identified by colony PCR. If desired, proper regulation of the target promoter by the inserted operator is confirmed by growing the identified colonies in medium containing or lacking IPTG. The colonies proliferate on medium containing IPTG but fail to grow on medium lacking IPTG, thereby confirming that the target promoter is properly regulated by the inserted operator. It will be appreciated that the preceding method may be performed with any target promoter and any operator to generate cells which overexpress or underexpress a gene encoding a gene product required for proliferation.

EXAMPLE 16

Screening Chemical Libraries

A. Protein-Based Assays

Having isolated and expressed bacterial proteins shown to be required for bacterial proliferation, the present invention further contemplates the use of these expressed target proteins in assays to screen libraries of compounds for potential drug candidates. The generation of chemical libraries is well known in the art. For example, combinatorial chemistry can be used to generate a library of compounds to be screened in the assays described herein. A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building block" reagents. For example, a linear combinatorial chemical library such as a polypeptide library is formed by combining amino acids in every possible combination to yield peptides of a given length. Millions of chemical compounds theoretically can be synthesized through such combinatorial mixings of chemical building blocks. For example, one commentator observed that the systematic, combinatorial mixing of 100 interchangeable

chemical building blocks results in the theoretical synthesis of 100 million tetrameric compounds or 10 billion pentameric compounds. (Gallop et al., "Applications of Combinatorial Technologies to Drug Discovery, Background and Peptide Combinatorial Libraries," *Journal of Medicinal Chemistry*, Vol. 37, No. 9, 1233-1250 (1994). Other chemical libraries known to those in the art may also be used, including natural product libraries.

Once generated, combinatorial libraries can be screened for compounds that possess desirable biological properties. For example, compounds which may be useful as drugs or to develop drugs would likely have the ability to bind to the target protein identified, expressed and purified as discussed above. Further, if the identified target protein is an enzyme, candidate compounds would likely interfere with the enzymatic properties of the target protein. For example, the enzymatic function of a target protein may be to serve as a protease, nuclease, phosphatase, dehydrogenase, transporter protein, transcriptional enzyme, and any other type of enzyme known or unknown. Thus, the present invention contemplates using the protein products described above to screen combinatorial chemical libraries.

In one example, the target protein is a serine protease and the substrate of the enzyme is known. The present example is directed towards the analysis of libraries of compounds to identify compounds that function as inhibitors of the target enzyme. First, a library of small molecules is generated using methods of combinatorial library formation well known in the art. U.S. Patent Nos. 5,463,564 and 5,574, 656, to Agrafiotis, et al., entitled "System and Method of Automatically Generating Chemical Compounds with Desired Properties," are two such teachings. Then the library compounds are screened to identify those compounds that possess desired structural and functional properties. U.S. Patent No. 5,684,711, also discusses a method for screening libraries.

To illustrate the screening process, the target polypeptide and chemical compounds of the library are combined with one another and permitted to interact with one another. A labeled substrate is added to the incubation. The label on the substrate is such that a detectable signal is emitted from the products of the substrate molecules that result from the activity of the target polypeptide. The emission of this signal permits one to measure the effect of the combinatorial library compounds on the enzymatic activity of target enzymes by comparing it to the signal emitted in the absence of combinatorial library compounds. The characteristics of each library compound are encoded so that compounds demonstrating activity against the enzyme can be analyzed and features common to the various compounds identified can be isolated and combined into future iterations of libraries.

Once a library of compounds is screened, subsequent libraries are generated using those chemical building blocks that possess the features shown in the first round of screen to have activity against the target enzyme. Using this method, subsequent iterations of candidate compounds will possess more and more of those structural and functional features required to inhibit the function of the target enzyme, until a group of enzyme inhibitors with high specificity for the enzyme can be found. These compounds can then be further tested for their safety and efficacy as antibiotics for use in mammals.

It will be readily appreciated that this particular screening methodology is exemplary only. Other methods are well known to those skilled in the art. For example, a wide variety of screening techniques are known for a large number of naturally-occurring targets when the biochemical function of the target protein is known. For example, some techniques involve the generation and use of small peptides to probe and analyze target proteins both biochemically and genetically in order to identify and develop drug leads. Such techniques include the methods described in PCT publications No. WO9935494, WO9819162, WO9954728. Other techniques utilize natural product libraries or libraries of larger molecules such as proteins.

It will be appreciated that the above protein-based assays may be performed with any of the proliferation-required polypeptides from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* (including the polypeptides of SEQ ID NOs.: 42398-78581) or portions thereof. In addition, the above protein-based assays may be performed with homologous polypeptides or portions thereof.

B. Cell-Based Assays

Current cell-based assays used to identify or to characterize compounds for drug discovery and development frequently depend on detecting the ability of a test compound to modulate the activity of a target molecule located within a cell or located on the surface of a cell. An advantage of cell-based assays is that they allow the effect of a compound on a target molecule's activity to be detected within the physiologically relevant environment of the cell as opposed to an *in vitro* environment. Most often such target molecules are proteins such as enzymes, receptors and the like. However, target molecules may also include other molecules such as DNAs, lipids, carbohydrates and RNAs including messenger RNAs, ribosomal RNAs, tRNAs, regulatory RNAs and the like. A number of highly sensitive cell-based assay methods are available to those of skill in the art to detect binding and interaction of test compounds with specific target molecules. However, these methods are generally not highly effective when the test compound binds to or otherwise interacts with its target molecule with moderate or low affinity. In addition, the target molecule may not be

readily accessible to a test compound in solution, such as when the target molecule is located inside the cell or within a cellular compartment. Thus, current cell-based assay methods are limited in that they are not effective in identifying or characterizing compounds that interact with their targets with moderate to low affinity or compounds that interact with targets that are not readily accessible.

5 The cell-based assay methods of the present invention have substantial advantages over current cell-based assays. These advantages derive from the use of sensitized cells in which the level or activity of at least one proliferation-required gene product (the target molecule) has been specifically reduced to the point where the presence or absence of its function becomes a rate-determining step for cellular proliferation. Bacterial, fungal, plant, or animal cells can all be used
10 with the present method. Such sensitized cells become much more sensitive to compounds that are active against the affected target molecule. Thus, cell-based assays of the present invention are capable of detecting compounds exhibiting low or moderate potency against the target molecule of interest because such compounds are substantially more potent on sensitized cells than on non-sensitized cells. The effect may be such that a test compound may be two to several times more
15 potent, at least 10 times more potent, at least 20 times more potent, at least 50 times more potent, at least 100 times more potent, at least 1000 times more potent, or even more than 1000 times more potent when tested on the sensitized cells as compared to the non-sensitized cells. The proliferation-required nucleic acids or polypeptides from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*,
20 *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*,
25 *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*,
30 *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis*, or portions thereof, may be employed in any of the cell-based assays described herein. Similarly, homologous coding nucleic acids, homologous antisense nucleic acids, or homologous polypeptides or portions of the homologous nucleic acids or homologous polypeptides, may be employed in any of the cell-based assays described herein.

35 Due in part to the increased appearance of antibiotic resistance in pathogenic microorganisms and to the significant side-effects associated with some currently used antibiotics, novel antibiotics acting at new targets are highly sought after in the art. Yet, another limitation in the current art related to cell-based assays is the problem of repeatedly identifying hits against the

same kinds of target molecules in the same limited set of biological pathways. This may occur when compounds acting at such new targets are discarded, ignored or fail to be detected because compounds acting at the "old" targets are encountered more frequently and are more potent than compounds acting at the new targets. As a result, the majority of antibiotics in use currently
5 interact with a relatively small number of target molecules within an even more limited set of biological pathways.

The use of sensitized cells of the current invention provides a solution to the above problem in two ways. First, desired compounds acting at a target of interest, whether a new target or a previously known but poorly exploited target, can now be detected above the "noise" of compounds
10 acting at the "old" targets due to the specific and substantial increase in potency of such desired compounds when tested on the sensitized cells of the current invention. Second, the methods used to sensitize cells to compounds acting at a target of interest may also sensitize these cells to compounds acting at other target molecules within the same biological pathway. For example, expression of an antisense molecule to a gene encoding a ribosomal protein is expected to sensitize
15 the cell to compounds acting at that ribosomal protein and may also sensitize the cells to compounds acting at any of the ribosomal components (proteins or rRNA) or even to compounds acting at any target which is part of the protein synthesis pathway. Thus an important advantage of the present invention is the ability to reveal new targets and pathways that were previously not readily accessible to drug discovery methods.

20 Sensitized cells of the present invention are prepared by reducing the activity or level of a target molecule. The target molecule may be a gene product, such as an RNA or polypeptide produced from the proliferation-required nucleic acids from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*,
25 *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* (including a gene product produced from the
30 nucleic acids of SEQ ID NOs.: 6214-42397, such as the polypeptides of SEQ ID NOs.: 42398-78581) or from homologous nucleic acids. For example, the target molecule may be one of the polypeptides of SEQ ID NOs. 42398-78581 or a homologous polypeptide. Alternatively, the target

may be a gene product such as an RNA or polypeptide which is produced from a sequence within the same operon as the proliferation-required nucleic acids *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or from homologous nucleic acids. In addition, the target may be an RNA or polypeptide in the same biological pathway as the proliferation-required nucleic acids from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or from homologous nucleic acids. Such biological pathways include, but are not limited to, enzymatic, biochemical and metabolic pathways as well as pathways involved in the production of cellular structures such as the cell wall.

Current methods employed in the arts of medicinal and combinatorial chemistries are able to make use of structure-activity relationship information derived from testing compounds in various biological assays including direct binding assays and cell-based assays. Occasionally compounds are directly identified in such assays that are sufficiently potent to be developed as drugs. More often, initial hit compounds exhibit moderate or low potency. Once a hit compound is identified with low or moderate potency, directed libraries of compounds are synthesized and tested

in order to identify more potent leads. Generally these directed libraries are combinatorial chemical libraries consisting of compounds with structures related to the hit compound but containing systematic variations including additions, subtractions and substitutions of various structural features. When tested for activity against the target molecule, structural features are identified that either alone or in combination with other features enhance or reduce activity. This information is used to design subsequent directed libraries containing compounds with enhanced activity against the target molecule. After one or several iterations of this process, compounds with substantially increased activity against the target molecule are identified and may be further developed as drugs. This process is facilitated by use of the sensitized cells of the present invention since compounds acting at the selected targets exhibit increased potency in such cell-based assays, thus; more compounds can now be characterized providing more useful information than would be obtained otherwise.

Thus, it is now possible using cell-based assays of the present invention to identify or characterize compounds that previously would not have been readily identified or characterized including compounds that act at targets that previously were not readily exploited using cell-based assays. The process of evolving potent drug leads from initial hit compounds is also substantially improved by the cell-based assays of the present invention because, for the same number of test compounds, more structure-function relationship information is likely to be revealed.

The method of sensitizing a cell entails selecting a suitable gene or operon. A suitable gene or operon is one whose transcription and/or expression is required for the proliferation of the cell to be sensitized. The next step is to introduce into the cells to be sensitized, an antisense RNA capable of hybridizing to the suitable gene or operon or to the RNA encoded by the suitable gene or operon. Introduction of the antisense RNA can be in the form of a vector in which antisense RNA is produced under the control of an inducible promoter. The amount of antisense RNA produced is modulated by varying an inducer concentration to which the cell is exposed and thereby varying the activity of the promoter driving transcription of the antisense RNA. Thus, cells are sensitized by exposing them to an inducer concentration that results in a sub-lethal level of antisense RNA expression. The requisite amount of inducer may be derived empirically by one of skill in the art.

In one embodiment of the cell-based assays, antisense nucleic acids complementary to the identified *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria*

meningitidis, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* nucleotide sequences or portions thereof (including antisense nucleic acids comprising a nucleotide sequence complementary to one of SEQ ID NOs.: 6214-42397, and the antisense nucleic acids of SEQ ID NOs.: 1-6213 or antisense nucleic acids comprising a nucleotide sequence complementary to portions of the foregoing nucleic acids thereof), antisense nucleic complementary to homologous coding nucleic acids or portions thereof or homologous antisense nucleic acids are used to inhibit the production of a proliferation-required protein. Vectors producing antisense RNA complementary to identified genes required for proliferation, or portions thereof, are used to limit the concentration of a proliferation-required protein without severely inhibiting growth. The proliferation-required protein may be one of the proteins of SEQ ID NOs.: 42398-78581 or a homologous polypeptide. To achieve that goal, a growth inhibition dose curve of inducer is calculated by plotting various doses of inducer against the corresponding growth inhibition caused by the antisense expression. From this curve, the concentration of inducer needed to achieve various percentages of antisense induced growth inhibition, from 1 to 100% can be determined.

In some embodiments of the present invention, promoter replacement methods, such as those describe above and in U.S. Patent Application Serial Number 09/948,993, are used to express the proliferation-inhibiting nucleic acid. In other embodiments, the methods for the production of stabilized RNA in Gram-negative organisms, as described in U.S. Provisional Patent Application Serial Number 60/343,512, are used for the production of proliferation-inhibiting transcripts corresponding to the nucleic acid sequences described herein. Briefly, the stabilized antisense RNA may comprise an antisense RNA which was identified as inhibiting proliferation as described above which has been engineered to contain at least one stem loop flanking each end of the antisense nucleic acid. In some embodiments, the at least one stem-loop structure formed at the 5' end of the stabilized antisense nucleic acid comprises a flush, double stranded 5' end. In some embodiments, one or more of the stem loops comprises a rho independent terminator. In additional embodiments, the stabilized antisense RNA lacks a ribosome binding site. In further embodiments, the stabilized RNA lacks sites which are cleaved by one or more RNases, such as RNase E or RNase III. In some embodiments, the stabilized antisense RNA may be transcribed in a cell which the activity of at least one enzyme involved in RNA degradation has been reduced. For example, the activity of an enzyme such as RNase E, RNase II, RNase III, polynucleotide phosphorylase, and poly(A) polymerase, RNA helicase, enolase or an enzyme having similar functions may be reduced in the cell.

A variety of different regulatable promoters may be used to produce the antisense nucleic acid. Transcription from the regulatable promoters may be modulated by controlling the activity of a transcription factor repressor which acts at the regulatable promoter. For example, if transcription

is modulated by affecting the activity of a repressor, the choice of inducer to be used depends on the repressor/operator responsible for regulating transcription of the antisense nucleic acid. If the regulatable promoter comprises a T5 promoter fused to a *xyIO* (xylose operator; e.g. derived from *Staphylococcus xylosis* (Schnappinger, D. et al., FEMS Microbiol. Let. 129: 126214-423978 (1995)), then transcription of the antisense nucleic acid may be regulated by a xylose repressor. The xylose repressor may be provided by ectopic expression within an *S. aureus* cell of an exogenous xylose repressor gene, e.g. derived from *S. xylosis* DNA. In such cases transcription of antisense RNA from the promoter is inducible by adding xylose to the medium and the promoter is thus "xylose inducible." Similarly, IPTG inducible promoters may be used. For example, the highest concentration of the inducer that does not reduce the growth rate significantly can be estimated from the curve. Cellular proliferation can be monitored by growth medium turbidity via OD measurements. In another example, the concentration of inducer that reduces growth by 25% can be predicted from the curve. In still another example, a concentration of inducer that reduces growth by 50% can be calculated. Additional parameters such as colony forming units (cfu) can be used to measure cellular viability. Some embodiments of the present invention contemplate the use of a vector that comprises a regulatable fusion promoter selected from a suite of fusion promoters wherein the promoter suite is useful for modulating both the basal and maximal levels of transcription of a nucleic acid over a wide dynamic range thus allowing the desired level of production of a transcript which corresponds to a nucleic acid described herein. Such promoters are described in U.S. Patent Application Serial Number 10/032,393, filed December 21, 2001, the disclosure of which is incorporated herein by reference in its entirety.

Cells to be assayed are exposed to the above-determined concentrations of inducer. The presence of the inducer at this sub-lethal concentration reduces the amount of the proliferation required gene product to a sub-optimal amount in the cell that will still support growth. Cells grown in the presence of this concentration of inducer are therefore specifically more sensitive to inhibitors of the proliferation-required protein or RNA of interest or to inhibitors of proteins or RNAs in the same biological pathway as the proliferation-required protein or RNA of interest but not to inhibitors of unrelated proteins or RNAs.

Cells pretreated with sub-inhibitory concentrations of inducer and thus containing a reduced amount of proliferation-required target gene product are then used to screen for compounds that reduce cell growth. The sub-lethal concentration of inducer may be any concentration consistent with the intended use of the assay to identify candidate compounds to which the cells are more sensitive. For example, the sub-lethal concentration of the inducer may be such that growth inhibition is at least about 5%, at least about 8%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60% at least about 75%, or more. Cells which are pre-sensitized using the preceding method are more sensitive to inhibitors of the target protein because these cells contain less target protein to inhibit than do wild-type cells.

It will be appreciated that the above cell-based assays may be performed using antisense nucleic acids comprising a nucleotide sequence complementary to any of the proliferation-required nucleic acids from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*,
5 *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*,
10 *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*,
15 *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or portions thereof, antisense nucleic acids complementary to homologous coding nucleic acids or portions thereof or homologous antisense nucleic acids. In this way, the level or activity of a target, such as any of the proliferation-required polypeptides from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*,
20 *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or homologous polypeptides.

In another embodiment of the cell-based assays of the present invention, the level or activity of a proliferation required gene product is reduced using a mutation, such as a temperature sensitive mutation, in the gene encoding a gene product required for proliferation and an antisense
35 nucleic acid comprising a nucleotide sequence complementary to the gene encoding the gene product required for proliferation or a portion thereof. Growing the cells at an intermediate temperature between the permissive and restrictive temperatures of the temperature sensitive mutant where the mutation is in a proliferation-required gene produces cells with reduced activity

of the proliferation-required gene product. The antisense RNA complementary to the proliferation-required sequence further reduces the activity of the proliferation required gene product. Drugs that may not have been found using either the temperature sensitive mutation or the antisense nucleic acid alone may be identified by determining whether cells in which transcription of the antisense nucleic acid has been induced and which are grown at a temperature between the permissive temperature and the restrictive temperature are substantially more sensitive to a test compound than cells in which expression of the antisense nucleic acid has not been induced and which are grown at a permissive temperature. Also drugs found previously from either the antisense nucleic acid alone or the temperature sensitive mutation alone may have a different sensitivity profile when used in cells combining the two approaches, and that sensitivity profile may indicate a more specific action of the drug in inhibiting one or more activities of the gene product.

Temperature sensitive mutations may be located at different sites within the gene and correspond to different domains of the protein. For example, the *dnaB* gene of *Escherichia coli* encodes the replication fork DNA helicase. DnaB has several domains, including domains for oligomerization, ATP hydrolysis, DNA binding, interaction with primase, interaction with DnaC, and interaction with DnaA [(Biswas, E.E. and Biswas, S.B. 1999. Mechanism and DnaB helicase of *Escherichia coli*: structural domains involved in ATP hydrolysis, DNA binding, and oligomerization. *Biochem.* 38:10919-10928; Hiasa, H. and Marians, K.J. 1999. Initiation of bidirectional replication at the chromosomal origin is directed by the interaction between helicase and primase. *J. Biol. Chem.* 274:27244-27248; San Martin, C., Radermacher, M., Wolpensinger, B., Engel, A., Miles, C.S., Dixon, N.E., and Carazo, J.M. 1998. Three-dimensional reconstructions from cryoelectron microscopy images reveal an intimate complex between helicase DnaB and its loading partner DnaC. *Structure* 6:501-9; Sutton, M.D., Carr, K.M., Vicente, M., and Kaguni, J.M. 1998. *Escherichia coli* DnaA protein. The N-terminal domain and loading of DnaB helicase at the *E. coli* chromosomal origin. *J. Biol. Chem.* 273:34255-62.). Temperature sensitive mutations in different domains of DnaB confer different phenotypes at the restrictive temperature, which include either an abrupt stop or slow stop in DNA replication with or without DNA breakdown (Wechsler, J.A. and Gross, J.D. 1971. *Escherichia coli* mutants temperature-sensitive for DNA synthesis. *Mol. Gen. Genetics* 113:273-284, and termination of growth or cell death. Combining the use of temperature sensitive mutations in the *dnaB* gene that cause cell death at the restrictive temperature with an antisense to the *dnaB* gene could lead to the discovery of very specific and effective inhibitors of one or a subset of activities exhibited by DnaB.

It will be appreciated that the above method may be performed with any mutation which reduces but does not eliminate the activity or level of the gene product which is required for proliferation.

It will be appreciated that the above cell-based assays may be performed using mutations in, such as temperature sensitive mutations, and antisense nucleic acids comprising a nucleotide sequence complementary to any of the genes encoding proliferation-required gene products from

from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*,
5 *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria*
10 *meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or portions thereof (including the nucleic acids of SEQ ID NOs.: 6214-42397), mutations in and antisense
15 nucleic acids complementary to homologous coding nucleic acids or portions thereof or homologous antisense nucleic acids. In this way, the level or activity of a target, such as any of the proliferation-required polypeptides from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*,
20 *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
25 *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio*
30 *cholerae* or *Yersinia pestis* (including the polypeptides of SEQ ID NOs.: 42398-78581), or homologous polypeptides may be reduced.

When screening for antimicrobial agents against a gene product required for proliferation, growth inhibition of cells containing a limiting amount of that proliferation-required gene product can be assayed. Growth inhibition can be measured by directly comparing the amount of growth,
35 measured by the optical density of the growth medium, between an experimental sample and a control sample. Alternative methods for assaying cell proliferation include measuring the signal from a reporter construct, various enzymatic activity assays, and other methods well known in the art.

It will be appreciated that the above method may be performed in solid phase, liquid phase or a combination of the two. For example, cells grown on nutrient agar containing the inducer of the antisense construct may be exposed to compounds spotted onto the agar surface. If desired, the cells may be grown on agar containing varying concentrations of the inducer. A compound's effect may be judged from the diameter of the resulting killing zone, the area around the compound application point in which cells do not grow. Multiple compounds may be transferred to agar plates and simultaneously tested using automated and semi-automated equipment including but not restricted to multi-channel pipettes (for example the Beckman Multimek) and multi-channel spotters (for example the Genomic Solutions Flexys). In this way multiple plates and thousands to millions of compounds may be tested per day.

The compounds may also be tested entirely in liquid phase using microtiter plates as described below. Liquid phase screening may be performed in microtiter plates containing 96, 384, 1536 or more wells per microtiter plate to screen multiple plates and thousands to millions of compounds per day. Automated and semi-automated equipment may be used for addition of reagents (for example cells and compounds) and determination of cell density.

EXAMPLE 17

Cell-Based Assay Using Antisense Complementary to Genes Encoding Ribosomal Proteins

The effectiveness of the above cell-based assay was validated using constructs transcribing antisense RNA to the proliferation required *E. coli* genes *rplL*, *rplJ*, and *rplW* encoding ribosomal proteins L7/L12, L10 and L23 respectively. These proteins are essential components of the protein synthesis apparatus of the cell and as such are required for proliferation. These constructs were used to test the effect of antisense transcription on cell sensitivity to antibiotics known to bind to the ribosome and thereby inhibit protein synthesis. Constructs transcribing antisense RNA to several other genes (*elaD*, *visC*, *yohH*, and *atpE/B*), the products of which are not involved in protein synthesis were used for comparison.

First, pLex5BA (Krause et al., J. Mol. Biol. 274: 365 (1997)), vectors containing antisense constructs to either *rplW* or to *elaD* were introduced into separate *E. coli* cell populations. Vector introduction is a technique well known to those of ordinary skill in the art. The vectors of this example contain IPTG inducible promoters that drive the transcription of the antisense RNA in the presence of the inducer. However, those skilled in the art will appreciate that other inducible promoters may also be used. Suitable vectors are also well known in the art. For example, a number of promoters useful for nucleic acid transcription (including the nucleic acids described herein) in *Enterococcus faecalis*, *Staphylococcus aureus* as well as other Gram positive organisms are described in U.S. Patent Application Serial Number 10/032,393, filed December 21, 2001. Antisense clones to genes encoding different ribosomal proteins or to genes encoding proteins that are not involved in protein synthesis were utilized to test the effect of antisense transcription on cell sensitivity to the antibiotics known to bind to ribosomal proteins and inhibit protein synthesis. Antisense nucleic acids comprising a nucleotide sequence complementary to the *elaD*, *atpB* & *atpE*,

visC and *yohH* genes are referred to as AS-*elaD*, AS-*atpB/E*, AS-*visC*, AS-*yohH* respectively. These genes are not known to be involved in protein synthesis. Antisense nucleic acids to the *rplL*, *rplL&rplJ* and *rplW* genes are referred to as AS-*rplL*, AS-*rplL/J*, and AS-*rplW* respectively. These genes encode ribosomal proteins L7/L12 (*rplL*) L10 (*rplJ*) and L23 (*rplW*). Vectors containing these antisense nucleic acids were introduced into separate *E. coli* cell populations.

The cell populations containing vectors producing AS-*elaD* or AS-*rplW* were exposed to a range of IPTG concentrations in liquid medium to obtain the growth inhibitory dose curve for each clone (Figure 7). First, seed cultures were grown to a particular turbidity measured by the optical density (OD) of the growth solution. The OD of the solution is directly related to the number of bacterial cells contained therein. Subsequently, sixteen 200 μ l liquid medium cultures were grown in a 96 well microtiter plate at 37° C with a range of IPTG concentrations in duplicate two-fold serial dilutions from 1600 μ M to 12.5 μ M (final concentration). Additionally, control cells were grown in duplicate without IPTG. These cultures were started from an inoculum of equal amounts of cells derived from the same initial seed culture of a clone of interest. The cells were grown for up to 15 hours and the extent of growth was determined by measuring the optical density of the cultures at 600 nm. When the control culture reached mid-log phase the percent growth (relative to the control culture) for each of the IPTG containing cultures was plotted against the log concentrations of IPTG to produce a growth inhibitory dose response curve for the IPTG. The concentration of IPTG that inhibits cell growth to 50% (IC₅₀) as compared to the 0 mM IPTG control (0% growth inhibition) was then calculated from the curve. Under these conditions, an amount of antisense RNA was produced that reduced the expression levels of *rplW* or *elaD* to a degree such that growth of cells containing their respective antisense vectors was inhibited by 50%.

Alternative methods of measuring growth are also contemplated. Examples of these methods include measurements of proteins, the expression of which is engineered into the cells being tested and can readily be measured. Examples of such proteins include luciferase and various enzymes.

Cells were pretreated with the selected concentration of IPTG and then used to test the sensitivity of cell populations to tetracycline, erythromycin and other known protein synthesis inhibitors. Figure 7 is an IPTG dose response curve in *E. coli* transformed with an IPTG-inducible plasmid containing either an antisense clone to the *E. coli rplW* gene (AS-*rplW*) which encodes ribosomal protein L23 which is required for protein synthesis and essential for cell proliferation, or an antisense clone to the *elaD* (AS-*elaD*) gene which is not known to be involved in protein synthesis.

An example of a tetracycline dose response curve is shown in Figures 8A and 13B for the *rplW* and *elaD* genes, respectively. Cells were grown to log phase and then diluted into medium alone or medium containing IPTG at concentrations which give 20% and 50% growth inhibition as determined by IPTG dose response curves. After 2.5 hours, the cells were diluted to a final OD₆₀₀ of 0.002 into 96 well plates containing (1) +/- IPTG at the same concentrations used for the 2.5 hour

pre-incubation; and (2) serial two-fold dilutions of tetracycline such that the final concentrations of tetracycline range from 1 $\mu\text{g/ml}$ to 15.6 ng/ml and 0 $\mu\text{g/ml}$. The 96 well plates were incubated at 37°C and the OD₆₀₀ was read by a plate reader every 5 minutes for up to 15 hours. For each IPTG concentration and the no IPTG control, tetracycline dose response curves were determined when the control (absence of tetracycline) reached 0.1 OD₆₀₀.

To compare tetracycline sensitivity with and without IPTG, tetracycline IC_{50s} were determined from the dose response curves (Figures 8A-B). Cells transcribing antisense nucleic acids AS-*rplL* or AS-*rplW* to genes encoding ribosomal proteins L7/L12 and L23 respectively showed increased sensitivity to tetracycline (Figure 8A) as compared to cells with reduced levels of the *elaD* gene product (AS-*elaD*) (Figure 8B). Figure 9 shows a summary bar chart in which the ratios of tetracycline IC_{50s} determined in the presence of IPTG which gives 50% growth inhibition versus tetracycline IC_{50s} determined without IPTG (fold increase in tetracycline sensitivity) were plotted. Cells with reduced levels of either L7/L12 (encoded by genes *rplL*, *rplJ*) or L23 (encoded by the *rplW* gene) showed increased sensitivity to tetracycline (Figure 9). Cells expressing antisense to genes not known to be involved in protein synthesis (AS-*atpB/E*, AS-*visC*, AS-*elaD*, AS-*yohH*) did not show the same increased sensitivity to tetracycline, validating the specificity of this assay (Figure 9).

In addition to the above, it has been observed in initial experiments that clones transcribing antisense RNA to genes involved in protein synthesis (including genes encoding ribosomal proteins L7/L12 & L10, L7/L12 alone, L22, and L18, as well as genes encoding rRNA and Elongation Factor G) have increased sensitivity to the macrolide, erythromycin, whereas clones transcribing antisense to the non-protein synthesis genes *elaD*, *atpB/E* and *visC* do not. Furthermore, the clone transcribing antisense to *rplL* and *rplJ* (AS-*rplL/J*) does not show increased sensitivity to nalidixic acid and ofloxacin, antibiotics which do not inhibit protein synthesis.

The results with the ribosomal protein genes *rplL*, *rplJ*, and *rplW* as well as the initial results using various other antisense clones and antibiotics show that limiting the concentration of an antibiotic target makes cells more sensitive to the antimicrobial agents that specifically interact with that protein. The results also show that these cells are sensitized to antimicrobial agents that inhibit the overall function in which the protein target is involved but are not sensitized to antimicrobial agents that inhibit other functions. It will be appreciated that the cell-based assays described above may be implemented using the *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,

Mycobacterium leprae, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* antisense nucleotide sequences which inhibit the activity of genes required for proliferation described herein (including the antisense nucleic acids of SEQ ID NOs.: 1-6213) or antisense nucleic acids comprising nucleotide sequences which are complementary to the sequences of SEQ ID NOs.: 6214-42397 or portions thereof.

- 10 It will be appreciated that the above cell-based assays may be performed using antisense nucleic acids complementary to any of the proliferation-required nucleic acids from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*,
- 15 *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or portions thereof, antisense nucleic acids
- 20 complementary to homologous coding nucleic acids or portions thereof, or homologous antisense nucleic acids. In this way, the level or activity of a target, such as any of the proliferation-required polypeptides from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*,
- 30 *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*,

Streptococcus pyogenes, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or homologous polypeptides may be reduced.

In some embodiments of the present invention, the methods for the production of stabilized RNA, as described in U.S. Provisional Patent Application Serial Number 60/343,512, can be used
 5 in the above cell-based assays in Gram-negative organisms to extend the lifetime of transcripts corresponding to the nucleic acids described herein.

The cell-based assay described above may also be used to identify the biological pathway in which a proliferation-required nucleic acid or its gene product lies. In such methods, cells transcribing a sub-lethal level of antisense to a target proliferation-required nucleic acid and control
 10 cells in which transcription of the antisense has not been induced are contacted with a panel of antibiotics known to act in various pathways. If the antibiotic acts in the pathway in which the target proliferation-required nucleic acid or its gene product lies, cells in which transcription of the antisense has been induced will be more sensitive to the antibiotic than cells in which expression of the antisense has not been induced.

As a control, the results of the assay may be confirmed by contacting a panel of cells
 15 transcribing antisense nucleic acids to many different proliferation-required genes including the target proliferation-required gene. If the antibiotic is acting specifically, heightened sensitivity to the antibiotic will be observed only in the cells transcribing antisense to a target proliferation-required gene (or cells expressing antisense to other proliferation-required genes in the same
 20 pathway as the target proliferation-required gene) but will not be observed generally in all cells expressing antisense to proliferation-required genes.

It will be appreciated that the above cell-based assays may be performed using antisense nucleic acids complementary to any of the proliferation-required nucleic acids from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas*
 25 *aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter*
 30 *pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus*
 35 *mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* (including antisense nucleic acids complementary to SEQ ID NOs: 6214-42397, or the antisense nucleic acids of SEQ ID NOs: 1-6213) or portions thereof, antisense nucleic acids comprising nucleotide sequences complementary to homologous

coding nucleic acids or portions thereof, or homologous antisense nucleic acids. In this way, the level or activity of a target, such as any of the proliferation-required polypeptides from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* (including the polypeptides of SEQ ID NOs.: 42398-78581), or homologous polypeptides may be reduced.

In some embodiments of the present invention, the methods for the production of stabilized RNA, as described in U.S. Provisional Patent Application Serial Number 60/343,512, can be used in the above cell-based assays in Gram-negative organisms to extend the lifetime of transcripts corresponding to the nucleic acids described herein.

Similarly, the above method may be used to determine the pathway on which a test compound, such as a test antibiotic acts. A panel of cells, each of which transcribes an antisense to a proliferation-required nucleic acid in a known pathway, is contacted with a compound for which it is desired to determine the pathway on which it acts. The sensitivity of the panel of cells to the test compound is determined in cells in which transcription of the antisense has been induced and in control cells in which expression of the antisense has not been induced. If the test compound acts on the pathway on which an antisense nucleic acid acts, cells in which expression of the antisense has been induced will be more sensitive to the compound than cells in which expression of the antisense has not been induced. In addition, control cells in which expression of antisense to proliferation-required genes in other pathways has been induced will not exhibit heightened sensitivity to the compound. In this way, the pathway on which the test compound acts may be determined.

It will be appreciated that the above cell-based assays may be performed using antisense nucleic acids comprising nucleotide sequences complementary to any of the proliferation-required nucleic acids from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia*

pneumoniae, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*,
5 *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or
10 *Yersinia pestis* (including antisense nucleic acids complementary to SEQ ID NOs: 6214-42397, such as the antisense nucleic acids of SEQ ID NOs: 1-6213) or portions thereof, antisense nucleic acids complementary to homologous coding nucleic acids or portions thereof, or homologous antisense nucleic acids. In this way, the level or activity of a target, such as any of the proliferation-required polypeptides from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*,
15 *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
20 *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*,
25 *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* (including the polypeptides of SEQ ID NOs: 42398-78581) or homologous polypeptides may be reduced.

In some embodiments of the present invention, the methods for the production of stabilized
30 RNA, as described in U.S. Provisional Patent Application Serial Number 60/343,512, can be used in the above cell-based assays in Gram-negative organisms to extend the lifetime of transcripts corresponding to the nucleic acids described herein.

The Example below provides one method for performing such assays.

EXAMPLE 18

35 Identification of the Pathway in which a Proliferation-Required

Gene Lies or the Pathway on which an Antibiotic Acts

A. Preparation of Bacterial Stocks for Assay

To provide a consistent source of cells to screen, frozen stocks of host bacteria containing the desired antisense construct are prepared using standard microbiological techniques. For example, a single clone of the microorganism can be isolated by streaking out a sample of the original stock onto an agar plate containing nutrients for cell growth and an antibiotic for which the antisense construct contains a selectable marker which confers resistance. After overnight growth an isolated colony is picked from the plate with a sterile needle and transferred to an appropriate liquid growth medium containing the antibiotic required for maintenance of the plasmid. The cells are incubated at 30°C to 37°C with vigorous shaking for 4 to 6 hours to yield a culture in exponential growth. Sterile glycerol is added to 15% (volume to volume) and 100µL to 500 µL aliquots are distributed into sterile cryotubes, snap frozen in liquid nitrogen, and stored at -80°C for future assays.

B. Growth of Bacteria for Use in the Assay

A day prior to an assay, a stock vial is removed from the freezer, rapidly thawed (37°C water bath) and a loop of culture is streaked out on an agar plate containing nutrients for cell growth and an antibiotic to which the selectable marker of the antisense construct confers resistance. After overnight growth at 37°C, ten randomly chosen, isolated colonies are transferred from the plate (sterile inoculum loop) to a sterile tube containing 5 mL of LB medium containing the antibiotic to which the antisense vector confers resistance. After vigorous mixing to form a homogeneous cell suspension, the optical density of the suspension is measured at 600 nm (OD₆₀₀) and if necessary an aliquot of the suspension is diluted into a second tube of 5 mL, sterile, LB medium plus antibiotic to achieve an OD₆₀₀ ≤ 0.02 absorbance units. The culture is then incubated at 37° C for 1-2 hrs with shaking until the OD₆₀₀ reaches OD 0.2 – 0.3. At this point the cells are ready to be used in the assay.

C. Selection of Media to be Used in Assay

Two-fold dilution series of the inducer are generated in culture media containing the appropriate antibiotic for maintenance of the antisense construct. Several media are tested side by side and three to four wells are used to evaluate the effects of the inducer at each concentration in each media. For example, LB broth, TBD broth and Muller-Hinton media may be tested with the inducer xylose at the following concentrations, 5 mM, 10 mM, 20 mM, 40 mM, 80 mM, 120 mM and 160 mM. Equal volumes of test media-inducer and cells are added to the wells of a 384 well microtiter plate and mixed. The cells are prepared as described above and diluted 1:100 in the appropriate media containing the test antibiotic immediately prior to addition to the microtiter plate wells. For a control, cells are also added to several wells of each media that do not contain inducer, for example 0 mM xylose. Cell growth is monitored continuously by incubation at 37°C in a microtiter plate reader monitoring the OD₆₀₀ of the wells over an 18-hour period. The percent inhibition of growth produced by each concentration of inducer is calculated by comparing the rates of logarithmic growth against that exhibited by cells growing in medium without inducer. The medium yielding greatest sensitivity to inducer is selected for use in the assays described below.

D. Measurement of Test Antibiotic Sensitivity in the Absence of Antisense Construct Induction

Two-fold dilution series of antibiotics of known mechanism of action are generated in the culture medium selected for further assay development that has been supplemented with the antibiotic used to maintain the construct. A panel of test antibiotics known to act on different pathways is tested side by side with three to four wells being used to evaluate the effect of a test antibiotic on cell growth at each concentration. Equal volumes of test antibiotic and cells are added to the wells of a 384 well microtiter plate and mixed. Cells are prepared as described above using the medium selected for assay development supplemented with the antibiotic required to maintain the antisense construct and are diluted 1:100 in identical medium immediately prior to addition to the microtiter plate wells. For a control, cells are also added to several wells that lack antibiotic, but contain the solvent used to dissolve the antibiotics. Cell growth is monitored continuously by incubation at 37°C in a microtiter plate reader monitoring the OD₆₀₀ of the wells over an 18-hour period. The percent inhibition of growth produced by each concentration of antibiotic is calculated by comparing the rates of logarithmic growth against that exhibited by cells growing in medium without antibiotic. A plot of percent inhibition against log[antibiotic concentration] allows extrapolation of an IC₅₀ value for each antibiotic.

E. Measurement of Test Antibiotic Sensitivity in the Presence of Antisense Construct Inducer

The culture medium selected for use in the assay is supplemented with inducer at concentrations shown to inhibit cell growth by 50% and 80% as described above, as well as the antibiotic used to maintain the construct. Two-fold dilution series of the panel of test antibiotics used above are generated in each of these media. Several antibiotics are tested side by side in each medium with three to four wells being used to evaluate the effects of an antibiotic on cell growth at each concentration. Equal volumes of test antibiotic and cells are added to the wells of a 384 well

microtiter plate and mixed. Cells are prepared as described above using the medium selected for use in the assay supplemented with the antibiotic required to maintain the antisense construct. The cells are diluted 1:100 into two 50 mL aliquots of identical medium containing concentrations of inducer that have been shown to inhibit cell growth by 50% and 80 % respectively and incubated at 37°C with shaking for 2.5 hours. Immediately prior to addition to the microtiter plate wells, the cultures are adjusted to an appropriate OD₆₀₀ (typically 0.002) by dilution into warm (37°C) sterile medium supplemented with identical concentrations of the inducer and antibiotic used to maintain the antisense construct. For a control, cells are also added to several wells that contain solvent used to dissolve test antibiotics but which contain no antibiotic. Cell growth is monitored continuously by incubation at 37°C in a microtiter plate reader monitoring the OD₆₀₀ of the wells over an 18-hour period. The percent inhibition of growth produced by each concentration of antibiotic is calculated by comparing the rates of logarithmic growth against that exhibited by cells growing in medium without antibiotic. A plot of percent inhibition against log[antibiotic concentration] allows extrapolation of an IC₅₀ value for each antibiotic.

15 F. Determining the Specificity of the Test Antibiotics

A comparison of the IC₅₀s generated by antibiotics of known mechanism of action under antisense induced and non-induced conditions allows the pathway in which a proliferation-required nucleic acid lies to be identified. If cells expressing an antisense nucleic acid comprising a nucleotide sequence complementary to a proliferation-required gene are selectively sensitive to an antibiotic acting via a particular pathway, then the gene against which the antisense acts is involved in the pathway on which the antibiotic acts.

20 G. Identification of Pathway in which a Test Antibiotic Acts

As discussed above, the cell-based assay may also be used to determine the pathway against which a test antibiotic acts. In such an analysis, the pathways against which each member of a panel of antisense nucleic acids acts are identified as described above. A panel of cells, each containing an inducible vector which transcribes an antisense nucleic acid comprising a nucleotide sequence complementary to a gene in a known proliferation-required pathway, is contacted with a test antibiotic for which it is desired to determine the pathway on which it acts under inducing and non-inducing conditions. If heightened sensitivity is observed in induced cells transcribing antisense complementary to a gene in a particular pathway but not in induced cells transcribing antisense nucleic acids comprising nucleotide sequences complementary to genes in other pathways, then the test antibiotic acts against the pathway for which heightened sensitivity was observed.

One skilled in the art will appreciate that further optimization of the assay conditions, such as the concentration of inducer used to induce antisense transcription and/or the growth conditions used for the assay (for example incubation temperature and medium components) may further increase the selectivity and/or magnitude of the antibiotic sensitization exhibited.

It will be appreciated that the above cell-based assays may be performed using antisense nucleic acids comprising nucleotide sequences complementary to any of the proliferation-required nucleic acids from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*,
5 *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*,
10 *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*,
15 *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* (including antisense nucleic acids comprising nucleotide sequences complementary to SEQ ID NOs: 6214-42397, such as the antisense nucleic acids of SEQ ID NOs: 1-6213) or portions thereof, antisense nucleic acids complementary to homologous coding nucleic acids or portions thereof, or homologous antisense nucleic acids. In this way, the level or activity of a
20 target, such as any of the proliferation-required polypeptides from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*,
25 *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*,
30 *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* (including the polypeptides of SEQ ID NOs: 42398-78581), or homologous polypeptides may be reduced.

35 In some embodiments of the present invention, the methods for the production of stabilized RNA, as described in U.S. Provisional Patent Application Serial Number 60/343,512, can be used in the above cell-based assays in Gram-negative organisms to extend the lifetime of transcripts corresponding to the nucleic acids described herein.

The following example confirms the effectiveness of the methods described above.

EXAMPLE 19

Identification of the Biological Pathway in which a Proliferation-Required Gene Lies

The effectiveness of the above assays was validated using proliferation-required genes from
5 *E. coli* which were identified using procedures similar to those described above. Antibiotics of various chemical classes and modes of action were purchased from Sigma Chemicals (St. Louis, MO). Stock solutions were prepared by dissolving each antibiotic in an appropriate aqueous solution based on information provided by the manufacturer. The final working solution of each antibiotic contained no more than 0.2% (w/v) of any organic solvent. To determine their potency
10 against a bacterial strain engineered for transcription of an antisense comprising a nucleotide sequence complementary to a proliferation-required 50S ribosomal protein, each antibiotic was serially diluted two- or three- fold in growth medium supplemented with the appropriate antibiotic for maintenance of the antisense construct. At least ten dilutions were prepared for each antibiotic. 25 μ L aliquots of each dilution were transferred to discrete wells of a 384-well microplate (the
15 assay plate) using a multi-channel pipette. Quadruplicate wells were used for each dilution of an antibiotic under each treatment condition (plus and minus inducer). Each assay plate contained twenty wells for cell growth controls (growth medium replacing antibiotic), ten wells for each treatment (plus and minus inducer, in this example IPTG). Assay plates were usually divided into the two treatments: half the plate containing induced cells and an appropriate concentrations of
20 inducer (in this example IPTG) to maintain the state of induction, the other half containing non-induced cells in the absence of IPTG.

Cells for the assay were prepared as follows. Bacterial cells containing a construct, from which transcription of antisense nucleic acid comprising a nucleotide sequence complementary to *rplL* and *rplJ* (AS-*rplL/J*), which encode proliferation-required 50S ribosomal subunit proteins, is
25 inducible in the presence of IPTG, were grown into exponential growth (OD₆₀₀ 0.2 to 0.3) and then diluted 1:100 into fresh medium containing either 400 μ M or 0 μ M inducer (IPTG). These cultures were incubated at 37° C for 2.5 hr. After a 2.5 hr incubation, induced and non-induced cells were respectively diluted into an assay medium at a final OD₆₀₀ value of 0.0004. The medium contained an appropriate concentration of the antibiotic for the maintenance of the antisense construct. In
30 addition, the medium used to dilute induced cells was supplemented with 800 μ M IPTG so that addition to the assay plate would result in a final IPTG concentration of 400 μ M. Induced and non-induced cell suspensions were dispensed (25 μ L/well) into the appropriate wells of the assay plate as discussed previously. The plate was then loaded into a plate reader, incubated at constant temperature, and cell growth was monitored in each well by the measurement of light scattering at
35 595 nm. Growth was monitored every 5 minutes until the cell culture attained a stationary growth phase. For each concentration of antibiotic, a percentage inhibition of growth was calculated at the time point corresponding to mid-exponential growth for the associated control wells (no antibiotic, plus or minus IPTG). For each antibiotic

or minus IPTG), a plot of percent

inhibition versus log of antibiotic concentration was generated and the IC_{50} determined. A comparison of the IC_{50} for each antibiotic in the presence and absence of IPTG revealed whether induction of the antisense construct sensitized the cell to the mechanism of action exhibited by the antibiotic. Cells which exhibited a statistically significant decrease in the IC_{50} value in the presence of inducer were considered to have an increased sensitivity to the test antibiotic.

The results are provided in the table below, which lists the classes and names of the antibiotics used in the analysis, the targets of the antibiotics, the IC_{50} in the absence of IPTG, the IC_{50} in the presence of IPTG, the concentration units for the IC_{50} s, the fold increase in IC_{50} in the presence of IPTG, and whether increased sensitivity was observed in the presence of IPTG.

TABLE V
Effect of Expression of Antisense RNA to *rplL* and *rplJ* on Antibiotic Sensitivity

ANTIBIOTIC CLASS /Names	TARGET	IC ₅₀ (-IPTG)	IC ₅₀ (+IPTG)	Conc. Unit	Fold Increase in Sensitivity	Sensitivity Increased?
PROTEIN SYNTHESIS INHIBITOR						
AMINOGLYCOSIDES						
Gentamicin	30S ribosome function	2715	19.19	ng/ml	141	Yes
Streptomycin	30S ribosome function	11280	161	ng/ml	70	Yes
Spectinomycin	30S ribosome function	18050	<156	ng/ml		Yes
Tobramycin	30S ribosome function	3594	70.58	ng/ml	51	Yes
MACROLIDES						
Erythromycin	50S ribosome function	7467	187	ng/ml	40	Yes
AROMATIC POLYKETIDES						
Tetracycline	30S ribosome function	199.7	1.83	ng/ml	109	Yes
Minocycline	30S ribosome function	668.4	3.897	ng/ml	172	Yes
Doxycycline	30S ribosome function	413.1	27.81	ng/ml	15	Yes
OTHER PROTEIN SYNTHESIS INHIBITORS						
Fusidic acid	Elongation Factor G function	59990	641	ng/ml	94	Yes
Chloramphenicol	30S ribosome function	465.4	1.516	ng/ml	307	Yes
Lincomycin	50S ribosome function	47150	324.2	ng/ml	145	Yes
OTHER ANTIBIOTIC MECHANISMS						
B-LACTAMS						
Cefoxitin	Cell wall biosynthesis	2782	2484	ng/ml	1	No
Cefotaxime	Cell wall biosynthesis	24.3	24.16	ng/ml	1	No
DNA SYNTHESIS INHIBITORS						
Nalidixic acid	DNA Gyrase activity	6973	6025	ng/ml	1	No
Ofloxacin	DNA Gyrase activity	49.61	45.89	ng/ml	1	No
OTHER						
Bacitracin	Cell membrane function	4077	4677	mg/ml	1	No
Trimethoprim	Dihydrofolate Reductase activity	128.9	181.97	ng/ml	1	No
Vancomycin	Cell wall biosynthesis	145400	72550	ng/ml	2	No

The above results demonstrate that induction of an antisense RNA complementary to genes encoding 50S ribosomal subunit proteins results in a selective and highly significant sensitization of cells to antibiotics that inhibit ribosomal function and protein synthesis. The above results further demonstrate that induction of an antisense to an essential gene sensitizes a cell or microorganism to compounds that interfere with that gene product's biological role. This sensitization is restricted to compounds that interfere with pathways associated with the targeted gene and its product.

It will be appreciated that the above cell-based assays may be performed using antisense nucleic acids complementary to any of the proliferation-required nucleic acids from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* (including antisense nucleic acids complementary to SEQ ID NOs. 6214-42397, such as the antisense nucleic acids of SEQ ID NOs.: 1-6213) or portions thereof, antisense nucleic acids complementary to homologous coding nucleic acids or portions thereof or homologous antisense nucleic acids. In this way, the level or activity of a target, such as any of the proliferation-required polypeptides from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,

Mycobacterium leprae, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*,
5 *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* (including the polypeptides of SEQ ID NOs.: 42398-78581), or homologous polypeptides may be reduced.

In some embodiments of the present invention, the methods for the production of stabilized RNA, as described in U.S. Provisional Patent Application Serial Number 60/343,512,
10 can be used in the above cell-based assays in Gram-negative organisms to extend the lifetime of transcripts corresponding to the nucleic acids described herein.

Example 20 below describes an analysis performed in *Staphylococcus aureus*.

EXAMPLE 20

Identification of the Biological Pathway in which a Gene Required for

Proliferation of *Staphylococcus aureus* Lies

Antibiotics of various chemical classes and modes of action were purchased from chemical suppliers, for example Sigma Chemicals (St. Louis, MO). Stock solutions were prepared by dissolving each antibiotic in an appropriate aqueous solution based on information provided by the manufacturer. The final working solution of each antibiotic contained no more
20 than 0.2% (w/v) of any organic solvent.

To determine its potency against a bacterial strain containing an antisense nucleic acid comprising a nucleotide sequence complementary to the nucleotide sequence encoding the Beta subunit of DNA gyrase (which is required for proliferation) under the control of a xylose inducible promoter, each antibiotic was serially diluted two- or three- fold in growth medium supplemented with the appropriate antibiotic for maintenance of the antisense construct. At
25 least ten dilutions were prepared for each antibiotic.

Aliquots (25 μ L) of each dilution were transferred to discrete wells of a 384-well microplate (the assay plate) using a multi-channel pipette. Quadruplicate wells were used for each dilution of an antibiotic under each treatment condition (plus and minus inducer). Each
30 assay plate contained twenty wells for cell growth controls (growth medium, no antibiotic), ten wells for each treatment (plus and minus inducer, xylose, in this example). Half the assay plate contained induced cells (in this example *Staphylococcus aureus* cells) and appropriate concentrations of inducer (xylose, in this example) to maintain the state of induction while the other half of the assay plate contained non-induced cells maintained in the absence of inducer.

35

Preparation of Bacterial Cells

Cells of a bacterial clone containing a construct in which transcription of antisense comprising a nucleotide sequence complementary to the sequence encoding the Beta subunit of DNA gyrase under the control of the xylose inducible promoter (S1M10000001F08) were grown into exponential growth (OD_{600} 0.2 to 0.3) and then diluted 1:100 into fresh medium containing either 12 mM or 0 mM inducer (xylose). These cultures were incubated at 37° C for 2.5 hr. The presence of inducer (xylose) in the medium initiates and maintains production of antisense RNA from the antisense construct. After a 2.5 hr incubation, induced and non-induced cells were respectively diluted into an assay medium containing an appropriate concentration of the antibiotic for the maintenance of the antisense construct. In addition, medium used to dilute induced cells was supplemented with 24 mM xylose so that addition to the assay plate would result in a final xylose concentration of 12 mM. The cells were diluted to a final OD_{600} value of 0.0004.

Induced and non-induced cell suspensions were dispensed (25 μ l/well) into the appropriate wells of the assay plate as discussed previously. The plate was then loaded into a plate reader and incubated at constant temperature while cell growth was monitored in each well by the measurement of light scattering at 595 nm. Growth was monitored every 5 minutes until the cell culture attained a stationary growth phase. For each concentration of antibiotic, a percentage inhibition of growth was calculated at the time point corresponding to mid-exponential growth for the associated control wells (no antibiotic, plus or minus xylose). For each antibiotic and condition (plus or minus xylose), plots of percent inhibition versus Log of antibiotic concentration were generated and IC_{50} s determined.

A comparison of each antibiotic's IC_{50} in the presence and absence of inducer (xylose, in this example) reveals whether induction of the antisense construct sensitized the cell to the antibiotic's mechanism of action. If the antibiotic acts against the β subunit of DNA gyrase, the IC_{50} of induced cells will be significantly lower than the IC_{50} of uninduced cells.

Figure 10 lists the antibiotics tested, their targets, and their fold increase in potency between induced cells and uninduced cells. As illustrated in Figure 10, the potency of cefotaxime, ceftazidime, fusidic acid, lincomycin, tobramycin, trimethoprim and vancomycin, each of which act on targets other than the β subunit of gyrase, was not significantly different in induced cells as compared to uninduced cells. However, the potency of novobiocin, which is known to act against the Beta subunit of DNA gyrase, was significantly different between induced cells and uninduced cells.

Thus, induction of an antisense nucleic acid comprising a nucleotide sequence complementary to the sequence encoding the β subunit of gyrase results in a selective and

significant sensitization of *Staphylococcus aureus* cells to an antibiotic which inhibits the activity of this protein. Furthermore, the results demonstrate that induction of an antisense construct to an essential gene sensitizes a cell or microorganism to compounds that interfere with that gene product's biological role. This sensitization is apparently restricted to compounds that interfere with the targeted gene and its product.

It will be appreciated that the above cell-based assays may be performed using antisense nucleic acids complementary to any of the proliferation-required nucleic acids from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* (including antisense nucleic acids complementary to SEQ ID NOs.: 6214-42397, such as the antisense nucleic acids of SEQ ID NOs. 1-6213), or portions thereof, antisense nucleic acids complementary to homologous coding nucleic acids or portions thereof, or homologous antisense nucleic acids. In this way, the level or activity of a target, such as any of the proliferation-required polypeptides from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus*

mirabilis, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or homologous polypeptides may be reduced.

5 In some embodiments of the present invention, the methods for the production of stabilized RNA, as described in U.S. Provisional Patent Application Serial Number 60/343,512, can be used in the above cell-based assays in Gram-negative organisms to extend the lifetime of transcripts corresponding to the nucleic acids described herein.

10 Assays utilizing antisense constructs to essential genes or portions thereof can be used to identify compounds that interfere with the activity of those gene products. Such assays could be used to identify drug leads, for example antibiotics.

 Panels of cells transcribing different antisense nucleic acids can be used to characterize the point of intervention of a compound affecting an essential biochemical pathway including antibiotics with no known mechanism of action.

15 Assays utilizing antisense constructs to essential genes can be used to identify compounds that specifically interfere with the activity of multiple targets in a pathway. Such constructs can be used to simultaneously screen a sample against multiple targets in one pathway in one reaction (Combinatorial HTS).

20 Furthermore, as discussed above, panels of antisense construct-containing cells may be used to characterize the point of intervention of any compound affecting an essential biological pathway including antibiotics with no known mechanism of action.

 It will be appreciated that the above cell-based assays may be performed using antisense nucleic acids complementary to any of the proliferation-required nucleic acids from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*,
25 *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*,
30 *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
35 *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*,

Streptococcus pneumoniae, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* (including antisense nucleic acids comprising nucleotide sequences complementary to SEQ ID NOs.: 6214-42397, such as the antisense nucleic acids of SEQ ID NOs. 1-6213), or portions thereof, antisense nucleic acids complementary to homologous coding nucleic acids or portions thereof, or homologous antisense nucleic acids. In this way, the level or activity of a target, such as any of the proliferation-required polypeptides from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or homologous polypeptides may be reduced.

In some embodiments of the present invention, the methods for the production of stabilized RNA, as described in U.S. Provisional Patent Application Serial Number 60/343,512, can be used in the above cell-based assays in Gram-negative organisms to extend the lifetime of transcripts corresponding to the nucleic acids described herein.

Another embodiment of the present invention is a method for determining the pathway against which a test antibiotic compound is active, in which the activity of target proteins or nucleic acids involved in proliferation-required pathways is reduced by contacting cells with a sub-lethal concentration of a known antibiotic which acts against the target protein or nucleic acid. In one embodiment, the target protein or nucleic acid corresponds to a proliferation-required nucleic acid identified using the methods described above, such as the polypeptides of SEQ ID NOs.: 42398-78581, or homologous polypeptides. The method is similar to those described above for determining which pathway a test antibiotic acts against, except that rather than reducing the activity or level of a proliferation-required gene product using a sub-lethal level of antisense to a proliferation-required nucleic acid, the sensitized cell is generated by

reducing the activity or level of the proliferation-required gene product using a sub-lethal level of a known antibiotic which acts against the proliferation required gene product. Heightened sensitivity determines the pathway on which the test compound is active.

Interactions between drugs which affect the same biological pathway have been described in the literature. For example, Mecillinam (Amdinocillin) binds to and inactivates the penicillin binding protein 2 (PBP2, product of the *mrdA* in *E. coli*). This antibiotic interacts with other antibiotics that inhibit PBP2 as well as antibiotics that inhibit other penicillin binding proteins such as PBP3 [(Gutmann, L., Vincent, S., Billot-Klein, D., Acar, J.F., Mrena, E., and Williamson, R. (1986) Involvement of penicillin-binding protein 2 with other penicillin-binding proteins in lysis of *Escherichia coli* by some beta-lactam antibiotics alone and in synergistic lytic effect of amdinocillin (mecillinam). Antimicrobial Agents & Chemotherapy, 30:906-912). Interactions between drugs could, therefore, involve two drugs that inhibit the same target protein or nucleic acid or inhibit different proteins or nucleic acids in the same pathway [(Fukuoka, T., Domon, H., Kakuta, M., Ishii, C., Hirasawa, A., Utsui, Y., Ohya, S., and Yasuda, H. (1997) Combination effect between panipenem and vancomycin on highly methicillin-resistant *Staphylococcus aureus*. Japan. J. Antibio. 50:411-419; Smith, C.E., Foleno, B.E., Barrett, J.F., and Frosc, M.B. (1997) Assessment of the synergistic interactions of levofloxacin and ampicillin against *Enterococcus faecium* by the checkerboard agar dilution and time-kill methods. Diagnos. Microbiol. Infect. Disease 27:85-92; den Hollander, J.G., Horrevorts, A.M., van Goor, M.L., Verbrugh, H.A., and Mouton, J.W. (1997) Synergism between tobramycin and ceftazidime against a resistant *Pseudomonas aeruginosa* strain, tested in an in vitro pharmacokinetic model. Antimicrobial Agents & Chemotherapy. 41:95-110).

Two drugs may interact even though they inhibit different targets. For example, the proton pump inhibitor, Omeprazole, and the antibiotic, Amoxycillin, two synergistic compounds acting together, can cure *Helicobacter pylori* infection [(Gabryelewicz, A., Laszewicz, W., Dzieńszewski, J., Ciok, J., Marlicz, K., Bielecki, D., Popiela, T., Legutko, J., Knapik, Z., Poniewierka, E. (1997) Multicenter evaluation of dual-therapy (omeprazol and amoxycillin) for *Helicobacter pylori*-associated duodenal and gastric ulcer (two years of the observation). J. Physiol. Pharmacol. 48 Suppl 4:93-105).

The growth inhibition from the sub-lethal concentration of the known antibiotic may be at least about 5%, at least about 8%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, or at least about 75%, or more.

Alternatively, the sub-lethal concentration of the known antibiotic may be determined by measuring the activity of the target proliferation-required gene product rather than by measuring growth inhibition.

Cells are contacted with a combination of each member of a panel of known antibiotics at a sub-lethal level and varying concentrations of the test antibiotic. As a control, the cells are contacted with varying concentrations of the test antibiotic alone. The IC_{50} of the test antibiotic in the presence and absence of the known antibiotic is determined. If the IC_{50} s in the presence and absence of the known drug are substantially similar, then the test drug and the known drug act on different pathways. If the IC_{50} s are substantially different, then the test drug and the known drug act on the same pathway.

It will be appreciated that the above cell-based assays may be performed using a sub-lethal concentration of a known antibiotic which acts against the product of any of the proliferation-required nucleic acids from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* (including the products of SEQ ID NOs: 6214-42397, or portions thereof, or the products of homologous coding nucleic acids or portions thereof). In this way, the level or activity of a target, such as any of the proliferation-required polypeptides from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria*

meningitidis, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* (including the polypeptides of SEQ ID NOs.: 42398-78581), or homologous polypeptides may be reduced.

Another embodiment of the present invention is a method for identifying a candidate compound for use as an antibiotic in which the activity of target proteins or nucleic acids involved in proliferation-required pathways is reduced by contacting cells with a sub-lethal concentration of a known antibiotic which acts against the target protein or nucleic acid. In one embodiment, the target protein or nucleic acid is a target protein or nucleic acid corresponding to a proliferation-required nucleic acid identified using the methods described above. The method is similar to those described previously herein for identifying candidate compounds for use as antibiotics except that rather than reducing the activity or level of a proliferation-required gene product using a sub-lethal level of antisense to a proliferation-required nucleic acid, the activity or level of the proliferation-required gene product is reduced using a sub-lethal level of a known antibiotic which acts against the proliferation required gene product.

The growth inhibition from the sub-lethal concentration of the known antibiotic may be at least about 5%, at least about 8%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, or at least about 75%, or more.

Alternatively, the sub-lethal concentration of the known antibiotic may be determined by measuring the activity of the target proliferation-required gene product rather than by measuring growth inhibition.

In order to characterize test compounds of interest, cells are contacted with a panel of known antibiotics at a sub-lethal level and one or more concentrations of the test compound. As a control, the cells are contacted with the same concentrations of the test compound alone. The IC_{50} of the test compound in the presence and absence of the known antibiotic is determined. If the IC_{50} of the test compound is substantially different in the presence and absence of the known drug then the test compound is a good candidate for use as an antibiotic. As discussed above, once a candidate compound is identified using the above methods its structure may be optimized using standard techniques such as combinatorial chemistry.

Representative known antibiotics which may be used in each of the above methods are provided in Table VI below. However, it will be appreciated that other antibiotics may also be used.

TABLE VI
Antibiotics and Their Targets

ANTIBIOTIC	INHIBITS/TARGET	RESISTANT MUTANTS
Inhibitors of Transcription		
Rifamycin, Rifampicin	Inhibits initiation of transcription/ β -subunit RNA polymerase, <i>rpoB</i>	<i>rpoB</i> , <i>crp</i> , <i>cyoA</i>
Rifabutin Rifaximin	Accelerates transcription chain termination/ β -subunit RNA polymerase	<i>rpoB</i>
Streptolydigin	an acyclic ansamycin, inhibits RNA polymerase	<i>rpoB</i>
Streptovaricin	Intercalates between 2 successive G-C pairs, <i>rpoB</i> , inhibits RNA synthesis	<i>pldA</i>
Actinomycin D+EDTA		
Inhibitors of Nucleic Acid Metabolism		
Quinolones,	α subunit gyrase and/or topoisomerase IV, <i>gyrA</i>	<i>gyrA</i> or <i>B</i> , <i>icd</i> , <i>sloB</i>
Nalidixic acid Oxolinic acid		
Fluoroquinolones	α subunit gyrase, <i>gyrA</i> and/or topoisomerase IV (probable target in Staph)	<i>gyrA</i>
Ciprofloxacin, Norfloxacin		<i>norA</i> (efflux in Staph)
Coumerins	Inhibits ATPase activity of β -subunit gyrase, <i>gyrB</i>	<i>hipQ</i>
Novobiocin		<i>gyrB</i> , <i>cysB</i> , <i>cysE</i> , <i>nov</i> , <i>ompA</i>
Coumermycin	Inhibits ATPase activity of β -subunit gyrase, <i>gyrB</i>	<i>gyrB</i> , <i>hisW</i>
Albicidin	DNA synthesis	<i>tsx</i> (nucleoside channel)
Metronidazole	Causes single-strand breaks in DNA	<i>nar</i>
Inhibitors of Metabolic Pathways		
Sulfonamides,	blocks synthesis of dihydrofolate, dihydro-pterolate synthesis, <i>folP</i>	<i>folP</i> , <i>gpt</i> , <i>pabA</i> , <i>pabB</i> , <i>pabC</i>
Sulfanilamide		
Trimethoprim, Showdomycin	Inhibits dihydrofolate reductase, <i>folA</i>	<i>folA</i> , <i>thyA</i>
	Nucleoside analogue capable of alkylating sulfhydryl groups, inhibitor of thymidylate synthetase	<i>nupC</i> , <i>pnp</i>
Thiolactomycin	type II fatty acid synthase inhibitor	<i>emrB</i>
		<i>fadB</i> , <i>emrB</i> due to gene dosage
Psicofuranine	Adenosine glycoside antibiotic, target is GMP synthetase	<i>guaA</i> , <i>B</i>
Triclosan	Inhibits fatty acid synthesis	<i>fabI</i> (<i>envM</i>)
Diazaborines Isoniazid, Ethionamide	heterocyclic, contain boron, inhibit fatty acid synthesis, enoyl-ACP reductase, <i>fabI</i>	<i>fabI</i> (<i>envM</i>)

Inhibitors of Translation

Phenylpropanoids Chloramphenicol,	Binds to ribosomal peptidyl transfer center preventing peptide translocation/ binds to S6, L3, L6, L14, L16, L25, L26, L27, but preferentially to L16	<i>rrn, cmlA, marA, ompF, ompR</i>
Tetracyclines, type II polyketides Minocycline Doxycycline	Binding to 30S ribosomal subunit, "A" site on 30S subunit, blocks peptide elongation, strongest binding to S7	<i>clmA (cmr), mar, ompF</i>
Macrolides (type I polyketides) Erythromycin, Clarithromycin, Spiramycin etc	Binding to 50 S ribosomal subunit, 23S rRNA, blocks peptide translocation, L15, L4, L12	<i>rrn, rplC, rplD, rplV, mac</i>
Aminoglycosides Streptomycin, Neomycin Spectinomycin Kanamycin Kasugamycin Gentamicin, Amikacin Paromycin	Irreversible binding to 30S ribosomal subunit, prevents translation or causes mistranslation of mRNA/16S rRNA	<i>rpsL, strC,M, ubiF atpA-E, ecjB, hemA,C,D,E,G, topA, rpsC,D,E, rrn, spcB atpA-atpE, cpxA, ecjB, hemA,B,L, topA ksgA,B,C,D, rplB,K, rpsI,N,M,R rplF, ubiF cpxA rpsL</i>
Lincosamides Lincomycin, Clindamycin	Binding to 50 S ribosomal subunit, blocks peptide translocation	<i>linB, rplN,O, rpsG</i>
Streptogramins Virginiamycin, Pristinamycin	2 components, Streptogramins A&B, bind to the 50S ribosomal subunit blocking peptide translocation and peptide bond formation	
Synergist: quinupristin /dalfopristin		
Fusidanes Fusidic Acid	Inhibition of elongation factor G (EF-G) prevents peptide translocation	<i>fusA</i>
Kirromycin (Mocimycin)	Inhibition of elongation factor TU (EF-Tu), prevents peptide bond formation	<i>tufA,B</i>
Pulvomycin Thiopeptin	Binds to and inhibits EF-TU Sulfur-containing antibiotic, inhibits protein synthesis, EF-G	<i>rplE</i>
Tiamulin Negamycin	Inhibits protein synthesis Inhibits termination process of protein synthesis	<i>rplC, rplD prfB</i>
Oxazolidinones Linezolid Isoniazid	23S rRNA	
Nitrofurantoin	Inhibits protein synthesis,	<i>pdx nfnA,B</i>

	nitroreductases convert nitrofurantoin to highly reactive electrophilic intermediates which attack bacterial ribosomal proteins non-specifically	
Pseudomonic Acids Mupirocin (Bactroban)	Inhibition of isoleucyl tRNA synthetase-used for Staph, topical cream, nasal spray	<i>ileS</i>
Indolmycin Viomycin	Inhibits tryptophanyl-tRNA synthetase	<i>trpS</i> <i>rrmA</i> (23S rRNA methyltransferase; mutant has slow growth rate, slow chain elongation rate, and viomycin resistance)
Thiopeptides Thiostrepton Micrococcin	Binds to L11-23S RNA complex Inhibits GTP hydrolysis by EF-G Stimulates GTP hydrolysis by EF-G	
Inhibitors of Cell Walls/Membranes		
β -lactams Penicillin, Ampicillin Methicillin,	Inhibition of one or more cell wall transpeptidases, endopeptidases, and glycosidases (PBPs), of the 12 PBPs only 2 are essential: <i>mrdA</i> (PBP2) and <i>ftsI</i> (<i>pbpB</i> , PBP3)	<i>ampC</i> , <i>ampD</i> , <i>ampE</i> , <i>envZ</i> , <i>galU</i> , <i>hipA</i> , <i>hipQ</i> , <i>ompC</i> , <i>ompF</i> , <i>ompR</i> , <i>ptsI</i> , <i>rfa</i> , <i>tolD</i> , <i>tolE</i>
Cephalosporins, Mecillinam (amdinocillin)	Binds to and inactivates PBP2 (<i>mrdA</i>) Inactivates PBP3 (<i>ftsI</i>)	<i>tonB</i> <i>alaS</i> , <i>argS</i> , <i>crp</i> , <i>cyaA</i> , <i>envB</i> , <i>mrdA</i> , <i>B</i> , <i>mreB</i> , <i>C</i> , <i>D</i>
Aztreonam (Furazlocillin) Bacilysin, Tetaine	Dipeptide, inhib glucosamine synthase	<i>dppA</i>
Glycopeptides Vancomycin, Polypeptides Bacitracin	Inhib G^+ cell wall syn, binds to terminal D-ala-D-ala of pentapeptide, Prevents dephosphorylation and regeneration of lipid carrier	<i>rfa</i>
Cyclic lipopeptide Daptomycin,	Disrupts multiple aspects of membrane function, including peptidoglycan synthesis, lipoteichoic acid synthesis, and the bacterial membrane potential	
Cyclic polypeptides Polymixin,	Surfactant action disrupts cell membrane lipids, binds lipid A moiety of LPS	<i>pmrA</i>
Fosfomycin,	Analogue of P-enolpyruvate, inhibits 1 st step in peptidoglycan synthesis - UDP-N-acetylglucosamine	<i>murA</i> , <i>crp</i> , <i>cyaA</i> <i>glpT</i> , <i>hipA</i> , <i>ptsI</i> , <i>uhpT</i>

	enolpyruvyl transferase, <i>murA</i> . Also acts as Immunosuppressant	
Cycloserine	Prevents formation of D-ala dimer, inhibits D-ala ligase, <i>ddlA,B</i>	<i>hipA, cycA</i>
Alafosfalin	phosphonodipeptide, cell wall synthesis inhibitor, potentiator of β -lactams	<i>pepA, tpp</i>

Inhibitors of Protein Processing/Transport

Globomycin	Inhibits signal peptidase II (cleaves prolipoproteins subsequent to lipid modification, <i>lspA</i>)	<i>lpp, dnaE</i>
------------	---	------------------

It will be appreciated that the above cell-based assays may be performed using a sub-lethal concentration of a known antibiotic which acts against the product of any of the proliferation-required nucleic acids from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or portions thereof, or homologous nucleic acids. In this way, the level or activity of a target, such as any of the proliferation-required polypeptides from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria*

meningitidis, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or homologous polypeptides may be reduced.

EXAMPLE 21

Strains in which a Gene Encoding a Gene Product Required for Proliferation is Overexpressed are able to Grow at Elevated Antibiotic Concentrations

To confirm that cells which overexpress a gene product required for proliferation are able to grow at elevated antibiotic concentrations, 11 such genes from *Staphylococcus aureus* which are the targets of known antibiotics were operably linked to the xylose inducible promoter XylT5 (described in U.S. Patent Application Serial Number 10/032,393. The genes and the antibiotics which target the products of these genes are listed in Table VII below.

PCR primer pairs were designed for each of the 11 genes encoding a gene product required for proliferation of *Staphylococcus aureus* as shown in Table VII. The upstream primers for each gene included the native ribosomal binding sites (S-D sequences). In addition, restriction sites for appropriate restriction enzymes were designed into the primers to facilitate directional cloning of the genes. PCR reactions were carried out using Pfu DNA polymerase (Stratagene, San Diego) under the following conditions per 50 µl reaction: Pfu polymerase 2U, dNTP 200 µM, primers 400 nM each, *S. aureus* RN450 genomic DNA (template) 5-10 ng. The reaction involved an initial heating at 94°C for 5 min, followed by 25 cycles of 30 sec at 94°C/30 sec at 55°C/5 min at 72°C, and ending with 7 min of extension at 72°C.

The amplified genes were operably linked to the XylT5 promoter as follows. PCR products were cleaned using QIAGEN PCR Cleaning Kits and then were digested with the proper restriction enzymes. The resulting fragments were ligated overnight at 16°C with precut vector DNA containing the XylT5 promoter. Ligation mixtures were ethanol precipitated at -80°C for 20 min in the presence of 0.3 M sodium acetate. The precipitated DNA was spun down at 14,000 rpm for 30 min at 4°C and washed with 1 ml of 70% EtoH. The DNA pellets were air-dried and dissolved in EB or sterile water. To transform *Staphylococcus aureus* cells, the precipitated DNA was mixed with 45 µl of electroporation competent cells and incubated at room temperature for 30 min. The DNA/cell mixtures were electroporated (settings: 2 volts, 25 µF, 200 Ω) in 2 mm cuvettes and mixed with 450 µl B2 medium containing 0.2 µg/ml chloramphenicol. The cells were incubated at 37°C with shaking for 90 min. Transformed cells were plated onto LB agar plates containing chloramphenicol (34 µg/ml) for the selection of plasmids. Several colonies for each cloning reaction were picked and streaked to obtain a pure

culture. Colony PCR reactions using vector-specific primers were performed to verify the size and identity of the inserts.

Gene-walking sequencing was employed to completely sequence the entire insert for several clones of each cloned gene. This was carried out to avoid using a cloned gene whose
5 DNA sequence was mutated during the PCR process.

To demonstrate that genes encoding gene products required for proliferation can confer resistance to their specific inhibitors upon induction at proper inducer levels, cells of each clone in which the genes were operably linked to the xylose inducible promoter were grown in LB medium with chloramphenicol (34 µg/ml) at a combination of differing antibiotic and inducer
10 concentrations. This was accomplished by using microtitration plates (96 or 384 wells) which contained antibiotic and inducer at gradient concentrations in a matrix format in 10 times excess quantity (see Figure 11). Media containing inoculated cells (9 volume) was dispensed into the wells containing 1 volume of antibiotic/inducer for a final volume of 50 µl (for 384 well plates) or 200 µl (for 96 well plates). The plates were incubated at 37°C with periodic shaking and
15 growth of cells was monitored by automatic measurement of optical density at OD600 using a Ultramark reader. A clone over-expressing a particular gene was considered resistant to its specific antibiotic (inhibitor) if significant growth was observed at appropriate inducer concentrations in the presence of a particular concentration of antibiotic but not in the absence of inducer at that concentration of antibiotic.

The results are indicated in Figure 12 and Figure 13. As illustrated in Figure 12, at
20 appropriate concentrations of inducer cells which overexpress the *defB* gene product were able to grow at elevated concentrations of the antibiotic actinonin, which acts on the *defB* gene product. Similarly, as illustrated in Figure 13, at appropriate concentrations of inducer cells which overexpress the *folA* gene product were able to grow at elevated concentrations of the
25 antibiotic trimethoprim, which acts on the *folA* gene product.

Thus, elevated expression of a gene product required for proliferation enables cells to grow in the presence of antibiotic concentrations which inhibit or prevent growth of wild type cells.

Table VII - Essential Genes/Proteins and Specific Inhibitors

Gene	Target	Inhibitor	Primers
<i>gyrB</i>	β subunit of DNA gyrase or topoisomerase II	Novobiocin	GCCGGATCCTTATAAAGTAACAGAAAGCGATGTGTGACTGC (SEQ ID NO.: 78593); CAGGTCGACCGCGCTTAGAAGTCTAAGTTTGCAATAAACTG (SEQ ID NO.: 78594)
<i>murA</i>	UDP-N-acetylglucosamine enolpyruvyl transferase	Fosfomycin	CCTGGATCCTTCTAAGTGGAGGATTACG (SEQ ID NO.: 78595); CAGGTCGACGAAATTAATCGTTAATACGTT (SEQ ID NO.: 78596)
<i>fabI</i>	Enoyl-acyl carrier protein reductase	Triclosan	GCCGGATCCATAAGGAGTTATCTTACATG (SEQ ID NO.: 78597); CGCGTCGACCTATTAAATTCGTGGAATC (SEQ ID NO.: 78598)
<i>rpoB</i>	RNA polymerase β subunit	Rifampicin	GCTGGATCCTGAGGGGTGAATCTGTTGGC (SEQ ID NO.: 78599); CTGCTCGAGTGCCTATTAAATCAGTAACTT (SEQ ID NO.: 78600)
<i>fusA</i>	Elongation factor G	Fusidic acid	GCTGGATCCCTGGAAAGGAGAAAAAATACATGGCTAGAG (SEQ ID NO.: 78601); CCGGTCGACGGCTAGCTAGTCAAAAACAAGTTATATTATTCAC (SEQ ID NO.: 78602)
<i>folA</i>	Dihydrofolate reductase	Trimethoprim	GCTGGATCCAGAAAGAGGAGGATAATTATG (SEQ ID NO.: 78603); CCGGTCGACCTTTCCCCCTTATTTTAC (SEQ ID NO.: 78604)
<i>ileS</i>	Isoleucyl tRNA synthetase	Mupirocin (bactroban)*	GCTGGATCCTAAGGAGTGAAAAAATGGATTACAAAGAAACG (SEQ ID NO.: 78605); CCGGTCGACCAATTATACAAGTGATTTTACAACCTGTGTGGCATC (SEQ ID NO.: 78606)
<i>trpS</i>	Tryptophanyl tRNA synthetase	Indolmycin*	GCCGGATCCCTAAGAAAGTAGGCATTTAAATGGAGAC (SEQ ID NO.: 78607); CCGGTCGACGTTTATTTATCTCTTACGTCCTAAACC (SEQ ID NO.: 78608)
<i>fabF</i>	β keto-acyl carrier protein synthase	Cerulenin	GCTGGATCCAAATAGGAGGATAACGAATGAG (SEQ ID NO.: 78609); CAGGTCGACAAATTATGCTTCAAAATTTCTT (SEQ ID NO.: 78610)

<i>defB</i>	Peptide deformylase	Actinonin	GCTGGATCCATAAGGAAGGTGCAATATATG (SEQ ID NO.: 78611); CAGGTCGACGTTTAACTTCTACTGCGAT (SEQ ID NO.: 78612)
<i>PBP-2a</i>	Penicillin binding protein 2	Cloxacillin	GCCGGATCCCAAA TGTAGTCTTATATAAGGAGGATATTGATG (SEQ ID NO.: 78613); CAGGTCGACGCTTCACTGTTTGTATTTCATCTATATC (SEQ ID NO.: 78614)

* antibiotics unavailable commercially

EXAMPLE 22**Overexpression of Genes Encoding Gene Products Required for Proliferation Confers Specific Resistance to Antibiotics which Target the Overexpressed Gene Product**

To demonstrate that cells which overexpress a gene encoding a gene product required for proliferation are specifically resistant to antibiotics which target that gene product, the following experiments were performed. Several identical compound plates were prepared as described above in which different antibiotics were present in different wells. Media containing cells overexpressing different genes were separately dispensed into each one of these plates. Plate incubation and growth measurement were the same as described in Example 21 above. Growth was deemed specific if cells overexpressing one particular gene only gained resistance to antibiotics which target the product of the overexpressed gene but not to other antibiotics which target the products of genes which were not overexpressed.

As indicated in Figure 14 overexpression of the *fabI* gene conferred resistance to triclosan, which acts on the gene product of the *fabI* gene, enoyl-acyl carrier protein reductase. However, overexpression of the *fabI* gene did not confer resistance to cerulenin, trimethoprim, or actinonin, each of which act on other gene products.

Similarly, as indicated in Figure 15 overexpression of the *folA* gene conferred resistance to trimethoprim, which acts on the gene product of the *folA* gene, dihydrofolate reductase. However, overexpression of the *folA* gene did not confer resistance to triclosan, cerulenin, or actinonin, each of which act on other gene products.

As indicated in Figure 16 overexpression of the *defB* gene conferred resistance to actinonin, which acts on the gene product of the *defB* gene, peptide deformylase. However, overexpression of the *defB* gene did not confer resistance to cerulenin, trimethoprim, or triclosan, each of which act on other gene products.

As indicated in Figure 17 overexpression of the *fabF* gene conferred resistance to cerulenin, which acts on the gene product of the *fabF* gene, β keto-acyl carrier protein synthase II. However, overexpression of the *fabF* gene did not confer resistance to triclosan, trimethoprim, or actinonin, each of which act on other gene products.

Thus, overexpression of a gene encoding a gene product required for proliferation confers specific resistance to antibiotics which target the overexpressed gene product.

EXAMPLE 23**Selection of a Strain Overexpressing a Gene Encoding a Target Gene Product from a Mixture of Strains Overexpressing Genes Required for Proliferation**

To confirm that a strain expressing the gene product targeted by an antibiotic can be selected from a mixture of strains which each overexpress a different gene required for

proliferation, the following experiment was performed. *S. aureus* strains overexpressing one of nine genes encoding a gene product required for proliferation were constructed as described above. The nine overexpressed genes were *fabF*, *defB*, *folA*, *fabI*, *ileS*, *fusA*, *gyrB*, *murA*, *rpoB*. A mixture of the nine strains was grown wells in a 96 well plate in medium containing various concentrations of inducer and a sufficient concentration of actinonin, cerulenin, triclosan or trimethoprim to inhibit the growth of strains which do not overexpress the targets of these antibiotics.

Growth was observed in wells containing appropriate inducer concentrations and each one of the four antibiotics (See Figure 18). The cultures which grew in the presence of one of the antibiotics were analyzed as follows. The cultures were removed from the wells of the plate and single colonies were obtained by plating serial dilutions LB agar plates containing an appropriate antibiotic. Plasmids were isolated from at least 60 individual colonies for each culture and the genes which conferred antibiotic resistance were amplified by performing PCR reactions using vector-specific primers. The PCR products were then sequenced.

All of the plasmids obtained from the culture which grew in the presence of cerulenin contained the *fabF* sequence. Similarly, all of the plasmids obtained from clones which grew in the presence of triclosan contained the *fabI* gene. All of the plasmid obtained from colonies which grew in the presence of actinonin contained the *defB* gene. In addition, 81% of the plasmids obtained from colonies which grew in the presence of trimethoprim contained the *folA* gene. Growth conditions could be further optimized to provide 100% recovery of plasmids containing the *folA* gene.

These results demonstrate that a strain expressing the gene product targeted by an antibiotic can be selected from a mixture of strains which each overexpress a different gene required for proliferation.

EXAMPLE 24

Identification of Amplification Products Having Distinguishable Lengths

The following genes were identified as being required for proliferation as previously described in U.S. Patent Application Serial Number 09/815,242, filed march 21, 2001. Plasmids in which antisense nucleic acids complementary to nucleotide sequences the essential *pbpC*, *secA*, *ylaO(Bs)*, *yphC(Bs)*, *trpS*, *polC*, *fabI*, *rpsR (Bs)*, *fabF(yjaY)*, *ileS*, *murC*, *fmhB*, *murA (Bs)*, *murF(Bs)*, *fisZ*, *tufA*, *gyrA*, *rpoB*, *griA* or *folA(dfrA)* genes were transcribed from the XylT5 promoter in *Staphylococcus aureus*.

Amplification primers were designed which would yield amplification products of the following lengths if the plasmid encoding the corresponding antisense nucleic acid is present in a mixture of nucleic acids:

	<i>yphC</i>	260bp	<i>secA</i>	267bp
	<i>folA</i>	230 bp	<i>tufA</i>	243bp
	<i>fabI</i>	220bp	<i>gyrA</i>	225bp
	<i>trpS</i>	208bp	<i>ileS</i>	215bp
5	<i>fabF</i>	189bp	<i>murF</i>	203bp
	<i>murA</i>	176bp	<i>fmhB</i>	181bp
	<i>rpoB</i>	159bp	<i>ylaO</i>	169bp
	<i>grlA</i>	151bp	<i>pbpC</i>	156bp
	<i>murC</i>	129bp	<i>polC</i>	145bp
10	<i>rpsR</i>	109bp	<i>ftsZ</i>	117bp

The 5' primer of each pair was complementary to a nucleotide sequence within the *xylT5* promoter while 3' primer was complementary to a nucleotide sequence within the antisense clone. The 5' primer of each pair was identical for each amplification reaction. The nucleotide sequence GTTTCTT was appended on the 5' end of the 3' primers. One primer in each pair was labeled with either VIC or 6FAM.

Two sets of ten plasmids containing the antisense nucleic acids complementary to the genes listed in each of the columns above were mixed in equal amounts in 11 tubes except that either the plasmid encoding antisense nucleic acids complementary to a nucleotide sequence in the *grlA* gene or the plasmid encoding antisense nucleic acids complementary to nucleotide sequences in the *fmhB* gene were serially diluted two fold in each of the 11 tubes (i.e. the first tube had 100pg of the *grlA* plasmid or the *fmhB* plasmid while the last tube had 0.10pg of the *grlA* plasmid or the *fmhB* plasmid). Amplification reactions were conducted on the mixtures and the amplification products were separated on a 5% NuSieve 3:1 agarose gel (BioWhittaker Molecular Applications Rockland, ME). The levels of the 151bp or 181 amplification products for the *grlA* or *fmhB* primer respectively were specifically reduced in a stepwise fashion with increasing dilutions while the levels of the undiluted products remained constant. The assay readily detected a 10-fold decrease in template concentration reflected in the amplification products corresponding to the *grlA* or *fmhB* plasmids.

Although this method has been described using examples of antisense nucleic acids to specific essential genes, it will be appreciated that this method can be used with any of the antisense nucleic acids described herein, such as an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, an antisense nucleic acid comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a nucleic acid complementary to a nucleic acid comprising a nucleotide sequence

selected from the group consisting of SEQ ID NOs.: 6214-42397, a nucleic acid complementary to a nucleic acid comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, a nucleic acid complementary to a nucleic acid which encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581, a nucleic acid complementary to a nucleic acid which encodes at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of a polypeptide sequence selected from the group consisting of SEQ ID NOs.: 42398-78581, a homologous antisense nucleic acid, an antisense nucleic acid comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of a homologous nucleic acid, a nucleic acid complementary to a homologous coding nucleic acid, a nucleic acid complementary to at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of a homologous coding nucleic acid, a nucleic acid complementary to a nucleic acid which encodes a homologous polypeptide, or a nucleic acid complementary to a nucleic acid which encodes at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of a homologous polypeptide. It will also be appreciated that promoters other than XlyT5 can be used to express the gene products described herein. For example, a number of promoters useful for nucleic acid expression (including antisense nucleic acid expression) in *Enterococcus faecalis*, *Staphylococcus aureus* as well as other Gram positive organisms are described in U.S. Patent Application Serial Number 10/032,393, filed December 21, 2001.

Additionally, the above methods can be used with any organism including *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus*

mirabilis, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*,
 5 *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* or any species falling within the genera of any of the above species.

EXAMPLE 25

10 Selective Disappearance of Amplification Products Corresponding to Strains Underexpressing a Gene Product on which a Compound which Inhibits Proliferation Acts

Strains of *Staphylococcus aureus* containing plasmids encoding antisense nucleic acids complementary to nucleotide sequences within the *yphC*, *folA*, *fabI*, *trpS*, *fabF*, *murA*, *rpoB*, *griA*, *murC* or *rpsR* genes (described in Example 24 above) were mixed together in identical
 15 cultures such that the number of cells of each strain in the culture was identical. Each of the cultures containing the ten strains was contacted with one of the following antibiotics at one of the following concentrations:

spectinomycin- 2.5, 5.0ug/ml

mupriocin- 4.3, 8.6, 17.2ug/ml.

20 cerulenin- 4.5, 9.0, 18.0ug/ml

Spectinomycin acts on the product of the *rpsR* gene, mupriocin acts on the product of the *ileS* gene and cerulenin acts on the product of the *FabF* gene. The middle concentration for each antibiotic is its IC50.

The culture containing the ten strains were grown in rich medium (L-Broth; for
 25 antisense LB + chloroamphenicol to maintain antisense plasmid) until the cells reached early log phase then contacted with one of the above-stated compounds at one of the concentrations listed above (preferably near IC50). The cultures were grown for a sufficient length of time to permit the compounds to specifically inhibit the growth of strains underexpressing their targets. Preferably the cultures were grown at least 16 hr, more
 30 preferably between 24 and 48 hrs. It is desirable to avoid allowing the culture to grow for time periods which might place selective pressure on the strains which could lead to false positives.

The cells were harvested by centrifugation and plasmid DNA was isolated from the cultures. PCR amplifications were performed as described in Example 24. Amplification
 35 products were run on NuSieve agarose gels as described above. The amounts of the amplification products corresponding to each antisense nucleic acid were determined and

compared to those in a control culture which was not contacted with the drug or to the amounts of the amplification products corresponding to the other antisense nucleic acids which were not complementary to nucleotide sequences in the genes encoding the gene products on which the compounds act. In each case, only the amplification product corresponding to the target on which the antibiotic acts was not detectable on the gel.

It is desirable, in embodiments in which the level or activity of gene products is regulated by transcribing antisense nucleic acids complementary to gene products required for proliferation or by replacing the native promoters of such genes with regulatable promoters, to perform dose-response curve for the inducer used to induce transcription of the antisense nucleic acids or induce transcription from the regulatable promoter. In such embodiments, it is desirable to use the lowest concentration of inducer which provides optimal transcription levels for detecting the effects of a particular test compound while interfering as little as possible with the growth of strains which do not overexpress or underexpress the target on which the compound acts. It also desirable contact the cultures with varying amounts of test compounds to determine the optimal amounts for obtaining differential growth of strains which overexpress or underexpress the targets on which the compounds act. Preferably, if the strains overexpress gene products required for proliferation, the level of the compound is preferably about IC_{90} or above. Preferably, if the strains underexpress gene products required for proliferation, the level of the compound is preferably about IC_{50} or below.

It will be appreciated that, if desired, the amplification products may be detected using the dyes described above. It will also be appreciated that amplification products may be detected using any desired amplification method including RT-PCR and PCR.

Although this method has been described using examples of antisense nucleic acids to specific essential genes, it will be appreciated that this method can be used with any of the antisense nucleic acids described herein, such as an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a nucleic acid sequence complementary to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, a nucleic acid sequence complementary to a nucleic acid sequence which encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581, a homologous antisense nucleic acid, a nucleic acid sequence complementary to a homologous coding nucleic acid, or a nucleic acid complementary to a nucleic acid which encodes a homologous polypeptide. It will also be appreciated that promoters other than *XlyT5* can be used to express the gene products described herein. For example, a number of promoters useful for nucleic acid expression (including antisense nucleic acid expression) in *Enterococcus faecalis*, *Staphylococcus aureus* as well as

other Gram positive organisms are described in U.S. Patent Application Serial Number 10/032,393, filed December 21, 2001.

Additionally, the above methods can be used with any organism including *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*,
 5 *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*,
Burkholderia fungorum, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*,
Candida glabrata (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*,
Candida guilliermondii, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*),
Candida dubliniensis, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium*
 10 *acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*,
Coccidioides immitis, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter*
cloacae, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus*
influenzae, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella*
pneumophila, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*,
 15 *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma*
genitalium, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia*
asteroides, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus*
mirabilis, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas*
syringae, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella*
 20 *paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*,
Shigella flexneri, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*,
Staphylococcus haemolyticus, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus*
pyogenes, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio*
parahaemolyticus, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* or any species
 25 falling within the genera of any of the above species.

EXAMPLE 26

Use of Identified Nucleic Acid Sequences as Probes

The sequences from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*,
Klebsiella pneumoniae, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter*
 30 *baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*,
Burkholderia cepacia, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*,
Chlamydia pneumoniae, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium*
botulinum, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*,
Enterococcus faecium, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*,
 35 *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,

Mycobacterium leprae, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*,
5 *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* described herein, homologous coding nucleic acids, or homologous antisense nucleic acids can be used as probes to obtain the sequence of additional genes of interest from a second cell or microorganism. For example, probes to genes encoding potential bacterial target proteins may be hybridized to nucleic acids from other
10 organisms including other bacteria and higher organisms, to identify homologous sequences in these other organisms. For example, the identified sequences from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*,
15 *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*,
20 *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or
25 *Yersinia pestis*, homologous coding nucleic acids, or homologous antisense nucleic acids may be used to identify homologous sequences in *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*),
30 *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*,
35 *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*,

Klebsiella pneumoniae, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*,
 5 *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*,
 10 *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* or any species falling within the genera of any of the above species. In some embodiments of the present invention, the nucleic acids from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*,
 15 *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*,
 20 *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* described herein, homologous coding nucleic acids, or homologous antisense nucleic acids may be used to identify homologous nucleic acids from a heterologous organism other than *E. coli*.
 25

30 Hybridization between the nucleic acids from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*,
 35

Enterobacter cloacae, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*,
Legionella pneumophila, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium*
avium, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*,
Mycoplasma genitalium, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria*
5 *meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas*
syringae, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus*
haemolyticus, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*,
Treponema pallidum, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* described
herein, homologous coding nucleic acids, or homologous antisense nucleic acids and nucleic acids
10 from humans might indicate that the protein encoded by the gene to which the probe corresponds is
found in humans and therefore not necessarily an optimal drug target. Alternatively, the gene can
be conserved only in bacteria and therefore would be a good drug target for a broad spectrum
antibiotic or antimicrobial. These probes can also be used in a known manner to isolate
homologous nucleic acids from *Staphylococcus*, *Salmonella*, *Klebsiella*, *Pseudomonas*,
15 *Enterococcus* or other cells or microorganisms, e.g. by screening a genomic or cDNA library.

Probes derived from the nucleic acid sequences from *Escherichia coli*, *Staphylococcus*
aureus, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella*
typhimurium, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella*
pertussis, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia*
20 *mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium*
acetobutylicum, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*,
Enterobacter cloacae, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*,
Legionella pneumophila, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium*
avium, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*,
25 *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria*
meningitidis, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas*
syringae, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus*
haemolyticus, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*,
Treponema pallidum, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* described
30 herein, homologous coding nucleic acids, or homologous antisense nucleic acids, or portions
thereof, can be labeled with detectable labels familiar to those skilled in the art, including
radioisotopes and non-radioactive labels, to provide a detectable probe. The detectable probe can
be single stranded or double stranded and can be made using techniques known in the art, including
in vitro transcription, nick translation, or kinase reactions. A nucleic acid sample containing a
35 sequence capable of hybridizing to the labeled probe is contacted with the labeled probe. If the

nucleic acid in the sample is double stranded, it can be denatured prior to contacting the probe. In some applications, the nucleic acid sample can be immobilized on a surface such as a nitrocellulose or nylon membrane. The nucleic acid sample can comprise nucleic acids obtained from a variety of sources, including genomic DNA, cDNA libraries, RNA, or tissue samples.

5 Procedures used to detect the presence of nucleic acids capable of hybridizing to the detectable probe include well known techniques such as Southern blotting, Northern blotting, dot blotting, colony hybridization, and plaque hybridization. In some applications, the nucleic acid capable of hybridizing to the labeled probe can be cloned into vectors such as expression vectors, sequencing vectors, or in vitro transcription vectors to facilitate the characterization and expression
10 of the hybridizing nucleic acids in the sample. For example, such techniques can be used to isolate, purify and clone sequences from a genomic library, made from a variety of bacterial species, which are capable of hybridizing to probes made from the sequences identified as described herein.

EXAMPLE 27

Preparation of PCR Primers and Amplification of DNA

15 The identified *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium*
20 *botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus*
25 *mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* genes corresponding directly to or located within the operon of nucleic acid sequences required for proliferation, homologous coding nucleic acids,
30 or homologous antisense nucleic acids or portions thereof can be used to prepare PCR primers for a variety of applications, including the identification or isolation of homologous sequences from other species. For example, the *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*,
35 *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*,

Chlamydia pneumoniae, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
 5 *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* genes may be used to prepare PCR primers to identify or isolate homologous sequences from *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*),
 10 *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*,
 15 *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*,
 20 *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*,
 25 *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* or any species falling within the genera of any of the above species. In some embodiments of the present invention, the PCR primers may be used to identify or isolate homologous nucleic acids from an organism other than *E. coli*.
 30

The identified or isolated nucleic acids obtained using the PCR primers may contain part or all of the homologous nucleic acids. Because homologous nucleic acids are related but not identical in sequence, those skilled in the art will often employ degenerate sequence PCR primers. Such degenerate sequence primers are designed based on sequence regions that are either known to be conserved or suspected to be conserved such as conserved coding regions. The successful production of a PCR product using degenerate probes generated from the sequences identified herein would indicate the presence of a homologous gene sequence in the species being screened. The PCR primers are at least 10 nucleotides, and preferably at least 20 nucleotides in length. More preferably, the PCR primers are at least 20-30 nucleotides in length. In some embodiments, the PCR primers can be more than 30 nucleotides in length. It is preferred that the primer pairs have approximately the same G/C ratio, so that melting temperatures are approximately the same. A variety of PCR techniques are familiar to those skilled in the art. For a review of PCR technology, see Molecular Cloning to Genetic Engineering White, B.A. Ed. in **Methods in Molecular Biology** 67: Humana Press, Totowa 1997. When the entire coding sequence of the target gene is known, the 5' and 3' regions of the target gene can be used as the sequence source for PCR probe generation. In each of these PCR procedures, PCR primers on either side of the nucleic acid sequences to be amplified are added to a suitably prepared nucleic acid sample along with dNTPs and a thermostable polymerase such as Taq polymerase, Pfu polymerase, or Vent polymerase. The nucleic acid in the sample is denatured and the PCR primers are specifically hybridized to complementary nucleic acid sequences in the sample. The hybridized primers are extended. Thereafter, another cycle of denaturation, hybridization, and extension is initiated. The cycles are repeated multiple times to produce an amplified fragment containing the nucleic acid sequence between the primer sites.

EXAMPLE 28

Inverse PCR

The technique of inverse polymerase chain reaction can be used to extend the known nucleic acid sequence identified as described herein. The inverse PCR reaction is described generally by Ochman et al., in Ch. 10 of **PCR Technology: Principles and Applications for DNA Amplification**, (Henry A. Erlich, Ed.) W.H. Freeman and Co. (1992). Traditional PCR requires two primers that are used to prime the synthesis of complementary strands of DNA. In inverse PCR, only a core sequence need be known.

Using the sequences identified as relevant from the techniques taught in Examples 10 and 11 and applied to other species of bacteria, a subset of nucleic sequences are identified that correspond to genes or operons that are required for bacterial proliferation. In species for which a genome sequence is not known, the technique of inverse PCR provides a method for obtaining the

gene in order to determine the sequence or to place the probe sequences in full context to the target sequence to which the identified nucleic acid sequence binds.

To practice this technique, the genome of the target organism is digested with an appropriate restriction enzyme so as to create fragments of nucleic acid that contain the identified sequence as well as unknown sequences that flank the identified sequence. These fragments are then circularized and become the template for the PCR reaction. PCR primers are designed in accordance with the teachings of Example 27 and directed to the ends of the identified sequence.. The primers direct nucleic acid synthesis away from the known sequence and toward the unknown sequence contained within the circularized template. After the PCR reaction is complete, the resulting PCR products can be sequenced so as to extend the sequence of the identified gene past the core sequence of the identified exogenous nucleic acid sequence identified. In this manner, the full sequence of each novel gene can be identified. Additionally the sequences of adjacent coding and noncoding regions can be identified.

EXAMPLE 29

Identification of Genes Required for *Escherichia coli* Proliferation

Genes required for proliferation in *Escherichia coli* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 30

Identification of Genes Required for *Staphylococcus aureus* Proliferation

Genes required for proliferation in *Staphylococcus aureus* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 31

Identification of Genes Required for *Enterococcus faecalis* Proliferation

Genes required for proliferation in *Enterococcus faecalis* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 32

Identification of Genes Required for *Klebsiella pneumoniae* Proliferation

Genes required for proliferation in *Klebsiella pneumoniae* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 33**Identification of Genes Required for *Pseudomonas aeruginosa* Proliferation**

Genes required for proliferation in *Pseudomonas aeruginosa* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 34**Identification of Genes Required for *Salmonella typhimurium* Proliferation**

Genes required for proliferation in *Salmonella typhimurium* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 35**Identification of Genes Required for *Acinetobacter baumannii* Proliferation**

Genes required for proliferation in *Acinetobacter baumannii* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 36**Identification of Genes Required for *Bacillus anthracis* Proliferation**

Genes required for proliferation in *Bacillus anthracis* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 37**Identification of Genes Required for *Bordetella pertussis* Proliferation**

Genes required for proliferation in *Bordetella pertussis* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 38**Identification of Genes Required for *Borrelia burgdorferi* Proliferation**

Genes required for proliferation in *Borrelia burgdorferi* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 39**Identification of Genes Required for *Burkholderia cepacia* Proliferation**

Genes required for proliferation in *Burkholderia cepacia* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 40**Identification of Genes Required for *Burkholderia fungorum* Proliferation**

Genes required for proliferation in *Burkholderia fungorum* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 41**Identification of Genes Required for *Burkholderia mallei* Proliferation**

Genes required for proliferation in *Burkholderia mallei* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 42**Identification of Genes Required for *Campylobacter jejuni* Proliferation**

Genes required for proliferation in *Campylobacter jejuni* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 43**Identification of Genes Required for *Chlamydia pneumoniae* Proliferation**

Genes required for proliferation in *Chlamydia pneumoniae* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 44**Identification of Genes Required for *Chlamydia trachomatis* Proliferation**

Genes required for proliferation in *Chlamydia trachomatis* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 45**Identification of Genes Required for *Clostridium acetobutylicum* Proliferation**

Genes required for proliferation in *Clostridium acetobutylicum* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 46**Identification of Genes Required for *Clostridium botulinum* Proliferation**

Genes required for proliferation in *Clostridium botulinum* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 47**Identification of Genes Required for *Clostridium difficile* Proliferation**

Genes required for proliferation in *Clostridium difficile* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
5 identify essential genes described herein.

EXAMPLE 48**Identification of Genes Required for *Corynebacterium diphtheriae* Proliferation**

Genes required for proliferation in *Corynebacterium diphtheriae* are identified according to the methods described above. For example, promoters and vectors described herein can be
10 used to identify essential genes described herein.

EXAMPLE 49**Identification of Genes Required for *Enterobacter cloacae* Proliferation**

Genes required for proliferation in *Enterobacter cloacae* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
15 identify essential genes described herein.

EXAMPLE 50**Identification of Genes Required for *Enterococcus faecium* Proliferation**

Genes required for proliferation in *Enterococcus faecium* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
20 identify essential genes described herein.

EXAMPLE 51**Identification of Genes Required for *Haemophilus influenzae* Proliferation**

Genes required for proliferation in *Haemophilus influenzae* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
25 identify essential genes described herein.

EXAMPLE 52**Identification of Genes Required for *Helicobacter pylori* Proliferation**

Genes required for proliferation in *Helicobacter pylori* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
30 identify essential genes described herein.

EXAMPLE 53**Identification of Genes Required for *Legionella pneumophila* Proliferation**

Genes required for proliferation in *Legionella pneumophila* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
35 identify essential genes described herein.

EXAMPLE 54**Identification of Genes Required for *Listeria monocytogenes* Proliferation**

Genes required for proliferation in *Listeria monocytogenes* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
5 identify essential genes described herein.

EXAMPLE 55**Identification of Genes Required for *Moraxella catarrhalis* Proliferation**

Genes required for proliferation in *Moraxella catarrhalis* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
10 identify essential genes described herein.

EXAMPLE 56**Identification of Genes Required for *Mycobacterium avium* Proliferation**

Genes required for proliferation in *Mycobacterium avium* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
15 identify essential genes described herein.

EXAMPLE 57**Identification of Genes Required for *Mycobacterium bovis* Proliferation**

Genes required for proliferation in *Mycobacterium bovis* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
20 identify essential genes described herein.

EXAMPLE 58**Identification of Genes Required for *Mycobacterium leprae* Proliferation**

Genes required for proliferation in *Mycobacterium leprae* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
25 identify essential genes described herein.

EXAMPLE 59**Identification of Genes Required for *Mycobacterium tuberculosis* Proliferation**

Genes required for proliferation in *Mycobacterium tuberculosis* are identified according to the methods described above. For example, promoters and vectors described herein can be
30 used to identify essential genes described herein.

EXAMPLE 60**Identification of Genes Required for *Mycoplasma genitalium* Proliferation**

Genes required for proliferation in *Mycoplasma genitalium* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
35 identify essential genes described herein.

EXAMPLE 61**Identification of Genes Required for *Mycoplasma pneumoniae* Proliferation**

Genes required for proliferation in *Mycoplasma pneumoniae* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 62**Identification of Genes Required for *Neisseria gonorrhoeae* Proliferation**

Genes required for proliferation in *Neisseria gonorrhoeae* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 63**Identification of Genes Required for *Neisseria meningitidis* Proliferation**

Genes required for proliferation in *Neisseria meningitidis* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 64**Identification of Genes Required for *Pasteurella multocida* Proliferation**

Genes required for proliferation in *Pasteurella multocida* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 65**Identification of Genes Required for *Proteus mirabilis* Proliferation**

Genes required for proliferation in *Proteus mirabilis* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 66**Identification of Genes Required for *Pseudomonas putida* Proliferation**

Genes required for proliferation in *Pseudomonas putida* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 67**Identification of Genes Required for *Pseudomonas syringae* Proliferation**

Genes required for proliferation in *Pseudomonas syringae* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 68**Identification of Genes Required for *Salmonella paratyphi* Proliferation**

Genes required for proliferation in *Salmonella paratyphi* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
5 identify essential genes described herein.

EXAMPLE 69**Identification of Genes Required for *Salmonella typhi* Proliferation**

Genes required for proliferation in *Salmonella typhi* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
10 identify essential genes described herein.

EXAMPLE 70**Identification of Genes Required for *Staphylococcus epidermidis* Proliferation**

Genes required for proliferation in *Staphylococcus epidermidis* are identified according to the methods described above. For example, promoters and vectors described herein can be used
15 to identify essential genes described herein.

EXAMPLE 71**Identification of Genes Required for *Staphylococcus haemolyticus* Proliferation**

Genes required for proliferation in *Staphylococcus haemolyticus* are identified according to the methods described above. For example, promoters and vectors described herein can be
20 used to identify essential genes described herein.

EXAMPLE 72**Identification of Genes Required for *Streptococcus mutans* Proliferation**

Genes required for proliferation in *Streptococcus mutans* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
25 identify essential genes described herein.

EXAMPLE 73**Identification of Genes Required for *Streptococcus pneumoniae* Proliferation**

Genes required for proliferation in *Streptococcus pneumoniae* are identified according to the methods described above. For example, promoters and vectors described herein can be used
30 to identify essential genes described herein.

EXAMPLE 74**Identification of Genes Required for *Streptococcus pyogenes* Proliferation**

Genes required for proliferation in *Streptococcus pyogenes* are identified according to the methods described above. For example, promoters and vectors described herein can be used
35 to identify essential genes described herein.

EXAMPLE 75**Identification of Genes Required for *Treponema pallidum* Proliferation**

Genes required for proliferation in *Treponema pallidum* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
5 identify essential genes described herein.

EXAMPLE 76**Identification of Genes Required for *Ureaplasma urealyticum* Proliferation**

Genes required for proliferation in *Ureaplasma urealyticum* are identified according to the methods described above. For example, promoters and vectors described herein can be used
10 to identify essential genes described herein.

EXAMPLE 77**Identification of Genes Required for *Vibrio cholerae* Proliferation**

Genes required for proliferation in *Vibrio cholerae* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
15 identify essential genes described herein.

EXAMPLE 78**Identification of Genes Required for *Yersinia pestis* Proliferation**

Genes required for proliferation in *Yersinia pestis* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify
20 essential genes described herein.

EXAMPLE 79**Identification of Genes Required for *Salmonella enterica* Proliferation**

Genes required for proliferation in *Salmonella enterica* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
25 identify essential genes described herein.

EXAMPLE 80**Identification of Genes Required for *Aspergillus fumigatus* Proliferation**

Genes required for proliferation in *Aspergillus fumigatus* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
30 identify essential genes described herein.

EXAMPLE 81**Identification of Genes Required for *Plasmodium ovale* Proliferation**

Genes required for proliferation in *Plasmodium ovale* are identified according to the methods described above. For example, promoters and vectors described herein can be used to
35 identify essential genes described herein.

EXAMPLE 82**Identification of Genes Required for *Entamoeba histolytica* Proliferation**

Genes required for proliferation in *Entamoeba histolytica* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 83**Identification of Genes Required for *Candida albicans* Proliferation**

Genes required for proliferation in *Candida albicans* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 84**Identification of Genes Required for *Histoplasma capsulatum* Proliferation**

Genes required for proliferation in *Histoplasma capsulatum* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

EXAMPLE 85**Identification of Genes Required for *Salmonella choleraesuis* Proliferation**

Genes required for proliferation in *Salmonella choleraesuis* are identified according to the methods described above. For example, promoters and vectors described herein can be used to identify essential genes described herein.

Use of Isolated Exogenous Nucleic Acid Fragments as Antisense Antibiotics

In addition to using the identified sequences to enable screening of molecule libraries to identify compounds useful to identify antibiotics, antisense nucleic acids complementary to the proliferation-required sequences or portions thereof, antisense nucleic acids complementary to homologous coding nucleic acids, or homologous antisense nucleic acids can be used as therapeutic agents. Specifically, the proliferation-required sequences or homologous coding nucleic acids, or portions thereof, in an antisense orientation or homologous antisense nucleic acids can be provided to an individual to inhibit the translation of a bacterial target gene or the processing, folding, or assembly into a protein/RNA complex of a nontranslated RNA.

EXAMPLE 86**Generation of Antisense Therapeutics from Identified Exogenous Sequences**

Antisense nucleic acids complementary to the proliferation-required sequences described herein, or portions thereof, antisense nucleic acids complementary to homologous coding nucleic acids, or portions thereof, or homologous antisense nucleic acids or portions thereof can be used as antisense therapeutics for the treatment of bacterial infections or simply

for inhibition of bacterial growth *in vitro* or *in vivo*. For example, the antisense therapeutics may be used to treat bacterial infections caused by *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or to inhibit the growth of these organisms. The antisense therapeutics may also be used to treat infections caused by or to inhibit the growth of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*,

Streptococcus pneumoniae, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* or any species falling within the genera of any of the above species. In some embodiments of the present invention, the antisense therapeutics may be used to treat infection by or inhibit the growth of an organism other than *E. coli*.

The therapy exploits the biological process in cells where genes are transcribed into messenger RNA (mRNA) that is then translated into proteins. Antisense RNA technology contemplates the use of antisense nucleic acids, including antisense oligonucleotides, complementary to a target gene that will bind to its target nucleic acid and decrease or inhibit the expression of the target gene. For example, the antisense nucleic acid may inhibit the translation or transcription of the target nucleic acid. In one embodiment, antisense oligonucleotides can be used to treat and control a bacterial infection of a cell culture containing a population of desired cells contaminated with bacteria. In another embodiment, the antisense oligonucleotides can be used to treat an organism with a bacterial infection.

Antisense oligonucleotides can be synthesized from any of the sequences of the present invention using methods well known in the art. In a preferred embodiment, antisense oligonucleotides are synthesized using artificial means. Uhlmann & Peymann, Chemical Rev. 90:543-584 (1990) review antisense oligonucleotide technology in detail. Modified or unmodified antisense oligonucleotides can be used as therapeutic agents. Modified antisense oligonucleotides are preferred. Modification of the phosphate backbones of the antisense oligonucleotides can be achieved by substituting the internucleotide phosphate residues with methylphosphonates, phosphorothioates, phosphoramidates, and phosphate esters. Nonphosphate internucleotide analogs such as siloxane bridges, carbonate bridges, thioester bridges, as well as many others known in the art may also be used. The preparation of certain antisense oligonucleotides with modified internucleotide linkages is described in U.S. Patent No. 5,142,047.

Modifications to the nucleoside units of the antisense oligonucleotides are also contemplated. These modifications can increase the half-life and increase cellular rates of uptake for the oligonucleotides *in vivo*. For example, α -anomeric nucleotide units and modified nucleotides such as 1,2-dideoxy-d-ribofuranose, 1,2-dideoxy-1-phenylribofuranose, and N^4 , N^4 -ethano-5-methyl-cytosine are contemplated for use in the present invention.

An additional form of modified antisense molecules is found in peptide nucleic acids. Peptide nucleic acids (PNA) have been developed to hybridize to single and double stranded nucleic acids. PNA are nucleic acid analogs in which the entire deoxyribose-phosphate backbone

has been exchanged with a chemically different, but structurally homologous, polyamide (peptide) backbone containing 2-aminoethyl glycine units. Unlike DNA, which is highly negatively charged, the PNA backbone is neutral. Therefore, there is much less repulsive energy between complementary strands in a PNA-DNA hybrid than in the comparable DNA-DNA hybrid, and consequently they are much more stable. PNA can hybridize to DNA in either a Watson/Crick or Hoogsteen fashion (Demidov et al., *Proc. Natl. Acad. Sci. U.S.A.* 92:2637-2641, 1995; Egholm, *Nature* 365:566-568, 1993; Nielsen et al., *Science* 254:1497-1500, 1991; Dueholm et al., *New J. Chem.* 21:19-31, 1997).

Molecules called PNA "clamps" have been synthesized which have two identical PNA sequences joined by a flexible hairpin linker containing three 8-amino-3,6-dioxaoctanoic acid units. When a PNA clamp is mixed with a complementary homopurine or homopyrimidine DNA target sequence, a PNA-DNA-PNA triplex hybrid can form which has been shown to be extremely stable (Bentin et al., *Biochemistry* 35:8863-8869, 1996; Egholm et al., *Nucleic Acids Res.* 23:217-222, 1995; Griffith et al., *J. Am. Chem. Soc.* 117:831-832, 1995).

The sequence-specific and high affinity duplex and triplex binding of PNA have been extensively described (Nielsen et al., *Science* 254:1497-1500, 1991; Egholm et al., *J. Am. Chem. Soc.* 114:9677-9678, 1992; Egholm et al., *Nature* 365:566-568, 1993; Almarsson et al., *Proc. Natl. Acad. Sci. U.S.A.* 90:9542-9546, 1993; Demidov et al., *Proc. Natl. Acad. Sci. U.S.A.* 92:2637-2641, 1995). They have also been shown to be resistant to nuclease and protease digestion (Demidov et al., *Biochem. Pharm.* 48:1010-1313, 1994). PNA has been used to inhibit gene expression (Hanvey et al., *Science* 258:1481-1485, 1992; Nielsen et al., *Nucl. Acids. Res.*, 21:197-200, 1993; Nielsen et al., *Gene* 149:139-145, 1994; Good & Nielsen, *Science*, 95: 2073-2076, 1998; to block restriction enzyme activity (Nielsen et al., *supra.*, 1993), to act as an artificial transcription promoter (Mollegaard, *Proc. Natl. Acad. Sci. U.S.A.* 91:3892-3895, 1994) and as a pseudo restriction endonuclease (Demidov et al., *Nucl. Acids. Res.* 21:2103-2107, 1993). Recently, PNA has also been shown to have antiviral and antitumoral activity mediated through an antisense mechanism (Norton, *Nature Biotechnol.*, 14:615-619, 1996; Hirschman et al., *J. Investig. Med.* 44:347-351, 1996). PNAs have been linked to various peptides in order to promote PNA entry into cells (Basu et al., *Bioconj. Chem.* 8:481-488, 1997; Pardridge et al., *Proc. Natl. Acad. Sci. U.S.A.* 92:5592-5596, 1995).

The antisense oligonucleotides contemplated by the present invention can be administered by direct application of oligonucleotides to a target using standard techniques well known in the art. The antisense oligonucleotides can be generated within the target using a plasmid, or a phage. Alternatively, the antisense nucleic acid may be expressed from a sequence in the chromosome of the target cell. For example, a promoter may be introduced into

the chromosome of the target cell near the target gene such that the promoter directs the transcription of the antisense nucleic acid. Alternatively, a nucleic acid containing the antisense sequence operably linked to a promoter may be introduced into the chromosome of the target cell. It is further contemplated that the antisense oligonucleotides are incorporated in a ribozyme sequence to enable the antisense to specifically bind and cleave its target mRNA. For technical applications of ribozyme and antisense oligonucleotides see Rossi et al., **Pharmacol. Ther.** 50(2):245-254, (1991). The present invention also contemplates using a retron to introduce an antisense oligonucleotide to a cell. Retron technology is exemplified by U.S. Patent No. 5,405,775. Antisense oligonucleotides can also be delivered using liposomes or by electroporation techniques which are well known in the art.

The antisense nucleic acids described above can also be used to design antibiotic compounds comprising nucleic acids which function by intracellular triple helix formation. Triple helix oligonucleotides are used to inhibit transcription from a genome. The antisense nucleic acids can be used to inhibit cell or microorganism gene expression in individuals infected with such microorganisms or containing such cells. Traditionally, homopurine sequences were considered the most useful for triple helix strategies. However, homopyrimidine sequences can also inhibit gene expression. Such homopyrimidine oligonucleotides bind to the major groove at homopurine:homopyrimidine sequences. Thus, both types of sequences based on the sequences from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or homologous nucleic acids that are required for proliferation are contemplated for use as antibiotic compound templates.

The antisense nucleic acids, such as antisense oligonucleotides, which are complementary to the proliferation-required nucleic acids from *Escherichia coli*,

Staphylococcus aureus, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*,
 5 *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*,
 10 *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or to homologous coding nucleic acids, or portions thereof, may be used to induce bacterial cell death or at least bacterial stasis by inhibiting target nucleic acid transcription or translation. Antisense oligonucleotides complementary to about 8 to 40 nucleotides of the proliferation-required nucleic acids described herein or homologous coding nucleic acids have sufficient complementarity to form a duplex with the target sequence under physiological conditions.

20 To kill bacterial cells or inhibit their growth, the antisense oligonucleotides are applied to the bacteria or to the target cells under conditions that facilitate their uptake. These conditions include sufficient incubation times of cells and oligonucleotides so that the antisense oligonucleotides are taken up by the cells. In one embodiment, an incubation period of 7-10 days is sufficient to kill bacteria in a sample. An optimum concentration of antisense oligonucleotides is selected for use.

25 The concentration of antisense oligonucleotides to be used can vary depending on the type of bacteria sought to be controlled, the nature of the antisense oligonucleotide to be used, and the relative toxicity of the antisense oligonucleotide to the desired cells in the treated culture. Antisense oligonucleotides can be introduced to cell samples at a number of different concentrations preferably between 1×10^{-10} M to 1×10^{-4} M. Once the minimum concentration that can adequately control gene expression is identified, the optimized dose is translated into a dosage suitable for use *in vivo*. For example, an inhibiting concentration in culture of 1×10^{-7} translates into a dose of approximately 0.6 mg/kg body weight. Levels of oligonucleotide approaching 100 mg/kg body weight or higher may be possible after testing the toxicity of the oligonucleotide in laboratory animals. It is additionally contemplated that cells from the subject are removed, treated with the

antisense oligonucleotide, and reintroduced into the subject. This range is merely illustrative and one of skill in the art are able to determine the optimal concentration to be used in a given case.

After the bacterial cells have been killed or controlled in a desired culture, the desired cell population may be used for other purposes.

EXAMPLE 87

Use of Antisense Oligonucleotides to Treat Contaminated Cell Cultures

The following example demonstrates the ability of an *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* antisense oligonucleotide or an antisense oligonucleotide complementary to a homologous coding nucleic acid, or portions thereof, to act as a bacteriocidal or bacteriostatic agent to treat a contaminated cell culture system. The application of the antisense oligonucleotides of the present invention are thought to inhibit the translation of bacterial gene products required for proliferation. The antisense nucleic acids may also inhibit the transcription, folding or processing of the target RNA.

In one embodiment of the present invention, the antisense oligonucleotide may comprise a phosphorothioate modified nucleic acid comprising at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, or more than 40 consecutive nucleotides of an antisense nucleic acid listed in Table IA (SEQ ID NOs.: 1-6213). A sense oligodeoxynucleotide complementary to the antisense sequence is synthesized and used as a control. The oligonucleotides are synthesized and purified according to the procedures of Matsukura, et al., Gene 72:343 (1988). The test oligonucleotides are dissolved in a small volume of autoclaved water and added to culture medium to make a 100 micromolar stock solution.

Human bone marrow cells are obtained from the peripheral blood of two patients and cultured according standard procedures well known in the art. The culture is contaminated with *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or an organism containing a homologous nucleic acid and incubated at 37°C overnight to establish bacterial infection.

The control and antisense oligonucleotide containing solutions are added to the contaminated cultures and monitored for bacterial growth. After a 10 hour incubation of culture and oligonucleotides, samples from the control and experimental cultures are drawn and analyzed for the translation of the target bacterial gene using standard microbiological techniques well known in the art. The target *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* gene or an

organism containing the homologous coding nucleic acid is found to be translated in the control culture treated with the control oligonucleotide, however, translation of the target gene in the experimental culture treated with the antisense oligonucleotide of the present invention is not detected or reduced, indicating that the culture is no longer contaminated or is contaminated at a reduced level.

EXAMPLE 88

Use of Antisense Oligonucleotides to Treat Infections

A subject suffering from a *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Yersinia pestis* infection or an infection with an organism containing a homologous coding nucleic acid is treated with the antisense oligonucleotide preparation above. The antisense oligonucleotide is provided in a pharmaceutically acceptable carrier at a concentration effective to inhibit the transcription or translation of the target nucleic acid. The present subject is treated with a concentration of antisense oligonucleotide sufficient to achieve a blood concentration of about 0.1-100 micromolar. The patient receives daily injections of antisense oligonucleotide to maintain this concentration for a period of 1 week. At the end of the week a blood sample is drawn and analyzed for the presence or absence of the organism using standard techniques well known in the art. There is no detectable evidence of *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*,

Enterobacter cloacae, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Yersinia pestis* or an organism containing a homologous coding nucleic acid and the treatment is terminated.

Antisense nucleic acids complementary to a homologous coding nucleic acid or a portion thereof may be used in the preceding method to treat individuals infected with an organism containing the homologous coding nucleic acid.

EXAMPLE 89

Preparation and Use of Triple Helix Forming Oligonucleotides

The sequences of proliferation-required nucleic acids, homologous coding nucleic acids, or homologous antisense nucleic acids are scanned to identify 10-mer to 20-mer homopyrimidine or homopurine stretches that could be used in triple-helix based strategies for inhibiting gene expression. Following identification of candidate homopyrimidine or homopurine stretches, their efficiency in inhibiting gene expression is assessed by introducing varying amounts of oligonucleotides containing the candidate sequences into a population of bacterial cells that normally express the target gene. The oligonucleotides may be prepared on an oligonucleotide synthesizer or they may be purchased commercially from a company specializing in custom oligonucleotide synthesis.

The oligonucleotides can be introduced into the cells using a variety of methods known to those skilled in the art, including but not limited to calcium phosphate precipitation, DEAE-Dextran, electroporation, liposome-mediated transfection or native uptake.

Treated cells are monitored for a reduction in proliferation using techniques such as monitoring growth levels as compared to untreated cells using optical density measurements. The oligonucleotides that are effective in inhibiting gene expression in cultured cells can then be introduced *in vivo* using the techniques well known in that art at a dosage level shown to be effective.

In some embodiments, the natural (beta) anomers of the oligonucleotide units can be replaced with alpha anomers to render the oligonucleotide more resistant to nucleases. Further, an intercalating agent such as ethidium bromide, or the like, can be attached to the 3' end of the alpha oligonucleotide to stabilize the triple helix. For information on the generation of oligonucleotides

suitable for triple helix formation see Griffin et al. (Science 245:967-971 (1989), which is hereby incorporated by this reference).

EXAMPLE 90

Identification of Bacterial Strains from Isolated Specimens by PCR

5 Classical bacteriological methods for the detection of various bacterial species are time consuming and costly. These methods include growing the bacteria isolated from a subject in specialized medium, cultivation on selective agar medium, followed by a set of confirmation assays that can take from 8 to 10 days or longer to complete. Use of the identified sequences of the present invention provides a method to dramatically reduce the time necessary to detect and
10 identify specific bacterial species present in a sample.

 In one exemplary method, bacteria are grown in enriched medium and DNA samples are isolated from specimens of, for example, blood, urine, stool, saliva or central nervous system fluid by conventional methods. A panel of PCR primers based on identified sequences unique to various species or types of cells or microorganisms are then utilized in accordance with Example 27 to
15 amplify DNA of approximately 100-200 nucleotides in length from the specimen. A separate PCR reaction is set up for each pair of PCR primers and after the PCR reaction is complete, the reaction mixtures are assayed for the presence of PCR product. The presence or absence of bacteria from the species to which the PCR primer pairs belong is determined by the presence or absence of a PCR product in the various test PCR reaction tubes.

20 Although the PCR reaction is used to assay the isolated sample for the presence of various bacterial species, other assays such as the Southern blot hybridization are also contemplated.

 Compounds which inhibit the activity or reduce the amount of gene products required for proliferation may be identified using rational drug design. These methods may be used with the proliferation-required polypeptides described herein or homologous polypeptides. In such
25 methods, the structure of the gene product is determined using methods such as x-ray crystallography, NMR, or computer modelling. Compounds are screened to identify those which have a structure which allows them to interact with the gene product. In some embodiments, the compounds are screened to identify those which have structures which allow them to interact with regions of the gene product which are important for its activity. For example, the compounds may
30 be screened to identify those which have structures which allow them to bind to the active site of the gene product to inhibit its activity. For example, the compound may be a suicide substrate which binds to the active site with high affinity, thereby preventing the gene product from acting on its natural substrate. Alternatively, the compound may bind to a region of the gene product which is involved in complex formation with other biomolecules. In such instances, the activity of the

gene product is inhibited by blocking the interaction between the gene product and other members of the complex.

Thus, one embodiment of the present invention comprises a method of using a crystal of the gene products of the present invention and/or a dataset comprising the three-dimensional coordinates obtained from the crystal in a drug-screening assay. The present invention also includes agents (modulators or drugs) that are identified by the methods of the present invention, along with the method of using agents (modulators or drugs) identified by a method of the present invention, for inhibiting the activity of or modulating the amount of an essential gene product. The present invention also includes crystals comprising the gene products of the present invention or portions thereof.

In some embodiments of the present invention, the three-dimensional structure of the polypeptides required for proliferation is determined using X-ray crystallography or NMR. The coordinates of the determined structure are used in computer-assisted modeling programs to identify compounds that bind to and/or modulate the activity or amount of the encoded polypeptide. The method may include the following steps: 1) the generation of high-purity crystals of the encoded recombinant (or endogenous) polypeptide for analysis; 2) determination of the three-dimensional structure of the polypeptide; and, 3) the use of computer-assisted "docking" programs to analyze the molecular interaction of compound structure and the polypeptide (i.e., drug screening).

General methods for performing each of the above steps are described below and are also well known to those of skill in the art. Any method known to those of skill in the art, including those described herein, may be employed for generating the three-dimensional structure for each identified essential gene product and its use in the drug-screening assays.

Crystals of the gene products required for proliferation may be obtained as follows. Under certain conditions, molecules condense from solution into a highly-ordered crystalline lattice, which is defined by a unit cell, the smallest repeating volume of the crystalline array. The contents of such a cell can interact with and diffract certain electromagnetic and particle waves (e.g., X-rays, neutron beams, electron beams etc.). Due to the symmetry of the lattice, the diffracted waves interact to create a diffraction pattern. By measuring the diffraction pattern, crystallographers are able to reconstruct the three-dimensional structure of the atoms in the crystal.

Any method known to those of skill in the art, including those set forth below, may be employed to prepare high-purity crystals. For example, crystals of the product of the identified essential gene can be grown by a number of techniques including batch crystallization, vapor diffusion (either by sitting drop or hanging drop) and by microdialysis. Seeding of the crystals

in some instances is required to obtain X-ray quality crystals. Standard micro and/or macro seeding of crystals may therefore be used. Exemplified below is the hanging-drop vapor diffusion procedure. Hanging drops of an essential gene product (2.5 μ l, 10 mg/ml) in 20 mM Tris, pH=8.0, 100 mM NaCl are mixed with an equal amount of reservoir buffer containing 2.7-3.2 M sodium formate and 100 mM Tris buffer, pH=8.0, and kept at 4°C. Crystal showers may appear after 1-2 days with large single crystals growing to full size (0.3 X 0.3 X 0.15 mm³) within 2-3 weeks. Crystals are harvested in 3.5 M sodium formate and 100 mM Tris buffer, pH=8.0 and cryoprotected in 3.5 M sodium formate, 100 mM Tris buffer, pH=8.0, 10% (w/v) sucrose, and 10% (v/v) ethylene glycol before flash freezing in liquid propane. In some embodiments, the crystal may be obtained using the methods described in U.S. Patent No. 5,869,604. The method involves (a) contacting a mixture containing uncrystallized polypeptides with an exogenous nucleating agent that has an areal lattice match of at least 90.4% to the polypeptide, (b) crystallizing the polypeptides, thereby forming at least one crystal of the polypeptide attached to the nucleating agent, the attached crystal being of a high purity, and at least one polypeptide crystal unattached to the nucleating agent, the unattached crystal being of a lower purity than the attached crystal, and (c) separating the crystal attached to the nucleating agent from the crystal unattached to the nucleating agent. The crystallized polypeptide may also be purified from contaminants by (a) contacting a mixture containing uncrystallized polypeptides and a contaminant with an exogenous nucleating agent that has an areal lattice match of at least 90.4% to the polypeptide, (b) crystallizing the polypeptides, thereby forming at least one crystal of the polypeptide attached to the nucleating agent, the attached crystal being of a high purity and produced in a high yield, and at least one crystal unattached to the nucleating agent, the unattached crystal being of a lower purity than the attached crystal, and (c) separating the crystal attached to the nucleating agent from the crystal unattached to the nucleating agent.

Once a crystal of the present invention is grown, X-ray diffraction data can be collected using methods familiar to those skilled in the art. Therefore, any person with skill in the art of protein crystallization having the present teachings and without undue experimentation can crystallize a large number of alternative forms of the essential gene products from a variety of different organisms, or polypeptides having conservative substitutions in their amino acid sequence.

A crystal lattice is defined by the symmetry of its unit cell and any structural motifs the unit cell contains. For example, there are 230 possible symmetry groups for an arbitrary crystal lattice, while the unit cell of the crystal lattice group may have an arbitrary dimension that depends on the molecules making up the lattice. Biological macromolecules, however, have

asymmetric centers and are limited to 65 of the 230 symmetry groups. See Cantor et al., Biophysical Chemistry, Vol. III, W. H. Freeman & Company (1980).

5 A crystal lattice interacts with electromagnetic or particle waves, such as X-rays or electron beams respectively, that have a wavelength with the same order of magnitude as the spacing between atoms in the unit cell. The diffracted waves are measured as an array of spots on a detection surface positioned adjacent to the crystal. Each spot has a three-dimensional position, hkl , and an intensity, $I(hkl)$, both of which are used to reconstruct the three-dimensional electron density of the crystal with the so-called Electron Density Equation. The Electron Density Equation states that the three-dimensional electron density of the unit cell is
10 the Fourier transform of the structure factors. Thus, in theory, if the structure factors are known for a sufficient number of spots in the detection space, then the three-dimensional electron density of the unit cell could be calculated using the Electron Density Equation.

In some embodiments of the present invention, an image of a crystal of a gene product required for proliferation or a portion thereof is obtained with the aid of a digital computer and
15 the crystal's diffraction pattern as described in U.S. Patent No. 5,353,236. The diffraction pattern contains a plurality of reflections, each having an associated resolution. The image is obtained by (a) converting the diffraction pattern of the crystal into computer usable normalized amplitudes, the pattern being produced with a diffractometer; (b) determining from the diffraction pattern a dimension of a unit cell of the crystal; (c) providing an envelope defining
20 the region of the unit cell occupied by the gene product or portion thereof in the crystal; (d) distributing a collection of scattering bodies within said envelope, the collection of scattering bodies having various arrangements, each of which has an associated pattern of Fourier amplitudes; (e) condensing the collection of scattering bodies to a condensed arrangement that results in a high correlation between a diffraction pattern and the pattern of Fourier amplitudes
25 for said collection of scattering bodies; (f) determining the phase associated with at least one of the reflections of said diffraction pattern from the condensed arrangement of scattering bodies; (g) calculating an electron density distribution of the gene product or portion thereof within the unit cell from the phase determined in procedure f; and (h) displaying a graphical image of the gene product or portion thereof constructed from said electron density distribution.

30 The crystals of the gene products required for proliferation may be used in drug screening methods such as those described in U.S. Patent Number 6,156,526. Briefly, in such methods, a compound which inhibits the formation of a complex comprising the gene product or a portion thereof is identified as follows. A set of atomic coordinates defining the three-dimensional structure of a complex including the gene product of interest or a portion thereof
35 are determined. A potential compound that binds to the gene product or a portion thereof

involved in complex formation is selected using the atomic coordinates obtained above. The compound is contacted with the gene product or portion thereof and its binding partner(s) in the complex under conditions which would permit the complex to form in the absence of the potential compound. The binding affinity of the gene product or portion thereof for its binding partner(s) is determined and a potential compound is identified as a compound that inhibits the formation of the complex when there is a decrease in the binding affinity of the gene product or portion thereof for its binding partner(s).

In some embodiments of the present invention, the three dimensional structure of the essential gene product is determined and potential agonists and/or potential antagonists are designed with the aid of computer modeling [Bugg et al., *Scientific American*, Dec.:92-98 (1993); West et al., *TIPS*, 16:67-74 (1995); Dunbrack et al., *Folding & Design*, 2:27-42 (1997).

Computer analysis may be performed with one or more of the computer programs including: QUANTA, CHARMM, INSIGHT, SYBYL, MACROMODEL and ICM [Dunbrack et al., *Folding & Design*, 2:27-42 (1997)]. In a further embodiment of this aspect of the invention, an initial drug-screening assay is performed using the three-dimensional structure so obtained, preferably along with a docking computer program. Such computer modeling can be performed with one or more Docking programs such as FlexX, DOC, GRAM and AUTO DOCK [Dunbrack et al., *Folding & Design*, 2:27-42 (1997)].

It should be understood that for each drug screening assay provided herein, a number of iterative cycles of any or all of the steps may be performed to optimize the selection. The drug screening assays of the present invention may use any of a number of means for determining the interaction between an agent or drug and an essential gene product.

In some embodiments of the present invention, a drug can be specifically designed to bind to an essential gene product of the present invention through NMR based methodology. [Shuker et al., *pi Science* 274:1531-1534 (1996)]. NMR spectra may be recorded using devices familiar to those skilled in the art, such as the Varian Unity Plus 500 and unity 600 spectrometers, each equipped with a pulsed-field gradient triple resonance probe as analyzed as described in Bagby et al., [*Cell* 82:857-867 (1995)]. Sequential resonance assignments of backbone ^1H , ^{15}N , and ^{13}C atoms may be made using a combination of triple resonance experiments similar to those previously described [Bagby et al., *Biochemistry*, 33:2409-2421 (1994a), except with enhanced sensitivity [Muhandiram and Kay, *J. Magn. Reson.*, 103: 203-216 (1994), and minimal H_2O saturation [Kay et al., *J. Magn. Reson.*, 109:129-133 (1994)]. Side chain ^1H and ^{13}C assignments may be made using HCCH-TOCSY [Bax et al., *J. Magn. Reson.*, 87:620-627 (1990)] experiments with mixing times of 8 ms and 16 ms. in solution but need not be included in structure calculations. Nuclear Overhauser effect (NOE) cross peaks in

two-dimensional ^1H -- ^1H NOE spectroscopy (NOESY), three-dimensional ^{15}N -edited NOESY-HSQC [Zhang et al., *J. Biomol. NMR*, 4:845-858 (1994)] and three-dimensional simultaneous acquisition $^{15}\text{N}/^{13}\text{C}$ -edited NOE [Pascal et al., *J. Magn. Reson.*, 103:197-201 (1994)], spectra may be obtained with 100 ms NOE mixing times. Standard pseudo-atom distance corrections
5 [Wuthrich et al., *J. Mol. Biol.*, 169:949-961 (1983)], may be incorporated to account for center averaging. An additional 0.5 Å. may be added to the upper limits for distances involving methyl groups [Wagner et al., *J. Mol. Biol.*, 196:611-639 (1987); Clore et al., *Biochemistry*, 26:8012-8023 (1987)].

The structures can be calculated using a simulated annealing protocol [Nilges et al., In
10 computational Aspects of the Study of Biological Macromolecules by Nuclear Magnetic Resonance Spectroscopy, J. C. Hoch, F. M. Poulsen, and C. Redfield, eds., New York: Plenum Press, pp. 451-455 (1991)], within X-PLOR [Brunger, X-PLOR Manual, Version 3.1, New Haven, Conn.: Department of Molecular Biophysics and Biochemistry, Yale University (1993)], using the previously described strategy [Bagby et al., *Structure*, 2:107-122 (1994b)].
15 Interhelical angles may be calculated using a program written by K. Yap. Accessible surface areas were calculated using the program Naccess, available from Prof. J. Thornton, University College, London.

Compounds capable of reducing the activity or amount of gene products required for cellular proliferation may be identified using the methods described in US Pat. No. 6,077,682.
20 Briefly, the three-dimensional structure of the gene product or portion thereof may be used in a drug screening assay by (a) selecting a potential drug by performing rational drug design with the three-dimensional structure determined from one or more sets of atomic coordinates of the gene product or portion thereof in conjunction with computer modeling; (b) contacting the potential drug with a polypeptide comprising the gene product or portion thereof and (c)
25 detecting the binding of the potential drug with said polypeptide; wherein a potential drug is selected as a drug if the potential drug binds to the polypeptide. In some methods, the three-dimensional structure of the gene product or portion thereof is used in a drug screening assay involving (a) selecting a potential drug by performing structural based rotational drug design with the three-dimensional structure of the gene product or portion thereof; wherein said
30 selecting is performed in conjunction with computer modeling; (b) contacting the potential drug with a polypeptide comprising the gene product or portion thereof in the presence of a substrate of the gene product; wherein in the absence of the potential drug the substrate is acted upon by the gene product; and (c) determining the extent to which the gene product acted upon the substrate; wherein a drug is selected when a decrease in the action of the gene product on the
35 substrate is determined in the presence of the potential drug relative to in its absence. In some

embodiments, the preceding method further involves(d) contacting the potential drug with the gene product or portion thereof for NMR analysis; wherein a binding complex forms between the potential drug and said gene product or portion thereof for NMR analysis; wherein the gene product or portion thereof for NMR analysis comprises a conservative amino acid substitution; (e) determining the three-dimensional structure of the binding complex by NMR; and (f) selecting a candidate drug by performing structural based rational drug design with the three-dimensional structure determined for the binding complex; wherein said selecting is performed in conjunction with computer modeling; (g) contacting the candidate drug with a second polypeptide comprising the gene product or portion thereof in the presence of a substrate of the gene product or portion thereof; wherein in the absence of the candidate drug the substrate is acted upon by the second polypeptide; and (h) determining the amount of action of the second polypeptide on the substrate; wherein a drug is selected when a decrease in the amount of action of the second polypeptide is determined in the presence of the candidate drug relative to in its absence.

Once the three-dimensional structure of a crystal comprising an essential gene product is determined, a potential modulator of its activity, can be examined through the use of computer modeling using a docking program such as FlexX, GRAM, DOCK, or AUTODOCK [Dunbrack et al., 1997, supra], to identify potential modulators. This procedure can include computer fitting of potential modulators to the polypeptide or fragments thereof to ascertain how well the shape and the chemical structure of the potential modulator will bind. Computer programs can also be employed to estimate the attraction, repulsion, and steric hindrance of the two binding partners (e.g., the essential gene product and a potential modulator). Generally the tighter the fit, the lower the steric hindrances, and the greater the attractive forces, the more potent the potential modulator since these properties are consistent with a tighter binding constant. Furthermore, the more specificity in the design of a potential drug the more likely that the drug will not interact as well with other proteins. This will minimize potential side-effects due to unwanted interactions with other proteins.

Compound and compound analogs can be systematically modified by computer modeling programs until one or more promising potential analogs is identified. In addition systematic modification of selected analogs can then be systematically modified by computer modeling programs until one or more potential analogs are identified. Such analysis has been shown to be effective in the development of HIV protease inhibitors [Lam et al., Science 263:380-384 (1994); Wlodawer et al., Ann. Rev. Biochem. 62:543-585 (1993); Appelt, Perspectives in Drug Discovery and Design 1:23-48 (1993); Erickson, Perspectives in Drug Discovery and Design 1:109-128 (1993)]. Alternatively a potential modulator could be

obtained by initially screening a random peptide library produced by recombinant bacteriophage for example, [Scott and Smith, Science, 249:386-390 (1990); Cwirla et al., Proc. Natl. Acad. Sci., 87:6378-6382 (1990); Devlin et al., Science, 249:404-406 (1990)]. A peptide selected in this manner would then be systematically modified by computer modeling programs as described above, and then treated analogously to a structural analog.

Example 91 describes computer modelling of the structures of gene products required for proliferation.

EXAMPLE 91

Determination of the Structure of Gene Products Required for Proliferation Using Computer

Modelling

Three dimensional models were built by applying computer modelling methods to some of the gene products required for proliferation of *Staphylococcus aureus* using the amino acid sequences of the encoded proteins as follows. Sir Tom Blundell's program COMPOSER as provided by Tripos Associates in their BIOPOLYMER module to SYBYL was used to build the models. Skolnik's method of topology fingerprinting as implemented in Matchmaker was used to score the average mutation free energy. This number is in Boltzmanns (units of kT) and should be negative (the more negative, the better the model).

Composer uses a Needleman Wunsch alignment with jumbling to find significant alignments. The reported parameters are percent identity and significance as measured from the jumbling. Those matches which were 30% identical and had a significance greater than 4 on the scale were judged to be good candidates for model building templates. If no three dimensional structures met these criteria, then a BLAST search was conducted against the most recent PDB sequence database. Any significant hits discovered in this manner were then added to the binary protein structure database and the candidate search was repeated in the manner discussed above.

In the next phase, Composer assigned structurally conserved and structurally variable regions and built the backbone structure and then searched the database for structures of the variable loops. These were then spliced in and a model of the protein resulted. Any loops (variable regions) which were unassignable were manually built and refined with a combination of dynamics.

The structure was then refined. Hydrogen atoms were added and a non-active aggregate was defined. 1000ps of dynamics using AMBER ALL-ATOM and Kollman charges are performed. Next a minimization cycle of up to 5000 steepest descent steps were performed and then the aggregate was thawed and the process was repeated on the entire protein.

The resulting structure was then validated in MATCHMAKER. The topologically scanned free energy determined from empirically derived protein topologies was computed and the average energy/residue is reported in Boltzmann was reported. As this number represents a free energy the more negative it is the more favorable it is.

- 5 Sixty six proteins required for the proliferation of *Staphylococcus aureus* were modelled as described above. MATCHMAKER energies were computed for these. The distribution of the models built by class is shown in Table VIII below.

Table VIII: Distribution of models built with their MATCHMAKER energies in kT

Classification	Number of Models	Average Matchmaker Energy
Acylases	1	-0.10
Dehydrogenases	3	-0.12
DNA Related	3	-0.12
Heat Shock Protein	2	-0.16
Hydrolases	3	-0.16
Isomerases	1	0.05
Ligases	7	-0.07
Lyases	1	-0.09
Membrane Anchored	1	-0.12
Misc	18	-0.21
Oxidoreductases	6	-0.09
Proteases	1	-0.03
Ribosome	3	-0.11
Synthases	4	-0.14
Transferases	6	-0.12

- 10 The validity of the above method was confirmed using FtsZ. In the case of FtsZ, a crystal structure from M. Janeschi was available. Examination of the gross structural features determined using the above modelling showed all of the folds in the correct place, although there were some minor differences from the structure determined by x-ray crystallography.

EXAMPLE 92

Functional Complementation

- 15 In another embodiment, gene products whose activities may be complemented by a proliferation-required gene product from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*,
- 20

Mycoplasma genitalium, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*,
5 *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or homologous polypeptides are identified using merodiploids, created by introducing a plasmid or Bacterial Artificial Chromosome into an organism having a mutation in the essential gene which reduces or eliminates the activity of the gene product. In some embodiments, the mutation may be a conditional mutation, such as a temperature sensitive mutation, such that the
10 organism proliferates under permissive conditions but is unable to proliferate under non-permissive conditions in the absence of complementation by the gene on the plasmid or Bacterial Artificial Chromosome. Alternatively, duplications may be constructed as described in Roth et al. (1987) Biosynthesis of Aromatic Amino Acids in *Escherichia coli* and *Salmonella typhimurium*, F. C. *Neidhardt*, ed., American Society for Microbiology, publisher, pp. 2269-
15 2270. Such methods are familiar to those skilled in the art.

It will be appreciated that no matter how detailed the foregoing appears in text, the invention can be practiced in many ways. As is also stated above, it should further be noted that the use of particular terminology when describing certain features or aspects of the present invention should not be taken to imply that the broadest reasonable meaning of such terminology is
20 not intended, or that the terminology is being re-defined herein to be restricted to including any specific characteristics of the features or aspects of the invention with which that terminology is associated. Thus, although this invention has been described in terms of certain preferred embodiments, other embodiments which will be apparent to those of ordinary skill in the art in view of the disclosure herein are also within the scope of this invention. Accordingly, the scope of
25 the invention is intended to be defined only by reference to the appended claims and any equivalents thereof.

WHAT IS CLAIMED IS:

1. A purified or isolated nucleic acid sequence comprising a nucleotide sequence consisting essentially of one of SEQ ID NOs: 1-6213, wherein expression of said nucleic acid inhibits proliferation of a cell.

5 2. The nucleic acid sequence of Claim 1, wherein said nucleotide sequence is complementary to at least a portion of a coding sequence of a gene whose expression is required for proliferation of a cell.

3. The nucleic acid of Claim 1, wherein said nucleic acid sequence is complementary to at least a portion of a nucleotide sequence of an RNA required for proliferation of a cell.

10 4. The nucleic acid of Claim 3, wherein said RNA is an RNA comprising a sequence of nucleotides encoding more than one gene product.

5. A purified or isolated nucleic acid comprising a fragment of one of SEQ ID NOs: 1-6213, said fragment selected from the group consisting of fragments comprising at least 10, at least 20, at least 25, at least 30, at least 50 and more than 50 consecutive nucleotides of one of SEQ ID NOs: 1-6213.

6. The fragment of Claim 5, wherein said fragment is included in a nucleic acid obtained from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*,
20 *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefir* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium*
25 *botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
30 *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*,
35 *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella*

sonnei, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of

5 any of the above species.

7. The fragment of Claim 5, wherein said fragment is included in a nucleic acid obtained from an organism other than *Escherichia coli*.

8. A vector comprising a promoter operably linked to the nucleic acid of any one of Claims 1-7.

10 9. The vector of Claim 8, wherein said promoter is active in a microorganism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*),

15 *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*,

20 *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*,

25 *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*,

30 *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

10. A host cell containing the vector of Claim 8 or Claim 9.

11. A purified or isolated antisense nucleic acid comprising a nucleotide sequence complementary to at least a portion of an intragenic sequence, intergenic sequence, sequences spanning at least a portion of two or more genes, 5' noncoding region, or 3' noncoding region within an operon comprising a proliferation-required gene whose activity or expression is inhibited by an antisense nucleic acid comprising the nucleotide sequence of one of SEQ ID NOs.: 1-6213.

12. The purified or isolated antisense nucleic acid of Claim 11, wherein said antisense nucleic acid is complementary to a nucleic acid from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

13. The purified or isolated antisense nucleic acid of Claim 11, wherein said nucleotide sequence is complementary to a nucleotide sequence of a nucleic acid from an organism other than *E. coli*.

14. The purified or isolated antisense nucleic acid of Claim 11, wherein said proliferation-required gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397.

15. A purified or isolated nucleic acid comprising a nucleotide sequence having at least 70% identity to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, fragments comprising at least 25 consecutive nucleotides of SEQ ID NOS.: 1-6213, the nucleotide sequences complementary to SEQ ID NOS.: 1-6213 and the sequences complementary to fragments comprising at least 25 consecutive nucleotides of SEQ ID NOS.: 1-6213 as determined using BLASTN version 2.0 with the default parameters.

16. The purified or isolated nucleic acid of Claim 15, wherein said nucleic acid is obtained from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

17. The nucleic acid of Claim 15, wherein said nucleic acid is obtained from an organism other than *E. coli*.

18. A vector comprising a promoter operably linked to a nucleic acid encoding a polypeptide whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence of any one of SEQ ID NOs.: 1-6213.

19. The vector of Claim 18, wherein said nucleic acid encoding said polypeptide is
 5 obtained from an organism selected from the group consisting of *Acinetobacter baumannii*,
Anaplasma marginale, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*,
Bordetella pertussis, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*,
Burkholderia mallei, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called
Torulopsis glabrata), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*,
 10 *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*,
Chlamydia pneumoniae, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium*
botulinum, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*,
Corynebacterium diphtheriae, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus*
faecalis, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*,
 15 *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria*
monocytogenes, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
Mycobacterium leprae, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma*
pneumoniae, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella*
haemolytica, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*,
 20 *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*,
Salmonella choleraesuis, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*,
Salmonella typhimurium, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella*
sonnei, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*,
Streptococcus pneumoniae, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema*
 25 *pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio*
vulnificans, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of
 any of the above species.

20. The vector of Claim 18, wherein said nucleotide sequence encoding said polypeptide is obtained from an organism other than *E. coli*.

21. A host cell containing the vector of Claim 18.

22. The vector of Claim 18, wherein said polypeptide comprises a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 42398-78581.

23. The vector of Claim 18, wherein said promoter is operably linked to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397.

24. A purified or isolated polypeptide comprising a polypeptide whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence of any one of SEQ ID NOS.: 1-6213, or a fragment selected from the group consisting of fragments comprising at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60 or more than 60 consecutive amino acids of one of the said polypeptides.

25. The polypeptide of Claim 24, wherein said polypeptide comprises an amino acid sequence of any one of SEQ ID NOS.: 42398-78581 or a fragment comprising at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60 or more than 60 consecutive amino acids of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS.: 42398-78581.

26. The polypeptide of Claim 24, wherein said polypeptide is obtained from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio*

vulnificans, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

27. The polypeptide of Claim 24, wherein said polypeptide is obtained from an organism other than *E. coli*.

5 28. A purified or isolated polypeptide comprising a polypeptide having at least 25% amino acid identity to a polypeptide whose expression is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, or at least 25% amino acid identity to a fragment comprising at least 10, at least 20, at least 30, at least 40, at least 50, at least 60 or more than 60 consecutive amino acids of a polypeptide
10 whose expression is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 as determined using FASTA version 3.0t78 with the default parameters.

29. The polypeptide of Claim 28, wherein said polypeptide has at least 25% identity to a polypeptide comprising one of SEQ ID NOs: 42398-78581 or at least 25% identity
15 to a fragment comprising at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60 or more than 60 consecutive amino acids of a polypeptide comprising one of SEQ ID NOs.: 42398-78581 as determined using FASTA version 3.0t78 with the default parameters.

30. The polypeptide of Claim 28, wherein said polypeptide is obtained from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*,
20 *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*,
25 *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*,
30 *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*,
35 *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella*

boydii, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*,
Staphylococcus epidermidis, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*,
Streptococcus mutans, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*,
Vibrio cholerae, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia*
 5 *pestis* and any species falling within the genera of any of the above species.

31. The polypeptide of Claim 28, wherein said polypeptide is obtained from an organism other than *E. coli*.

32. An antibody capable of specifically binding the polypeptide of one of Claims 28-31.

10 33. A method of producing a polypeptide, comprising introducing a vector comprising a promoter operably linked to a nucleic acid comprising a nucleotide sequence encoding a polypeptide whose expression is inhibited by an antisense nucleic acid comprising one of SEQ ID NOs.: 1-6213 into a cell.

15 34. The method of Claim 33, further comprising the step of isolating said polypeptide.

35. The method of Claim 33, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

36. The method of Claim 33, wherein said nucleic acid encoding said polypeptide is obtained from an organism selected from the group consisting of *Acinetobacter baumannii*,
 20 *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*,
 25 *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*,
 30 *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*,
 35 *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*,

Salmonella typhimurium, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

37. The method of Claim 33, wherein said nucleic acid encoding said polypeptide is obtained from an organism other than *E. coli*.

38. The method of Claim 33, wherein said promoter is operably linked to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397.

39. A method of inhibiting proliferation of a cell in an individual comprising inhibiting the activity or reducing the amount of a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 or inhibiting the activity or reducing the amount of a nucleic acid encoding said gene product.

40. The method of Claim 39, wherein said method comprises inhibiting said activity or reducing said amount of a gene product in an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella*

boydii, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*,
Staphylococcus epidermidis, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*,
Streptococcus mutans, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*,
Vibrio cholerae, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia*
5 *pestis* and any species falling within the genera of any of the above species.

41. The method of Claim 39, wherein said method comprises inhibiting said activity or reducing said amount of a gene product in an organism other than *E. coli*.

42. The method of Claim 39, wherein said gene product is present in an organism other than *E. coli*.

10 43. The method of Claim 39, wherein said gene product comprises a polypeptide comprising a sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

44. A method for identifying a compound which influences the activity of a gene product required for proliferation, said gene product comprising a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected
15 from the group consisting of SEQ ID NOs.: 1-6213, said method comprising:

contacting said gene product with a candidate compound; and

determining whether said compound influences the activity of said gene product.

45. The method of Claim 44, wherein said gene product is from an organism
20 selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida*
25 *kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*,
30 *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*,
35 *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*,

Salmonella enterica, Salmonella paratyphi, Salmonella typhi, Salmonella typhimurium, Shigella boydii, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Streptococcus pneumoniae, Streptococcus mutans, Streptococcus pyogenes, Treponema pallidum, Ureaplasma urealyticum, Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificans, Yersinia enterocolitica, Yersinia pestis and any species falling within the genera of any of the above species.

46. The method of Claim 44, wherein said gene product is from an organism other than *E. coli*.

47. The method of Claim 44, wherein said gene product is a polypeptide and said activity is an enzymatic activity.

48. The method of Claim 44, wherein said gene product is a polypeptide and said activity is a carbon compound catabolism activity.

49. The method of Claim 44, wherein said gene product is a polypeptide and said activity is a biosynthetic activity.

50. The method of Claim 44, wherein said gene product is a polypeptide and said activity is a transporter activity.

51. The method of Claim 44, wherein said gene product is a polypeptide and said activity is a transcriptional activity.

52. The method of Claim 44, wherein said gene product is a polypeptide and said activity is a DNA replication activity.

53. The method of Claim 44, wherein said gene product is a polypeptide and said activity is a cell division activity.

54. The method of Claim 44, wherein said gene product is an RNA.

55. The method of Claim 44, wherein said gene product is a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

56. A compound identified using the method of Claim 44.

57. A method for identifying a compound or nucleic acid having the ability to reduce the activity or level of a gene product required for proliferation, said gene product comprising a gene product whose activity or expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, said method comprising:

(a) contacting a target gene or RNA encoding said gene product with a candidate compound or nucleic acid; and

(b) measuring an activity of said target.

58. The method of Claim 57, wherein said target gene or RNA is from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*,
5 *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*,
10 *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*,
20 *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

59. The method of Claim 57, wherein said target gene or RNA is from an organism
25 other than *E. coli*.

60. The method of Claim 57, wherein said gene product is from an organism other than *E. coli*.

61. The method of Claim 57, wherein said target is a messenger RNA molecule and said activity is translation of said messenger RNA.

62. The method of Claim 57, wherein said target is a messenger RNA molecule and said activity is transcription of a gene encoding said messenger RNA.

63. The method of Claim 57, wherein said target is a gene and said activity is transcription of said gene.

64. The method of Claim 57, wherein said target is a nontranslated RNA and said activity is processing or folding of said nontranslated RNA or assembly of said nontranslated RNA into a protein/RNA complex.

65. The method of Claim 57, wherein said target is a messenger RNA molecule encoding a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS.: 42398-78581.

66. The method of Claim 57, wherein said target comprises a nucleic acid selected from the group consisting of SEQ ID NOS.: 6214-42397.

67. A compound or nucleic acid identified using the method of Claim 57.

68. A method for identifying a compound which reduces the activity or level of a gene product required for proliferation of a cell, wherein the activity or expression of said gene product is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, said method comprising the steps of:

(a) providing a sublethal level of an antisense nucleic acid comprising a nucleotide sequence complementary to a nucleic acid comprising a nucleotide sequence encoding said gene product in a cell to reduce the activity or amount of said gene product in said cell, thereby producing a sensitized cell;

(b) contacting said sensitized cell with a compound; and

(c) determining the degree to which said compound inhibits proliferation of said sensitized cell relative to a cell which does not contain said antisense nucleic acid.

69. The method of Claim 68, wherein said determining step comprises determining whether said compound inhibits the growth of said sensitized cell to a greater extent than said compound inhibits the growth of a nonsensitized cell.

70. The method of Claim 68, wherein said cell is a Gram positive bacterium.

71. The method of Claim 68, wherein said Gram positive bacterium is selected from the group consisting of *Staphylococcus* species, *Streptococcus* species, *Enterococcus* species, *Mycobacterium* species, *Clostridium* species, and *Bacillus* species.

72. The method of Claim 68, wherein said bacterium is *Staphylococcus aureus*.

73. The method of Claim 72, wherein said *Staphylococcus* species is coagulase negative.

74. The method of Claim 72, wherein said bacterium is selected from the group consisting of *Staphylococcus aureus* RN450 and *Staphylococcus aureus* RN4220.

75. The method of Claim 68, wherein said cell is an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia*

cepacia, Burkholderia fungorum, Burkholderia mallei, Campylobacter jejuni, Candida albicans,
 Candida glabrata (also called Torulopsis glabrata), Candida tropicalis, Candida parapsilosis,
 Candida guilliermondii, Candida krusei, Candida kefyr (also called Candida pseudotropicalis),
 Candida dubliniensis, Chlamydia pneumoniae, Chlamydia trachomatis, Clostridium
 5 acetobutylicum, Clostridium botulinum, Clostridium difficile, Clostridium perfringens,
 Coccidioides immitis, Corynebacterium diphtheriae, Cryptococcus neoformans, Enterobacter
 cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Haemophilus
 influenzae, Helicobacter pylori, Histoplasma capsulatum, Klebsiella pneumoniae, Legionella
 pneumophila, Listeria monocytogenes, Moraxella catarrhalis, Mycobacterium avium,
 10 Mycobacterium bovis, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma
 genitalium, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis, Nocardia
 asteroides, Pasteurella haemolytica, Pasteurella multocida, Pneumocystis carinii, Proteus
 mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas
 syringae, Salmonella bongori, Salmonella choleraesuis, Salmonella enterica, Salmonella
 15 paratyphi, Salmonella typhi, Salmonella typhimurium, Shigella boydii, Shigella dysenteriae,
 Shigella flexneri, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis,
 Staphylococcus haemolyticus, Streptococcus pneumoniae, Streptococcus mutans, Streptococcus
 pyogenes, Treponema pallidum, Ureaplasma urealyticum, Vibrio cholerae, Vibrio
 parahaemolyticus, Vibrio vulnificans, Yersinia enterocolitica, Yersinia pestis and any species
 20 falling within the genera of any of the above species.

76. The method of Claim 68, wherein said cell is not an *E. coli* cell.

77. The method of Claim 68, wherein said gene product is from an organism other than *E. coli*.

78. The method of Claim 68, wherein said antisense nucleic acid is transcribed
 25 from an inducible promoter.

79. The method of Claim 68, further comprising the step of contacting said cell with a concentration of inducer which induces transcription of said antisense nucleic acid to a sublethal level.

80. The method of Claim 68, wherein growth inhibition is measured by monitoring
 30 optical density of a culture growth solution.

81. The method of Claim 68, wherein said gene product is a polypeptide.

82. The method of Claim 81, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

83. The method of Claim 68, wherein said gene product is an RNA.

84. The method of Claim 68, wherein nucleic acid encoding said gene product comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397.

85. A compound identified using the method of Claim 68.

5 86. A method for inhibiting cellular proliferation comprising introducing an effective amount of a compound with activity against a gene whose activity or expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 or a compound with activity against the product of said gene into a population of cells expressing said gene.

10 87. The method of Claim 86, wherein said compound is an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, or a proliferation-inhibiting portion thereof.

88. The method of Claim 86, wherein said proliferation inhibiting portion of one of SEQ ID NOS.: 1-6213 is a fragment comprising at least 10, at least 20, at least 25, at least 30, at
15 least 50 or more than 51 consecutive nucleotides of one of SEQ ID NOS.: 1-6213.

89. The method of Claim 86, wherein said population is a population of Gram positive bacteria.

90. The method of Claim 89, wherein said population of Gram positive bacteria is selected from the group consisting of a population of *Staphylococcus* species, *Streptococcus*
20 species, *Enterococcus* species, *Mycobacterium* species, *Clostridium* species, and *Bacillus* species.

91. The method of Claim 86, wherein said population is a population of *Staphylococcus aureus*.

92. The method of Claim 91, wherein said population is a population of a
25 bacterium selected from the group consisting of *Staphylococcus aureus* RN450 and *Staphylococcus aureus* RN4220.

93. The method of Claim 86, wherein said population is a population of a
bacterium selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*,
30 *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefir* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*,
35 *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*,

Cryptococcus neoformans, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Histoplasma capsulatum, Klebsiella pneumoniae, Legionella pneumophila, Listeria monocytogenes, Moraxella catarrhalis, Mycobacterium avium, Mycobacterium bovis, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma genitalium, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis, Nocardia asteroides, Pasteurella haemolytica, Pasteurella multocida, Pneumocystis carinii, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas syringae, Salmonella bongori, Salmonella choleraesuis, Salmonella enterica, Salmonella paratyphi, Salmonella typhi, Salmonella typhimurium, Shigella boydii, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Streptococcus pneumoniae, Streptococcus mutans, Streptococcus pyogenes, Treponema pallidum, Ureaplasma urealyticum, Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificans, Yersinia enterocolitica, Yersinia pestis and any species falling within the genera of any of the above species.

94. The method of Claim 86, wherein said population is a population of an organism other than *E. coli*.

95. The method of Claim 86, wherein said product of said gene is from an organism other than *E. coli*.

96. The method of Claim 86, wherein said gene encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

97. The method of Claim 86, wherein said gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397.

98. A composition comprising an effective concentration of an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, or a proliferation-inhibiting portion thereof in a pharmaceutically acceptable carrier.

99. The composition of Claim 98, wherein said proliferation-inhibiting portion of one of SEQ ID NOs.: 1-6213 comprises at least 20, at least 25, at least 30, at least 50 or more than 50 consecutive nucleotides of one of SEQ ID NOs.: 1-6213.

100. A method for inhibiting the activity or expression of a gene in an operon required for proliferation wherein the activity or expression of at least one gene in said operon is inhibited by an antisense nucleic acid comprising a sequence selected from the group consisting of SEQ ID NOs.: 1-6213, said method comprising contacting a cell in a cell population with an antisense nucleic acid complementary to at least a portion of said operon.

101. The method of Claim 100, wherein said antisense nucleic acid comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 or a proliferation-inhibiting portion thereof.

102. The method of Claim 100, wherein said cell is selected from the group
5 consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*,
10 *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*,
15 *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*,
20 *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of
25 any of the above species.

103. The method of Claim 100, wherein said cell is not an *E. coli* cell.

104. The method of Claim 100, wherein said gene is from an organism other than *E. coli*.

105. The method of Claim 100, wherein said cell is contacted with said antisense nucleic acid by introducing a plasmid which expresses said antisense nucleic acid into said cell population.

106. The method of Claim 100, wherein said cell is contacted with said antisense nucleic acid by introducing a phage which encodes said antisense nucleic acid into said cell population.

107. The method of Claim 100, wherein said cell is contacted with said antisense nucleic acid by expressing said antisense nucleic acid from the chromosome of cells in said cell population.

108. The method of Claim 100, wherein said cell is contacted with said antisense nucleic acid by introducing a promoter adjacent to a chromosomal copy of said antisense nucleic acid such that said promoter directs the transcription of said antisense nucleic acid.

109. The method of Claim 100, wherein said cell is contacted with said antisense nucleic acid by introducing a retron which expresses said antisense nucleic acid into said cell population.

110. The method of Claim 100, wherein said cell is contacted with said antisense nucleic acid by introducing a ribozyme into said cell-population, wherein a binding portion of said ribozyme comprises said antisense nucleic acid.

111. The method of Claim 100, wherein said cell is contacted with said antisense nucleic acid by introducing a liposome comprising said antisense nucleic acid into said cell.

112. The method of Claim 100, wherein said cell is contacted with said antisense nucleic acid by electroporation of said antisense nucleic acid into said cell.

113. The method of Claim 100, wherein said antisense nucleic acid is a fragment comprising at least 10, at least 20, at least 25, at least 30, at least 50 or more than 50 consecutive nucleotides of one of SEQ ID NOs.: 1-6213.

114. The method of Claim 100 wherein said antisense nucleic acid is a synthetic oligonucleotide.

115. The method of Claim 100, wherein said gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397.

116. A method for identifying a gene which is required for proliferation of a cell comprising:

(a) contacting a cell with an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, wherein said cell is a cell other than the organism from which said nucleic acid was obtained;

(b) determining whether said nucleic acid inhibits proliferation of said cell; and

(c) identifying the gene in said cell which encodes the mRNA which is complementary to said antisense nucleic acid or a portion thereof.

117. The method of Claim 116, wherein said cell is selected from the group consisting of *Staphylococcus* species, *Streptococcus* species, *Enterococcus* species, *Mycobacterium* species, *Clostridium* species, and *Bacillus* species.

118. The method of Claim 116 wherein said cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

119. The method of Claim 116, wherein said cell is not *E. coli*.

120. The method of Claim 116, further comprising operably linking said antisense nucleic acid to a promoter which is functional in said cell, said promoter being included in a vector, and introducing said vector into said cell.

121. A method for identifying a compound having the ability to inhibit proliferation of a cell comprising:

- (a) identifying a homolog of a gene or gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs. 1-6213 in a test cell, wherein said test cell is not the cell from which said nucleic acid was obtained;
- (b) identifying an inhibitory nucleic acid sequence which inhibits the activity of said homolog in said test cell;

(c) contacting said test cell with a sublethal level of said inhibitory nucleic acid, thus sensitizing said cell;

(d) contacting the sensitized cell of step (c) with a compound; and

(e) determining the degree to which said compound inhibits proliferation of said sensitized cell relative to a cell which does not contain said inhibitory nucleic acid.

122. The method of Claim 121, wherein said determining step comprises determining whether said compound inhibits proliferation of said sensitized test cell to a greater extent than said compound inhibits proliferation of a nonsensitized test cell.

123. The method of Claim 121, wherein step (a) comprises identifying a nucleic acid homologous to a gene or gene product whose activity or level is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs. 1-6213 or a nucleic acid encoding a homologous polypeptide to a polypeptide whose activity or level is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs. 1-6213 by using an algorithm selected from the group consisting of BLASTN version 2.0 with the default parameters and FASTA version 3.0t78 algorithm with the default parameters to identify said homologous nucleic acid or said nucleic acid encoding a homologous polypeptide in a database.

124. The method of Claim 121 wherein said step (a) comprises identifying a homologous nucleic acid or a nucleic acid comprising a sequence of nucleotides encoding a homologous polypeptide by identifying nucleic acids which hybridize to said nucleic acid selected from the group consisting of SEQ ID NOs. 1-6213 or the complement of said nucleic acid selected from the group consisting of SEQ ID NOs. 1-6213.

125. The method of Claim 121 wherein step (a) comprises expressing a nucleic acid selected from the group consisting of SEQ ID NOs. 1-6213 in said test cell.

126. The method of Claim 121, wherein step (a) comprises identifying a homologous nucleic acid or a nucleic acid encoding a homologous polypeptide in a test cell selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*,

Klebsiella pneumoniae, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*,
 5 *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*,
 10 *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

127. The method of Claim 121, wherein step (a) comprises identifying a
 15 homologous nucleic acid or a nucleic acid encoding a homologous polypeptide in a test cell other than *E. coli*.

128. The method of Claim 121, wherein said inhibitory nucleic acid is an antisense nucleic acid.

129. The method of Claim 121, wherein said inhibitory nucleic acid comprises an
 20 antisense nucleic acid to a portion of said homolog.

130. The method of Claim 121, wherein said inhibitory nucleic acid comprises an antisense nucleic acid to a portion of the operon encoding said homolog.

131. The method of Claim 121, wherein the step of contacting the cell with a
 25 sublethal level of said inhibitory nucleic acid comprises directly contacting the surface of said cell with said inhibitory nucleic acid.

132. The method of Claim 121, wherein the step of contacting the cell with a sublethal level of said inhibitory nucleic acid comprises transcribing an antisense nucleic acid complementary to at least a portion of the RNA transcribed from said homolog in said cell.

133. The method of Claim 121, wherein said gene product comprises a polypeptide
 30 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS.: 42398-78581.

134. The method of Claim 121, wherein said gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397.

135. A compound identified using the method of Claim 121.

136. A method of identifying a compound having the ability to inhibit proliferation comprising:

(a) contacting a test cell with a sublethal level of a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs. 1-6213 or a portion thereof which inhibits the proliferation of the cell from which said nucleic acid was obtained, thus sensitizing said test cell;

(b) contacting the sensitized test cell of step (a) with a compound; and

(c) determining the degree to which said compound inhibits proliferation of said sensitized test cell relative to a cell which does not contain said nucleic acid.

137. The method of Claim 136, wherein said determining step comprises determining whether said compound inhibits proliferation of said sensitized test cell to a greater extent than said compound inhibits proliferation of a nonsensitized test cell.

138. A compound identified using the method of Claim 136.

139. The method of Claim 136, wherein said test cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio*

vulnificans, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

140. The method of Claim 136, wherein the test cell is not *E. coli*.

141. A method for identifying a compound having activity against a biological
5 pathway required for proliferation comprising:

(a) sensitizing a cell by providing a sublethal level of an antisense nucleic acid complementary to a nucleic acid encoding a gene product required for proliferation, wherein the activity or expression of said gene product is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of
10 SEQ ID NOs.: 1-6213, in said cell to reduce the activity or amount of said gene product;

(b) contacting the sensitized cell with a compound; and

(c) determining the degree to which said compound inhibits the growth of said sensitized cell relative to a cell which does not contain said antisense nucleic acid.

142. The method of Claim 141, wherein said determining step comprises determining whether said compound inhibits the growth of said sensitized cell to a greater extent than said compound inhibits the growth of a nonsensitized cell.

143. The method of Claim 141, wherein said cell is selected from the group consisting of bacterial cells, fungal cells, plant cells, and animal cells.

144. The method of Claim 141, wherein said cell is a Gram positive bacterium.

145. The method of Claim 144, wherein said Gram positive bacterium is selected from the group consisting of *Staphylococcus* species, *Streptococcus* species, *Enterococcus* species, *Mycobacterium* species, *Clostridium* species, and *Bacillus* species.

146. The method of Claim 145, wherein said Gram positive bacterium is
25 *Staphylococcus aureus*.

147. The method of Claim 146, wherein said Gram positive bacterium is selected from the group consisting of *Staphylococcus aureus* RN450 and *Staphylococcus aureus* RN4220.

148. The method of Claim 141, wherein said cell is selected from the group
30 consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*,
35

Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Coccidioides immitis, Corynebacterium diphtheriae, Cryptococcus neoformans, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Histoplasma capsulatum, Klebsiella pneumoniae, Legionella pneumophila, Listeria monocytogenes, Moraxella catarrhalis, Mycobacterium avium, Mycobacterium bovis, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma genitalium, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis, Nocardia asteroides, Pasteurella haemolytica, Pasteurella multocida, Pneumocystis carinii, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas syringae, Salmonella bongori, Salmonella choleraesuis, Salmonella enterica, Salmonella paratyphi, Salmonella typhi, Salmonella typhimurium, Shigella boydii, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Streptococcus pneumoniae, Streptococcus mutans, Streptococcus pyogenes, Treponema pallidum, Ureaplasma urealyticum, Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificans, Yersinia enterocolitica, Yersinia pestis and any species falling within the genera of any of the above species.

149. The method of Claim 141, wherein said cell is not an *E. coli* cell.

150. The method of Claim 141, wherein said gene product is from an organism other than *E. coli*.

151. The method of Claim 141, wherein said antisense nucleic acid is transcribed from an inducible promoter.

152. The method of Claim 141, further comprising contacting the cell with an agent which induces transcription of said antisense nucleic acid from said inducible promoter, wherein said antisense nucleic acid is transcribed at a sublethal level.

153. The method of Claim 141, wherein inhibition of proliferation is measured by monitoring the optical density of a liquid culture.

154. The method of Claim 141, wherein said gene product comprises a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS.: 42398-78581.

155. The method of Claim 141, wherein said nucleic acid encoding said gene product comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397.

156. A compound identified using the method of Claim 141.

157. A method for identifying a compound having the ability to inhibit cellular proliferation comprising:

(a) contacting a cell with an agent which reduces the activity or level of a gene product required for proliferation of said cell, wherein said gene product is a gene product whose activity or expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213;

(b) contacting said cell with a compound; and

(c) determining whether said compound reduces proliferation of said contacted cell by acting on said gene product.

158. The method of Claim 157, wherein said determining step comprises determining whether said compound reduces proliferation of said contacted cell to a greater extent than said compound reduces proliferation of cells which have not been contacted with said agent.

159. The method of Claim 157, wherein said cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

160. The method of Claim 157, wherein said cell is not an *E. coli* cell.

161. The method of Claim 157, wherein said gene product is from an organism other than *E. coli*.

162. The method of Claim 157, wherein said agent which reduces the activity or level of a gene product required for proliferation of said cell comprises an antisense nucleic acid to a gene or operon required for proliferation.

163. The method of Claim 157, wherein said agent which reduces the activity or level of a gene product required for proliferation of said cell comprises a compound known to inhibit growth or proliferation of a cell.

164. The method of Claim 157, wherein said cell contains a mutation which reduces the activity or level of said gene product required for proliferation of said cell.

165. The method of Claim 157, wherein said mutation is a temperature sensitive mutation.

166. The method of Claim 157, wherein said gene product comprises a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

167. A compound identified using the method of Claim 157.

168. A method for identifying the biological pathway in which a proliferation-required gene or its gene product lies, wherein said gene or gene product comprises a gene or gene product whose activity or expression is inhibited by an antisense nucleic acid comprising a sequence selected from the group consisting of SEQ ID NOs.: 1-6213, said method comprising:

(a) providing a sublethal level of an antisense nucleic acid which inhibits the activity of said proliferation-required gene or gene product in a test cell;

(b) contacting said test cell with a compound known to inhibit growth or proliferation of a cell, wherein the biological pathway on which said compound acts is known; and

(c) determining the degree to which said proliferation of said test cell is inhibited relative to a cell which was not contacted with said compound.

169. The method of Claim 168, wherein said determining step comprises determining whether said test cell has a substantially greater sensitivity to said compound than a cell which does not express said sublethal level of said antisense nucleic acid.

170. The method of Claim 168, wherein said gene product comprises a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

171. The method of Claim 168, wherein said test cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

172. The method of Claim 168, wherein said test cell is not an *E. coli* cell.

173. The method of Claim 168, wherein said gene product is from an organism other than *E. coli*.

174. A method for determining the biological pathway on which a test compound acts comprising:

(a) providing a sublethal level of an antisense nucleic acid complementary to a proliferation-required nucleic acid in a first cell, wherein the activity or expression of said proliferation-required nucleic acid is inhibited by an antisense nucleic acid comprising a sequence selected from the group consisting of SEQ ID NOs.: 1-6213 and wherein the biological pathway in which said proliferation-required nucleic acid or a protein encoded by said proliferation-required nucleic acid lies is known,

(b) contacting said first cell with said test compound; and

(c) determining the degree to which said test compound inhibits proliferation of said first cell relative to a cell which does not contain said antisense nucleic acid.

175. The method of Claim 174, wherein said determining step comprises determining whether said first cell has a substantially greater sensitivity to said test compound than a cell which does not express said sublethal level of said antisense nucleic acid.

176. The method of Claim 174, further comprising:

(d) providing a sublethal level of a second antisense nucleic acid complementary to a second proliferation-required nucleic acid in a second cell, wherein said second proliferation-required nucleic acid is in a different biological pathway than said proliferation-required nucleic acid in step (a); and

(e) determining whether said second cell does not have a substantially greater sensitivity to said test compound than a cell which does not express said sublethal level of said second antisense nucleic acid, wherein said test compound is specific for the biological pathway against which the antisense nucleic acid of step (a) acts if said first cell has a substantially greater sensitivity to said test compound than said second cell.

177. The method of Claim 174, wherein said first cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema*

pallidum, Ureaplasma urealyticum, Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificans, Yersinia enterocolitica, Yersinia pestis and any species falling within the genera of any of the above species.

178. The method of Claim 174, wherein said first cell is not an *E. coli* cell.

5 179. The method of Claim 174, wherein said proliferation-required nucleic acid is from an organism other than *E. coli*.

180. A purified or isolated nucleic acid comprising a sequence selected from the group consisting of SEQ ID NOs.: 1-6213.

10 181. A compound which interacts with a gene or gene product whose activity or expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence of one of SEQ ID NOs.: 1-6213 to inhibit proliferation.

182. The compound of Claim 181, wherein said gene product is a polypeptide comprising one of SEQ ID NOs.: 42398-78581.

15 183. The compound of Claim 181, wherein said gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397.

184. A compound which interacts with a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence of one of SEQ ID NOs.: 1-6213 to inhibit proliferation.

20 185. A method for manufacturing an antibiotic comprising the steps of:
screening one or more candidate compounds to identify a compound that reduces the activity or level of a gene product required for proliferation, said gene product comprising a gene product whose activity or expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213; and
manufacturing the compound so identified.

25 186. The method of Claim 185, wherein said screening step comprises performing any one of the methods of Claims 44, 68, 121, 136, 141, and 157.

187. The method of Claim 185, wherein said gene product is a polypeptide comprising one of SEQ ID NOs.: 42398-78581.

30 188. A method for inhibiting proliferation of a cell in a subject comprising administering an effective amount of a compound that reduces the activity or level of a gene product required for proliferation of said cell, said gene product comprising a gene product whose activity or expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 to said subject.

35 189. The method of Claim 188 wherein said subject is selected from the group consisting of vertebrates, mammals, avians, and human beings.

190. The method of Claim 188, wherein said gene product comprises a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

191. The method of Claim 188, wherein said cell is selected from the group
 5 consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*,
 10 *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*,
 15 *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*,
 20 *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of
 25 any of the above species.

192. The method of Claim 188, wherein said cell is not *E. coli*.

193. The method of Claim 188, wherein said gene product is from an organism other than *E. coli*.

30 194. A purified or isolated nucleic acid consisting essentially of the coding sequence of one of SEQ ID NOs: 6214-42397.

195. A fragment of the nucleic acid of Claim 8, said fragment comprising at least 10, at least 20, at least 25, at least 30, at least 50 or more than 50 consecutive nucleotides of one of SEQ ID NOs: 6214-42397.

196. A purified or isolated nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity to a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, fragments comprising at least 25 consecutive nucleotides of SEQ ID NOs.: 6214-42397, the nucleotide sequences complementary to SEQ ID NOs.: 6214-42397, and the nucleotide sequences complementary to fragments comprising at least 25 consecutive nucleotides of SEQ ID NOs.: 6214-42397 as determined using BLASTN version 2.0 with the default parameters.

197. The nucleic acid of Claim 196, wherein said nucleic acid is from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

198. The nucleic acid of Claim 196, wherein said nucleic acid is from an organism other than *E. coli*.

199. A method of inhibiting proliferation of a cell comprising inhibiting the activity or reducing the amount of a gene product in said cell or inhibiting the activity or reducing the amount of a nucleic acid encoding said gene product in said cell, wherein said gene product is

selected from the group consisting of a gene product having having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6213.

200. The method of Claim 199, wherein said method comprises inhibiting said activity or reducing said amount of said gene product or inhibiting the activity or reducing the amount of a nucleic acid encoding said gene product in an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*,

Pneumocystis carinii, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*,
 5 *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

201. The method of Claim 199, wherein said method comprises inhibiting said
 10 activity or reducing said amount of said gene product or inhibiting the activity or reducing the amount of a nucleic acid encoding said gene product in an organism other than *E. coli*.

202. The method of Claim 199, wherein said gene product is from an organism other than *E. coli*.

203. The method of Claim 199, wherein said gene product comprises a polypeptide
 15 selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs.: 42398-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42398-78581.

204. The method of Claim 199, wherein said gene product is encoded by a nucleic
 20 acid selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent
 25 conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions.

205. A method for identifying a compound which influences the activity of a gene product required for proliferation comprising:

30 contacting a candidate compound with a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product
 35 encoded by a nucleic acid having at least 70% nucleotide sequence identity as

determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6213, a gene product having at least 25% amino acid identity as determined using
 5 FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product
 10 encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs: 1-6213; and
 15 determining whether said candidate compound influences the activity of said gene product.

206. The method of Claim 205, wherein said gene product is from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*,
 25 *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*,
 30 *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*,
 35

Staphylococcus epidermidis, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

5 207. The method of Claim 205, wherein said gene product is from an organism other than *E. coli*.

 208. The method of Claim 205, wherein said gene product is a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of
10 SEQ ID NOS.: 42398-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS: 42398-78581.

 209. The method of Claim 205, wherein said gene product is encoded by a nucleic acid selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the
15 default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions.

20 210. A compound identified using the method of Claim 205.

 211. A method for identifying a compound or nucleic acid having the ability to reduce the activity or level of a gene product required for proliferation comprising:

 (a) providing a target that is a gene or RNA, wherein said target comprises a nucleic acid that encodes a gene product selected from the group consisting of a gene
25 product having having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleic acid identity as determined using BLASTN version 2.0 with
30 the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a
35 sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product

encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs: 1-6213;

(b) contacting said target with a candidate compound or nucleic acid; and

(c) measuring an activity of said target.

212. The method of Claim 211, wherein said target gene or RNA is from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

213. The method of Claim 211, wherein said target gene or RNA is from an organism other than *E. coli*.

214. The method of Claim 211, wherein said gene product is from an organism other than *E. coli*.

215. The method of Claim 211, wherein said target is a messenger RNA molecule and said activity is translation of said messenger RNA.

5 216. The method of Claim 211, wherein said compound is a nucleic acid and said activity is translation of said gene product.

217. The method of Claim 211, wherein said target is a gene and said activity is transcription of said gene.

218. The method of Claim 211, wherein said target is a nontranslated RNA and said activity is processing or folding of said nontranslated RNA or assembly of said nontranslated RNA into a protein/RNA complex.

219. The method of Claim 211, wherein said target gene is a messenger RNA molecule encoding a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOS.: 42398-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS: 42398-78581.

220. The method of Claim 11, wherein said target gene comprises a nucleic acid selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397; a nucleic acid which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions.

221. A compound or nucleic acid identified using the method of Claim 211.

222. A method for identifying a compound which reduces the activity or level of a gene product required for proliferation of a cell comprising:

(a) providing a sublethal level of an antisense nucleic acid complementary to a nucleic acid encoding said gene product in a cell to reduce the activity or amount of said gene product in said cell, thereby producing a sensitized cell, wherein said gene product is selected from the group consisting of a gene product having having at least 70% nucleic acid identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.:

1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs: 1-6213;

(b) contacting said sensitized cell with a compound; and

(c) determining the degree to which said compound inhibits the growth of said sensitized cell relative to a cell which does not contain said antisense nucleic acid.

223. The method of Claim 222, wherein said determining step comprises determining whether said compound inhibits the growth of said sensitized cell to a greater extent than said compound inhibits the growth of a nonsensitized cell.

224. The method of Claim 222, wherein said sensitized cell is a Gram positive bacterium.

225. The method of Claim 224, wherein said Gram positive bacterium is selected from the group consisting of *Staphylococcus* species, *Streptococcus* species, *Enterococcus* species, *Mycobacterium* species, *Clostridium* species, and *Bacillus* species.

226. The method of Claim 225, wherein said bacterium is *Staphylococcus aureus*.

227. The method of Claim 224, wherein said *Staphylococcus* species is coagulase negative.

228. The method of Claim 226, wherein said bacterium is selected from the group consisting of *Staphylococcus aureus* RN450 and *Staphylococcus aureus* RN4220.

229. The method of Claim 222, wherein said sensitized cell is an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*,

Candida albicans, Candida glabrata (also called Torulopsis glabrata), Candida tropicalis, Candida parapsilosis, Candida guilliermondii, Candida krusei, Candida kefyr (also called Candida pseudotropicalis), Candida dubliniensis, Chlamydia pneumoniae, Chlamydia trachomatis, Clostridium acetobutylicum, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Coccidioides immitis, Corynebacterium diphtheriae, Cryptococcus neoformans, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Histoplasma capsulatum, Klebsiella pneumoniae, Legionella pneumophila, Listeria monocytogenes, Moraxella catarrhalis, Mycobacterium avium, Mycobacterium bovis, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma genitalium, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis, Nocardia asteroides, Pasteurella haemolytica, Pasteurella multocida, Pneumocystis carinii, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas syringae, Salmonella bongori, Salmonella choleraesuis, Salmonella enterica, Salmonella paratyphi, Salmonella typhi, Salmonella typhimurium, Shigella boydii, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Streptococcus pneumoniae, Streptococcus mutans, Streptococcus pyogenes, Treponema pallidum, Ureaplasma urealyticum, Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificans, Yersinia enterocolitica, Yersinia pestis and any species falling within the genera of any of the above species.

- 20 230. The method of Claim 222, wherein said cell is an organism other than *E. coli*.
231. The method of Claim 222, wherein said gene product is from an organism other than *E. coli*.
232. The method of Claim 222, wherein said antisense nucleic acid is transcribed from an inducible promoter.
- 25 233. The method of Claim 222, further comprising the step of contacting said cell with a concentration of inducer which induces transcription of said antisense nucleic acid to a sublethal level.
234. The method of Claim 222, wherein growth inhibition is measured by monitoring optical density of a culture medium.
- 30 235. The method of Claim 222, wherein said gene product is a polypeptide.
236. The method of Claim 235, wherein said polypeptide comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs: 42398-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42398-78581.
- 35

237. The method of Claim 222, wherein said gene product is an RNA.

238. The method of Claim 222, wherein said nucleic acid encoding said gene product comprises a nucleic acid selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleic acid identity as determined using
5 BLASTN version 2.0 with the default parameters to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions.

10 239. A compound identified using the method of Claim 222.

240. A method for inhibiting cellular proliferation comprising introducing a compound with activity against a gene product or a compound with activity against a gene encoding said gene product into a population of cells expressing said gene product, wherein said gene product is selected from the group consisting of a gene product having at least 70%
15 nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a
20 gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213,
25 a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene
30 product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213.

241. The method of Claim 240, wherein said compound is an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, or a proliferation-inhibiting portion thereof.

242. The method of Claim 240, wherein said proliferation inhibiting portion of one of SEQ ID NOs.: 1-6213 is a fragment comprising at least 10, at least 20, at least 25, at least 30, at least 50 or more than 51 consecutive nucleotides of one of SEQ ID NOs.: 1-6213.

243. The method of Claim 240, wherein said population is a population of Gram positive bacteria.

244. The method of Claim 243, wherein said population of Gram positive bacteria is selected from the group consisting of a population of *Staphylococcus* species, *Streptococcus* species, *Enterococcus* species, *Mycobacterium* species, *Clostridium* species, and *Bacillus* species.

245. The method of Claim 243, wherein said population is a population of *Staphylococcus aureus*.

246. The method of Claim 245, wherein said population is a population of a bacterium selected from the group consisting of *Staphylococcus aureus* RN450 and *Staphylococcus aureus* RN4220.

247. The method of Claim 240, wherein said population is a population of a bacterium selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*,

Vibrio cholerae, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

248. The method of Claim 240, wherein said population is a population of an organism other than *E. coli*.

5 249. The method of Claim 240, wherein said product of said gene is from an organism other than *E. coli*.

250. The method of Claim 240, wherein said gene product is selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOS.: 42398-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS.: 42398-78581.

251. The method of Claim 240, wherein said gene comprises a nucleic acid selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions.

252. A preparation comprising an effective concentration of an antisense nucleic acid in a pharmaceutically acceptable carrier wherein said antisense nucleic acid is selected from the group consisting of a nucleic acid comprising a sequence having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 or a proliferation-inhibiting portion thereof, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213 under moderate conditions.

253. The preparation of Claim 252, wherein said proliferation-inhibiting portion of one of SEQ ID NOS.: 1-6213 comprises at least 10, at least 20, at least 25, at least 30, at least 50 or more than 50 consecutive nucleotides of one of SEQ ID NOS.: 1-6213.

254. A method for inhibiting the activity or expression of a gene in an operon which encodes a gene product required for proliferation comprising contacting a cell in a cell

population with an antisense nucleic acid comprising at least a proliferation-inhibiting portion of said operon in an antisense orientation, wherein said gene product is selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213.

255. The method of Claim 254, wherein said antisense nucleic acid comprises a nucleotide sequence having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a proliferation inhibiting portion thereof, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, and a nucleic acid which comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions.

256. The method of Claim 254, wherein said cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*,

Corynebacterium diphtheriae, Cryptococcus neoformans, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Histoplasma capsulatum, Klebsiella pneumoniae, Legionella pneumophila, Listeria monocytogenes, Moraxella catarrhalis, Mycobacterium avium, Mycobacterium bovis, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma genitalium, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis, Nocardia asteroides, Pasteurella haemolytica, Pasteurella multocida, Pneumocystis carinii, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas syringae, Salmonella bongori, Salmonella choleraesuis, Salmonella enterica, Salmonella paratyphi, Salmonella typhi, Salmonella typhimurium, Shigella boydii, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Streptococcus pneumoniae, Streptococcus mutans, Streptococcus pyogenes, Treponema pallidum, Ureaplasma urealyticum, Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificans, Yersinia enterocolitica, Yersinia pestis and any species falling within the genera of any of the above species.

257. The method of Claim 254, wherein said cell is not an *E. coli* cell.

258. The method of Claim 254, wherein said gene is from an organism other than *E. coli*.

259. The method of Claim 254, wherein said cell is contacted with said antisense nucleic acid by introducing a plasmid which transcribes said antisense nucleic acid into said cell population.

260. The method of Claim 254, wherein said cell is contacted with said antisense nucleic acid by introducing a phage which transcribes said antisense nucleic acid into said cell population.

261. The method of Claim 254, wherein said cell is contacted with said antisense nucleic acid by transcribing said antisense nucleic acid from the chromosome of cells in said cell population.

262. The method of Claim 254, wherein said cell is contacted with said antisense nucleic acid by introducing a promoter adjacent to a chromosomal copy of said antisense nucleic acid such that said promoter directs the synthesis of said antisense nucleic acid.

263. The method of Claim 254, wherein said cell is contacted with said antisense nucleic acid by introducing a retron which expresses said antisense nucleic acid into said cell population.

264. The method of Claim 254, wherein said cell is contacted with said antisense nucleic acid by introducing a ribozyme into said cell-population, wherein a binding portion of said ribozyme is complementary to said antisense oligonucleotide.

5 265. The method of Claim 254, wherein said cell is contacted with said antisense nucleic acid by introducing a liposome comprising said antisense oligonucleotide into said cell.

266. The method of Claim 254, wherein said cell is contacted with said antisense nucleic acid by electroporation of said antisense nucleic acid into said cell.

10 267. The method of Claim 254, wherein said antisense nucleic acid has at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence comprising at least 10, at least 20, at least 25, at least 30, at least 50 or more than 50 consecutive nucleotides of one of SEQ ID NOS.: 1-6213.

268. The method of Claim 254 wherein said antisense nucleic acid is a synthetic oligonucleotide.

15 269. The method of Claim 254, wherein said gene comprises a nucleic acid selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a
20 nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions.

270. A method for identifying a gene which is required for proliferation of a cell comprising:

25 (a) contacting a cell with an antisense nucleic acid selected from the group consisting of a nucleic acid at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 or a proliferation-inhibiting portion thereof, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213 under stringent
30 conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213 under moderate conditions, wherein said cell is a cell other than the organism from which said nucleic acid was obtained;

(b) determining whether said nucleic acid inhibits proliferation of said cell; and

(c) identifying the gene in said cell which encodes the mRNA which is complementary to said antisense nucleic acid or a portion thereof.

271. The method of Claim 270, wherein said cell is selected from the group consisting of *Staphylococcus* species, *Streptococcus* species, *Enterococcus* species, *Mycobacterium* species, *Clostridium* species, and *Bacillus* species.

272. The method of Claim 270 wherein said cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

273. The method of Claim 270, wherein said cell is not *E. coli*.

274. The method of Claim 270, further comprising operably linking said antisense nucleic acid to a promoter which is functional in said cell, said promoter being included in a vector, and introducing said vector into said cell.

275. A method for identifying a compound having the ability to inhibit proliferation of a cell comprising:

(a) identifying a homolog of a gene or gene product whose activity or level is inhibited by an antisense nucleic acid in a test cell, wherein said test cell is not the microorganism from which the antisense nucleic acid was obtained, wherein said antisense nucleic acid is selected from the group consisting of a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOs. 1-6213, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions;

(b) identifying an inhibitory nucleic acid sequence which inhibits the activity of said homolog in said test cell;

(c) contacting said test cell with a sublethal level of said inhibitory nucleic acid, thus sensitizing said cell;

(d) contacting the sensitized cell of step (c) with a compound; and

(e) determining the degree to which said compound inhibits proliferation of said sensitized cell relative to a cell which does not express said inhibitory nucleic acid.

276. The method of Claim 275, wherein said determining step comprises determining whether said compound inhibits proliferation of said sensitized test cell to a greater extent than said compound inhibits proliferation of a nonsensitized test cell.

277. The method of Claim 275, wherein step (a) comprises identifying a homologous nucleic acid to a gene or gene product whose activity or level is inhibited by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOs. 1-6213 or a nucleic acid encoding a homologous polypeptide to a polypeptide whose activity or level is inhibited by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOs. 1-6213 by using an algorithm selected from the group consisting of BLASTN version 2.0 with the default parameters and FASTA version 3.0t78 algorithm with the default parameters to identify said homologous nucleic acid or said nucleic acid encoding a homologous polypeptide in a database.

278. The method of Claim 275 wherein said step (a) comprises identifying a homologous nucleic acid or a nucleic acid encoding a homologous polypeptide by identifying nucleic acids comprising nucleotide sequences which hybridize to said nucleic acid having at

least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOs. 1-6213 or the complement of the nucleotide sequence of said nucleic acid selected from the group consisting of SEQ ID NOs. 1-6213.

5 279. The method of Claim 275 wherein step (a) comprises expressing a nucleic acid having at least 70% nucleic acid identity as determined using BLASTN version 2.0 with the default parameters to a sequence selected from the group consisting of SEQ ID NOs. 1-6213 in said test cell.

10 280. The method of Claim 275, wherein step (a) comprises identifying a homologous nucleic acid or a nucleic acid encoding a homologous polypeptide in an test cell selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*),
 15 *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*,
 20 *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*,
 25 *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*,
 30 *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

281. The method of Claim 275, wherein step (a) comprises identifying a homologous nucleic acid or a nucleic acid encoding a homologous polypeptide in a test cell other than *E. coli*.

5 282. The method of Claim 275, wherein said inhibitory nucleic acid is an antisense nucleic acid.

283. The method of Claim 275, wherein said inhibitory nucleic acid comprises an antisense nucleic acid to a portion of said homolog.

284. The method of Claim 275, wherein said inhibitory nucleic acid comprises an antisense nucleic acid to a portion of the operon encoding said homolog.

10 285. The method of Claim 275, wherein the step of contacting the cell with a sublethal level of said inhibitory nucleic acid comprises directly contacting said cell with said inhibitory nucleic acid.

286. The method of Claim 275, wherein the step of contacting the cell with a sublethal level of said inhibitory nucleic acid comprises expressing an antisense nucleic acid to
15 said homolog in said cell.

287. The method of Claim 275, wherein said gene product comprises a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

288. The method of Claim 275, wherein said gene comprises a nucleic acid selected
20 from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions,
25 and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions.

289. A compound identified using the method of Claim 275.

290. A method of identifying a compound having the ability to inhibit proliferation comprising:

30 (a) sensitizing a test cell by contacting said test cell with a sublethal level of an antisense nucleic acid, wherein said antisense nucleic acid is selected from the group consisting of a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOs. 1-6213 or a portion
35 thereof which inhibits the proliferation of the cell from which said nucleic acid was

obtained, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditionst;

(b) contacting the sensitized test cell of step (a) with a compound; and

(c) determining the degree to which said compound inhibits proliferation of said sensitized test cell relative to a cell which does not contain said antisense nucleic acid.

291. The method of Claim 290, wherein said determining step comprises determining whether said compound inhibits proliferation of said sensitized test cell to a greater extent than said compound inhibits proliferation of a nonsensitized test cell.

292. A compound identified using the method of Claim 290.

293. The method of Claim 290, wherein said test cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio*

vulnificans, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

294. The method of Claim 290, wherein the test cell is not *E. coli*.

295. A method for identifying a compound having activity against a biological pathway required for proliferation comprising:

(a) sensitizing a cell by providing a sublethal level of an antisense nucleic acid complementary to a nucleic acid encoding a gene product required for proliferation, wherein said gene product is selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213;

(b) contacting the sensitized cell with a compound; and

(c) determining the extent to which said compound inhibits the growth of said sensitized cell relative to a cell which does not contain said antisense nucleic acid.

296. The method of Claim 295, wherein said determining step comprises determining whether said compound inhibits the growth of said sensitized cell to a greater extent than said compound inhibits the growth of a nonsensitized cell.

297. The method of Claim 295, wherein said cell is selected from the group consisting of bacterial cells, fungal cells, plant cells, and animal cells.

298. The method of Claim 295, wherein said cell is a Gram positive bacterium.

299. The method of Claim 298, wherein said Gram positive bacterium is selected from the group consisting of *Staphylococcus* species, *Streptococcus* species, *Enterococcus* species, *Mycobacterium* species, *Clostridium* species, and *Bacillus* species.

5 300. The method of Claim 299, wherein said Gram positive bacterium is *Staphylococcus aureus*.

301. The method of Claim 298, wherein said Gram positive bacterium is selected from the group consisting of *Staphylococcus aureus* RN450 and *Staphylococcus aureus* RN4220.

10 302. The method of Claim 295, wherein said cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*,
15 *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*,
20 *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*,
25 *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of
30 any of the above species.

303. The method of Claim 295, wherein said cell is not an *E. coli* cell.

304. The method of Claim 295, wherein said gene product is from an organism other than *E. coli*.

305. The method of Claim 295, wherein said antisense nucleic acid is transcribed from an inducible promoter.

306. The method of Claim 305, further comprising contacting the cell with an agent which induces expression of said antisense nucleic acid from said inducible promoter, wherein
5 said antisense nucleic acid is expressed at a sublethal level.

307. The method of Claim 295, wherein inhibition of proliferation is measured by monitoring the optical density of a liquid culture.

308. The method of Claim 295, wherein said gene product comprises a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the
10 default parameters to a sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

309. The method of Claim 295, wherein said nucleic acid encoding said gene product comprises a nucleic acid selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using
15 BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ
20 ID NOS.: 6214-42397 under moderate conditions.

310. A compound identified using the method of Claim 295.

311. A method for identifying a compound having the ability to inhibit cellular proliferation comprising:

(a) contacting a cell with an agent which reduces the activity or level of a gene
25 product required for proliferation of said cell, wherein said gene product is selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a
30 gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as
35 determined using FASTA version 3.0t78 with the default parameters to a gene product

whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs: 1-6213;

(b) contacting said cell with a compound; and

(c) determining the degree to which said compound reduces proliferation of said contacted cell relative to a cell which was not contacted with said agent.

312. The method of Claim 311, wherein said determining step comprises determining whether said compound reduces proliferation of said contacted cell to a greater extent than said compound reduces proliferation of cells which have not been contacted with said agent.

313. The method of Claim 311, wherein said cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*,

Streptococcus pneumoniae, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

5 314. The method of Claim 311, wherein said cell is not an *E. coli* cell.

315. The method of Claim 311, wherein said gene product is from an organism other than *E. coli*.

10 316. The method of Claim 311, wherein said agent which reduces the activity or level of a gene product required for proliferation of said cell comprises an antisense nucleic acid to a gene or operon required for proliferation.

317. The method of Claim 311, wherein said agent which reduces the activity or level of a gene product required for proliferation of said cell comprises a compound known to inhibit growth or proliferation of a cell.

15 318. The method of Claim 311, wherein said cell contains a mutation which reduces the activity or level of said gene product required for proliferation of said cell.

319. The method of Claim 311, wherein said mutation is a temperature sensitive mutation.

20 320. The method of Claim 311, wherein said gene product comprises a gene product comprises a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

321. A compound identified using the method of Claim 311.

322. A method for identifying the biological pathway in which a proliferation-required gene product or a gene encoding a proliferation-required gene product lies comprising:

25 (a) providing a sublethal level of an antisense nucleic acid which inhibits the activity or reduces the level of said gene encoding a proliferation-required gene product or said proliferation-required gene product in a test cell, wherein said proliferation-required gene product is selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with
30 the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default
35 parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group

consisting of SEQ ID NOs: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a
5 gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product
10 whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs: 1-6213;

(b) contacting said test cell with a compound known to inhibit growth or proliferation of a cell, wherein the biological pathway on which said compound acts is known; and

15 (c) determining the degree to which said compound inhibits proliferation of said test cell relative to a cell which does not contain said antisense nucleic acid.

323. The method of Claim 322, wherein said determining step comprises determining whether said test cell has a substantially greater sensitivity to said compound than a cell which does not express said sublethal level of said antisense nucleic acid.

20 324. The method of Claim 322, wherein said gene product comprises a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

325. The method of Claim 322, wherein said test cell is selected from the group
25 consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*,
30 *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
35

Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma genitalium, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis, Nocardia asteroides, Pasteurella haemolytica, Pasteurella multocida, Pneumocystis carinii, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas syringae, Salmonella bongori,
 5 Salmonella choleraesuis, Salmonella enterica, Salmonella paratyphi, Salmonella typhi, Salmonella typhimurium, Shigella boydii, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Streptococcus pneumoniae, Streptococcus mutans, Streptococcus pyogenes, Treponema pallidum, Ureaplasma urealyticum, Vibrio cholerae, Vibrio parahaemolyticus, Vibrio
 10 vulnificans, Yersinia enterocolitica, Yersinia pestis and any species falling within the genera of any of the above species.

326. The method of Claim 322, wherein said test cell is not an *E. coli* cell.

327. The method of Claim 322, wherein said gene product is from an organism other than *E. coli*.

15 328. A method for determining the biological pathway on which a test compound acts comprising:

(a) providing a sublethal level of an antisense nucleic acid complementary to a proliferation-required nucleic acid in a cell, thereby producing a sensitized cell, wherein said antisense nucleic acid is selected from the group consisting of a nucleic acid having
 20 at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6213 or a proliferation-inhibiting portion thereof, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, and a nucleic acid
 25 comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions and wherein the biological pathway in which said proliferation-required nucleic acid or a protein encoded by said proliferation-required polypeptide lies is known,

30 (b) contacting said cell with said test compound; and

(c) determining the degree to which said compound inhibits proliferation of said sensitized cell relative to a cell which does not contain said antisense nucleic acid.

329. The method of Claim 328, wherein said determining step comprises determining whether said sensitized cell has a substantially greater sensitivity to said test compound than a cell which does not express said sublethal level of said antisense nucleic acid.

35 330. The method of Claim 328, further comprising:

(d) providing a sublethal level of a second antisense nucleic acid complementary to a second proliferation-required nucleic acid in a second cell, wherein said second proliferation-required nucleic acid is in a different biological pathway than said proliferation-required nucleic acid in step (a); and

5 (e) determining whether said second cell does not have a substantially greater sensitivity to said test compound than a cell which does not express said sublethal level of said second antisense nucleic acid, wherein said test compound is specific for the biological pathway against which the antisense nucleic acid of step (a) acts if said sensitized cell has substantially greater sensitivity to said test compound than said
10 second cell.

331. The method of Claim 328, wherein said sensitized cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*,
15 *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*,
25 *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

332. The method of Claim 328, wherein said sensitized cell is not an *E. coli* cell.

333. The method of Claim 328, wherein said proliferation-required nucleic acid is from an organism other than *E. coli*.

334. A compound which inhibits proliferation by interacting with a gene encoding a gene product required for proliferation or with a gene product required for proliferation, wherein said gene product is selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213.

335. The compound of Claim 334, wherein said gene product comprises a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

336. The compound of Claim 334, wherein said gene comprises a nucleic acid selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions.

337. A method for manufacturing an antibiotic comprising the steps of:

screening one or more candidate compounds to identify a compound that reduces the activity or level of a gene product required for proliferation wherein said gene product is selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product
5 whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose
10 expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded
15 by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is
20 inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 ; and manufacturing the compound so identified.

338. The method of Claim 337, wherein said screening step comprises performing any one of the methods of Claims 205, 211, 222, 275, 290, 295, 311.

339. The method of Claim 337, wherein said gene product comprises a polypeptide
25 having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

340. A method for inhibiting proliferation of a cell in a subject comprising administering an effective amount of a compound that reduces the activity or level of a gene
30 product required for proliferation of said cell, wherein said gene product is selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid
35 having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with

the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs: 1-6213.

341. The method of Claim 340 wherein said subject is selected from the group consisting of vertebrates, mammals, avians, and human beings.

342. The method of Claim 340, wherein said gene product comprises a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to an amino acid sequence selected from the group consisting of SEQ ID NOs: 42398-78581.

343. The method of Claim 340, wherein said cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*,

Salmonella typhimurium, Shigella boydii, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Streptococcus pneumoniae, Streptococcus mutans, Streptococcus pyogenes, Treponema pallidum, Ureaplasma urealyticum, Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificans, Yersinia enterocolitica, Yersinia pestis and any species falling within the genera of any of the above species.

344. The method of Claim 340, wherein said cell is not *E. coli*.

345. The method of Claim 340, wherein said gene product is from an organism other than *E. coli*.

346. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain in said culture overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture.

347. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain in said culture overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture.

348. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

5 obtaining a culture comprising a plurality of strains wherein each strain in said culture overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed;

10 contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

15 identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture.

349. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

20 obtaining a culture comprising a plurality of strains wherein each strain in said culture overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a
25 nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of
30 SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide
35 sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent

conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture.

350. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain in said culture overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture.

351. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

5 obtaining a culture comprising a plurality of strains wherein each strain in said culture overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 is overexpressed;

10 contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

15 identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture.

352. The method of Claim 346, 347, 348, 349, 350 or 351, wherein said culture includes at least one strain which does not overexpresses a gene product which is essential for proliferation of said organism.

20 353. The method of Claim 346, 347, 348, 349, 350 or 351, wherein said strains which overexpress said gene products comprise a nucleic acid encoding said gene product which is essential for proliferation of said organism operably linked to a regulatable promoter.

25 354. The method of Claim 346, 347, 348, 349, 350 or 351, wherein said strains which overexpress said gene products a nucleic acid encoding said gene product which is essential for proliferation of said organism operably linked to a constitutive promoter.

355. The method of Claim 346, 347, 348, 349, 350 or 351, wherein said identification step comprises determining the nucleotide sequence of a nucleic acid encoding said gene product in said cell which proliferated more rapidly in said culture.

30 356. The method of Claim 346, 347, 348, 349, 350 or 351, wherein said identification step comprises performing an amplification reaction to identify the nucleic acid encoding said gene product in said cell which proliferated more rapidly in said cell culture.

357. The method of Claim 356, wherein the products of said amplification reaction are labeled with a detectable dye.

358. The method of Claim 346, 347, 348, 349, 350 or 351, wherein said identification step comprises performing a hybridization procedure.

359. The method of Claim 346, 347, 348, 349, 350 or 351, wherein said identification step comprises contacting a nucleic acid array with a nucleic acid encoding said gene product in said cell which proliferated more rapidly in said cell culture.

360. The method of Claim 346, 347, 348, 349, 350 or 351, wherein said organism is selected from the group consisting of bacteria, fungi, and protozoa.

361. The method of Claim 346, 347, 348, 349, 350 or 351, wherein said culture is a culture of an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

362. The method of Claim 346, 347, 348, 349, 350 or 351, wherein said compound is obtained from a library of natural compounds.

363. The method of Claim 346, 347, 348, 349, 350 or 351, wherein said compound is obtained from a library of synthetic compounds.

364. The method of Claim 346, 347, 348, 349, 350 or 351, wherein said compound is present in a crude or partially purified state.

365. The method of Claim 346, 347, 348, 349, 350 or 351, further comprising determining whether said gene product in said strain which proliferated more rapidly in said culture has a counterpart in at least one other organism.

366. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining an array of strains on a solid growth medium wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed;

contacting said array of strains with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly on said solid medium.

367. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining an array of strains on a solid growth medium wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed;

contacting said array of strains with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly on said solid medium.

368. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining an array of strains on a solid growth medium wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed;

contacting said array of strains with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly on said solid medium.

369. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining an array of strains on a solid growth medium wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide

sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed;

5 contacting said array of strains with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts;
10 and

 identifying the gene product which is overexpressed in a strain which proliferated more rapidly on said solid medium.

370. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

15 obtaining an array of strains on a solid growth medium wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a
20 nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a
25 nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed;

 contacting said array of strains with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which
30 overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts;
 and

 identifying the gene product which is overexpressed in a strain which proliferated more rapidly on said solid medium.

371. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

5 obtaining an array of strains on a solid growth medium wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed;

10 contacting said array of strains with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts;

15 and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly on said solid medium.

372. The method of Claim 366, 367, 368, 369, 370 or 371, wherein at least one strain in said array does not overexpresses a gene product which is essential for proliferation of said organism.

20

373. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

25 obtaining a plurality of cultures, wherein each culture comprises a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed;

30 contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is overexpressed in a strain whose proliferation is inhibited by said compound.

374. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures, wherein each culture comprises a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed;

contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is overexpressed in a strain whose proliferation is inhibited by said compound.

375. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures, wherein each culture comprises a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed;

contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is overexpressed in a strain whose proliferation is inhibited by said compound.

376. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures, wherein each culture comprises a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product

whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed;

contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is overexpressed in a strain whose proliferation is inhibited by said compound.

377. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures, wherein each culture comprises a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed;

contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is overexpressed in a strain whose proliferation is inhibited by said compound.

378. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures, wherein each culture comprises a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 is overexpressed;

contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is overexpressed in a strain whose proliferation is inhibited by said compound.

379. The method of Claim 373, 374, 375, 376, 377 or 378, wherein at least one strain in said plurality of cultures does not overexpress a gene product which is essential for proliferation of said organism.

380. A method of profiling a compound's activity comprising:
performing the method of Claim 346 on a first culture using a first compound;
performing the method of Claim 346 on a second culture using a second compound; and

comparing the strains identified in said first culture to the strains identified in said second culture.

381. A method of profiling a compound's activity comprising:
performing the method of Claim 347 on a first culture using a first compound;
performing the method of Claim 347 on a second culture using a second compound; and

comparing the strains identified in said first culture to the strains identified in said second culture.

382. A method of profiling a compound's activity comprising:
performing the method of Claim 348 on a first culture using a first compound;
performing the method of Claim 348 on a second culture using a second compound; and

comparing the strains identified in said first culture to the strains identified in said second culture.

383. A method of profiling a compound's activity comprising:
performing the method of Claim 349 on a first culture using a first compound;

performing the method of Claim 349 on a second culture using a second compound; and

comparing the strains identified in said first culture to the strains identified in said second culture.

5 384. A method of profiling a compound's activity comprising:
performing the method of Claim 350 on a first culture using a first compound;
performing the method of Claim 350 on a second culture using a second compound; and

10 comparing the strains identified in said first culture to the strains identified in said second culture.

385. A method of profiling a compound's activity comprising:
performing the method of Claim 351 on a first culture using a first compound;
performing the method of Claim 351 on a second culture using a second compound; and

15 comparing the strains identified in said first culture to the strains identified in said second culture.

386. A method of profiling a first compound's activity comprising:
growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein
20 each strain in said array overexpresses a different gene product which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed, and wherein said first compound and said second compound inhibit the proliferation of
25 said organism; and

comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

387. A method of profiling a first compound's activity comprising:
growing an array of strains on a first solid medium comprising said first
30 compound and on a second solid medium comprising a second compound, wherein each strain in said array overexpresses a different gene product which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed, and wherein said first
35 compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

388. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first
5 compound and on a second solid medium comprising a second compound, wherein
each strain in said array overexpresses a different gene product which is essential for
proliferation of an organism, wherein said culture comprises a strain in which a gene
product comprising an amino acid sequence selected from the group consisting of SEQ
ID NOs.: 42938-78581 is overexpressed, and wherein said first compound and said
10 second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the
pattern of strains which grow on said second solid medium.

389. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first
15 compound and on a second solid medium comprising a second compound, wherein
each strain in said array overexpresses a different gene product which is essential for
proliferation of an organism, wherein said culture comprises a strain in which a gene
product selected from the group consisting of a gene product having at least 70%
nucleotide sequence identity as determined using BLASTN version 2.0 with the default
20 parameters to a gene product whose expression is inhibited by an antisense nucleic acid
comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.:
1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide
sequence identity as determined using BLASTN version 2.0 with the default parameters
to a nucleic acid encoding a gene product whose expression is inhibited by an antisense
25 nucleic acid comprising a nucleotide sequence selected from the group consisting of
SEQ ID NOs: 1-6213, a gene product having at least 25% amino acid identity as
determined using FASTA version 3.0t78 with the default parameters to a gene product
whose expression is inhibited by an antisense nucleic acid comprising a nucleotide
sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product
30 encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide
sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent
conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid
comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.:
1-6213 under moderate conditions, and a gene product whose activity may be
35 complemented by the gene product whose activity is inhibited by a nucleic acid

comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6213 is overexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

390. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein each strain in said array overexpresses a different gene product which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

391. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein each strain in said array overexpresses a different gene product which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

392. The method of any one of Claims 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390 or 391, wherein said first compound is present in a crude or partially purified state.

393. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

5 obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed;

10 contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress said gene product on which said compound acts; and

15 identifying the gene product which is underexpressed in a strain which proliferated more slowly in said culture.

394. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

20 obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is underexpressed;

25 contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress said gene product on which said compound acts; and

30 identifying the gene product which is underexpressed in a strain which proliferated more slowly in said culture.

395. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

35 obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprising

an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is underexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress said gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which proliferated more slowly in said culture.

396. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene

product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress said gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which proliferated more slowly in said culture.

397. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is underexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress said gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which proliferated more slowly in said culture.

398. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOS.: 42938-78581 and a polypeptide

whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 is underexpressed;

5 contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress said gene product on which said compound acts; and

 identifying the gene product which is underexpressed in a strain which proliferated more slowly in said culture.

10 399. The method of Claim 393, 394, 395, 396, 397 or 398, wherein at least one strain in said culture does not underexpresses a gene product which is essential for proliferation of said organism.

 400. The method of Claim 393, 394, 395, 396, 397 or 398, wherein said strains which underexpresses said gene products comprise a nucleic acid complementary to at least a portion of a gene encoding said gene product which is essential for proliferation of said organism operably linked to a regulatable promoter.

15 401. The method of Claim 393, 394, 395, 396, 397 or 398, wherein said strains which underexpress said gene products express an antisense nucleic acid complementary to at least a portion of a gene encoding said gene product which is essential for proliferation of said organism, wherein expression of said antisense nucleic acid reduces expression of said gene product in said strain.

 402. The method of Claim 393, 394, 395, 396, 397 or 398, wherein said identification step comprises determining the nucleotide sequence of a nucleic acid encoding said gene product in said strain which proliferated more slowly.

25 403. The method of Claim 393, 394, 395, 396, 397 or 398, wherein said identification step comprises performing an amplification reaction to identify the nucleic acid encoding said gene product in said cell which proliferated more slowly.

 404. The method of Claim 393, 394, 395, 396, 397 or 398, wherein the products of said amplification reaction are labeled with a detectable dye.

30 405. The method of Claim 404, wherein said identification step comprises performing a hybridization procedure.

 406. The method of Claim 393, 394, 395, 396, 397 or 398, wherein said identification step comprises contacting a nucleic acid array with a nucleic acid encoding said gene product in said cell which proliferated more slowly.

407. The method of Claim 393, 394, 395, 396, 397 or 398, wherein said organism is selected from the group consisting of bacteria, fungi, protozoa.

408. The method of Claim 393, 394, 395, 396, 397 or 398, wherein said culture is a culture of an organism selected from the group consisting of *Acinetobacter baumannii*,
 5 *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*,
Bordetella pertussis, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*,
Burkholderia mallei, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called
Torulopsis glabrata), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*,
 10 *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*,
Chlamydia pneumoniae, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium*
botulinum, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*,
Corynebacterium diphtheriae, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus*
faecalis, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*,
Histoplasma capsulatum, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria*
 15 *monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
Mycobacterium leprae, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma*
pneumoniae, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella*
haemolytica, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*,
Pseudomonas aeruginosa, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*,
 20 *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*,
Salmonella typhimurium, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella*
sonnei, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*,
Streptococcus pneumoniae, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema*
pallidum, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio*
 25 *vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of
 any of the above species.

409. The method of Claim 393, 394, 395, 396, 397 or 398, wherein said compound is obtained from a library of natural compounds.

410. The method of Claim 393, 394, 395, 396, 397 or 398, wherein said compound
 30 is obtained from a library of synthetic compounds.

411. The method of Claim 393, 394, 395, 396, 397 or 398, wherein said compound is present in a crude or partially purified state.

412. The method of Claim 393, 394, 395, 396, 397 or 398, further comprising
 determining whether said gene product in said strain which proliferated more slowly in said
 35 culture has a counterpart in at least one other organism.

413. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures, each culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed;

contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

414. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures, each culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is underexpressed;

contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

415. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures, each culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is underexpressed;

contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

416. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

5 obtaining a plurality of cultures, each culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed;

contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

417. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

35 obtaining a plurality of cultures, each culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the

group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is underexpressed;

contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

418. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures, each culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOS.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS: 42938-78581 is underexpressed;

contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

419. A method of profiling a compound's activity comprising:

performing the method of Claim 393 on a first culture using a first compound;

performing the method of Claim 393 on a second culture using a second

compound; and

comparing the strains identified in said first culture to the strains identified in said second culture.

420. A method of profiling a compound's activity comprising:

performing the method of Claim 394 on a first culture using a first compound;

performing the method of Claim 394 on a second culture using a second compound; and

comparing the strains identified in said first culture to the strains identified in said second culture.

5 421. A method of profiling a compound's activity comprising:

performing the method of Claim 395 on a first culture using a first compound;

performing the method of Claim 395 on a second culture using a second compound; and

10 comparing the strains identified in said first culture to the strains identified in said second culture.

422. A method of profiling a compound's activity comprising

performing the method of Claim 396 on a first culture using a first compound;

performing the method of Claim 396 on a second culture using a second compound; and

15 comparing the strains identified in said first culture to the strains identified in said second culture.

423. A method of profiling a compound's activity comprising

performing the method of Claim 397 on a first culture using a first compound;

20 performing the method of Claim 397 on a second culture using a second compound; and

comparing the strains identified in said first culture to the strains identified in said second culture.

424. A method of profiling a compound's activity comprising

performing the method of Claim 398 on a first culture using a first compound;

25 performing the method of Claim 398 on a second culture using a second compound; and

comparing the strains identified in said first culture to the strains identified in said second culture.

425. A method of profiling a first compound's activity comprising:

30 growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein said array comprises a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a
35 nucleic acid comprising a nucleotide sequence selected from the group consisting of

SEQ ID NOs.: 1-6213 is underexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

5 426. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein said array comprises a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of an organism, wherein said culture
10 comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is underexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the
15 pattern of strains which grow on said second solid medium.

427. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein said array comprises a plurality of strains wherein each strain underexpresses a different
20 gene product which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is underexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

25 comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

428. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein said
30 array comprises a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited
35 by an antisense nucleic acid comprising a nucleotide sequence selected from the group

consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

429. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein said array comprises a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is underexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

430. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein said array comprises a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 is underexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

431. The method of any one of Claims 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429 or 430, wherein said first compound is present in a crude or partially purified state.

432. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed;

contacting each of said plurality of cultures with a varying concentration of a regulatory agent which regulates the level of expression of said gene products which are essential for proliferation of said organism; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

433. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a

nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is underexpressed;

contacting each of said plurality of cultures with a varying concentration of a regulatory agent which regulates the level of expression of said gene products which are essential for proliferation of said organism; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

434. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is underexpressed;

contacting each of said plurality of cultures with a varying concentration of a regulatory agent which regulates the level of expression of said gene products which are essential for proliferation of said organism; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

435. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from

the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed;

contacting each of said plurality of cultures with a varying concentration of a regulatory agent which regulates the level of expression of said gene products which are essential for proliferation of said organism; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

436. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is underexpressed;

contacting each of said plurality of cultures with a varying concentration of a regulatory agent which regulates the level of expression of said gene products which are essential for proliferation of said organism; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

437. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 is underexpressed;

contacting each of said plurality of cultures with a varying concentration of a regulatory agent which regulates the level of expression of said gene products which are essential for proliferation of said organism; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

438. A culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed.

439. A culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed.

440. A culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed.

441. A culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising

a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6213 is overexpressed.

442. A culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed.

443. A culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 is overexpressed.

444. The culture of Claim 438, 439, 440, 441, 442 or 443, wherein said strains which overexpress said gene products comprise a nucleic acid encoding said gene product which is essential for proliferation of said organism operably linked to a regulatable promoter.

445. The culture of Claim 438, 439, 440, 441, 442 or 443, wherein said strains which overexpress said gene products comprise a nucleic acid encoding said gene product which is essential for proliferation of said organism operably linked to a constitutive promoter.

446. The culture of Claim 438, 439, 440, 441, 442 or 443, wherein said culture is a culture of an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

447. A culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed.

448. A culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a

nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is underexpressed.

449. A culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is underexpressed.

450. A culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed.

451. A culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent

conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is underexpressed.

452. A culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOS.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS: 42938-78581 is underexpressed.

453. The culture of Claim 447, 448, 449, 450, 451 or 452, wherein said strains which underexpress said gene products comprise a nucleic acid encoding said gene product which is essential for proliferation of said organism operably linked to a regulatable promoter.

454. The culture of Claim 447, 448, 449, 450, 451 or 452, wherein said strains which underexpress said gene products comprise a nucleic acid encoding said gene product which is essential for proliferation of said organism operably linked to a constitutive promoter.

455. The culture of Claim 447, 448, 449, 450, 451 or 452, wherein said culture is a culture of an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella*

sonnei, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

456. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the overexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the overexpressed genes, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

457. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the overexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the overexpressed genes, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene

product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

5 identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

458. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

10 obtaining a culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the overexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the overexpressed genes, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed;

15 contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

20 identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

459. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

25 obtaining a culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the overexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the overexpressed genes, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at

least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1-6213 is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

460. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the overexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the overexpressed genes, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a

nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

461. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the overexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the overexpressed genes, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOS.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS.: 42938-78581 is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

462. The method of Claim 456, 457, 458, 459, 460 or 461, wherein the nucleotide sequence of each of the genes encoding an overexpressed gene product has been altered by replacing the native promoters of said genes with promoters which facilitate overexpression of said gene products.

5 463. The method of Claim 456, 457, 458, 459, 460 or 461, wherein the nucleotide sequence of each of the genes encoding an overexpressed gene product has been altered by inserting a regulatory element into the native promoters of said genes with a promoter which facilitates overexpression of said gene products.

10 464. The method of Claim 463, wherein said regulatory element is selected from the group consisting of a regulatable promoter, an operator which is recognized by a repressor, a nucleotide sequence which is recognized by a transcriptional activator, a transcriptional terminator, a nucleotide sequence which introduces a bend in the DNA and an upstream activating sequence.

15 465. The method of Claim 456, 457, 458, 459, 460 or 461, wherein the step of identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene comprises performing an amplification reaction and detecting a unique amplification product corresponding to said gene.

20 466. The method of Claim 462, wherein the native promoter of each of the genes encoding a gene product essential for proliferation is replaced with the same promoter.

467. The method of Claim 462, wherein the native promoters of the genes encoding gene products essential for proliferation are replaced with a plurality of promoters selected to give a desired expression level for each gene product.

25 468. The method of Claim 462, wherein said promoters which replaced the native promoters in each strain comprise regulatable promoters.

469. The method of Claim 462, wherein said promoters which replaced the native promoters in each strain each strain comprise constitutive promoters.

470. The method of Claim 456, 457, 458, 459, 460 or 461, wherein said organism is selected from the group consisting of bacteria, fungi, and protozoa.

30 471. The method of Claim 456, 457, 458, 459, 460 or 461, wherein said culture is a culture of an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called
35 *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*,

Candida krusei, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*,
Chlamydia pneumoniae, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium*
botulinum, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*,
Corynebacterium diphtheriae, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus*
5 *faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*,
Histoplasma capsulatum, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria*
monocytogenes, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
Mycobacterium leprae, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma*
pneumoniae, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella*
10 *haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*,
Pseudomonas aeruginosa, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*,
Salmonella choleraesuis, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*,
Salmonella typhimurium, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella*
sonnei, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*,
15 *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema*
pallidum, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio*
vulnificans, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of
any of the above species.

472. A method for identifying the gene product on which a compound which inhibits
20 proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain
underexpresses a different gene product which is essential for proliferation of said
organism and wherein the nucleotide sequence of each of the underexpressed genes has
been altered so as to include a nucleotide sequence which can be used to generate a
25 unique product corresponding to each of the underexpressed genes and wherein said
culture comprises a strain in which a gene product whose activity or level is inhibited
by a nucleic acid comprising a nucleotide sequence selected from the group consisting
of SEQ ID NOs.: 1-6213 is underexpressed;

contacting said culture with a sufficient concentration of said compound to
30 inhibit the proliferation of strains of said organism which underexpress said gene
product on which said compound acts, such that strains which underexpress said gene
product on which said compound acts proliferate more slowly than strains which do not
underexpress the gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

5 473. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the underexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a
10 unique product corresponding to each of the underexpressed genes and wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is underexpressed;

contacting said culture with a sufficient concentration of said compound to
15 inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress the gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which
20 proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

474. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain
25 underexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the underexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the underexpressed genes, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected
30 from the group consisting of SEQ ID NOs.: 42938-78581 is underexpressed;

contacting said culture with a sufficient concentration of said compound to
inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not
35 underexpress the gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

475. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the underexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the underexpressed genes, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress the gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

5 476. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the underexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a
10 unique product corresponding to each of the underexpressed genes, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using
15 BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is underexpressed;
20

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not
25 underexpress the gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

30 477. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the underexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a
35 unique product corresponding to each of the underexpressed genes, wherein said

5 culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 is underexpressed;

10 contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress the gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

15 478. The method of Claim 472, 473, 474, 475, 476 or 477, wherein the nucleotide sequence of each of the genes encoding an underexpressed gene product has been altered by replacing the native promoters of said genes with promoters which facilitate underexpression of said gene products.

20 479. The method of Claim 472, 473, 474, 475, 476 or 477, wherein the nucleotide sequence of each of the genes encoding an underexpressed gene product has been altered by inserting a regulatory element into the native promoters of said genes with a promoter which facilitates underexpression of said gene products.

25 480. The method of Claim 479, wherein said regulatory element is selected from the group consisting of a regulatable promoter, an operator which is recognized by a repressor, a nucleotide sequence which is recognized by a transcriptional activator, a transcriptional terminator, a nucleotide sequence which introduces a bend in the DNA and an upstream activating sequence.

30 481. The method of Claim 472, 473, 474, 475, 476 or 477, wherein the step of identifying the gene product which is underexpressed in a strain which proliferated more slowly in said culture by detecting the unique product corresponding to said gene comprises performing an amplification reaction and detecting a unique amplification product corresponding to said gene.

482. The method of Claim 478, wherein the native promoter of each of the genes encoding a gene product essential for proliferation is replaced with the same promoter.

483. The method of Claim 478, wherein the native promoters of the genes encoding gene products essential for proliferation are replaced with a plurality of promoters selected to give a desired expression level for each gene product.

484. The method of Claim 478, wherein said promoters which replaced the native promoters in each strain comprise regulatable promoters.

485. The method of Claim 478, wherein said promoters which replaced the native promoters in each strain each strain comprise constitutive promoters.

486. The method of Claim 472, 473, 474, 475, 476 or 477, wherein said organism is selected from the group consisting of bacteria, fungi, and protozoa.

487. The method of Claim 472, 473, 474, 475, 476 or 477, wherein said culture is a culture of an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

488. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed or underexpressed;

performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction.

489. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed or underexpressed;

performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction.

490. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed or underexpressed;

performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction.

491. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a

gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 is overexpressed or underexpressed;

performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction.

492. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed or underexpressed;

performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode

said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction.

493. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprising a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 is overexpressed or underexpressed;

performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction.

494. The method of Claim 488, 489, 490, 491, 492 or 493, wherein one member of each primer pair for each of said genes is labeled with a detectable dye.

495. The method of Claim 488, 489, 490, 491, 492 or 493, wherein:

said nucleic acid sample is divided into N aliquots; and

said amplification reaction is performed on each aliquot using primer pairs complementary to nucleotide sequences within or adjacent to 1/N of the genes which encode said gene products, wherein one of the members of each primer pair in each

aliquot is labeled with a dye and wherein the dyes on the primers in each aliquot are distinguishable from one another.

5 496. The method of Claim 494, further comprising pooling the amplification products from each of the aliquots prior to determining the lengths of the amplification products.

 497. The method of Claim 488, 489, 490, 491, 492 or 493, wherein the native promoters of said genes which encode said gene products have been replaced with a regulatable promoter and one of the primers in said primer pairs is complementary to a nucleotide sequence within said regulatable promoter.

10 498. The method of Claim 496, wherein the native promoters for each of said genes were replaced with the same regulatable promoter.

 499. The method of Claim 496, wherein more than one regulatable promoter was used to replace the promoters of said genes such that some of said genes are under the control of a different regulatable promoter.

15 500. A method for identifying the target of a compound which inhibits the proliferation of an organism comprising:

 obtaining a first nucleic acid sample comprising nucleic acids from a first culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism and wherein said culture or collection of strains has been contacted with said compound;

 obtaining a second nucleic acid sample comprising nucleic acids from a second culture or collection of strains wherein said culture or collection of strains comprises the same strains as said first culture or collection of strains wherein said second culture or collection of strains has not been contacted with said compound;

 performing a first amplification reaction on said first nucleic acid sample using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains;

 performing a second amplification reaction on said second nucleic acid sample using the same set of primer pairs used in said first amplification reaction;

and comparing the amount of each amplification product in said first amplification reaction to the amount of that amplification product in said second amplification reaction, wherein an increased level of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products and a decreased level of of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products, wherein said first and second cultures or collection of strains comprise a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed or underexpressed.

501. A method for identifying the target of a compound which inhibits the proliferation of an organism comprising:

obtaining a first nucleic acid sample comprising nucleic acids from a first culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism and wherein said culture or collection of strains has been contacted with said compound;

obtaining a second nucleic acid sample comprising nucleic acids from a second culture or collection of strains wherein said culture or collection of strains comprises the same strains as said first culture or collection of strains wherein said second culture or collection of strains has not been contacted with said compound;

performing a first amplification reaction on said first nucleic acid sample using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains;

performing a second amplification reaction on said second nucleic acid sample using the same set of primer pairs used in said first amplification reaction;

and comparing the amount of each amplification product in said first amplification reaction to the amount of that amplification product in said second

amplification reaction, wherein an increased level of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products and a decreased level of of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products, wherein said first and second cultures or collection of strains comprise a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed or underexpressed.

502. A method for identifying the target of a compound which inhibits the proliferation of an organism comprising:

obtaining a first nucleic acid sample comprising nucleic acids from a first culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism and wherein said culture or collection of strains has been contacted with said compound;

obtaining a second nucleic acid sample comprising nucleic acids from a second culture or collection of strains wherein said culture or collection of strains comprises the same strains as said first culture or collection of strains wherein said second culture or collection of strains has not been contacted with said compound;

performing a first amplification reaction on said first nucleic acid sample using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains;

performing a second amplification reaction on said second nucleic acid sample using the same set of primer pairs used in said first amplification reaction;

and comparing the amount of each amplification product in said first amplification reaction to the amount of that amplification product in said second amplification reaction, wherein an increased level of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that

the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products and a decreased level of of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products, wherein said first and second cultures or collection of strains comprise a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed or underexpressed.

503. A method for identifying the target of a compound which inhibits the proliferation of an organism comprising:

obtaining a first nucleic acid sample comprising nucleic acids from a first culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism and wherein said culture or collection of strains has been contacted with said compound;

obtaining a second nucleic acid sample comprising nucleic acids from a second culture or collection of strains wherein said culture or collection of strains comprises the same strains as said first culture or collection of strains wherein said second culture or collection of strains has not been contacted with said compound;

performing a first amplification reaction on said first nucleic acid sample using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains;

performing a second amplification reaction on said second nucleic acid sample using the same set of primer pairs used in said first amplification reaction;

and comparing the amount of each amplification product in said first amplification reaction to the amount of that amplification product in said second amplification reaction, wherein an increased level of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products and a decreased

level of of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products, wherein said first and second cultures or collection of strains comprise a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed or underexpressed.

504. A method for identifying the target of a compound which inhibits the proliferation of an organism comprising:

obtaining a first nucleic acid sample comprising nucleic acids from a first culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism and wherein said culture or collection of strains has been contacted with said compound;

obtaining a second nucleic acid sample comprising nucleic acids from a second culture or collection of strains wherein said culture or collection of strains comprises the same strains as said first culture or collection of strains wherein said second culture or collection of strains has not been contacted with said compound;

performing a first amplification reaction on said first nucleic acid sample using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains;

performing a second amplification reaction on said second nucleic acid sample using the same set of primer pairs used in said first amplification reaction;

and comparing the amount of each amplification product in said first amplification reaction to the amount of that amplification product in said second amplification reaction, wherein an increased level of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products and a decreased level of of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products, wherein said first and second cultures or collection of strains comprise a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed or underexpressed.

505. A method for identifying the target of a compound which inhibits the proliferation of an organism comprising:

obtaining a first nucleic acid sample comprising nucleic acids from a first culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene

product which is required for proliferation of said organism and wherein said culture or collection of strains has been contacted with said compound;

obtaining a second nucleic acid sample comprising nucleic acids from a second culture or collection of strains wherein said culture or collection of strains comprises the same strains as said first culture or collection of strains wherein said second culture or collection of strains has not been contacted with said compound;

performing a first amplification reaction on said first nucleic acid sample using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains;

performing a second amplification reaction on said second nucleic acid sample using the same set of primer pairs used in said first amplification reaction;

and comparing the amount of each amplification product in said first amplification reaction to the amount of that amplification product in said second amplification reaction, wherein an increased level of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products and a decreased level of of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products, wherein said first and second culture or collection of strains comprise a strain in which a gene product comprising a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 is overexpressed or underexpressed.

506. The method of Claim 500, 501, 502, 503, 504 or 505, wherein one member of each primer pair for each of said genes is labeled with a detectable dye.

507. The method of Claim 500, 501, 502, 503, 504 or 505, wherein the native promoters of said genes which encode said gene products have been replaced with a regulatable

promoter and one of the primers in said primer pairs is complementary to a nucleotide sequence within said regulatable promoter.

508. The method of Claim 500, 501, 502, 503, 504 or 505, wherein the native promoters for each of said genes were replaced with the same regulatable promoter.

5 509. The method of Claim 500, 501, 502, 503, 504 or 505, wherein more than one regulatable promoter was used to replace the promoters of said genes such that some of said genes are under the control of a different regulatable promoter.

510. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

10 obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which transcribe an antisense nucleic acid complementary to a different gene product which is required for proliferation of said organism;

performing an amplification reaction using a set of primer pairs which are
15 complementary to nucleotide sequences within or adjacent to the nucleic acids which encode said antisense nucleic acids, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said
20 primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed or
25 underexpressed.

511. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of
30 strains which transcribe an antisense nucleic acid complementary to a different gene product which is required for proliferation of said organism;

performing an amplification reaction using a set of primer pairs which are
complementary to nucleotide sequences within or adjacent to the nucleic acids which
35 encode said antisense nucleic acids, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a

length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

5 determining the lengths of the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed or underexpressed.

512. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

10 obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which transcribe an antisense nucleic acid complementary to a different gene product which is required for proliferation of said organism;

15 performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the nucleic acids which encode said antisense nucleic acids, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said
20 primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed or underexpressed.

25 513. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which transcribe an antisense nucleic acid complementary to a different gene
30 product which is required for proliferation of said organism;

performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the nucleic acids which encode said antisense nucleic acids, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a
35 length distinguishable from the lengths of the amplification products from the other

primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed or underexpressed.

514. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which transcribe an antisense nucleic acid complementary to a different gene product which is required for proliferation of said organism;

performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the nucleic acids which encode said antisense nucleic acids, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other

primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed or underexpressed.

515. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which transcribe an antisense nucleic acid complementary to a different gene product which is required for proliferation of said organism;

performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the nucleic acids which encode said antisense nucleic acids, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product comprising a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOS.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS: 42938-78581 is overexpressed or underexpressed.

516. The method of Claim 510, 511, 512, 513, 514 or 515, wherein one member of each primer pair for each of said genes is labeled with a detectable dye.

517. The method of Claim 510, 511, 512, 513, 514 or 515, wherein:

said nucleic acid sample is divided into N aliquots; and

said amplification reaction is performed on each aliquot using primer pairs complementary to nucleotide sequences within or adjacent to 1/N of the genes which encode said gene products, wherein one of the members of each primer pair in each aliquot is labeled with a dye and wherein the dyes on the primers in each aliquot are distinguishable from one another.

518. The method of Claim 517, further comprising pooling the amplification products from each of the aliquots prior to determining the lengths of the amplification products.

519. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which overexpress or underexpress a different gene product which is required for proliferation of said organism;

performing an amplification reaction using primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein said primer pairs are designed such that each primer pair would yield an amplification product which is distinguishable from the amplification products produced by the other primer pairs on the basis selected from the group consisting of length, detectable label and both length and detectable label if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

identifying the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed or underexpressed.

520. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which overexpress or underexpress a different gene product which is required for proliferation of said organism;

performing an amplification reaction using primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein said primer pairs are designed such that each primer pair would yield an amplification product which is distinguishable from the amplification products produced by the other primer pairs on the a basis selected from the group consisting of length, detectable label and both length and detectable label if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

identifying the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed or underexpressed.

521. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which overexpress or underexpress a different gene product which is required for proliferation of said organism;

performing an amplification reaction using primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein said primer pairs are designed such that each primer pair would yield an amplification product which is distinguishable from the amplification products produced by the other primer pairs on the a basis selected from the group consisting of length, detectable label and both length and detectable label if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

identifying the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed or underexpressed.

522. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of

strains which overexpress or underexpress a different gene product which is required for proliferation of said organism;

5 performing an amplification reaction using primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein said primer pairs are designed such that each primer pair would yield an amplification product which is distinguishable from the amplification products produced by the other primer pairs on the a basis selected from the group consisting of length, detectable label and both length and detectable label if a strain comprising the nucleotide sequences complementary to said primer pair is present in
10 said culture or collection of strains; and

identifying the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product
15 whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid
20 comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid
25 which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene
30 product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed or underexpressed.

523. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which overexpress or underexpress a different gene product which is required for proliferation of said organism;

5 performing an amplification reaction using primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein said primer pairs are designed such that each primer pair would yield an amplification product which is distinguishable from the amplification products produced by the other primer pairs on the a basis selected from the group consisting of length, detectable label and both length and detectable label if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

10 identifying the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed or underexpressed.

15 524. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

20 obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which overexpress or underexpress a different gene product which is required for proliferation of said organism;

25 performing an amplification reaction using primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein said primer pairs are designed such that each primer pair would yield an amplification product which is distinguishable from the amplification products produced by the other primer pairs on the a basis selected from the group consisting of length, detectable label and both length and detectable label if a strain

30

35

comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

identifying the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product comprising a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 is overexpressed or underexpressed.

525. The method of Claim 519, 520, 521, 522, 523 or 524, wherein said primer pairs are divided into at least two sets, each primer pair comprises a primer which is labeled with a distinguishable dye, and the distinguishable dye used to label each set of primer pairs is distinguishable from the dye used to label the other sets of primer pairs.

526. The method of Claim 519, 520, 521, 522, 523 or 524, wherein:

said nucleic acid sample is divided into N aliquots; and

said amplification reaction is performed on each aliquot using primer pairs complementary to nucleotide sequences within or adjacent to 1/N of the genes which encode said gene products, wherein one of the members of each primer pair in each aliquot is labeled with a dye and wherein the dyes on the primers in each aliquot are distinguishable from one another.

527. The method of Claim 526, further comprising pooling the amplification products from each of the aliquots prior to determining the lengths of the amplification products.

528. The method of Claim 519, 520, 521, 522, 523 or 524, wherein the native promoters of said genes which encode said gene products have been replaced with a regulatable promoter and one of the primers in said primer pairs is complementary to a nucleotide sequence within said regulatable promoter.



529. The method of Claim 528, wherein the native promoters for each of said genes were replaced with the same regulatable promoter.


530. The method of Claim 528, wherein more than one regulatable promoter was used to replace the promoters of said genes such that some of said genes are under the control of a different regulatable promoter.

1/22

 P_R = Regulatable promoter P_C = Chromosomal promoter

▨ = Homology region

 P_S = Promoter operably linked to gene G_S = Gene encoding selectable or identifiable marker T_T = Transcriptional terminator



3/22





FIG. 2B

4/22

FIG. 3

FIG. 3A
FIG. 3B

FIG. 3A



5/22





FIG. 3B

6/22

FIG. 4

Hypothetical 3D Matrix Hybridization Results for Nonspecific Clones



7/22

Hypothetical 3 D Matrix Hybridization Results for A Specific Clone

FIG. 5





FIG. 6

PROMOTER FOR yabB yabC flsL murE OPERON



OLIGO USED FOR lacO INSERTION

9/22




FIG. 7

10/22




FIG. 8A

11/22




FIG. 8B

AS-e|aD

% NO TETRACYCLINE CONTROL

12/22




FIG. 9

THE SELECTIVE SENSITIZATION TO AN ANTIBIOTIC INHIBITING GYRASE B SUBUNIT ACTIVITY FOLLOWING THE INDUCTION OF AN ANTISENSE CONSTRUCT TO THE B SUBUNIT OF GYRASE.





FIG. 10

14/22

FIG. 11


		Inducer Concentration											
		High										Low	
A B C D E F G H	1	2	3	4	5	6	7	8	9	10			

15/22




16/22

FIG. 13




17/22

FIG. 14




18/22

FIG. 15



19/22

FIG. 16



20/22

FIG. 17




FIG. 18A

FIG. 18A
FIG. 18B

Target Clone Amplification in a mixed Culture (Nine Staph Clones)






FIG. 18

FIG. 18B

FIG. 18A
FIG. 18B



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.